id	title	pub_title	doi	url	total_versions	first_reg_date	final_status	original_start_date	original_completion_date	publication_date	has_pre_recruitment_phase	has_recruitment_phase	has_post_completion_phase	has_post_publication_phase	has_unknown_phase	outcome_changed_recruitment	outcome_changed_postcompletion	outcome_changed_postpublication	outcome_changed_unknown	trial_phase_start	outcome_start	outcome_last_recruitment	outcome_last_postcompletion	outcome_last_postpublication	outcome_last_unknown
DRKS00000003	OSAKA: A multicenter, four arm, randomized, open label clinical study investigating optimized dosing in a Prograf®/Advagraf®-based immunosuppressive regimen in kidney transplant subjects. Short Title: OSAKA Study (Optimizing ImmunoSuppression After Kidney Transplantation With Advagraf) ISN: PMR-EC-1210Transplantation with ADVAGRAF)	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005376-13/results	8	2008-08-08	Recruiting complete, follow-up complete	2008-06-02	2010-05-03	2010-11-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate. The secondary objective is to compare the efficacy and safety profiles of the four therapy regimens with each other. Efficacy failure rate will be assessed using a composite endpoint consisting of graft loss, biopsy confirmed acute rejection (BCAR) and graft dysfunction.""]	[""The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate. The secondary objective is to compare the efficacy and safety profiles of the four therapy regimens with each other. Efficacy failure rate will be assessed using a composite endpoint consisting of graft loss, biopsy confirmed acute rejection (BCAR) and graft dysfunction.""]	[""The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate. The secondary objective is to compare the efficacy and safety profiles of the four therapy regimens with each other. Efficacy failure rate will be assessed using a composite endpoint consisting of graft loss, biopsy confirmed acute rejection (BCAR) and graft dysfunction.""]	[""The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate. The secondary objective is to compare the efficacy and safety profiles of the four therapy regimens with each other. Efficacy failure rate will be assessed using a composite endpoint consisting of graft loss, biopsy confirmed acute rejection (BCAR) and graft dysfunction.""]	NA
DRKS00000005	DISPACT: Distal Pancreatectomy - A randomized controlled trial to compare two different surgical techniques	Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial	10.1016/s0140-6736(11)60237-7	http://www.sciencedirect.com/science/article/pii/S0140673611602377	10	2008-08-08	Recruiting complete, follow-up complete	2007-08-22	2009-07-03	2011-04-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Combined primary endpoint: presence of a pancreatic fistula and / or death due to any cause on day 7 postoperatively.""]	[""Combined primary endpoint: presence of a pancreatic fistula and / or death due to any cause on day 7 postoperatively.""]	[""Combined primary endpoint: presence of a pancreatic fistula and / or death due to any cause on day 7 postoperatively.""]	[""Combined primary endpoint: presence of a pancreatic fistula and / or death due to any cause on day 7 postoperatively.""]	NA
DRKS00000041	Open Reduction and Internal Fixation versus Casting for Highly comminuted and Intraarticular Fractures of the Distal Radius	NA	NA	https://www.aerzteblatt.de/pdf.asp?id=163519	11	2008-11-26	Recruiting stopped after recruiting started	2008-09-14	NA	2014-11-14	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[""Primary efficacy endpoint: Physical Component Score (PCS) of the Short Form 36 (SF36) 12 ± 1 months after randomizationKey""]	NA	NA	[""Primary efficacy endpoint: Physical Component Score (PCS) of the Short Form 36 (SF36) 12 ± 1 months after randomizationKey""]	[""Primary efficacy endpoint: Physical Component Score (PCS) of the Short Form 36 (SF36) 12 ± 1 months after randomizationKey""]
DRKS00000043	Assessment of the inflammation of oral mucosa in lymphoma patients receiving Palifermin  after high-dose conditioning with BEAM and autologous peripheral blood stem cell transplantation	NA	NA	https://www.karger.com/Article/PDF/333305	10	2008-11-06	Recruiting complete, follow-up complete	2008-08-21	2011-07-01	2011-03-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Incidence of severe oral mucositis (WHO grade 3/4)\nIncidence of severe oral mucositis (WHO grade 3/4) whithin 30 days after autologous PBSCT""]	[""Incidence of severe oral mucositis (WHO grade 3/4)\nIncidence of severe oral mucositis (WHO grade 3/4) whithin 30 days after autologous PBSCT""]	NA	[""Incidence of severe oral mucositis (WHO grade 3/4)\nIncidence of severe oral mucositis (WHO grade 3/4) whithin 30 days after autologous PBSCT""]	NA
DRKS00000053	The effectiveness of occupational therapy at home in persons with dementia and their primary caregiver - a multicentre randomised controlled trial evaluating the Dutch occupational therapy programme within the German context.	A multicentre RCT on community occupational therapy in Alzheimer's disease: 10 sessions are not better than one consultation	10.1136/bmjopen-2011-000096	https://www.ncbi.nlm.nih.gov/pubmed/22021760	10	2008-11-14	Recruiting complete, follow-up complete	2008-08-20	2010-08-31	2011-08-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Patients functioning in daily life and quality of life""]	[""Patients functioning in daily life and quality of life""]	[""Patients functioning in daily life and quality of life""]	[""Patients functioning in daily life and quality of life""]	NA
DRKS00000058	Pro-Active Rehabilitation and Telephone Intervention in Type 2 Diabetics: a randomized controlled trial of patients enrolled in a DMP.	[Feasibility and benefit of an active screening for rehab need and subsequent written advice to file an application for rehab treatment in AOK-insurants enrolled in the disease management program diabetes type 2 (PARTID-trial)]	10.1055/s-0034-1370984	NA	9	2008-12-19	Recruiting complete, follow-up complete	2009-02-12	2012-09-30	2014-10-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[""Change in HbA1c (<\/= 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Framingham-Score),\ncomplications.""]	[""Change in HbA1c (≤ 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Framingham-Score),\ncomplications.\n""]	NA	[""Change in HbA1c (≤ 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Cederholm, 2008),\ncomplications. Assessments by questionnaire at screening for rehabilitation need and 12 months after screening.\n\nStudy arm 2 - telephone follow-up: Behavior change in physical activity (Stender et al., 1991), diet (food list based on Keller, 1998), medication adherence (MARS-D), smoking, improvements in depression (PHQ-9), well-being (WHO-5) and diabetes-related burden (PAID). Assessments by questionnaire at begin of inpatient rehabilitation and 12 months after discharge.\n""]	NA
DRKS00000060	A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone	Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement	10.1016/j.clinthera.2012.06.023	https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(12)00386-4	6	2009-08-07	Recruiting complete, follow-up complete	2009-07-20	2010-05-24	2012-07-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""To compare the side effects with multiple dose intravenous co administration of morphine and oxycodone vs. morphine alone at doses that result in effective relief of pain, defined as a score of 2 or less on the 11 point NPRS""]	[""To compare the side effects with multiple dose intravenous co administration of morphine and oxycodone vs. morphine alone at doses that result in effective relief of pain, defined as a score of 2 or less on the 11 point NPRS""]	[""To compare the side effects with multiple dose intravenous co administration of morphine and oxycodone vs. morphine alone at doses that result in effective relief of pain, defined as a score of 2 or less on the 11 point NPRS""]	[""To compare the side effects with multiple dose intravenous co administration of morphine and oxycodone vs. morphine alone at doses that result in effective relief of pain, defined as a score of 2 or less on the 11 point NPRS""]	NA
DRKS00000068	Psychoanalytic-interactional therapy in Cluster B personality disorders	Psychoanalytic-Interactional Therapy versus Psychodynamic Therapy by Experts for Personality Disorders: A Randomized Controlled Efficacy-Effectiveness Study in Cluster B Personality Disorders	10.1159/000441731	https://www.ncbi.nlm.nih.gov/pubmed/26808580	7	2009-08-18	Recruiting complete, follow-up complete	2008-10-01	2012-06-26	2016-01-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Under the condition of a specific manual guided psychoanalytic-interactional method a significantly greater improvement is expected compared to a comparison group under the condition of dynamic psycho-therapy \""as usual\"" in terms of improving the level of mental functioning (Borderline Personality Inventory, BPI), as well as the overall symptom severity in the global symptom index (SCL-90-R-GSI). The level of mental functioning and the symptom severity of patients are assessed at the beginning of the waiting period, at admission, at discharge and after six and twelve month after discharge with the Borderline Personality Inventory (BPI) and the SCL-90-R (GSI).""]	[""Under the condition of a specific manual guided psychoanalytic-interactional method a significantly greater improvement is expected compared to a comparison group under the condition of dynamic psycho-therapy \""as usual\"" in terms of improving the level of mental functioning (Borderline Personality Inventory, BPI), as well as the overall symptom severity in the global symptom index (SCL-90-R-GSI). The level of mental functioning and the symptom severity of patients are assessed at the beginning of the waiting period, at admission, at discharge and after six and twelve month after discharge with the Borderline Personality Inventory (BPI) and the SCL-90-R (GSI).""]	[""Under the condition of a specific manual guided psychoanalytic-interactional method a significantly greater improvement is expected compared to a comparison group under the condition of dynamic psycho-therapy \""as usual\"" in terms of improving the level of mental functioning (Borderline Personality Inventory, BPI), as well as the overall symptom severity in the global symptom index (SCL-90-R-GSI). The level of mental functioning and the symptom severity of patients are assessed at the beginning of the waiting period, at admission, at discharge and after six and twelve month after discharge with the Borderline Personality Inventory (BPI) and the SCL-90-R (GSI).""]	NA	NA
DRKS00000081	Internet-based relapse prevention for eating disorders following inpatient treatment: randomised controlled trial for anorexia nervosa	Does internet-based prevention reduce the risk of relapse for anorexia nervosa?	10.1016/j.brat.2011.12.003	NA	9	2009-02-13	Recruiting complete, follow-up complete	2007-04-05	2013-03-31	2012-01-16	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Body weight (Body Mass Index BMI): Difference of BMI at randomization and end of intervention (9 months)""]	[""Body weight (Body Mass Index BMI): Difference of BMI at randomization and end of intervention (9 months)""]	NA	[""Body weight (Body Mass Index BMI): Difference of BMI at randomization and end of intervention (9 months)""]	NA
DRKS00000086	Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.	Controlled trial for long-term low-dose erythromycin after sinus surgery for chronic rhinosinusitis	10.1002/lary.25052	https://www.ncbi.nlm.nih.gov/pubmed/25425539	10	2009-02-19	Recruiting stopped after recruiting started	2009-07-05	NA	2015-05-01	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[""Concentration changes of inflammation mediatiors MPO and ECP in nasal discharge under a low-dose erythromycin or placebo post-operative treatment.""]	NA	NA	[""Concentration changes of inflammation mediatiors MPO and ECP in nasal discharge under a low-dose erythromycin or placebo post-operative treatment.""]	[""Concentration changes of inflammation mediatiors MPO and ECP in nasal discharge under a low-dose erythromycin or placebo post-operative treatment.""]
DRKS00000093	Comparison of torsional and longitudinal phacoemulsification through measurement of endothelial cellcount, ultrasound total energy and time	Comparison of endothelial changes and power settings between torsional and longitudinal phacoemulsification	10.1016/j.jcrs.2010.06.060	http://www.sciencedirect.com/science/article/pii/S0886335010012630	10	2009-03-25	Recruiting complete, follow-up complete	2008-08-14	2009-12-31	2010-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Endothelium cell counts preoperativ and postoperativ""]	[""Endothelium cell counts preoperativ and postoperativ""]	[""Endothelium cell counts preoperativ and postoperativ""]	[""Endothelium cell counts preoperativ and postoperativ""]	NA
DRKS00000096	Patient information via multimedia in radical prostatectomy	Multimedia support in preoperative patient education for radical prostatectomy: the physicians' point of view	10.1016/j.pec.2011.08.014	http://www.sciencedirect.com/science/article/pii/S0738399111004654	10	2009-03-04	Recruiting complete, follow-up complete	2009-03-06	2010-07-27	2011-09-25	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""patient satisfaction\nmeasured in the evening before surgery following the informed consent procedure by standardised interview and self-designed questionnaire (27 items)""]	[""patient satisfaction\nmeasured in the evening before surgery following the informed consent procedure by standardised interview and self-designed questionnaire (27 items)""]	[""patient satisfaction\nmeasured in the evening before surgery following the informed consent procedure by standardised interview and self-designed questionnaire (27 items)""]	[""patient satisfaction\nmeasured in the evening before surgery following the informed consent procedure by standardised interview and self-designed questionnaire (27 items)""]	NA
DRKS00000101	Treatment of Childhood and Adolescent Anorexia Nervosa - A Comparison of a Day treatment and an Inpatient Treatment Setting	Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial	10.1016/s0140-6736(13)62411-3	NA	8	2009-03-17	Recruiting complete, follow-up complete	2007-03-08	2012-10-18	2014-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""difference of the BMI at admission compared to 52nd-week-follow-up""]	[""difference of the BMI at admission compared to 52nd-weeks after admission; additional follow up: difference of the BMI at admission compared to 130th-weeks after admission""]	[""difference of the BMI at admission compared to 52nd-weeks after admission; additional follow up: difference of the BMI at admission compared to 130th-weeks after admission""]	NA	NA
DRKS00000104	Hypocaloric nutrition in intensive care medicine and its clinical relevance	Hypocaloric vs Normocaloric Nutrition in Critically Ill Patients: A Prospective Randomized Pilot Trial	10.1177/0148607114528980	http://journals.sagepub.com/doi/10.1177/0148607114528980	8	2009-03-26	Recruiting complete, follow-up complete	2008-10-01	2011-02-28	2014-04-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""Rate of nosocomial infection (microbiological diagnosis of tracheal secretion, urin and blood culture, clinical and radiological criteria of nosocomial infection)""]	NA
DRKS00000115	Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy	NA	10.1186/s13023-019-1066-9	https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1066-9#article-info	10	2009-11-18	Recruiting complete, follow-up complete	2009-10-01	2015-12-11	2019-05-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""To evaluate the effect and safety of a preventive treatment with ACE-Inhibitor and a Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy .\nTime to first diagnosis of left ventricular dysfunction defined as fraction shortening < 28% in standard echocardiography.""]	[""To evaluate the effect and safety of a preventive treatment with ACE-Inhibitor and a Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy .\nTime to first diagnosis of left ventricular dysfunction defined as fraction shortening < 28% in standard echocardiography.""]	[""To evaluate the effect and safety of a preventive treatment with ACE-Inhibitor and a Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy .\nTime to first diagnosis of left ventricular dysfunction defined as fraction shortening < 28% in standard echocardiography.""]	[""To evaluate the effect and safety of a preventive treatment with ACE-Inhibitor and a Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy .\nTime to first diagnosis of left ventricular dysfunction defined as fraction shortening < 28% in standard echocardiography.""]	NA
DRKS00000125	Implementation of shared decision-making by physician training to optimise hypertension treatment in Southern Baden.	Shared decision-making in antihypertensive therapy: a cluster randomised controlled trial	10.1186/1471-2296-14-135	https://www.ncbi.nlm.nih.gov/pubmed/24024587	7	2009-06-02	Recruiting complete, follow-up complete	2009-06-05	2011-09-27	2013-09-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\nBlood pressure values (RR, systolic : diastolic):\nRR 24-h mean < 130:80;\nRR daytime mean < 135:85;\nRR nighttime mean < 120:70.\n\nParticipation in the decision making regarding the treatment.""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\nBlood pressure values (RR, systolic : diastolic):\nRR 24-h mean < 130:80;\nRR daytime mean < 135:85;\nRR nighttime mean < 120:70.\n\nParticipation in the decision making regarding the treatment.""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\n(1) Change of systolic blood pressure (mean of 24-h-measurement) from baseline\n\n(2) Change of patients' perceived participation (SDM-Q-9) from baseline""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\n(1) Change of systolic blood pressure (mean of 24-h-measurement) from baseline\n\n(2) Change of patients' perceived participation (SDM-Q-9) from baseline""]	NA
DRKS00000138	Conservative treatment of fecal incontinence: Triple target treatment versus low frequent electrostimulation	Triple-target treatment versus low-frequency electrostimulation for anal incontinence: a randomized, controlled trial	10.3238/arztebl.2011.0653	https://www.ncbi.nlm.nih.gov/pubmed/?term=Triple-Target+Treatment+Versus+Low-Frequency+Electrostimulation+for+Anal+Incontinence	5	2009-05-25	Recruiting complete, follow-up complete	2009-05-25	2010-12-17	2011-09-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The Primary endpoint is based on the Cleveland Clinic Score (CCS) in its validated German version. Primary endpoint is the difference of the CCS (continent 0, incontinent 20) between baseline and six month after randomization.""]	[""The Primary endpoint is based on the Cleveland Clinic Score (CCS) in its validated German version. Primary endpoint is the difference of the CCS (continent 0, incontinent 20) between baseline and six month after randomization.""]	[""The Primary endpoint is based on the Cleveland Clinic Score (CCS) in its validated German version. Primary endpoint is the difference of the CCS (continent 0, incontinent 20) between baseline and six month after randomization.""]	[""The Primary endpoint is based on the Cleveland Clinic Score (CCS) in its validated German version. Primary endpoint is the difference of the CCS (continent 0, incontinent 20) between baseline and six month after randomization.""]	NA
DRKS00000145	Patient safety culture in General Practice: investigation of the effects of the Frankfurt Patient Safety Matrix on safety culture in general practices	Effects of a team-based assessment and intervention on patient safety culture in general practice: an open randomised controlled trial	10.1136/bmjqs-2013-001899	https://www.ncbi.nlm.nih.gov/pubmed/23955468	8	2009-10-12	Recruiting complete, follow-up complete	2009-08-05	2011-12-31	2013-08-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Patient safety indicator \""A systematic error management is established in the surgery and in use.\"" after 12 months time, consisting of eleven criteria. Each criterion will be judged if present. The end point consists of a summary score of up to eleven (ordinal scale).\n(Measured by interview and self-assessment: a practice nurse and a physician will be interviewed in the surgery)""]	[""Patient safety indicator \""A systematic error management is established in the surgery and in use.\"" after 12 months time, consisting of eleven criteria. Each criterion will be judged if present. The end point consists of a summary score of up to eleven (ordinal scale).\n(Measured by interview and self-assessment: a practice nurse and a physician will be interviewed in the surgery)""]	[""Patient safety indicator \""A systematic error management is established in the surgery and in use.\"" after 12 months time, consisting of eleven criteria. Each criterion will be judged if present. The end point consists of a summary score of up to eleven (ordinal scale).\n(Measured by interview and self-assessment: a practice nurse and a physician will be interviewed in the surgery)""]	[""Patient safety indicator \""A systematic error management is established in the surgery and in use.\"" after 12 months time, consisting of eleven criteria. Each criterion will be judged if present. The end point consists of a summary score of up to eleven (ordinal scale).\n(Measured by interview and self-assessment: a practice nurse and a physician will be interviewed in the surgery)""]	NA
DRKS00000148	Effect of a fructose reduced diet in children and adolescents with proven fructose malabsorption with regard to recurrent abdominal pain	Positive or negative fructose breath test results do not predict response to fructose restricted diet in children with recurrent abdominal pain: results from a prospective randomized trial	10.1055/s-0034-1383653	https://www.ncbi.nlm.nih.gov/pubmed/25153911	8	2009-09-14	Recruiting complete, follow-up complete	2009-09-15	2011-08-15	2014-08-25	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""1. Pain frequency\n2. Pain intensity\nQuestionaire two weeks after inital inquiry, scale 1-10 for pains, frequency: pain episodes/week""]	[""1. Pain frequency\n2. Pain intensity\nQuestionaire two weeks after inital inquiry, scale 1-10 for pains, frequency: pain episodes/week""]	[""1. Pain frequency\n2. Pain intensity\nQuestionaire two weeks after inital inquiry, scale 1-10 for pains, frequency: pain episodes/week""]	NA	NA
DRKS00000157	CLINICAL LONG-TERM EVALUATION OF AN AUTOMATIC CONTROL OF THE INSPIRED OXYGEN FRACTION IN VENTILATED PRETERM INFANTS	Closed-loop automatic oxygen control (CLAC) in preterm infants: a randomized controlled trial	10.1542/peds.2013-1834	https://www.ncbi.nlm.nih.gov/pubmed/?term=Closed-Loop+Automatic+Oxygen+Control+(CLAC)+in+Preterm+Infants%3A+A+Randomized+Controlled+Trial	10	2009-08-19	Recruiting stopped after recruiting started	2009-04-21	2012-03-31	2014-01-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The primary outcome variable is the percentage of time within a predefined target range of the puls oximetry-derived haemoglobin oxygen saturation. The target range depends on the study center.""]	[""The primary outcome variable is the percentage of time within a predefined target range of the puls oximetry-derived haemoglobin oxygen saturation. The target range depends on the study center.""]	[""The primary outcome variable is the percentage of time within a predefined target range of the puls oximetry-derived haemoglobin oxygen saturation. The target range depends on the study center.""]	[""The primary outcome variable is the percentage of time within a predefined target range of the puls oximetry-derived haemoglobin oxygen saturation. The target range depends on the study center.""]	NA
DRKS00000195	A randomized placebo-controlled trial about the effect of UVB-irradiated white button mushrooms (Agaricus bisporus) and a vitamin D2 supplement on the 25(OH)D levels in healthy adults.	Bioavailability of vitamin D₂ from UV-B-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial	10.1038/ejcn.2011.53	https://www.ncbi.nlm.nih.gov/pubmed/21540874	4	2009-10-21	Recruiting complete, follow-up complete	2010-01-27	2010-11-10	2011-05-04	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Significant rising of the serum 25(OH)D level from young healthy adults by the consumption of UV-B treated mushrooms compared to non-treated mushrooms. Serum 25(OH)D level will be measured 4 times on each weekly encounter and 1 time a week after the last soup administration.""]	NA	NA	[""Significant rising of the serum 25(OH)D level from young healthy adults by the consumption of UV-B treated mushrooms compared to non-treated mushrooms. Serum 25(OH)D level will be measured 4 times on each weekly encounter and 1 time a week after the last soup administration.""]	NA
DRKS00000214	Saving and Empowering Young Lives in Europe: promoting health through the prevention of risk-taking and self-destructive behaviours	School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial	10.1016/s0140-6736(14)61213-7	https://www.ncbi.nlm.nih.gov/pubmed/25579833	6	2009-10-27	Recruiting complete, follow-up complete	2009-11-15	2012-01-31	2015-01-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""In each arm, the primary outcome is to measure the number of referrals, number of attempted suicides, and number of completed suicides, suicidal ideation and general well-being""]	[""In each arm, the primary outcome is to measure the number of referrals, number of attempted suicides, and number of completed suicides, suicidal ideation and general well-being""]	[""In each arm, the primary outcome is to measure the number of referrals, number of attempted suicides, and number of completed suicides, suicidal ideation and general well-being""]	NA	NA
DRKS00000245	Short-term psychotherapy for patients with panic disorder with or without agoraphobia - a randomised comparative study between the panic-focused psychodynamic and cognitive behavioural psychotherapy	Implementing panic-focused psychodynamic psychotherapy into clinical practice	10.1177/070674371305800604	https://www.ncbi.nlm.nih.gov/pubmed/23768260	7	2009-12-08	Recruiting complete, follow-up complete	2006-01-27	2011-05-29	2013-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Principal outcome criterion is the reduction of panic-related symptoms at the follow-up 6-months after treatment. Panic-related symptoms are measured with standardized questionnaires and interviews, e. g. the AKV-MI/BSQ/ACQ questionnaires, the Hamilton Anxiety Scale, HAMA, and the Panic Disorder Severity scale, PDSS. To test the hypothized equivalence of both interventional arms adequate statistical procedures will be used.\nAll questionnaires and interviews were conducted at all occasions of mneasurement.""]	[""Principal outcome criterion is the reduction of panic-related symptoms at the follow-up 6-months after treatment. Panic-related symptoms are measured with standardized questionnaires and interviews, e. g. the AKV-MI/BSQ/ACQ questionnaires, the Hamilton Anxiety Scale, HAMA, and the Panic Disorder Severity scale, PDSS. To test the hypothized equivalence of both interventional arms adequate statistical procedures will be used.\nAll questionnaires and interviews were conducted at all occasions of mneasurement.""]	[""Principal outcome criterion is the reduction of panic-related symptoms at the follow-up 6-months after treatment. Panic-related symptoms are measured with standardized questionnaires and interviews, e. g. the AKV-MI/BSQ/ACQ questionnaires, the Hamilton Anxiety Scale, HAMA, and the Panic Disorder Severity scale, PDSS. To test the hypothized equivalence of both interventional arms adequate statistical procedures will be used.\nAll questionnaires and interviews were conducted at all occasions of mneasurement.""]	[""Principal outcome criterion is the reduction of panic-related symptoms at the follow-up 6-months after treatment. Panic-related symptoms are measured with standardized questionnaires and interviews, e. g. the AKV-MI/BSQ/ACQ questionnaires, the Hamilton Anxiety Scale, HAMA, and the Panic Disorder Severity scale, PDSS. To test the hypothized equivalence of both interventional arms adequate statistical procedures will be used.\nAll questionnaires and interviews were conducted at all occasions of mneasurement.""]	NA
DRKS00000297	Vasoprotection by Atorvastatin in Children and Adolescents with Diabetes Type 1, a 2-Year Pilot Study	Cardiovascular risk in pediatric type 1 diabetes: sex-specific intima-media thickening verified by automatic contour identification and analyzing systems	10.1111/j.1399-5448.2011.00814.x	NA	6	2010-01-11	Recruiting complete, follow-up complete	2005-01-15	2010-07-31	2011-09-20	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Regression of Intima media thickness / roughness of the carotic arteries by B-mode ultra- sound in children with type 1 diabetes mellitus after 24 months.""]	[""Regression of Intima media thickness / roughness of the carotic arteries by B-mode ultra- sound in children with type 1 diabetes mellitus after 24 months.""]	[""Regression of Intima media thickness / roughness of the carotic arteries by B-mode ultra- sound in children with type 1 diabetes mellitus after 24 months.""]	[""Regression of Intima media thickness / roughness of the carotic arteries by B-mode ultra- sound in children with type 1 diabetes mellitus after 24 months.""]	NA
DRKS00000304	Clinical effectiveness of the newer antipsychotic compounds olanzapine, quetiapine and aripiprazole in comparison with low dose conventional  antipsychotics (haloperidol and flupentixol) in patients with schizophrenia	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study	10.1016/s2215-0366(16)00085-7	https://pubmed.ncbi.nlm.nih.gov/27265548/	12	2009-12-21	Recruiting complete, follow-up complete	2010-04-16	2014-03-31	2016-06-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[""Primary efficacy endpoint:\nContentment with treatment in 1) patients and 2) psychiatrists;\nPatient: SF-36 (interviewer version with a time frame of one week); Psychiatrist: CGI-S.\nKey secondary endpoints:\nSubscores of SF-36, SWN-K, PSP, PANSS, matrics (selected centres).\nAssessment of safety:\nAdverse events, drop-out rates, SAS / AIMS / BARS and sexual dysfunction changes. Metabolic side effects: body mass index (BMI), waist circumference, HbA1c, fast blood glucose levels, lipid profile.""]	[""Primary efficacy endpoint:\nContentment with treatment in 1) patients and 2) psychiatrists;\nPatient: SF-36 (interviewer version with a time frame of one week); Psychiatrist: CGI-S.\nKey secondary endpoints:\nSubscores of SF-36, SWN-K, PSP, PANSS, matrics (selected centres).\nAssessment of safety:\nAdverse events, drop-out rates, SAS / AIMS / BARS and sexual dysfunction changes. Metabolic side effects: body mass index (BMI), waist circumference, HbA1c, fast blood glucose levels, lipid profile changes (total cholesterol / LDL cholesterol /HDL cholesterol, triglycerides) from baseline to week 24 (visit 6), serum concentration of the respective study drug (olanzapine, quetiapine, aripiprazole, haloperidol, flupentixol).""]	[""Two primary efficacy endpoints used in the study. 1) Quality of life from the patient's perspective with SF-36 (interviewer version with a time frame of one week) and 2) the change in clinical status from the perspective of the investigator with CGI. The change from baseline at week 24 is measured by AUC based on logarithmic transformed time scale.\n""]	[""Two primary efficacy endpoints used in the study. 1) Quality of life from the patient's perspective with SF-36 (interviewer version with a time frame of one week) and 2) the change in clinical status from the perspective of the investigator with CGI. The change from baseline at week 24 is measured by AUC based on logarithmic transformed time scale.\n""]	NA
DRKS00000311	Clinical impact of non invasive pressure support ventilation after extubation in major lung resectional surgery	NA	10.4236/ojts.2012.23014	https://file.scirp.org/pdf/OJTS20120300005_14362903.pdf	5	2010-01-13	Recruiting suspended on temporary hold	2005-04-22	NA	2012-09-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[""Reintubation and mortality rate in the first 30 days postoperative""]	NA	NA	NA	[""Reintubation and mortality rate in the first 30 days postoperative""]
DRKS00000315	Placebo controlled fMRT assessment of the effects of the cannabinoid receptor agonist dronabinol (THC) on pain associated brain activation	Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix	10.1038/npp.2015.336	NA	2	2010-06-22	Recruiting complete, follow-up complete	2010-07-01	2011-12-31	2015-10-30	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Intensity of brain activation during nociceptive stimulation measured 2 hours after dronabinol application using functional magnetic resonance imaging""]	NA	[""Intensity of brain activation during nociceptive stimulation measured 2 hours after dronabinol application using functional magnetic resonance imaging""]	NA	NA
DRKS00000328	Prospective randomised multi-centre trial (Phase III) on the improvement of cochlear and facial nerve functions after vestibular schwannoma surgery by prophylactic vasoactive treatment.	Stability of hearing preservation and regeneration capacity of the cochlear nerve following vestibular schwannoma surgery via a retrosigmoid approach	10.3171/2015.10.jns15926	https://www.ncbi.nlm.nih.gov/pubmed/26824379	12	2010-02-17	Recruiting complete, follow-up complete	2010-01-27	2013-02-26	2016-01-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Binary outcome value. Deterioration of facial nerve functions 12 month after surgery for at least 1 grade (House-Brackmann classification)""]	[""Binary outcome value. Deterioration of facial nerve functions 12 month after surgery for at least 1 grade (House-Brackmann classification)""]	[""Binary outcome value. Deterioration of facial nerve functions 12 month after surgery for at least 1 grade (House-Brackmann classification)""]	[""Binary outcome value. Deterioration of facial nerve functions 12 month after surgery for at least 1 grade (House-Brackmann classification)""]	NA
DRKS00000337	Effectiveness and cost-analysis of a three-week multimodal inpatient pain treatment for children and adolescents suffering from chronic pain	Inpatient-based intensive interdisciplinary pain treatment for highly impaired children with severe chronic pain: randomized controlled trial of efficacy and economic effects	10.1016/j.pain.2013.09.015	https://www.ncbi.nlm.nih.gov/pubmed/?term=Inpatient-based+intensive+interdisciplinary+pain+treatment+for+highly+impaired+children+with+severe+chronic+pain%3A+Randomized+controlled+trial+of+efficacy+and+economic+effects	11	2010-03-02	Recruiting complete, follow-up complete	2009-11-02	2011-09-07	2013-09-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""To assess the therapeutic effectiveness of the therapy based on a composite endpoint overall amelioration is evaluated. This endpoint is composed of 3 parameters: pain intensity, pain-related disability and pain-related school absence. For these parameters by the method of Jacobson and Truax five outcome groups are determined depending on the occurring change (reliable change) and the value of the follow-up time:\n1. Reliable deterioration\n2. No change with prevalue outside normal range\n(problematic)\n3. No change with prevalue in normal range\n(unproblematic)\n4. Positive change but not clinically\nsignificant\n5. Clinically significant change\n\nThe composite endpoint consists of the following parameters:\na) Mean pain intensity in the last 7 days/ 4 weeks: This parameter is assessed for children between 9, 0 and 10, and 11 using the Faces Pain Scale-Revised. This scale consists of 6 faces, showing from left to right more pain. A numerical rating scale of 0-10 is assigned to the faces, without the children seeing these numbers. Adolescents reported their pain intensity on a NRS (with 0=no pain to 10=maximal pain). Based on findings of the adult area we defined a reduction of -1.74 as clinically relevant change.\nb) Pain-related disability: The P-PDI assesses\ndisability in daily activities due to pain on 12 items rated\non a 5-point scale (1=never to 5=always). The items assess how often the children and adolescents are impaired in daily activities due to pain (score range: 12-60). Owing to large SD for P-PDI in our sample, we defined a change in P-PDI as clinically relevant if the values of a given patient ranges below a 90% interval of the patient population defined as X1 (score at assessment before treatment)?(1.6 SD).\nc) Pain-related school absence: School absence was assessed via parental report as the number of days the child missed school within the preceding 4 weeks or 3 months. A clinically relevant change occurs if there are less than 2 days absent from school in the last four weeks.""]	[""To assess the therapeutic effectiveness of the therapy based on a composite endpoint overall amelioration is evaluated. This endpoint is composed of 3 parameters: pain intensity, pain-related disability and pain-related school absence. For these parameters by the method of Jacobson and Truax five outcome groups are determined depending on the occurring change (reliable change) and the value of the follow-up time:\n1. Reliable deterioration\n2. No change with prevalue outside normal range\n(problematic)\n3. No change with prevalue in normal range\n(unproblematic)\n4. Positive change but not clinically\nsignificant\n5. Clinically significant change\n\nThe composite endpoint consists of the following parameters:\na) Mean pain intensity in the last 7 days/ 4 weeks: This parameter is assessed for children between 9, 0 and 10, and 11 using the Faces Pain Scale-Revised. This scale consists of 6 faces, showing from left to right more pain. A numerical rating scale of 0-10 is assigned to the faces, without the children seeing these numbers. Adolescents reported their pain intensity on a NRS (with 0=no pain to 10=maximal pain). Based on findings of the adult area we defined a reduction of -1.74 as clinically relevant change.\nb) Pain-related disability: The P-PDI assesses\ndisability in daily activities due to pain on 12 items rated\non a 5-point scale (1=never to 5=always). The items assess how often the children and adolescents are impaired in daily activities due to pain (score range: 12-60). Owing to large SD for P-PDI in our sample, we defined a change in P-PDI as clinically relevant if the values of a given patient ranges below a 90% interval of the patient population defined as X1 (score at assessment before treatment)?(1.6 SD).\nc) Pain-related school absence: School absence was assessed via parental report as the number of days the child missed school within the preceding 4 weeks or 3 months. A clinically relevant change occurs if there are less than 2 days absent from school in the last four weeks.""]	[""To assess the therapeutic effectiveness of the therapy based on a composite endpoint overall amelioration is evaluated. This endpoint is composed of 3 parameters: pain intensity, pain-related disability and pain-related school absence. For these parameters by the method of Jacobson and Truax five outcome groups are determined depending on the occurring change (reliable change) and the value of the follow-up time:\n1. Reliable deterioration\n2. No change with prevalue outside normal range\n(problematic)\n3. No change with prevalue in normal range\n(unproblematic)\n4. Positive change but not clinically\nsignificant\n5. Clinically significant change\n\nThe composite endpoint consists of the following parameters:\na) Mean pain intensity in the last 7 days/ 4 weeks: This parameter is assessed for children between 9, 0 and 10, and 11 using the Faces Pain Scale-Revised. This scale consists of 6 faces, showing from left to right more pain. A numerical rating scale of 0-10 is assigned to the faces, without the children seeing these numbers. Adolescents reported their pain intensity on a NRS (with 0=no pain to 10=maximal pain). Based on findings of the adult area we defined a reduction of -1.74 as clinically relevant change.\nb) Pain-related disability: The P-PDI assesses\ndisability in daily activities due to pain on 12 items rated\non a 5-point scale (1=never to 5=always). The items assess how often the children and adolescents are impaired in daily activities due to pain (score range: 12-60). Owing to large SD for P-PDI in our sample, we defined a change in P-PDI as clinically relevant if the values of a given patient ranges below a 90% interval of the patient population defined as X1 (score at assessment before treatment)?(1.6 SD).\nc) Pain-related school absence: School absence was assessed via parental report as the number of days the child missed school within the preceding 4 weeks or 3 months. A clinically relevant change occurs if there are less than 2 days absent from school in the last four weeks.""]	[""To assess the therapeutic effectiveness of the therapy based on a composite endpoint overall amelioration is evaluated. This endpoint is composed of 3 parameters: pain intensity, pain-related disability and pain-related school absence. For these parameters by the method of Jacobson and Truax five outcome groups are determined depending on the occurring change (reliable change) and the value of the follow-up time:\n1. Reliable deterioration\n2. No change with prevalue outside normal range\n(problematic)\n3. No change with prevalue in normal range\n(unproblematic)\n4. Positive change but not clinically\nsignificant\n5. Clinically significant change\n\nThe composite endpoint consists of the following parameters:\na) Mean pain intensity in the last 7 days/ 4 weeks: This parameter is assessed for children between 9, 0 and 10, and 11 using the Faces Pain Scale-Revised. This scale consists of 6 faces, showing from left to right more pain. A numerical rating scale of 0-10 is assigned to the faces, without the children seeing these numbers. Adolescents reported their pain intensity on a NRS (with 0=no pain to 10=maximal pain). Based on findings of the adult area we defined a reduction of -1.74 as clinically relevant change.\nb) Pain-related disability: The P-PDI assesses\ndisability in daily activities due to pain on 12 items rated\non a 5-point scale (1=never to 5=always). The items assess how often the children and adolescents are impaired in daily activities due to pain (score range: 12-60). Owing to large SD for P-PDI in our sample, we defined a change in P-PDI as clinically relevant if the values of a given patient ranges below a 90% interval of the patient population defined as X1 (score at assessment before treatment)?(1.6 SD).\nc) Pain-related school absence: School absence was assessed via parental report as the number of days the child missed school within the preceding 4 weeks or 3 months. A clinically relevant change occurs if there are less than 2 days absent from school in the last four weeks.""]	NA
DRKS00000341	Needlescopic versus transvaginal/transumbilical cholecystectomy: a randomized clinical trial	Transvaginal/transumbilical hybrid--NOTES--versus 3-trocar needlescopic cholecystectomy: short-term results of a randomized clinical trial	10.1097/sla.0000000000000218	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337615/	10	2010-02-24	Recruiting complete, follow-up complete	2010-02-19	2013-01-04	2015-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Intensity of pain in motion measured from operation day to postoperative day 2. This outcome includes a total of 4 measurements.""]	[""Intensity of pain in motion measured from operation day to postoperative day 2. This outcome includes a total of 4 measurements.""]	[""Intensity of pain in motion measured from operation day to postoperative day 2. This outcome includes a total of 4 measurements.""]	[""Intensity of pain in motion measured from operation day to postoperative day 2. This outcome includes a total of 4 measurements.""]	NA
DRKS00000356	Safety evaluation of Hylase® Dessau 150 IU (bovine testicular hyaluronidase) vs. placebo as adjuvant to local anaesthesia in wound healing by means of a suction blister model in healthy volunteers	Clinical trial for safety evaluation of hyaluronidase as diffusion enhancing adjuvant for infiltration analgesia of skin with lidocaine	10.1111/j.1524-4725.2011.02146.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2011.02146.x/full	8	2010-03-03	Recruiting complete, follow-up complete	2010-03-08	NA	2011-09-07	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[""time to suction blister healing\n(defined as TEWL decreased to maximally normal TEWL+25% as measured at the corresponding area of the opposite arm)""]	NA	NA	[""time to suction blister healing\n(defined as TEWL decreased to maximally normal TEWL+25% as measured at the corresponding area of the opposite arm)""]	[""time to suction blister healing\n(defined as TEWL decreased to maximally normal TEWL+25% as measured at the corresponding area of the opposite arm)""]
DRKS00000371	Comparison of extracorporeal liver support systems MARS and SPAD in a cross over design	Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure--a prospective, randomised crossover study	10.1186/s13054-015-1159-3	https://www.ncbi.nlm.nih.gov/pubmed/26728364	7	2010-04-08	Recruiting complete, follow-up complete	2010-08-17	2013-04-18	2016-01-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Changes of serum bilirubin concentrations, blood samples before and after albumin dialysis""]	[""Changes of serum bilirubin concentrations, blood samples before and after albumin dialysis""]	[""Changes of serum bilirubin concentrations, blood samples before and after albumin dialysis""]	NA	NA
DRKS00000390	Prevention of abdominal wound infection: PROUD-Trial A randomized controlled trial	Effectiveness of triclosan-coated PDS Plus versus uncoated PDS II sutures for prevention of surgical site infection after abdominal wall closure: the randomised controlled PROUD trial	10.1016/s0140-6736(14)60238-5	https://www.ncbi.nlm.nih.gov/pubmed/24718270	17	2010-04-27	Recruiting complete, follow-up complete	2010-04-07	2012-11-18	2014-04-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Wound infection (deep and superficial according to CDC definition) within 30 days after surgery""]	[""Wound infection (deep and superficial according to CDC definition) within 30 days after surgery""]	[""Wound infection (deep and superficial according to CDC definition) within 30 days after surgery""]	[""Wound infection (deep and superficial according to CDC definition) within 30 days after surgery""]	NA
DRKS00000396	Exploratory, Randomized, Cross-over Physiological Examination of Capability to Swallow and Acceptability of Two Oral Placebo Formulations for Children of Six Different Age Groups	Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study	10.1136/archdischild-2011-300958	NA	4	2010-09-03	Recruiting complete, follow-up complete	2010-05-18	2010-06-16	2012-01-17	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""To investigate differences in the capability of children of six paediatric age groups to swallow two different oral placebo formulations.\n\nTo investigate differences in the acceptability of two different oral placebo formulations in six paediatric age groups.\n\nThese parameters are collected right after oral application by oral inspection.""]	NA	[""To investigate differences in the capability of children of six paediatric age groups to swallow two different oral placebo formulations.\n\nTo investigate differences in the acceptability of two different oral placebo formulations in six paediatric age groups.\n\nThese parameters are collected right after oral application by oral inspection.""]	[""To investigate differences in the capability of children of six paediatric age groups to swallow two different oral placebo formulations.\n\nTo investigate differences in the acceptability of two different oral placebo formulations in six paediatric age groups.\n\nThese parameters are collected right after oral application by oral inspection.""]	NA
DRKS00000397	Selective Tissue elevation by pressure injection (STEP 2)	Submucosal injection with waterjet improves endoscopic mucosal resection of colorectal adenoma - a randomised controlled clinical trial	10.1080/00365521.2016.1246606	https://www.ncbi.nlm.nih.gov/pubmed/27797282	12	2010-04-21	Recruiting complete, follow-up complete	2007-11-16	2012-03-30	2016-10-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Intervention time""]	[""Intervention time""]	[""Intervention time""]	NA	NA
DRKS00000419	Prospective randomized study for the comparision of two different reconstructive regarding the incidence of pancreatic fistula and other complications following partial pancreaticoduodenectomy	Randomized controlled single-center trial comparing pancreatogastrostomy versus pancreaticojejunostomy after partial pancreatoduodenectomy	10.1007/s11605-012-1940-4	NA	9	2010-06-07	Recruiting complete, follow-up complete	2006-03-31	2011-06-30	2012-06-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""postoperative pancreatic fistula\nsurvival at 90 days postoperatively""]	[""postoperative pancreatic fistula\nsurvival at 90 days postoperatively""]	[""postoperative pancreatic fistula\nsurvival at 90 days postoperatively""]	[""postoperative pancreatic fistula\nsurvival at 90 days postoperatively""]	NA
DRKS00000423	Effects of Ginkgo biloba extract (EGb 761®) on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in adult healthy volunteers	Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial	10.1002/hup.2534	http://onlinelibrary.wiley.com/doi/10.1002/hup.2534/full	7	2010-06-07	Recruiting complete, follow-up complete	2010-10-04	2012-04-23	2016-05-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""none""]	[""none""]	[""none""]	NA	NA
DRKS00000432	Randomized, Cross-over Physiological Examination of Acceptability and Capability to Swallow Three Oral Placebo Formulations for Children of Six Different Age Groups	Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children	10.1016/j.jpeds.2013.07.014	NA	4	2011-04-01	Recruiting complete, follow-up complete	2011-02-14	2011-05-31	2013-08-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""To prove that the acceptability of the uncoated minitablet is superior to the acceptability of the syrup in the group of children between 0.5 and 5 years inclusive.\n\nThese parameters are collected right after oral application by oral inspection.""]	[""To prove that the acceptability of the uncoated minitablet is superior to the acceptability of the syrup in the group of children between 0.5 and 5 years inclusive.\n\nThese parameters are collected right after oral application by oral inspection.""]	[""To prove that the acceptability of the uncoated minitablet is superior to the acceptability of the syrup in the group of children between 0.5 and 5 years inclusive.\n\nThese parameters are collected right after oral application by oral inspection.""]	[""To prove that the acceptability of the uncoated minitablet is superior to the acceptability of the syrup in the group of children between 0.5 and 5 years inclusive.\n\nThese parameters are collected right after oral application by oral inspection.""]	NA
DRKS00000446	Effect of an automatic continuous positive airway pressure (APAP) ventilation therapy on exercise capacity in patients with congestive heart failure and obstructive sleep apnoea	Automatic positive airway pressure for obstructive sleep apnea in heart failure with reduced ejection fraction	10.1007/s00392-020-01701-1	https://link.springer.com/article/10.1007/s00392-020-01701-1#article-info	10	2010-06-29	Recruiting complete, follow-up complete	2009-02-12	2016-11-23	2020-07-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Changes in maximum oxygen uptake (VO2 peak) and oxygen uptake at the aerobic-anaerob threshold (VO2 AT) during cardiopulmonary exercise testing after 6 months""]	[""Changes in maximum oxygen uptake (VO2 peak) and oxygen uptake at the aerobic-anaerob threshold (VO2 AT) during cardiopulmonary exercise testing after 6 months""]	[""Changes in maximum oxygen uptake (VO2 peak) and oxygen uptake at the aerobic-anaerob threshold (VO2 AT) during cardiopulmonary exercise testing after 6 months""]	[""Changes in maximum oxygen uptake (VO2 peak) and oxygen uptake at the aerobic-anaerob threshold (VO2 AT) during cardiopulmonary exercise testing after 6 months""]	NA
DRKS00000449	Oxygenation during noninvasive ventilation: active valve- versus leak-circuit	Oxygen supplementation in noninvasive home mechanical ventilation: the crucial roles of CO2 exhalation systems and leakages	10.4187/respcare.02596	https://www.ncbi.nlm.nih.gov/pubmed/23801785	5	2010-10-05	Recruiting complete, follow-up complete	2009-12-11	2010-08-05	2013-06-25	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Difference of FiO2 at FiO2-sensor 2 (at the interface) between active valve circuit and leak circuit""]	NA	[""Difference of FiO2 at FiO2-sensor 2 (at the interface) between active valve circuit and leak circuit""]	[""Difference of FiO2 at FiO2-sensor 2 (at the interface) between active valve circuit and leak circuit""]	NA
DRKS00000450	Impact of target-volume noninvasive positive pressure ventilation on sleep: A randomized cross-over trial	Home mechanical ventilation for COPD: high-intensity versus target volume noninvasive ventilation	10.4187/respcare.02941	https://www.ncbi.nlm.nih.gov/pubmed/25074944	5	2010-10-05	Recruiting complete, follow-up complete	2010-02-16	2011-02-15	2014-07-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Sleep efficiency (comparison between NPPV with and without target volume)""]	[""Sleep efficiency (comparison between NPPV with and without target volume)""]	[""Sleep efficiency (comparison between NPPV with and without target volume)""]	[""Sleep efficiency (comparison between NPPV with and without target volume)""]	NA
DRKS00000454	Effectiveness of Yoga in patients with chronic neck pain. A randomized controlled trial.	Yoga for chronic neck pain: a pilot randomized controlled clinical trial	10.1016/j.jpain.2012.08.004	http://www.sciencedirect.com/science/article/pii/S1526590012007791	4	2011-04-01	Recruiting complete, follow-up complete	2010-02-19	2010-08-30	2012-10-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""100 mm VAS for average neck pain/cervical spine pain intensity during the last week, baseline (week 0) versus end (week 9).""]	NA	[""100 mm VAS for average neck pain/cervical spine pain intensity during the last week, baseline (week 0) versus end (week 9).""]	NA	NA
DRKS00000460	Effectiveness of mindfulness meditation for neck pain: a randomized controlled trial	Effectiveness of jyoti meditation for patients with chronic neck pain and psychological distress--a randomized controlled clinical trial	10.1016/j.jpain.2014.10.009	http://www.sciencedirect.com/science/article/pii/S1526590014009961	4	2010-08-13	Recruiting complete, follow-up complete	2010-04-20	2011-03-24	2015-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""100 mm VAS for average neck pain/cervical spine pain intensity during the last week""]	[""100 mm VAS for average neck pain/cervical spine pain intensity during the last week""]	[""100 mm VAS for average neck pain/cervical spine pain intensity during the last week""]	NA	NA
DRKS00000467	Pathophysiology of Cheyne-Stokes respiration: lowering of the pulmonary capillary wedge pressure as a causal therapeutic option	Acute improvement of pulmonary hemodynamics does not alleviate Cheyne-Stokes respiration in chronic heart failure-a randomized, controlled, double-blind, crossover trial	10.1007/s11325-015-1300-1	https://www.ncbi.nlm.nih.gov/pubmed/?term=DRKS00000467	7	2010-06-30	Recruiting complete, follow-up complete	2010-07-19	2011-11-26	2016-01-19	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Is lowering of PCWP associated with an improvement in severity of Cheyne-Stokes respiration (apnoea-hypopniea index, AHI)?\n\nMeasurement of PCWP during daytime, using right-heart catheterization. Measurement of AHI with nocturnal sleep studies (polysomnography)""]	NA	[""Is lowering of PCWP associated with an improvement in severity of Cheyne-Stokes respiration (apnoea-hypopniea index, AHI)?\n\nMeasurement of PCWP during daytime, using right-heart catheterization. Measurement of AHI with nocturnal sleep studies (polysomnography)""]	[""Is lowering of PCWP associated with an improvement in severity of Cheyne-Stokes respiration (apnoea-hypopniea index, AHI)?\n\nMeasurement of PCWP during daytime, using right-heart catheterization. Measurement of AHI with nocturnal sleep studies (polysomnography)""]	NA
DRKS00000486	prevention of depressive episodes on patients with Inflammatory Bowel Diesease	NA	NA	https://elibrary.klett-cotta.de/article/99.120110/aep-8-3-175	8	2011-08-26	Recruiting complete, follow-up complete	2010-08-30	2011-12-22	2013-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale)\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale)\n\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale)\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale)\n\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale).\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale).\n\nto compare both groups: IBDQ-D (Inflammatoy-bowel-disease-questionnaire - german version).\nlevel of diesase-specific quality of life.\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale).\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale).\n\nto compare both groups: IBDQ-D (Inflammatoy-bowel-disease-questionnaire - german version).\nlevel of diesase-specific quality of life.\n""]	NA
DRKS00000494	Join the Healthy Boat - Primary School	Intervention effects of a school-based health promotion programme on obesity related behavioural outcomes	10.1155/2014/476230	https://www.hindawi.com/journals/jobe/2014/476230/	6	2010-08-25	Recruiting complete, follow-up complete	2010-07-01	2011-11-30	2014-09-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary outcomes are the reduction of increases of age related growth in the anthropometric parameters like subscapular skin fold thickness, abdominal circumference and the covered distance in a six-minute-run as difference between the follow-up measurements and baseline measurements.\nFor this purpose, trained teams will test not only the children’s motor skills but also carry out physical examinations within a regular school day at two points in time.\n""]	[""Primary outcomes are the reduction of increases of age related growth in the anthropometric parameters like subscapular skin fold thickness, abdominal circumference and the covered distance in a six-minute-run as difference between the follow-up measurements and baseline measurements.\nFor this purpose, trained teams will test not only the children’s motor skills but also carry out physical examinations within a regular school day at two points in time.\n""]	[""Primary outcomes are the reduction of increases of age related growth in the anthropometric parameters like subscapular skin fold thickness, abdominal circumference and the covered distance in a six-minute-run as difference between the follow-up measurements and baseline measurements.\nFor this purpose, trained teams will test not only the children’s motor skills but also carry out physical examinations within a regular school day at two points in time.\n""]	[""Primary outcomes are the reduction of increases of age related growth in the anthropometric parameters like subscapular skin fold thickness, abdominal circumference and the covered distance in a six-minute-run as difference between the follow-up measurements and baseline measurements.\nFor this purpose, trained teams will test not only the children’s motor skills but also carry out physical examinations within a regular school day at two points in time.\n""]	NA
DRKS00000520	Quality of sleep during noninvasive positive pressure ventilation with high inspiratory pressures in patients with stable hypercapnic COPD	Noninvasive ventilation in COPD: impact of inspiratory pressure levels on sleep quality	10.1378/chest.11-0253	NA	4	2010-10-05	Recruiting complete, follow-up complete	2008-02-10	2010-08-05	2011-05-12	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Polysomnographic assessment of NREM sleep stage 3 and 4 during nighttime noninvasive ventilation""]	NA	[""Polysomnographic assessment of NREM sleep stage 3 and 4 during nighttime noninvasive ventilation""]	[""Polysomnographic assessment of NREM sleep stage 3 and 4 during nighttime noninvasive ventilation""]	NA
DRKS00000534	The impact of noise on patients of the intensive care units - evaluation of active and passive noise reducing methods	Psychoacoustic analysis of noise and the application of earplugs in an ICU: A randomised controlled clinical trial	10.1097/eja.0000000000000313	NA	7	2010-09-29	Recruiting complete, follow-up complete	2010-11-04	2011-05-26	2016-01-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""salivatory cortisol and alpha-amylase, taken at 8pm, 11pm, 3am, 6am.""]	[""salivatory cortisol and alpha-amylase, taken at 8pm, 11pm, 3am, 6am.""]	[""salivatory cortisol and alpha-amylase, taken at 8pm, 11pm, 3am, 6am.""]	NA	NA
DRKS00000539	Efficacy of a combined shared decision-making intervention including a training program for oncologists and decision aids for breast and colon cancer patients	Shared Decision Making and the Use of Decision Aids	10.3238/arztebl.2015.0672	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640071/	5	2010-10-07	Recruiting complete, follow-up complete	2010-01-27	2012-06-05	2015-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""1) Decisional Conflict (Decisional Conflict Scale; O'Connor et al., 2005).\n2) Saticfaction with Decision (Saticfaction with Decision Scale; Holmes-Rovner, 1996)\n\nBoth primary endpoints are assessed by psychometrically defined scales. Patients complete a questionnaire including these scales immediately after the medical consultation. We expect the decisional conflict to be lower and the satisfaction with decision to be higher in the intervention group, compared with the control group.""]	[""1) Decisional Conflict (Decisional Conflict Scale; O'Connor et al., 2005).\n2) Saticfaction with Decision (Saticfaction with Decision Scale; Holmes-Rovner, 1996)\n\nBoth primary endpoints are assessed by psychometrically defined scales. Patients complete a questionnaire including these scales immediately after the medical consultation. We expect the decisional conflict to be lower and the satisfaction with decision to be higher in the intervention group, compared with the control group.""]	[""1) Decisional Conflict (Decisional Conflict Scale; O'Connor et al., 2005).\n2) Saticfaction with Decision (Saticfaction with Decision Scale; Holmes-Rovner, 1996)\n\nBoth primary endpoints are assessed by psychometrically defined scales. Patients complete a questionnaire including these scales immediately after the medical consultation. We expect the decisional conflict to be lower and the satisfaction with decision to be higher in the intervention group, compared with the control group.""]	[""1) Decisional Conflict (Decisional Conflict Scale; O'Connor et al., 2005).\n2) Saticfaction with Decision (Saticfaction with Decision Scale; Holmes-Rovner, 1996)\n\nBoth primary endpoints are assessed by psychometrically defined scales. Patients complete a questionnaire including these scales immediately after the medical consultation. We expect the decisional conflict to be lower and the satisfaction with decision to be higher in the intervention group, compared with the control group.""]	NA
DRKS00000542	Treatment of Binge eating disorder in adolescents	Cognitive-Behavioral Therapy for Adolescents with an Age-Adapted Diagnosis of Binge-Eating Disorder: A Randomized Clinical Trial	10.1159/000503116	https://www.karger.com/Article/Abstract/503116	17	2012-05-22	Recruiting complete, follow-up complete	2012-04-27	2016-12-07	2019-09-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[""Number of binge eating days during the last 28 days before end of treatment or rather waiting phase (4 months after randomization for CBT and WL) using EDE interview (eating disorder examination) and EDE-questionnaire""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	NA
DRKS00000549	The surgical treatment of obstructive sleep apnea (OSA) using tonsillectomy with uvulapalatopharyngoplasty - A clinical randomized study	Tonsillectomy with Uvulopalatopharyngoplasty in Obstructive Sleep Apnea	10.3238/arztebl.2016.0001	NA	5	2010-09-08	Recruiting complete, follow-up complete	2010-09-15	2015-01-12	2016-01-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""respiratory parameter of polysomnography (AI, AHI, RDI, ODI)\nquality of sleep parameter in polysomnography (Arousal-Index, Sleep-Efficency, Sleep-Stages)""]	[""respiratory parameter of polysomnography (AI, AHI, RDI, ODI)\nquality of sleep parameter in polysomnography (Arousal-Index, Sleep-Efficency, Sleep-Stages)""]	[""respiratory parameter of polysomnography (AI, AHI, RDI, ODI)\nquality of sleep parameter in polysomnography (Arousal-Index, Sleep-Efficency, Sleep-Stages)""]	[""respiratory parameter of polysomnography (AI, AHI, RDI, ODI)\nquality of sleep parameter in polysomnography (Arousal-Index, Sleep-Efficency, Sleep-Stages)""]	NA
DRKS00000550	Day clinic and inpatient psychotherapy of depression – a randomized controlled 		pilot study	Day-clinic and inpatient psychotherapy for depression (DIP-D): a randomized controlled pilot study in routine clinical care	10.1159/000357437	https://www.karger.com/Article/FullText/357437	4	2010-11-25	Recruiting complete, follow-up complete	2011-02-01	2012-12-31	2014-04-17	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary Outcome of the study are depressive symptoms 3 months after termination of therapy. The primary outcome will be rated by trained observes with the Hamilton Ratings Scale of Depression (HAM-D).""]	[""Primary Outcome of the study are depressive symptoms 3 months after termination of therapy. The primary outcome will be rated by trained observes with the Hamilton Ratings Scale of Depression (HAM-D).""]	[""Primary Outcome of the study are depressive symptoms 3 months after termination of therapy. The primary outcome will be rated by trained observes with the Hamilton Ratings Scale of Depression (HAM-D).""]	[""Primary Outcome of the study are depressive symptoms 3 months after termination of therapy. The primary outcome will be rated by trained observes with the Hamilton Ratings Scale of Depression (HAM-D).""]	NA
DRKS00000555	Effects of quercetin on blood pressure and endothelial function in subjects with a high CVD risk phenotype (clinical intervention study)	Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial	10.1017/s0007114515002950	https://www.ncbi.nlm.nih.gov/pubmed/26328470	6	2010-12-22	Recruiting complete, follow-up complete	2011-05-01	2012-03-21	2015-09-02	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Systolic and diastolic blood pressure; measurement at the beginning of the study, after 3 and after 6 weeks; measurement at the upper arm with a validated blood pressure instrument according to the method of Riva Rocci and Korotkow""]	[""Systolic and diastolic blood pressure; measurement at the beginning of the study, after 3 and after 6 weeks; measurement at the upper arm with a validated blood pressure instrument according to the method of Riva Rocci and Korotkow""]	[""Systolic and diastolic blood pressure; measurement at the beginning of the study, after 3 and after 6 weeks; measurement at the upper arm with a validated blood pressure instrument according to the method of Riva Rocci and Korotkow""]	[""Systolic and diastolic blood pressure; measurement at the beginning of the study, after 3 and after 6 weeks; measurement at the upper arm with a validated blood pressure instrument according to the method of Riva Rocci and Korotkow""]	NA
DRKS00000570	Transfer of manualized Short Term Psychodynamic Psychotherapy (STPP based on SET) for Social Phobia into clinical practice	Transfer of manualized Short Term Psychodynamic Psychotherapy (STPP) for social anxiety disorder into clinical practice: results from a cluster-randomised controlled trial	10.1186/s12888-017-1257-7	NA	4	2011-03-03	Recruiting complete, follow-up complete	2011-04-26	2015-06-09	2017-03-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary endpoint: assessment after 25 sessions;\nPrimary outcome measure: Liebowitz Social Anxiety Scale (LSAS) <= 30 (remission).""]	[""Primary endpoint: assessment after 25 sessions;\nPrimary outcome measure: Liebowitz Social Anxiety Scale (LSAS) <= 30 (remission).""]	[""Primary endpoint: assessment after 25 sessions;\nPrimary outcome measure: Liebowitz Social Anxiety Scale (LSAS) <= 30 (remission).""]	[""Primary endpoint: assessment after 25 sessions;\nPrimary outcome measure: Liebowitz Social Anxiety Scale (LSAS) <= 30 (remission).""]	NA
DRKS00000579	CRAIL-study: Prospektive randomized multicenter study for optimization of therapy of the acute ischemic limb by controlled reperfusion.	Controlled reperfusion versus conventional treatment of the acutely ischemic limb: results of a randomized, open-label, multicenter trial	10.1161/circinterventions.112.000371	NA	3	2010-10-15	Recruiting stopped after recruiting started	2002-09-30	2009-01-13	2013-07-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""survival free of amputation (after 4 weeks)""]	NA	[""survival free of amputation (after 4 weeks)""]	[""survival free of amputation (after 4 weeks)""]	NA
DRKS00000623	Decompressive Surgery Plus Hypothermia for Space occupying Stroke (Depth-SOS)	Outcomes of Hypothermia in Addition to Decompressive Hemicraniectomy in Treatment of Malignant Middle Cerebral Artery Stroke: A Randomized Clinical Trial	10.1001/jamaneurol.2018.4822	https://jamanetwork.com/journals/jamaneurology/fullarticle/2721091	14	2011-03-21	Recruiting complete, follow-up complete	2011-04-01	2016-09-08	2019-01-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The primary endpoint is mortality at discharge (day 14).""]	[""The primary endpoint is mortality at discharge (day 14).""]	[""The primary endpoint is mortality at discharge (day 14).""]	[""The primary endpoint is mortality at discharge (day 14).""]	NA
DRKS00000644	Clinical application of CAD/CAM manufactured fixed partial dentures as long-term provisionasl made from PMMA	First clinical experiences with CAD/CAM-fabricated PMMA-based fixed dental prostheses as long-term temporaries	10.1007/s00784-015-1475-7	https://www.ncbi.nlm.nih.gov/pubmed/?term=First+clinical+experiences+with+CAD%2FCAM-fabricated+PMMA-based+fixed+dental+prostheses+as+long-term+temporaries	3	2013-06-24	Recruiting complete, follow-up complete	2009-03-23	2013-01-14	2015-04-22	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""90% free of complication within 2 years of clinical service OR among 5% incidence of complication which call for interventions""]	NA	[""90% free of complication within 2 years of clinical service OR among 5% incidence of complication which call for interventions""]	[""90% free of complication within 2 years of clinical service OR among 5% incidence of complication which call for interventions""]	NA
DRKS00000651	Efficacy of conservative treatment regime for hip osteoarthritis - Evaluation of the therapeutic exercise regime ""Hipschool""	Exercise therapy in hip osteoarthritis--a randomized controlled trial	10.3238/arztebl.2014.0592	https://www.aerzteblatt.de/int/archive/article/161393	7	2011-03-08	Recruiting complete, follow-up complete	2010-08-20	2013-01-22	2014-07-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Subscale Pain SF36. M2 versus M1. Comparison of Hipschool versus no intervention.""]	[""Subscale Pain SF36. M2 versus M1. Comparison of Hipschool versus no intervention.""]	[""Subscale Pain SF36. M2 versus M1. Comparison of Hipschool versus no intervention.""]	[""Subscale Pain SF36. M2 versus M1. Comparison of Hipschool versus no intervention.""]	NA
DRKS00000662	A telephone- and text-message based telemedical care concept for patients with mental health disorders	A Telephone- and Text Message-Based Telemedicine Concept for Patients with Mental Health Disorders: Results of a Randomized Controlled Trial	10.1159/000369468	https://www.ncbi.nlm.nih.gov/pubmed/25721861	3	2011-01-24	Recruiting complete, follow-up complete	2009-09-01	2013-01-31	2015-02-21	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Primary outcome of the study ist the evaluation of the effects of the telemedical interventions on psychopathological outcomes. Psychopathological outcomes are measured after 6 months in the context of a telephone interview using the questionnaire BSI 18.\n""]	[""Primary outcome of the study ist the evaluation of the effects of the telemedical interventions on psychopathological outcomes. Psychopathological outcomes are measured after 6 months in the context of a telephone interview using the questionnaire BSI 18.\n""]	NA	[""Primary outcome of the study ist the evaluation of the effects of the telemedical interventions on psychopathological outcomes. Psychopathological outcomes are measured after 6 months in the context of a telephone interview using the questionnaire BSI 18.\n""]	NA
DRKS00000666	Effect of remote preconditioning on contrast medium induced renal failure	Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial)	10.1161/circulationaha.112.096370	http://circ.ahajournals.org/content/126/3/296.long	6	2011-01-04	Recruiting complete, follow-up complete	2011-01-06	2011-05-30	2012-06-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Incidence of contrast medium induced nephropathy, defined as increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake.""]	[""Incidence of contrast medium induced nephropathy, defined as increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake.""]	[""Incidence of contrast medium induced nephropathy, defined as increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake.""]	[""Incidence of contrast medium induced nephropathy, defined as increment of serum-creatinin of 0.5 mg/dl or of at least 25% in 48 hours after contrast medium intake.""]	NA
DRKS00000671	Evaluation of an integrative therapy approach for the comorbidity of psychosis and addiction.	Trans-Sector Integrated Treatment in Psychosis and Addiction	10.3238/arztebl.2015.0683	https://www.aerzteblatt.de/int/archive/article?id=172416	16	2011-03-02	Recruiting complete, follow-up complete	2011-01-18	2013-07-05	2015-10-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""- change/reduction of drug consumption\n- motivation of change the drug consumption\n\nquesstionaries: criteries of their drugs, motivation of change\n""]	[""- change/reduction of drug consumption\n- motivation of change the drug consumption\n\nquesstionaries: criteries of their drugs, motivation of change\n""]	[""- change/reduction of drug consumption\n- motivation of change the drug consumption\n\nquesstionaries: criteries of their drugs, motivation of change\n""]	[""- change/reduction of drug consumption\n- motivation of change the drug consumption\n\nquesstionaries: criteries of their drugs, motivation of change\n""]	NA
DRKS00000688	Invasive versus non-invasive methods of blood gas measurement	Spot check analysis of gas exchange: invasive versus noninvasive methods	10.1159/000371769	NA	4	2011-02-23	Recruiting complete, follow-up complete	2010-09-08	2011-02-14	2015-03-18	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""method comparison of transcutaneous PO2 and capillary PaO2 at right ear, each with the goldstandard PaO2""]	NA	[""method comparison of transcutaneous PO2 and capillary PaO2 at right ear, each with the goldstandard PaO2""]	NA	NA
DRKS00000691	Strain-counterstrain to treat restrictions of the mobility of the cervical spine - a randomized trial	Strain-counterstrain to treat restrictions of the mobility of the cervical spine in patients with neck pain: a sham-controlled randomized trial	10.1016/j.ctim.2012.11.003	https://www.ncbi.nlm.nih.gov/pubmed/23374199	5	2011-02-02	Recruiting complete, follow-up complete	2011-02-06	2011-08-03	2012-12-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Main outcome measure is the sum of changes (in %) in mobility restriction (measured with the CROM) after treatment compared to normal mobility.""]	[""Main outcome measure is the sum of changes (in %) in mobility restriction (measured with the CROM) after treatment compared to normal mobility.""]	[""Main outcome measure is the sum of changes (in %) in mobility restriction (measured with the CROM) after treatment compared to normal mobility.""]	[""Main outcome measure is the sum of changes (in %) in mobility restriction (measured with the CROM) after treatment compared to normal mobility.""]	NA
DRKS00000696	Fear of coronary artery bypass surgery: What do patients experience as helpful?	Anxiety and fear in patients with short waiting times before coronary artery bypass surgery--a qualitative study	10.1111/jocn.12467	NA	5	2011-01-19	Recruiting complete, follow-up complete	2010-06-01	2012-04-30	2013-12-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""change in situational fear before the operation before and after intervention (STOA-S, linear fear scale)""]	[""change in situational fear before the operation before and after intervention (STOA-S, linear fear scale)""]	[""change in situational fear before the operation before and after intervention (STOA-S, linear fear scale)""]	[""change in situational fear before the operation before and after intervention (STOA-S, linear fear scale)""]	NA
DRKS00000697	COSTA - Closure of median sternotomy in high-risk patients with the sternal talon system	The COSTA Study: Sternal Closure in High-Risk Patients - A Prospective Randomized Multicenter Trial	10.1055/s-0037-1618584	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0037-1618584	5	2011-01-19	Recruiting complete, follow-up complete	2008-12-01	2014-05-02	2018-02-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Incidence of mediastinitis or sternal instability within the first 30 (+/- 5) days after primary sternal closure""]	[""Incidence of mediastinitis or sternal instability within the first 30 (+/- 5) days after primary sternal closure""]	[""Incidence of mediastinitis or sternal instability within the first 30 (+/- 5) days after primary sternal closure""]	[""Incidence of mediastinitis or sternal instability within the first 30 (+/- 5) days after primary sternal closure""]	NA
DRKS00000710	Continuous positive airway pressure during stair climbing in patients with very severe COPD	The effect of continuous positive airway pressure on stair-climbing performance in severe COPD patients	10.3109/15412555.2012.734872	http://www.tandfonline.com/doi/full/10.3109/15412555.2012.734872	6	2011-02-01	Recruiting complete, follow-up complete	2008-12-01	2010-09-01	2013-04-02	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""absolute difference in blood gas parameters (PaO2, PaCO2, pH) measured prior and post intervention""]	NA	[""absolute difference in blood gas parameters (PaO2, PaCO2, pH) measured prior and post intervention""]	[""absolute difference in blood gas parameters (PaO2, PaCO2, pH) measured prior and post intervention""]	NA
DRKS00000711	Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion	Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)	10.1007/s00417-013-2528-8	https://www.ncbi.nlm.nih.gov/pubmed/24346235	4	2011-02-17	Recruiting complete, follow-up complete	2011-03-01	2012-09-18	2013-12-18	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Change in the best corrected visual acuity (BCVA) from baseline to 6 months (week 24)measured in ETDRS letters""]	[""Change in the best corrected visual acuity (BCVA) from baseline to 6 months (week 24)measured in ETDRS letters""]	[""Change in the best corrected visual acuity (BCVA) from baseline to 6 months (week 24)measured in ETDRS letters""]	NA	NA
DRKS00000713	Quality of sleep during conventional noninvasive ventilation and noninvasive ventilation with „intelligent volume assured pressure support (iVAPS)“	Impact of intelligent volume-assured pressure support on sleep quality in stable hypercapnic chronic obstructive pulmonary disease patients: a randomized, crossover study	10.1159/000364946	NA	5	2011-02-24	Recruiting complete, follow-up complete	2011-01-05	2011-11-15	2014-08-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""sleep efficiency (percentage of sleep time compared to \""total in bed time\"")""]	[""sleep efficiency (percentage of sleep time compared to \""total in bed time\"")""]	[""Stadium 3/4 sleep (assessed by polysomnography)""]	[""Stadium 3/4 sleep (assessed by polysomnography)""]	NA
DRKS00000715	Evaluation of endotracheal intubation performed with a semirigid endoscope (Bonfils-Fibrescope) in toddlers and infants.	A randomized controlled comparison of the Bonfils fiberscope and the GlideScope Cobalt AVL video laryngoscope for visualization of the larynx and intubation of the trachea in infants and small children with normal airways	10.1111/pan.12137	http://onlinelibrary.wiley.com/doi/10.1111/pan.12137/abstract	10	2011-02-07	Recruiting complete, follow-up complete	2011-03-01	2013-03-15	2013-03-18	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[""time needed for intubation, measured with a stop-watch""]	[""time needed for intubation, from touching the instruments until firts Ventilation with measured exhaled CO2, measured with a stop-watch during intubation""]	NA	[""time needed for intubation, from touching the instruments until firts Ventilation with measured exhaled CO2, measured with a stop-watch during intubation""]	NA
DRKS00000738	Intervention study of school refusing students and truants in Essen	The Treatment of School Avoidance in Children and Adolescents With Psychiatric Illness	10.3238/arztebl.2015.0655	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627210/	4	2011-09-28	Recruiting complete, follow-up complete	2011-03-01	2013-10-01	2015-09-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Percentage of attended school lessons within the five school days before the initial interview, after 16 weeks (post), after 26 (follow-up 1) and after 52 weeks (follow-up 2), each with teachers’ and parents’ information. For data analysis teachers’ information are favored. If teachers’ information are not available, parents’ information are used. The data are surveyed using the SV-outcome-questionnaire.""]	[""Percentage of attended school lessons within the five school days before the initial interview, after 16 weeks (post), after 26 (follow-up 1) and after 52 weeks (follow-up 2), each with teachers’ and parents’ information. For data analysis teachers’ information are favored. If teachers’ information are not available, parents’ information are used. The data are surveyed using the SV-outcome-questionnaire.""]	[""Percentage of attended school lessons within the five school days before the initial interview, after 16 weeks (post), after 26 (follow-up 1) and after 52 weeks (follow-up 2), each with teachers’ and parents’ information. For data analysis teachers’ information are favored. If teachers’ information are not available, parents’ information are used. The data are surveyed using the SV-outcome-questionnaire.""]	[""Percentage of attended school lessons within the five school days before the initial interview, after 16 weeks (post), after 26 (follow-up 1) and after 52 weeks (follow-up 2), each with teachers’ and parents’ information. For data analysis teachers’ information are favored. If teachers’ information are not available, parents’ information are used. The data are surveyed using the SV-outcome-questionnaire.""]	NA
DRKS00000741	Sepsis survivors Monitoring and coordination in Outpatient Health care	Effect of a Primary Care Management Intervention on Mental Health-Related Quality of Life Among Survivors of Sepsis: A Randomized Clinical Trial	10.1001/jama.2016.7207	https://pubmed.ncbi.nlm.nih.gov/27367877/	5	2011-03-02	Recruiting complete, follow-up complete	2011-02-28	2015-12-31	2016-06-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Health related quality of life / Physical Health Summary Scale (SF-36 – Patient survey) after 6 months""]	[""Health related quality of life / Physical Health Summary Scale (SF-36 – Patient survey) after 6 months""]	NA	[""Health related quality of life / Physical Health Summary Scale (SF-36 – Patient survey) after 6 months""]	NA
DRKS00000747	Physiological reactions in virtual reality in acrophobia	Fear and physiological arousal during a virtual height challenge--effects in patients with acrophobia and healthy controls	10.1016/j.janxdis.2015.10.007	https://www.ncbi.nlm.nih.gov/pubmed/?term=Fear+and+physiological+arousal+during+a+virtual+height+challenge%E2%80%94effects+in+patients+with+acrophobia+and+healthy+controls	12	2011-03-04	Recruiting complete, follow-up complete	2011-03-04	2013-11-18	2015-11-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Severity of acophobic symptoms, evalued wiht Acrophobia Questionnaire (before and after each of the 3 exposures) and SUDS (Subjective Units of Discomfort; assessed during each of the 3 exposures)\n""]	[""Severity of acophobic symptoms, evalued wiht Acrophobia Questionnaire (before and after each of the 3 exposures) and SUDS (Subjective Units of Discomfort; assessed during each of the 3 exposures)\n""]	[""Severity of acophobic symptoms, evalued wiht Acrophobia Questionnaire (before and after each of the 3 exposures) and SUDS (Subjective Units of Discomfort; assessed during each of the 3 exposures)\n""]	[""Severity of acophobic symptoms, evalued wiht Acrophobia Questionnaire (before and after each of the 3 exposures) and SUDS (Subjective Units of Discomfort; assessed during each of the 3 exposures)\n""]	NA
DRKS00000751	Impact of a postoperative short term NIV  on lung function and oxygenation	Short term non-invasive ventilation post-surgery improves arterial blood-gases in obese subjects compared to supplemental oxygen delivery - a randomized controlled trial	10.1186/1471-2253-11-10	https://www.ncbi.nlm.nih.gov/pubmed/21605450	2	2011-04-06	Recruiting complete, follow-up complete	2009-01-05	2010-09-01	2011-05-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Postoperative spirometric lung function (Measured parameters FEV1 - forced expiratory lung volume/1s , FVC-forced vital capacity ,MEF25-75 - mid expiratory flow 25-75%, PEF - peak expiratory flow, FIVC - forced inspiratory vital capacity, PIF - peak inspiratory flow) measurements at the respective fixed time points after achieving a fast track score >10 (White et al).T0h= after achieving a fast track score >10, all patients included have to achieve a fast-track score >10 within 20 minutes after surgery. All further time points are fixed time points after surgery.T1h = 1 hour after surgery, T2h = 2 hours after surgery, T6h = 6hours after surgery after first mobilisation of the patients. T24h= 24 hours after surgery""]	NA	[""Postoperative spirometric lung function (Measured parameters FEV1 - forced expiratory lung volume/1s , FVC-forced vital capacity ,MEF25-75 - mid expiratory flow 25-75%, PEF - peak expiratory flow, FIVC - forced inspiratory vital capacity, PIF - peak inspiratory flow) measurements at the respective fixed time points after achieving a fast track score >10 (White et al).T0h= after achieving a fast track score >10, all patients included have to achieve a fast-track score >10 within 20 minutes after surgery. All further time points are fixed time points after surgery.T1h = 1 hour after surgery, T2h = 2 hours after surgery, T6h = 6hours after surgery after first mobilisation of the patients. T24h= 24 hours after surgery""]	[""Postoperative spirometric lung function (Measured parameters FEV1 - forced expiratory lung volume/1s , FVC-forced vital capacity ,MEF25-75 - mid expiratory flow 25-75%, PEF - peak expiratory flow, FIVC - forced inspiratory vital capacity, PIF - peak inspiratory flow) measurements at the respective fixed time points after achieving a fast track score >10 (White et al).T0h= after achieving a fast track score >10, all patients included have to achieve a fast-track score >10 within 20 minutes after surgery. All further time points are fixed time points after surgery.T1h = 1 hour after surgery, T2h = 2 hours after surgery, T6h = 6hours after surgery after first mobilisation of the patients. T24h= 24 hours after surgery""]	NA
DRKS00000752	Impact of a sigle shot femoralis block on postoperative lung function and haemodynamic stability	Impact of regional femoral nerve block during general anesthesia for hip arthoplasty on blood pressure, heart rate and pain control: A randomized controlled study	10.3233/thc-150898	https://www.ncbi.nlm.nih.gov/pubmed/25669214	2	2011-03-30	Recruiting complete, follow-up complete	2009-01-01	2010-10-01	2015-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""lung function within the first 24 postoperative hours at fixed time points: T0h after achieving a modified fast track score >10 (White et al), T1h = 1h post-OP, T2h= 2h post OP, T6h= 6 h post-op, T24h = 24hours post OP. , Spirometric lung function (GE easy one spirometer), Pulsseoximetric saturation (GE Monitoring), VAS scale""]	NA	[""lung function within the first 24 postoperative hours at fixed time points: T0h after achieving a modified fast track score >10 (White et al), T1h = 1h post-OP, T2h= 2h post OP, T6h= 6 h post-op, T24h = 24hours post OP. , Spirometric lung function (GE easy one spirometer), Pulsseoximetric saturation (GE Monitoring), VAS scale""]	NA	NA
DRKS00000755	Assistance of pain treatment through a continuous algesia-measurement for postoperative patients in the recovery room	Acute pain therapy in postanesthesia care unit directed by skin conductance: a randomized controlled trial	10.1371/journal.pone.0041758	https://www.ncbi.nlm.nih.gov/pubmed/22848592	7	2011-04-11	Recruiting complete, follow-up complete	2011-04-28	2011-06-10	2012-07-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""mean numeric rating score given by the patient""]	[""mean numeric rating score given by the patient""]	[""mean numeric rating score given by the patient""]	[""mean numeric rating score given by the patient""]	NA
DRKS00000760	I-GelTM,  LMA SupremeTM and Laryngeal Tube Suction - D – A detailed prospective randomized comparative evaluation including fibreoptic and colour indicator assessment techniques	Randomized comparison of the i-gel™, the LMA Supreme™, and the Laryngeal Tube Suction-D using clinical and fibreoptic assessments in elective patients	10.1186/1471-2253-12-18	https://www.ncbi.nlm.nih.gov/pubmed/?term=DRKS00000760	3	2011-04-13	Recruiting complete, follow-up complete	2008-10-12	2010-02-12	2012-08-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""success rates of insertion""]	NA	[""success rates of insertion""]	NA	NA
DRKS00000767	Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction after partial PANCreatoduodenectomy – A randomized controlled trial	Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial	10.1097/sla.0000000000001240	NA	15	2011-03-23	Recruiting complete, follow-up complete	2011-06-01	2013-12-05	2016-03-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""postoperative pancreatic fistula (Grade B or C)defined according to International Study Group of Pancreatic Surgery, ISGPS within 30 days after reconstruction""]	[""postoperative pancreatic fistula (Grade B or C)defined according to International Study Group of Pancreatic Surgery, ISGPS within 30 days after reconstruction""]	[""postoperative pancreatic fistula (Grade B or C)defined according to International Study Group of Pancreatic Surgery, ISGPS within 30 days after reconstruction""]	[""postoperative pancreatic fistula (Grade B or C)defined according to International Study Group of Pancreatic Surgery, ISGPS within 30 days after reconstruction""]	NA
DRKS00000788	Differential effect of Carbamazepine on cortical excitability in subjects with different genotypes for SCN1A as measured by transcranial magnetic stimulation (TMS)	A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability--a pharmacogenetic transcranial magnetic stimulation study	10.1111/epi.12515	https://www.ncbi.nlm.nih.gov/pubmed/?term=A+common+SCN1A+splice-site+polymorphism+modifies+the+effect+of+carbamazepine+on+cortical+excitability%E2%80%94A+pharmacogenetic+transcranial+magnetic+stimulation+study	10	2011-04-05	Recruiting complete, follow-up complete	2009-09-16	2011-06-24	2014-01-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The primary endpoint of the study is the difference (RMTcarbamazepine-RMTbaseline,c)-(RMTplacebo-RMTbaseline,p) ( RMT=RESTING MOTOR THRESHOLD).\nMeasurement technique: transcranial magnetstimulation (TMS)\nTimepoint of measurement:each time before intake of medikation (Carbamazepin or Placebo) and approx.5,5h after intake of medication(Carbamazepin or Placebo)\n""]	[""The primary endpoint of the study is the difference (RMTcarbamazepine-RMTbaseline,c)-(RMTplacebo-RMTbaseline,p) ( RMT=RESTING MOTOR THRESHOLD).\nMeasurement technique: transcranial magnetstimulation (TMS)\nTimepoint of measurement:each time before intake of medikation (Carbamazepin or Placebo) and approx.5,5h after intake of medication(Carbamazepin or Placebo)\n""]	[""The primary endpoint of the study is the difference (RMTcarbamazepine-RMTbaseline,c)-(RMTplacebo-RMTbaseline,p) ( RMT=RESTING MOTOR THRESHOLD).\nMeasurement technique: transcranial magnetstimulation (TMS)\nTimepoint of measurement:each time before intake of medikation (Carbamazepin or Placebo) and approx.5,5h after intake of medication(Carbamazepin or Placebo)\n""]	[""The primary endpoint of the study is the difference (RMTcarbamazepine-RMTbaseline,c)-(RMTplacebo-RMTbaseline,p) ( RMT=RESTING MOTOR THRESHOLD).\nMeasurement technique: transcranial magnetstimulation (TMS)\nTimepoint of measurement:each time before intake of medikation (Carbamazepin or Placebo) and approx.5,5h after intake of medication(Carbamazepin or Placebo)\n""]	NA
DRKS00000815	ctivation of respiratory muscles by respiratory muscle training - EMG quantification	NA	NA	http://erj.ersjournals.com/content/erj/42/Suppl_57/P3729.full.pdf	4	2011-04-15	Recruiting complete, follow-up complete	2011-04-18	2011-07-28	2013-09-01	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Primary endpoint is the amount of innervation of the respiratory muscles during specific training with regard to the maximal innervation pattern assessed by EMG in voluntary maneuvers.""]	NA	[""Primary endpoint is the amount of innervation of the respiratory muscles during specific training with regard to the maximal innervation pattern assessed by EMG in voluntary maneuvers.""]	[""Primary endpoint is the amount of innervation of the respiratory muscles during specific training with regard to the maximal innervation pattern assessed by EMG in voluntary maneuvers.""]	NA
DRKS00003111	Effects of Regulat® Spezial Diabetic on metabolic control in patients with type 2 diabetes mellitus	Effect of a fermented dietary supplement containing chromium and zinc on metabolic control in patients with type 2 diabetes: a randomized, placebo-controlled, double-blind cross-over study	10.3402/fnr.v60.30298	https://www.ncbi.nlm.nih.gov/pubmed/?term=Effect+of+a+fermented+dietary+supplement+containing+chromium+and+zinc+on+metabolic+control+in+patients+with+type+2+diabetes%3A+a+randomized%2C+placebo-controlled%2C+double-blind+cross-over+study	10	2011-07-18	Recruiting complete, follow-up complete	2010-10-28	2012-03-09	2016-06-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The HbA1c is measured in the blood at the beginning and the end of the treatment period of 12 weeks.""]	[""The HbA1c is measured in the blood at the beginning and the end of the treatment period of 12 weeks.""]	[""The HbA1c is measured in the blood at the beginning and the end of the treatment period of 12 weeks.""]	[""The HbA1c is measured in the blood at the beginning and the end of the treatment period of 12 weeks.""]	NA
DRKS00003117	The effects of structured Relearning methods on Daily Living task performance of persons with Dementia - the multi-site randomised controlled REDALI-DEM trial	Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning	10.1186/s13195-017-0247-9	https://link.springer.com/article/10.1186/s13195-017-0247-9#article-info	4	2011-05-31	Recruiting complete, follow-up complete	2012-04-23	2016-11-30	2017-03-23	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Performance of two selected daily living tasks in week 0, 11, 16 (=primary measurement timepoint) and 26, assessed with the Task Performace Scale.""]	[""Performance of two selected daily living tasks in week 0, 11, 16 (=primary measurement timepoint) and 26, assessed with the Task Performace Scale.""]	NA	[""Performance of two selected daily living tasks in week 0, 11, 16 (=primary measurement timepoint) and 26, assessed with the Task Performace Scale.""]	NA
DRKS00003121	The role of routine chest radiography after percutaneous dilatational tracheostomy	[The role of routine chest radiography after percutaneous dilatational tracheostomy. A prospective randomized study]	10.1007/s00063-013-0269-4	https://link.springer.com/article/10.1007%2Fs00063-013-0269-4	5	2011-06-30	Recruiting complete, follow-up complete	2011-07-01	2012-01-31	2013-07-13	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""pulmonary complication rate related to PDT, assessed by the clinically indicated chest radiographies in the first 48 hours after PDT""]	NA	[""pulmonary complication rate related to PDT, assessed by the clinically indicated chest radiographies in the first 48 hours after PDT""]	[""pulmonary complication rate related to PDT, assessed by the clinically indicated chest radiographies in the first 48 hours after PDT""]	NA
DRKS00003132	GREAT - a randomised aneurysm trial	GREAT-a randomized controlled trial comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment: procedural safety and core-lab-assessedangiographic results	10.1007/s00234-016-1693-y	https://link.springer.com/article/10.1007/s00234-016-1693-y	4	2011-07-06	Recruiting complete, follow-up complete	2009-10-01	2016-05-02	2016-04-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""Recanalisationrate at angiographic follow-up 18 months after initial treatment""]	[""Recanalisationrate at angiographic follow-up 18 months after initial treatment""]	NA	[""Composite outcome of major aneurysm recurrence on follow-up angiography and clinical outcome within 18 months\n(Formulation of endpoint amended for clarification; primary endpoint combining angiographic outcomes [major recurrence], re-treatment, and clinical outcomes in the absence of angiographic follow-up was specified before the trial started)\n""]	NA
DRKS00003136	Comparison of clinical and metabolic effects of testosterone and estrogens in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)	Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial	10.1016/s2213-8587(18)30197-9	https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30197-9/fulltext	5	2011-10-11	Recruiting complete, follow-up complete	2011-11-07	2016-01-31	2018-07-31	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary objective: To detect differences in the effects of testosterone versus estrogen treatment on quality of life and mental health/psychological well being in patients with complete androgen insensitivity at seven visit dates (after 0, 2, 5, 8, 11, 14, 17 treatment months).\nmeasuring instrument: psychological sum scale of the SF-36-questionnaire (= Short Form Health Survey)""]	[""Primary objective: To detect differences in the effects of testosterone versus estrogen treatment on quality of life and mental health/psychological well being in patients with complete androgen insensitivity at seven visit dates (after 0, 2, 5, 8, 11, 14, 17 treatment months).\nmeasuring instrument: psychological sum scale of the SF-36-questionnaire (= Short Form Health Survey)""]	[""Primary objective: To detect differences in the effects of testosterone versus estrogen treatment on quality of life and mental health/psychological well being in patients with complete androgen insensitivity at seven visit dates (after 0, 2, 5, 8, 11, 14, 17 treatment months).\nmeasuring instrument: psychological sum scale of the SF-36-questionnaire (= Short Form Health Survey)""]	[""Primary objective: To detect differences in the effects of testosterone versus estrogen treatment on quality of life and mental health/psychological well being in patients with complete androgen insensitivity at seven visit dates (after 0, 2, 5, 8, 11, 14, 17 treatment months).\nmeasuring instrument: psychological sum scale of the SF-36-questionnaire (= Short Form Health Survey)""]	NA
DRKS00003139	Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma	NA	10.1200/jco.2016.34.15_suppl.11004	https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.11004	9	2012-01-17	Recruiting complete, follow-up complete	2011-09-26	2016-10-05	2016-05-20	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Progression-free survival Rate (PFSR) after 12 weeks""]	[""Progression-free survival Rate (PFSR) after 12 weeks""]	NA	[""Progression-free survival Rate (PFSR) after 12 weeks""]	NA
DRKS00003159	Effect of an education and counselling programme on self-care and care dependency in patients with heart failure	Effects of a hospital-based education programme on self-care behaviour, care dependency and quality of life in patients with heart failure--a randomised controlled trial	10.1111/jocn.12766	https://onlinelibrary.wiley.com/doi/abs/10.1111/jocn.12766	5	2011-07-25	Recruiting complete, follow-up complete	2011-04-05	2014-01-02	2015-02-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Self-care measured with the German version of the 9-item European Heart Failure Self-care Behaviour Scale (at time of enrolment and after three months).""]	[""Self-care measured with the German version of the 9-item European Heart Failure Self-care Behaviour Scale (at time of enrolment and after three months).""]	[""Self-care measured with the German version of the 9-item European Heart Failure Self-care Behaviour Scale (at time of enrolment and after three months).""]	[""Self-care measured with the German version of the 9-item European Heart Failure Self-care Behaviour Scale (at time of enrolment and after three months).""]	NA
DRKS00003167	Internet-based program for coping with cancer: a randomized controlled trial with leukemia patients	Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients	10.1002/pon.3104	https://www.ncbi.nlm.nih.gov/pubmed/22565413	3	2011-07-04	Recruiting complete, follow-up complete	2009-07-09	2010-12-31	2012-05-04	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Mental adjustment to cancer (fighting spirit, helplessness/hopelessness,anxious preoccupation, fatalism, avoidance) assessed using the Mental Adjustment to Cancer-Scale (MAC).\n\nAssessment at time T1: during registration\nAssessment at time T2: following completion of the program or waiting period (after 4 weeks)\n\nAll assessments are conducted online.""]	NA	[""Mental adjustment to cancer (fighting spirit, helplessness/hopelessness,anxious preoccupation, fatalism, avoidance) assessed using the Mental Adjustment to Cancer-Scale (MAC).\n\nAssessment at time T1: during registration\nAssessment at time T2: following completion of the program or waiting period (after 4 weeks)\n\nAll assessments are conducted online.""]	[""Mental adjustment to cancer (fighting spirit, helplessness/hopelessness,anxious preoccupation, fatalism, avoidance) assessed using the Mental Adjustment to Cancer-Scale (MAC).\n\nAssessment at time T1: during registration\nAssessment at time T2: following completion of the program or waiting period (after 4 weeks)\n\nAll assessments are conducted online.""]	NA
DRKS00003170	AN EVALUATOR-BLIND CONTROLLED PARALLEL-GROUP  STUDY TO ASSESS EFFICACY AND SAFETY OF  SKINOREN® 15% GEL AND DIFFERIN® 0.1% GEL FOR THE TREATMENT AND MAINTENANCE TREATMENT OF FACIAL ACNE VULGARIS AND LATE-TYPE ACNE IN FEMALES	A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne	10.1111/jdv.12823	http://onlinelibrary.wiley.com/doi/10.1111/jdv.12823/abstract	13	2011-07-20	Recruiting complete, follow-up complete	2011-08-12	2012-10-15	2014-11-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""mild to moderate acne vulgaris, or late-type acne on the face, is in accordance with the general severity of acne, according to the \""Investigator's Static Global Assessment (ISGA)\"" (Grade 2-4) visually by the investigator or the \""Revised Leeds Acne Grading Scale\"" Photo by (Grade 2-7) in all visits assessed\n""]	[""mild to moderate acne vulgaris, or late-type acne on the face, is in accordance with the general severity of acne, according to the \""Investigator's Static Global Assessment (ISGA)\"" (Grade 2-4) visually by the investigator or the \""Revised Leeds Acne Grading Scale\"" Photo by (Grade 2-7) in all visits assessed\n""]	[""mild to moderate acne vulgaris, or late-type acne on the face, is in accordance with the general severity of acne, according to the \""Investigator's Static Global Assessment (ISGA)\"" (Grade 2-4) visually by the investigator or the \""Revised Leeds Acne Grading Scale\"" Photo by (Grade 2-7) in all visits assessed\n""]	[""mild to moderate acne vulgaris, or late-type acne on the face, is in accordance with the general severity of acne, according to the \""Investigator's Static Global Assessment (ISGA)\"" (Grade 2-4) visually by the investigator or the \""Revised Leeds Acne Grading Scale\"" Photo by (Grade 2-7) in all visits assessed\n""]	NA
DRKS00003172	MRI-based evaluation of extraglottic airway devices	Magnetic resonance imaging study of the in vivo position of the extraglottic airway devices i-gel™ and LMA-Supreme™ in anaesthetized human volunteers	10.1093/bja/aes314	https://www.ncbi.nlm.nih.gov/pubmed/23015619	2	2011-07-01	Recruiting complete, follow-up complete	2010-04-11	2011-02-20	2012-09-25	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""depth of insertion into hypopharyngeal structures for each airway device, determined based on the performed MRI-scans""]	NA	[""depth of insertion into hypopharyngeal structures for each airway device, determined based on the performed MRI-scans""]	NA	NA
DRKS00003174	Incidence of suboptimal positioning in-situ of the LMA-Supreme in relation to the chosen insertion technique	The effect of changing the sequence of cuff inflation and device fixation with the LMA-Supreme® on device position, ventilatory complications, and airway morbidity: a clinical and fiberscopic study	10.1186/1471-2253-14-2	https://bmcanesthesiol.biomedcentral.com/articles/10.1186/1471-2253-14-2	5	2012-03-19	Recruiting complete, follow-up complete	2011-04-04	2012-04-25	2014-01-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Sufficient insertion of the LMA-Supreme into the upper esophageal sphincter, evaluated by the so called lube-tube-test, performed immediately after successful insertion of the LMA-Supreme""]	[""Sufficient insertion of the LMA-Supreme into the upper esophageal sphincter, evaluated by the so called lube-tube-test, performed immediately after successful insertion of the LMA-Supreme""]	[""Sufficient insertion of the LMA-Supreme into the upper esophageal sphincter, evaluated by the so called lube-tube-test, performed immediately after successful insertion of the LMA-Supreme""]	[""Sufficient insertion of the LMA-Supreme into the upper esophageal sphincter, evaluated by the so called lube-tube-test, performed immediately after successful insertion of the LMA-Supreme""]	NA
DRKS00003246	Investigation of Radiation Retinopathy (Radi-Ret Study) Subtitle: Influence of Lucentis® on radiation retinopathy after irradiation of choroidal melanoma	Influence of Ranibizumab versus laser photocoagulation on radiation retinopathy (RadiRet) - a prospective randomized controlled trial	10.1007/s00417-020-04618-7	https://pubmed.ncbi.nlm.nih.gov/32112140/	9	2013-05-31	Recruiting stopped after recruiting started	2013-10-23	2016-12-02	2020-02-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Change from baseline in BCVA (Best Corrected Visual Acuity) over 6 months (area under curve / 6 months)""]	[""Change from baseline in BCVA (Best Corrected Visual Acuity) over 6 months (area under curve / 6 months)""]	[""Change from baseline in BCVA (Best Corrected Visual Acuity) over 6 months (area under curve / 6 months)""]	NA	NA
DRKS00003252	Use of Acetylsalicylic Acid (ASA) for Enhanced Early Detection of Colorectal Neoplasms	Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial	10.1001/jama.2019.4755	https://pubmed.ncbi.nlm.nih.gov/31063574/	11	2013-03-13	Recruiting complete, follow-up complete	2013-06-18	2017-01-27	2019-05-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""To evaluate diagnostic performance (sensitivity, specificity, positive and negative predictive values, likelihood ratios, area under the curve) of 2 imunochemical Fecal Occult Blood Tests for detecting advanced colorectal neoplasms after a single dose of aspirin as compared to application of the tests without prior use of aspirin.""]	[""To evaluate diagnostic performance (sensitivity, specificity, positive and negative predictive values, likelihood ratios, area under the curve) of 2 imunochemical Fecal Occult Blood Tests for detecting advanced colorectal neoplasms after a single dose of aspirin as compared to application of the tests without prior use of aspirin.""]	[""To evaluate diagnostic performance (sensitivity, specificity, positive and negative predictive values, likelihood ratios, area under the curve) of 2 imunochemical Fecal Occult Blood Tests for detecting advanced colorectal neoplasms after a single dose of aspirin as compared to application of the tests without prior use of aspirin.""]	[""To evaluate diagnostic performance (sensitivity, specificity, positive and negative predictive values, likelihood ratios, area under the curve) of 2 imunochemical Fecal Occult Blood Tests for detecting advanced colorectal neoplasms after a single dose of aspirin as compared to application of the tests without prior use of aspirin.""]	NA
DRKS00003269	Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca	[Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca]	10.1055/s-0031-1281862	https://www.ncbi.nlm.nih.gov/pubmed/22189827	2	2011-10-04	Recruiting complete, follow-up complete	2007-01-15	2009-11-16	2012-05-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""after 3 months treatment:\n\nstandardized questionnaire for clinical diagnosis features:\n\nLIPCOF; tear break-up time (BUT);\nfluorescein and rose bengal staining; basal secretion of the tear film (Jones test);\nintraocular pressure (IOP);\nOcular Surface Disease Index (OSDI-Score): quality of life questionnaire; profile of cytokines in the tear fluid""]	NA	[""after 3 months treatment:\n\nstandardized questionnaire for clinical diagnosis features:\n\nLIPCOF; tear break-up time (BUT);\nfluorescein and rose bengal staining; basal secretion of the tear film (Jones test);\nintraocular pressure (IOP);\nOcular Surface Disease Index (OSDI-Score): quality of life questionnaire; profile of cytokines in the tear fluid""]	NA	NA
DRKS00003270	Clinical examination of metal free interdental brushes	Clinical efficacy and patients' acceptance of a rubber interdental bristle. A randomized controlled trial	10.1007/s00784-013-1164-3	https://www.ncbi.nlm.nih.gov/pubmed/24407549	4	2011-09-29	Recruiting complete, follow-up complete	2010-01-10	2010-08-19	2014-01-10	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Analysis of the differences between both groups. Measurements in form of Plaque-Index (Quigley und Hein, Tureskey Mod. 1970), Gingiva-Index (Eastman Interdental Bleeding Index) and analysis of the questionnaire (patient satisfaction)""]	NA	[""Analysis of the differences between both groups. Measurements in form of Plaque-Index (Quigley und Hein, Tureskey Mod. 1970), Gingiva-Index (Eastman Interdental Bleeding Index) and analysis of the questionnaire (patient satisfaction)""]	[""Analysis of the differences between both groups. Measurements in form of Plaque-Index (Quigley und Hein, Tureskey Mod. 1970), Gingiva-Index (Eastman Interdental Bleeding Index) and analysis of the questionnaire (patient satisfaction)""]	NA
DRKS00003308	MUKIS - Munich analysis of headaches in highschool students - intervention study	High diagnostic stability of confirmed migraine and confirmed tension-type headache according to the ICHD-3 beta in adolescents	10.1186/1129-2377-15-36	https://www.ncbi.nlm.nih.gov/pubmed/24916858	4	2011-11-07	Recruiting complete, follow-up complete	2011-11-10	2012-07-27	2014-06-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Change of the headache prevalence among highschool pupils with versus without intervention. Investigation of the headache prevalence according to the criteria of the International Headache Society (IHS) via written questionnaire; time of measurement: right before the intervention (first survey) and at least 6 months afterward (second survey)""]	[""Change of the headache prevalence among highschool pupils with versus without intervention. Investigation of the headache prevalence according to the criteria of the International Headache Society (IHS) via written questionnaire; time of measurement: right before the intervention (first survey) and at least 6 months afterward (second survey)""]	[""Change of the headache prevalence among highschool pupils with versus without intervention. Investigation of the headache prevalence according to the criteria of the International Headache Society (IHS) via written questionnaire; time of measurement: right before the intervention (first survey) and at least 6 months afterward (second survey)""]	NA	NA
DRKS00003322	Development and Evaluation of an Interactive Health Communication Application for Chronically Ill Patients	Effectiveness of a Web-based tailored interactive health communication application for patients with type 2 diabetes or chronic low back pain: randomized controlled trial	10.2196/jmir.3904	https://www.ncbi.nlm.nih.gov/pubmed/25736340	4	2012-07-03	Recruiting complete, follow-up complete	2012-08-01	2013-12-31	2015-03-03	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Condition-specific knowledge (measured during the intervention and at follow-up 3 months after the intervention with questionnaires that were developed on the basis of the information system)\n\nEmpowerment (measured immediateliy after the intervention and at 3 month follow-up with the Health Education Impact Questionnaire HeiQ)\n\n""]	[""Condition-specific knowledge (measured during the intervention and at follow-up 3 months after the intervention with questionnaires that were developed on the basis of the information system)\n\nEmpowerment (measured immediateliy after the intervention and at 3 month follow-up with the Health Education Impact Questionnaire HeiQ)\n\n""]	[""Condition-specific knowledge (measured during the intervention and at follow-up 3 months after the intervention with questionnaires that were developed on the basis of the information system)\n\nEmpowerment (measured immediateliy after the intervention and at 3 month follow-up with the Health Education Impact Questionnaire HeiQ)\n\n""]	NA	NA
DRKS00003332	Early functional Results after Hemiarthroplasty for Fractured Neck Femur: A Randomized Comparison between a Minimal Invasive (DAA) and a Conventional (Watson-Jones) Approach	Early functional results after hemiarthroplasty for femoral neck fracture: a randomized comparison between a minimal invasive and a conventional approach	10.1186/1471-2474-13-141	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488324/	2	2011-12-15	Recruiting complete, follow-up complete	2008-01-01	2010-12-31	2012-08-08	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""4 item Barthel Index (Measurement of Mobility)\nDay 1,5,16,40""]	NA	[""4 item Barthel Index (Measurement of Mobility)\nDay 1,5,16,40""]	[""4 item Barthel Index (Measurement of Mobility)\nDay 1,5,16,40""]	NA
DRKS00003347	Randomized, controlled clinical trial evaluating the efficacy and clinical effectiveness of negative pressure wound therapy for the treatment of diabetic foot wounds when compared to standard wound therapy A study project with a pragmatic approach to evaluate the negative pressure wound therapy in the medical treatment sectors in Germany	Negative pressure wound therapy compared with standard moist wound care on diabetic foot ulcers in real-life clinical practice: results of the German DiaFu-RCT	10.1136/bmjopen-2018-026345	https://bmjopen.bmj.com/content/10/3/e026345.long	9	2011-11-22	Recruiting complete, follow-up complete	2011-12-23	2015-04-17	2020-03-24	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Number of achieved and confirmed wound closures within a maximum treatment time of 16 weeks plus the time until complete wound closure (in days)\nThe wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\nThe closure must remain at least for a period of 14 days.""]	[""Number of achieved and confirmed wound closures within a maximum treatment time of 16 weeks plus the time until complete wound closure (in days)\nThe wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\nThe closure must remain at least for a period of 14 days.""]	[""Number of achieved and confirmed wound closures within a maximum treatment time of 16 weeks plus the time until complete wound closure (in days)\nThe wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\nThe closure must remain at least for a period of 14 days.""]	NA	NA
DRKS00003352	Use of whole body vibration training as a company-facilitated sports activitiy fpr people with chronic back disorders	Whole-body vibration training as a workplace-based sports activity for employees with chronic low-back pain	10.1111/sms.12852	http://onlinelibrary.wiley.com/doi/10.1111/sms.12852/full	6	2011-11-30	Recruiting complete, follow-up complete	2011-12-04	2012-05-24	2017-04-06	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The back-pain will be messured with the Roland-Morris low-back-pain questionnaire at start (T0) and after 12 weeks (T1)""]	[""The back-pain will be messured with the Roland-Morris low-back-pain questionnaire at start (T0) and after 12 weeks (T1)""]	[""The back-pain will be messured with the Roland-Morris low-back-pain questionnaire at start (T0) and after 12 weeks (T1)""]	NA	NA
DRKS00003355	Effect of a preoperative calorie restriction on renal function after cardiac surgery in patients at risk	Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial	10.1161/jaha.117.008181	https://pubmed.ncbi.nlm.nih.gov/29535139/	9	2011-11-23	Recruiting complete, follow-up complete	2012-02-01	2015-02-01	2018-03-13	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary outcome is loss of renal function after cardiac surgery. The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (“cross clamping”) in comparison to baseline value obtained in the morning of the day of surgery (day 0).""]	[""Primary outcome is loss of renal function after cardiac surgery. The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (“cross clamping”) in comparison to baseline value obtained in the morning of the day of surgery (day 0).""]	[""Primary outcome is loss of renal function after cardiac surgery. The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (“cross clamping”) in comparison to baseline value obtained in the morning of the day of surgery (day 0).""]	[""Primary outcome is loss of renal function after cardiac surgery. The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (“cross clamping”) in comparison to baseline value obtained in the morning of the day of surgery (day 0).""]	NA
DRKS00003388	Reward learning and extinction training in alcohol dependence: impact of fronto-striatal connectivity	Real-time functional magnetic resonance imaging neurofeedback can reduce striatal cue-reactivity to alcohol stimuli	10.1111/adb.12278	https://onlinelibrary.wiley.com/doi/abs/10.1111/adb.12278	5	2011-12-14	Recruiting complete, follow-up complete	2012-06-01	2015-09-01	2015-06-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Extent of changes of functional and structural connectivity between prefrontal and striatal brain regions caused by the cue-exposure-based extinction training (CET) or neurofeedback as measured by magnetoresonance tomographic methods. Two MRI examinations: Baseline (5 to 21 days after detoxification) and the second three weeks later after the completion of the therapy.""]	[""Extent of changes of functional and structural connectivity between prefrontal and striatal brain regions caused by the cue-exposure-based extinction training (CET) or neurofeedback as measured by magnetoresonance tomographic methods. Two MRI examinations: Baseline (5 to 21 days after detoxification) and the second three weeks later after the completion of the therapy.""]	NA	[""Extent of changes of functional and structural connectivity between prefrontal and striatal brain regions caused by the cue-exposure-based extinction training (CET) or neurofeedback as measured by magnetoresonance tomographic methods. Two MRI examinations: Baseline (5 to 21 days after detoxification) and the second three weeks later after the completion of the therapy.""]	NA
DRKS00003407	Project B4: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome -  male infertility due to infection and inflammation	Metabolic syndrome and the seminal cytokine network in morbidly obese males	10.1111/andr.12296	https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12296	6	2011-12-22	Recruiting stopped after recruiting started	2011-12-22	2014-06-03	2016-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Increase of the spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit\nto get the required information ejaculate testing will be performed at baseline and at the 12 months follow-up visit""]	[""Increase of the spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit\nto get the required information ejaculate testing will be performed at baseline and at the 12 months follow-up visit""]	[""Increase of the spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit\nto get the required information ejaculate testing will be performed at baseline and at the 12 months follow-up visit""]	[""Increase of the spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit\nto get the required information ejaculate testing will be performed at baseline and at the 12 months follow-up visit""]	NA
DRKS00003442	Behavioral and neural effects of mothers´history of childhood abuse on the interaction with their child	Neural processing of the own child's facial emotions in mothers with a history of early life maltreatment	10.1007/s00406-018-0929-8	https://link.springer.com/article/10.1007/s00406-018-0929-8	6	2012-07-04	Recruiting complete, follow-up complete	2012-07-23	2014-12-31	2018-07-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Mother: Changes in maternal sensitivity baseline to Follow-up I in EA-score. Child: Changes in child well-being from baseline to Follow-up I in KIDS-SCREEN scres""]	[""Mother: Changes in maternal sensitivity baseline to Follow-up I in EA-score. Child: Changes in child well-being from baseline to Follow-up I in KIDS-SCREEN scres""]	[""Mother: Changes in maternal sensitivity baseline to Follow-up I in EA-score. Child: Changes in child well-being from baseline to Follow-up I in KIDS-SCREEN scres""]	NA	NA
DRKS00003452	Improving the quality of life in patients with idiopathic Parkinson's disease through individualized holistic care within the framework of the Cologne PD Network	Patient-centered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial	10.1007/s00415-018-8761-7	https://pubmed.ncbi.nlm.nih.gov/29392459/	7	2011-12-23	Recruiting complete, follow-up complete	2012-01-01	2015-07-22	2018-02-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Survey of quality of life at baseline and after six months by a questionnaire (Parkinson's Disease Quality of Life Questionnaire (PDQ-39))""]	[""Survey of quality of life at baseline and after six months by a questionnaire (Parkinson's Disease Quality of Life Questionnaire (PDQ-39))""]	[""Survey of quality of life at baseline and after six months by a questionnaire (Parkinson's Disease Quality of Life Questionnaire (PDQ-39))""]	NA	NA
DRKS00003488	Comparison of techniques of oral hygiene - a multidisciplinary randomised study on training of oral hygiene skills	Improving oral hygiene skills by computer-based training: a randomized controlled comparison of the modified Bass and the Fones techniques	10.1371/journal.pone.0037072	https://www.ncbi.nlm.nih.gov/pubmed/22629353	7	2012-01-20	Recruiting complete, follow-up complete	2009-11-11	2010-09-06	2012-05-21	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Gingivitis; 6,12, 28 weeks after intervention; assessed by the papillary bleeding index""]	NA	[""Gingivitis; 6,12, 28 weeks after intervention; assessed by the papillary bleeding index""]	[""Gingivitis; 6,12, 28 weeks after intervention; assessed by the papillary bleeding index""]	NA
DRKS00003512	Comparison of techniques of oral hygiene - a multidisciplinary randomised study on training of oral hygiene skills	Training in different brushing techniques in relation to efficacy of oral hygiene in young adults: a randomized controlled trial	10.1111/jcpe.12489	https://www.ncbi.nlm.nih.gov/pubmed/?term=Training+in+different+brushing+techniques+in+relation+to+efficacy+of+oral+hygiene+in+young+adults%3A+a+randomized+controlled+trial	6	2012-01-25	Recruiting complete, follow-up complete	2011-04-13	2012-05-04	2016-02-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Oral Hygiene skills assessed via plaque after thorough oral hygiene via marginal plaque index, 6, 12 and 28 weeks after intervention""]	[""Oral Hygiene skills assessed via plaque after thorough oral hygiene via marginal plaque index, 6, 12 and 28 weeks after intervention""]	[""Oral Hygiene skills assessed via plaque after thorough oral hygiene via marginal plaque index, 6, 12 and 28 weeks after intervention""]	[""Oral Hygiene skills assessed via plaque after thorough oral hygiene via marginal plaque index, 6, 12 and 28 weeks after intervention""]	NA
DRKS00003514	A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation	The PRAISE study: a prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749)	10.1186/1471-2482-13-1	https://pubmed.ncbi.nlm.nih.gov/23356494/	4	2012-03-20	Recruiting stopped after recruiting started	2012-04-30	NA	2013-01-29	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[""primary graft dysfunction (PDF) after liver transplantation characterized as\npresentation of one or more of the following criteria: ALAT or ASAT level > 2000\nIU/ml within the first 7 postoperative days, bilirubin ≥ 10 mg/dl on postoperative\nday 7; INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function\n(INF) defined as graft failure originating from the graft itself, excluding hepatic\nartery thrombosis (HAT), biliary complication, recurrent disease or acute rejection\nand resulting in retransplantation or patient death within 14 days after initial LT""]	NA	NA	[""primary graft dysfunction (PDF) after liver transplantation characterized as\npresentation of one or more of the following criteria: ALAT or ASAT level > 2000\nIU/ml within the first 7 postoperative days, bilirubin ≥ 10 mg/dl on postoperative\nday 7; INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function\n(INF) defined as graft failure originating from the graft itself, excluding hepatic\nartery thrombosis (HAT), biliary complication, recurrent disease or acute rejection\nand resulting in retransplantation or patient death within 14 days after initial LT""]	[""primary graft dysfunction (PDF) after liver transplantation characterized as\npresentation of one or more of the following criteria: ALAT or ASAT level > 2000\nIU/ml within the first 7 postoperative days, bilirubin ≥ 10 mg/dl on postoperative\nday 7; INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function\n(INF) defined as graft failure originating from the graft itself, excluding hepatic\nartery thrombosis (HAT), biliary complication, recurrent disease or acute rejection\nand resulting in retransplantation or patient death within 14 days after initial LT""]
DRKS00003534	Incidence of parastomal hernias after lateral pararectal versus transrectal stoma placement	A pilot single-centre randomized trial assessing the safety and efficacy of lateral pararectus abdominis compared with transrectus abdominis muscle stoma placement in patients with temporary loop ileostomies: the PATRASTOM trial	10.1111/codi.13251	https://pubmed.ncbi.nlm.nih.gov/26713666/	6	2012-02-14	Recruiting complete, follow-up complete	2012-04-16	2014-09-15	2015-12-29	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary endpoint is the incidence of parastomal hernias defined by any of the following events:\n\na) clinically manifest parastomal hernia as any palpable bulge or defect that appears after removal of the appliance while the patient is erect or coughing (photodocumentation)\nb) sonographically diagnosed parastomal hernia (definition: protrusion of intraabdominal contents adjacent to the stoma)\nc) intraoperative finding when the ileostomy is taken down (questionnaire for the surgeon)\n\nStandardized approach to detect the primary endpoint:\nAll patients are screened for parastomal hernia clinically and sonographically. The surgeon who performs the ileostomy take-down documents the intraoperative finding using a standardized questionnaire.\nThe follow-up duration is about 3-6 months. This observation period corresponds to the time period between stoma placement and ileostomy takedown.""]	[""Primary endpoint is the incidence of parastomal hernias defined by any of the following events:\n\na) clinically manifest parastomal hernia as any palpable bulge or defect that appears after removal of the appliance while the patient is erect or coughing (photodocumentation)\nb) sonographically diagnosed parastomal hernia (definition: protrusion of intraabdominal contents adjacent to the stoma)\nc) intraoperative finding when the ileostomy is taken down (questionnaire for the surgeon)\n\nStandardized approach to detect the primary endpoint:\nAll patients are screened for parastomal hernia clinically and sonographically. The surgeon who performs the ileostomy take-down documents the intraoperative finding using a standardized questionnaire.\nThe follow-up duration is about 3-6 months. This observation period corresponds to the time period between stoma placement and ileostomy takedown.""]	[""Primary endpoint is the incidence of parastomal hernias defined by any of the following events:\n\na) clinically manifest parastomal hernia as any palpable bulge or defect that appears after removal of the appliance while the patient is erect or coughing (photodocumentation)\nb) sonographically diagnosed parastomal hernia (definition: protrusion of intraabdominal contents adjacent to the stoma)\nc) intraoperative finding when the ileostomy is taken down (questionnaire for the surgeon)\n\nStandardized approach to detect the primary endpoint:\nAll patients are screened for parastomal hernia clinically and sonographically. The surgeon who performs the ileostomy take-down documents the intraoperative finding using a standardized questionnaire.\nThe follow-up duration is about 3-6 months. This observation period corresponds to the time period between stoma placement and ileostomy takedown.""]	[""Primary endpoint is the incidence of parastomal hernias defined by any of the following events:\n\na) clinically manifest parastomal hernia as any palpable bulge or defect that appears after removal of the appliance while the patient is erect or coughing (photodocumentation)\nb) sonographically diagnosed parastomal hernia (definition: protrusion of intraabdominal contents adjacent to the stoma)\nc) intraoperative finding when the ileostomy is taken down (questionnaire for the surgeon)\n\nStandardized approach to detect the primary endpoint:\nAll patients are screened for parastomal hernia clinically and sonographically. The surgeon who performs the ileostomy take-down documents the intraoperative finding using a standardized questionnaire.\nThe follow-up duration is about 3-6 months. This observation period corresponds to the time period between stoma placement and ileostomy takedown.""]	NA
DRKS00003545	Coping with non-cardiac chest pain: A randomised clinical trial to evaluate a short psychoeducational intervention	Cognitive-perceptual factors in noncardiac chest pain and cardiac chest pain	10.1097/psy.0b013e31826ae4ae	https://www.ncbi.nlm.nih.gov/pubmed/23006429	4	2012-03-15	Recruiting complete, follow-up complete	2010-05-31	2013-01-31	2012-09-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""1. Chest pain characteristics (Pain Questionnaire of the German Pain Society).\n\n2. Subjective Illness Perceptions (Donkin-Scale, IPQ-Brief).\n\nAssessments were done prior to the intervention as well as 4 week and 6 months following the intervention.""]	[""1. Chest pain characteristics (Pain Questionnaire of the German Pain Society).\n\n2. Subjective Illness Perceptions (Donkin-Scale, IPQ-Brief).\n\nAssessments were done prior to the intervention as well as 4 week and 6 months following the intervention.""]	NA	[""1. Chest pain characteristics (Pain Questionnaire of the German Pain Society).\n\n2. Subjective Illness Perceptions (Donkin-Scale, IPQ-Brief).\n\nAssessments were done prior to the intervention as well as 4 week and 6 months following the intervention.""]	NA
DRKS00003560	Impact of a six months dance intervention on sensorimotor, cognitive, postural, and cardio-respiratory performance in the elderly.	Six months of dance intervention enhances postural, sensorimotor, and cognitive performance in elderly without affecting cardio-respiratory functions	10.3389/fnagi.2013.00005	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581819/	3	2012-03-29	Recruiting complete, follow-up complete	2012-03-20	2012-10-05	2013-02-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Assessment of\n\nPosture and balance\n(displacement of centre of pressure (COP) using a force platform)\nreactiontimes ( choice-reaction times (WTS - system),\ninformation processing (WTS - System), multiple-choice reaction time analysis)\nmotor performance ( Jebsen-Taylor Hand Funktion Test\nfine-motor performance (MLS - battery)\nmotor coordination (WTS-System)\ngrip-strength)\ncognitive performance ( non-verbal geriatric concentration test (AKT)\nFrankfurt attention inventory (FAIR)\nRepeatable Battery for the Assessment of Neuropsychological Status (RBANS)\nnon-verbal learning)\nintelligence( Raven Standard Progressive Matrices (RSPM))\nLifestyle und activity ( everyday competence questionnaire (ECQ)\nlife contentment questionnaire (FLZ))\ncardio-respiratory performance\n(peak oxygen uptake, spirometrie)\nelectrophysiological measures using high-density EEG\n\nbefore and after 6 months of dance intervention""]	[""Assessment of\n\nPosture and balance\n(displacement of centre of pressure (COP) using a force platform)\nreactiontimes ( choice-reaction times (WTS - system),\ninformation processing (WTS - System), multiple-choice reaction time analysis)\nmotor performance ( Jebsen-Taylor Hand Funktion Test\nfine-motor performance (MLS - battery)\nmotor coordination (WTS-System)\ngrip-strength)\ncognitive performance ( non-verbal geriatric concentration test (AKT)\nFrankfurt attention inventory (FAIR)\nRepeatable Battery for the Assessment of Neuropsychological Status (RBANS)\nnon-verbal learning)\nintelligence( Raven Standard Progressive Matrices (RSPM))\nLifestyle und activity ( everyday competence questionnaire (ECQ)\nlife contentment questionnaire (FLZ))\ncardio-respiratory performance\n(peak oxygen uptake, spirometrie)\nelectrophysiological measures using high-density EEG\n\nbefore and after 6 months of dance intervention""]	[""Assessment of\n\nPosture and balance\n(displacement of centre of pressure (COP) using a force platform)\nreactiontimes ( choice-reaction times (WTS - system),\ninformation processing (WTS - System), multiple-choice reaction time analysis)\nmotor performance ( Jebsen-Taylor Hand Funktion Test\nfine-motor performance (MLS - battery)\nmotor coordination (WTS-System)\ngrip-strength)\ncognitive performance ( non-verbal geriatric concentration test (AKT)\nFrankfurt attention inventory (FAIR)\nRepeatable Battery for the Assessment of Neuropsychological Status (RBANS)\nnon-verbal learning)\nintelligence( Raven Standard Progressive Matrices (RSPM))\nLifestyle und activity ( everyday competence questionnaire (ECQ)\nlife contentment questionnaire (FLZ))\ncardio-respiratory performance\n(peak oxygen uptake, spirometrie)\nelectrophysiological measures using high-density EEG\n\nbefore and after 6 months of dance intervention""]	NA	NA
DRKS00003568	Effectiveness of a trans-sectoral gender-specific intervention to improve health behavior in rehabilitants with coronary heart disease.	The Efficacy of Goal Setting in Cardiac Rehabilitation-a Gender-Specific Randomized Controlled Trial	10.3238/arztebl.2016.0525	https://pubmed.ncbi.nlm.nih.gov/27581505/	7	2012-02-22	Recruiting complete, follow-up complete	2011-11-30	2014-12-31	2016-08-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change and continuity in the areas of physical activity, dietary habits, smoking, mental health, compliance to medication. Self-reported questionnaire at begin, end of rehabilitation and follow-up at 6 and 12 month after the end of rehabilitation.""]	[""Change and continuity in the areas of physical activity, dietary habits, smoking, mental health, compliance to medication. Self-reported questionnaire at begin, end of rehabilitation and follow-up at 6 and 12 month after the end of rehabilitation.""]	[""Change and continuity in the areas of physical activity, dietary habits, smoking, mental health, compliance to medication. Self-reported questionnaire at begin, end of rehabilitation and follow-up at 6 and 12 month after the end of rehabilitation.""]	[""Change and continuity in the areas of physical activity, dietary habits, smoking, mental health, compliance to medication. Self-reported questionnaire at begin, end of rehabilitation and follow-up at 6 and 12 month after the end of rehabilitation.""]	NA
DRKS00003574	Cross-interface, work-related case management in therapeutic aftercare of addiction as key to integration through employment and relapse prevention	Is employment-focused case management effective for patients with substance use disorders? Results from a controlled multi-site trial in Germany covering a 2-years-period after inpatient rehabilitation	10.1186/s12888-016-0990-7	https://www.readcube.com/articles/10.1186%2Fs12888-016-0990-7	6	2012-03-12	Recruiting complete, follow-up complete	2011-10-17	2014-09-30	2016-08-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Occupational reintegration (work time ≥15h/week) into the regular labour market\nMeasurement time: 12 and 24 months after discharge from withdrawal symptoms treatment\nResearch instruments: standardized survey, questions about work history in accordance with the Socio-Economic Panel (SOEP)\n""]	[""Occupational reintegration (work time ≥15h/week) into the regular labour market\nMeasurement time: 12 and 24 months after discharge from withdrawal symptoms treatment\nResearch instruments: standardized survey, questions about work history in accordance with the Socio-Economic Panel (SOEP)\n""]	[""Occupational reintegration (work time ≥15h/week) into the regular labour market\nMeasurement time: 12 and 24 months after discharge from withdrawal symptoms treatment\nResearch instruments: standardized survey, questions about work history in accordance with the Socio-Economic Panel (SOEP)\n""]	[""Occupational reintegration (work time ≥15h/week) into the regular labour market\nMeasurement time: 12 and 24 months after discharge from withdrawal symptoms treatment\nResearch instruments: standardized survey, questions about work history in accordance with the Socio-Economic Panel (SOEP)\n""]	NA
DRKS00003589	Collaborative treatment of late-life depression in primary care: Implementation of the IMPACT program in Germany	Coordinated Treatment of Depression in Elderly People in Primary Care	10.3238/arztebl.2018.0741	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318433/	8	2012-09-13	Recruiting complete, follow-up complete	2012-10-01	2015-09-18	2018-11-02	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The primary outcome variable is the PHQ-9 score (Kroenke et al. 2001) as a measure of change in the depressive symptoms over the course of the trial. The PHQ-9 questionnaire is the 9-item depression module of the \""Patient Health Questionnaire\"" which has proven to be a valid instrument for the population of older people with depression in international trials.\n\nAlong the lines of similar trials (Unützer et al. 2002; IJiff et al. 2007; Gensichen et al. 2009), the change of symptoms in terms of a \""response to treatment\"" is defined as a decrease of symptoms (PHQ-9 score) by 50% or more. Remission is defined as a reduction of the PHQ-9 score to a score of 4 or less.\n\nThe PHQ-9 will be assessed at the involvement of the patient, after 6 months and after 12 months.""]	[""The primary outcome variable is the PHQ-9 score (Kroenke et al. 2001) as a measure of change in the depressive symptoms over the course of the trial. The PHQ-9 questionnaire is the 9-item depression module of the \""Patient Health Questionnaire\"" which has proven to be a valid instrument for the population of older people with depression in international trials.\n\nAlong the lines of similar trials (Unützer et al. 2002; IJiff et al. 2007; Gensichen et al. 2009), the change of symptoms in terms of a \""response to treatment\"" is defined as a decrease of symptoms (PHQ-9 score) by 50% or more. Remission is defined as a reduction of the PHQ-9 score to a score of 4 or less.\n\nThe PHQ-9 will be assessed at the involvement of the patient, after 6 months and after 12 months.""]	[""The primary outcome variable is the PHQ-9 score (Kroenke et al. 2001) as a measure of change in the depressive symptoms over the course of the trial. The PHQ-9 questionnaire is the 9-item depression module of the \""Patient Health Questionnaire\"" which has proven to be a valid instrument for the population of older people with depression in international trials.\n\nAlong the lines of similar trials (Unützer et al. 2002; IJiff et al. 2007; Gensichen et al. 2009), the change of symptoms in terms of a \""response to treatment\"" is defined as a decrease of symptoms (PHQ-9 score) by 50% or more. Remission is defined as a reduction of the PHQ-9 score to a score of 4 or less.\n\nThe PHQ-9 will be assessed at the involvement of the patient, after 6 months and after 12 months.""]	NA	NA
DRKS00003623	Pilot evaluation of modified cognitive behavioral therapy for elderly patients with schizophrenia	NA	10.1093/schbul/sby016.317	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887335/	2	2012-03-27	Recruiting complete, follow-up complete	2012-04-12	2015-05-15	2018-04-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Improvement in one of three:\n1. Symptoms: Positive and negative syndrom scale (PANSS) total score: Structured Interview on symptoms in schizophrenia;\n2. Depression symptoms: Calgary Depression Rating Scale for Schizophrenia German Version (CDSS-G), Questionaire to be conducted by study participants\n3. Functional abilities: UPSA-Brief - University of California, San Diego, Performance-Based Skills Assessment, Rating of study participants behaviour in simple tasks related to standardized situations.\nPrimary endpoints are assessed following randomization (before treatment start), following 4.5 month in the study, following 9 month in the study (treatment end) and following 15 month in the study (6 month follow-up). Outcome no. 3 is not assessed at 4.5 month.""]	NA	[""Improvement in one of three:\n1. Symptoms: Positive and negative syndrom scale (PANSS) total score: Structured Interview on symptoms in schizophrenia;\n2. Depression symptoms: Calgary Depression Rating Scale for Schizophrenia German Version (CDSS-G), Questionaire to be conducted by study participants\n3. Functional abilities: UPSA-Brief - University of California, San Diego, Performance-Based Skills Assessment, Rating of study participants behaviour in simple tasks related to standardized situations.\nPrimary endpoints are assessed following randomization (before treatment start), following 4.5 month in the study, following 9 month in the study (treatment end) and following 15 month in the study (6 month follow-up). Outcome no. 3 is not assessed at 4.5 month.""]	NA	NA
DRKS00003660	Development of Fecal Microbiota in Infants Fed With Formula With or Without Probiotics. Randomized, double-blind, controlled pilot study	Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome	10.3945/ajcn.117.157529	NA	3	2012-08-03	Recruiting complete, follow-up complete	2012-09-01	2014-07-30	2017-09-06	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Bacterial Diversity. Analysis from fecal samples, taken once per month for 12 months. Bacterial diversity will be determined via 16S rRNA pyrosequencing""]	NA	[""Bacterial Diversity. Analysis from fecal samples, taken once per month for 12 months. Bacterial diversity will be determined via 16S rRNA pyrosequencing""]	[""Bacterial Diversity. Analysis from fecal samples, taken once per month for 12 months. Bacterial diversity will be determined via 16S rRNA pyrosequencing""]	NA
DRKS00003681	Transcutaneous Vagus Nerve Stimulation for the treatment of chronic migraine	Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial	10.1186/s10194-015-0543-3	NA	9	2012-03-23	Recruiting complete, follow-up complete	2012-04-16	2014-11-30	2015-07-09	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Proof a the therapeutic efficacy of t-VNS for chronic migraine estimated via the number of headache days per 28 days.""]	[""Proof a the therapeutic efficacy of t-VNS for chronic migraine estimated via the number of headache days per 28 days.""]	[""Proof a the therapeutic efficacy of t-VNS for chronic migraine estimated via the number of headache days per 28 days.""]	[""Proof a the therapeutic efficacy of t-VNS for chronic migraine estimated via the number of headache days per 28 days.""]	NA
DRKS00003690	Euthymic Therapy: a Randomised Controlled Trial	NA	NA	http://www.gjpsy.uni-goettingen.de/gjp-article-kiermeir.pdf	1	2012-04-02	Recruiting complete, follow-up complete	2007-10-24	2009-05-15	2012-05-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Our project thus aimes to assess the effects of ET on reduction of depressive symptoms (HAMD-21, BDI), anhedonia (TAF) and a patient's health resources (MR FSF) in a randomized, controlled, parallel-group design. We expect ET to reduce depressive residual symptoms and anhedonia and improve self care as effectively as the validated reference treatment (psychoeducation). 3 measuring times: baseline, post intervention an follow-up (after 3 month).\nFollowing questionaires were used:\n• Hamilton Depression Scale (HAMD)\n• Tübinger-Anhedonie-Fragebogen (TAF)\n• Becks Depressions Inventar (BDI II)\n• Marburger Skalen zur Selbstfürsorge (MR FSF)\n""]	NA	[""Our project thus aimes to assess the effects of ET on reduction of depressive symptoms (HAMD-21, BDI), anhedonia (TAF) and a patient's health resources (MR FSF) in a randomized, controlled, parallel-group design. We expect ET to reduce depressive residual symptoms and anhedonia and improve self care as effectively as the validated reference treatment (psychoeducation). 3 measuring times: baseline, post intervention an follow-up (after 3 month).\nFollowing questionaires were used:\n• Hamilton Depression Scale (HAMD)\n• Tübinger-Anhedonie-Fragebogen (TAF)\n• Becks Depressions Inventar (BDI II)\n• Marburger Skalen zur Selbstfürsorge (MR FSF)\n""]	NA	NA
DRKS00003691	Eletrical cardioversion versus defibrillation of atrial fibrilation - a clinical trial	NA	10.4126/frl01-006416711	https://repository.publisso.de/resource/frl%3A6416711	4	2012-03-29	Recruiting complete, follow-up complete	2008-02-19	2015-10-15	2019-07-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Induction of ventricular fibbrilation or ventricular tachycardia""]	[""Induction of ventricular fibbrilation or ventricular tachycardia""]	[""Induction of ventricular fibbrilation or ventricular tachycardia during treatment""]	[""Induction of ventricular fibbrilation or ventricular tachycardia during treatment""]	NA
DRKS00003802	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31] Cytogenetic Abnormality	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)	10.3324/haematol.2013.098103	http://www.haematologica.org/content/99/6/1041.long	11	2012-05-07	Recruiting complete, follow-up complete	2005-07-31	2010-06-01	2014-03-28	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""- Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days); time frame: Up to 52 weeks; The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.\n""]	NA	[""- Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days); time frame: Up to 52 weeks; The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.\n""]	[""- Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days); time frame: Up to 52 weeks; The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.\n""]	NA
DRKS00003839	Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP	Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)	10.1200/jco.2013.49.0771	https://www.ncbi.nlm.nih.gov/pubmed/24127442?dopt=Abstract	9	2012-05-11	Recruiting complete, follow-up complete	2002-09-30	2012-02-01	2013-10-14	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""- Overall survival\n""]	NA	[""- Overall survival\n""]	[""- Overall survival\n""]	NA
DRKS00003856	Reducing stress and supporting positive relations in families of young children with type 1 diabetes: A randomized controlled study for evaluating the effects of the DELFIN parenting program	Reducing stress and supporting positive relations in families of young children with type 1 diabetes: a randomized controlled study for evaluating the effects of the DELFIN parenting program	10.1186/1471-2431-12-152	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512538/	2	2012-05-04	Recruiting complete, follow-up complete	2008-08-01	2010-11-01	2012-09-20	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Parenting skills, parents’ psychological burden, children's behavior difficulties were collected before and 3 months after the intervention. Additionally at 12 month follow-up for the parents of the intervention group. The \""Parenting Scale\"" (Arnold, O'Leary, Wolff & Acker, 1993) was used in the German version (\""Erziehungsfragebogen\"", Miller, 2001) to measure parent education skills in conflict situations. The Questions to Education Behavior (\""Fragen zum Erziehungsverhalten\"", Miller, 2001; Heinrichs, Hahlweg, Bertram, Kuschel, Naumann & Harstick, 2006) form was used to assess the amount of positive, helping and reinforcing parental behavior. The Depression-Anxiety-Stress Scale (Lovibond & Lovibond, 1995) was used in the German version (\""Depressions-Angst-Stress Skala\"", Köppe, 2001) to measure depressed mood, anxiety and stress. Further the German version of the \""Strengths and Difficulties Questionnaires\"" (Goodman, 1999; Woerner, Becker & Rothenberger, 2004) was used to assess potential child difficulties (emotional symptoms, hyperactivity, conduct and peer relationship problems) and child's prosocial behavior.\n\n""]	NA	[""Parenting skills, parents’ psychological burden, children's behavior difficulties were collected before and 3 months after the intervention. Additionally at 12 month follow-up for the parents of the intervention group. The \""Parenting Scale\"" (Arnold, O'Leary, Wolff & Acker, 1993) was used in the German version (\""Erziehungsfragebogen\"", Miller, 2001) to measure parent education skills in conflict situations. The Questions to Education Behavior (\""Fragen zum Erziehungsverhalten\"", Miller, 2001; Heinrichs, Hahlweg, Bertram, Kuschel, Naumann & Harstick, 2006) form was used to assess the amount of positive, helping and reinforcing parental behavior. The Depression-Anxiety-Stress Scale (Lovibond & Lovibond, 1995) was used in the German version (\""Depressions-Angst-Stress Skala\"", Köppe, 2001) to measure depressed mood, anxiety and stress. Further the German version of the \""Strengths and Difficulties Questionnaires\"" (Goodman, 1999; Woerner, Becker & Rothenberger, 2004) was used to assess potential child difficulties (emotional symptoms, hyperactivity, conduct and peer relationship problems) and child's prosocial behavior.\n\n""]	[""Parenting skills, parents’ psychological burden, children's behavior difficulties were collected before and 3 months after the intervention. Additionally at 12 month follow-up for the parents of the intervention group. The \""Parenting Scale\"" (Arnold, O'Leary, Wolff & Acker, 1993) was used in the German version (\""Erziehungsfragebogen\"", Miller, 2001) to measure parent education skills in conflict situations. The Questions to Education Behavior (\""Fragen zum Erziehungsverhalten\"", Miller, 2001; Heinrichs, Hahlweg, Bertram, Kuschel, Naumann & Harstick, 2006) form was used to assess the amount of positive, helping and reinforcing parental behavior. The Depression-Anxiety-Stress Scale (Lovibond & Lovibond, 1995) was used in the German version (\""Depressions-Angst-Stress Skala\"", Köppe, 2001) to measure depressed mood, anxiety and stress. Further the German version of the \""Strengths and Difficulties Questionnaires\"" (Goodman, 1999; Woerner, Becker & Rothenberger, 2004) was used to assess potential child difficulties (emotional symptoms, hyperactivity, conduct and peer relationship problems) and child's prosocial behavior.\n\n""]	NA
DRKS00003894	Aerobic endurance training during therapy in lymphoma patients	Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy	10.1093/annonc/mdt568	https://academic.oup.com/annonc/article/25/2/493/193220/Exercise-program-improves-therapy-related-side	10	2012-08-20	Recruiting complete, follow-up complete	2008-05-27	2013-06-01	2014-02-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""improvement of QoL Fatigue\nimprovement of QoL (EORTC QLQ-C30)""]	[""improvement of QoL Fatigue\nimprovement of QoL (EORTC QLQ-C30)""]	[""improvement of QoL Fatigue\nimprovement of QoL (EORTC QLQ-C30)""]	[""improvement of QoL Fatigue\nimprovement of QoL (EORTC QLQ-C30)""]	NA
DRKS00003934	Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel or Fluanxol	Quetiapine and flupentixol differentially improve anterior cingulate cortex function in schizophrenia patients: an event-related potential study	10.1017/s1461145713000540	https://www.ncbi.nlm.nih.gov/pubmed/23759203	3	2012-05-11	Recruiting complete, follow-up complete	2008-01-14	2012-01-10	2013-06-12	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""ERN/Ne (error-related negativity or error-negativity) as a neurophysiological marker of frontal lobe function measured at day 1 and day 30""]	NA	[""ERN/Ne (error-related negativity or error-negativity) as a neurophysiological marker of frontal lobe function measured at day 1 and day 30""]	[""ERN/Ne (error-related negativity or error-negativity) as a neurophysiological marker of frontal lobe function measured at day 1 and day 30""]	NA
DRKS00003943	Treosulfan oral versus intravenous in recurrent ovarian cancer. An open-label, randomized, controlled, phase 3-b clinical trial	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)	10.1007/s00432-016-2307-0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306340/	7	2012-12-20	Recruiting complete, follow-up complete	2003-01-23	2014-02-04	2016-11-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Comparison of the tolerance of the different schemata in regards to hemotoxicity and gastro-intestinal toxicity grade 3-4 according to the Common Toxicity Criteria of the NCI.""]	[""Comparison of the tolerance of the different schemata in regards to hemotoxicity and gastro-intestinal toxicity grade 3-4 according to the Common Toxicity Criteria of the NCI.""]	[""Comparison of the tolerance of the different schemata in regards to hemotoxicity and gastro-intestinal toxicity grade 3-4 according to the Common Toxicity Criteria of the NCI.""]	[""Comparison of the tolerance of the different schemata in regards to hemotoxicity and gastro-intestinal toxicity grade 3-4 according to the Common Toxicity Criteria of the NCI.""]	NA
DRKS00003961	Anthocyanins in berry fruit juices – bioavailability and effects on the microbiota in humans	Anthocyanins from fruit juices improve the antioxidant status of healthy young female volunteers without affecting anti-inflammatory parameters: results from the randomised, double-blind, placebo-controlled, cross-over ANTHONIA (ANTHOcyanins in Nutrition Investigation Alliance) study	10.1017/s0007114514001482	https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/anthocyanins-from-fruit-juices-improve-the-antioxidant-status-of-healthy-young-female-volunteers-without-affecting-anti-inflammatory-parameters-results-from-the-randomised-double-blind-placebo-controlled-cross-over-anthonia-anthocyanins-in-nutrition-investigation-alliance-study/F4A59E6A76DFE1A48630C86A94686E6D	1	2012-05-25	Recruiting complete, follow-up complete	2010-04-19	2010-08-19	2014-08-04	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Investigation of the intestinal microbiota in humans with the use of Lactose-[13C,15N]-ureide, p-cresol in urine and short chain fatty acids in faeces on T0 (before 14-day intervention-period) and T1 (after 14-day intervention-period)""]	NA	[""Investigation of the intestinal microbiota in humans with the use of Lactose-[13C,15N]-ureide, p-cresol in urine and short chain fatty acids in faeces on T0 (before 14-day intervention-period) and T1 (after 14-day intervention-period)""]	NA	NA
DRKS00003979	Implementation and Evaluation of a Needs- and Community-Based Managed Mental Healthcare for Children and Adolescents after Abuse and Neglect - Case-Management Intervention Study	Effectiveness of manualized case management on utilization of evidence-based treatments for children and adolescents after maltreatment: A randomized controlled trial	10.1016/j.chiabu.2017.03.008	https://www.sciencedirect.com/science/article/pii/S014521341730100X	11	2012-07-03	Recruiting complete, follow-up complete	2012-10-29	2017-05-04	2017-03-31	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Number of children with clinically relevant psychological symptoms that are receiving evidence based therapy 6 months after the implementation of the intervention""]	[""Number of children with clinically relevant psychological symptoms that are receiving evidence based therapy 6 months after the implementation of the intervention""]	NA	[""Number of children with clinically relevant psychological symptoms that are receiving evidence based therapy 6 months after the implementation of the intervention""]	NA
DRKS00003980	EVALUATION OF ANTIHYPERTENSIVE EFFECTS OF FREQUENT thermoneutral  BATHS, A RANDOMIZED CONTROLLED TRIAL	Outcomes from a three-arm randomized controlled trial of frequent immersion in thermoneutral water on cardiovascular risk factors	10.1186/s12906-016-1241-7	NA	2	2012-07-10	Recruiting complete, follow-up complete	2012-07-23	2013-10-08	2016-07-27	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""morning blood pressure and 24-hour-RR measurement (diastolic, systolic, and MAP) before treatment, after 4 weeks of therapy and after 24 weeks of therapy""]	NA	[""morning blood pressure and 24-hour-RR measurement (diastolic, systolic, and MAP) before treatment, after 4 weeks of therapy and after 24 weeks of therapy""]	NA	NA
DRKS00004034	Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival	10.1038/nm.2883	https://www.ncbi.nlm.nih.gov/pubmed/22842478	6	2013-06-06	Recruiting complete, follow-up complete	2007-05-31	2009-08-01	2012-07-29	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""- Disease control rate; time frame: after 26 weeks\n""]	NA	NA	[""- Disease control rate; time frame: after 26 weeks\n""]	NA
DRKS00004158	Periimplantitis and soft-tissue defects of dental implants – A pilot study on the fixing of the suprastructure as a possible factor affecting aetiology	Undetected residual cement on standard or individualized all-ceramic abutments with cemented zirconia single crowns - a prospective randomized pilot trial	10.1111/clr.12691	https://onlinelibrary.wiley.com/doi/abs/10.1111/clr.12691	4	2012-07-27	Recruiting complete, follow-up complete	2013-11-11	2016-12-31	2015-09-18	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""The primary outcome is to examine the undetected excess cement on standard and individual abutments after 2 weeks (explorative examination).""]	NA	NA	[""The primary outcome is to examine the undetected excess cement on standard and individual abutments after 2 weeks (explorative examination).""]	NA
DRKS00004163	Influence of two different concepts for positioning on passive range of motion, comfort and vital parameters in severely affected patients with CNS lesion	Conventional versus neutral positioning in central neurological disease: a multicenter randomized controlled trial	10.3238/arztebl.2015.0035	NA	12	2012-06-11	Recruiting complete, follow-up complete	2011-04-04	2012-09-30	2015-01-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""difference of degrees of passive range of motion of flexion of the hip joints before and after being positioned for two hours""]	[""difference of degrees of passive range of motion of flexion of the hip joints before and after being positioned for two hours""]	[""difference of degrees of passive range of motion of flexion of the hip joints before and after being positioned for two hours""]	[""difference of degrees of passive range of motion of flexion of the hip joints before and after being positioned for two hours""]	NA
DRKS00004195	A Structured, manual-based low-level intervention vs. treatment as usual evaluated in a randomized controlled trial for adolescents with extreme obesity, Subproject 2	A Structured, Manual-Based Low-Level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents with Extreme Obesity - the STEREO Trial	10.1159/000475717	https://pubmed.ncbi.nlm.nih.gov/28787738/	13	2012-08-15	Recruiting complete, follow-up complete	2012-08-15	2014-06-30	2017-08-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Composite of:\na) Compliance rate: Number of regular participants at the time of the 6 months follow up.\nb) Changes (randomization-6 months follow up) in the 37 item DISABKIDS questionnaire.""]	[""Composite of:\na) Compliance rate: Number of regular participants at the time of the 6 months follow up.\nb) Changes (randomization-6 months follow up) in the 37 item DISABKIDS questionnaire.""]	[""Composite of:\na) Compliance rate: Number of regular participants at the time of the 6 months follow up.\nb) Changes (randomization-6 months follow up) in the 37 item DISABKIDS questionnaire.""]	[""Composite of:\na) Compliance rate: Number of regular participants at the time of the 6 months follow up.\nb) Changes (randomization-6 months follow up) in the 37 item DISABKIDS questionnaire.""]	NA
DRKS00004199	Optimisation of the peri-operative mechanical ventilation in normal-weight and morbid obese patients by PEEP-Titration using electric impedance tomography – a randomised controlled clinical trial	Individualized positive end-expiratory pressure in obese patients during general anaesthesia: a randomized controlled clinical trial using electrical impedance tomography	10.1093/bja/aex192	https://www.sciencedirect.com/science/article/pii/S0007091217541483	4	2012-07-27	Recruiting complete, follow-up complete	2012-11-01	2017-12-07	2017-12-01	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""postoperative oxygenation, measured by ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) directly before extubation""]	[""postoperative oxygenation, measured by ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) directly before extubation""]	NA	[""postoperative oxygenation, measured by ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) directly before extubation""]	NA
DRKS00004210	Effects of DBS on cognition of ppatients with essential tremor	Verbal fluency in essential tremor patients: the effects of deep brain stimulation	10.1016/j.brs.2014.02.012	https://www.ncbi.nlm.nih.gov/pubmed/24661791	4	2012-06-27	Recruiting complete, follow-up complete	2012-06-28	2012-10-01	2014-02-28	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Cognitive assessment through questionnaires: 1. Stroop-Test, 2. Hamilton anxiety rating scale (HARS), 3. Verbal fluency. 1+3 are tested in every condition and 2 is tested only once""]	NA	[""Cognitive assessment through questionnaires: 1. Stroop-Test, 2. Hamilton anxiety rating scale (HARS), 3. Verbal fluency. 1+3 are tested in every condition and 2 is tested only once""]	[""Cognitive assessment through questionnaires: 1. Stroop-Test, 2. Hamilton anxiety rating scale (HARS), 3. Verbal fluency. 1+3 are tested in every condition and 2 is tested only once""]	NA
DRKS00004220	The clinical success of the permanent posterior filling alternative Equia ®	Clinical performance during 48 months of two current glass ionomer restorative systems with coatings: a randomized clinical trial in the field	10.1186/s13063-016-1339-8	https://pubmed.ncbi.nlm.nih.gov/27156000/	10	2012-09-06	Recruiting complete, follow-up complete	2010-09-01	2015-07-31	2016-05-08	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Survival rate of the compared two arms in a 5 year follow up according to a calibrated evaluation based on FDI standard (Hickel et al 2010) beginning from baseline""]	[""Survival rate of the compared two arms in a 5 year follow up according to a calibrated evaluation based on FDI standard (Hickel et al 2010) beginning from baseline""]	NA	[""Survival rate of the compared two arms in a 5 year follow up according to a calibrated evaluation based on FDI standard (Hickel et al 2010) beginning from baseline""]	NA
DRKS00004223	Evaluation of electrical impedance tomography to optimise mechanical ventilation in laparoscopic bariatric surgery	Brief report: leaking esophageal probe may lead to false ventilator settings when guiding positive end-expiratory pressure by transpulmonary pressure	10.1213/ane.0b013e31829ec090	https://www.ncbi.nlm.nih.gov/pubmed/?term=Leaking+Esophageal+Probe+May+Lead+to+False+Ventilator+Settings+When+Guiding+Positive+End-Expiratory+Pressure+by+Transpulmonary+Pressure	5	2012-06-28	Recruiting complete, follow-up complete	2012-05-28	2013-03-25	2013-07-18	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Lung volume measurement using electrical impedance tomography intra/during/post operative in bariatric surgery""]	[""Lung volume measurement using electrical impedance tomography intra/during/post operative in bariatric surgery""]	NA	[""Lung volume measurement using electrical impedance tomography intra/during/post operative in bariatric surgery""]	NA
DRKS00004226	The impact of pre-operative patient education on post-operative outcome after major visceral surgery - A cluster-randomized controlled trial (PEDUCAT  Trial)	Impact of preoperative patient education on the prevention of postoperative complications after major visceral surgery: the cluster randomized controlled PEDUCAT trial	10.1186/s13063-018-2676-6	https://pubmed.ncbi.nlm.nih.gov/29793527/	8	2012-10-23	Recruiting complete, follow-up complete	2012-10-15	2014-03-08	2018-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""1. Feasibility\nThe aim of the study is to analyze the feasibility of the planned sequel study (e.g. feasibility of cluster-randomization and recruitment of patients)\n2. Generation of hypotheses\nFurthermore, the aim of the explorative study is to investigate the impact of the pre-operative education program on\n- post-operative morbidity (pulmonary, thrombotic, surgical, traumatic) (on day 2+7+30 after surgery)\n-mortality (on day 2+7+30 after surgery)\n- post-operative pain (at baseline, day 2+7 after surgery; with modified Brief Pain Inventory)\n- peri-operative anxiety/depression (at baseline, day 7+30 after surgery; with Hospital Anxiety and Depression Scale)\n- quality of life (at baseline, and day 30 after surgery; with SF-12) and length of hospital stay for 204 patients to detect suitable endpoints.\n""]	[""1. Feasibility\nThe aim of the study is to analyze the feasibility of the planned sequel study (e.g. feasibility of cluster-randomization and recruitment of patients)\n2. Generation of hypotheses\nFurthermore, the aim of the explorative study is to investigate the impact of the pre-operative education program on\n- post-operative morbidity (pulmonary, thrombotic, surgical, traumatic) (on day 2+7+30 after surgery)\n-mortality (on day 2+7+30 after surgery)\n- post-operative pain (at baseline, day 2+7 after surgery; with modified Brief Pain Inventory)\n- peri-operative anxiety/depression (at baseline, day 7+30 after surgery; with Hospital Anxiety and Depression Scale)\n- quality of life (at baseline, and day 30 after surgery; with SF-12) and length of hospital stay for 204 patients to detect suitable endpoints.\n""]	[""1. Feasibility\nThe aim of the study is to analyze the feasibility of the planned sequel study (e.g. feasibility of cluster-randomization and recruitment of patients)\n2. Generation of hypotheses\nFurthermore, the aim of the explorative study is to investigate the impact of the pre-operative education program on\n- post-operative morbidity (pulmonary, thrombotic, surgical, traumatic) (on day 2+7+30 after surgery)\n-mortality (on day 2+7+30 after surgery)\n- post-operative pain (at baseline, day 2+7 after surgery; with modified Brief Pain Inventory)\n- peri-operative anxiety/depression (at baseline, day 7+30 after surgery; with Hospital Anxiety and Depression Scale)\n- quality of life (at baseline, and day 30 after surgery; with SF-12) and length of hospital stay for 204 patients to detect suitable endpoints.\n""]	NA	NA
DRKS00004227	Propofol Sedation for Colonoscopy with a New Ultrathin or a Standard Endoscope: a Prospective Randomized Controlled Study	Propofol sedation for colonoscopy with a new ultrathin or a standard endoscope: a prospective randomized controlled study	10.1055/s-0032-1326270	https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0032-1326270	1	2012-07-04	Recruiting complete, follow-up complete	2011-05-17	2012-01-27	2013-03-06	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Consumption of propofol (mg) until colonoscope reaches caecum""]	NA	[""Consumption of propofol (mg) until colonoscope reaches caecum""]	NA	NA
DRKS00004235	Prospective, controlled study of deep brain stimulation (DBS) in the region of the posterior subthalamic area (PSA) with a randomized, double-blinded, cross-over comparison between PSA- and nucleus ventralis intermedius (VIM)-DBS for the treatment of essential tremor (ET).	DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial	10.1212/wnl.0000000000005956	https://pubmed.ncbi.nlm.nih.gov/29970404/	8	2013-07-09	Recruiting complete, follow-up complete	2013-01-07	2017-01-11	2018-07-03	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""Reduction of tremor 12 months after implantation in the PSA measured on tremor rating scale. Tremor rating scale Baseline versus Tremor rating scale 12 months follow up""]	[""Reduction of the Fahn Tremor Rating Scale (FTRS) at 3, 5 and 7 months after implantation and stimulation by PSA-DBS com-pared to baseline\n\nPlease note: Amendment from 04.11.2014 regarding the timepoint of Assesment of primary Endpoint. Approved by the Ethics Commitee.""]	[""Reduction of the Fahn Tremor Rating Scale (FTRS) at 3, 5 and 7 months after implantation and stimulation by PSA-DBS com-pared to baseline\n\nPlease note: Amendment from 04.11.2014 regarding the timepoint of Assesment of primary Endpoint. Approved by the Ethics Commitee.""]	NA	NA
DRKS00004239	Intervention Study on the Development and Implementation of a Practice Guideline for the Appropriate Pain Management of Older Persons in Nursing Homes	Nonpharmacologic Pain Management Interventions in German Nursing Homes: A Cluster Randomized Trial	10.1016/j.pmn.2014.09.002	https://www.linkedin.com/pulse/nonpharmacologic-pain-management-interventions-german-velandy-manohar	8	2012-07-25	Recruiting complete, follow-up complete	2012-02-13	2012-12-31	2015-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.\n\n\n\n\n""]	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.\n\n\n\n\n""]	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.""]	no maximum age	NA
DRKS00004241	Culture-sensitive information for patients with migration background and a chronic disease	Effects of culture-sensitive adaptation of patient information material on usefulness in migrants: a multicentre, blinded randomised controlled trial	10.1136/bmjopen-2016-012008	https://bmjopen.bmj.com/content/6/11/e012008.abstract	6	2013-04-17	Recruiting complete, follow-up complete	2013-06-21	2014-08-31	2016-11-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Perceived usefullness of patient information material assessed after consultation (T0; Usefulness Scale for Patient Information Material [USE])""]	[""Perceived usefullness of patient information material assessed after consultation (T0; Usefulness Scale for Patient Information Material [USE])""]	[""Perceived usefullness of patient information material assessed after consultation (T0; Usefulness Scale for Patient Information Material [USE])""]	[""Perceived usefullness of patient information material assessed after consultation (T0; Usefulness Scale for Patient Information Material [USE])""]	NA
DRKS00004245	Immediate load of implant retained overdenture prothesis on the edentulous mandible	Immediate Loading of Two Dental Implants, in Edentulous Mandibles, with Locator® Attachments or Dolder® Bars: First Results from a Prospective Randomized Clinical Study	10.1111/cid.12173	https://onlinelibrary.wiley.com/doi/abs/10.1111/cid.12173	7	2012-10-19	Recruiting complete, follow-up complete	2010-07-07	2014-11-30	2013-11-11	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Recalls after 3, 6, 12, and 24 month. the examination in clinically cumulative survivalrate of implants""]	[""Recalls after 3, 6, 12, and 24 month. the examination in clinically cumulative survivalrate of implants""]	NA	[""Recalls after 3, 6, 12, and 24 month. the examination in clinically cumulative survivalrate of implants""]	NA
DRKS00004257	Effectivity of different oxygen therapy devices in patients with chronic lung disease in the inflight environment: oxygen cylinders vs. oxygen concentrators	Comparison of portable oxygen concentrators in a simulated airplane environment	10.1016/j.rmed.2012.10.001	https://www.ncbi.nlm.nih.gov/pubmed/23085214	1	2012-07-20	Recruiting complete, follow-up complete	2011-07-01	2011-07-30	2012-10-22	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Main study objective was the arterial oxygenation after 30 min of exposure with each of the tested devices or after room air at 2650 m. Oxygenation was evaluated by blood gases from the arterialised ear lobe (PaO2, partial oxygen pressure).""]	NA	[""Main study objective was the arterial oxygenation after 30 min of exposure with each of the tested devices or after room air at 2650 m. Oxygenation was evaluated by blood gases from the arterialised ear lobe (PaO2, partial oxygen pressure).""]	NA	NA
DRKS00004271	What influence do information brochures have on the decision-making of women to take part in mammographic screening?	Willingness to participate in mammography screening: a randomized controlled questionnaire study of responses to two patient information leaflets with different factual content	10.3238/arztebl.2015.0061	https://pubmed.ncbi.nlm.nih.gov/25686383/	5	2012-08-27	Recruiting complete, follow-up complete	2012-07-15	2014-05-28	2015-01-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Percentage of the expressed willingness of participation compared to the group with the new brochure (Group A) versus the group with the old brochure (Group B).""]	[""Percentage of the expressed willingness of participation compared to the group with the new brochure (Group A) versus the group with the old brochure (Group B).""]	[""Percentage of the expressed willingness of participation compared to the group with the new brochure (Group A) versus the group with the old brochure (Group B).""]	[""Percentage of the expressed willingness of participation compared to the group with the new brochure (Group A) versus the group with the old brochure (Group B).""]	NA
DRKS00004275	Randomised clinical trial in subjects with temporomandibular dysfunction treated with Michigan Splint versus CAD/CAM Splint	Parallel Randomized Controlled Clinical Trial in Patients with Temporomandibular Disorders Treated with a CAD/CAM Versus a Conventional Stabilization Splint	10.11607/ijp.4711	https://www.ncbi.nlm.nih.gov/pubmed/27479339	4	2012-08-09	Recruiting complete, follow-up complete	2012-07-24	2013-10-31	2016-07-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""The primary outcome is the pain reduction measurement by numerical scale.\nThe measurement is going to be made befor the intervention and than monthly during 9 months.""]	[""The primary outcome is the pain reduction measurement by numerical scale.\nThe measurement is going to be made befor the intervention and than monthly during 9 months.""]	NA	[""The primary outcome is the pain reduction measurement by numerical scale.\nThe measurement is going to be made befor the intervention and than monthly during 9 months.""]	NA
DRKS00004288	Cognitive-behavioral treatment for female patients with PTSD and SUD	A multisite randomized controlled trial of Seeking Safety vs. Relapse Prevention Training for women with co-occurring posttraumatic stress disorder and substance use disorders	10.1080/20008198.2019.1577092	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383607/	9	2012-09-18	Recruiting complete, follow-up complete	2012-10-01	2016-05-20	2019-02-19	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""PTSD symptoms\nMethod: interview: SCID-I, PSS-I, self-report questionnaire: PDS,\ntime points: T0: before therapy, T1: after therapy (16 weeks later), T2: 3 months after the end of therapy, T3: 6 months after the end of theray""]	[""PTSD symptoms\nMethod: interview: SCID-I, PSS-I, self-report questionnaire: PDS,\ntime points: T0: before therapy, T1: after therapy (16 weeks later), T2: 3 months after the end of therapy, T3: 6 months after the end of theray""]	[""PTSD symptoms\nMethod: interview: SCID-I, PSS-I, self-report questionnaire: PDS,\ntime points: T0: before therapy, T1: after therapy (16 weeks later), T2: 3 months after the end of therapy, T3: 6 months after the end of theray""]	[""PTSD symptoms\nMethod: interview: SCID-I, PSS-I, self-report questionnaire: PDS,\ntime points: T0: before therapy, T1: after therapy (16 weeks later), T2: 3 months after the end of therapy, T3: 6 months after the end of theray""]	NA
DRKS00004309	Study to pilot-test an oral care self-management support protocol (OrCaSS) regarding feasability and effectiveness in patients with acute myeloid leukemia prior to allogeneic stem cell transplantation to prevent chemotherapy-related oral mucositis: a randomized, controlled pilot study	An oral care self-management support protocol (OrCaSS) to reduce oral mucositis in hospitalized patients with acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation: a randomized controlled pilot study	10.1007/s00520-015-2843-1	https://link.springer.com/article/10.1007/s00520-015-2843-1	9	2012-08-16	Recruiting complete, follow-up complete	2012-08-20	2013-05-01	2015-07-21	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Duration, severity and incidence of OM\n\nOM is measured daily with the WHO toxicity scale from the day of admission until day 20 after transplantation""]	[""Duration, severity and incidence of OM\n\nOM is measured daily with the WHO toxicity scale from the day of admission until day 20 after transplantation""]	[""Duration, severity and incidence of OM\n\nOM is measured daily with the WHO toxicity scale from the day of admission until day 20 after transplantation""]	[""Duration, severity and incidence of OM\n\nOM is measured daily with the WHO toxicity scale from the day of admission until day 20 after transplantation""]	NA
DRKS00004312	Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy, a randomized, placebo controlled cross over study	Efficacy of a Nasal Spray from Citrus limon and Cydonia oblonga for the Treatment of Hay Fever Symptoms-A Randomized, Placebo Controlled Cross-Over Study	10.1002/ptr.5649	NA	2	2012-10-29	Recruiting complete, follow-up complete	2012-10-29	2012-12-04	2016-06-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""•Rhinomanometrically measured inspiratory nasal flow at 150 Pascal after provocation with grass pollen in an intraindividual comparison between Gencydo and placebo treatment""]	[""•Rhinomanometrically measured inspiratory nasal flow at 150 Pascal after provocation with grass pollen in an intraindividual comparison between Gencydo and placebo treatment""]	[""•Rhinomanometrically measured inspiratory nasal flow at 150 Pascal after provocation with grass pollen in an intraindividual comparison between Gencydo and placebo treatment""]	NA	NA
DRKS00004313	Randomized comparison of two different treatment concepts in newly diagnosed acute promyelocytic leukemia (APL). A randomized study for comparison of the effects of ATRA and intensified double induction therapy incorporating high dose ara-C followed by TAD consolidation and cyclic maintenance therapy (AMLCG concept) and induction therapy with ATRA and idarubicin (AIDA) followed by three anthracyclin/ATRA- based consloidation courses and maintenance therapy (PETHEMA conzept).	Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines	10.1111/ejh.12994	NA	5	2012-08-20	Recruiting complete, follow-up complete	2005-11-24	2015-12-31	2017-11-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Assessment of the molecular and hematological remission rate, early death rate, toxicity, description of the kinetics of the minimal residual disease.\n\n\n\n""]	[""Assessment of the molecular and hematological remission rate, early death rate, toxicity, description of the kinetics of the minimal residual disease.\n\n\n\n""]	[""Assessment of the molecular and hematological remission rate, early death rate, toxicity, description of the kinetics of the minimal residual disease.\n\n\n\n""]	[""Assessment of the molecular and hematological remission rate, early death rate, toxicity, description of the kinetics of the minimal residual disease.\n\n\n\n""]	NA
DRKS00004327	Measurements of the sympathetic nerve activity to control the general anesthesia, with respect to hemodynamic stability, the occurrence of post-operative complications, and process times. Admentment 2012	Remifentanil added to sufentanil-sevoflurane anesthesia suppresses hemodynamic and metabolic stress responses to intense surgical stimuli more effectively than high-dose sufentanil-sevoflurane alone	10.1186/1471-2253-15-3	https://www.ncbi.nlm.nih.gov/pubmed/?term=DRKS00004327	3	2012-08-31	Recruiting complete, follow-up complete	2012-06-09	2013-04-12	2015-01-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""WHAT:. By controlling the depth of anesthesia and the sympathetic nervous system: reduction of intraoperative hemodynamic stress and thus stabilierer Operation in cardiopulmonary surgery\nWHEN: baseline, saw on the thoracotomy, sternum, chest retractor, recovery measurement, Aorta Injection\nHOW: reduction of oxygen consumption VO2 during thoracotomy, measurement of cardiac output, SVRI, CI, TEA ejection fraction, pulmonary wedge pressure, ESG, SPI and entropy.""]	[""WHAT:. By controlling the depth of anesthesia and the sympathetic nervous system: reduction of intraoperative hemodynamic stress and thus stabilierer Operation in cardiopulmonary surgery\nWHEN: baseline, saw on the thoracotomy, sternum, chest retractor, recovery measurement, Aorta Injection\nHOW: reduction of oxygen consumption VO2 during thoracotomy, measurement of cardiac output, SVRI, CI, TEA ejection fraction, pulmonary wedge pressure, ESG, SPI and entropy.""]	[""WHAT:. By controlling the depth of anesthesia and the sympathetic nervous system: reduction of intraoperative hemodynamic stress and thus stabilierer Operation in cardiopulmonary surgery\nWHEN: baseline, saw on the thoracotomy, sternum, chest retractor, recovery measurement, Aorta Injection\nHOW: reduction of oxygen consumption VO2 during thoracotomy, measurement of cardiac output, SVRI, CI, TEA ejection fraction, pulmonary wedge pressure, ESG, SPI and entropy.""]	NA	NA
DRKS00004350	Bioavailability of quercetin in healthy men and women	Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans	10.1007/s00394-015-1084-x	https://www.ncbi.nlm.nih.gov/pubmed/26482244	3	2012-08-29	Recruiting complete, follow-up complete	2012-09-24	2012-10-11	2015-10-20	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""concentration of quercetin in plasma (before bolus intake and after 0,5, 1, 1,5, 2, 3, 4, 5, 6, 7, 8, 9, 24 h)""]	NA	[""concentration of quercetin in plasma (before bolus intake and after 0,5, 1, 1,5, 2, 3, 4, 5, 6, 7, 8, 9, 24 h)""]	[""concentration of quercetin in plasma (before bolus intake and after 0,5, 1, 1,5, 2, 3, 4, 5, 6, 7, 8, 9, 24 h)""]	NA
DRKS00004386	Evaluation of a practice team-supported, self-managed exposure training for patients with panic disorder and agoraphobia in primary care	Cost-effectiveness of Practice Team-Supported Exposure Training for Panic Disorder and Agoraphobia in Primary Care: a Cluster-Randomized Trial	10.1007/s11606-020-05658-9	https://pubmed.ncbi.nlm.nih.gov/31965532/	4	2012-09-25	Recruiting complete, follow-up complete	2012-08-28	2016-02-17	2020-01-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Severity of anxiety, measured by the Beck Anxiety Inventory (BAI, sum of scores at measurement point T1 six months after baseline)""]	[""Severity of anxiety, measured by the Beck Anxiety Inventory (BAI, sum of scores at measurement point T1 six months after baseline)""]	[""Severity of anxiety, measured by the Beck Anxiety Inventory (BAI, sum of scores at measurement point T1 six months after baseline)""]	NA	NA
DRKS00004454	Novel three dimensional echocardiographic guided optimization improves clinical outcome in cardiac resynchronization therapy compared to electrocardiographic optimization - results of a randomized comparison	Acute beneficial hemodynamic effects of a novel 3D-echocardiographic optimization protocol in cardiac resynchronization therapy	10.1371/journal.pone.0030964	https://www.ncbi.nlm.nih.gov/pubmed/?term=Acute+Beneficial+Hemodynamic+Effects+of+a+Novel+3D-Echocardiographic+Optimization+Protocol+in+Cardiac+Resynchronization+Therapy	2	2012-10-09	Recruiting complete, follow-up complete	2010-01-07	2011-12-20	2012-02-03	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Response to CRT was defined as a reduction of NYHA class by ≥1 score.\nThe primary endpoint of the study was a comparison of this clinical response between group 1 and 2.\nNYHA-class was evaluated at the beginning of the study during the hospital stay before cardiac resynchronization therapy and at 3 months follow up in the hospital clinic with a patient history and documented in the patients records.""]	NA	NA	[""Response to CRT was defined as a reduction of NYHA class by ≥1 score.\nThe primary endpoint of the study was a comparison of this clinical response between group 1 and 2.\nNYHA-class was evaluated at the beginning of the study during the hospital stay before cardiac resynchronization therapy and at 3 months follow up in the hospital clinic with a patient history and documented in the patients records.""]	NA
DRKS00004513	Prospective randomized trial to compare postoperative results concerning anterior knee pain after total knee arthroplasty with or without augmented reconstruction of the medial patellofemoral ligament (mpfl)	Stability of capsule closure and postoperative anterior knee pain after medial parapatellar approach in TKA	10.1007/s00402-017-2706-y	https://link.springer.com/article/10.1007%2Fs00402-017-2706-y	7	2012-11-07	Recruiting complete, follow-up complete	2012-11-10	2017-06-09	2017-05-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""patellar tilt (Laurin et al.) or patellar shift (Merchant et al.) on x-rays of the knee 1 year postoperative""]	[""patellar tilt (Laurin et al.) or patellar shift (Merchant et al.) on x-rays of the knee 1 year postoperative""]	NA	[""patellar tilt (Laurin et al.) or patellar shift (Merchant et al.) on x-rays of the knee 1 year postoperative""]	NA
DRKS00004537	Ultrasound-guided peripheral nerve blocks in combination with general anesthesia on an outpatient basis, in terms of processing time, hemodynamic stability, complications, postoperative pain, and sympathetic activity compared to general anesthesia	Combination of general anesthesia and peripheral nerve block with low-dose ropivacaine reduces postoperative pain for several days after outpatient arthroscopy: A randomized controlled clinical trial	10.1097/md.0000000000006046	https://pubmed.ncbi.nlm.nih.gov/28178149/	3	2013-03-25	Recruiting complete, follow-up complete	2012-06-15	2015-07-31	2017-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""operational process times - perioperative documentation OP changing times / PACU (post-anesthesia care unit) discharge home\n\nPostoperative pain 3 days - telephone interview on 2 postoperative day""]	[""operational process times - perioperative documentation OP changing times / PACU (post-anesthesia care unit) discharge home\n\nPostoperative pain 3 days - telephone interview on 2 postoperative day""]	[""incidence and severity of postoperative pain, and time spent in recovery room - telephone interview on PACU and 2 postoperative days""]	NA	NA
DRKS00004541	The administration of biofeedback in patients with preterm labour	The effects of heart rate variability biofeedback in patients with preterm labour	10.1007/s10484-013-9238-1	https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Effects+of+Heart+Rate+Variability+Biofeedback+in+Patients+with+Preterm+Labour	2	2012-11-19	Recruiting complete, follow-up complete	2006-10-20	2009-10-28	2014-03-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Root mean square of successive differences of RR intervals (RMSSD) prior and post HRV biofeedback as well as 4 weeks later (follow up) by means of pulse wave analysis""]	NA	[""Root mean square of successive differences of RR intervals (RMSSD) prior and post HRV biofeedback as well as 4 weeks later (follow up) by means of pulse wave analysis""]	[""Root mean square of successive differences of RR intervals (RMSSD) prior and post HRV biofeedback as well as 4 weeks later (follow up) by means of pulse wave analysis""]	NA
DRKS00004570	Oral hygiene promotion in patients with fixed dental protheses. A randomised controlled study.	Effectiveness of Computer-Based Training on Toothbrush Skills of Patients Treated With Crowns: A Randomized Controlled Trial	10.1902/jop.2016.160099	https://aap.onlinelibrary.wiley.com/doi/full/10.1902/jop.2016.160099	7	2012-11-29	Recruiting complete, follow-up complete	2013-02-19	2014-04-29	2016-02-19	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Oral hygiene skills after 6 and 12 weeks assessed via marginal plaque index after thorough oral hygiene""]	[""Oral hygiene skills after 6 and 12 weeks assessed via marginal plaque index after thorough oral hygiene""]	[""Oral hygiene skills after 6 and 12 weeks assessed via marginal plaque index after thorough oral hygiene""]	[""Oral hygiene skills after 6 and 12 weeks assessed via marginal plaque index after thorough oral hygiene""]	NA
DRKS00004583	Feasibility and efficacy of a weight maintenance treatment approach for adolescent obesity via telephone counseling following an obesity treatment program: a randomized controlled trial	Case management via telephone counseling and SMS for weight maintenance in adolescent obesity: study concept of the TeAM program	10.1186/2052-9538-1-8	https://pubmed.ncbi.nlm.nih.gov/26217500/	10	2012-11-30	Recruiting complete, follow-up complete	2012-12-19	2015-04-30	2014-05-29	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""The primary outcome is BMI-SDS. Study visits, performed by trained medical staff, include one baseline visit (T0), after written agreement into participation and prior to randomization, and one closing visit after the end of intervention (T1) and two follow up visits (12 and 24 months after randomization (T2+T3)) for both groups (i.e. intervention and control group) to determine baseline and endpoint data.""]	[""The primary outcome is BMI-SDS. Study visits, performed by trained medical staff, include one baseline visit (T0), after written agreement into participation and prior to randomization, and one closing visit after the end of intervention (T1) and two follow up visits (12 and 24 months after randomization (T2+T3)) for both groups (i.e. intervention and control group) to determine baseline and endpoint data.""]	NA	[""The primary outcome is BMI-SDS. Study visits, performed by trained medical staff, include one baseline visit (T0), after written agreement into participation and prior to randomization, and one closing visit after the end of intervention (T1) and two follow up visits (12 and 24 months after randomization (T2+T3)) for both groups (i.e. intervention and control group) to determine baseline and endpoint data.""]	NA
DRKS00004595	The value of intraglandular application of botulinum toxin for prevention of radiation-induced sialadenitis in head and neck cancer: a scintigraphic analysis.	Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial	10.1371/journal.pone.0151316	https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+Efficacy+of+Botulinum+Toxin+to+Preserve+Gland+Function+after+Radiotherapy+in+Patients+with+Head+and+Neck+Cancer%3A+A+Prospective%2C+Randomized%2C+Placebo-Controlled%2C+Double-Blinded+Phase+I+Clinical+Trial	6	2012-12-14	Recruiting complete, follow-up complete	2010-07-12	2012-11-01	2016-03-18	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[""Difference of the\nproportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	NA	[""Difference of the\nproportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	[""Difference of the proportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	NA
DRKS00004622	Sentinel lymph node excision in the head and neck area for cutaneous malignancies: clinical evaluation of a hybrid tracer (technetium and indocyanine) versus technetium labeling	Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid	10.1007/s00259-015-3093-7	https://link.springer.com/article/10.1007/s00259-015-3093-7	10	2013-01-22	Recruiting complete, follow-up complete	2013-01-25	2014-12-31	2015-05-31	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Rate of SN positivity in the two arms, examined by histopathology after the operative procedure""]	[""Rate of SN positivity in the two arms, examined by histopathology after the operative procedure""]	[""Rate of SN positivity in the two arms, examined by histopathology after the operative procedure""]	[""Rate of SN positivity in the two arms, examined by histopathology after the operative procedure""]	NA
DRKS00004649	Multicentric investigation of behavioral and neuronal influences of adverse childhood experiences on mother-child interaction	EMOTIONAL AVAILABILITY IN MOTHER-CHILD INTERACTION: THE EFFECTS OF MATERNAL DEPRESSION IN REMISSION AND ADDITIONAL HISTORY OF CHILDHOOD ABUSE	10.1002/da.22462	https://pubmed.ncbi.nlm.nih.gov/26697826/	5	2013-01-31	Recruiting complete, follow-up complete	2013-01-01	2016-05-31	2015-12-23	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Mother: Changes in maternal sensitivity from baseline to follow-up I (after intervention) (EA-score). Child: Changes in the child's well-being from baseline to follow-up I (after intervention) (KIDS-SCREEN-score).""]	[""Mother: Changes in maternal sensitivity from baseline to follow-up I (after intervention) (EA-score). Child: Changes in the child's well-being from baseline to follow-up I (after intervention) (KIDS-SCREEN-score).""]	NA	[""Mother: Changes in maternal sensitivity from baseline to follow-up I (after intervention) (EA-score). Child: Changes in the child's well-being from baseline to follow-up I (after intervention) (KIDS-SCREEN-score).""]	NA
DRKS00004653	Influence of 10 Hz rTMS and noradrenergic modulation on motor learning in healthy humans	Synergistic effects of noradrenergic modulation with atomoxetine and 10 Hz repetitive transcranial magnetic stimulation on motor learning in healthy humans	10.1186/1471-2202-15-46	https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-15-46	1	2013-01-16	Recruiting complete, follow-up complete	2012-05-28	2012-10-01	2014-04-02	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Assessment of motor potentials evoked by transcranial magnetic stimulation, potentials were recorded with surface EMG-electrodes from the first dorsal interosseus muscle of the left hand (peak-to-peak-amplitudes in mV):\nresting motor threshold, short-intracortical-inhibition, intracortical facilitation, stimulus response curve\n\nMeasured by the raw data of the fingertapping task:\ntarget score (total number of correct responses), execution time (time required to the subsequent correct response in ms)""]	NA	[""Assessment of motor potentials evoked by transcranial magnetic stimulation, potentials were recorded with surface EMG-electrodes from the first dorsal interosseus muscle of the left hand (peak-to-peak-amplitudes in mV):\nresting motor threshold, short-intracortical-inhibition, intracortical facilitation, stimulus response curve\n\nMeasured by the raw data of the fingertapping task:\ntarget score (total number of correct responses), execution time (time required to the subsequent correct response in ms)""]	NA	NA
DRKS00004675	The impact on training results of assigning either one or two test persons to work stations in multimodal laparascopic training courses.	One or two trainees per workplace for laparoscopic surgery training courses: results from a randomized controlled trial	10.1007/s00464-018-6440-5	https://link.springer.com/article/10.1007/s00464-018-6440-5	6	2013-06-11	Recruiting complete, follow-up complete	2012-10-19	2014-12-23	2018-09-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The main-objective criterion is the operative performance of the study participants during the final laparoscopic cholecystectomy based on the standardized validated OSATS-criteria. The operative performance of the study participants is measured by two scales. The scale \""generic technical skills\"" covers a range from 6 (min) to 30 points (max). The maximal achievable score of \""specific technical skills\"" is 70 points and the minimal score 14 points. Both scales will be evaluated separately. The OSATS-scores are based on a Gaussian distribution. The scale \""specific technical skills\"" will be applied in a modified way in this study due to its specific circumstances. The criteria \""incision & insertion of the port\"" and \"" extraction of the gallbladder\"" refer to surgeries on humans or on living animals and cannot be rated appropriately on the P.O.P.-trainer. Both are replaced by the criteria \""knowledge of surgery specific aspects\"" and \""quality of the final product\"".\n""]	[""The main-objective criterion is the operative performance of the study participants during the final laparoscopic cholecystectomy based on the standardized validated OSATS-criteria. The operative performance of the study participants is measured by two scales. The scale \""generic technical skills\"" covers a range from 6 (min) to 30 points (max). The maximal achievable score of \""specific technical skills\"" is 70 points and the minimal score 14 points. Both scales will be evaluated separately. The OSATS-scores are based on a Gaussian distribution. The scale \""specific technical skills\"" will be applied in a modified way in this study due to its specific circumstances. The criteria \""incision & insertion of the port\"" and \"" extraction of the gallbladder\"" refer to surgeries on humans or on living animals and cannot be rated appropriately on the P.O.P.-trainer. Both are replaced by the criteria \""knowledge of surgery specific aspects\"" and \""quality of the final product\"".\n""]	[""The main-objective criterion is the operative performance of the study participants during the final laparoscopic cholecystectomy based on the standardized validated OSATS-criteria. The operative performance of the study participants is measured by two scales. The scale \""generic technical skills\"" covers a range from 6 (min) to 30 points (max). The maximal achievable score of \""specific technical skills\"" is 70 points and the minimal score 14 points. Both scales will be evaluated separately. The OSATS-scores are based on a Gaussian distribution. The scale \""specific technical skills\"" will be applied in a modified way in this study due to its specific circumstances. The criteria \""incision & insertion of the port\"" and \"" extraction of the gallbladder\"" refer to surgeries on humans or on living animals and cannot be rated appropriately on the P.O.P.-trainer. Both are replaced by the criteria \""knowledge of surgery specific aspects\"" and \""quality of the final product\"".\n""]	NA	NA
DRKS00004685	Pre-study on the mobile Augmented Reality blended learning environment with students at Hannover Medical School	Effects of mobile augmented reality learning compared to textbook learning on medical students: randomized controlled pilot study	10.2196/jmir.2497	https://www.ncbi.nlm.nih.gov/pubmed/23963306	1	2013-02-01	Recruiting complete, follow-up complete	2012-02-23	2012-02-24	2013-08-20	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Learning efficiency before and after the learning phase measured with a 10-item SC-test""]	NA	[""Learning efficiency before and after the learning phase measured with a 10-item SC-test""]	NA	NA
DRKS00004721	Longitudinal Urban Cohort Ageing Study, Subproject 6: Potentially Inappropriate Medication (PIM) and in-hospital falls	Geriatric patients with cognitive impairment	10.3238/arztebl.2015.0103	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353868/	6	2013-02-11	Recruiting complete, follow-up complete	2012-02-01	2013-08-30	2015-02-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""PRISCUS-PIMs (as measured by PIM-Alert, during hospital stay and at discharge compared to PIMs on admission);\n\nChanges in PIMs by PIM Alert\n""]	[""PRISCUS-PIMs (as measured by PIM-Alert, during hospital stay and at discharge compared to PIMs on admission);\n\nChanges in PIMs by PIM Alert\n""]	[""PRISCUS-PIMs (as measured by PIM-Alert, during hospital stay and at discharge compared to PIMs on admission);\n\nChanges in PIMs by PIM Alert\n""]	[""PRISCUS-PIMs (as measured by PIM-Alert, during hospital stay and at discharge compared to PIMs on admission);\n\nChanges in PIMs by PIM Alert\n""]	NA
DRKS00004791	Sedation for CVL in children - influence of parent's voice on consumption of sedative drugs	The influence of parents' voice on the consumption of propofol for pediatric procedural sedation-a randomized controlled trial	10.1111/pan.13078	https://onlinelibrary.wiley.com/doi/abs/10.1111/pan.13078	2	2013-03-05	Recruiting complete, follow-up complete	2013-04-01	2015-09-14	2017-02-08	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""amount of propofol needed in both groups""]	NA	[""amount of propofol needed in both groups""]	NA	NA
DRKS00004826	Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standart clinical care within outcome research.	Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study	10.1186/1471-2407-13-407	https://www.ncbi.nlm.nih.gov/pubmed/24006873	1	2013-03-19	Recruiting complete, follow-up complete	2006-04-03	2010-12-31	2013-09-04	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""proportion of patients classified “adherent” after 12 months; patients were classified adherent if both self-report and prescription refill revealed an adherence above 80%""]	NA	[""proportion of patients classified “adherent” after 12 months; patients were classified adherent if both self-report and prescription refill revealed an adherence above 80%""]	NA	NA
DRKS00004841	Effectiveness of a self-management patient education program ""Curriculum Heart Failure"" for inpatient cardiac rehabilitation.	The impact of a self-management patient education program for patients with chronic heart failure undergoing inpatient cardiac rehabilitation	10.1016/j.pec.2016.02.010	https://www.sciencedirect.com/science/article/pii/S0738399116300714?via%3Dihub	5	2013-04-05	Recruiting complete, follow-up complete	2012-01-02	2014-12-31	2016-02-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""1) Self-management competence; Health Education Impact Questionnaire HeiQ - Scales Self-monitoring and insight, Skill and technique acquisition (german version; Schuler et al., 2012); time frame: admission, discharge, after 6 months, after 12 months.\n2) Self-efficacy; Kansas City Cardiomyopathy Questionnaire KCCQ (german version; Faller et al., 2005); time frame: admission, discharge, after 6 months, after 12 months.""]	[""1) Self-management competence; Health Education Impact Questionnaire HeiQ - Scales Self-monitoring and insight, Skill and technique acquisition (german version; Schuler et al., 2012); time frame: admission, discharge, after 6 months, after 12 months.\n2) Self-efficacy; Kansas City Cardiomyopathy Questionnaire KCCQ (german version; Faller et al., 2005); time frame: admission, discharge, after 6 months, after 12 months.""]	[""1) Self-management competence; Health Education Impact Questionnaire HeiQ - Scales Self-monitoring and insight, Skill and technique acquisition (german version; Schuler et al., 2012); time frame: admission, discharge, after 6 months, after 12 months.\n2) Self-efficacy; Kansas City Cardiomyopathy Questionnaire KCCQ (german version; Faller et al., 2005); time frame: admission, discharge, after 6 months, after 12 months.""]	[""1) Self-management competence; Health Education Impact Questionnaire HeiQ - Scales Self-monitoring and insight, Skill and technique acquisition (german version; Schuler et al., 2012); time frame: admission, discharge, after 6 months, after 12 months.\n2) Self-efficacy; Kansas City Cardiomyopathy Questionnaire KCCQ (german version; Faller et al., 2005); time frame: admission, discharge, after 6 months, after 12 months.""]	NA
DRKS00004846	3D evaluation of postoperative swelling in treatment of zygomatic bone fractures using 2 different cooling therapy methods: - A randomized observer blind prospective study –	Three-dimensional evaluation of postoperative swelling in treatment of zygomatic bone fractures using two different cooling therapy methods: a randomized, observer-blind, prospective study	10.1186/1745-6215-14-238	https://www.ncbi.nlm.nih.gov/pubmed/23895539	1	2013-03-26	Recruiting complete, follow-up complete	2009-01-12	2012-10-30	2013-07-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""swelling: 3D optical scans were recorded at 6 points in time: on the 1st day after surgery (T1), on the 2nd (T2), the 3rd (T3), the 7th (T4) and the 28th (T5) and the 90th (T6) postoperative day\npain: 10-point visual analogue scale (VAS) based on measurements before surgery (T0), on the 1st (T1), 2nd (T2) and 7th (T3) day after operation\neye motility and diplopia: For the analysis of eye motility and diplopia the patient was required to fix a light source at a distance of 30 cm. While the head was fixed, the light source was guided in different directions of view. The relative displacement of the reflected images to each other and the movement of the eye were analyzed. Meanwhile, the patient was asked about diplopia. The data were collected at 4 points in time: before surgery (T0), on the 1st (T1), the 7th (T2) and the 28th (T3) postoperative day.\nneurological complaints: The skin of the upper lip was checked using a cotton test for touch sensation, a pinprick test using a needle for sharp pain and a blunt instrument for testing pressure. Additionally, a two-point discrimination test was executed on the lip. The results were recorded on a score that ranges between 0 and 9, with 9 being the worst neurological score. The neurological score was assessed at 5 points in time: before surgery (T0), on the 1st (T1), the 7nd (T2), the 28th (T3), and the 90th (T4) postoperative day\npatient satisfaction:Each patient was asked to complete a questionnaire on the 10th postoperative day subjectively rating their comfort and satisfaction with the applied postoperative cooling therapy. The grading scale ranged from 1 to 4, where 1 denoted “very satisfied” and 4 for “not satisfied”.""]	NA	[""swelling: 3D optical scans were recorded at 6 points in time: on the 1st day after surgery (T1), on the 2nd (T2), the 3rd (T3), the 7th (T4) and the 28th (T5) and the 90th (T6) postoperative day\npain: 10-point visual analogue scale (VAS) based on measurements before surgery (T0), on the 1st (T1), 2nd (T2) and 7th (T3) day after operation\neye motility and diplopia: For the analysis of eye motility and diplopia the patient was required to fix a light source at a distance of 30 cm. While the head was fixed, the light source was guided in different directions of view. The relative displacement of the reflected images to each other and the movement of the eye were analyzed. Meanwhile, the patient was asked about diplopia. The data were collected at 4 points in time: before surgery (T0), on the 1st (T1), the 7th (T2) and the 28th (T3) postoperative day.\nneurological complaints: The skin of the upper lip was checked using a cotton test for touch sensation, a pinprick test using a needle for sharp pain and a blunt instrument for testing pressure. Additionally, a two-point discrimination test was executed on the lip. The results were recorded on a score that ranges between 0 and 9, with 9 being the worst neurological score. The neurological score was assessed at 5 points in time: before surgery (T0), on the 1st (T1), the 7nd (T2), the 28th (T3), and the 90th (T4) postoperative day\npatient satisfaction:Each patient was asked to complete a questionnaire on the 10th postoperative day subjectively rating their comfort and satisfaction with the applied postoperative cooling therapy. The grading scale ranged from 1 to 4, where 1 denoted “very satisfied” and 4 for “not satisfied”.""]	NA	NA
DRKS00004871	Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study	The Effectiveness of Leech Therapy in Chronic Low Back Pain	10.3238/arztebl.2018.0785	https://pubmed.ncbi.nlm.nih.gov/30636672/	5	2013-04-26	Recruiting complete, follow-up complete	2013-05-02	2015-12-14	2018-11-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""global back pain on a 100mm VAS (visual analog scale) at day 28+-3\n""]	[""global back pain on a 100mm VAS (visual analog scale) at day 28+-3\n""]	[""global back pain on a 100mm VAS (visual analog scale) at day 28+-3\n""]	NA	NA
DRKS00004885	Bottle-feeding in infants: a randomized and controlled clinical trial to suction behaviour by use of feading teats with and without anticolic system	Sucking behaviour using feeding teats with and without an anticolic system: a randomized controlled clinical trial	10.1186/s12887-018-1092-0	https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-018-1092-0	9	2013-04-16	Recruiting complete, follow-up complete	2013-11-18	2015-07-01	2018-03-16	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""At the beginning of trial participation the parents will be handed out a documentation sheet and one randomly allocated feeding teat with a corresponding bottle for their infant. Then the parents feed their infant at home exclusively with the assigned bottle and feeding teat. In this period, they document the child's behavior (drinking behavior, colic behavior) in the documentation sheet handed out.\nAfter an acclimatization period of 14 to 21 days, the parents visit the UKM (University clinic of Münster) with their child. Here a parent feeds the infant as usual with the allotted feeding teat and the corresponding bottle with the usual determined by the parents themselves bottle contents until the child has finished or no longer wants to drink. The first 10 to 15 minutes (depending on the age of the child) are being watched by an examiner to observe appropriate sucks and pauses during the feeding process and is being documented. Moreover, heart rate, respiratory rate and oxygen saturation of the child (ECG monitor VitaGuard VG3100) are being recorded simultaneously.""]	[""At the beginning of trial participation the parents will be handed out a documentation sheet and one randomly allocated feeding teat with a corresponding bottle for their infant. Then the parents feed their infant at home exclusively with the assigned bottle and feeding teat. In this period, they document the child's behavior (drinking behavior, colic behavior) in the documentation sheet handed out.\nAfter an acclimatization period of 14 to 21 days, the parents visit the UKM (University clinic of Münster) with their child. Here a parent feeds the infant as usual with the allotted feeding teat and the corresponding bottle with the usual determined by the parents themselves bottle contents until the child has finished or no longer wants to drink. The first 10 to 15 minutes (depending on the age of the child) are being watched by an examiner to observe appropriate sucks and pauses during the feeding process and is being documented. Moreover, heart rate, respiratory rate and oxygen saturation of the child (ECG monitor VitaGuard VG3100) are being recorded simultaneously.""]	[""At the beginning of trial participation the parents will be handed out a documentation sheet and one randomly allocated feeding teat with a corresponding bottle for their infant. Then the parents feed their infant at home exclusively with the assigned bottle and feeding teat. In this period, they document the child's behavior (drinking behavior, colic behavior) in the documentation sheet handed out.\nAfter an acclimatization period of 14 to 21 days, the parents visit the UKM (University clinic of Münster) with their child. Here a parent feeds the infant as usual with the allotted feeding teat and the corresponding bottle with the usual determined by the parents themselves bottle contents until the child has finished or no longer wants to drink. The first 10 to 15 minutes (depending on the age of the child) are being watched by an examiner to observe appropriate sucks and pauses during the feeding process and is being documented. Moreover, heart rate, respiratory rate and oxygen saturation of the child (ECG monitor VitaGuard VG3100) are being recorded simultaneously.""]	[""At the beginning of trial participation the parents will be handed out a documentation sheet and one randomly allocated feeding teat with a corresponding bottle for their infant. Then the parents feed their infant at home exclusively with the assigned bottle and feeding teat. In this period, they document the child's behavior (drinking behavior, colic behavior) in the documentation sheet handed out.\nAfter an acclimatization period of 14 to 21 days, the parents visit the UKM (University clinic of Münster) with their child. Here a parent feeds the infant as usual with the allotted feeding teat and the corresponding bottle with the usual determined by the parents themselves bottle contents until the child has finished or no longer wants to drink. The first 10 to 15 minutes (depending on the age of the child) are being watched by an examiner to observe appropriate sucks and pauses during the feeding process and is being documented. Moreover, heart rate, respiratory rate and oxygen saturation of the child (ECG monitor VitaGuard VG3100) are being recorded simultaneously.""]	NA
DRKS00004887	Changing lifestyle and improving subjective judgment of occupation by a  planning-competence-training with follow-up care among type II diabetes mellitus and adiposity inpatients: a randomized controlled trail.	[Supporting Patients with Diabetes mellitus type 2 and Obesity in Transfer of Medically Indicated Lifestyle Changes into Everyday Life by a Planning Competence Training in a Randomized Controlled Trial]	10.1055/a-0891-3505	https://pubmed.ncbi.nlm.nih.gov/31108553/	2	2013-10-07	Recruiting complete, follow-up complete	2013-01-16	2015-04-30	2019-05-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Return to work prediction: „Skala der subjektiven Prognose der Erwerbstätigkeit“ (SPE-Skala), Mittag & Raspe (2003);\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation\n\ndaily routine (dietary and exercise habits):\ndietary habits: „Fragebogen zum Ernährungsverhalten“\nMeasured at the beginning of the rehabilitation (t1) and six months after the rehabilitation (t3)\n\nexercise habits: metabolic equivalent\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation (t3)""]	[""Return to work prediction: „Skala der subjektiven Prognose der Erwerbstätigkeit“ (SPE-Skala), Mittag & Raspe (2003);\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation\n\ndaily routine (dietary and exercise habits):\ndietary habits: „Fragebogen zum Ernährungsverhalten“\nMeasured at the beginning of the rehabilitation (t1) and six months after the rehabilitation (t3)\n\nexercise habits: metabolic equivalent\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation (t3)""]	[""Return to work prediction: „Skala der subjektiven Prognose der Erwerbstätigkeit“ (SPE-Skala), Mittag & Raspe (2003);\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation\n\ndaily routine (dietary and exercise habits):\ndietary habits: „Fragebogen zum Ernährungsverhalten“\nMeasured at the beginning of the rehabilitation (t1) and six months after the rehabilitation (t3)\n\nexercise habits: metabolic equivalent\nMeasured at the beginning of the rehabilitation (t1), at the end (t2) and six months after the rehabilitation (t3)""]	NA	NA
DRKS00004900	Multicenter, randomized, controlled trial comparing complication rates of open and closed implantation strategies for insertion of a totally implantable venous access port (TIVAP) in oncological patients	Primary Open Versus Closed Implantation Strategy for Totally Implantable Venous Access Ports: The Multicentre Randomized Controlled PORTAS-3 Trial (DRKS 00004900)	10.1097/sla.0000000000003705	https://pubmed.ncbi.nlm.nih.gov/31800490/	7	2014-08-28	Recruiting complete, follow-up complete	2014-11-10	2016-10-07	2019-11-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Frequency of pneumo-/hemothorax after TIVAP implantation diagnosed by means of a chest x-ray on the day of operation. Telephone interview on postoperative day 30""]	[""Frequency of pneumo-/hemothorax after TIVAP implantation diagnosed by means of a chest x-ray on the day of operation. Telephone interview on postoperative day 30""]	[""Frequency of pneumo-/hemothorax after TIVAP implantation diagnosed by means of a chest x-ray on the day of operation. Telephone interview on postoperative day 30""]	NA	NA
DRKS00004911	Cardiovascular effects of aerobic and isometric exercise in patients with arterial hypertension	Aerobic versus isometric handgrip exercise in hypertension: a randomized controlled trial	10.1097/hjh.0000000000001445	https://pubmed.ncbi.nlm.nih.gov/28622156/	3	2013-04-29	Recruiting complete, follow-up complete	2013-02-27	2014-11-28	2017-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Reduction of systolic and diastolic blood pressure in the clinic and ambulatory 24-hour blood-pressure measurement after the exercise training (12 weeks).""]	[""Reduction of systolic and diastolic blood pressure in the clinic and ambulatory 24-hour blood-pressure measurement after the exercise training (12 weeks).""]	[""Reduction of systolic and diastolic blood pressure in the clinic and ambulatory 24-hour blood-pressure measurement after the exercise training (12 weeks).""]	NA	NA
DRKS00004968	A psycho educational group intervention to support patient competence: a multicenter evaluation study	Psychoeducational group intervention for breast cancer survivors: a non-randomized multi-center pilot study	10.1007/s00520-019-05076-6	https://link.springer.com/article/10.1007/s00520-019-05076-6#rightslink	5	2013-05-15	Recruiting complete, follow-up complete	2013-12-01	2015-02-28	2019-10-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""According to the intended effects of the training the primary outcome is the subscale 'ability to cope with emotional stress' of the self-assessment instrument for patient competency (FEPK-2-57) developed by Giesler & Weis (2008). The review of the achievement of objectives is based on the survey of the time points T1-T3: T1 after study inclusion and prior randomization, T2 after the end of training for immediate / intervention group or after an appropriate time of 6-8weeks for waiting / control group and T3 after 6-8 weeks for both groups. The completion of the data collection is planned at the beginning of the third year of the study.""]	NA	[""According to the intended effects of the training the primary outcome is the subscale 'ability to cope with emotional stress' of the self-assessment instrument for patient competency (FEPK-2-57) developed by Giesler & Weis (2008). The review of the achievement of objectives is based on the survey of the time points T1-T3: T1 after study inclusion and prior randomization, T2 after the end of training for immediate / intervention group or after an appropriate time of 6-8weeks for waiting / control group and T3 after 6-8 weeks for both groups. The completion of the data collection is planned at the beginning of the third year of the study.""]	NA	NA
DRKS00004978	Neuropsychological intervention in Parkinson's disease	Cognitive training in Parkinson's disease reduces cognitive decline in the long term	10.1111/ene.12621	https://www.onlinelibrary.wiley.com/doi/10.1111/ene.12621	3	2013-05-29	Recruiting complete, follow-up complete	2013-05-31	2014-01-01	2014-12-22	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Effects on cognitive total scores (DemTect, MMSE). The primary outcomes are examined at T0 (pretest), T1 (examination after the intervention or after 6 weeks without intervention), T2 (one year follow-up), T3 (2 year follow-up).""]	[""Effects on cognitive total scores (DemTect, MMSE). The primary outcomes are examined at T0 (pretest), T1 (examination after the intervention or after 6 weeks without intervention), T2 (one year follow-up), T3 (2 year follow-up).""]	[""Effects on cognitive total scores (DemTect, MMSE). The primary outcomes are examined at T0 (pretest), T1 (examination after the intervention or after 6 weeks without intervention), T2 (one year follow-up), T3 (2 year follow-up).""]	NA	NA
DRKS00005034	Pilot test of feasibility and effects of the implementation of a self-management support intervention for patients with cancer and their family caregivers to reduce pain and related symptoms	Testing the Implementation of a Pain Self-management Support Intervention for Oncology Patients in Clinical Practice: A Randomized Controlled Pilot Study (ANtiPain)	10.1097/ncc.0000000000000502	https://journals.lww.com/cancernursingonline/Abstract/2018/09000/Testing_the_Implementation_of_a_Pain.3.aspx	3	2013-08-15	Recruiting complete, follow-up complete	2013-12-01	2015-01-31	2018-09-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The primary outcome will be average and worst pain intensity, measured on the widely used numeric rating scale from 0 (no pain) to 10 (worst imaginable pain) measured at T0, T1 und T2 (T0 before, T1 one week and T2 six weeks after discharge).""]	NA	[""The primary outcome will be average and worst pain intensity, measured on the widely used numeric rating scale from 0 (no pain) to 10 (worst imaginable pain) measured at T0, T1 und T2 (T0 before, T1 one week and T2 six weeks after discharge).""]	NA	NA
DRKS00005054	Effect of 10% Fluoride on Remineralization of Dentin in situ	Effect of 10% fluoride on the remineralization of dentin in situ	10.1590/1678-775720150239	NA	1	2013-06-19	Recruiting complete, follow-up complete	2010-10-04	2011-09-13	2015-11-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The effectiveness of Bifluorid 10® und Cervitec® in preventing mineral loss and the lesion deep of caries like lesions; after four weeks in mouth; with transversal microradiography mineral content and lesion depth is to be determined""]	NA	[""The effectiveness of Bifluorid 10® und Cervitec® in preventing mineral loss and the lesion deep of caries like lesions; after four weeks in mouth; with transversal microradiography mineral content and lesion depth is to be determined""]	NA	NA
DRKS00005076	Human intervention study to examine interactions between alpha-linolenic acid and quercetin	Effects of the flavonol quercetin and α-linolenic acid on n-3 PUFA status in metabolically healthy men and women: a randomised, double-blinded, placebo-controlled, crossover trial	10.1017/s0007114517000241	https://pubmed.ncbi.nlm.nih.gov/28366181/	3	2013-08-01	Recruiting complete, follow-up complete	2013-05-06	2015-12-01	2017-04-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Fatty acid composition (blood); measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8)""]	[""Fatty acid composition (blood); measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8)""]	[""Fatty acid composition (blood); measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8)""]	[""Fatty acid composition (blood); measurement at the beginning of the intervention periods (week 0), after 4 weeks (halftime) and at the end of the intervention periods (week 8)""]	NA
DRKS00005118	Effects of combining 2 weeks of passive sensory stimulation with active hand motor training in healthy adults	Effects of combining 2 weeks of passive sensory stimulation with active hand motor training in healthy adults	10.1371/journal.pone.0084402	https://www.ncbi.nlm.nih.gov/pubmed/24416229	4	2013-06-28	Recruiting complete, follow-up complete	2012-01-02	2012-12-28	2014-01-09	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Tests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the combined intervention consisting of 10x rES and arm-ability-training (AAT) for all subjects of the target group.\nTests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the intervention consisting of 10x arm-ability-training (AAT) for all subjects of the control group.""]	NA	[""Tests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the combined intervention consisting of 10x rES and arm-ability-training (AAT) for all subjects of the target group.\nTests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the intervention consisting of 10x arm-ability-training (AAT) for all subjects of the control group.""]	[""Tests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the combined intervention consisting of 10x rES and arm-ability-training (AAT) for all subjects of the target group.\nTests of sensorimotor performance (touch thresholds, tactile discrimination thresholds, grip strenght, manual dexterity) prior to and after the intervention consisting of 10x arm-ability-training (AAT) for all subjects of the control group.""]	NA
DRKS00005120	Endurance Exercise versus Whole Body Vibration as adjuvant therapy in depressed adolescents: effects on clinical outcome, neurocognitive and humoral parameters and morphological changes of the hippocampus and other brain regions	NA	10.4126/frl01-006402624	https://repository.publisso.de/resource/frl:6402624	7	2013-07-10	Recruiting complete, follow-up complete	2013-07-12	2015-05-31	2017-05-03	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Physical exercise improves depressive symptoms in adolescents, measured by a significant decrease in the DIKJ-Scores (Depression Inventory for Children and Adolescents) under a T-Score of 60 (PR 86,2). Whole Body Vibration shows equivalent or superior effects compared to bicycle ergometer.\nMeasurement points: t0 baseline, t1 after 6 weeks intervention, t2 8-weeks post intervention""]	NA	[""Physical exercise improves depressive symptoms in adolescents, measured by a significant decrease in the DIKJ-Scores (Depression Inventory for Children and Adolescents) under a T-Score of 60 (PR 86,2). Whole Body Vibration shows equivalent or superior effects compared to bicycle ergometer.\nMeasurement points: t0 baseline, t1 after 6 weeks intervention, t2 8-weeks post intervention""]	[""Physical exercise improves depressive symptoms in adolescents, measured by a significant decrease in the DIKJ-Scores (Depression Inventory for Children and Adolescents) under a T-Score of 60 (PR 86,2). Whole Body Vibration shows equivalent or superior effects compared to bicycle ergometer.\nMeasurement points: t0 baseline, t1 after 6 weeks intervention, t2 8-weeks post intervention""]	NA
DRKS00005127	Whole brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma – a randomized trial	Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial	10.2147/cmar.s204729	https://www.dovepress.com/whole-brain-helical-tomotherapy-with-integrated-boost-for-brain-metast-peer-reviewed-fulltext-article-CMAR	4	2013-07-03	Recruiting stopped after recruiting started	2013-08-16	2017-07-31	2019-02-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Toxicity quantified by absolute frequencies and percentages of side effects according to CTC Criteria Version 4. Follow-up visits every ~2 months for in total 1 year""]	[""Toxicity quantified by absolute frequencies and percentages of side effects according to CTC Criteria Version 4. Follow-up visits every ~2 months for in total 1 year""]	NA	[""Toxicity quantified by absolute frequencies and percentages of side effects according to CTC Criteria Version 4. Follow-up visits every ~2 months for in total 1 year""]	NA
DRKS00005132	Nasal high - flow - oxygen therapy in patients with hypoxic respiratory failure: Effect on functional and subjective respiratory parameters compared to conventional O2 therapy and non-invasive ventilation (NIV)	Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV)	10.1186/1471-2253-14-66	https://www.ncbi.nlm.nih.gov/pubmed/25110463	1	2013-07-08	Recruiting complete, follow-up complete	2009-03-25	2011-03-24	2014-08-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""At the end of each 30 min intervention phase the following primary endpoints are measured:\n• Respiratory rate\n• Arterial oxygen partial pressure (paO2)\n• Dyspnea (10 point numeric Borg – Scale)\n• Patient comfort (10 point numeric scale)\n\nAt the end of the investigation the patients rate all three devices using German school grades (1=very good, 6= failed) und can choose one device for further treatment.\n\n""]	NA	[""At the end of each 30 min intervention phase the following primary endpoints are measured:\n• Respiratory rate\n• Arterial oxygen partial pressure (paO2)\n• Dyspnea (10 point numeric Borg – Scale)\n• Patient comfort (10 point numeric scale)\n\nAt the end of the investigation the patients rate all three devices using German school grades (1=very good, 6= failed) und can choose one device for further treatment.\n\n""]	NA	NA
DRKS00005140	STEpS – stage-by-stage psychotherapy for patients with physical diseases and depressive or adjustement disorders.	Cognitive behavioral group therapy for patients with physical diseases and comorbid depressive or adjustment disorders on a waiting list for individual therapy: results from a randomized controlled trial	10.1186/s12888-017-1494-9	https://link.springer.com/article/10.1186/s12888-017-1494-9#article-info	9	2013-08-27	Recruiting complete, follow-up complete	2013-09-02	2015-07-31	2016-10-10	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Primary outcome is the psychological distress of the patients. Psychological distress will be assessed by self-report questionnaires at three measurement points (before the intervention, after the intervention and 8 weeks after the intervention). Equal measurement intervals will be used for the control group (at the beginning of the study, after 8 weeks, after 16 weeks).\n\nFollowing aspects will be assessed: physical and psychological well-being by the german version of the Short Form Health Survey (SF-36; Bullinger & Kirchberger, 1998), current distress by the first part of the german version of the NCCN Distress-Thermometer (Mehnert, Müller, Lehmann & Koch, 2006), anxious and depressive symptoms by the german version of the Hospital Anxiety and Depression Scale (HADS-D; Herrmann-Lingen, Buss & Snaith, 2011), psychological distress by the german version of the Brief Symptom Inventory (BSI; Franke, 2000) and subjective changes in experience and behavior by the german change-questionnaire of experience and behavior (VEV; Zielke & Kopf-Mehnert, 1978).\n\n\nBullinger, M. & Kirchberger, I. (1998). SF-36, Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.\nFranke, G. H. (2000). Brief Symptom Inventory von L. R. Derogatis: BSI. Deutsche Version. Göttingen: Beltz Test.\nHerrmann-Lingen, C., Buss, U. & Snaith, P. (2011). Hospital anxiety and depression scale : deutsche Version; HADS-D. Bern: Huber.\nMehnert, A., Müller, D., Lehmann, C. & Koch, U. (2006). Die deutsche Version des NCCN Distress-Thermometers. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54 (3), 213–223.\nZielke, M. & Kopf-Mehnert, C. (1978). Veränderungsfragebogen des Erlebens und Verhaltens: VEV. Weinheim: Beltz Test.\n""]	[""Primary outcome is the psychological distress of the patients. Psychological distress will be assessed by self-report questionnaires at three measurement points (before the intervention, after the intervention and 8 weeks after the intervention). Equal measurement intervals will be used for the control group (at the beginning of the study, after 8 weeks, after 16 weeks).\n\nFollowing aspects will be assessed: physical and psychological well-being by the german version of the Short Form Health Survey (SF-36; Bullinger & Kirchberger, 1998), current distress by the first part of the german version of the NCCN Distress-Thermometer (Mehnert, Müller, Lehmann & Koch, 2006), anxious and depressive symptoms by the german version of the Hospital Anxiety and Depression Scale (HADS-D; Herrmann-Lingen, Buss & Snaith, 2011), psychological distress by the german version of the Brief Symptom Inventory (BSI; Franke, 2000) and subjective changes in experience and behavior by the german change-questionnaire of experience and behavior (VEV; Zielke & Kopf-Mehnert, 1978).\n\n\nBullinger, M. & Kirchberger, I. (1998). SF-36, Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.\nFranke, G. H. (2000). Brief Symptom Inventory von L. R. Derogatis: BSI. Deutsche Version. Göttingen: Beltz Test.\nHerrmann-Lingen, C., Buss, U. & Snaith, P. (2011). Hospital anxiety and depression scale : deutsche Version; HADS-D. Bern: Huber.\nMehnert, A., Müller, D., Lehmann, C. & Koch, U. (2006). Die deutsche Version des NCCN Distress-Thermometers. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54 (3), 213–223.\nZielke, M. & Kopf-Mehnert, C. (1978). Veränderungsfragebogen des Erlebens und Verhaltens: VEV. Weinheim: Beltz Test.\n""]	[""Primary outcome is the psychological distress of the patients. Psychological distress will be assessed by self-report questionnaires at three measurement points (before the intervention, after the intervention and 8 weeks after the intervention). Equal measurement intervals will be used for the control group (at the beginning of the study, after 8 weeks, after 16 weeks).\n\nFollowing aspects will be assessed: physical and psychological well-being by the german version of the Short Form Health Survey (SF-36; Bullinger & Kirchberger, 1998), current distress by the first part of the german version of the NCCN Distress-Thermometer (Mehnert, Müller, Lehmann & Koch, 2006), anxious and depressive symptoms by the german version of the Hospital Anxiety and Depression Scale (HADS-D; Herrmann-Lingen, Buss & Snaith, 2011), psychological distress by the german version of the Brief Symptom Inventory (BSI; Franke, 2000) and subjective changes in experience and behavior by the german change-questionnaire of experience and behavior (VEV; Zielke & Kopf-Mehnert, 1978).\n\n\nBullinger, M. & Kirchberger, I. (1998). SF-36, Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.\nFranke, G. H. (2000). Brief Symptom Inventory von L. R. Derogatis: BSI. Deutsche Version. Göttingen: Beltz Test.\nHerrmann-Lingen, C., Buss, U. & Snaith, P. (2011). Hospital anxiety and depression scale : deutsche Version; HADS-D. Bern: Huber.\nMehnert, A., Müller, D., Lehmann, C. & Koch, U. (2006). Die deutsche Version des NCCN Distress-Thermometers. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54 (3), 213–223.\nZielke, M. & Kopf-Mehnert, C. (1978). Veränderungsfragebogen des Erlebens und Verhaltens: VEV. Weinheim: Beltz Test.\n""]	[""Primary outcome is the psychological distress of the patients. Psychological distress will be assessed by self-report questionnaires at three measurement points (before the intervention, after the intervention and 8 weeks after the intervention). Equal measurement intervals will be used for the control group (at the beginning of the study, after 8 weeks, after 16 weeks).\n\nFollowing aspects will be assessed: physical and psychological well-being by the german version of the Short Form Health Survey (SF-36; Bullinger & Kirchberger, 1998), current distress by the first part of the german version of the NCCN Distress-Thermometer (Mehnert, Müller, Lehmann & Koch, 2006), anxious and depressive symptoms by the german version of the Hospital Anxiety and Depression Scale (HADS-D; Herrmann-Lingen, Buss & Snaith, 2011), psychological distress by the german version of the Brief Symptom Inventory (BSI; Franke, 2000) and subjective changes in experience and behavior by the german change-questionnaire of experience and behavior (VEV; Zielke & Kopf-Mehnert, 1978).\n\n\nBullinger, M. & Kirchberger, I. (1998). SF-36, Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.\nFranke, G. H. (2000). Brief Symptom Inventory von L. R. Derogatis: BSI. Deutsche Version. Göttingen: Beltz Test.\nHerrmann-Lingen, C., Buss, U. & Snaith, P. (2011). Hospital anxiety and depression scale : deutsche Version; HADS-D. Bern: Huber.\nMehnert, A., Müller, D., Lehmann, C. & Koch, U. (2006). Die deutsche Version des NCCN Distress-Thermometers. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54 (3), 213–223.\nZielke, M. & Kopf-Mehnert, C. (1978). Veränderungsfragebogen des Erlebens und Verhaltens: VEV. Weinheim: Beltz Test.\n""]	NA
DRKS00005159	Improvement of endogenous regeneration in female healthy volunteers through physical exercise “REBIRTH aktiv women”	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women	10.1177/2047487319849505	https://journals.sagepub.com/doi/10.1177/2047487319849505	5	2013-09-25	Recruiting complete, follow-up complete	2013-11-20	2015-03-26	2019-05-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	NA	NA
DRKS00005181	Evaluation of computer-assisted mandibular reconstruction with free vascularized iliac crest bone graft compared to conventional surgery: a randomized prospective study.	Evaluation of computer-assisted mandibular reconstruction with vascularized iliac crest bone graft compared to conventional surgery: a randomized prospective clinical trial	10.1186/1745-6215-15-114	NA	1	2013-08-22	Recruiting complete, follow-up complete	2011-08-01	2013-08-21	2014-04-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""During surgery the time needed for shaping the iliac crest bone graft, reconstructino time and ischaemic time were measured in both groups.\nFurthermore the condyle position before and after surgery was measured using 3D models.""]	NA	[""During surgery the time needed for shaping the iliac crest bone graft, reconstructino time and ischaemic time were measured in both groups.\nFurthermore the condyle position before and after surgery was measured using 3D models.""]	NA	NA
DRKS00005200	transcranial random noise stimulation for the treatment cognitive symptoms in the cluster of negative syndrome in schizophrenia.	Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study	10.1093/schbul/sbw041	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988747/	6	2013-08-20	Recruiting complete, follow-up complete	2013-10-01	2016-10-30	2016-04-20	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""(I) Significant improvement of verbal learning and memory test (VLMT) and n-back-test and (II) reduction of score in the Positive and Negative Symptom Scale (PANSS) from Baseline to immediately after the 10th intervention.""]	[""(I) Significant improvement of verbal learning and memory test (VLMT) and n-back-test and (II) reduction of score in the Positive and Negative Symptom Scale (PANSS) from Baseline to immediately after the 10th intervention.""]	NA	[""(I) Significant improvement of verbal learning and memory test (VLMT) and n-back-test and (II) reduction of score in the Positive and Negative Symptom Scale (PANSS) from Baseline to immediately after the 10th intervention.""]	NA
DRKS00005241	Effects of hypoxia-supported endurance training on Pulmonary and Cardiovascular Parameters in Patients older than 65.	Endurance Training in Normobaric Hypoxia Imposes Less Physical Stress for Geriatric Rehabilitation	10.3389/fphys.2017.00514	https://www.frontiersin.org/articles/10.3389/fphys.2017.00514/full	4	2013-09-02	Recruiting complete, follow-up complete	2013-11-01	2015-07-25	2017-07-20	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The data will be collected at the first day of accomodation in the Hospital via Ergospirometry and Echokardiography. Then each Patient will have to perform 7 trainings each second day. The final test will be after 3 weeks via Ergospirometry and Echokardiography.\n\nMain Parameter: Vo2peak""]	[""The data will be collected at the first day of accomodation in the Hospital via Ergospirometry and Echokardiography. Then each Patient will have to perform 7 trainings each second day. The final test will be after 3 weeks via Ergospirometry and Echokardiography.\n\nMain Parameter: Vo2peak""]	[""The data will be collected at the first day of accomodation in the Hospital via Ergospirometry and Echokardiography. Then each Patient will have to perform 7 trainings each second day. The final test will be after 3 weeks via Ergospirometry and Echokardiography.\n\nMain Parameter: Vo2peak""]	NA	NA
DRKS00005254	middle molecular clearance in citrate-based dialysis using a conventional vs. high-cutoff dialyzer	Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: A prospective randomized controlled trial	10.1371/journal.pone.0215823	https://pubmed.ncbi.nlm.nih.gov/31026303/	3	2013-11-26	Recruiting complete, follow-up complete	2013-12-01	2015-05-31	2019-04-26	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""β2-Mikroglobulin Clearance after 1 h, 6 h, 12 h, 24 h und 48 h (estimated by serum levels before and after dialyzer)""]	NA	[""β2-Mikroglobulin Clearance after 1 h, 6 h, 12 h, 24 h und 48 h (estimated by serum levels before and after dialyzer)""]	[""β2-Mikroglobulin Clearance after 1 h, 6 h, 12 h, 24 h und 48 h (estimated by serum levels before and after dialyzer)""]	NA
DRKS00005295	combining gerneral anaesthesia with interscalene brachial plexus block for outpatient shoulder surgery - incidence of hypotension events, process times and postoperative pain	Blood pressure response to combined general anaesthesia/interscalene brachial plexus block for outpatient shoulder arthroscopy	10.1186/1471-2253-14-50	https://www.ncbi.nlm.nih.gov/pubmed/?term=DRKS00005295	1	2013-12-12	Recruiting complete, follow-up complete	2011-10-01	2013-05-13	2014-06-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Haemodynamics (RR, HF) - anesthesia protocol\nPostoperative pain - Interview, NRS 1-10 pain scores\nProcess times - anesthesia protocol (min)""]	NA	[""Haemodynamics (RR, HF) - anesthesia protocol\nPostoperative pain - Interview, NRS 1-10 pain scores\nProcess times - anesthesia protocol (min)""]	NA	NA
DRKS00005333	Effects of remote ischemic preconditioning in cardiac surgery on incidence and severity of acute kidney injury	Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial	10.1001/jama.2015.4189	https://jamanetwork.com/journals/jama/fullarticle/2299339	7	2013-11-05	Recruiting complete, follow-up complete	2013-11-07	2014-10-23	2015-06-02	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Incidence of acute renal failure""]	[""Incidence of acute renal failure""]	[""Incidence of acute renal failure""]	[""Incidence of acute renal failure""]	NA
DRKS00005353	Comparison  of a structured progressive task-oriented circuit Training with an individual face-to-face physiotherapy program regarding walking competency after stroke	Group therapy task training versus individual task training during inpatient stroke rehabilitation: a randomised controlled trial	10.1177/0269215515600206	http://journals.sagepub.com/doi/10.1177/0269215515600206	7	2013-11-18	Recruiting complete, follow-up complete	2008-11-10	2012-05-02	2015-08-27	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Stroke Impact scale Version 3.0 , the mobility domain,a self reported scale including 9 questions, performed after 6 weeks of Training and after 24 weeks post inclusion in the study""]	NA	[""Stroke Impact scale Version 3.0 , the mobility domain,a self reported scale including 9 questions, performed after 6 weeks of Training and after 24 weeks post inclusion in the study""]	[""Stroke Impact scale Version 3.0 , the mobility domain,a self reported scale including 9 questions, performed after 6 weeks of Training and after 24 weeks post inclusion in the study""]	NA
DRKS00005408	Non invasive mechanical ventilation with neurally adjusted ventilatory assist compared to conventional pressure support ventilation in patients that require non invasive ventilation	Noninvasive Neurally Adjusted Ventilator Assist Ventilation in the Postoperative Period Produces Better Patient-Ventilator Synchrony but Not Comfort	10.1155/2020/4705042	https://pubmed.ncbi.nlm.nih.gov/32655950/	2	2013-10-30	Recruiting complete, follow-up complete	2012-04-15	2016-03-31	2020-06-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Patient-ventilator interaction (synchrony).\n\nDuring minimum of 20 minute period data from the Ventilator are collected, including:\n- Electrical diaphragmatic activity (Eadi signal)\n- Flow\n- pressure\n- respiratory rate\n\n\nAssessment of patient ventilator interaction is performed offline by analyzing the data after stabilization of NIV.""]	[""Patient-ventilator interaction (synchrony).\n\nDuring minimum of 20 minute period data from the Ventilator are collected, including:\n- Electrical diaphragmatic activity (Eadi signal)\n- Flow\n- pressure\n- respiratory rate\n\n\nAssessment of patient ventilator interaction is performed offline by analyzing the data after stabilization of NIV.""]	[""Patient-ventilator interaction (synchrony).\n\nDuring minimum of 20 minute period data from the Ventilator are collected, including:\n- Electrical diaphragmatic activity (Eadi signal)\n- Flow\n- pressure\n- respiratory rate\n\n\nAssessment of patient ventilator interaction is performed offline by analyzing the data after stabilization of NIV.""]	NA	NA
DRKS00005419	Impact of physical exercise on neuropathic symptoms in cancer patients	It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial	10.1186/s12885-019-5522-7	https://pubmed.ncbi.nlm.nih.gov/31046719/	9	2013-11-19	Recruiting complete, follow-up complete	2013-12-13	2015-05-26	2019-05-02	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change (%) of sway path (cm) of CoF (=centre of force) [force plate]\nTo be measured at all three measurement-times: T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up).""]	[""Change (%) of sway path (cm) of CoF (=centre of force) [force plate]\nTo be measured at all three measurement-times: T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up).""]	[""Change (%) of sway path (cm) of CoF (=centre of force) [force plate]\nTo be measured at all three measurement-times: T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up).""]	[""Change (%) of sway path (cm) of CoF (=centre of force) [force plate]\nTo be measured at all three measurement-times: T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up).""]	NA
DRKS00005475	Comparison of three different preoxygenation methods ahead of bariatric and cardiac surgery and consecutive postextubation respiratory care	NA	10.13188/2377-9284.1000003	http://www.avensonline.org/wp-content/uploads/JOAB-2377-9284-01-0003.pdf	1	2013-11-27	Recruiting complete, follow-up complete	2013-03-27	2013-11-01	2014-12-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Primary outcome is the last blood gas analysis 180min postoperative.""]	NA	[""Primary outcome is the last blood gas analysis 180min postoperative.""]	NA	NA
DRKS00005481	Comparison of two formula diets for weight reduction	NA	10.4172/2165-7904.1000266	https://www.omicsonline.org/open-access/efficacy-of-high-carbohydrate-versus-high-protein-meal-replacements-onweight-reduction--a-randomized-controlled-trial-2165-7904-1000266.php?aid=54708	4	2013-11-28	Recruiting complete, follow-up complete	2014-02-10	2014-07-10	2015-06-30	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""body weight, waist circumference at any appointment (week 0, week 2, week 8, week 20)""]	NA	[""body weight, waist circumference at any appointment (week 0, week 2, week 8, week 20)""]	[""body weight, waist circumference at any appointment (week 0, week 2, week 8, week 20)""]	NA
DRKS00005497	Clinical pilot trial of diameter reduced implant retained overdenture prothesis in the edentulous mandible with 2 or 4 locatorlike attachments	Immediate and delayed loading of two-piece reduced-diameter implants with locator-analog attachments in edentulous mandibles: One-year results from a randomized clinical trial examining clinical outcome and patient expectation	10.1111/cid.12489	https://pubmed.ncbi.nlm.nih.gov/28440024/	7	2014-02-25	Recruiting complete, follow-up complete	2013-07-08	2016-10-05	2017-04-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Chancge of masticatory efficacy (chewing test) on lower jaw prothesis retained with/without llocatorlike attachments on interforaminal diameter reduced implants after 3, 6, and 9 months post operative\n""]	[""Chancge of masticatory efficacy (chewing test) on lower jaw prothesis retained with/without llocatorlike attachments on interforaminal diameter reduced implants after 3, 6, and 9 months post operative\n""]	NA	[""Chancge of masticatory efficacy (chewing test) on lower jaw prothesis retained with/without llocatorlike attachments on interforaminal diameter reduced implants after 3, 6, and 9 months post operative\n""]	NA
DRKS00005500	WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue	NA	10.15761/nns.1000103	https://www.oatext.com/wake-up-pilot-study-for-patients-with-multiple-sclerosis-and-fatigue-how-mindfulness-can-help.php#gsc.tab=0	4	2013-12-03	Recruiting complete, follow-up complete	2013-10-09	2016-12-03	2018-04-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The training can significantly improve the patients' cognitive performance. This will be quanitified with standardized neuropsychological tests before and after 6-week-training: The d2-attention stress test and the VLMT verbal learn and memorizing test""]	[""The training can significantly improve the patients' cognitive performance. This will be quanitified with standardized neuropsychological tests before and after 6-week-training: The d2-attention stress test and the VLMT verbal learn and memorizing test""]	[""The training can significantly improve the patients' cognitive performance. This will be quanitified with standardized neuropsychological tests before and after 6-week-training: The d2-attention stress test and the VLMT verbal learn and memorizing test""]	NA	NA
DRKS00005594	Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial (APREPRU)	NA	10.2340/00015555-3120	https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3120	10	2014-01-16	Recruiting complete, follow-up complete	2014-06-30	2016-01-04	2019-01-17	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]	[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]	[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]	[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]	NA
DRKS00005595	Improvement of diabetes screening in general practice via selection of at-risk patients from medical assistences by the exampla of the FINDRISK-test.	[Early Selection of At-risk Patients for Type 2 Diabetes in the GP Surgery by Medical Assistants - A Feasibility Study]	10.1055/s-0035-1548858	https://pubmed.ncbi.nlm.nih.gov/25918931/	6	2014-01-15	Recruiting complete, follow-up complete	2013-11-18	2015-04-15	2015-04-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Average risk score of intervention- and controll group using the FINDRISC-questionnaire""]	[""Average risk score of intervention- and controll group using the FINDRISC-questionnaire""]	NA	[""Average risk score of intervention- and controll group using the FINDRISC-questionnaire""]	NA
DRKS00005596	Psychophysiological effects of stress management in patients with gingivitis as well as in patients with gingivitis and additional atopic dermatitis	Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial	10.2340/00015555-1415	https://www.ncbi.nlm.nih.gov/pubmed/?term=Psychophysiological+Effects+of+Stress+Management+in+Patients+with+Atopic+Dermatitis%3A+A+Randomized+Controlled+Trial	1	2013-12-13	Recruiting complete, follow-up complete	2009-06-18	2010-08-04	2013-01-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""At baseline and after 15hour stress management training: cortisol-awakening-response measured by salivary cortisol in the morning on two consecutive days; BDNF in serum; IL-1ß and IL-8 in crevicular fluid;\n\nAfter 15hour stress management training under acute stress: salivary cortisol, IL-1ß, IL-8 and BDNF in crevicular fluid\n\n\n""]	NA	NA	[""At baseline and after 15hour stress management training: cortisol-awakening-response measured by salivary cortisol in the morning on two consecutive days; BDNF in serum; IL-1ß and IL-8 in crevicular fluid;\n\nAfter 15hour stress management training under acute stress: salivary cortisol, IL-1ß, IL-8 and BDNF in crevicular fluid\n\n\n""]	NA
DRKS00005602	Effects of telephone-based health coaching for patients with chronic conditions	Long-term effectiveness of telephone-based health coaching for heart failure patients: A post-only randomised controlled trial	10.1177/1357633x16668436	https://www.ncbi.nlm.nih.gov/pubmed/?term=Long-term+effectiveness+of+telephone-based+health+coaching+for+heart+failure+patients%3A+A+post-only+randomised+controlled+trial	1	2013-12-18	Recruiting complete, follow-up complete	2008-07-01	2011-12-31	2016-09-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The primary outcome is the time till rehospitalisation. It will be assessed in days through the routine data of the health insurance.""]	NA	[""The primary outcome is the time till rehospitalisation. It will be assessed in days through the routine data of the health insurance.""]	NA	NA
DRKS00005604	Clinical and biometric analysis of different trunk orthesis	Spinal Orthoses: The Crucial Role of Comfort on Compliance of Wearing - Monocentric Prospective Pilot Study of Randomized Cross-Over Design	NA	https://pubmed.ncbi.nlm.nih.gov/28809624/	7	2014-01-22	Recruiting complete, follow-up complete	2014-02-06	2015-06-24	2017-09-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Wearing comfort: is determined by daily wearing time.\n\nTo ensure compliance a minimal daily wearing time of 14 hours for at least 5 out of 7 days is necessary.\nOn 2 out of 7 days( at a maximum) the compliance can be reduced to a minimal daily wearing time of 10 hours.\nWearing comfort will be evalutated wiith the questionnaires SF-12 and an individual questionnaire, at the end of each wearing period, on day 7 for each orthosis.""]	[""Wearing comfort: is determined by daily wearing time.\n\nTo ensure compliance a minimal daily wearing time of 14 hours for at least 5 out of 7 days is necessary.\nOn 2 out of 7 days( at a maximum) the compliance can be reduced to a minimal daily wearing time of 10 hours.\nWearing comfort will be evalutated wiith the questionnaires SF-12 and an individual questionnaire, at the end of each wearing period, on day 7 for each orthosis.""]	[""Wearing comfort: is determined by daily wearing time.\n\nTo ensure compliance a minimal daily wearing time of 14 hours for at least 5 out of 7 days is necessary.\nOn 2 out of 7 days( at a maximum) the compliance can be reduced to a minimal daily wearing time of 10 hours.\nWearing comfort will be evalutated wiith the questionnaires SF-12 and an individual questionnaire, at the end of each wearing period, on day 7 for each orthosis.""]	[""Wearing comfort: is determined by daily wearing time.\n\nTo ensure compliance a minimal daily wearing time of 14 hours for at least 5 out of 7 days is necessary.\nOn 2 out of 7 days( at a maximum) the compliance can be reduced to a minimal daily wearing time of 10 hours.\nWearing comfort will be evalutated wiith the questionnaires SF-12 and an individual questionnaire, at the end of each wearing period, on day 7 for each orthosis.""]	NA
DRKS00005664	Electroacustimulation for the prevention of PONV- A multimodal approach	CHRM3 rs2165870 polymorphism is independently associated with postoperative nausea and vomiting, but combined prophylaxis is effective	10.1016/j.bja.2018.02.025	https://www.sciencedirect.com/science/article/pii/S0007091218301417	4	2014-05-08	Recruiting complete, follow-up complete	2012-10-01	2015-12-15	2018-02-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Incidence of postoperative nausea and vomiting within 6h after end of operation by questionnaire""]	[""Incidence of postoperative nausea and vomiting within 6h after end of operation by questionnaire""]	[""Incidence of postoperative nausea and vomiting within 6h after end of operation by questionnaire""]	NA	NA
DRKS00005679	Online- versus face-to-face-couselling – a comparison addressing procrastination	NA	10.1016/j.chb.2015.08.027	https://www.sciencedirect.com/science/article/abs/pii/S0747563215301035	4	2014-01-28	Recruiting complete, follow-up complete	2013-03-08	2014-04-15	2015-09-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Procrastination: German version of the Academic Procrastination State Inventory (APSI; Helmke & Schrader, 2000; engl. version: Schouwenburg, 1995);\n\nDepression: German Version of the Center for Epidemiological Studies Depression Scale (ADS; Hautzinger & Bailer, 2012; engl. version: CES-D; Radloff, 1977);\n\nMeasuring times: Pre-test, post-test after one week, follow-up after 6 months""]	[""Procrastination: German version of the Academic Procrastination State Inventory (APSI; Helmke & Schrader, 2000; engl. version: Schouwenburg, 1995);\n\nDepression: German Version of the Center for Epidemiological Studies Depression Scale (ADS; Hautzinger & Bailer, 2012; engl. version: CES-D; Radloff, 1977);\n\nMeasuring times: Pre-test, post-test after one week, follow-up after 6 months""]	[""Procrastination: German version of the Academic Procrastination State Inventory (APSI; Helmke & Schrader, 2000; engl. version: Schouwenburg, 1995);\n\nDepression: German Version of the Center for Epidemiological Studies Depression Scale (ADS; Hautzinger & Bailer, 2012; engl. version: CES-D; Radloff, 1977);\n\nMeasuring times: Pre-test, post-test after one week, follow-up after 6 months""]	[""Procrastination: German version of the Academic Procrastination State Inventory (APSI; Helmke & Schrader, 2000; engl. version: Schouwenburg, 1995);\n\nDepression: German Version of the Center for Epidemiological Studies Depression Scale (ADS; Hautzinger & Bailer, 2012; engl. version: CES-D; Radloff, 1977);\n\nMeasuring times: Pre-test, post-test after one week, follow-up after 6 months""]	NA
DRKS00005682	Effect of different milk fractions on the metabolic response in healthy and prediabetic volunteers	Metabolic responses of healthy or prediabetic adults to bovine whey protein and sodium caseinate do not differ	10.3945/jn.114.199190	NA	4	2014-02-25	Recruiting complete, follow-up complete	2009-10-05	2014-08-27	2015-01-21	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Hemocue: glucose\nMultiplex: insulin,GIP, C-peptides, glucagon\nElisa: GLP-1\n\ntime span: up to 240 min after intake in the fasting state\n\nreading points: 0, 15, 30, 45, 60, 90, 120, 180, and 240 min""]	[""Hemocue: glucose\nMultiplex: insulin,GIP, C-peptides, glucagon\nElisa: GLP-1\n\ntime span: up to 240 min after intake in the fasting state\n\nreading points: 0, 15, 30, 45, 60, 90, 120, 180, and 240 min""]	NA	[""Hemocue: glucose\nMultiplex: insulin,GIP, C-peptides, glucagon\nElisa: GLP-1\n\ntime span: up to 240 min after intake in the fasting state\n\nreading points: 0, 15, 30, 45, 60, 90, 120, 180, and 240 min""]	NA
DRKS00005692	Determination of respiratory mechanics, arterial oxygenation and functional lung ventilation under a prospective change of the end-expiratory pressure in healthy, intubated and mechanically ventilated patients in the prone position.	Increasing positive end-expiratory pressure (re-)improves intraoperative respiratory mechanics and lung ventilation after prone positioning	10.1093/bja/aew115	https://academic.oup.com/bja/article/116/6/838/2566519	4	2014-02-26	Recruiting complete, follow-up complete	2014-03-03	2014-09-17	2016-05-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Calculation of the respiratory system compliance using airway pressure and tidal volume (measured by volume flow) at each PEEP level""]	[""Calculation of the respiratory system compliance using airway pressure and tidal volume (measured by volume flow) at each PEEP level""]	[""Calculation of the respiratory system compliance using airway pressure and tidal volume (measured by volume flow) at each PEEP level""]	NA	NA
DRKS00005720	Noninvasive ventilation versus supplemental oxygen supply during walking in patients with severe COPD	Walking with Non-Invasive Ventilation Does Not Prevent Exercise-Induced Hypoxaemia in Stable Hypercapnic COPD Patients	10.3109/15412555.2015.1008690	https://www.tandfonline.com/doi/abs/10.3109/15412555.2015.1008690	1	2014-03-13	Recruiting complete, follow-up complete	2008-11-27	2014-02-28	2015-08-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Changes in PaO2 after a 6 minute walking test wit NIV compared to the application of supplemental oxygen""]	NA	[""Changes in PaO2 after a 6 minute walking test wit NIV compared to the application of supplemental oxygen""]	NA	NA
DRKS00005802	Acute influence of a nutritional ergogenic aid on endurance performance – a placebo controlled double blind trial	Increasing effort without noticing: A randomized controlled pilot study about the ergogenic placebo effect in endurance athletes and the role of supplement salience	10.1371/journal.pone.0198388	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198388	5	2014-02-24	Recruiting complete, follow-up complete	2014-02-25	2015-11-26	2018-06-11	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""VO2 max, lactate threshold, power output and lactate values over 45min (isokinetic at 95 rpm), ratings of perceived exertion (RPE)""]	[""VO2 max, lactate threshold, power output and lactate values over 45min (isokinetic at 95 rpm), ratings of perceived exertion (RPE)""]	[""VO2 max, lactate threshold, power output and lactate values over 45min (isokinetic at 95 rpm), ratings of perceived exertion (RPE)""]	NA	NA
DRKS00005943	The role of different brain regions in motor learning.	NA	NA	https://hds.hebis.de/ubgi/Record/HEB425132986	7	2014-04-02	Recruiting complete, follow-up complete	2014-05-12	2014-07-21	2017-10-05	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Amount of explicit Learning as indicated by the result of the explicit test when comparing pre and post training phase (cf. Hegele, M., & Heuer, H. (2010a). Consciousness and Cognition, 19(4), 906–917.;\nHegele, M., & Heuer, H. (2010b). PLoS One, 5(8), e12071. doi:10.1371/journal.pone.0012071;\nHegele, M., & Heuer, H. (2013). Psychology and Aging, 28(2), 333–9.;\nHeuer, H., & Hegele, M. (2011). Journal of Neurophysiology, 106(4), 2078–85.)""]	[""Amount of explicit Learning as indicated by the result of the explicit test when comparing pre and post training phase (cf. Hegele, M., & Heuer, H. (2010a). Consciousness and Cognition, 19(4), 906–917.;\nHegele, M., & Heuer, H. (2010b). PLoS One, 5(8), e12071. doi:10.1371/journal.pone.0012071;\nHegele, M., & Heuer, H. (2013). Psychology and Aging, 28(2), 333–9.;\nHeuer, H., & Hegele, M. (2011). Journal of Neurophysiology, 106(4), 2078–85.)""]	[""Amount of explicit Learning as indicated by the result of the explicit test when comparing pre and post training phase (cf. Hegele, M., & Heuer, H. (2010a). Consciousness and Cognition, 19(4), 906–917.;\nHegele, M., & Heuer, H. (2010b). PLoS One, 5(8), e12071. doi:10.1371/journal.pone.0012071;\nHegele, M., & Heuer, H. (2013). Psychology and Aging, 28(2), 333–9.;\nHeuer, H., & Hegele, M. (2011). Journal of Neurophysiology, 106(4), 2078–85.)""]	[""Amount of explicit Learning as indicated by the result of the explicit test when comparing pre and post training phase (cf. Hegele, M., & Heuer, H. (2010a). Consciousness and Cognition, 19(4), 906–917.;\nHegele, M., & Heuer, H. (2010b). PLoS One, 5(8), e12071. doi:10.1371/journal.pone.0012071;\nHegele, M., & Heuer, H. (2013). Psychology and Aging, 28(2), 333–9.;\nHeuer, H., & Hegele, M. (2011). Journal of Neurophysiology, 106(4), 2078–85.)""]	NA
DRKS00005989	Spinal anaesthesia with chloroprocain versus total intravenous anaesthesia for outpatient knee arthroscopy	Spinal anaesthesia with chloroprocaine 1% versus total intravenous anaesthesia for outpatient knee arthroscopy: A randomised controlled trial	10.1097/eja.0000000000000794	NA	4	2014-04-15	Recruiting complete, follow-up complete	2014-04-03	2015-08-24	2018-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Duration of stay in the day-surgery centre measured from anaesthesia induction until discharge in minutes.""]	[""Duration of stay in the day-surgery centre measured from anaesthesia induction until discharge in minutes.""]	[""Duration of stay in the day-surgery centre measured from anaesthesia induction until discharge in minutes.""]	[""Duration of stay in the day-surgery centre measured from anaesthesia induction until discharge in minutes.""]	NA
DRKS00006033	Dependency of respiratory mechanics and ventilation from PEEP during mechanical ventilation for elective surgery by children	Intratidal recruitment/derecruitment persists at low and moderate positive end-expiratory pressure in paediatric patients	10.1016/j.resp.2016.08.008	https://www.sciencedirect.com/science/article/abs/pii/S1569904816301409	6	2014-04-22	Recruiting complete, follow-up complete	2015-03-01	2015-10-08	2016-08-29	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	NA
DRKS00006087	Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD – A randomised, double-blind, parallel group, multicenter, phase IIa pilot study –	A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial	10.1186/s12931-018-0751-x	https://link.springer.com/article/10.1186/s12931-018-0751-x#citeas	3	2014-06-05	Recruiting complete, follow-up complete	2014-07-15	2016-12-22	2018-04-04	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Assessment of feasibility of conducting a larger phase II trial as determined by:\n- number of eligible patients / screening failures in light of specific inclusion / exclusion criteria;\n- duration of recruiting period;\n- number of randomized patients not evaluable due to, e.g. non-evaluable sputum;\n- suitability of inhalation device, patient compliance, and device handling\n- compliance to schedule for screening procedures (Day -28 to -7)\n\n""]	NA	NA	[""Assessment of feasibility of conducting a larger phase II trial as determined by:\n- number of eligible patients / screening failures in light of specific inclusion / exclusion criteria;\n- duration of recruiting period;\n- number of randomized patients not evaluable due to, e.g. non-evaluable sputum;\n- suitability of inhalation device, patient compliance, and device handling\n- compliance to schedule for screening procedures (Day -28 to -7)\n\n""]	NA
DRKS00006098	Saarland against colorectal cancer - Join in!	Screening for Bowel Cancer: Increasing Participation via Personal Invitation	10.3238/arztebl.2017.0087	https://www.aerzteblatt.de/int/archive/article/186297	4	2014-04-23	Recruiting complete, follow-up complete	2012-05-02	2014-04-30	2017-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n• To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n• To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n• To what extend is a colonoscopy performed in case of a positive test result?\n• To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n• What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n• For all questions: Are there differences between women and men?""]	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n• To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n• To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n• To what extend is a colonoscopy performed in case of a positive test result?\n• To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n• What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n• For all questions: Are there differences between women and men?""]	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n- To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n- To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n- To what extend is a colonoscopy performed in case of a positive test result?\n- To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n- What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n- For all questions: Are there differences between women and men?""]	NA	NA
DRKS00006102	Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting	Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy	10.1016/j.jacc.2016.04.056	https://www.onlinejacc.org/content/68/3/286.abstract	7	2014-05-21	Recruiting complete, follow-up complete	2014-06-11	2015-03-31	2016-04-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min tested 1 hour following loading dose""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min tested 1 hour following loading dose""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min tested 1 hour following loading dose""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min tested 1 hour following loading dose""]	NA
DRKS00006137	Music therapy in palliative care - Psychophysiological effects of a music-based relaxation intervention	Music Therapy in Palliative Care	10.3238/arztebl.2015.0788	https://pubmed.ncbi.nlm.nih.gov/26806566/	5	2014-07-04	Recruiting complete, follow-up complete	2013-05-01	2015-03-10	2015-11-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Subjective perception of:\n- relaxation\n- well-being\n- pain\n\n(VAS pre-post, respectively)""]	[""Subjective perception of:\n- relaxation\n- well-being\n- pain\n\n(VAS pre-post, respectively)""]	[""Subjective perception of:\n- relaxation\n- well-being\n- pain\n\n(VAS pre-post, respectively)""]	NA	NA
DRKS00006139	Effects of implementation of KDIGO guidelines controlled by biomarkers in cardiac surgery on incidence and severity of acute kidney injury	Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial	10.1007/s00134-016-4670-3	https://link.springer.com/article/10.1007/s00134-016-4670-3	3	2014-07-03	Recruiting complete, follow-up complete	2014-08-12	2015-03-10	2017-01-21	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Incidence of acute kidney injury in the first three postoperative days""]	[""Incidence of acute kidney injury in the first three postoperative days""]	[""Incidence of acute kidney injury in the first three postoperative days""]	NA	NA
DRKS00006147	Incidence of phrenic nerve palsy following interscalene versus supraclavicular nerve block catheter insertion	Phrenic palsy and analgesic quality of continuous supraclavicular vs. interscalene plexus blocks after shoulder surgery	10.1111/aas.12732	https://onlinelibrary.wiley.com/doi/full/10.1111/aas.12732	3	2014-06-02	Recruiting complete, follow-up complete	2014-06-30	2015-04-21	2016-04-20	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Measurements for signs of phrenic nerve palsy are performed before nerve block, after nerve block, postoperatively in the PACU and at the first postoperative day.\n\nUltrasound is used for evaluation of phrenic nerve dysfunction resulting in hemidiaphragmatic paresis.\nUsing B-Mode, diaphragm is displayed at midaxillary line. Normal excursions are shown as cephalad move and inspirations are shown as caudal movement of diaphragm and are measured in cm in normal breathing maneuvers as well as during \""sniffing maneuver\"". Moreover, paradoxic movements are investigated. Hemidiaphragmatic paresis is defined as paradoxic movement as well as incomplete movements of diaphragm during investigations using B-Mode and M-Mode for detailed analysis of movement.""]	[""Measurements for signs of phrenic nerve palsy are performed before nerve block, after nerve block, postoperatively in the PACU and at the first postoperative day.\n\nUltrasound is used for evaluation of phrenic nerve dysfunction resulting in hemidiaphragmatic paresis.\nUsing B-Mode, diaphragm is displayed at midaxillary line. Normal excursions are shown as cephalad move and inspirations are shown as caudal movement of diaphragm and are measured in cm in normal breathing maneuvers as well as during \""sniffing maneuver\"". Moreover, paradoxic movements are investigated. Hemidiaphragmatic paresis is defined as paradoxic movement as well as incomplete movements of diaphragm during investigations using B-Mode and M-Mode for detailed analysis of movement.""]	NA	[""Measurements for signs of phrenic nerve palsy are performed before nerve block, after nerve block, postoperatively in the PACU and at the first postoperative day.\n\nUltrasound is used for evaluation of phrenic nerve dysfunction resulting in hemidiaphragmatic paresis.\nUsing B-Mode, diaphragm is displayed at midaxillary line. Normal excursions are shown as cephalad move and inspirations are shown as caudal movement of diaphragm and are measured in cm in normal breathing maneuvers as well as during \""sniffing maneuver\"". Moreover, paradoxic movements are investigated. Hemidiaphragmatic paresis is defined as paradoxic movement as well as incomplete movements of diaphragm during investigations using B-Mode and M-Mode for detailed analysis of movement.""]	NA
DRKS00006183	Effectiveness and cost-effectiveness of a guided and unguided internet-based acceptance and commitment therapy for chronic pain: a three-armed randomised controlled trial	An Internet-Based Intervention for Chronic Pain	10.3238/arztebl.2017.0681	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672594/	3	2014-10-02	Recruiting complete, follow-up complete	2014-10-06	2016-02-29	2017-10-13	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""pain interference (MPI Interference-Scale) at pre-(T1), post-(T2) and at follow-up (T2) of the intervention. T0= before randomisation, T1= 9 weeks after randomisation, T2= 6 months after randomisation""]	[""pain interference (MPI Interference-Scale) at pre-(T1), post-(T2) and at follow-up (T2) of the intervention. T0= before randomisation, T1= 9 weeks after randomisation, T2= 6 months after randomisation""]	[""pain interference (MPI Interference-Scale) at pre-(T1), post-(T2) and at follow-up (T2) of the intervention. T0= before randomisation, T1= 9 weeks after randomisation, T2= 6 months after randomisation""]	NA	NA
DRKS00006189	Effect of a dietary supplement with red rice on LDL-cholesterol	Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention	10.1016/j.nutres.2016.07.005	https://www.sciencedirect.com/science/article/pii/S0271531716302317	3	2014-07-03	Recruiting complete, follow-up complete	2014-07-07	2015-05-08	2016-10-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""LDL-Cholesterol from week 0 to 6 and week 0 to 12 compared to placebo""]	[""LDL-Cholesterol from week 0 to 6 and week 0 to 12 compared to placebo""]	[""LDL-Cholesterol from week 0 to 6 and week 0 to 12 compared to placebo""]	NA	NA
DRKS00006206	Evaluating a stress prevention programme for sixth form pupils	NA	10.1016/j.mhp.2016.03.002	https://www.sciencedirect.com/science/article/pii/S2212657015300118	4	2014-07-01	Recruiting complete, follow-up complete	2014-03-24	2014-12-31	2016-03-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Subjective levels of stress pose the primary dependent outcome of this study. It will be measured using questionnaires at baseline as well as postline assessment with an interval of three months. The instrument used to assess subjective levels of stress is, amongst others, the german version of the Problem Questionnaire (PQ).""]	[""Subjective levels of stress pose the primary dependent outcome of this study. It will be measured using questionnaires at baseline as well as postline assessment with an interval of three months. The instrument used to assess subjective levels of stress is, amongst others, the german version of the Problem Questionnaire (PQ).""]	[""Subjective levels of stress pose the primary dependent outcome of this study. It will be measured using questionnaires at baseline as well as postline assessment with an interval of three months. The instrument used to assess subjective levels of stress is, amongst others, the german version of the Problem Questionnaire (PQ).""]	[""Subjective levels of stress pose the primary dependent outcome of this study. It will be measured using questionnaires at baseline as well as postline assessment with an interval of three months. The instrument used to assess subjective levels of stress is, amongst others, the german version of the Problem Questionnaire (PQ).""]	NA
DRKS00006215	Effect of Curodont TM Protect on prevention of artificial carious lesions of bovine enamel-an in-situ study	Randomised in situ clinical trial investigating self-assembling peptide matrix P11-4 in the prevention of artificial caries lesions	10.1038/s41598-018-36536-4	https://www.nature.com/articles/s41598-018-36536-4	7	2014-06-04	Recruiting complete, follow-up complete	2014-12-15	2015-07-15	2019-01-22	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Endpoint each arm: 4 weeks after wearing the appliance with specimen.\nEndpoint of the study: due to the crossover design 12 weeks.\nMeasuring method: loss of mineral in enamel measured by micro-ct and fluoreszence.\n""]	[""Endpoint each arm: 4 weeks after wearing the appliance with specimen.\nEndpoint of the study: due to the crossover design 12 weeks.\nMeasuring method: loss of mineral in enamel measured by micro-ct and fluoreszence.\n""]	[""Endpoint each arm: 4 weeks after wearing the appliance with specimen.\nEndpoint of the study: due to the crossover design 12 weeks.\nMeasuring method: loss of mineral in enamel measured by micro-ct and fluoreszence.\n""]	[""Endpoint each arm: 4 weeks after wearing the appliance with specimen.\nEndpoint of the study: due to the crossover design 12 weeks.\nMeasuring method: loss of mineral in enamel measured by micro-ct and fluoreszence.\n""]	NA
DRKS00006217	Decrease of incidence of postoperative delirium by optimizing orientation stimuli in cardiosurgery patients of an intensive care unit. A trial using the CAM-ICU	Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium	10.1186/s40560-017-0224-1	https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-017-0224-1	3	2014-06-05	Recruiting complete, follow-up complete	2014-06-01	2014-12-20	2017-05-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Incidence of postoperative delirium diagnosed by CAM-ICU. CAM-ICU is conducted twice a day at the first three days after surgery.""]	[""Incidence of postoperative delirium diagnosed by CAM-ICU. CAM-ICU is conducted twice a day at the first three days after surgery.""]	[""Incidence of postoperative delirium diagnosed by CAM-ICU. CAM-ICU is conducted twice a day at the first three days after surgery.""]	[""Incidence of postoperative delirium diagnosed by CAM-ICU. CAM-ICU is conducted twice a day at the first three days after surgery.""]	NA
DRKS00006220	Support of pain therapy by continuous algesia measurements by A.N.I. monitor in postoperative patients at the recovery room	NA	10.4172/2167-0846.1000343	https://www.omicsonline.org/peer-reviewed/support-of-acute-pain-therapy-by-analgesia-nociception-index-in-post-anesthesia-care-unit-a-randomized-controlled-trial-108115.html	2	2014-07-16	Recruiting complete, follow-up complete	2014-06-09	2016-07-01	2019-03-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Numeric Rating Score (average point value), measured pain intensity""]	[""Numeric Rating Score (average point value), measured pain intensity""]	[""Numeric Rating Score (average point value), measured pain intensity""]	NA	NA
DRKS00006301	Influence of an oral-health-optimised diet on clinical oral parameters.	An oral health optimized diet can reduce gingival and periodontal inflammation in humans - a randomized controlled pilot study	10.1186/s12903-016-0257-1	https://link.springer.com/article/10.1186/s12903-016-0257-1#rightslink	2	2015-05-21	Recruiting complete, follow-up complete	2015-05-31	2015-12-15	2016-07-26	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Reduction of Bleeding on Probing, comparing baseline with the last examination (after 6 weeks intervenion / 8 weeks after baseline).""]	NA	NA	[""Reduction of Bleeding on Probing, comparing baseline with the last examination (after 6 weeks intervenion / 8 weeks after baseline).""]	NA
DRKS00006349	Individual short-term coaching against exam-related stress	Resource-oriented coaching for reduction of examination-related stress in medical students: an exploratory randomized controlled trial	10.2147/amep.s110424	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003014/	5	2014-07-17	Recruiting complete, follow-up complete	2014-07-25	2014-08-24	2016-08-22	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Medical school stress (PMSS-D) at t1 (day of the group coaching), t2 (after the individual coaching, before the exam), t3 (directly after the exam)""]	NA	[""Medical school stress (PMSS-D) at t1 (day of the group coaching), t2 (after the individual coaching, before the exam), t3 (directly after the exam)""]	NA	NA
DRKS00006359	Minimal hepatic encephalopathy (MHE) – influence of therapy with rifaximin on MHE and on the intestinal microbiome in patients with liver cirrhosis – the RiMINI-Trial	Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy	10.1159/000494216	https://pubmed.ncbi.nlm.nih.gov/30428474/	2	2015-11-25	Recruiting stopped after recruiting started	2015-03-17	2016-11-05	2018-11-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Primary efficacy variable: neurocognitive function measured in CFF( Critical Flicker Test), NCT(Number Cancellation Test),VEP (Visually Evoked Potentials)\n\n\nTreatment Phase (EOT):\nScreening,\nVisit1 after 30 days +/-3 days,\nVisit 2 after 60 days +/-3 days,\nVisit 3 after 90 days +/-3 days,\n\n\nFollow up after 120 days:\nVisit 5 6 weeks after end of Treatment (EOT)\nVisit 6 12 weeks after end of Treatment (EOT) = end of study\n""]	[""Primary efficacy variable: neurocognitive function measured in CFF( Critical Flicker Test), NCT(Number Cancellation Test),VEP (Visually Evoked Potentials)\n\n\nTreatment Phase (EOT):\nScreening,\nVisit1 after 30 days +/-3 days,\nVisit 2 after 60 days +/-3 days,\nVisit 3 after 90 days +/-3 days,\n\n\nFollow up after 120 days:\nVisit 5 6 weeks after end of Treatment (EOT)\nVisit 6 12 weeks after end of Treatment (EOT) = end of study\n""]	[""Primary efficacy variable: neurocognitive function measured in CFF( Critical Flicker Test), NCT(Number Cancellation Test),VEP (Visually Evoked Potentials)\n\n\nTreatment Phase (EOT):\nScreening,\nVisit1 after 30 days +/-3 days,\nVisit 2 after 60 days +/-3 days,\nVisit 3 after 90 days +/-3 days,\n\n\nFollow up after 120 days:\nVisit 5 6 weeks after end of Treatment (EOT)\nVisit 6 12 weeks after end of Treatment (EOT) = end of study\n""]	NA	NA
DRKS00006585	Early recognition and preventive care for persons being at risk for type 2 diabetes in community pharmacies in Bavaria, Germany	Effects of the lifestyle intervention program GLICEMIA in people at risk for type 2 diabetes: a cluster-randomized controlled trial	10.2337/dc14-2206	NA	2	2014-09-17	Recruiting complete, follow-up complete	2013-10-01	2014-01-14	2015-03-17	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""FINDRISC score: Is there a significant difference of the change of the FINDRISC score between the intervention and the control group after 12 months?""]	NA	[""FINDRISC score: Is there a significant difference of the change of the FINDRISC score between the intervention and the control group after 12 months?""]	[""FINDRISC score: Is there a significant difference of the change of the FINDRISC score between the intervention and the control group after 12 months?""]	NA
DRKS00006736	TALENT Study weight reduction - A randomized controlled trial to investigate the effectiveness of 'Individual Health Management' for weight reduction	Effects of a tailored lifestyle self-management intervention (TALENT) study on weight reduction: a randomized controlled trial	10.2147/dmso.s135572	NA	9	2014-09-29	Recruiting complete, follow-up complete	2014-10-07	2016-03-10	2017-06-19	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change in body weight after 12 months""]	[""Change in body weight after 12 months""]	[""Change in body weight after 12 months""]	[""Change in body weight after 12 months""]	NA
DRKS00006743	Internet-based psychotherapy for family-caregivers of people with dementia	Acceptance and treatment effects of an internet-delivered cognitive-behavioral intervention for family caregivers of people with dementia: A randomized-controlled trial	10.1002/jclp.22739	https://pubmed.ncbi.nlm.nih.gov/30597537/	6	2014-09-25	Recruiting complete, follow-up complete	2014-10-15	2017-10-01	2018-12-31	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Subjective health status (GBB-24 subscales)\nbody discomfort (GBB-24)\nability to solve problems relating to focused problem areas (Goal Attainment Scaling)\n\nAll measured at all three assessments: pre-intervention, post-intervention, 6-month follow pp""]	[""Subjective health status (GBB-24 subscales)\nbody discomfort (GBB-24)\nability to solve problems relating to focused problem areas (Goal Attainment Scaling)\n\nAll measured at all three assessments: pre-intervention, post-intervention, 6-month follow pp""]	[""Subjective health status (GBB-24 subscales)\nbody discomfort (GBB-24)\nability to solve problems relating to focused problem areas (Goal Attainment Scaling)\n\nAll measured at all three assessments: pre-intervention, post-intervention, 6-month follow pp""]	[""Subjective health status (GBB-24 subscales)\nbody discomfort (GBB-24)\nability to solve problems relating to focused problem areas (Goal Attainment Scaling)\n\nAll measured at all three assessments: pre-intervention, post-intervention, 6-month follow pp""]	NA
DRKS00006755	The influence of collagen hydrolysate on functional knee discomforts	Improvement of activity-related knee joint discomfort following supplementation of specific collagen peptides	10.1139/apnm-2016-0390	https://www.nrcresearchpress.com/doi/full/10.1139/apnm-2016-0390#.X1KYTfzgqUl	5	2014-09-24	Recruiting complete, follow-up complete	2013-06-26	2014-03-26	2017-01-10	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""change in pain intensity during exercise after 12 weeks of supplementation, which is assessed using a visual analogue scale (VAS) by the study participants and a licensed physician.""]	NA	[""change in pain intensity during exercise after 12 weeks of supplementation, which is assessed using a visual analogue scale (VAS) by the study participants and a licensed physician.""]	[""change in pain intensity during exercise after 12 weeks of supplementation, which is assessed using a visual analogue scale (VAS) by the study participants and a licensed physician.""]	NA
DRKS00006782	The effect of feedback on antibiotics provision in paediatrics: Evidence from a randomised, controlled, framed field experiment	The Effect of Expert Feedback on Antibiotic Prescribing in Pediatrics: Experimental Evidence	10.1177/0272989x19866699	https://journals.sagepub.com/doi/full/10.1177/0272989X19866699	1	2016-10-18	Recruiting complete, follow-up complete	2014-10-01	2015-06-10	2019-08-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Outcome:\nDuration of antibiotics therapy among individual pediatricians working in German pediatric departments.\n\nMittel:\nOnline experimental questionnaire consisting of 40 stylized pediatric cases (vignettes), using a PC / tablet in a session directly after the recruitment and randomization.\n\nPlanned Analysis:\nInfluence of the provision of feedback on the duration of the antibiotic therapy.""]	NA	[""Outcome:\nDuration of antibiotics therapy among individual pediatricians working in German pediatric departments.\n\nMittel:\nOnline experimental questionnaire consisting of 40 stylized pediatric cases (vignettes), using a PC / tablet in a session directly after the recruitment and randomization.\n\nPlanned Analysis:\nInfluence of the provision of feedback on the duration of the antibiotic therapy.""]	NA	NA
DRKS00006866	European Comparative Effectiveness Research on Internet-based Depression Treatment	Barriers and facilitators for the implementation of blended psychotherapy for depression: A qualitative pilot study of therapists' perspective	10.1016/j.invent.2018.01.002	https://pubmed.ncbi.nlm.nih.gov/30135779/	6	2014-12-02	Recruiting complete, follow-up complete	2015-03-11	2017-06-30	2018-01-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	NA
DRKS00006882	Collection and analysis of wound exudate from human digit tip amputations	Collection of Wound Exudate From Human Digit Tip Amputations Does Not Impair Regenerative Healing: A Randomized Trial	10.1097/md.0000000000001764	https://pubmed.ncbi.nlm.nih.gov/26469916/	4	2014-10-21	Recruiting complete, follow-up complete	2014-10-15	2015-01-27	2015-10-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""healing state weekly, legthening, fingerprint, microbiological smear, questionnaire""]	[""healing state weekly, legthening, fingerprint, microbiological smear, questionnaire""]	[""healing state weekly, legthening, fingerprint, microbiological smear, questionnaire""]	NA	NA
DRKS00006887	The influence of a SOC-oriented coaching and physiotherapy on health and work ability in nurses with non-specific musculoskeletal complaints	The prevention of musculoskeletal complaints: a randomized controlled trial on additional effects of a work-related psychosocial coaching intervention compared to physiotherapy alone	10.1007/s00420-017-1202-6	https://link.springer.com/article/10.1007/s00420-017-1202-6#article-info	7	2014-11-07	Recruiting complete, follow-up complete	2014-04-14	2015-03-13	2017-03-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline and after 12 weeks], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12 and 22 weeks], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks.\n\n""]	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline and after 12 weeks], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12 and 22 weeks], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks.\n\n""]	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline, after 12 weeks and 24 months], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12, 22 weeks and 24 months], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months.\n\n""]	[""The effectiveness is measured primarily by musculoskeletal complaints. The physical examination is implemented at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline, after 12 weeks and 24 months], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12, 22 weeks and 24 months], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months].\n""]	NA
DRKS00007117	The Charité Cesarean Birth - A Family and Partner Orientated Approach of Cesarean Section	The Charité cesarean birth: a family orientated approach of cesarean section	10.3109/14767058.2014.991917	https://pubmed.ncbi.nlm.nih.gov/25572878/	1	2014-11-05	Recruiting complete, follow-up complete	2014-01-01	2014-10-01	2015-01-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""1. Perinatal safety: APGAR Scores. Admission to an intensive care unit. Cardiorespiratory\nproblems. Blood gas analysis umbilical cord (arterial pH value). Satisfaction with birth\n2. Mothers safety: cardiorespiratory disorders. Blood loss.\nModified Likert Scales were used to assess parameters of birth experience/satisfaction. Patients were asked with a standardized questionnaire between the second and fourth day after surgery.\n""]	NA	[""1. Perinatal safety: APGAR Scores. Admission to an intensive care unit. Cardiorespiratory\nproblems. Blood gas analysis umbilical cord (arterial pH value). Satisfaction with birth\n2. Mothers safety: cardiorespiratory disorders. Blood loss.\nModified Likert Scales were used to assess parameters of birth experience/satisfaction. Patients were asked with a standardized questionnaire between the second and fourth day after surgery.\n""]	NA	NA
DRKS00007121	Dosage finding for spinal anaesthesia using chloroprocaine 1% in patients undergoing perianal outpatient surgery.	Chloroprocaine 10 mg/ml for low-dose spinal anaesthesia in perianal surgery - a randomised dose finding study	10.1111/aas.12839	NA	7	2014-10-30	Recruiting complete, follow-up complete	2015-01-13	2015-09-23	2016-11-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Duration of stay in the day-surgery centre (from induction of anesthesia to readiness for home discharge in minutes)""]	[""Duration of stay in the day-surgery centre (from induction of anesthesia to readiness for home discharge in minutes)""]	[""Duration of stay in the day-surgery centre (from induction of anesthesia to readiness for home discharge in minutes)""]	[""Duration of stay in the day-surgery centre (from induction of anesthesia to readiness for home discharge in minutes)""]	NA
DRKS00007128	The impact of insomnia treatment on cardiovascuklar risk factors - a randomised controlled trial.	Cognitive behavioural therapy for insomnia does not appear to have a substantial impact on early markers of cardiovascular disease: A preliminary randomized controlled trial	10.1111/jsr.13102	https://onlinelibrary.wiley.com/doi/full/10.1111/jsr.13102	4	2014-10-30	Recruiting complete, follow-up complete	2015-03-04	2017-07-31	2020-06-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Systolic blood pressure, diastolic blood pressure, heart rate variability parameters (LF/HF, SDNN), heart rate will be measured at baseline (pre-treatment) and 8 weeks later (post-treatment)""]	[""Systolic blood pressure, diastolic blood pressure, heart rate variability parameters (LF/HF, SDNN), heart rate will be measured at baseline (pre-treatment) and 8 weeks later (post-treatment)""]	[""Systolic blood pressure, diastolic blood pressure, heart rate variability parameters (LF/HF, SDNN), heart rate will be measured at baseline (pre-treatment) and 8 weeks later (post-treatment)""]	NA	NA
DRKS00007140	The effect of a midday-sleep intervention on motor learning in healthy young, old and after stroke	Daytime sleep has no effect on the time course of motor sequence and visuomotor adaptation learning	10.1016/j.nlm.2016.03.017	https://www.sciencedirect.com/science/article/abs/pii/S1074742716300077?via%3Dihub#!	2	2015-08-20	Recruiting complete, follow-up complete	2014-02-10	2017-09-30	2016-03-25	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Change in motor performance (i.e. sequence learning- number of correct sequences or motor adaptation- number of trials) is measured prior to and directly after the diurnal break (sleep/wake) as well as in the morning of the following day.""]	[""Change in motor performance (i.e. sequence learning- number of correct sequences or motor adaptation- number of trials) is measured prior to and directly after the diurnal break (sleep/wake) as well as in the morning of the following day.""]	NA	[""Change in motor performance (i.e. sequence learning- number of correct sequences or motor adaptation- number of trials) is measured prior to and directly after the diurnal break (sleep/wake) as well as in the morning of the following day.""]	NA
DRKS00007171	Nasal noninvasive high frequency oscillatory ventilation in premature infants below 32 weeks gestational age  - a pilot study	Non-invasive high-frequency oscillatory ventilation in preterm infants: a randomised controlled cross-over trial	10.1136/archdischild-2017-313190	https://pubmed.ncbi.nlm.nih.gov/28918395/	2	2015-06-16	Recruiting complete, follow-up complete	2014-07-20	2016-09-23	2017-09-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Invasive measurement of partial pressure of carbon dioxide after 4 h nHFOV vs 4 h nCPAP""]	[""Invasive measurement of partial pressure of carbon dioxide after 4 h nHFOV vs 4 h nCPAP""]	[""Invasive measurement of partial pressure of carbon dioxide after 4 h nHFOV vs 4 h nCPAP""]	NA	NA
DRKS00007477	Mindfulness-Based Cognitive Therapy as an Intervention for Migraine	Is Mindfulness-Based Stress Reduction a Promising and Feasible Intervention for Patients Suffering from Migraine? A Randomized Controlled Pilot Trial	10.1159/000501425	https://www.karger.com/Article/Abstract/501425	2	2014-11-24	Recruiting complete, follow-up complete	2014-11-19	2016-01-04	2019-08-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""migraine related disability assessed by headache diaries for three times for 4 weeks (intervention group: pre, post, 9-months-follow-up from baseline; control group: pre and post according to the waiting period and post2 according to the intervention that followed) by means of an eleven-scale numerical analogue scale (no impairment - complete impairment)""]	[""migraine related disability assessed by headache diaries for three times for 4 weeks (intervention group: pre, post, 9-months-follow-up from baseline; control group: pre and post according to the waiting period and post2 according to the intervention that followed) by means of an eleven-scale numerical analogue scale (no impairment - complete impairment)""]	[""migraine related disability assessed by headache diaries for three times for 4 weeks (intervention group: pre, post, 9-months-follow-up from baseline; control group: pre and post according to the waiting period and post2 according to the intervention that followed) by means of an eleven-scale numerical analogue scale (no impairment - complete impairment)""]	NA	NA
DRKS00007634	Telemedically supported aftercare after living donor renal transplantation	Telemedically Supported Case Management of Living-Donor Renal Transplant Recipients to Optimize Routine Evidence-Based Aftercare: A Single-Center Randomized Controlled Trial	10.1111/ajt.14138	https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.14138	7	2015-01-28	Recruiting complete, follow-up complete	2011-10-28	2014-04-30	2016-11-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[""unplanned hospital re-admission""]	NA	[""Unplanned inpatient hospitalization (unplanned admission rate)""]	[""Unplanned inpatient hospitalization (unplanned admission rate) at 3,6, 12 months after transplantation""]	NA
DRKS00007685	Promoting academic resilience in preterm infants with adaptive computerized training - a multi-center randomised controlled trial	Preterm children's long-term academic performance after adaptive computerized training: an efficacy and process analysis of a randomized controlled trial	10.1038/s41390-020-01114-w	https://pubmed.ncbi.nlm.nih.gov/32919388/	9	2015-01-13	Recruiting complete, follow-up complete	2015-06-01	2017-12-20	2020-09-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""TAAS-Score (Teacher Academic Attainment Scale) for school performance as change from baseline to 12 month.""]	[""TAAS-Score (Teacher Academic Attainment Scale) for school performance as change from baseline to 12 month.""]	[""TAAS-Score (Teacher Academic Attainment Scale) for school performance as change from baseline to 12 month.""]	NA	NA
DRKS00007689	Impulsivity-focused group intervention to reduce binge eating episodes in patients with binge eating disorder	IMPULS: Impulsivity-Focused Group Intervention to Reduce Binge Eating Episodes in Patients with Binge Eating Disorder - A Randomised Controlled Trial	10.1159/000499696	https://www.karger.com/Article/FullText/499696	10	2015-01-14	Recruiting complete, follow-up complete	2015-02-01	2017-09-30	2019-05-20	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	no maximum age	NA
DRKS00007697	Simple Improvement of Cardiovascular Health and Cognitive Function in Elderly by Intermittant Tai Chi Training.	[Adherence to Phase III Cardiac Rehabilitation Programs: A Prospective, Randomized Comparison between a Conventionally Conducted Program and a Tai Chi-Based Program]	10.1055/s-0042-100952	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-100952	1	2015-01-14	Recruiting complete, follow-up complete	2013-03-12	2014-06-30	2016-04-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""adherence to the study groups (Proportion of participation of the provided training sessions, Drop-Outs)""]	NA	[""adherence to the study groups (Proportion of participation of the provided training sessions, Drop-Outs)""]	NA	NA
DRKS00007770	Effectiveness of work-related medical rehabilitation in cancer patients: a cluster randomized multicenter trial	[Work-Related Medical Rehabilitation in Cancer Rehabilitation - Short-Term Results from a Cluster-Randomized Multicenter-Trial]	10.1055/a-0604-0157	https://pubmed.ncbi.nlm.nih.gov/29801187/	11	2015-05-13	Recruiting complete, follow-up complete	2015-06-01	2017-11-08	2018-05-25	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome is self-reported role functioning 12 months after Rehabilitation. The role functioning will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire (EORTC QLQ-C30, Aaronson et al. 1993).""]	NA
DRKS00007784	Intravenous vs. epidural analgesia to reduce the incidence of gastrointestinal complications after elective pancreatoduodenectomy	Gastrointestinal Complications After Pancreatoduodenectomy With Epidural vs Patient-Controlled Intravenous Analgesia: A Randomized Clinical Trial	10.1001/jamasurg.2020.0794	https://jamanetwork.com/journals/jamasurgery/article-abstract/2765992	7	2015-03-23	Recruiting complete, follow-up complete	2015-06-30	2017-09-19	2020-05-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Combined endpoint of gastrointestinal complications (Delayed gastric emptying, pancreatic fistula, biliary leak, gastrointestinal bleeding, postoperative ileus) until postoperative day 30.\n""]	[""Combined endpoint of gastrointestinal complications (Delayed gastric emptying, pancreatic fistula, biliary leak, gastrointestinal bleeding, postoperative ileus) until postoperative day 30.\n""]	[""Combined endpoint of gastrointestinal complications (Delayed gastric emptying, pancreatic fistula, biliary leak, gastrointestinal bleeding, postoperative ileus) until postoperative day 30.\n""]	[""Combined endpoint of gastrointestinal complications (Delayed gastric emptying, pancreatic fistula, biliary leak, gastrointestinal bleeding, postoperative ileus) until postoperative day 30.\n""]	NA
DRKS00007800	Pilot trial on safety, feasibility and effectiveness of Osteopathic MANipulative Treatment following major abdominal surgery	NA	10.1016/j.ijosm.2016.03.002	https://www.journalofosteopathicmedicine.com/article/S1746-0689(16)30004-9/fulltext	3	2015-02-10	Recruiting complete, follow-up complete	2015-02-15	2015-04-29	2016-03-16	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Pilot study without primary endpoint.\n\nGeneral endpoints:\n- Mortality and morbidity until discharge (to Clavien-Dindo)\n- Complications caused by the intervention (quantitative and qualitative)\n- Problems in the implementation of the intervention (quantitative and qualitative)\n- Pain caused by intervention (NRS; before and after each treatment)\n- Length of stay (in days in intensive care and general ward)\n- Time to first bowel movement (hours postoperatively)\n- Time to first flatus (hours postoperatively)\n- Time to tolerance of solid food (postoperative day)\n- Vomiting (events in the first five days)\n- Pain (NRS; at each postoperative day until postoperative day 5)\n- Pain medication use (in mg for each drug until postoperative day 5)\n- Postoperative quality of life (PQL, pre-op, post-operative day 5, dismissal)""]	NA	[""Pilot study without primary endpoint.\n\nGeneral endpoints:\n- Mortality and morbidity until discharge (to Clavien-Dindo)\n- Complications caused by the intervention (quantitative and qualitative)\n- Problems in the implementation of the intervention (quantitative and qualitative)\n- Pain caused by intervention (NRS; before and after each treatment)\n- Length of stay (in days in intensive care and general ward)\n- Time to first bowel movement (hours postoperatively)\n- Time to first flatus (hours postoperatively)\n- Time to tolerance of solid food (postoperative day)\n- Vomiting (events in the first five days)\n- Pain (NRS; at each postoperative day until postoperative day 5)\n- Pain medication use (in mg for each drug until postoperative day 5)\n- Postoperative quality of life (PQL, pre-op, post-operative day 5, dismissal)""]	[""Pilot study without primary endpoint.\n\nGeneral endpoints:\n- Mortality and morbidity until discharge (to Clavien-Dindo)\n- Complications caused by the intervention (quantitative and qualitative)\n- Problems in the implementation of the intervention (quantitative and qualitative)\n- Pain caused by intervention (NRS; before and after each treatment)\n- Length of stay (in days in intensive care and general ward)\n- Time to first bowel movement (hours postoperatively)\n- Time to first flatus (hours postoperatively)\n- Time to tolerance of solid food (postoperative day)\n- Vomiting (events in the first five days)\n- Pain (NRS; at each postoperative day until postoperative day 5)\n- Pain medication use (in mg for each drug until postoperative day 5)\n- Postoperative quality of life (PQL, pre-op, post-operative day 5, dismissal)""]	NA
DRKS00007840	Sectio caesarea and the impact of music on anxiety	NA	10.1186/s12884-018-2069-6	https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-018-2069-6#article-info	8	2015-06-16	Recruiting complete, follow-up complete	2015-03-16	2017-08-02	2018-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Impact of music on anxiety measured by salivary cortisol, STAI questionnaire, mini EEG at the time of skin closure.""]	[""Impact of music on anxiety measured by salivary cortisol, STAI questionnaire, mini EEG at the time of skin closure.""]	[""Impact of music on anxiety measured by salivary cortisol, STAI questionnaire, mini EEG at the time of skin closure.""]	[""Impact of music on anxiety measured by salivary cortisol, STAI questionnaire, mini EEG at the time of skin closure.""]	NA
DRKS00007875	Effects of noisy galvanic vestibular stimulation on walking performance in patients with bilateral vestibulopathy	Noisy vestibular stimulation improves dynamic walking stability in bilateral vestibulopathy	10.1212/wnl.0000000000002748	NA	4	2015-03-13	Recruiting complete, follow-up complete	2015-03-15	2015-08-30	2016-05-06	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Changes in spatiotemporal gait parameters derived from treadmill recordings at three different walking speeds (slow, preferred, and fast walking) during stimulation condition and sham stimulation conditions. Each of the total six walking trials will last for two minutes. Ten gait parameters will be analyzed: stride time, stride length, base of support, swing time percentage, double support time percentage as well as gait asymmetry, bilateral phase coordination and the coefficient of variation (CV) of stride time, stride length and base of support.""]	NA	[""Changes in spatiotemporal gait parameters derived from treadmill recordings at three different walking speeds (slow, preferred, and fast walking) during stimulation condition and sham stimulation conditions. Each of the total six walking trials will last for two minutes. Ten gait parameters will be analyzed: stride time, stride length, base of support, swing time percentage, double support time percentage as well as gait asymmetry, bilateral phase coordination and the coefficient of variation (CV) of stride time, stride length and base of support.""]	[""Changes in spatiotemporal gait parameters derived from treadmill recordings at three different walking speeds (slow, preferred, and fast walking) during stimulation condition and sham stimulation conditions. Each of the total six walking trials will last for two minutes. Ten gait parameters will be analyzed: stride time, stride length, base of support, swing time percentage, double support time percentage as well as gait asymmetry, bilateral phase coordination and the coefficient of variation (CV) of stride time, stride length and base of support.""]	NA
DRKS00007888	Effects of an online intervention for depression on mood and positive symptoms in psychosis	Effects of online intervention for depression on mood and positive symptoms in schizophrenia	10.1016/j.schres.2016.04.033	https://pubmed.ncbi.nlm.nih.gov/27210726/	5	2015-03-19	Recruiting complete, follow-up complete	2014-07-15	2015-01-15	2016-05-18	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Center for Epidemiologic Studies-Depression Scale (CES-D): a 20 item questionnaire covering depressive symptoms. Two measuring times: Baseline and Post-assessment (3 month after baseline)""]	NA	[""Center for Epidemiologic Studies-Depression Scale (CES-D): a 20 item questionnaire covering depressive symptoms. Two measuring times: Baseline and Post-assessment (3 month after baseline)""]	[""Center for Epidemiologic Studies-Depression Scale (CES-D): a 20 item questionnaire covering depressive symptoms. Two measuring times: Baseline and Post-assessment (3 month after baseline)""]	NA
DRKS00007907	Evaluation of Metacognitive Training for Depression (D-MKT) in psychosomatic rehabilitation	Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial	10.1159/000443699	https://pubmed.ncbi.nlm.nih.gov/27230865/	5	2015-04-30	Recruiting complete, follow-up complete	2012-04-24	2014-05-02	2016-05-27	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Primary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0-t2).""]	NA	[""Primary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0-t2).""]	[""Primary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0-t2).""]	NA
DRKS00008023	Randomized-controlled pilot trial to compare continuous wound infiltration with local anesthetics via elastomer pump versus epidural analgesia following elective upper abdominal surgery via midline laparotomy	Continuous wound infiltration versus epidural analgesia for midline abdominal incisions - a randomized-controlled pilot trial (Painless-Pilot trial; DRKS Number: DRKS00008023)	10.1371/journal.pone.0229898	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229898	4	2015-12-04	Recruiting complete, follow-up complete	2015-10-20	2017-01-15	2020-03-06	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""1. Feasibility of assessing post-operative patient mobility with a pedometer\n2. Feasibility of patient recruitment in the planned time frame\n3. Evaluation of the comprehensive complication index (CCI) by examining the overall postoperative morbidity of patients in the study\n4. Pain scores at rest and on movement 48 and 72 hours post-operatively according to the numeric rating scale (NRS)\n5. Total amount of opioids administered during 0–24, 24–48 and 48-72 hours post-operatively\n6. Time to first flatus/bowel movement\n7. Body weight\n8. Rate of treatment failure, defined as the need for the use of an intravenous patient-controlled analgesia PCA system\n9. Rate of catheter-related complication\n10. Rate of surgical side infection according to the definition of the Centre for Disease Control and Prevention (CDC)\n11. Days of catheter-therapy\n12. Length of hospital stay\n13. Rate of serious adverse events (SAEs) in both groups.""]	[""1. Feasibility of assessing post-operative patient mobility with a pedometer\n2. Feasibility of patient recruitment in the planned time frame\n3. Evaluation of the comprehensive complication index (CCI) by examining the overall postoperative morbidity of patients in the study\n4. Pain scores at rest and on movement 48 and 72 hours post-operatively according to the numeric rating scale (NRS)\n5. Total amount of opioids administered during 0–24, 24–48 and 48-72 hours post-operatively\n6. Time to first flatus/bowel movement\n7. Body weight\n8. Rate of treatment failure, defined as the need for the use of an intravenous patient-controlled analgesia PCA system\n9. Rate of catheter-related complication\n10. Rate of surgical side infection according to the definition of the Centre for Disease Control and Prevention (CDC)\n11. Days of catheter-therapy\n12. Length of hospital stay\n13. Rate of serious adverse events (SAEs) in both groups.""]	[""1. Feasibility of assessing post-operative patient mobility with a pedometer\n2. Feasibility of patient recruitment in the planned time frame\n3. Evaluation of the comprehensive complication index (CCI) by examining the overall postoperative morbidity of patients in the study\n4. Pain scores at rest and on movement 48 and 72 hours post-operatively according to the numeric rating scale (NRS)\n5. Total amount of opioids administered during 0–24, 24–48 and 48-72 hours post-operatively\n6. Time to first flatus/bowel movement\n7. Body weight\n8. Rate of treatment failure, defined as the need for the use of an intravenous patient-controlled analgesia PCA system\n9. Rate of catheter-related complication\n10. Rate of surgical side infection according to the definition of the Centre for Disease Control and Prevention (CDC)\n11. Days of catheter-therapy\n12. Length of hospital stay\n13. Rate of serious adverse events (SAEs) in both groups.""]	[""1. Feasibility of assessing post-operative patient mobility with a pedometer\n2. Feasibility of patient recruitment in the planned time frame\n3. Evaluation of the comprehensive complication index (CCI) by examining the overall postoperative morbidity of patients in the study\n4. Pain scores at rest and on movement 48 and 72 hours post-operatively according to the numeric rating scale (NRS)\n5. Total amount of opioids administered during 0–24, 24–48 and 48-72 hours post-operatively\n6. Time to first flatus/bowel movement\n7. Body weight\n8. Rate of treatment failure, defined as the need for the use of an intravenous patient-controlled analgesia PCA system\n9. Rate of catheter-related complication\n10. Rate of surgical side infection according to the definition of the Centre for Disease Control and Prevention (CDC)\n11. Days of catheter-therapy\n12. Length of hospital stay\n13. Rate of serious adverse events (SAEs) in both groups.""]	NA
DRKS00008054	Development and evaluation of a communication skills training to improve social participation of persons with rheumatic diseases	Development and Formative Evaluation of a Communication Skills Training Program for Persons with Rheumatic and Musculoskeletal Diseases	10.1080/10410236.2018.1431760	https://pubmed.ncbi.nlm.nih.gov/29388797/	6	2015-09-07	Recruiting complete, follow-up complete	2016-02-13	2016-12-08	2018-02-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""There are three measurement points: before the training (t0), after the training (t1) and three months after the training (t2). Primary, proximal outcomes are participants’ communication competence (CoCo-questionnaire, Farin et al., 2014 and an adaption to the communication situations relevant in the project) and patient activation (PAM13-D, Hibbard et al., 2005, and an adaption to the communication situations relevant in the project). Moreover, we evaluate the acceptability, usefulness and achievement of objectives of the training at the end of the training (t1) with the COHEP-questionnaire (Farin et al., 2013) and newly developed questions.""]	[""There are three measurement points: before the training (t0), after the training (t1) and three months after the training (t2). Primary, proximal outcomes are participants’ communication competence (CoCo-questionnaire, Farin et al., 2014 and an adaption to the communication situations relevant in the project) and patient activation (PAM13-D, Hibbard et al., 2005, and an adaption to the communication situations relevant in the project). Moreover, we evaluate the acceptability, usefulness and achievement of objectives of the training at the end of the training (t1) with the COHEP-questionnaire (Farin et al., 2013) and newly developed questions.""]	[""There are three measurement points: before the training (t0), after the training (t1) and three months after the training (t2). Primary, proximal outcomes are participants’ communication competence (CoCo-questionnaire, Farin et al., 2014 and an adaption to the communication situations relevant in the project) and patient activation (PAM13-D, Hibbard et al., 2005, and an adaption to the communication situations relevant in the project). Moreover, we evaluate the acceptability, usefulness and achievement of objectives of the training at the end of the training (t1) with the COHEP-questionnaire (Farin et al., 2013) and newly developed questions.""]	[""There are three measurement points: before the training (t0), after the training (t1) and three months after the training (t2). Primary, proximal outcomes are participants’ communication competence (CoCo-questionnaire, Farin et al., 2014 and an adaption to the communication situations relevant in the project) and patient activation (PAM13-D, Hibbard et al., 2005, and an adaption to the communication situations relevant in the project). Moreover, we evaluate the acceptability, usefulness and achievement of objectives of the training at the end of the training (t1) with the COHEP-questionnaire (Farin et al., 2013) and newly developed questions.""]	NA
DRKS00008197	Direct endurance enhancing effect of a functional food - an EEG study.	The neurobiology of placebo effects in sports: EEG frontal alpha asymmetry increases in response to a placebo ergogenic aid	10.1038/s41598-019-38828-9	https://www.nature.com/articles/s41598-019-38828-9	3	2015-06-02	Recruiting complete, follow-up complete	2015-06-09	2015-11-25	2019-02-20	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""1. Performance change from baseline to intervention calculated in rerference to the individual anaerobic threshhold (Watt).\n\n2. Change in fatigue perception from baseline to intervention (rating of perceived exertion - RPE).\n\n3. Changes in cotrical activation (EEG).""]	[""1. Performance change from baseline to intervention calculated in rerference to the individual anaerobic threshhold (Watt).\n\n2. Change in fatigue perception from baseline to intervention (rating of perceived exertion - RPE).\n\n3. Changes in cotrical activation (EEG).""]	[""1. Performance change from baseline to intervention calculated in rerference to the individual anaerobic threshhold (Watt).\n\n2. Change in fatigue perception from baseline to intervention (rating of perceived exertion - RPE).\n\n3. Changes in cotrical activation (EEG).""]	NA	NA
DRKS00008204	Clinical efficacy and adherence of Philips Sonicare AirFloss Ultra on approximal health in adults	Efficacy and acceptance of a high-velocity microdroplet device for interdental cleaning in gingivitis patients-A monitored, randomized controlled trial	10.1111/idh.12292	https://pubmed.ncbi.nlm.nih.gov/28544397/	1	2016-10-10	Recruiting complete, follow-up complete	2015-06-18	2015-12-30	2017-05-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""papillary bleeding index (PBI) Baseline and after 4 weeks""]	NA	[""papillary bleeding index (PBI) Baseline and after 4 weeks""]	NA	NA
DRKS00008545	Effects of intraoperative recruitment manoeuvres on the respiratory sytem mechanics of lung-healthy children during elective surgery with general anesthesia	Dependency of respiratory system mechanics on positive end-expiratory pressure and recruitment maneuvers in lung healthy pediatric patients-A randomized crossover study	10.1111/pan.13927	https://onlinelibrary.wiley.com/doi/full/10.1111/pan.13927	9	2015-06-08	Recruiting complete, follow-up complete	2015-06-09	2016-12-20	2020-05-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	[""Perioperative non-lineare compliance (ml/mbar) fom the end of the induction of anaesthesia till the end of the surgery""]	NA	NA
DRKS00008548	Post stationary telemedical care of patients with severe psychiatric disorders	Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla)	10.1186/s12888-018-1737-4	https://pubmed.ncbi.nlm.nih.gov/29843676/	4	2015-05-21	Recruiting complete, follow-up complete	2015-01-30	2017-07-21	2018-05-29	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""The primary endpoint is the evaluation medication adherence. The assesssment instrument is the MARS-D (German version of the Medication Adherence Report Scale). Times of measurement are baseline, 3- and 6-months-follow ups. The hypothesis is that after 6 months, the medication adherence in the intervention group is better than the control group.""]	[""The primary endpoint is the evaluation medication adherence. The assesssment instrument is the MARS-D (German version of the Medication Adherence Report Scale). Times of measurement are baseline, 3- and 6-months-follow ups. The hypothesis is that after 6 months, the medication adherence in the intervention group is better than the control group.""]	NA	no maximum age	NA
DRKS00008555	Respiratory mechanics and ventilation using controlled expiration (FLEX) in lung-healthy adults during elective surgery with general anesthesia.	Application of the Novel Ventilation Mode FLow-Controlled EXpiration (FLEX): A Crossover Proof-of-Principle Study in Lung-Healthy Patients	10.1213/ane.0000000000001991	https://www.ingentaconnect.com/content/wk/ane/2017/00000125/00000004/art00027	8	2015-06-05	Recruiting complete, follow-up complete	2015-06-09	2016-01-01	2017-10-04	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	NA
DRKS00008561	Comprehension of confidence intervals in audio-visual patient information materials for people with multiple sclerosis: a web-based randomised controlled, parallel group trial.	Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial	10.1186/s12911-016-0362-8	https://pubmed.ncbi.nlm.nih.gov/27650788/	4	2015-06-08	Recruiting complete, follow-up complete	2015-06-22	2016-02-07	2018-02-08	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""The primary study outcome ist comprehension about confidence intervals measured by a six-item multiple choice questionnaire directly after the intervention""]	NA	NA	[""The primary study outcome ist comprehension about confidence intervals measured by a six-item multiple choice questionnaire directly after the intervention""]	NA
DRKS00008668	Sequential Learning of Psychomotor and Visuospatial Skills for Laparoscopic Suturing and Knot Tying – Study Protocol for a Randomized Trial “The Shoebox Study”	Sequential learning of psychomotor and visuospatial skills for laparoscopic suturing and knot tying - study protocol for a randomized controlled trial ""The shoebox study""	10.1186/s13063-015-1145-8	https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1145-8	5	2015-08-12	Recruiting complete, follow-up complete	2015-04-21	2015-08-08	2016-01-07	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""The primary endpoint is total training time needed to reach proficiency in a predefined standardized suturing and knot tying technique. Proficiency levels werde defined with the use of standardized checklists with data from tests with laparoscopic experts at our institution in concordance with the existuing literature. Operative time is recorded for each attempt, starting from when a trainee picks up the needle to when he or she fastens the final knot.""]	NA	[""The primary endpoint is total training time needed to reach proficiency in a predefined standardized suturing and knot tying technique. Proficiency levels werde defined with the use of standardized checklists with data from tests with laparoscopic experts at our institution in concordance with the existuing literature. Operative time is recorded for each attempt, starting from when a trainee picks up the needle to when he or she fastens the final knot.""]	[""The primary endpoint is total training time needed to reach proficiency in a predefined standardized suturing and knot tying technique. Proficiency levels werde defined with the use of standardized checklists with data from tests with laparoscopic experts at our institution in concordance with the existuing literature. Operative time is recorded for each attempt, starting from when a trainee picks up the needle to when he or she fastens the final knot.""]	NA
DRKS00008767	Comparison ultrasound-guided vs. Nerve-controlled peripheral nerve blocks of the lower extremity in terms of needle-nerve distance, block characteristics and magnetic resonance tomographic and sonographic changes in the nerve	Subparaneural Injection in Popliteal Sciatic Nerve Blocks Evaluated by MRI	10.1515/med-2019-0034	https://pubmed.ncbi.nlm.nih.gov/31157299/	3	2015-06-23	Recruiting complete, follow-up complete	2015-10-16	2016-10-16	2019-04-24	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""1) Sonografic distance between needle tip and nerve at a stimulation current of 0.5mA while nerve blockade preoperatively\n2) Sonographic measurement of nerve cross-section before and after injection of the local anesthetic at the plant nerve block preoperatively\n3) Acquisition MRI-morphological changes (nervous edema, inflammation, density) MRI pre- ( 12 hours ago) and postoperatively (12 hours later)\n""]	NA	[""1) Sonografic distance between needle tip and nerve at a stimulation current of 0.5mA while nerve blockade preoperatively\n2) Sonographic measurement of nerve cross-section before and after injection of the local anesthetic at the plant nerve block preoperatively\n3) Acquisition MRI-morphological changes (nervous edema, inflammation, density) MRI pre- ( 12 hours ago) and postoperatively (12 hours later)\n""]	NA	NA
DRKS00008843	A Randomized, Single-dose, Cross-over Study to Investigate the Suitability of Multiple Placebo Mini-tablet Administration in Small Children	Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial	10.1016/j.jpeds.2018.05.031	https://www.sciencedirect.com/science/article/abs/pii/S0022347618307443	6	2015-06-29	Recruiting complete, follow-up complete	2015-06-30	2016-01-18	2018-06-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""To demonstrate non-inferiority in suitability of 25 uncoated mini-tablets administered at a time in comparison to 5 ml glucose syrup in children between 6 months and 1 year inclusive.\n\nThis outcome will be determined after one administration of mini-tablets and one administration of sirup and will be evaluated with predefined evaluationcriteria at the bedside.""]	[""To demonstrate non-inferiority in suitability of 25 uncoated mini-tablets administered at a time in comparison to 5 ml glucose syrup in children between 6 months and 1 year inclusive.\n\nThis outcome will be determined after one administration of mini-tablets and one administration of sirup and will be evaluated with predefined evaluationcriteria at the bedside.""]	[""To demonstrate non-inferiority in suitability of 25 uncoated mini-tablets administered at a time in comparison to 5 ml glucose syrup in children between 6 months and 1 year inclusive.\n\nThis outcome will be determined after one administration of mini-tablets and one administration of sirup and will be evaluated with predefined evaluationcriteria at the bedside.""]	NA	NA
DRKS00008924	Application of the positive endexpiratory pressure (PEEP) based on intratidal respiratory system mechanics compared with the empirical setting	Effect of individualized PEEP titration guided by intratidal compliance profile analysis on regional ventilation assessed by electrical impedance tomography - a randomized controlled trial	10.1186/s12871-020-00960-9	https://link.springer.com/article/10.1186/s12871-020-00960-9#article-info	10	2015-08-10	Recruiting complete, follow-up complete	2015-11-05	2016-12-20	2020-02-20	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	[""Perioperative non-linear intratidal compliance, continously measured [ml/mbar] from the end of induction until the end of the surgery""]	NA
DRKS00008927	Development and evaluation of a virtual exposure therapy in a driving simulator for patients with driving phobia - A pilot study	Treating patients with driving phobia by virtual reality exposure therapy - a pilot study	10.1371/journal.pone.0226937	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226937	10	2015-11-02	Recruiting complete, follow-up complete	2016-04-08	2017-06-02	2020-01-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Avoidance behavior during the driving test in real traffic. The most important criterion is if the patients are able to manage at least one task/situation/individualized part of the course in the driving training with the driving instructor, which the patients rated before the treatment as not being manageable (or only with very strong anxiety).\nThe decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form) and subjectively by the patient himself with anxiety ratings (Subjective-Unit-of –Distress-Scale).\n""]	[""Avoidance behavior during the driving test in real traffic. The most important criterion is if the patients are able to manage at least one task/situation/individualized part of the course in the driving training with the driving instructor, which the patients rated before the treatment as not being manageable (or only with very strong anxiety).\nThe decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form) and subjectively by the patient himself with anxiety ratings (Subjective-Unit-of –Distress-Scale).\n""]	[""Avoidance behavior during the driving test in real traffic. The primary criterion is if the patients are able to master at least one driving task/situation in the driving test with a driving instructor, which they had rated before as not being manageable (or only with very strong anxiety). The decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form).""]	[""Avoidance behavior during the driving test in real traffic. The primary criterion is if the patients are able to master at least one driving task/situation in the driving test with a driving instructor, which they had rated before as not being manageable (or only with very strong anxiety). The decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form).""]	NA
DRKS00008985	Laryngeal tube suction II or endotracheal intubation for laparoscopic radical prostatectomy in a head down position: A randomised controlled trial.	Laryngeal tube suction II or endotracheal intubation for laparoscopic radical prostatectomy in a head down position: A randomised controlled trial	10.1097/eja.0000000000000547	https://pubmed.ncbi.nlm.nih.gov/27798454/	3	2015-09-23	Recruiting stopped after recruiting started	2014-04-23	2015-05-04	2017-07-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Successfull ventilation with LTS II""]	NA	[""Successfull ventilation with LTS II""]	NA	NA
DRKS00009221	Recording of psychological distress in the context of occupational medicine screenings after occupational exposure to carcinogenic substances - Possible influence of a modified invitation letter	NA	NA	http://digital.bibliothek.uni-halle.de/ulbhalhs/urn/urn:nbn:de:gbv:3:4-18063	2	2016-01-12	Recruiting complete, follow-up complete	2015-05-02	2015-11-01	2016-01-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""The primary outcome is the amount of the state anxiety (State-Trait-Anxiety Inventory). A difference of 5 score-points between the groups was selected.""]	NA	NA	[""The primary outcome is the amount of the state anxiety (State-Trait-Anxiety Inventory). A difference of 5 score-points between the groups was selected.""]	NA
DRKS00009232	Impact of intraoperative target-controlled EEG sedation monitoring on intraoperative vasopressor support in cardiac surgical patients - an interventional trial	Intraoperative reduction of vasopressors using processed electroencephalographic monitoring in patients undergoing elective cardiac surgery: a randomized clinical trial	10.1007/s10877-019-00284-1	https://pubmed.ncbi.nlm.nih.gov/30784008/	6	2015-08-19	Recruiting complete, follow-up complete	2015-10-06	2016-10-28	2019-02-19	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""To evaluate the impact of EEG processed neuromonitoring on intraoperative vasopressor support. Primary endpoint: cumulative intraoperative vasopressor application""]	[""To evaluate the impact of EEG processed neuromonitoring on intraoperative vasopressor support. Primary endpoint: cumulative intraoperative vasopressor application""]	NA	[""To evaluate the impact of EEG processed neuromonitoring on intraoperative vasopressor support. Primary endpoint: cumulative intraoperative vasopressor application""]	NA
DRKS00009249	Immediate pain reduction in adhesive capsulitis by acupuncture	Immediate Pain Relief in Adhesive Capsulitis by Acupuncture-A Randomized Controlled Double-Blinded Study	10.1093/pm/pnx052	https://academic.oup.com/painmedicine/article/18/11/2235/3076187	1	2015-11-18	Recruiting complete, follow-up complete	2013-06-12	2014-09-01	2017-03-20	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""CMSS pain subscore immediately before and after treatment""]	NA	[""CMSS pain subscore immediately before and after treatment""]	NA	NA
DRKS00009294	Comparing unilateral and bilateral computer-supported arm training for the severely affected arm after stroke	Bilateral Arm Training vs Unilateral Arm Training for Severely Affected Patients With Stroke: Exploratory Single-Blinded Randomized Controlled Trial	10.1016/j.apmr.2020.02.007	https://pubmed.ncbi.nlm.nih.gov/32145277/	5	2016-01-28	Recruiting complete, follow-up complete	2011-01-30	2016-10-01	2020-03-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change of Fugl-Meyr-Sccore will be measured 6 and 8 weeks post inclusion""]	[""Change of Fugl-Meyr-Sccore will be measured 6 and 8 weeks post inclusion""]	[""Change of Fugl-Meyr-Sccore will be measured 6 and 8 weeks post inclusion""]	[""Change of Fugl-Meyr-Sccore will be measured 6 and 8 weeks post inclusion""]	NA
DRKS00009368	Adjuvant Antifungal Therapy Using Tissue Tolerable Plasma on Oral Mucosa and Removable Dentures in Oral Candidiasis Patients: A Double-Blinded Split-Mouth Pilot Study.	Adjuvant antifungal therapy using tissue tolerable plasma on oral mucosa and removable dentures in oral candidiasis patients: a randomised double-blinded split-mouth pilot study	10.1111/myc.12495	https://pubmed.ncbi.nlm.nih.gov/26932256/	5	2015-09-21	Recruiting complete, follow-up complete	2015-03-11	2015-08-05	2016-03-02	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""At the end of treatment after six-time plasma application there is a remission of erythema. The evaluation is carried out using a digital measurement of the photographs made.""]	NA	[""At the end of treatment after six-time plasma application there is a remission of erythema. The evaluation is carried out using a digital measurement of the photographs made.""]	[""At the end of treatment after six-time plasma application there is a remission of erythema. The evaluation is carried out using a digital measurement of the photographs made.""]	NA
DRKS00009387	Adjunctive use of essential oils following Scaling and root planing	Adjunctive use of essential oils following scaling and root planing -a randomized clinical trial	10.1186/s12906-016-1117-x	https://pubmed.ncbi.nlm.nih.gov/27266517/	1	2015-09-30	Recruiting complete, follow-up complete	2013-04-02	2014-09-28	2016-06-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""probing depth measured with a manual periodontometer at baseline as well as after three and six months""]	NA	[""probing depth measured with a manual periodontometer at baseline as well as after three and six months""]	NA	NA
DRKS00009394	Evaluation of peri-implant mucositis at microgrooved and machined abutments: A two-center study	Onset, progression and resolution of experimental peri-implant mucositis at different abutment surfaces: A randomized controlled two-centre study	10.1111/jcpe.12868	https://onlinelibrary.wiley.com/doi/10.1111/jcpe.12868	2	2015-10-14	Recruiting complete, follow-up complete	2015-11-03	2017-06-12	2018-01-13	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Clinical changes during the exposition and resolution period with regard to the following parameter at days 0, 7, 14 and 21 (exposition period), as well as at 2, 4, and 16 weeks (resolution period): Bleeding on Probing (BOP)\n\n""]	NA	[""Clinical changes during the exposition and resolution period with regard to the following parameter at days 0, 7, 14 and 21 (exposition period), as well as at 2, 4, and 16 weeks (resolution period): Bleeding on Probing (BOP)\n\n""]	NA	NA
DRKS00009530	Therapeutic Window, Efficiency and Efficacy of Directional stimulation	Directional DBS increases side-effect thresholds-A prospective, double-blind trial	10.1002/mds.27093	https://pubmed.ncbi.nlm.nih.gov/28843009/	2	2015-11-11	Recruiting complete, follow-up complete	2015-10-23	2016-11-10	2017-08-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Therapeutic window, defined as the difference between the stimulation amplitude threshold needed for effective suppression of the target symptom (rigidity, tremor or akinesia depending on the patient) and the side effect threshold for irreversible side effects.""]	[""Therapeutic window, defined as the difference between the stimulation amplitude threshold needed for effective suppression of the target symptom (rigidity, tremor or akinesia depending on the patient) and the side effect threshold for irreversible side effects.""]	[""Therapeutic window, defined as the difference between the stimulation amplitude threshold needed for effective suppression of the target symptom (rigidity, tremor or akinesia depending on the patient) and the side effect threshold for irreversible side effects.""]	NA	NA
DRKS00009541	Prehospital ultrasound-guided nerve blocks improve reduction-feasibility of dislocated extremity injuries compared to systemic analgesia. A randomized controlled trial.	Prehospital ultrasound-guided nerve blocks improve reduction-feasibility of dislocated extremity injuries compared to systemic analgesia. A randomized controlled trial	10.1371/journal.pone.0199776	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199776	4	2016-02-09	Recruiting complete, follow-up complete	2016-02-15	2017-02-15	2018-07-02	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Pain measurement - In arrive the emergency doctor / After analgesia / on first and second day after intervention - by Nummeric Rating Scale Interview by investigator\n\nReposition possibility- After reposition maneuver in ambulance - through questionnaires to the emergency""]	NA	[""Pain measurement - In arrive the emergency doctor / After analgesia / on first and second day after intervention - by Nummeric Rating Scale Interview by investigator\n\nReposition possibility- After reposition maneuver in ambulance - through questionnaires to the emergency""]	[""Pain measurement - In arrive the emergency doctor / After analgesia / on first and second day after intervention - by Nummeric Rating Scale Interview by investigator\n\nReposition possibility- After reposition maneuver in ambulance - through questionnaires to the emergency""]	NA
DRKS00009547	A randomized, double-blind, vehicle-controlled, parallel-group trial to assess the efficacy, safety and tolerability of P-3073 for topical treatment of nail psoriasis	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002365-34/results	5	2015-11-05	Recruiting complete, follow-up complete	2015-12-22	2017-02-08	2018-02-20	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Primary Objective:\nTo assess the efficacy of topical P-3073 in the treatment of mild to moderate psoriatic fingernail/s (defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score greater or equal to 1 and less than or equal to 3 at baseline).\n\nPrimary endpoint:\nThe primary endpoint is the change from baseline in total NAPSI to Week 24 (end of treatment).\n\nNAPSI:\nTo assign a score to each nail for nail bed and nail matrix psoriasis, the Nail Psoriasis Severity Index (NAPSI) will be used. The nail plate is divided into four quadrants by imaginary longitudinal and horizontal lines. Nail matrix psoriasis is assessed by the presence of any feature of nail matrix psoriasis, including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail.\n\nNail bed psoriasis is assessed by the presence of any features of nail bed psoriasis, including onycholysis, oil drop (salmon patch) dyschromia, splinter haemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. The score is 0 if the findings are not present, 1 if they are present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail has a matrix score (0-4) and a nail bed score (0-4), and the total nail score is the sum of those two (0-8). The sum of the scores from all involved fingernails is 0-80 (total NAPSI score for that patient at that time) and represents the total score.""]	[""Primary Objective:\nTo assess the efficacy of topical P-3073 in the treatment of mild to moderate psoriatic fingernail/s (defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score greater or equal to 1 and less than or equal to 3 at baseline).\n\nPrimary endpoint:\nThe primary endpoint is the change from baseline in total NAPSI to Week 24 (end of treatment).\n\nNAPSI:\nTo assign a score to each nail for nail bed and nail matrix psoriasis, the Nail Psoriasis Severity Index (NAPSI) will be used. The nail plate is divided into four quadrants by imaginary longitudinal and horizontal lines. Nail matrix psoriasis is assessed by the presence of any feature of nail matrix psoriasis, including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail.\n\nNail bed psoriasis is assessed by the presence of any features of nail bed psoriasis, including onycholysis, oil drop (salmon patch) dyschromia, splinter haemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. The score is 0 if the findings are not present, 1 if they are present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail has a matrix score (0-4) and a nail bed score (0-4), and the total nail score is the sum of those two (0-8). The sum of the scores from all involved fingernails is 0-80 (total NAPSI score for that patient at that time) and represents the total score.""]	[""Primary Objective:\nTo assess the efficacy of topical P-3073 in the treatment of mild to moderate psoriatic fingernail/s (defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score greater or equal to 1 and less than or equal to 3 at baseline).\n\nPrimary endpoint:\nThe primary endpoint is the change from baseline in total NAPSI to Week 24 (end of treatment).\n\nNAPSI:\nTo assign a score to each nail for nail bed and nail matrix psoriasis, the Nail Psoriasis Severity Index (NAPSI) will be used. The nail plate is divided into four quadrants by imaginary longitudinal and horizontal lines. Nail matrix psoriasis is assessed by the presence of any feature of nail matrix psoriasis, including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail.\n\nNail bed psoriasis is assessed by the presence of any features of nail bed psoriasis, including onycholysis, oil drop (salmon patch) dyschromia, splinter haemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. The score is 0 if the findings are not present, 1 if they are present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail has a matrix score (0-4) and a nail bed score (0-4), and the total nail score is the sum of those two (0-8). The sum of the scores from all involved fingernails is 0-80 (total NAPSI score for that patient at that time) and represents the total score.""]	NA	NA
DRKS00009565	Anterior suprascapular nerve block vs. interscalene brachial plexus block for shoulder surgery in the outpatient setting: a randomized, controlled, patient and assessor blinded trial	Anterior Suprascapular Nerve Block Versus Interscalene Brachial Plexus Block for Shoulder Surgery in the Outpatient Setting: A Randomized Controlled Patient- and Assessor-Blinded Trial	10.1097/aap.0000000000000573	https://pubmed.ncbi.nlm.nih.gov/28257388/	3	2016-01-04	Recruiting complete, follow-up complete	2013-02-18	2014-04-17	2017-05-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The primary outcome measures of this study were\n1) the quality of pain control (numerical rating scale, NRS, at rest, with 0 = no pain, 10 = worst imaginable pain), and\n\n2) and the intensity of motor block of the hand, assessed using the Modified Medical Research Council Scale for measuring hand muscles strength, cf. Brandsma JW, Schreuders TA: Sensible manual muscle strength testing to evaluate and monitor strength of the intrinsic muscles of the hand: a commentary. J Hand Ther 2001; 14:273-8, grade 1 = no motion / palpable muscle contraction only, grade 2 = reduced motion / no muscle resistance, Grad 3 = full motion / no muscle resistance, Grad 4 = full motion / reduced muscle resistance, Grad 5 = full motion / normal muscle resistance.\n\nData was assessed prior to the operation as well as 10 min, 30 min, 240 min and 1440 minutes after the operation.""]	NA	[""The primary outcome measures of this study were\n1) the quality of pain control (numerical rating scale, NRS, at rest, with 0 = no pain, 10 = worst imaginable pain), and\n\n2) and the intensity of motor block of the hand, assessed using the Modified Medical Research Council Scale for measuring hand muscles strength, cf. Brandsma JW, Schreuders TA: Sensible manual muscle strength testing to evaluate and monitor strength of the intrinsic muscles of the hand: a commentary. J Hand Ther 2001; 14:273-8, grade 1 = no motion / palpable muscle contraction only, grade 2 = reduced motion / no muscle resistance, Grad 3 = full motion / no muscle resistance, Grad 4 = full motion / reduced muscle resistance, Grad 5 = full motion / normal muscle resistance.\n\nData was assessed prior to the operation as well as 10 min, 30 min, 240 min and 1440 minutes after the operation.""]	NA	NA
DRKS00009602	Efficacy of a participation-oriented outpatient neurorehabilitation program in patients with chronic acquired brain injury	Long-term Rehabilitation in Patients With Acquired Brain Injury	10.3238/arztebl.2016.0634	NA	2	2015-11-19	Recruiting complete, follow-up complete	2012-12-03	2015-09-30	2016-09-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Achieving an individually defined therapeutic goal, assessed by means of the Goal Attainment Scale (GAS) at the start of the study (t1), after 1 month (t2), after 3 months (t3), after 4 months (t4), after 6 months (t5), and after 12 months (t6; all time points given in relation to the baseline t1 measurement)""]	NA	[""Achieving an individually defined therapeutic goal, assessed by means of the Goal Attainment Scale (GAS) at the start of the study (t1), after 1 month (t2), after 3 months (t3), after 4 months (t4), after 6 months (t5), and after 12 months (t6; all time points given in relation to the baseline t1 measurement)""]	[""Achieving an individually defined therapeutic goal, assessed by means of the Goal Attainment Scale (GAS) at the start of the study (t1), after 1 month (t2), after 3 months (t3), after 4 months (t4), after 6 months (t5), and after 12 months (t6; all time points given in relation to the baseline t1 measurement)""]	NA
DRKS00009637	The neurochemical basis of individual pain sensitivity and pain modulation, Part II, Study 1	The effect of dopamine on conditioned placebo analgesia in healthy individuals: a double-blind randomized trial	10.1007/s00213-018-4951-3	https://link.springer.com/article/10.1007%2Fs00213-018-4951-3#article-info	6	2015-11-26	Recruiting complete, follow-up complete	2015-12-17	2016-04-28	2018-06-25	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Outcome variable: Heat pain ratings (visal analog scale, 101-points) obtained for the skin patches with placebo treatment and the skin patch with control treatment at identical stimulus intensities.\nOutcome comparison: The interaction effect between factors Group (between-subject, levels: LDopa, Placebo) and Patch (within-subject, levels: Placebo-Treatment, Control-Treatment) tested in a full-factorial Mixed-Model ANOVA with maximum random effects structure.""]	NA	[""Outcome variable: Heat pain ratings (visal analog scale, 101-points) obtained for the skin patches with placebo treatment and the skin patch with control treatment at identical stimulus intensities.\nOutcome comparison: The interaction effect between factors Group (between-subject, levels: LDopa, Placebo) and Patch (within-subject, levels: Placebo-Treatment, Control-Treatment) tested in a full-factorial Mixed-Model ANOVA with maximum random effects structure.""]	[""Outcome variable: Heat pain ratings (visal analog scale, 101-points) obtained for the skin patches with placebo treatment and the skin patch with control treatment at identical stimulus intensities.\nOutcome comparison: The interaction effect between factors Group (between-subject, levels: LDopa, Placebo) and Patch (within-subject, levels: Placebo-Treatment, Control-Treatment) tested in a full-factorial Mixed-Model ANOVA with maximum random effects structure.""]	NA
DRKS00009688	Study on the requirement of drain placement during open partial nephrectomy	Drain placement can safely be omitted for open partial nephrectomy: Results from a prospective randomized trial	10.1111/iju.13063	NA	1	2015-11-17	Recruiting complete, follow-up complete	2009-10-01	2015-10-01	2016-02-18	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Postoperative complications within the first 30d""]	NA	[""Postoperative complications within the first 30d""]	NA	NA
DRKS00009739	Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting	Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The ExcelsiorLOAD2 Trial	10.1016/j.jcin.2016.10.004	https://pubmed.ncbi.nlm.nih.gov/28104204/	7	2016-01-26	Recruiting complete, follow-up complete	2016-01-26	2016-06-07	2017-01-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min (Multiplate-Test, Roche Diagnostics) tested 1 hour after discontinuation of cangrelor.""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min (Multiplate-Test, Roche Diagnostics) tested 1 hour after discontinuation of cangrelor.""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min (Multiplate-Test, Roche Diagnostics) tested 1 hour after discontinuation of cangrelor.""]	[""Proportion of patients with ADP-induced platelet aggregation < 468 AU x min (Multiplate-Test, Roche Diagnostics) tested 1 hour after discontinuation of cangrelor.""]	NA
DRKS00009792	Strauss by stress? Influence of different Music styles on the cardiovascular System in humans. A prospective randomized study	The Cardiovascular Effect of Musical Genres	10.3238/arztebl.2016.0347	https://www.aerzteblatt.de/archiv/179297/Einfluss-unterschiedlicher-Musikstile-auf-das-Herz-Kreislauf-System	2	2015-12-23	Recruiting complete, follow-up complete	2012-03-01	2015-11-30	2016-03-14	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Mesaurement of blood pressure (systolic and diastolic) and heart rate during Music application (Duration ca. 25 minutes). Venous mesaurement of Cortisol Prior to and after Music application. Music was applied in healthy volunteers. After Music application continuous mesasurement of blood pressure and heart rate until 1.00 p.m (total Duration 3 hours).\nControl Group: identical study protocol with venous blood for Cortisol mesaurement at 10.00 a.m., ca. 25 minutes headphones without Music, only silence, continuos Registration of blood pressure and heart rate from 10.00 a.m. to 1.00 p.m. (total Duration 3 hours).""]	NA	[""Mesaurement of blood pressure (systolic and diastolic) and heart rate during Music application (Duration ca. 25 minutes). Venous mesaurement of Cortisol Prior to and after Music application. Music was applied in healthy volunteers. After Music application continuous mesasurement of blood pressure and heart rate until 1.00 p.m (total Duration 3 hours).\nControl Group: identical study protocol with venous blood for Cortisol mesaurement at 10.00 a.m., ca. 25 minutes headphones without Music, only silence, continuos Registration of blood pressure and heart rate from 10.00 a.m. to 1.00 p.m. (total Duration 3 hours).""]	[""Mesaurement of blood pressure (systolic and diastolic) and heart rate during Music application (Duration ca. 25 minutes). Venous mesaurement of Cortisol Prior to and after Music application. Music was applied in healthy volunteers. After Music application continuous mesasurement of blood pressure and heart rate until 1.00 p.m (total Duration 3 hours).\nControl Group: identical study protocol with venous blood for Cortisol mesaurement at 10.00 a.m., ca. 25 minutes headphones without Music, only silence, continuos Registration of blood pressure and heart rate from 10.00 a.m. to 1.00 p.m. (total Duration 3 hours).""]	NA
DRKS00009828	Overcoming Disembodiment: The Effect of Movement Therapy on Negative Symptoms in Schizophrenia - A Multicenter Randomized Controlled Trial	Overcoming Disembodiment: The Effect of Movement Therapy on Negative Symptoms in Schizophrenia-A Multicenter Randomized Controlled Trial	10.3389/fpsyg.2016.00483	https://www.frontiersin.org/articles/10.3389/fpsyg.2016.00483/full	3	2015-12-30	Recruiting complete, follow-up complete	2012-05-30	2015-03-31	2016-03-31	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Improvement of Negative Symptoms, particularly Blunted Affect, measured with the Scale for the Assessment of Negative Symptoms (SANS), before and after 20 sessions (10 weeks) of movement therapy""]	NA	[""Improvement of Negative Symptoms, particularly Blunted Affect, measured with the Scale for the Assessment of Negative Symptoms (SANS), before and after 20 sessions (10 weeks) of movement therapy""]	[""Improvement of Negative Symptoms, particularly Blunted Affect, measured with the Scale for the Assessment of Negative Symptoms (SANS), before and after 20 sessions (10 weeks) of movement therapy""]	NA
DRKS00009891	RHAPSODY: A pilot study evaluating the usability and benefits of an online learning programme for carers of people with young onset dementia	Online information and support for carers of people with young-onset dementia: A multi-site randomised controlled pilot study	10.1002/gps.5154	NA	2	2016-04-21	Recruiting complete, follow-up complete	2016-05-17	2017-02-28	2019-05-20	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""All data will be assessedat baseline as well in weeks 6 and 12 in caregivers:\nSelf-efficacy (Revised Scale for Caregiving Self-Efficacy, RSCSE);\nDisease-related knowledge (Coping With the Caregiving Role Questionnaire, self-designed).\n""]	NA	[""All data will be assessedat baseline as well in weeks 6 and 12 in caregivers:\nSelf-efficacy (Revised Scale for Caregiving Self-Efficacy, RSCSE);\nDisease-related knowledge (Coping With the Caregiving Role Questionnaire, self-designed).\n""]	NA	NA
DRKS00009914	Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MRAngiography in patients with cerebrovascular disease	Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography	10.1007/s00234-017-1922-z	https://link.springer.com/article/10.1007/s00234-017-1922-z	1	2016-01-21	Recruiting complete, follow-up complete	2012-12-01	2016-01-14	2017-09-06	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""To compare Gadobutrol to Gadoterate in DSC-MRperfusion imaging and contrast-enhanced MR\nangiography in acute stroke subjects and/or subjects\nharboring an intracranial stenosis or extracranial ICA\nstenosis\n\nAll MRI images will be evaluated for technical adequacy by on site and off site readers to check\ntheir eligibility. A blinded read will be performed off site using appropriate technology and\nequipment. The preparation of the reading will be adhering to international quality standards\nand documented accordingly. On site, the MR perfusion source data will be analyzed in a\nstandardized way using the Siemens \""MRPerf\"" software.""]	NA	[""To compare Gadobutrol to Gadoterate in DSC-MRperfusion imaging and contrast-enhanced MR\nangiography in acute stroke subjects and/or subjects\nharboring an intracranial stenosis or extracranial ICA\nstenosis\n\nAll MRI images will be evaluated for technical adequacy by on site and off site readers to check\ntheir eligibility. A blinded read will be performed off site using appropriate technology and\nequipment. The preparation of the reading will be adhering to international quality standards\nand documented accordingly. On site, the MR perfusion source data will be analyzed in a\nstandardized way using the Siemens \""MRPerf\"" software.""]	NA	NA
DRKS00009915	Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects.	Standardized acquisition and post-processing of dynamic susceptibility contrast perfusion in patients with brain tumors, cerebrovascular disease and dementia: comparability of post-processing software	10.1259/bjr.20190543	https://www.birpublications.org/doi/abs/10.1259/bjr.20190543	1	2016-01-22	Recruiting complete, follow-up complete	2013-01-01	2016-01-14	2019-10-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""To compare the robustness of Gadobutrol enhanced DSC-MRP with ASL-MRP in subjects with MCI and minor Alzheimer´s disease (AD);""]	NA	[""To compare the robustness of Gadobutrol enhanced DSC-MRP with ASL-MRP in subjects with MCI and minor Alzheimer´s disease (AD);""]	NA	NA
DRKS00009979	Evaluation of the influence of active controlled motion (ACM) after operatively treated ankle fractures type Weber-B and -C with the necessity for partial weightbearing for 6 weeks	Active controlled motion in early rehabilitation improves outcome after ankle fractures: a randomized controlled trial	10.1177/0269215517724192	https://journals.sagepub.com/doi/full/10.1177/0269215517724192	1	2016-02-02	Recruiting complete, follow-up complete	2010-11-01	2014-01-10	2017-08-14	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Range of motion of the ankle joint after 6 weeks""]	NA	[""Range of motion of the ankle joint after 6 weeks""]	NA	NA
DRKS00009997	Self-directed training with e-learning using the first-person perspective for laparoscopic suturing and knot tying: a randomized-controlled trial - Learning from the surgeon`s real perspective -	Self-directed training with e-learning using the first-person perspective for laparoscopic suturing and knot tying: a randomised controlled trial : Learning from the surgeon's real perspective	10.1007/s00464-019-06842-7	https://link.springer.com/article/10.1007%2Fs00464-019-06842-7	4	2016-05-06	Recruiting complete, follow-up complete	2016-05-16	2016-10-11	2019-05-28	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""total training time needed to reach competency in the predefined laparoscopic suturing and knot tying technique in [s]""]	NA	[""total training time needed to reach competency in the predefined laparoscopic suturing and knot tying technique in [s]""]	[""total training time needed to reach competency in the predefined laparoscopic suturing and knot tying technique in [s]""]	NA
DRKS00010011	Does therapist’s attitude affect clinical outcome of lumbar facet joint injections?	Does therapist's attitude affect clinical outcome of lumbar facet joint injections?	10.4329/wjr.v8.i6.628	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919763/	1	2016-02-10	Recruiting complete, follow-up complete	2015-04-17	2015-12-31	2016-06-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Therapy effect after 6 months (pain documented by the verbal numeric scale)""]	NA	[""Therapy effect after 6 months (pain documented by the verbal numeric scale)""]	NA	NA
DRKS00010030	Randomized controlled trial of efficacy of the pain provocation technique in adolescents with chronic pain disorders	Efficacy of adding interoceptive exposure to intensive interdisciplinary treatment for adolescents with chronic pain: a randomized controlled trial	10.1097/j.pain.0000000000001321	https://journals.lww.com/pain/Fulltext/2018/11000/Efficacy_of_adding_interoceptive_exposure_to.10.aspx	4	2016-03-18	Recruiting complete, follow-up complete	2015-07-05	2017-01-13	2018-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Fear of pain measured with the German Fear of Pain Questionnaire for Children (GFOPQ-C) at discharge""]	[""Fear of pain measured with the German Fear of Pain Questionnaire for Children (GFOPQ-C) at discharge""]	[""Fear of pain measured with the German Fear of Pain Questionnaire for Children (GFOPQ-C) at discharge""]	[""Fear of pain measured with the German Fear of Pain Questionnaire for Children (GFOPQ-C) at discharge""]	NA
DRKS00010037	Pilot study on a complex intervention targeting social participation and quality of life of nursing home residents with joint contractures	Improved participation of older people with joint contractures living in nursing homes: feasibility of study procedures in a cluster-randomised pilot trial	10.1186/s13063-019-3522-1	https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3522-1	8	2016-02-12	Recruiting complete, follow-up complete	2016-02-25	2016-09-09	2019-07-09	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Social participation (instrument: PaArticular Scale (Sub-Skala 2)), developed by the working group in preparatory studies) assessed at baseline, three-month and six-month follow-up\n""]	NA	[""Social participation (instrument: PaArticular Scale (Sub-Skala 2)), developed by the working group in preparatory studies) assessed at baseline, three-month and six-month follow-up\n""]	[""Social participation (instrument: PaArticular Scale (Sub-Skala 2)), developed by the working group in preparatory studies) assessed at baseline, three-month and six-month follow-up\n""]	NA
DRKS00010089	""Healthy Eating, Active Play - Promoting a healthy lifestyle in Young CHILDren (HEALTH SURVEY)"" – Study for the investigation of efficacy and cost effectiveness of the prevention program ""Join the healthy boat - kindergarten""	Intervention effects of a kindergarten-based health promotion programme on obesity related behavioural outcomes and BMI percentiles	10.1016/j.pmedr.2019.100931	https://www.sciencedirect.com/science/article/pii/S2211335519301056	6	2016-02-24	Recruiting complete, follow-up complete	2016-09-12	2017-11-30	2019-06-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: June/July 2017""]	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: June/July 2017""]	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: September/October 2017""]	NA	NA
DRKS00010096	Effectiveness of a computer-based, personalized cognitive training program in healthy elderly individuals - a study within the ""NeuroCare"" project funded by the German Ministry of Education and Research (BMBF)	NA	10.4236/health.2017.101003	https://www.scirp.org/journal/paperabs.aspx?paperid=81558	1	2016-03-14	Recruiting complete, follow-up complete	2015-03-16	2015-10-31	2018-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Before and after the intervention:\nVerbal memory (VLMT - Verbaler Lern- und Merkfähigkeitstest)\nVisual memory (WMS - Wechsler Memory Scale, Visuelle Wiedergabe)\nVisuo-spatial skills (LPS 50+ - Leistungsprüfsystem, subtest 9)\nAttention (BTA - Brief Test of Attention)""]	NA	[""Before and after the intervention:\nVerbal memory (VLMT - Verbaler Lern- und Merkfähigkeitstest)\nVisual memory (WMS - Wechsler Memory Scale, Visuelle Wiedergabe)\nVisuo-spatial skills (LPS 50+ - Leistungsprüfsystem, subtest 9)\nAttention (BTA - Brief Test of Attention)""]	NA	NA
DRKS00010133	Testing of foods and validation of biomarkers to assess nutritional status	Specificity, Dose Dependency, and Kinetics of Markers of Chicken and Beef Intake Using Targeted Quantitative LC-MS/MS: A Human Intervention Trial	10.1002/mnfr.201900921	NA	10	2016-04-06	Recruiting complete, follow-up complete	2016-03-09	2017-01-30	2020-01-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Analysis of metabolites in plasma and urine using LC-MS/MS, GCxGC-MS, and NMR after a single consumption of chickenbreast (100g and 200g), fibers (inulin and beta-glucan), and egg compared to controlfood (for chickenbreast and egg:rice; for fibers:toastbred). Timepoints for taking blood samples are 0, 1,2,4,6,12,and 24 hours. Timepoints for urinesampling are 0-1h, 1-2h, 2-4h, 4-6h, 6-12h, 12-24h, 48h.""]	[""Analysis of metabolites in plasma and urine using LC-MS/MS, GCxGC-MS, and NMR after a single consumption of chickenbreast (100g and 200g), fibers (inulin and beta-glucan), and egg compared to controlfood (for chickenbreast and egg:rice; for fibers:toastbred). Timepoints for taking blood samples are 0, 1,2,4,6,12,and 24 hours. Timepoints for urinesampling are 0-1h, 1-2h, 2-4h, 4-6h, 6-12h, 12-24h, 48h.""]	[""Analysis of metabolites in plasma and urine using LC-MS/MS, GCxGC-MS, and NMR after a single consumption of chickenbreast (100g and 200g), fibers (inulin and beta-glucan), and egg compared to controlfood (for chickenbreast and egg:rice; for fibers:toastbred). Timepoints for taking blood samples are 0, 1,2,4,6,12,and 24 hours. Timepoints for urinesampling are 0-1h, 1-2h, 2-4h, 4-6h, 6-12h, 12-24h, 48h.""]	[""Analysis of metabolites in plasma and urine using LC-MS/MS, GCxGC-MS, and NMR after a single consumption of chickenbreast (100g and 200g), fibers (inulin and beta-glucan), and egg compared to controlfood (for chickenbreast and egg:rice; for fibers:toastbred). Timepoints for taking blood samples are 0, 1,2,4,6,12,and 24 hours. Timepoints for urinesampling are 0-1h, 1-2h, 2-4h, 4-6h, 6-12h, 12-24h, 48h.""]	NA
DRKS00010157	Implementation of a short screening (UKS) for psychosocial problems for need-based referall to rehabilitation for patients with musculoskeletal diseases and psychosocial stress in primary care	NA	10.1055/a-0842-6901	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-0842-6901	4	2016-05-30	Recruiting complete, follow-up complete	2016-06-15	2017-06-30	2019-05-02	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""The decision about the concept of medical rehabilitation is applicable when patients applying for it. Possible concepts for them can be: traditional orthopedic rehabilitation, behaviour-medical rehabilitation or psychosomatic rehabilitation. The medical reviewer document the decision for the scientists.""]	[""The decision about the concept of medical rehabilitation is applicable when patients applying for it. Possible concepts for them can be: traditional orthopedic rehabilitation, behaviour-medical rehabilitation or psychosomatic rehabilitation. The medical reviewer document the decision for the scientists.""]	[""The decision about the concept of medical rehabilitation is applicable when patients applying for it. Possible concepts for them can be: traditional orthopedic rehabilitation, behaviour-medical rehabilitation or psychosomatic rehabilitation. The medical reviewer document the decision for the scientists.""]	NA	NA
DRKS00010190	Brief behavioral therapeutic intervention for reducing depersonalization during exams in test anxiety	Evaluation of a brief cognitive behavioral group intervention to reduce depersonalization in students with high levels of trait test anxiety: a randomized controlled trial	10.1080/10615806.2020.1736936	https://www.tandfonline.com/doi/abs/10.1080/10615806.2020.1736936	8	2016-03-22	Recruiting complete, follow-up complete	2016-04-10	2017-09-30	2020-03-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	70 Years	NA
DRKS00010212	Online based self-help stress management program for students with feedback on demand	Effectiveness of an Internet- and App-Based Intervention for College Students With Elevated Stress: Randomized Controlled Trial	10.2196/jmir.9293	https://www.jmir.org/2018/4/e136/	2	2016-05-12	Recruiting complete, follow-up complete	2016-05-09	2017-01-30	2018-04-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Perceived Stress, measured with the Perceived Stress Scale (PSS-10, Cohen, Kamarck & Mermelstein, 1983) at Baseline, after the training (7 weeks) and at 3-months follow-up.""]	[""Perceived Stress, measured with the Perceived Stress Scale (PSS-10, Cohen, Kamarck & Mermelstein, 1983) at Baseline, after the training (7 weeks) and at 3-months follow-up.""]	[""Perceived Stress, measured with the Perceived Stress Scale (PSS-10, Cohen, Kamarck & Mermelstein, 1983) at Baseline, after the training (7 weeks) and at 3-months follow-up.""]	NA	NA
DRKS00010231	Approach Bias Modification Training In Bulimia Nervosa and Binge Eating Disorder: A Randomised Controlled Pilot Trial	NA	10.1002/eat.23024	https://onlinelibrary.wiley.com/doi/abs/10.1002/eat.23024	5	2016-03-24	Recruiting complete, follow-up complete	2015-12-18	2017-09-01	2019-05-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""Number of subjective and objective binge eating attacks and global eating disorder psychopathology during the previous 2 months prior and after the intervention.""]	[""Number of subjective and objective binge eating attacks and global eating disorder psychopathology during the previous 2 months prior and after the intervention.""]	[""Number of subjective and objective binge eating attacks and global eating disorder psychopathology during the previous 2 months prior and after the intervention.""]	NA	NA
DRKS00010439	Effects of psychosocial Stress (TSST) on cerebral energy metabolism and food intake.	Psychosocial stress promotes food intake and enhances the neuroenergetic level in men	10.1080/10253890.2018.1485645	https://www.tandfonline.com/doi/abs/10.1080/10253890.2018.1485645?journalCode=ists20&	1	2016-05-18	Recruiting complete, follow-up complete	2013-05-01	2014-04-22	2018-07-03	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Using 31-phosphorus magnetic resonance spectroscopy changes in cerebral energy metabolites adenosine triphosphate (ATP) and phosphocreatine (PCr) (3.0 Tesla) were recorded in the magnetic resonance imaging scanner before, while and after stress intervention as well as before while and after no-stress condition.""]	NA	[""Using 31-phosphorus magnetic resonance spectroscopy changes in cerebral energy metabolites adenosine triphosphate (ATP) and phosphocreatine (PCr) (3.0 Tesla) were recorded in the magnetic resonance imaging scanner before, while and after stress intervention as well as before while and after no-stress condition.""]	NA	NA
DRKS00010522	Effectiveness of a chat-based short-time intervention to treat primary insomnia compared to a face-to-face intervention and a wait-list control group	The effects of brief chat-based and face-to-face psychotherapy for insomnia: a randomized waiting list controlled trial	10.1016/j.sleep.2019.03.024	https://www.sciencedirect.com/science/article/abs/pii/S1389945719301145?via%3Dihub	9	2016-05-18	Recruiting complete, follow-up complete	2014-03-19	2016-02-23	2019-04-19	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Subjective Sleep Quality: PSQI Pittsburgh Sleep Inventory (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989), questionnaire, pre - post - follow-up""]	NA	[""Subjective Sleep Quality: PSQI Pittsburgh Sleep Inventory (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989), questionnaire, pre - post - follow-up""]	[""Subjective Sleep Quality: PSQI Pittsburgh Sleep Inventory (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989), questionnaire, pre - post - follow-up""]	NA
DRKS00010523	The Turnout in Classical Dance – Is it possible to enhance the external rotation of the lower limb by a myofascial manipulation?	Turnout in Classical Dance: Is It Possible to Enhance the External Rotation of the Lower Limb by a Myofascial Manipulation? A Pilot Study	10.12678/1089-313x.21.4.168	https://pubmed.ncbi.nlm.nih.gov/29166987/	1	2016-05-13	Recruiting complete, follow-up complete	2014-04-04	2014-07-10	2017-12-15	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""External rotation of the hip, measured by plurimeter before first treatment, after last treatement and one week after last treatment""]	NA	[""External rotation of the hip, measured by plurimeter before first treatment, after last treatement and one week after last treatment""]	NA	NA
DRKS00010530	Early diagnosis and Treatment of acute kidney injury	The Effects of Intensive Versus Routine Treatment in Patients with Acute Kidney Injury	10.3238/arztebl.2020.0289	https://www.aerzteblatt.de/archiv/213628/Effekte-einer-intensivierten-Versorgung-im-Vergleich-zur-ueblichen-Versorgung-bei-akuter-Nierenschaedigung	6	2016-05-18	Recruiting complete, follow-up complete	2016-06-01	2016-10-26	2020-04-24	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	NA	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	NA
DRKS00010553	comparison of piezosurgery and conventional instruments in cranioplasty	Comparison between piezosurgery and conventional osteotomy in cranioplasty with fronto-orbital advancement	10.1016/j.jcms.2016.12.018	https://www.sciencedirect.com/science/article/abs/pii/S1010518216303407	2	2016-06-08	Recruiting complete, follow-up complete	2014-07-24	2016-05-22	2016-12-21	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""surgery time, complete blood count and amount of blood transfusion, soft tissue tears, edema, pain and bone healing are documented. The data evaluation is finished with the last parameters 4 - 6 month after cranioplasty (at the time of plate removal): the appraisal of ossification""]	NA	[""surgery time, complete blood count and amount of blood transfusion, soft tissue tears, edema, pain and bone healing are documented. The data evaluation is finished with the last parameters 4 - 6 month after cranioplasty (at the time of plate removal): the appraisal of ossification""]	[""surgery time, complete blood count and amount of blood transfusion, soft tissue tears, edema, pain and bone healing are documented. The data evaluation is finished with the last parameters 4 - 6 month after cranioplasty (at the time of plate removal): the appraisal of ossification""]	NA
DRKS00010584	DECADE-pilot. Study to reduce the 10-year risk for cardiovascular diseases in primary care	Encouraging Self-Management in Cardiovascular Disease Prevention	10.3238/arztebl.2018.0469	https://pubmed.ncbi.nlm.nih.gov/30064627/	9	2016-07-07	Recruiting complete, follow-up complete	2016-07-14	2017-03-23	2018-06-09	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change of patient activation (PAM-13-D) from the beginning of the study (inclusion of patient = T0) to the end of the intervention (T1).""]	[""Change of patient activation (PAM-13-D) from the beginning of the study (inclusion of patient = T0) to the end of the intervention (T1).""]	[""Change of patient activation (PAM-13-D) from the beginning of the study (inclusion of patient = T0) to the end of the intervention (T1).""]	[""Change of patient activation (PAM-13-D) from the beginning of the study (inclusion of patient = T0) to the end of the intervention (T1).""]	NA
DRKS00010623	Investigation of the autonomic regulation of delayed onset muscle soreness	The pain threshold of high-threshold mechanosensitive receptors subsequent to maximal eccentric exercise is a potential marker in the prediction of DOMS associated impairment	10.1371/journal.pone.0185463	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630131/	5	2016-06-08	Recruiting complete, follow-up complete	2016-04-29	2016-07-15	2016-10-06	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""Pressure pain threshold (over time) when comparing\na) Group 1 (preventive) to control\nOR\nb) Group 2 (rehabilitative) to control""]	[""Pressure pain threshold (over time) when comparing\na) Group 1 (preventive) to control\nOR\nb) Group 2 (rehabilitative) to control""]	NA	99 Years	NA
DRKS00010625	Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN)	Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography	10.1136/acupmed-2011-010034	https://journals.sagepub.com/doi/10.1136/acupmed-2011-010034	1	2016-06-23	Recruiting complete, follow-up complete	2012-01-02	2015-09-22	2012-03-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Sensory sural nerve action potential amplitude (SNAP) as measured by nerve conduction studies. Evaluation at baseline, at week 14 after treatment or wait list period, and at week 28 after wait list period or treatment""]	NA	NA	[""Sensory sural nerve action potential amplitude (SNAP) as measured by nerve conduction studies. Evaluation at baseline, at week 14 after treatment or wait list period, and at week 28 after wait list period or treatment""]	NA
DRKS00010728	The effect of oxytocin on food intake in obese men	Oxytocin's inhibitory effect on food intake is stronger in obese than normal-weight men	10.1038/ijo.2016.149	https://www.nature.com/articles/ijo2016149	4	2016-06-22	Recruiting complete, follow-up complete	2013-03-06	2015-01-16	2016-08-24	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Eating behavior following oxytocin/placebo administration is assessed by means of a rich breakfast buffet. Subjects are asked to eat ad libitum and according to their desires for 30 min. Subsequently, i.e., in the postprandial period, subjects are offered a selection of snacks under the pretext of a taste test. The ingested amount is protocolled to measure hedonic food intake.""]	NA	[""Eating behavior following oxytocin/placebo administration is assessed by means of a rich breakfast buffet. Subjects are asked to eat ad libitum and according to their desires for 30 min. Subsequently, i.e., in the postprandial period, subjects are offered a selection of snacks under the pretext of a taste test. The ingested amount is protocolled to measure hedonic food intake.""]	[""Eating behavior following oxytocin/placebo administration is assessed by means of a rich breakfast buffet. Subjects are asked to eat ad libitum and according to their desires for 30 min. Subsequently, i.e., in the postprandial period, subjects are offered a selection of snacks under the pretext of a taste test. The ingested amount is protocolled to measure hedonic food intake.""]	NA
DRKS00010732	Influence of antimicrobial photodynamic therapy compared to local application of minocycline microspheres on the healing results after non-surgical periodontal therapy: a controlled randomized clinical trial over 12 months	Antimicrobial photodynamic therapy vs. local minocycline in addition to non-surgical therapy of deep periodontal pockets: a controlled randomized clinical trial	10.1007/s00784-016-2018-6	https://link.springer.com/article/10.1007%2Fs00784-016-2018-6	1	2016-06-28	Recruiting complete, follow-up complete	2008-11-05	2014-03-19	2016-12-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""clinical healing results after 6 weeks, 3 months, 6 months and 12 months following non-surgical periondontal therapy (Δ probing pocket depth, Δ clinical attachment level, Δ bleeding on probing)""]	NA	[""clinical healing results after 6 weeks, 3 months, 6 months and 12 months following non-surgical periondontal therapy (Δ probing pocket depth, Δ clinical attachment level, Δ bleeding on probing)""]	NA	NA
DRKS00010810	Yoga as therapeutic intervention in women with breast cancer during chemotherapy	Iyengar-Yoga Compared to Exercise as a Therapeutic Intervention during (Neo)adjuvant Therapy in Women with Stage I-III Breast Cancer: Health-Related Quality of Life, Mindfulness, Spirituality, Life Satisfaction, and Cancer-Related Fatigue	10.1155/2016/5931816	NA	2	2016-07-12	Recruiting complete, follow-up complete	2011-03-18	2014-09-25	2016-02-25	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Inner correspondence (Measurement with a questionnaire at intervention start, in the middle and after the intervention period)""]	NA	NA	[""Inner correspondence (Measurement with a questionnaire at intervention start, in the middle and after the intervention period)""]	NA
DRKS00010845	Evaluation of the safety and tolerability of the primary posterior capsulotomy during femtosecond laser-assisted cataract surgery	Safety of femtosecond laser-assisted primary posterior capsulotomy immediately after cataract surgery	10.1016/j.jcrs.2017.06.041	https://www.sciencedirect.com/science/article/abs/pii/S0886335017305503	1	2016-08-03	Recruiting complete, follow-up complete	2015-04-09	2016-07-07	2017-09-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Retinal thickness (center thickness, central minimum central maximum, central volume, measuring diameter 1, 3 and 6 mm) using optical coherence tomography (SD-OCT Spectralis, Heidelberg Engineering) at time points: preoperative and postoperative 1 week, 8 weeks, 6 months""]	NA	[""Retinal thickness (center thickness, central minimum central maximum, central volume, measuring diameter 1, 3 and 6 mm) using optical coherence tomography (SD-OCT Spectralis, Heidelberg Engineering) at time points: preoperative and postoperative 1 week, 8 weeks, 6 months""]	NA	NA
DRKS00010860	Development of a home-based auditory training to improve speech recognition on the telephone for patients with cochlear implants: a randomized trial	Development of a home-based auditory training to improve speech recognition on the telephone for patients with cochlear implants: A randomised trial	10.1111/coa.12871	https://pubmed.ncbi.nlm.nih.gov/28317321/	3	2016-08-01	Recruiting complete, follow-up complete	2012-11-15	2014-10-01	2017-03-20	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Difference in speech recognition in a modified version of the Oldenburg Sentence Test, assessed at visit 1 and after 10-14 weeks at visit 2""]	NA	[""Difference in speech recognition in a modified version of the Oldenburg Sentence Test, assessed at visit 1 and after 10-14 weeks at visit 2""]	[""Difference in speech recognition in a modified version of the Oldenburg Sentence Test, assessed at visit 1 and after 10-14 weeks at visit 2""]	NA
DRKS00010915	Evaluation of a trauma-pedagogic group intervention for young unaccompanied refugees: ""Mein Weg""	Effectiveness of a trauma-focused group intervention for young refugees: a randomized controlled trial	10.1111/jcpp.12908	https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/jcpp.12908	4	2016-09-15	Recruiting complete, follow-up complete	2016-11-17	2017-09-01	2018-04-06	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Posttraumatic stress symptoms, measured by the Child and Adolescent Trauma Screen (CATS), before (t1) and after taking part in the intervention (t2) as well as 3 months later (t3). The measurement points are analog for the comparison group that only receives the regular pedagogic care.""]	[""Posttraumatic stress symptoms, measured by the Child and Adolescent Trauma Screen (CATS), before (t1) and after taking part in the intervention (t2) as well as 3 months later (t3). The measurement points are analog for the comparison group that only receives the regular pedagogic care.""]	[""Posttraumatic stress symptoms, measured by the Child and Adolescent Trauma Screen (CATS), before (t1) and after taking part in the intervention (t2) as well as 3 months later (t3). The measurement points are analog for the comparison group that only receives the regular pedagogic care.""]	[""Posttraumatic stress symptoms, measured by the Child and Adolescent Trauma Screen (CATS), before (t1) and after taking part in the intervention (t2) as well as 3 months later (t3). The measurement points are analog for the comparison group that only receives the regular pedagogic care.""]	NA
DRKS00010960	Psychologically optimised hand hygiene promotion (PSYGIENE): a cluster-randomised trial	Promoting Hand Hygiene Compliance: PSYGIENE—a Cluster-Randomized Controlled Trial of Tailored Interventions	10.3238/arztebl.2017.0029	https://www.aerzteblatt.de/int/archive/article/185607/Promoting-hand-hygiene-compliance-PSYGIENE-a-cluster-randomized-controlled-trial-of-tailored-interventions	4	2016-08-19	Recruiting complete, follow-up complete	2013-06-08	2016-02-11	2017-01-20	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Ward-specific hand hygiene compliance rates 2014-2015: Hand hygiene compliance with guidelines based on WHO-concept \""Five Moments for Hand Hygiene), assessed using the German translation of the respective observation sheet (German Clean Care is Safer Care-campaign) by internally trained nurses and hygiene specialists (in training) during specific time slots in the course of each calendar year.""]	NA	[""Ward-specific hand hygiene compliance rates 2014-2015: Hand hygiene compliance with guidelines based on WHO-concept \""Five Moments for Hand Hygiene), assessed using the German translation of the respective observation sheet (German Clean Care is Safer Care-campaign) by internally trained nurses and hygiene specialists (in training) during specific time slots in the course of each calendar year.""]	[""Ward-specific hand hygiene compliance rates 2014-2015: Hand hygiene compliance with guidelines based on WHO-concept \""Five Moments for Hand Hygiene), assessed using the German translation of the respective observation sheet (German Clean Care is Safer Care-campaign) by internally trained nurses and hygiene specialists (in training) during specific time slots in the course of each calendar year.""]	NA
DRKS00011013	Effect of hyperthermic baths (HTB) on depression	NA	10.1101/409276	https://www.biorxiv.org/content/10.1101/409276v1.abstract	6	2016-09-19	Recruiting complete, follow-up complete	2016-09-30	2017-03-20	2018-09-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of hot bath group with control group (physical exercise).""]	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of hot bath group with control group (physical exercise).""]	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of HTB group with control group (physical exercise).""]	NA	NA
DRKS00011040	A randomized controled trial evaluating the impact of a multimodal training curriculum on surgical interns performing laparoscopic cholecystectomy	LapTrain: multi-modality training curriculum for laparoscopic cholecystectomy-results of a randomized controlled trial	10.1007/s00464-018-6110-7	https://pubmed.ncbi.nlm.nih.gov/29435758/	1	2016-10-31	Recruiting complete, follow-up complete	2011-09-24	2016-02-03	2018-09-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Operative performance as measured by Global Operative Assessment of Laparoscopic Skills (GOALS) Score in a cadaver model of laparoscopic cholecystectomy""]	NA	[""Operative performance as measured by Global Operative Assessment of Laparoscopic Skills (GOALS) Score in a cadaver model of laparoscopic cholecystectomy""]	NA	NA
DRKS00011045	efficacy of an online intervention including a smartphone application for participants with depressive symptoms	Evaluation of a brief unguided psychological online intervention for depression: A controlled trial including exploratory moderator analyses	10.1016/j.invent.2018.06.004	https://www.sciencedirect.com/science/article/pii/S2214782918300137	8	2016-09-01	Recruiting complete, follow-up complete	2016-09-01	2017-06-25	2018-06-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""The primary outcome is the reduction of depression symptom severity at post assessment (controlled for pre assessment scores), comparing the experimental and control group. For this purpose, participants complete the Patient Health Questionnaire (PHQ-9) at two times of measurement (pre - post, 4 weeks apart).""]	[""The primary outcome is the reduction of depression symptom severity at post assessment (controlled for pre assessment scores), comparing the experimental and control group. For this purpose, participants complete the Patient Health Questionnaire (PHQ-9) at two times of measurement (pre - post, 4 weeks apart).""]	[""The primary outcome is the reduction of depression symptom severity at post assessment (controlled for pre assessment scores), comparing the experimental and control group. For this purpose, participants complete the Patient Health Questionnaire (PHQ-9) at two times of measurement (pre - post, 4 weeks apart).""]	[""The primary outcome is the reduction of depression symptom severity at post assessment (controlled for pre assessment scores), comparing the experimental and control group. For this purpose, participants complete the Patient Health Questionnaire (PHQ-9) at two times of measurement (pre - post, 4 weeks apart).""]	NA
DRKS00011054	shoulder tendinopathy	Electromagnetic transduction therapy and shockwave therapy in 86 patients with rotator cuff tendinopathy: A prospective randomized controlled trial	10.1080/15368378.2018.1499030	https://pubmed.ncbi.nlm.nih.gov/30183430/	2	2017-01-16	Recruiting complete, follow-up complete	2016-02-10	2016-09-01	2018-09-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""shoulder pain measured by visual analogue scale (VAS) 6, 12 and 24 month after last intervention""]	NA	[""shoulder pain measured by visual analogue scale (VAS) 6, 12 and 24 month after last intervention""]	NA	NA
DRKS00011067	Determination of the Antibacterial Effect of Biodentine in vivo - Identification of Polybacterial 16S rRNA Genes in Caries Samples by T-RFLP and Direct Sequencing	Effect of a bioactive cement on the microbial community in carious dentin after selective caries removal - An in-vivo study	10.1016/j.jdent.2019.103264	https://www.sciencedirect.com/science/article/pii/S030057121930274X	5	2016-09-15	Recruiting complete, follow-up complete	2016-02-10	2017-05-11	2020-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Determination of the antibacterial effect of Biodentine when sealing residual caries after partial caries excavation. Quantification and qualification of reproducible bacteria (culture-dependent) and bacterial DNA (molecular biological by PCR, TRFLP and subsequent sequencing) before and after partial caries removal (stepwise caris therapy).""]	[""Determination of the antibacterial effect of Biodentine when sealing residual caries after partial caries excavation. Quantification and qualification of reproducible bacteria (culture-dependent) and bacterial DNA (molecular biological by PCR, TRFLP and subsequent sequencing) before and after partial caries removal (stepwise caris therapy).""]	[""Determination of the antibacterial effect of Biodentine when sealing residual caries after partial caries excavation. Quantification and qualification of reproducible bacteria (culture-dependent) and bacterial DNA (molecular biological by PCR, TRFLP and subsequent sequencing) before and after partial caries removal (stepwise caris therapy).""]	[""Determination of the antibacterial effect of Biodentine when sealing residual caries after partial caries excavation. Quantification and qualification of reproducible bacteria (culture-dependent) and bacterial DNA (molecular biological by PCR, TRFLP and subsequent sequencing) before and after partial caries removal (stepwise caris therapy).""]	NA
DRKS00011193	Tightening behaviour of compression stockings of Ccl 1 A-D with and without tightening aid in comparison to compression stockings of Ccl 2 A-D and compared to commercially available Kneestockings in people of higher age and movement restrictions as well as an analisis of their ""wearing-behaviour""/comfort (wear test)	Better wearing comfort of knee-length elastic compression stockings with an interface pressure of 18-21 mmHg compared to 23-32 mmHg in elderly people after a one day trial - Influence on foot deformities, rheumatism and arthritis	10.3233/ch-199207	https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch199207	3	2016-10-13	Recruiting complete, follow-up complete	2016-10-10	2016-12-20	2019-11-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[""tightening and correct positioning of the compression stockings Ccl1 and Ccl 2 as well as of the convential knee-stocking without and with a tightening aid\nafter each dressing-complexe quesionairs are used, they are developed at the clinicl center; questionaired will be for example fatigue of the patient, the correct position of the stocking on the patient's leg and assessment of the time and effort required, etc.""]	[""tightening and correct positioning of the compression stockings Ccl1 and Ccl 2 as well as of the convential knee-stocking without and with a tightening aid\nafter each dressing-complexe quesionairs are used, they are developed at the clinicl center; questionaired will be for example fatigue of the patient, the correct position of the stocking on the patient's leg and assessment of the time and effort required, etc.""]	[""tightening and correct positioning of the compression stockings Ccl1 and Ccl 2 as well as of the convential knee-stocking without and with a tightening aid\nafter each dressing-complexe quesionairs are used, they are developed at the clinicl center; questionaired will be for example fatigue of the patient, the correct position of the stocking on the patient's leg and assessment of the time and effort required, etc.""]	NA	NA
DRKS00011212	Determination of the antioxidative potential of the skin before and after ingestion of green tea	A Randomized Controlled Trial of Green Tea Beverages on the in vivo Radical Scavenging Activity in Human Skin	10.1159/000477355	https://pubmed.ncbi.nlm.nih.gov/28723689/	1	2016-10-28	Recruiting complete, follow-up complete	2015-10-16	2016-06-10	2017-07-20	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Radical scavenging activity in the skin at baseline and after 14 days, measured with electron paramagnetic resonance spectroscopy""]	NA	[""Radical scavenging activity in the skin at baseline and after 14 days, measured with electron paramagnetic resonance spectroscopy""]	NA	NA
DRKS00011245	Effectivity of an wholistic Training based on Kyusho Jitsu with breast cancer patients in the aftercare.	NA	10.21873/invivo.112313	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117768/	4	2017-02-14	Recruiting complete, follow-up complete	2014-10-23	2015-09-30	2018-07-03	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""The measurement of the primary endpoint (quality of life) was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) Quality-of-Life Questionnaire “QLQ-C30” and “BR 23“ at Baseline, after 12 (T1), 24 (T2), 28 (T3), 40 (T4) and 52 Wochen (T5).""]	NA	[""The measurement of the primary endpoint (quality of life) was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) Quality-of-Life Questionnaire “QLQ-C30” and “BR 23“ at Baseline, after 12 (T1), 24 (T2), 28 (T3), 40 (T4) and 52 Wochen (T5).""]	[""The measurement of the primary endpoint (quality of life) was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) Quality-of-Life Questionnaire “QLQ-C30” and “BR 23“ at Baseline, after 12 (T1), 24 (T2), 28 (T3), 40 (T4) and 52 Wochen (T5).""]	NA
DRKS00011325	A Randomized, Single-dose, Cross-over Study to Investigate the Acceptability of an Orodispersible Film Compared to Syrup in Neonates and Infants	Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial	10.1016/j.ejpb.2020.03.018	https://pubmed.ncbi.nlm.nih.gov/32348882/	2	2016-11-21	Recruiting complete, follow-up complete	2017-02-20	2017-04-24	2020-06-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""To demonstrate non-inferiority in acceptability of an orodispersible film in comparison to an age adapted amount of glucose-syrup in children between 2 days and 12 months.""]	NA	[""To demonstrate non-inferiority in acceptability of an orodispersible film in comparison to an age adapted amount of glucose-syrup in children between 2 days and 12 months.""]	NA	NA
DRKS00011422	Effectiveness of different power tooth brushes in comparison of instructed and non-instructed patients - a randomized clinical case control study	No difference between manual and different power toothbrushes with and without specific instructions in young, oral healthy adults-results of a randomized clinical trial	10.1007/s00784-017-2200-5	https://pubmed.ncbi.nlm.nih.gov/28905123/	1	2017-01-23	Recruiting complete, follow-up complete	2015-07-01	2016-11-30	2017-09-13	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""papilla-bleeding-index (PBI) at each investigation time point with a periodontal probe (PCP 15, Hu-Friedy, Chicago, IL, USA) and marginal-plaque-index (MPI) at each investigation time point visually""]	NA	[""papilla-bleeding-index (PBI) at each investigation time point with a periodontal probe (PCP 15, Hu-Friedy, Chicago, IL, USA) and marginal-plaque-index (MPI) at each investigation time point visually""]	NA	NA
DRKS00011500	The influence of an alkalizing or acidizing diet on anaerobic performance under normobaric hypoxic conditions	Effects of an Alkalizing or Acidizing Diet on High-Intensity Exercise Performance under Normoxic and Hypoxic Conditions in Physically Active Adults: A Randomized, Crossover Trial	10.3390/nu12030688	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146607/	2	2016-12-23	Recruiting complete, follow-up complete	2016-11-10	2016-12-03	2020-03-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The 60-second sprint-test is an all-out test and is performed in a stationary setting. Participants wear a belt around their waist, which is attached to a static rope with an included force transducer. The rope is fixed at a strong anchor point. To assess anaerobic performance, subjects sprint against the resistance at maximal speed (maximal step frequency). Blood gas analyses are carried out using capillary blood samples (100µl) before entering the hypoxic chamber and before and after the sprint-test. In order to assess blood lactate values, capillary blood samples are collected pre-exercise and 2, 5, 7 and 10 minutes after sprinting. Additionally, heart rate is controlled before and directly after the sprint-test.""]	NA	[""The 60-second sprint-test is an all-out test and is performed in a stationary setting. Participants wear a belt around their waist, which is attached to a static rope with an included force transducer. The rope is fixed at a strong anchor point. To assess anaerobic performance, subjects sprint against the resistance at maximal speed (maximal step frequency). Blood gas analyses are carried out using capillary blood samples (100µl) before entering the hypoxic chamber and before and after the sprint-test. In order to assess blood lactate values, capillary blood samples are collected pre-exercise and 2, 5, 7 and 10 minutes after sprinting. Additionally, heart rate is controlled before and directly after the sprint-test.""]	NA	NA
DRKS00011585	Comparative study for ultrasound guided placement of femoral nerve katheters in out-of-plane versus in-plane technique, in patients with femoral neck frakture.	Paths of femoral nerve catheters placed using ultrasound-guided in plane vs out of plane techniques: A randomized controlled clinical trial	10.1097/md.0000000000012958	https://pubmed.ncbi.nlm.nih.gov/30412115/	3	2017-01-18	Recruiting complete, follow-up complete	2017-02-01	2017-08-01	2018-10-26	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""The postoperative pain level and the degree of paraesthesia will be measured bevore as well as the first and second day after surgery (Using the Quips Chart).\n\nUltrasoundcontrolled determination of the catheter position will be performed during the procedure.\n\nThe postoperative X-ray of the hip will be done on the second postoperative day\n\n""]	NA	[""The postoperative pain level and the degree of paraesthesia will be measured bevore as well as the first and second day after surgery (Using the Quips Chart).\n\nUltrasoundcontrolled determination of the catheter position will be performed during the procedure.\n\nThe postoperative X-ray of the hip will be done on the second postoperative day\n\n""]	NA	NA
DRKS00011648	Electromagnetic transduction therapy in low back pain: a prospective randomised controlled trial	Electromagnetic transduction therapy in non-specific low back pain: A prospective randomised controlled trial	10.1016/j.jor.2017.06.016	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510490/	1	2017-02-02	Recruiting complete, follow-up complete	2016-02-15	2016-08-15	2017-06-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Primary endpoints were at least 60 % reduction of pain in 10-point visual analogue scale (VAS) from baseline to 12 weeks' follow-up. The change in pain sensation was defined as change of back pain while doing daily activities. The pressure level that just elicited unbearable pain was related to a VAS score 10.""]	NA	[""Primary endpoints were at least 60 % reduction of pain in 10-point visual analogue scale (VAS) from baseline to 12 weeks' follow-up. The change in pain sensation was defined as change of back pain while doing daily activities. The pressure level that just elicited unbearable pain was related to a VAS score 10.""]	NA	NA
DRKS00011665	Parameter-based evaluation of attentional impairments in schizophrenia and their modulation by prefrontal transcranial direct current stimulation: a randomized, double-blind, sham-controlled study	Parameter-Based Evaluation of Attentional Impairments in Schizophrenia and Their Modulation by Prefrontal Transcranial Direct Current Stimulation	10.3389/fpsyt.2017.00259	NA	1	2017-01-30	Recruiting complete, follow-up complete	2015-05-01	2016-10-31	2017-11-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Directly after and 24h after stimulation; completion of rating instrument: parametric attentional assessment based on Bundesen’s Theory of Visual Attention (TVA; Bundesen, 1990). (The assessed attentional parameters are: processing speed, visual short-term memory capacity, top-down control)""]	NA	[""Directly after and 24h after stimulation; completion of rating instrument: parametric attentional assessment based on Bundesen’s Theory of Visual Attention (TVA; Bundesen, 1990). (The assessed attentional parameters are: processing speed, visual short-term memory capacity, top-down control)""]	NA	NA
DRKS00011688	The effect of gustatory stimulation on analgesic processes	Combined glutamate and glutamine levels in pain-processing brain regions are associated with individual pain sensitivity	10.1097/j.pain.0000000000000634	https://journals.lww.com/pain/Abstract/2016/10000/Combined_glutamate_and_glutamine_levels_in.14.aspx	4	2017-02-07	Recruiting complete, follow-up complete	2016-12-16	2017-03-07	2016-06-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Area-under-the-curve of pain-ratings obtained in the Cold Pressor Test. The Cold Pressor Test is performed before and after treatment. Main group comparison: interaction of neutral placebo vs bitter placebo with pre vs post treatment.""]	[""Area-under-the-curve of pain-ratings obtained in the Cold Pressor Test. The Cold Pressor Test is performed before and after treatment. Main group comparison: interaction of neutral placebo vs bitter placebo with pre vs post treatment.""]	NA	[""Area-under-the-curve of pain-ratings obtained in the Cold Pressor Test. The Cold Pressor Test is performed before and after treatment. Main group comparison: interaction of neutral placebo vs bitter placebo with pre vs post treatment.""]	NA
DRKS00011719	Essen&Cologne - exercise program in metastasiszed colorectal cancer patients	Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial	10.1007/s00520-017-3875-5	https://link.springer.com/article/10.1007/s00520-017-3875-5#article-info	1	2017-03-17	Recruiting complete, follow-up complete	2015-04-10	2016-04-10	2017-09-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""FACT/GOG-NTX (version 4) questionnaire: Trial Outcome Index (consists of physical well-being, functional well-being and neuropathic symptoms); three investigations at baseline, after the intervention and four weeks after""]	NA	[""FACT/GOG-NTX (version 4) questionnaire: Trial Outcome Index (consists of physical well-being, functional well-being and neuropathic symptoms); three investigations at baseline, after the intervention and four weeks after""]	NA	NA
DRKS00011783	D-dimer plasma levels and risk for thromboembolism after surgery for intracranial tumors with intraoperative administration of intermittent pneumatic compression of the legs	Reduced risk of venous thromboembolism with the use of intermittent pneumatic compression after craniotomy: a randomized controlled prospective study	10.3171/2017.9.jns17533	https://pubmed.ncbi.nlm.nih.gov/29600912/	2	2017-02-20	Recruiting complete, follow-up complete	2013-03-14	2015-04-28	2018-03-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Incidence of deep venuous thrombosis in patients undergoing surgery for intracranial pathology with/without IPC, determined by Doppler sonography of the legs within the first week after surgery.""]	NA	[""Incidence of deep venuous thrombosis in patients undergoing surgery for intracranial pathology with/without IPC, determined by Doppler sonography of the legs within the first week after surgery.""]	[""Incidence of deep venuous thrombosis in patients undergoing surgery for intracranial pathology with/without IPC, determined by Doppler sonography of the legs within the first week after surgery.""]	NA
DRKS00011837	Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus.	Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers	10.1002/cpt.1529	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1529	7	2017-03-09	Recruiting complete, follow-up complete	2017-03-31	2017-11-10	2019-06-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Change in tacrolimus exposition (AUC) due to voriconazole. Comparison of inhibition by voriconazole after administration of two different tacrolimus preparations (Envarsus® and Prograf®).""]	[""Change in tacrolimus exposition (AUC) due to voriconazole. Comparison of inhibition by voriconazole after administration of two different tacrolimus preparations (Envarsus® and Prograf®).""]	[""Change in tacrolimus exposition (AUC) due to voriconazole. Comparison of inhibition by voriconazole after administration of two different tacrolimus preparations (Envarsus® and Prograf®).""]	[""Change in tacrolimus exposition (AUC) due to voriconazole. Comparison of inhibition by voriconazole after administration of two different tacrolimus preparations (Envarsus® and Prograf®).""]	NA
DRKS00011963	Influence of a vegan diet on immunological parameters related to rheumatoid arthritis in healthy volunteers – a randomised controlled trial	Vegan diet reduces neutrophils, monocytes and platelets related to branched-chain amino acids - A randomized, controlled trial	10.1016/j.clnu.2020.02.011	https://www.sciencedirect.com/science/article/abs/pii/S0261561420300595	9	2017-03-30	Recruiting complete, follow-up complete	2017-03-30	2017-06-13	2020-02-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""metabolic function of B-cells, measured by the sialylation of anti-bodies; count of regulatory T-cells, measured by the concentration of FoxP3; serum-concentration of Interleukin 10; redox status of immune cells, measured by the intracellular ROS-concentration\nIn the beginning and in the end of the intervention we will take blood samples of all probands. Examination of the samples will be done in the end.""]	[""metabolic function of B-cells, measured by the sialylation of anti-bodies; count of regulatory T-cells, measured by the concentration of FoxP3; serum-concentration of Interleukin 10; redox status of immune cells, measured by the intracellular ROS-concentration\nIn the beginning and in the end of the intervention we will take blood samples of all probands. Examination of the samples will be done in the end.""]	[""metabolic function of B-cells, measured by the sialylation of anti-bodies; count of regulatory T-cells, measured by the concentration of FoxP3; serum-concentration of Interleukin 10; redox status of immune cells, measured by the intracellular ROS-concentration\nIn the beginning and in the end of the intervention we will take blood samples of all probands. Examination of the samples will be done in the end.""]	[""metabolic function of B-cells, measured by the sialylation of anti-bodies; count of regulatory T-cells, measured by the concentration of FoxP3; serum-concentration of Interleukin 10; redox status of immune cells, measured by the intracellular ROS-concentration\nIn the beginning and in the end of the intervention we will take blood samples of all probands. Examination of the samples will be done in the end.""]	NA
DRKS00012258	Influence of compression stockings on the skin hydration in patients with chronic venous insufficiency	NA	10.1024/0301-1526/a000812	https://econtent.hogrefe.com/doi/full/10.1024/0301-1526/a000812	5	2017-04-20	Recruiting complete, follow-up complete	2017-04-24	2017-08-11	2019-07-31	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Visit 1 (start of study) und Visit 28 (end of study after 28 days): measurement of skin hydration and measurement of the transepidermal water loss of the skin by means of Tewameter and Corneometer""]	NA	[""Visit 1 (start of study) und Visit 28 (end of study after 28 days): measurement of skin hydration and measurement of the transepidermal water loss of the skin by means of Tewameter and Corneometer""]	[""Visit 1 (start of study) und Visit 28 (end of study after 28 days): measurement of skin hydration and measurement of the transepidermal water loss of the skin by means of Tewameter and Corneometer""]	NA
DRKS00012382	Does dual task training improve walking performance of older adults with concern of falling?	Does dual task training improve walking performance of older adults with concern of falling?	10.1186/s12877-017-0610-5	https://pubmed.ncbi.nlm.nih.gov/28893187/	1	2017-05-11	Recruiting complete, follow-up complete	2015-04-01	2016-07-15	2017-09-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Gait parameters (step length, step width, and gait line) assessed on a treadmill prior to the initial intervention and immediately after the final intervention.""]	NA	[""Gait parameters (step length, step width, and gait line) assessed on a treadmill prior to the initial intervention and immediately after the final intervention.""]	NA	NA
DRKS00012404	Comparison of web based with personal CPR Training for dental students	NA	10.2196/preprints.18952	https://preprints.jmir.org/preprint/18952	3	2017-05-02	Recruiting complete, follow-up complete	2017-05-02	2017-12-31	2020-03-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""Delay Chestcompression after Diagnosis Cardiac Arrest; measured directly after Training in both groups""]	[""Delay Chestcompression after Diagnosis Cardiac Arrest; measured directly after Training in both groups""]	[""Delay Chestcompression after Diagnosis Cardiac Arrest; measured directly after Training in both groups""]	[""Delay Chestcompression after Diagnosis Cardiac Arrest; measured directly after Training in both groups""]	NA
DRKS00012409	Acute effects of moderate walking on postprandial events after consuming different high-energy meals in elderly men and women with a risk phenotype for cardiovascular disease	Acute Impact of Dietary Pattern and Walking on Postprandial Attention, Mood, and Satiety in Older Adults: A Randomized Crossover Trial	10.3390/nu11102294	https://www.mdpi.com/2072-6643/11/10/2294	11	2017-05-03	Recruiting complete, follow-up complete	2017-06-06	2017-07-30	2019-09-26	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[""Parameter of endothelial function, inflammation, oxidation and lipid and glucose metabolism; at fasting state and 1.5, 3.0 and 4.5 hours postprandially""]	NA	[""serum triglycerides, measured at fasting state and 1.5, 3.0 and 4.5 hours postprandially\n""]	80 Years	NA
DRKS00012439	Acute Effects of Blood Flow Restriction on Exercise-Induced Free Radical Production in Young and Healthy Subjecty: A Randomized Controlled Trial	Acute effects of blood flow restriction on exercise-induced free radical production in young and healthy subjects	10.1080/10715762.2018.1440293	https://www.tandfonline.com/doi/abs/10.1080/10715762.2018.1440293?journalCode=ifra20	2	2017-07-24	Recruiting complete, follow-up complete	2017-01-09	2017-09-29	2018-03-15	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[""Ex vivo free radical production measured with electron paramagnetic resonance technique immediately before and after the training session""]	[""Ex vivo free radical production measured with electron paramagnetic resonance technique immediately before and after the training session""]	NA	[""Ex vivo free radical production measured with electron paramagnetic resonance technique immediately before and after the training session""]	NA
DRKS00012464	Acupuncture as complementary treatment for acute tinnitus - a pilot study	Acupuncture as Complementary Treatment for Acute Tinnitus: A Randomized Controlled Pilot Study	10.1159/000508630	https://www.karger.com/Article/Abstract/508630	1	2017-05-30	Recruiting complete, follow-up complete	2013-12-01	2015-07-31	2020-07-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Visual Analogue Scale for tinniitus severity directly at the end of the acupuncture treatment""]	NA	[""Visual Analogue Scale for tinniitus severity directly at the end of the acupuncture treatment""]	NA	NA
DRKS00012565	Comparison of a full-core end-cut biopsy device with a side-notch device: diagnostic valence of the specimen	Full-Core Biopsy Systems Take Larger Liver Tissue Samples with Lower Fragmentation Rates Than Conventional Side-Notch Systems: A Randomized Trial	10.2147/cmar.s209824	https://www.dovepress.com/full-core-biopsy-systems-take-larger-liver-tissue-samples-with-lower-f-peer-reviewed-article-CMAR	2	2017-06-22	Recruiting complete, follow-up complete	2017-07-05	2017-12-22	2020-02-13	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Primary endpoint is diagnostic valence of the specimen; i.e. if the specimen is sufficient to establish a diagnosis. This is rated by two independent pathologists unaware of the device used.""]	NA	[""Primary endpoint is diagnostic valence of the specimen; i.e. if the specimen is sufficient to establish a diagnosis. This is rated by two independent pathologists unaware of the device used.""]	NA	NA
DRKS00012769	Effectiveness of a smartphone intervention for the mitigation of depression. A randomized controlled trial.	An app-based blended intervention to reduce body dissatisfaction: A randomized controlled pilot study	10.1037/ccp0000246	https://pubmed.ncbi.nlm.nih.gov/28857576/	7	2017-08-15	Recruiting complete, follow-up complete	2017-05-01	2017-07-18	2017-08-31	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""After 14 days: Depressiveness collected by means of PHQ-9 questionnaire using an online survey assessment\n""]	NA	[""After 14 days: Depressiveness collected by means of PHQ-9 questionnaire using an online survey assessment\n""]	[""After 14 days: Depressiveness collected by means of PHQ-9 questionnaire using an online survey assessment\n""]	NA
DRKS00012863	Open flap debridement and guided tissue regeneration after 20 years in infrabony defects	Infrabony defects 20 years after open flap debridement and guided tissue regeneration	10.1111/jcpe.13110	https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpe.13110	5	2017-08-03	Recruiting complete, follow-up complete	2017-07-25	2017-12-12	2019-04-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[""(1) PAL-V gained 240 months after therapy, i.e. change of PAL-V from 12/120 to 240 months after therapy, (2) number of defects with attachment loss >2mm from 12/120 to 240 months, (3) tooth loss""]	[""(1) PAL-V gained 240 months after therapy, i.e. change of PAL-V from 12/120 to 240 months after therapy, (2) number of defects with attachment loss >2mm from 12/120 to 240 months, (3) tooth loss""]	[""(1) PAL-V gained 240 months after therapy, i.e. change of PAL-V from 12/120 to 240 months after therapy, (2) number of defects with attachment loss >2mm from 12/120 to 240 months, (3) tooth loss""]	[""(1) PAL-V gained 240 months after therapy, i.e. change of PAL-V from 12/120 to 240 months after therapy, (2) number of defects with attachment loss >2mm from 12/120 to 240 months, (3) tooth loss""]	NA
DRKS00012980	Mobile Augmented Reality as a Feature for Self-Oriented, Blended Learning in Medicine: A Randomized Controlled Study	Mobile Augmented Reality as a Feature for Self-Oriented, Blended Learning in Medicine: Randomized Controlled Trial	10.2196/mhealth.7943	https://pubmed.ncbi.nlm.nih.gov/28912113/	1	2017-09-20	Recruiting complete, follow-up complete	2014-04-01	2014-08-01	2017-09-14	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[""Learning efficiency before and after the learning phase measured by a 10 item Single Choice test.""]	NA	NA	[""Learning efficiency before and after the learning phase measured by a 10 item Single Choice test.""]	NA
DRKS00013162	Development and evaluation of an adaptive working memory training (WOME)	WOME: Theory-Based Working Memory Training - A Placebo-Controlled, Double-Blind Evaluation in Older Adults	10.3389/fnagi.2018.00247	https://www.frontiersin.org/articles/10.3389/fnagi.2018.00247/full	3	2017-11-03	Recruiting complete, follow-up complete	2013-03-12	2014-07-31	2018-08-14	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Primary Outcome is working memory functioning. Performance is analyzed with multiple standardized neuropsychological tests. A recent meta-analysis showed that the Span Board task backwards is the most sensitive variable to assess changes in working memory, therefore it was chosen as a criterion task. Further outcome measures regarding working memory are: Digit and Span Board tasks (WMS-R), Spatial Addition and Symbol Span (WMS-IV), n-back Aufgabe (TAP), Operation Span Task, PASAT (Paced Auditory Serial Addition Test).\n\nAll outcomes are measured 3 times: pre/post intervention as well as at a 3-month follow-up. Examinations are individual and take place in quite separate rooms. The examiners are blind with respect to group allocation.""]	NA	[""Primary Outcome is working memory functioning. Performance is analyzed with multiple standardized neuropsychological tests. A recent meta-analysis showed that the Span Board task backwards is the most sensitive variable to assess changes in working memory, therefore it was chosen as a criterion task. Further outcome measures regarding working memory are: Digit and Span Board tasks (WMS-R), Spatial Addition and Symbol Span (WMS-IV), n-back Aufgabe (TAP), Operation Span Task, PASAT (Paced Auditory Serial Addition Test).\n\nAll outcomes are measured 3 times: pre/post intervention as well as at a 3-month follow-up. Examinations are individual and take place in quite separate rooms. The examiners are blind with respect to group allocation.""]	[""Primary Outcome is working memory functioning. Performance is analyzed with multiple standardized neuropsychological tests. A recent meta-analysis showed that the Span Board task backwards is the most sensitive variable to assess changes in working memory, therefore it was chosen as a criterion task. Further outcome measures regarding working memory are: Digit and Span Board tasks (WMS-R), Spatial Addition and Symbol Span (WMS-IV), n-back Aufgabe (TAP), Operation Span Task, PASAT (Paced Auditory Serial Addition Test).\n\nAll outcomes are measured 3 times: pre/post intervention as well as at a 3-month follow-up. Examinations are individual and take place in quite separate rooms. The examiners are blind with respect to group allocation.""]	NA
DRKS00013512	Influence of retrograde autologous priming (RAP) on the safety and efficacy of cardiopulmonary bypass (CPB) and transfusion requirements	Positive impact of retrograde autologous priming in adult patients undergoing cardiac surgery: a randomized clinical trial	10.1186/s13019-018-0739-0	https://pubmed.ncbi.nlm.nih.gov/29784004/	1	2017-12-04	Recruiting complete, follow-up complete	2012-08-23	2015-10-21	2018-05-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[""Reduction of the need for intraoperative blood transfusion through the use of the RAP bag for retrograde autologous priming compared to conventional priming in patients undergoing cardiac surgery for the treatment of coronary heart disease or aortic valve defect.""]	NA	[""Reduction of the need for intraoperative blood transfusion through the use of the RAP bag for retrograde autologous priming compared to conventional priming in patients undergoing cardiac surgery for the treatment of coronary heart disease or aortic valve defect.""]	NA	NA
DRKS00013513	SIlver-coated lumbar drainage trial	The SiLuDrain Trial: a prospective randomized controlled trial comparing standard versus silver-impregnated lumbar drains	10.3171/2018.1.jns181522	https://thejns.org/view/journals/j-neurosurg/130/6/article-p2040.xml	3	2017-12-04	Recruiting complete, follow-up complete	2013-05-04	2015-06-29	2018-06-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[""Usability of silver-coated lumbar drains.\nNon inferiority of silver-coated vs. conventional lumbar drains. Usability is assessed by the implanting physician with a questionnaire in semiquantitative fashion. The primary endpoint is obtained immediately after the lumbar drain is placed.""]	NA	[""Usability of silver-coated lumbar drains.\nNon inferiority of silver-coated vs. conventional lumbar drains. Usability is assessed by the implanting physician with a questionnaire in semiquantitative fashion. The primary endpoint is obtained immediately after the lumbar drain is placed.""]	[""Usability of silver-coated lumbar drains.\nNon inferiority of silver-coated vs. conventional lumbar drains. Usability is assessed by the implanting physician with a questionnaire in semiquantitative fashion. The primary endpoint is obtained immediately after the lumbar drain is placed.""]	NA
NCT00047099	Combination Chemotherapy in Treating Women With Breast Cancer	Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study	10.1038/bjc.2016.82	https://www.ncbi.nlm.nih.gov/pubmed/27031854	26	2005-06-23	Completed	NA	NA	2016-03-31	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of time to progression""}]
NCT00052468	Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer	CXCL12 expression by healthy and malignant ovarian epithelial cells	10.1186/1471-2407-11-97	https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-97	14	2005-06-23	Completed	NA	NA	2011-03-16	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: Whole Study Period ]\n\nSurvival time is calculated from the date of enrollment into the study until the date of death from any cause""}]	[]
NCT00055874	Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV	10.1182/blood-2009-08-237115	https://pubmed.ncbi.nlm.nih.gov/19965667/	45	2005-06-23	Completed	NA	2012-03-31	2009-11-18	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Risk group-dependent survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Hematologic, cytogenetic, and molecular response rates""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Risk group-dependent survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Hematologic, cytogenetic, and molecular response rates""}]
NCT00056056	Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)	10.1111/j.1365-2133.2012.11156.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2012.11156.x/abstract	35	2005-06-23	Terminated	NA	NA	2012-09-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate (complete clinical response [CCR) and partial response [PR])\n[ Time Frame: 35 months after first patient in ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate (complete clinical response [CCR) and partial response [PR])\n[ Time Frame: 35 months after first patient in ]""}]
NCT00061984	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial	10.1016/s1470-2045(14)70063-4	https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(14)70063-4	38	2005-06-23	Completed	NA	NA	2014-03-05	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]
NCT00079105	A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years	Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study	10.1182/blood-2011-12-396556	https://www.ncbi.nlm.nih.gov/pubmed/22577177	52	2005-06-23	Completed	NA	2010-12-01	2012-05-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging\n[ Time Frame: 6 month intervals ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""}]
NCT00086580	Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients	Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial	10.1016/s1470-2045(11)70242-x	https://www.ncbi.nlm.nih.gov/pubmed/21992852?dopt=Abstract	18	2005-06-23	Completed	NA	NA	2011-10-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00088530	BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial	10.1016/s1470-2045(12)70212-7	https://www.ncbi.nlm.nih.gov/pubmed/22652183?dopt=Abstract	16	2005-06-23	Completed	2004-07-01	2008-08-01	2012-05-30	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response\n[ Time Frame: 84 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response\n[ Time Frame: 84 days ]""}]	[See Results Section.]	NA
NCT00094497	Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)	Combination chemotherapy in advanced adrenocortical carcinoma	10.1056/nejmoa1200966	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00094497	21	2005-06-23	Completed	2004-06-01	2010-10-01	2012-05-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: At the final analysis ]""}]	[See Results Section.]	NA
NCT00094653	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma	Improved survival with ipilimumab in patients with metastatic melanoma	10.1056/nejmoa1003466	https://www.ncbi.nlm.nih.gov/pubmed/20525992?dopt=Abstract	50	2005-06-26	Completed	2004-09-01	2009-01-01	2010-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best Objective Response Rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best Objective Response Rate (BORR)\n[ Time Frame: BORR will be measure at 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of overall survival of patients administered MDX-010 in combination with gp 100 melanoma peptide vaccine versus those administered gp 100 melanoma peptide vaccine alone\n[ Time Frame: The study will end when 481 deaths are observed ]""}]	[See Results Section.]	NA
NCT00095875	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial	10.1016/s1470-2045(13)70011-1	http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970011-1/abstract	49	2005-06-23	Completed	NA	2012-04-01	2013-02-13	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival at 3 years""}]
NCT00098137	Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation	Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial	10.1161/circep.111.965178	https://www.ncbi.nlm.nih.gov/pubmed/22157519	9	2005-06-23	Completed	2005-01-01	2008-05-01	2011-12-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)\n[ Time Frame: 12 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)\n[ Time Frame: 12 months follow-up ]""}]	NA
NCT00111345	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004	10.1182/blood-2013-02-484097	https://pubmed.ncbi.nlm.nih.gov/23704089/	9	2005-06-23	Unknown status	2004-03-01	NA	2013-05-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""}]
NCT00114348	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group	10.1200/jco.2012.48.5680	https://www.ncbi.nlm.nih.gov/pubmed/23775972?dopt=Abstract	4	2005-06-23	Completed	2003-08-01	2012-07-01	2013-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD\n[ Time Frame: a ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival\n[ Time Frame: a ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy\n[ Time Frame: a ]""}]	NA	NA
NCT00118573	Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair	Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial	10.1016/j.ejvs.2010.08.026	https://linkinghub.elsevier.com/retrieve/pii/S1078-5884(10)00527-7	7	2005-06-30	Terminated	2004-09-01	2010-05-01	2010-09-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years\n[ Time Frame: 3 years ]""}]	NA
NCT00119717	Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)	Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial	10.1161/strokeaha.110.609933	NA	32	2005-07-07	Completed	2005-06-01	2010-04-01	2011-05-12	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""All adverse events out to 90 days will be reported""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Efficacy will be assessed at 90 days using a global outcome score.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone\n[ Time Frame: 90 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy will be assessed using a global outcome score\n[ Time Frame: 90 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone\n[ Time Frame: 90 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy will be assessed using a global outcome score\n[ Time Frame: 90 days ]""}]	NA
NCT00120406	Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery	Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results	10.1161/circinterventions.111.962324	https://www.ncbi.nlm.nih.gov/pubmed/21953370?dopt=Abstract	23	2005-07-11	Completed	2005-03-01	2011-01-01	2011-09-27	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months\n[ Time Frame: 12 months. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months\n[ Time Frame: 12 months. ]""}]	[See Results Section.]	NA
NCT00124813	Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma	Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma	10.1007/s12288-011-0103-1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332274/	9	2005-07-27	Unknown status	2002-08-01	NA	2012-06-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Induction therapy:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""- Response Rate""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""- Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""- Death rate""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Maintenance therapy:""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""- Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""- Number of patients discontinuing therapy due to toxicity""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Induction therapy: response rate, overall survival, death rate""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Maintenance therapy: progression-free survival, overall survival, number of patients discontinuing therapy due to toxicity""}]
NCT00133978	Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients	A randomized trial of glutamine and antioxidants in critically ill patients	10.1056/nejmoa1212722	https://www.ncbi.nlm.nih.gov/pubmed/23594003?dopt=Abstract	16	2005-08-22	Completed	2005-04-01	2011-12-01	2013-04-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.\n[ Time Frame: 28 day mortality ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.\n[ Time Frame: 28 day mortality ]\n\n28-day mortality/status: at 28 days after randomization; 14 day mortality/status: at 14 days after randomization; Hospital mortality, % died in hospital, % discharged from hospital, % alive and still in hospital; Kaplan-Meier survival curves to 6 months; Subgroup analyses: two vs more than two organ failures on presentation, severity of illness, sepsis vs other admission diagnosis, age, comorbidity""}]	[See Results Section.]	NA
NCT00150878	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial	10.1016/s1470-2045(12)70349-2	https://www.ncbi.nlm.nih.gov/pubmed/22959335?dopt=Abstract	6	2005-09-06	Terminated	2003-12-01	2009-12-01	2012-09-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation\n[ Time Frame: 12 months ]\n\nProportion of patients dying without prior relapse""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation\n[ Time Frame: 12 months ]\n\nProportion of patients dying without prior relapse""}]	NA
NCT00151242	Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B	10.3324/haematol.13378	https://www.ncbi.nlm.nih.gov/pubmed/19059939?dopt=Abstract	13	2005-09-06	Completed	2004-07-01	2011-08-01	2008-12-04	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CR-rate after induction therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete remission (CR)-rate after induction therapy\n[ Time Frame: after the second induction cycle ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse-free survival, one year after consolidation therapy with high-dose cytarabine considering different temporal sequences (1-3-5 versus 1-2-3) of the consolidation therapy\n[ Time Frame: One year after consolidation therapy ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Event-free survival\n[ Time Frame: two years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete remission (CR)-rate after induction therapy\n[ Time Frame: after the second induction cycle ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse-free survival, one year after consolidation therapy with high-dose cytarabine considering different temporal sequences (1-3-5 versus 1-2-3) of the consolidation therapy\n[ Time Frame: One year after consolidation therapy ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Event-free survival\n[ Time Frame: two years ]""}]	NA
NCT00163267	Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel	Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease	10.1583/13-4275mr.1	https://www.ncbi.nlm.nih.gov/pubmed/24093324	6	2005-09-12	Completed	2005-09-01	2009-12-01	2013-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention\n[ Time Frame: 6-12 hours ]\n\nmeasured in a chandler loop model""}]	NA	NA
NCT00167583	NA	NA	NA	NA	8	2005-09-09	Completed	NA	2014-12-01	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 yearss)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to improvement and remission""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 years)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to improvement and remission\n[ Time Frame: 2 years ]""}]
NCT00170326	Progressive Ventricular Dysfunction Prevention in Pacemaker Patients	Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF)	10.1093/eurjhf/hfr041	https://www.ncbi.nlm.nih.gov/pubmed/21613427	6	2005-09-13	Completed	2002-01-01	2009-03-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.\n[ Time Frame: 12 months ]""}]	NA
NCT00170690	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial	10.1186/s40661-017-0040-2	https://gynoncrp.biomedcentral.com/articles/10.1186/s40661-017-0040-2	7	2005-09-12	Completed	NA	2011-12-01	2017-03-07	FALSE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of patient´s compliance in both arms defined as therapy break-offs\n[ Time Frame: during study treatment ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of patient´s compliance in both arms defined as therapy break-offs\n[ Time Frame: during study treatment ]""}]
NCT00180089	Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation	Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)	10.1186/s12876-014-0197-7	https://www.ncbi.nlm.nih.gov/pubmed/25425214	4	2005-09-09	Completed	2004-01-01	2009-03-01	2014-11-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of acute gastrointestinal (GI) GVHD in the active group versus placebo group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of acute gastrointestinal (GI) GVHD in the active group versus placebo group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of acute gastrointestinal (GI) GVHD in the active group versus placebo group""}]	NA	NA
NCT00180102	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years	High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial	10.1200/jco.2012.46.4743	https://www.ncbi.nlm.nih.gov/pubmed/23630210	7	2005-09-12	Completed	2003-12-01	2009-11-01	2013-04-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""- overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""- relapse-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""relapse-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""relapse-free survival""}]	NA	NA
NCT00182819	Radiation Therapy or Temozolomide in Treating Patients With Gliomas	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study	10.1016/s1470-2045(16)30313-8	https://www.ncbi.nlm.nih.gov/pubmed/27686946?dopt=Abstract	57	2005-09-15	Completed	NA	2013-01-01	2016-09-27	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]
NCT00185159	Olmesartan Medoxomil in Diabetes Mellitus	Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study	10.1007/s00125-009-1577-3	https://www.ncbi.nlm.nih.gov/pubmed/19876613?dopt=Abstract	6	2005-09-12	Completed	2004-10-01	NA	2009-10-30	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine\n[ Time Frame: Time to the first occurrence ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine\n[ Time Frame: Time to the first occurrence ]""}]
NCT00204529	Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB	Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial	10.1093/annonc/mdw225	https://www.sciencedirect.com/science/article/pii/S0923753419347532?via%3Dihub	10	2005-09-12	Completed	NA	NA	2020-01-06	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to distant metastasis""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to distant metastasis\n[ Time Frame: From date of randomization until the date of first documented distant metastases or date of death from any cause, whichever came first, assessed up to 60 months ]""}]
NCT00204542	Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head	Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group	10.1111/j.1468-3083.2011.04005.x	https://www.ncbi.nlm.nih.gov/pubmed/21414035	10	2005-09-13	Completed	2005-06-01	2009-03-01	2011-03-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	NA
NCT00211237	CAFE Study - Cancer Patient Fracture Evaluation	Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial	10.1016/s1470-2045(11)70008-0	https://www.ncbi.nlm.nih.gov/pubmed/21333599	25	2005-09-13	Completed	2005-05-01	2008-04-01	2011-02-16	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint of the study is the improvement in functional status, as measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 month.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The improvement in functional status, as measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 month""}]	[See Results Section.]	[See Results Section.]	NA
NCT00224770	Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation	Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial	10.1016/s1474-4422(16)30234-4	NA	11	2005-09-21	Completed	2005-08-01	2011-08-01	2016-10-11	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Procedure related mortality""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cerebritis, meningitis""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Rate of rebleeding""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mortality\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Procedure related mortality\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cerebritis, meningitis\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Rate of rebleeding\n[ Time Frame: 30 days ]""}]	[See Results Section.]	NA	NA
NCT00232830	The Study to Assess AMI Treated With Balloon Angioplasty.	Sirolimus-eluting versus uncoated stents in acute myocardial infarction	10.1056/nejmoa062006	http://www.nejm.org/doi/full/10.1056/NEJMoa062006	17	2005-10-04	Completed	2003-10-01	NA	2006-09-14	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 1 year post-procedure.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vesselpost-procedure.\n[ Time Frame: 1 and 6 months and at 1, 3, 4, and 5 years post-procedure. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 1 year post-procedure.""}]
NCT00251251	Resynchronization/Defibrillation for Ambulatory Heart Failure Trial	Cardiac-resynchronization therapy for mild-to-moderate heart failure	10.1056/nejmoa1009540	http://www.nejm.org/doi/full/10.1056/NEJMoa1009540	10	2005-11-08	Completed	2003-04-01	2010-09-01	2010-11-14	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF\n[ Time Frame: Study end ]""}]	NA
NCT00256152	Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial	Subclinical atrial fibrillation and the risk of stroke	10.1056/nejmoa1105575	http://www.nejm.org/doi/full/10.1056/NEJMoa1105575	7	2005-11-17	Completed	2004-09-01	2010-06-01	2012-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study outcome will be a composite of:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Ischemic stroke, Non-CNS systemic embolism""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study outcome will be a composite of:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Ischemic stroke, Non-CNS systemic embolism""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of ischemic stroke & Non-CNS systemic embolism\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Symptomatic or Asymptomatic AT documented by ECG\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of ischemic stroke & Non-CNS systemic embolism\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Symptomatic or Asymptomatic AT documented by ECG\n[ Time Frame: 3 years ]""}]	NA
NCT00262119	MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial	10.1093/eurheartj/ehu165	https://www.ncbi.nlm.nih.gov/pubmed/24771721?dopt=Abstract	17	2005-12-04	Completed	2006-02-01	2012-02-01	2014-04-25	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cardiovascular hospitalization at 2 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of Cardiovascular hospitalizations at 2 years\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00263419	Stress-relief Management for Treatment of Late Complications in Type 2 Diabetes	Sustained effects of a mindfulness-based stress-reduction intervention in type 2 diabetic patients: design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-study)	10.2337/dc11-1343	http://care.diabetesjournals.org/content/35/5/945	5	2005-12-07	Unknown status	2005-01-01	NA	2012-02-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression of albuminuria""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression of albuminuria\n[ Time Frame: 1,2,3,4 and 5 year ]""}]
NCT00268853	A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin	Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma	10.1093/annonc/mdt289	NA	10	2005-12-21	Completed	2005-11-01	2010-11-01	2013-08-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to compare the standard CHOP-R and to show that the response rate for CPOP-R is not inferior to that of CHOP-R""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	NA
NCT00272948	Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial	10.1016/s0140-6736(11)61938-7	http://www.sciencedirect.com/science/article/pii/S0140673611619387?via%3Dihub	8	2006-01-04	Completed	2005-12-01	2009-12-01	2012-02-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The aim of this trial is to evaluate prophylactic Defibrotide (DF) in a pediatric patient population at high risk for Veno-occlusive Disease (VOD).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the:""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""- incidence of VOD,""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""- the severity of VOD and""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""- the mortality due to VOD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD\n[ Time Frame: Day + 30 post HSCT ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD\n[ Time Frame: Day + 30 post HSCT ]""}]	NA	NA
NCT00275054	Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in ""Real-Life"" Outside of Clinical Trials	10.21873/anticanres.13382	https://pubmed.ncbi.nlm.nih.gov/31092457/	51	2006-01-10	Completed	NA	2007-07-01	2019-05-01	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]
NCT00281515	Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer	Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV	10.1016/j.ygyno.2012.04.050	https://www.ncbi.nlm.nih.gov/pubmed/22564713?dopt=Abstract	6	2006-01-24	Completed	2006-01-01	NA	2012-05-04	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: every 3 months until PD ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]
NCT00282646	Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)	Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA)	10.1161/circinterventions.110.958348	http://circinterventions.ahajournals.org/content/4/1/26	7	2006-01-25	Completed	2005-10-01	2010-10-01	2011-01-04	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index\n[ Time Frame: 6 months ]""}]	NA
NCT00284713	Progenitor Cell Therapy in Dilative Cardiomyopathy	Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease	10.1016/j.jacc.2012.02.033	http://www.sciencedirect.com/science/article/pii/S156919931000144X?via%3Dihub	7	2006-01-31	Completed	2004-05-01	2009-01-01	2012-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson\n[ Time Frame: 4 months ]""}]	NA	NA
NCT00298363	Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease	10.1002/hep.23952	https://www.ncbi.nlm.nih.gov/pubmed/21254162?dopt=Abstract	17	2006-02-28	Completed	2006-03-01	2010-12-01	2010-10-27	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety (adverse events and laboratory tests, discontinuations due to adverse events)\n[ Time Frame: Week 48 ]""}]	NA	[See Results Section.]	NA
NCT00298597	Influence of G-CSF and EPO on Associative Learning and Motor Skills	G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial	10.1371/journal.pone.0017770	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0017770	6	2006-03-01	Completed	2006-03-01	2009-03-01	2011-03-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Learning success in a word learning model""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Response time in motor function tests""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Learning success in a word learning model""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Response time in motor function tests""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Learning success in a word learning model""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Response time in motor function tests""}]	NA	NA
NCT00303459	Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension	10.1183/13993003.02044-2014	http://erj.ersjournals.com/content/46/2/405.long	31	2006-03-16	Completed	2006-04-01	2013-09-01	2015-06-25	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from baseline to first adjudicated morbidity/mortality event""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline to Week 16 in 6 Minute Walk Test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from baseline to first adjudicated morbidity/mortality event\n[ Time Frame: From baseline to first adjudicated morbidity/mortality event ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00307450	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease	Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial	10.1007/s00702-010-0472-x	https://www.ncbi.nlm.nih.gov/pubmed/20803300	4	2006-03-27	Completed	2006-03-01	2009-03-01	2010-08-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS\n[ Time Frame: 11 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""UPDRS items 32 & 33\n[ Time Frame: 11 weeks ]""}]	NA	NA
NCT00312845	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial	10.1016/s1470-2045(11)70150-4	NA	20	2006-04-07	Completed	NA	2010-03-01	2011-07-01	FALSE	FALSE	TRUE	TRUE	TRUE	NA	TRUE	FALSE	TRUE	unknown	[]	NA	[See Results Section.]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: 40 months to the end of the study ]""}]
NCT00317642	A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)	Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial	10.1200/jco.2011.37.9743	http://ascopubs.org/doi/abs/10.1200/JCO.2011.37.9743?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed	38	2006-04-24	Completed	NA	2012-09-01	2012-05-14	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""}]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation	10.1111/bjh.13476	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526353/	50	2006-05-02	Completed	NA	2013-02-01	2016-08-01	FALSE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	TRUE	unknown	[]	NA	[See Results Section.]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: At 2 years ]""}]
NCT00323297	Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial	10.1186/s12872-017-0674-3	https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-017-0674-3	81	2006-05-05	Completed	2006-09-01	2012-08-01	2017-09-06	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the effect on exercise capacity (as measured by the 6 Minute Walk Test) after 12 weeks of treatment of sildenafil (20mg TID) or placebo, when added to subjects with PAH who are stabilized on bosentan therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the effect on exercise capacity (as measured by the 6 Minute Walk Test) after 12 weeks\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00324311	Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care	A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT	10.1016/j.burns.2013.08.013	https://www.ncbi.nlm.nih.gov/pubmed/24074719	6	2006-05-10	Completed	2005-12-01	2009-10-01	2013-09-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point is % treated wound excised (tangential and/or minor excision), in first surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds\n[ Time Frame: Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Co-primary: % treated wound autografted of deep partial wounds\n[ Time Frame: Post-debridement autografts ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds\n[ Time Frame: Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Co-primary: % treated wound autografted of deep partial wounds\n[ Time Frame: Post-debridement autografts ]""}]	NA	NA
NCT00326066	A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.	Fluorophotometric study of the effect of the glaukos trabecular microbypass stent on aqueous humor dynamics	10.1167/iovs.09-3972	https://www.ncbi.nlm.nih.gov/pubmed/20207977?dopt=Abstract	8	2006-05-12	Completed	2005-02-01	NA	2010-03-05	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary effectiveness measure will be intraocular pressure measurement from preoperative baseline.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Incidence of adverse events during the surgical procedure and postoperative period.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]
NCT00326079	A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2	Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study	10.1136/bjophthalmol-2011-300218	http://bjo.bmj.com/content/96/5/645.short	8	2006-05-12	Unknown status	2004-08-01	NA	2012-01-23	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary effectiveness measure will be intraocular pressure measurement from preoperative baseline.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Incidence of adverse events during the surgical procedure and postoperative period.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]
NCT00326989	Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium	Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial	10.1001/jama.2013.3527	http://jamanetwork.com/journals/jama/fullarticle/1679402	8	2006-05-16	Completed	2006-05-01	2011-09-01	2013-04-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	NA
NCT00330369	DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial	10.1016/s0140-6736(09)61500-2	https://www.sciencedirect.com/science/article/pii/S0140673609615002	14	2006-05-24	Completed	2006-06-01	2009-04-01	2009-09-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy measure is change from baseline in trough sitting systolic blood pressure measured by sphygmomanometry""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Baseline to Week 14 ]""}]	NA
NCT00331890	ICTUS Study: International Citicoline Trial on Acute Stroke	Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)	10.1016/s0140-6736(12)60813-7	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60813-7/abstract	28	2006-05-30	Terminated	2006-10-01	2012-02-01	2012-06-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a GEE analysis including NIHSS, mRS and Barthel Index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	NA
NCT00334594	Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial	10.1016/s1470-2045(15)00208-9	http://www.sciencedirect.com/science/article/pii/S1470204515002089?via%3Dihub	29	2006-06-07	Completed	NA	2013-12-01	2015-11-02	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]
NCT00335543	Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery	Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial	10.1007/s00066-014-0737-7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289008/	24	2006-06-08	Completed	NA	2009-06-01	2014-09-25	FALSE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median survival""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median survival""}]
NCT00338689	European Childhood Obesity Project: Early Programming by Infant Nutrition?	Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial	10.3945/ajcn.2008.27091	NA	7	2006-06-19	Active, not recruiting	2002-10-01	NA	2009-04-22	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""anthropometry at birth and at 3, 6, 12, 24, 30, 36, 42, 48, 54, 60, 66 and 72 months of age""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body mass index BMI: derived from measured body height (m) and body weight (kg) as body weight / height²\n[ Time Frame: At age 11 years ]\n\nBody height (cm) will be determined with calibrated clinical equipment Body weight (kg) will be determined with calibrated clinical equipment BMI calculated""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""anthropometry\n[ Time Frame: at birth and at 3, 6, 12, 24, 30, 36, 42, 48, 54, 60, 66 and 72, 84, 96 months of age ]""}]
NCT00344253	Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis	Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial	10.1016/j.ajo.2013.05.002	https://www.ncbi.nlm.nih.gov/pubmed/23786783	4	2006-06-22	Completed	2006-03-01	2011-03-01	2013-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12\n[ Time Frame: at month 1,3,6 and 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12\n[ Time Frame: at month 1,3,6 and 12 ]""}]	NA	NA
NCT00349076	Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial	10.1016/s1470-2045(15)00159-x	https://pubmed.ncbi.nlm.nih.gov/26189067/	13	2006-07-05	Completed	2006-07-01	2010-12-01	2015-07-15	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	NA
NCT00349089	Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study	10.1093/annonc/mds578	https://pubmed.ncbi.nlm.nih.gov/23161898/	9	2006-07-04	Completed	2006-10-01	2013-12-01	2012-11-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin\n[ Time Frame: 4 month ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin\n[ Time Frame: 4 month ]""}]	NA
NCT00353496	Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours	Lanreotide in metastatic enteropancreatic neuroendocrine tumors	10.1056/nejmoa1316158	https://www.ncbi.nlm.nih.gov/pubmed/25014687?dopt=Abstract	26	2006-07-17	Completed	2006-06-01	2013-06-01	2014-07-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death within 96 weeks after the first study drug administration.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death\n[ Time Frame: Within 96 weeks after the first study drug administration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death\n[ Time Frame: Within 96 weeks after the first study drug administration ]""}]	[See Results Section.]	NA
NCT00354133	Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease	Neurostimulation for Parkinson's disease with early motor complications	10.1056/nejmoa1205158	https://www.ncbi.nlm.nih.gov/pubmed/23406026?dopt=Abstract	9	2006-07-19	Active, not recruiting	2006-07-01	2011-12-01	2013-02-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PDQ-39\n[ Time Frame: 24 months ]\n\nDifference in the PDQ-39 summary index at 24 months compared to the baseline assessment.""}]	NA
NCT00355095	Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis	A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis	10.1002/ana.23573	http://onlinelibrary.wiley.com/doi/10.1002/ana.23573/abstract	9	2006-07-20	Completed	2006-08-01	2011-02-01	2012-08-27	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	NA
NCT00355862	Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial	10.1097/tp.0000000000000965	https://pubmed.ncbi.nlm.nih.gov/26555945/	10	2006-07-24	Completed	2006-01-01	2009-03-01	2016-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival\n[ Time Frame: 5 year follow up after last patient in ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival\n[ Time Frame: 5 year follow up after last patient in ]""}]	NA	NA
NCT00359424	Interventional Management of Stroke (IMS) III Trial	Endovascular therapy after intravenous t-PA versus t-PA alone for stroke	10.1056/nejmoa1214300	https://www.ncbi.nlm.nih.gov/pubmed/23390923?dopt=Abstract	23	2006-07-31	Terminated	2006-08-01	2014-05-01	2013-02-07	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy: modified Rankin Scale score, dichotomized to 0-2 verses greater than 2 at 3 months from randomization.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety:(1) death due to any cause within 3 months""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""(2) presence of symptomatic ICH (intracranial hemorrhage) within the first 24 (+ 6 hours) hours.""}]	[See Results Section.]	NA	NA	NA
NCT00359918	Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)	Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction)	10.1016/j.jcin.2011.01.013	https://www.ncbi.nlm.nih.gov/pubmed/21700245?dopt=Abstract	5	2006-08-01	Completed	2006-08-01	2009-08-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""}]	NA
NCT00366158	EVITA: Evaluation of VIP Feature in Pacemaker Patients	Minimizing right ventricular pacing in pacemaker patients with intact and compromised atrioventricular conduction : Results from the EVITA Trial	10.1007/s00399-015-0394-2	https://link.springer.com/article/10.1007%2Fs00399-015-0394-2	7	2006-08-18	Completed	2006-08-01	2009-02-01	2015-08-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	NA
NCT00368953	YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus	Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial	10.1016/j.jcin.2010.11.016	https://www.ncbi.nlm.nih.gov/pubmed/21511226?dopt=Abstract	7	2006-08-28	Completed	2006-09-01	2009-12-01	2011-04-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)\n[ Time Frame: 9 months ]""}]	NA	NA
NCT00369018	A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.	Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate--a double-blind, dose-finding study	10.1002/lsm.22041	https://www.ncbi.nlm.nih.gov/pubmed/22693121	4	2006-08-28	Completed	2006-08-01	2009-07-01	2012-06-12	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00372216	CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction	Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial	10.1007/s00392-011-0393-1	NA	10	2006-09-04	Completed	2006-10-01	2009-10-01	2011-12-21	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI\n[ Time Frame: Assessment at primary PCI, asap after inclusion of the subject ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI\n[ Time Frame: Assessment at primary PCI, asap after inclusion of the subject ]""}]	NA	NA
NCT00373373	Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial	10.1200/jco.2012.46.4990	https://www.ncbi.nlm.nih.gov/pubmed/23897964	7	2006-09-06	Completed	2006-09-01	2011-09-01	2013-07-29	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Event Free Survival of all AML patients""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Event Free Survival of all AML patients""}]	NA	NA	NA
NCT00373425	A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial	10.1200/jco.2015.61.8918	https://www.ncbi.nlm.nih.gov/pubmed/26324372?dopt=Abstract	63	2006-09-07	Completed	NA	2013-06-01	2015-08-31	FALSE	FALSE	TRUE	TRUE	TRUE	NA	TRUE	FALSE	TRUE	unknown	[]	NA	[See Results Section.]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease Free Survival (DFS)\n[ Time Frame: Every 3 months during active phase and every 6 months during long term follow-up (up to 6 years) ]\n\nDFS is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse.""}]
NCT00373451	Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction	10.1056/nejmoa1109596	NA	15	2006-09-07	Completed	2006-07-01	2011-05-01	2011-11-13	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite end point of death, large recurrent MI, urgent TVR or major bleeding within 30 days from randomization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding\n[ Time Frame: 30 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding\n[ Time Frame: 30 days ]""}]	NA
NCT00379470	Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality	10.1016/j.ejca.2012.04.011	http://www.sciencedirect.com/science/article/pii/S0959804912003528?via%3Dihub	28	2006-09-20	Completed	2006-09-01	2009-11-01	2012-05-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 2 years from initiation of accrual ]""}]	NA	NA
NCT00382967	A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms	Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study	10.1136/jnnp-2011-301695	https://www.ncbi.nlm.nih.gov/pubmed/22492213?dopt=Abstract	10	2006-09-29	Completed	NA	2010-07-01	2012-04-06	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	TRUE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical management from Visit 1 to Visit 3.\n[ Time Frame: Visit 1 (baseline) and Visit 3 (3 months) ]""}]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical management from Visit 1 to Visit 3.\n[ Time Frame: Visit 1 (baseline) and Visit 3 (3 months) ]""}]
NCT00385697	The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus	Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial	10.1016/s0140-6736(11)60931-8	https://www.sciencedirect.com/science/article/pii/S0140673611609318	63	2006-10-10	Completed	2006-10-01	2010-03-01	2011-06-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful versus unsuccessful clinical responses at 12 months. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful versus unsuccessful clinical responses. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.\n[ Time Frame: at 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.\n[ Time Frame: at 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The second primary endpoint is the mean HbA1c change from baseline at 52 weeks after randomization.\n[ Time Frame: at 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.\n[ Time Frame: at 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The second primary endpoint is the mean HbA1c change from baseline at 52 weeks after randomization.\n[ Time Frame: at 12 months ]""}]	NA
NCT00388505	Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial	10.1016/j.jcf.2010.10.003	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086197/	8	2006-10-16	Completed	2006-02-01	2009-03-01	2010-11-12	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results\n[ Time Frame: AEs - weeks 1, 2, 3, 5, 7, 9, 13, 17, 21 and 25. Safety labs - weeks -4, 1, 5, 9, 13, 17, 21 and 25. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results\n[ Time Frame: AEs - weeks 1, 2, 3, 5, 7, 9, 13, 17, 21 and 25. Safety labs - weeks -4, 1, 5, 9, 13, 17, 21 and 25. ]""}]	[See Results Section.]	NA
NCT00389181	A Randomized Trial of Unruptured Brain AVMs	Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial	10.1016/s0140-6736(13)62302-8	https://www.ncbi.nlm.nih.gov/pubmed/24268105?dopt=Abstract	20	2006-10-16	Completed	2006-10-01	2013-12-01	2013-11-20	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite event of death from any cause or symptomatic stroke (hemorrhage or infarction confirmed by imaging)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite event of death from any cause or symptomatic stroke (hemorrhage or infarction confirmed by imaging)\n[ Time Frame: from enrollment to study end for primary outcomes of death or symptomatic stroke including hemorrhage ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of 5-year event rates between two arms\n[ Time Frame: 5 years ]\n\nThe hypothesis to be tested is that there is no difference between medical management and interventional therapy in the time to stroke or death from any cause.""}]	NA
NCT00389779	DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial	10.1161/hypertensionaha.110.156976	https://www.ncbi.nlm.nih.gov/pubmed/20921430	12	2006-10-18	Completed	2006-12-01	2009-08-01	2010-10-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Baseline to Week 14 ]""}]	NA
NCT00391443	BUILD 3: Bosentan Use in Interstitial Lung Disease	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis	10.1164/rccm.201011-1874oc	http://www.atsjournals.org/doi/abs/10.1164/rccm.201011-1874OC	40	2006-10-20	Completed	2006-11-01	2009-06-01	2011-04-07	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.\n[ Time Frame: 18-32 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.\n[ Time Frame: 18-32 months ]""}]	[See Results Section.]	NA
NCT00391612	EASE Trial: Exhale Airway Stents for Emphysema	Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial	10.1016/s0140-6736(11)61050-7	http://www.sciencedirect.com/science/article/pii/S0140673611610507	56	2006-10-20	Unknown status	2006-05-01	2009-10-01	2011-09-10	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FVC""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""mMRC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced Vital Capacity (FVC)\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""modified Medical Research Council (mMRC) score (breathlessness)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced Vital Capacity (FVC)\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""modified Medical Research Council (mMRC) score (breathlessness)\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00392054	First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)	Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial	10.1001/jama.2014.467	https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2014.467	4	2006-10-23	Completed	2006-08-01	2012-01-01	2014-02-19	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy: Time to first recurrence of electrocardiographically documented symptomatic atrial fibrillation lasting >30 seconds during Follow-up Period.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety: Ablation Arm: Severe (>70%) PV stenosis at 3 and 12 month follow-up. Thromboembolic event with residual sequelae, TIA, pericarditis, myocardial infarction, diaphragmatic paralysis, procedural complication requiring intervention and death.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Primary Safety: AAD Arm: Torsade de Pointes, syncope, bradycardia requiring pacemaker, other pro-arrhythmic events, any other significant adverse events leading to drug discontinuation. Bleeding complications associated with OAC therapy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first episode of symptomatic atrial fibrillation\n[ Time Frame: Assessed during 21 month follow-up period ]\n\nTime to first recurrence of electrocardiographically documented symptomatic atrial fibrillation lasting >30 seconds during Follow-up Period. The follow-up period begins 90 days after randomization.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Comparison of proportion of patients with an occurrence of any of a cluster of serious complications in either arm\n[ Time Frame: Assessed during entire 24 month study period ]\n\n\n\nAblation arm cluster: death, cardiac tamponade, severe PV stenosis>70%, atrioesophageal fistula, thromboembolism, vascular complications (i.e. arterial pseudoaneurysm, arteriovenous fistula and hematoma leading to transfusion), phrenic nerve injury or complete AV block requiring permanent pacemaker implantation.\n\nAntiarrhythmic drug arm cluster: Death, torsade de pointes, bradycardia leading to pacemaker insertion, syncope, QRS duration prolongation > 50% of baseline, 1:1 atrial flutter or any other significant adverse events that leads to drug discontinuation.""}]	NA	[See Results Section.]	NA
NCT00393679	Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children	A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial	10.1371/journal.pmed.1001119	http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001119	10	2006-10-27	Completed	2007-07-01	2009-07-01	2011-11-08	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	NA
NCT00396981	MAPS Trial: Matrix And Platinum Science	Stent-assisted coiling versus coiling alone in unruptured intracranial aneurysms in the matrix and platinum science trial: safety, efficacy, and mid-term outcomes	10.3174/ajnr.a3755	NA	20	2006-11-06	Completed	2007-03-01	2011-03-01	2013-11-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or patient death at 12 months ±3 months post procedure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or neurologic patient death.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or death from an unknown cause.\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00397345	TroVax Renal Immunotherapy Survival Trial	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study	10.1158/1078-0432.ccr-10-2082	https://www.ncbi.nlm.nih.gov/pubmed/20881001	14	2006-11-08	Completed	2006-09-01	2009-07-01	2010-09-29	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	NA
NCT00400387	Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss	Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme	10.7326/m14-2062	https://www.annals.org/article.aspx?doi=10.7326/M14-2062	7	2006-11-15	Completed	2006-11-01	2012-12-01	2015-05-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation\n[ Time Frame: at 24 weeks of gestation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation\n[ Time Frame: at 24 weeks of gestation ]""}]	NA	NA
NCT00401453	OatMeal and Insulin Resistance: OMA-IR	NA	10.1055/s-0029-1222046	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0029-1222046	7	2006-11-17	Completed	2007-01-01	2010-02-01	2009-04-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control\n[ Time Frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control\n[ Time Frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention ]""}]	NA
NCT00402168	A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids	Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study	10.2215/cjn.05840710	https://www.ncbi.nlm.nih.gov/pubmed/21051752	92	2006-11-21	Completed	2006-12-01	2009-06-01	2010-11-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR) from baseline to 12 months post randomization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR)\n[ Time Frame: from baseline to 12 months post randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR)\n[ Time Frame: from baseline to 12 months post randomization ]""}]	[See Results Section.]	NA
NCT00402428	Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients	Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1	10.1053/j.gastro.2010.06.066	http://www.sciencedirect.com/science/article/pii/S0016508510010097?via%3Dihub	18	2006-11-20	Completed	2006-12-01	NA	2010-06-27	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) at Week 72""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR)\n[ Time Frame: Week 72 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR)\n[ Time Frame: Week 72 ]""}]
NCT00402532	Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation	Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial	10.1111/ajt.13835	https://www.ncbi.nlm.nih.gov/pubmed/27104933	6	2006-11-20	Completed	2005-03-01	2011-11-01	2016-06-15	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and Severity of Bronchiolitis obliterans syndrome within 2 years from Transplantation""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mortality within 2 years of Transplantation""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Need for Change of Immunosuppressive Medication within 2 years of Transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation\n[ Time Frame: 2 years ]""}]	NA	NA
NCT00402675	Randomized Trial of Immediate Versus Early and Selective Invasive Percutaneous Coronary Intervention in NSTEMI	Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial)	10.1093/eurheartj/ehr418	NA	2	2006-11-21	Completed	2006-07-01	2009-12-01	2012-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite: death, re-myocardial infarction, recurrent unstable angina within 6 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite: death, re-myocardial infarction, recurrent unstable angina within 6 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""peak creatine kinase- MB level\n[ Time Frame: 5 days ]""}]	NA	NA
NCT00405756	A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.	Continuous lenalidomide treatment for newly diagnosed multiple myeloma	10.1056/nejmoa1112704	https://www.ncbi.nlm.nih.gov/pubmed/22571200?dopt=Abstract	24	2006-11-29	Completed	2007-01-01	NA	2012-05-10	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00410384	A Study of Belimumab in Subjects With Systemic Lupus Erythematosus	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus	10.1002/art.30613	https://www.ncbi.nlm.nih.gov/pubmed/22127708?dopt=Abstract	37	2006-12-08	Completed	2006-12-01	2009-06-01	2011-12-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is response rate at Week 52.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""At Wk 52 the % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in PGA & no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.\n[ Time Frame: 52 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00412893	Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial	10.1016/s0140-6736(15)01159-9	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)01159-9	35	2006-12-18	Completed	2006-12-01	NA	2015-12-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall outcome (clinical, mycological and radiological response)""}]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00418574	Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients	Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study	10.1200/jco.2012.46.4057	https://www.ncbi.nlm.nih.gov/pubmed/23478059?dopt=Abstract	56	2007-01-04	Terminated	2006-12-01	2010-12-01	2013-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival to be documented in double blind condition by CT scan every 12 weeks up to recurrence or up to 3 months after last administered dose""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival to be documented in double blind condition by CT scan\n[ Time Frame: Every 12 weeks up to recurrence or up to 3 months after last administered dose ]""}]	[See Results Section.]	NA	NA
NCT00419250	A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia	10.3109/10428194.2011.618232	https://www.ncbi.nlm.nih.gov/pubmed/21879809?dopt=Abstract	40	2007-01-05	Completed	2006-12-01	2009-12-01	2011-11-15	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: June 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: February 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: February 2010 ]""}]	NA
NCT00419601	Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants	Remifentanil/midazolam versus fentanyl/midazolam for analgesia and sedation of mechanically ventilated neonates and young infants: a randomized controlled trial	10.1007/s00134-012-2532-1	https://dx.doi.org/10.1007/s00134-012-2532-1	4	2007-01-05	Completed	2006-11-01	2010-04-01	2012-03-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion\n[ Time Frame: End of study medication and time of extubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion\n[ Time Frame: at time of extubation (expected to be within 48 hours following discontinuation of the opioid infusion) ]\n\nExtubation time point after discontinuation of the opioid infusion. Start of opioid infusion at the latest 12 h after intubation. Maximum duration of the opioid infusion 96 h.""}]	NA	NA
NCT00422916	Treatment of Overweight Children and Adolescents	An effective lifestyle intervention in overweight children: findings from a randomized controlled trial on ""Obeldicks light""	10.1016/j.clnu.2009.12.010	http://www.sciencedirect.com/science/article/pii/S0261561410000038?via%3Dihub	5	2007-01-16	Completed	2007-01-01	NA	2010-01-27	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status""}]
NCT00425698	Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation	High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation	10.1038/ki.2011.349	https://www.ncbi.nlm.nih.gov/pubmed/22012130	10	2007-01-22	Completed	2007-02-01	2009-05-01	2011-10-19	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Kidney graft function 6 weeks after transplantation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Kidney graft function\n[ Time Frame: 6 weeks after transplantation ]""}]	[See Results Section.]	NA	NA
NCT00428948	Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Tolvaptan in patients with autosomal dominant polycystic kidney disease	10.1056/nejmoa1205511	http://www.nejm.org/doi/full/10.1056/NEJMoa1205511	18	2007-01-29	Completed	2007-01-01	2011-01-01	2012-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate long-term efficacy of tolvaptan in ADPKD through rate of renal volume change (%) for tolvaptan-treated compared to placebo-treated subjects.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate long-term efficacy of tolvaptan in ADPKD through rate of renal volume change (%) for tolvaptan-treated compared to placebo-treated subjects.\n[ Time Frame: 36 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of total kidney volume change(%)\n[ Time Frame: 36 months ]""}]	[See Results Section.]	NA
NCT00430118	Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia	Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome	10.3324/haematol.2011.045229	http://www.haematologica.org/content/97/3/402	36	2007-01-30	Completed	2000-07-01	2012-01-01	2012-03-01	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk (HR) patients""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in medium-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in HR patients""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in intermediate-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in high-risk patients""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in intermediate-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in high-risk patients\n[ Time Frame: End of Trial ]""}]	NA
NCT00431561	Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma	Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study	10.1093/neuonc/noq142	https://www.ncbi.nlm.nih.gov/pubmed/20980335	5	2007-02-05	Completed	2003-04-01	NA	2010-10-27	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans""}]
NCT00433927	5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial	10.1016/s1470-2045(14)70330-4	NA	7	2007-02-09	Unknown status	2007-01-01	2013-12-01	2014-07-31	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate\n[ Time Frame: approximate 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate\n[ Time Frame: approximate 6 months after randomisation ]""}]	NA	NA
NCT00434161	A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma	In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden	10.1038/bmt.2012.257	https://www.ncbi.nlm.nih.gov/pubmed/23241739	29	2007-02-08	Completed	2006-12-01	2009-02-01	2012-12-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)\n[ Time Frame: at Day 32 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of cataract development or progression (change of ≥0.3 in LOCS III score)\n[ Time Frame: at month 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)\n[ Time Frame: at Day 32 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of cataract development or progression (change of ≥0.3 in LOCS III score)\n[ Time Frame: at month 12 ]""}]	[See Results Section.]	NA
NCT00437307	Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)	10.1093/annonc/mdw418	https://pubmed.ncbi.nlm.nih.gov/27789470/	9	2007-02-20	Completed	2007-03-01	2010-07-01	2015-10-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival after 1 year-follow-up""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	NA
NCT00437385	Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients	Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial	10.1016/j.biopsych.2013.11.030	https://www.ncbi.nlm.nih.gov/pubmed/24462229?dopt=Abstract	2	2007-02-20	Completed	2005-03-01	2010-03-01	2013-12-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months\n[ Time Frame: 6 and 12 months after enetering continuation phase ]""}]	NA	NA
NCT00438451	Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs	A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy	10.1111/epi.12926	NA	6	2007-02-21	Completed	2007-01-01	2011-12-01	2015-02-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""58-week retention rate measured by the number of drop outs due to adverse events or seizures from day 1 of treatment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""58-week retention rate measured by the number of drop outs due to adverse events or seizures from day 1 of treatment""}]	[See Results Section.]	NA	NA
NCT00440167	Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)	10.1136/gutjnl-2012-302759	NA	4	2007-02-22	Unknown status	2006-06-01	NA	2012-07-07	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TTF2\n[ Time Frame: approximate 6 months after first line treatment ]\n\nTime to treatment failure, after 2nd line (crossover) therapy""}]
NCT00445081	Prednisolone vs. Ciclosporine in Severe Atopic Eczema	Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial	10.1111/j.1365-2133.2009.09561.x	https://www.ncbi.nlm.nih.gov/pubmed/19863501	7	2007-03-07	Completed	2007-03-01	2009-09-01	2009-10-26	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stable remission in both treatment groups""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stable remission in both treatment groups""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stable remission in both treatment groups""}]	NA
NCT00447187	Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk	High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty	10.1016/j.ophtha.2014.03.016	http://www.sciencedirect.com/science/article/pii/S0161642014002401	12	2007-03-12	Terminated	2007-03-01	2009-09-01	2014-04-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""immunological rejection""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""graft loss""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""immunological rejection""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""graft loss""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""graft rejection or graft failure\n[ Time Frame: 52 weeks ]""}]	NA	NA
NCT00447304	Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy	Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304)	10.1097/sla.0b013e3182a1599b	http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2013&issue=09000&article=00002&type=abstract	2	2007-03-13	Completed	2006-10-01	2010-11-01	2013-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""morbidity at the test-of-cure visit""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""morbidity at the test-of-cure visit""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""morbidity at the test-of-cure visit""}]	NA	NA
NCT00449969	Out-of-hospital Cardiopulmonary Resuscitation and AED Feedback	The addition of voice prompts to audiovisual feedback and debriefing does not modify CPR quality or outcomes in out of hospital cardiac arrest--a prospective, randomized trial	10.1016/j.resuscitation.2010.11.006	http://www.sciencedirect.com/science/article/pii/S0300957210010713?via%3Dihub	9	2007-03-20	Completed	2007-04-01	2009-12-01	2012-10-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation until admission to the hospital""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation\n[ Time Frame: admission to the hospital ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation\n[ Time Frame: admission to the hospital ]""}]	NA	NA
NCT00450684	Cardiac Resynchronization Therapy in Congenital Heart Defects	NA	NA	http://scidok.sulb.uni-saarland.de/volltexte/2017/6827/pdf/Dissertation_ohne_Lebenslauf.pdf	26	2007-03-21	Completed	2007-05-01	2013-09-01	2016-01-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""VO2max""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""QRS-interval""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction\n[ Time Frame: 7 visits ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""QRS-interval\n[ Time Frame: 7 visits ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction\n[ Time Frame: 7 visits ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""QRS-interval\n[ Time Frame: 7 visits ]""}]	NA	NA
NCT00451958	A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy	Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer	10.1111/j.1742-1241.2011.02637.x	https://www.ncbi.nlm.nih.gov/pubmed/21342376	15	2007-03-23	Completed	2007-03-01	NA	2011-02-22	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical safety parameters (adverse events including death from any causse, physical examination, vtal signs, ECGs, and body weight)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical significant changes in laboratory safety parameters (clinical chemistry, haematology, and urinalysis)""}]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical safety parameters (adverse events including death from any cause, physical examination, vital signs, ECGs and body weight)\n[ Time Frame: 6 months, until all patients have been treated for at least 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical significant changes in laboratory safety parameters (clinical chemistry, haematology and urinalysis)\n[ Time Frame: 3 months, until all patients have been treated for at least 5 years ]""}]
NCT00454389	A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration	Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET)	10.1016/j.ophtha.2012.07.068	https://www.ncbi.nlm.nih.gov/pubmed/23174399	10	2007-03-29	Unknown status	2007-04-01	2010-09-01	2012-11-20	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline. Gain of 15 more letters of best correct visual acuity score compared to baseline\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00456092	Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis	Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study	10.1002/art.34627	http://onlinelibrary.wiley.com/doi/10.1002/art.34627/abstract	12	2007-04-02	Completed	2007-01-01	2009-05-01	2012-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline\n[ Time Frame: Monthly ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline\n[ Time Frame: Monthly ]""}]	[See Results Section.]	NA
NCT00461656	Povidone-iodine Antisepsis for Strabismus Surgery	NA	NA	http://iovs.arvojournals.org/article.aspx?articleid=2351700	6	2007-04-17	Completed	2009-09-01	2012-12-01	2012-03-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	NA
NCT00464204	Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis	Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study	10.1186/cc11358	https://www.ncbi.nlm.nih.gov/pubmed/22624531?dopt=Abstract	21	2007-04-20	Completed	2007-07-01	2010-02-01	2012-05-24	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of study drug required to achieve initial hemodynamic stabilization""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Amount of enteral calories during 7 days after hemodynamic stabilization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of study drug required to achieve initial hemodynamic stabilization\n[ Time Frame: until hemodynamic stabilization (max. 48 hours) ]""}]	[See Results Section.]	NA	NA
NCT00466102	Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study	10.1007/s00432-013-1518-x	http://onlinelibrary.wiley.com/doi/10.1002/ejp.843/full	12	2007-04-25	Unknown status	2006-12-01	2010-12-01	2013-09-27	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo\n[ Time Frame: 40 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo\n[ Time Frame: 40 weeks ]""}]	NA	NA
NCT00467857	Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination	A randomized trial of a skin sealant to reduce the risk of incision contamination in cardiac surgery	10.1016/j.athoracsur.2011.03.132	https://www.ncbi.nlm.nih.gov/pubmed/21704290?dopt=Abstract	8	2007-04-30	Completed	2007-04-01	2009-03-01	2011-06-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.\n[ Time Frame: 6 months ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00469638	Efficacy and Safety Study on Agilis NxT Introducer in AF Patients	Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study	10.1161/circep.110.957761	https://www.ncbi.nlm.nih.gov/pubmed/21248246	5	2007-05-03	Completed	2007-05-01	2010-04-01	2011-01-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""rate of patients in stable sinus rhythm (free of Atrial Fibrillation and Left Atrial Flutter)\n[ Time Frame: 6 months post ablation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""rate of patients in stable sinus rhythm (free of Atrial Fibrillation and Left Atrial Flutter)\n[ Time Frame: 6 months post ablation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""rate of patients in stable sinus rhythm (free of Atrial Fibrillation and Left Atrial Flutter)\n[ Time Frame: 6 months post ablation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""rate of patients in stable sinus rhythm (free of Atrial Fibrillation and Left Atrial Flutter)\n[ Time Frame: 6 months post ablation ]""}]	NA
NCT00473499	PEPCAD III Substudy: Stem Cell Mobilization	Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent	10.1002/ccd.25184	http://onlinelibrary.wiley.com/doi/10.1002/ccd.25184/abstract	4	2007-05-14	Completed	2007-07-01	2009-03-01	2013-09-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stem cell mobilization and differentiation\n[ Time Frame: 7 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""endothelial function\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stem cell mobilization and differentiation\n[ Time Frame: 7 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""endothelial function\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""stem cell mobilization and differentiation\n[ Time Frame: 7 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""endothelial function\n[ Time Frame: 9 months ]""}]	NA	NA
NCT00479557	Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease	Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease	10.3233/jad-150376	https://www.ncbi.nlm.nih.gov/pubmed/26967206?dopt=Abstract	18	2007-05-24	Completed	2007-05-01	2012-02-01	2016-04-12	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adverse events and other safety assessment, tolerability, and immunogenicity.\n[ Time Frame: 2 years participation per patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the safety and tolerability of multiple doses of ACC-001 in subjects with mild to moderate AD.\n[ Time Frame: 2 years participation per patient ]""}]	[See Results Section.]	NA	NA
NCT00479609	Testosterone Therapy in Men With Low Testosterone Levels and Metabolic Syndrome or Early Stages of Type 2 Diabetes	Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study)	10.2337/dc10-1233	NA	3	2007-05-25	Unknown status	2007-04-01	NA	2011-03-08	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin sensitivity,\n[ Time Frame: q2 2007- q3 2008 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin sensitivity,\n[ Time Frame: q2 2007- q3 2008 ]""}]
NCT00479661	Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)	Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials	10.1001/jama.2012.304	https://www.ncbi.nlm.nih.gov/pubmed/22436955?dopt=Abstract	10	2007-05-25	Completed	2007-05-01	2010-03-01	2012-03-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required.\n[ Time Frame: 2 hourly and before each rescue treatment dose during the treatment period and the 48-hour follow-up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation\n[ Time Frame: Start and stop times of mechanical ventilation while the patient is treated in the ICU ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required.\n[ Time Frame: 2 hourly and before each rescue treatment dose during the treatment period and the 48-hour follow-up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation\n[ Time Frame: Start and stop times of mechanical ventilation while the patient is treated in the ICU ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required.\n[ Time Frame: 2 hourly and before each rescue treatment dose during the treatment period and the 48-hour follow-up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation\n[ Time Frame: Start and stop times of mechanical ventilation while the patient is treated in the ICU ]""}]	NA	NA
NCT00480077	Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)	Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure	10.1161/circulationaha.111.043042	http://circ.ahajournals.org/content/124/16/1719.long	7	2007-05-29	Terminated	2007-03-01	2012-01-01	2011-09-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective is to investigate if a reduction in combined endpoint of HF hospitalizations and all-cause mortality, in HF subjects managed with standard clinical assessment and using OptiVol® Fluid Status Monitoring with Cardiac Compass Report\n[ Time Frame: study duration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective is to investigate if a reduction in combined endpoint of HF hospitalizations and all-cause mortality, in HF subjects managed with standard clinical assessment and using OptiVol® Fluid Status Monitoring with Cardiac Compass Report\n[ Time Frame: study duration ]""}]	NA	[See Results Section.]	NA
NCT00481312	Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)	Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials	10.1001/jama.2012.304	https://www.ncbi.nlm.nih.gov/pubmed/22436955?dopt=Abstract	9	2007-05-31	Completed	2007-06-01	2009-08-01	2012-03-21	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required\n[ Time Frame: RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded\n[ Time Frame: This variable will be dependent on the individual patient and the number of days they require mechanical ventilation . ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required\n[ Time Frame: RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded\n[ Time Frame: This variable will be dependent on the individual patient and the number of days they require mechanical ventilation . ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required\n[ Time Frame: RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded\n[ Time Frame: This variable will be dependent on the individual patient and the number of days they require mechanical ventilation . ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required\n[ Time Frame: RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded\n[ Time Frame: This variable will be dependent on the individual patient and the number of days they require mechanical ventilation . ]""}]	NA
NCT00491036	Intraaortic Balloon Pump in Cardiogenic Shock II	Intraaortic balloon support for myocardial infarction with cardiogenic shock	10.1056/nejmoa1208410	https://pubmed.ncbi.nlm.nih.gov/22920912/	8	2007-06-22	Completed	2009-06-01	2012-06-01	2012-08-26	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	NA
NCT00499265	Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer	10.1038/bjc.2013.62	https://www.ncbi.nlm.nih.gov/pubmed/23412098	18	2007-07-10	Completed	2007-04-01	NA	2013-02-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Antitumor activity""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events\n[ Time Frame: 3 years ]""}]
NCT00502554	Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation	Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients	10.1111/ajt.12155	https://www.ncbi.nlm.nih.gov/pubmed/23406373	4	2007-07-16	Terminated	2007-08-01	2010-04-01	2013-02-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	NA	NA
NCT00505570	PRIMA PFO Migraine Trial	Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial	10.1093/eurheartj/ehw027	NA	13	2007-07-20	Terminated	2006-05-01	2013-01-01	2016-02-22	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	NA
NCT00506688	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial	10.1164/rccm.201303-0427oc	http://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0427OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&	7	2007-07-24	Completed	2007-07-01	2010-07-01	2013-07-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)\n[ Time Frame: 24 weeks ]""}]	NA	NA
NCT00507832	Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease	Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial	10.1159/000355671	https://www.ncbi.nlm.nih.gov/pubmed/24281309	4	2007-07-26	Completed	2007-04-01	2009-06-01	2013-11-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypothesis: pimecrolimus is superior in the reduction of the itch intensity on a visual analogue scale (VAS) compared to hydrocortisone cream 1%. H1: mean value VAS pimecrolimus < mean value VAS hydrocortisone\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypothesis: pimecrolimus is superior in the reduction of the itch intensity on a visual analogue scale (VAS) compared to hydrocortisone cream 1%. H1: mean value VAS pimecrolimus < mean value VAS hydrocortisone\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypothesis: pimecrolimus is superior in the reduction of the itch intensity on a visual analogue scale (VAS) compared to hydrocortisone cream 1%. H1: mean value VAS pimecrolimus < mean value VAS hydrocortisone\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00507988	Complex Problem Solving Training in Schizophrenic Patients	Planning and problem-solving training for patients with schizophrenia: a randomized controlled trial	10.1186/1471-244x-11-73	https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-11-73	3	2007-07-25	Completed	2007-08-01	2009-02-01	2011-04-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Capacity as assessed by Osnabrücker Arbeitsfähigkeitsprofil \""learning ability\"" subscale\n[ Time Frame: 3 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Capacity as assessed by Osnabrücker Arbeitsfähigkeitsprofil \""learning ability\"" subscale\n[ Time Frame: 3 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Capacity as assessed by Osnabrücker Arbeitsfähigkeitsprofil \""learning ability\"" subscale\n[ Time Frame: 3 weeks ]""}]	NA	NA
NCT00508664	Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)	Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II	10.1093/annonc/mdy332	https://pubmed.ncbi.nlm.nih.gov/30412221/	11	2007-07-27	Completed	2007-07-01	2009-12-01	2018-08-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation\n[ Time Frame: LFS-rate 2 years after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation\n[ Time Frame: LFS-rate 2 years after randomisation ]""}]	NA	NA
NCT00510393	Drug Eluting Stents In The Critically Ischemic Lower Leg	Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease	10.1016/j.jvs.2011.07.099	https://www.ncbi.nlm.nih.gov/pubmed/22169682	5	2007-08-01	Completed	2008-03-01	2009-03-01	2011-12-14	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic patency, defined as angiographic binary in-stent restenosis rate (>50% stenosis).\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic patency, defined as angiographic binary in-stent restenosis rate (>50% stenosis).\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic patency, defined as angiographic binary in-stent restenosis rate (>50% stenosis).\n[ Time Frame: one year ]""}]	NA	NA
NCT00512993	Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy	Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)	10.1016/j.ejca.2016.05.015	NA	9	2007-08-07	Completed	2004-12-01	2013-12-01	2016-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with \""chemo-insensitive\"" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy.\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with \""chemo-insensitive\"" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy.\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with \""chemo-insensitive\"" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy.\n[ Time Frame: 5 years ]""}]	NA	NA
NCT00518895	Trial of Dacarbazine With or Without Genasense in Advanced Melanoma	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'	10.1097/cmr.0000000000000056	https://insights.ovid.com/pubmed?pmid=24667300	15	2007-08-17	Completed	2007-08-01	2011-03-01	2014-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: progression-free survival; overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and overall survival\n[ Time Frame: Every 42 days from date of randomization during protocol therapy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and overall survival\n[ Time Frame: Every 42 days from date of randomization during protocol therapy ]""}]	NA	NA
NCT00521664	A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups	Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study	10.1016/s0140-6736(12)60689-8	https://www.ncbi.nlm.nih.gov/pubmed/22877506	4	2007-08-27	Completed	2004-09-01	2010-09-01	2012-10-13	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)\n[ Time Frame: 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)\n[ Time Frame: 2010 ]""}]	NA	NA
NCT00522834	Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma	10.1200/jco.2012.44.5585	http://ascopubs.org/doi/10.1200/JCO.2012.44.5585	30	2007-08-29	Terminated	2007-08-01	2009-06-01	2013-02-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: June 2009 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: June 2009 ]""}]	NA
NCT00523393	Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells	Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter study	10.1186/s12933-014-0137-4	https://cardiab.biomedcentral.com/articles/10.1186/s12933-014-0137-4	2	2007-08-29	Unknown status	2007-08-01	NA	2014-10-11	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis\n[ Time Frame: 4 weaks of treatment ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis\n[ Time Frame: 4 weaks of treatment ]""}]
NCT00528073	Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease	Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease	10.1053/j.gastro.2011.11.032	http://www.sciencedirect.com/science/article/pii/S0016508511016283	9	2007-09-10	Completed	2007-09-01	2009-03-01	2011-12-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical remission (Crohn's Disease Activity Index < 150 points)\n[ Time Frame: After 12 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical remission (Crohn's Disease Activity Index < 150 points)\n[ Time Frame: After 12 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical remission (Crohn's Disease Activity Index < 150 points)\n[ Time Frame: After 12 weeks of treatment ]""}]	NA	NA
NCT00528671	Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications	Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement	10.1016/j.athoracsur.2010.06.069	https://www.ncbi.nlm.nih.gov/pubmed/20971245	8	2007-09-11	Terminated	2006-01-01	2013-11-01	2010-11-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Thromboembolic events, Bleeding events, Survival rates\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Thromboembolic events, Bleeding events, Survival rates\n[ Time Frame: 2 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Thromboembolic events, Bleeding events, Survival rates\n[ Time Frame: 2 years ]""}]	NA
NCT00529503	A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial	10.3109/10428194.2015.1007504	http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1007504	19	2007-09-12	Terminated	2007-09-01	2010-02-01	2015-02-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.\n[ Time Frame: 9 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.\n[ Time Frame: 9 weeks ]""}]	NA	NA
NCT00530348	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial	10.1016/s0140-6736(12)61769-3	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61769-3	47	2007-09-13	Completed	2007-09-01	2011-03-01	2012-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00530738	Safety and Efficacy of Longterm HPN With Two Lipid Emulsions	Efficacy of a long-term home parenteral nutrition regimen containing fish oil-derived n-3 polyunsaturated fatty acids: a single-centre, randomized, double blind study	10.1186/s12937-018-0419-x	https://pubmed.ncbi.nlm.nih.gov/30501620/	10	2007-09-14	Completed	2007-09-01	2014-01-01	2018-11-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proof of non-inferiority of a HPN regimen containing Lipidem compared to a Lipofundin MCT containing regimen as indicated by the BMI\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proof of non-inferiority of a HPN regimen containing Lipidem compared to a Lipofundin MCT containing regimen as indicated by the BMI\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proof of non-inferiority of a HPN regimen containing Lipidem compared to a Lipofundin MCT containing regimen as indicated by the BMI\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT00530764	A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.	Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial	10.1016/j.jpain.2012.01.003	http://www.sciencedirect.com/science/article/pii/S1526590012000193?via%3Dihub	26	2007-09-13	Completed	2007-11-01	2009-10-01	2012-04-05	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain) during the last three days of week 5.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain).""}]	[See Results Section.]	[See Results Section.]	NA
NCT00531726	Berlin Deep Brain Stimulation Depression Study	Antidepressant effects after short-term and chronic stimulation of the subgenual cingulate gyrus in treatment-resistant depression	10.1016/j.expneurol.2013.08.017	http://www.sciencedirect.com/science/article/pii/S0014488613002574?via%3Dihub	5	2007-09-18	Completed	2007-09-01	2012-09-01	2013-11-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HAMD/MARS score reduction\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HAMD/MARS score reduction\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HAMD/MARS score reduction\n[ Time Frame: 4 weeks ]""}]	NA
NCT00533221	Pilot Study of Growth Hormon to Treat SMA Typ II and III	Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study	10.1016/j.nmd.2013.10.011	https://www.ncbi.nlm.nih.gov/pubmed/24300782?dopt=Abstract	4	2007-09-20	Completed	2007-10-01	2009-05-01	2013-11-13	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	NA
NCT00534287	Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock	Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial	10.1001/jama.2012.5833	http://jamanetwork.com/journals/jama/fullarticle/1163895	12	2007-09-21	Completed	2007-10-01	2010-04-01	2012-06-13	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean total SOFA score\n[ Time Frame: study duration but not longer than 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean total SOFA score\n[ Time Frame: study duration but not longer than 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean total SOFA score\n[ Time Frame: study duration but not longer than 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean total SOFA score\n[ Time Frame: study duration but not longer than 14 days ]""}]	NA
NCT00536640	Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab	Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer	10.1183/09031936.00229014	https://www.ncbi.nlm.nih.gov/pubmed/25792638	18	2007-09-27	Completed	2007-11-01	NA	2015-03-18	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The main efficacy parameter is the progression free survival.\n[ Time Frame: Recruitment 1 year, Follow up 2 years ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The main efficacy parameter is the progression free survival.\n[ Time Frame: Recruitment 1 year, Follow up 2 years ]""}]
NCT00538356	Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function	Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial	10.1016/s0140-6736(14)61176-4	https://www.ncbi.nlm.nih.gov/pubmed/25131977?dopt=Abstract	17	2007-10-01	Completed	2007-07-01	2012-01-01	2014-08-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite Score of death, hospitalization for heart failure, NYHA class and global assessment (Packer Score)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite Score of death, hospitalization for heart failure, NYHA class and global assessment (Packer Score)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite Score of death, hospitalization for heart failure, NYHA class and global assessment (Packer Score)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite Score of death, hospitalization for heart failure, NYHA class and global assessment (Packer Score)\n[ Time Frame: 12 months ]""}]	NA
NCT00538590	Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery	Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery	10.1007/s00417-010-1385-y	https://link.springer.com/article/10.1007/s00417-010-1385-y	5	2007-10-01	Completed	2007-07-01	2010-08-01	2010-04-20	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""IOP<18mmHg at 180 days after surgery without anti-glaucoma medication""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""IOP<18mmHg at 180 days after surgery without anti-glaucoma medication\n[ Time Frame: 180 days ]""}]	NA	[See Results Section.]	NA
NCT00538928	Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS)	Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study	10.1007/s00134-012-2787-6	https://link.springer.com/article/10.1007%2Fs00134-012-2787-6	3	2007-10-02	Completed	2007-09-01	2011-01-01	2013-01-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator free days within 28 days after enrollment\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator free days within 28 days after enrollment\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator free days within 28 days after enrollment\n[ Time Frame: 28 days ]""}]	NA	NA
NCT00543686	Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma	Predicting short term response to anti-inflammatory therapy in young children with asthma	10.1185/03007990903485148	http://www.tandfonline.com/doi/abs/10.1185/03007990903485148?journalCode=icmo20	2	2007-10-12	Completed	2007-08-01	2009-01-01	2009-12-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the number of responders with a very good asthma symptom control defined as requiring no rapid acting beta agonist (RABA) between the 2. and 6th week of intervention (end of trial)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the number of responders with a very good asthma symptom control defined as requiring no rapid acting beta agonist (RABA) between the 2. and 6th week of intervention (end of trial)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the number of responders with a very good asthma symptom control defined as requiring no rapid acting beta agonist (RABA) between the 2. and 6th week of intervention (end of trial)""}]	NA	NA
NCT00543881	Telemedical Interventional Monitoring in Heart Failure	The 6-min walk test in heart failure: is it a max or sub-maximum exercise test?	10.1007/s00421-009-1128-0	https://www.ncbi.nlm.nih.gov/pubmed/19618202?dopt=Abstract	11	2007-10-12	Completed	2007-10-01	2009-04-01	2009-07-18	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Mortality\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Mortality\n[ Time Frame: 1 year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality""}]	NA
NCT00545077	Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study	10.1200/jco.2014.57.2388	http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388	12	2007-10-16	Completed	2007-11-01	2011-12-01	2015-02-17	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00545103	Prevention of Recurrence of Diverticulitis	Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials	10.1053/j.gastro.2014.07.004	https://www.ncbi.nlm.nih.gov/pubmed/25038431?dopt=Abstract	27	2007-10-16	Completed	2007-11-01	2011-11-01	2014-07-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in predefined lab parameters\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to presence of predefined symptoms of diverticulitis\n[ Time Frame: 104 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Abdominal pain\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""A 15% increase in white blood cell (WBC) count from baseline\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Bowel wall thickening (>5mm) and/or fat stranding as evidenced by spiral computerised axial tomography (CT) scan\n[ Time Frame: 104 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00545493	Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis	Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins	10.1111/epi.12042	http://onlinelibrary.wiley.com/doi/10.1111/epi.12042/pdf	4	2007-10-16	Unknown status	2002-11-01	NA	2012-12-06	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to exit, criteria: Deterioration of motor function of the affected side by 15 % (>11 yrs of age: 8%) measured by the \""Motricity Index\"" (scale 0-100) or deterioration of the \""Hemispheric ratio\"" assessed by regular MRI scans by 15% (>11 yrs: 8%).""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to exit, criteria: Deterioration of motor function of the affected side by 15 % (>11 yrs of age: 8%) measured by the \""Motricity Index\"" (scale 0-100) or deterioration of the \""Hemispheric ratio\"" assessed by regular MRI scans by 15% (>11 yrs: 8%).\n[ Time Frame: until final included subject has been followed for one yer ]""}]
NCT00547209	Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia	Nitrous oxide does not produce a clinically important sparing effect during closed-loop delivered propofol-remifentanil anaesthesia guided by the bispectral index: a randomized multicentre study	10.1093/bja/aet479	https://www.ncbi.nlm.nih.gov/pubmed/24486835	12	2007-10-19	Completed	2007-10-01	2009-11-01	2014-01-31	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure: influence of nitrous oxide on the automated administration of propofol and remifentanil.\n[ Time Frame: during anesthesia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure: influence of nitrous oxide on the automated administration of propofol and remifentanil.\n[ Time Frame: during anesthesia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure: influence of nitrous oxide on the automated administration of propofol and remifentanil.\n[ Time Frame: during anesthesia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure: influence of nitrous oxide on the automated administration of propofol and remifentanil.\n[ Time Frame: during anesthesia ]""}]	NA
NCT00547651	AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy	Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer	10.1200/jco.2013.54.5392	https://www.ncbi.nlm.nih.gov/pubmed/25385727?dopt=Abstract	50	2007-10-18	Completed	2007-09-01	2011-03-01	2014-11-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.\n[ Time Frame: Until death from any cause ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.\n[ Time Frame: Until death from any cause ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.\n[ Time Frame: Until death from any cause ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.\n[ Time Frame: Until death from any cause ]""}]	NA
NCT00548405	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial	10.1016/s0140-6736(12)61768-1	https://www.ncbi.nlm.nih.gov/pubmed/23122650?dopt=Abstract	63	2007-10-22	Completed	2007-10-01	2012-04-01	2012-11-01	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	NA	[See Results Section.]	NA
NCT00550004	Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine	RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients	10.1007/s00432-011-1005-1	https://link.springer.com/article/10.1007%2Fs00432-011-1005-1	11	2007-10-25	Terminated	2007-09-01	2009-08-01	2011-07-22	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 18 months ]""}]	NA	NA
NCT00550862	Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid	10.1053/j.gastro.2014.12.005	http://www.sciencedirect.com/science/article/pii/S0016508514015303?via%3Dihub	8	2007-10-27	Completed	2007-10-01	2009-08-01	2014-12-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC) taking UDCA, to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC) taking UDCA, to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA	NA
NCT00552981	Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)	Visiting a sauna: does inhaling hot dry air reduce common cold symptoms? A randomised controlled trial	10.5694/j.1326-5377.2010.tb04127.x	https://www.ncbi.nlm.nih.gov/pubmed/21143077	7	2007-11-01	Completed	2007-11-01	2009-04-01	2010-12-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Symptom Score for Common Cold\n[ Time Frame: Area under the curve day 2 to 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Symptom Score for Common Cold\n[ Time Frame: Area under the curve day 2 to 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Symptom Score for Common Cold\n[ Time Frame: Area under the curve day 2 to 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Symptom Score for Common Cold\n[ Time Frame: Area under the curve day 2 to 7 ]""}]	NA
NCT00554164	Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas	Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial	10.1200/jco.2017.76.8093	https://pubmed.ncbi.nlm.nih.gov/29750632/	11	2007-11-05	Completed	2007-11-01	2014-06-01	2018-05-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to treatment failure\n[ Time Frame: Two years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to treatment failure\n[ Time Frame: Two years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to treatment failure\n[ Time Frame: Two years ]""}]	NA	NA
NCT00554502	Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy	Intensive Supportive Care plus Immunosuppression in IgA Nephropathy	10.1056/nejmoa1415463	https://pubmed.ncbi.nlm.nih.gov/26630142/	13	2007-11-05	Completed	2008-02-01	2013-12-01	2015-12-03	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""- Patients reaching full clinical remission of their disease. - GFR loss of 15 ml/min or higher from baseline GFR at the end of the 3 year study period.\n[ Time Frame: at the end of the 3 year study period. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patients reaching full clinical remission of their disease\n[ Time Frame: at the end of the 3 year study period. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GFR loss of 15 ml/min or higher from baseline GFR\n[ Time Frame: at the end of the 3 year study period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patients reaching full clinical remission of their disease\n[ Time Frame: at the end of the 3 year study period. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GFR loss of 15 ml/min or higher from baseline GFR\n[ Time Frame: at the end of the 3 year study period ]""}]	NA	NA
NCT00556608	Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis	Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(®)) vs hylan G-F20 (Synvisc(®)) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study	10.1016/j.joca.2011.07.016	http://linkinghub.elsevier.com/retrieve/pii/S1063-4584(11)00230-5	6	2007-11-09	Completed	2007-11-01	NA	2011-08-16	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in WOMAC pain subscore from baseline\n[ Time Frame: to week 26 ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in WOMAC pain subscore from baseline\n[ Time Frame: to week 26 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in WOMAC pain subscore from baseline\n[ Time Frame: to week 26 ]""}]
NCT00557921	Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)	Clopidogrel with or without omeprazole in coronary artery disease	10.1056/nejmoa1007964	https://www.ncbi.nlm.nih.gov/pubmed/20925534?dopt=Abstract	17	2007-11-12	Terminated	2007-12-01	2009-11-01	2010-10-06	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforation\n[ Time Frame: Minimum of 48 weeks, up to 96 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforation\n[ Time Frame: Anticipated minimum of 48 weeks, up to end of study ]""}]	NA	NA	NA
NCT00558311	Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping	Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)	10.1016/s1474-4422(11)70108-9	https://www.ncbi.nlm.nih.gov/pubmed/21640651?dopt=Abstract	38	2007-11-13	Completed	2007-11-01	2010-07-01	2011-06-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	NA
NCT00560430	Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients	High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome	10.1161/hypertensionaha.111.173542	http://hyper.ahajournals.org/content/58/4/725.short	4	2007-11-16	Completed	2007-11-01	2009-09-01	2011-09-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in IL-6\n[ Time Frame: 14 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in IL-6\n[ Time Frame: 14 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in IL-6\n[ Time Frame: 14 weeks ]""}]	NA	NA
NCT00562107	Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication	Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population	10.1093/eurheartj/ehu336	https://www.ncbi.nlm.nih.gov/pubmed/25179761	7	2007-11-20	Completed	2007-12-01	2009-12-01	2014-09-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The outcome measure is the % of ventricular pacing and hospitalizations for specified cardiac reasons (symptomatic AF, cardioversions for AF and heart failure)\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The outcome measure is the % of ventricular pacing and hospitalizations for specified cardiac reasons (symptomatic AF, cardioversions for AF and heart failure)\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The outcome measure is the % of ventricular pacing and hospitalizations for specified cardiac reasons (symptomatic AF, cardioversions for AF and heart failure)\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The outcome measure is the % of ventricular pacing and hospitalizations for specified cardiac reasons (symptomatic AF, cardioversions for AF and heart failure)\n[ Time Frame: 3 years ]""}]	NA
NCT00564239	Psychological Prevention of Internalizing Disorders	NA	10.1026/0942-5403/a000046	https://econtent.hogrefe.com/doi/abs/10.1026/0942-5403/a000046	6	2007-11-26	Completed	2007-11-01	2009-05-01	2011-03-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Child Behavior Checklist (german version)\n[ Time Frame: 3, 6, 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Child Behavior Checklist (german version)\n[ Time Frame: 3, 6, 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Child Behavior Checklist (german version)\n[ Time Frame: 3, 6, 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Child Behavior Checklist (german version)\n[ Time Frame: 3, 6, 18 months ]""}]	NA
NCT00567554	Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial	10.1016/s1470-2045(11)70397-7	http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70397-7/abstract	7	2007-12-04	Completed	2007-10-01	2011-08-01	2012-01-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the pCR rates of neoadjuvant treatment in all 3 Settings\n[ Time Frame: 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the pCR rates of neoadjuvant treatment in all 3 Settings\n[ Time Frame: 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the pCR rates of neoadjuvant treatment in all 3 Settings\n[ Time Frame: 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the pCR rates of neoadjuvant treatment in all 3 Settings\n[ Time Frame: 2009 ]""}]	NA
NCT00567736	Efficacy of Disci/Rhus Toxicodendron Comp.®, in Patients With Chronic Low Back Pain	Efficacy of injections with Disci/Rhus toxicodendron compositum for chronic low back pain--a randomized placebo-controlled trial	10.1371/journal.pone.0026166	https://www.ncbi.nlm.nih.gov/pubmed/22087222	4	2007-12-04	Completed	2007-08-01	2008-12-01	2011-11-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual analogue scale (0-100 mm) low back pain\n[ Time Frame: once after 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual analogue scale (0-100 mm) low back pain\n[ Time Frame: once after 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual analogue scale (0-100 mm) low back pain\n[ Time Frame: once after 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual analogue scale (0-100 mm) low back pain\n[ Time Frame: once after 8 weeks ]""}]	NA
NCT00567801	CRAIL - Controlled Reperfusion of the Acutely Ischemic Limb	Controlled reperfusion versus conventional treatment of the acutely ischemic limb: results of a randomized, open-label, multicenter trial	10.1161/circinterventions.112.000371	http://circinterventions.ahajournals.org/content/6/4/417.short	5	2007-12-04	Terminated	2002-09-01	2009-09-01	2013-08-20	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amputation-free survival\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amputation-free survival\n[ Time Frame: 28 days ]""}]	NA	NA	NA
NCT00570765	Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)	NA	10.1016/s0168-8278(11)60030-5	http://www.journal-of-hepatology.eu/article/S0168-8278(11)60030-5/abstract	11	2007-12-07	Completed	2007-11-01	2010-04-01	2011-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA
NCT00571168	Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy	Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial	10.1200/jco.2013.55.0095	http://ascopubs.org/doi/10.1200/JCO.2013.55.0095	2	2007-12-10	Unknown status	2005-07-01	NA	2014-09-15	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall complete response (no emesis and no rescue therapy)\n[ Time Frame: During and post chemotherapy (0-120 h) ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall complete response (no emesis and no rescue therapy)\n[ Time Frame: During and post chemotherapy (0-120 h) ]""}]
NCT00574132	Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease	10.1056/nejmoa1304839	https://www.ncbi.nlm.nih.gov/pubmed/24450891	40	2007-12-13	Completed	2007-12-01	2012-08-01	2014-01-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive and Functional\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive and Functional\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive and Functional\n[ Time Frame: 18 months ]""}]	NA	NA
NCT00574873	Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial	10.1200/jco.2011.38.7522	NA	98	2007-12-14	Completed	2007-12-01	2010-07-01	2012-09-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[See Results Section.]	NA
NCT00575588	52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period	Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia	10.1185/03007995.2014.880674	http://www.tandfonline.com/doi/abs/10.1185/03007995.2014.880674?journalCode=icmo20	12	2007-12-14	Completed	2007-12-01	NA	2014-01-30	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c)""}]	NA	NA	NA	[See Results Section.]
NCT00579657	Protein, Fiber, and Metabolic Syndrome - The PROFIMET Study	Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans	10.3945/ajcn.110.004374	https://www.ncbi.nlm.nih.gov/pubmed/21633074	40	2007-12-21	Completed	2007-08-01	2008-09-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body composition and liver fat, peripheral and hepatic insulin sensitivity\n[ Time Frame: 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body composition and liver fat, peripheral and hepatic insulin sensitivity\n[ Time Frame: 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in insulin sensitivity\n[ Time Frame: 6 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamp""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""change in insulin sensitivity\n[ Time Frame: 18 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in insulin sensitivity\n[ Time Frame: 6 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps; relation with secondary outcome measures""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""change in insulin sensitivity\n[ Time Frame: 18 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps; relation with secondary outcome measures""}]	NA
NCT00583830	A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer	Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer	10.1016/j.cllc.2013.12.005	https://www.ncbi.nlm.nih.gov/pubmed/24560012?dopt=Abstract	8	2007-12-20	Completed	2007-11-01	2010-01-01	2013-12-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response and Progression free survival\n[ Time Frame: 6 cycles, or until disease progression or unacceptable toxicity develops ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response and Progression free survival\n[ Time Frame: 6 cycles, or until disease progression or unacceptable toxicity develops ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response and Progression free survival\n[ Time Frame: 6 cycles, or until disease progression or unacceptable toxicity develops ]""}]	NA	NA
NCT00592553	Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)	Ataluren treatment of patients with nonsense mutation dystrophinopathy	10.1002/mus.24332	https://www.ncbi.nlm.nih.gov/pubmed/25042182	37	2008-01-01	Completed	2008-02-01	2010-04-01	2014-10-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00598533	Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis	Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial	10.1161/circulationaha.111.026732	NA	8	2008-01-21	Completed	2008-02-01	2009-11-01	2011-07-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation\n[ Time Frame: at one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation\n[ Time Frame: at one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation\n[ Time Frame: at one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation\n[ Time Frame: at one year ]""}]	NA
NCT00598611	Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)	Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study	10.2340/00015555-1434	https://www.ncbi.nlm.nih.gov/pubmed/23053062	3	2008-01-10	Completed	2007-09-01	2009-08-01	2013-03-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.\n[ Time Frame: 5 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.\n[ Time Frame: 5 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.\n[ Time Frame: 5 hours ]""}]	NA	NA
NCT00598637	Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease	Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease	10.1016/j.jacc.2013.07.044	NA	7	2008-01-21	Completed	2007-12-01	2012-09-01	2013-08-21	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of MACE defined as a composite of death, MI and Target Lesion revascularization (TLR).\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of major adverse cardiac event (MACE) defined as a composite of death, myocardial infarction and target lesion revascularization.\n[ Time Frame: 1 year follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of major adverse cardiac event defined as a composite of death, myocardial infarction and target lesion revascularization.\n[ Time Frame: 1 year follow-up ]""}]	NA	NA
NCT00598676	3 Limus Agent Eluting Stents With Different Polymer Coating	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents	10.1002/ccd.22823	http://onlinelibrary.wiley.com/doi/10.1002/ccd.22823/full	4	2008-01-21	Completed	2007-09-01	2008-02-01	2011-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00598715	Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial	10.1016/j.carrev.2014.02.001	http://www.sciencedirect.com/science/article/pii/S1553838914000475?via%3Dihub	5	2008-01-21	Completed	2007-10-01	2009-08-01	2014-02-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6-8 months ]""}]	NA	NA
NCT00600444	PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port	Insertion of totally implantable venous access devices: an expertise-based, randomized, controlled trial (NCT00600444)	10.1097/sla.0b013e318214ba21	http://journals.lww.com/annalsofsurgery/Abstract/2011/06000/Insertion_of_Totally_Implantable_Venous_Access.10.aspx	3	2008-01-24	Completed	2008-02-01	2009-05-01	2011-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Operation day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Operation day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Assessed on the day of surgery (day 0) ]""}]	NA	NA
NCT00605748	Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins	A prospective randomized study comparing isolation of the arrhythmogenic vein versus all veins in paroxysmal atrial fibrillation	10.1002/clc.22132	http://onlinelibrary.wiley.com/doi/10.1002/clc.22132/abstract;jsessionid=818786552FB049B44A99258D3004084F.f04t02	2	2008-01-18	Unknown status	2007-12-01	NA	2013-05-13	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""freedom of atrial tachycardia 6 months after ablation\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""freedom of atrial tachycardia 6 months after ablation\n[ Time Frame: 6 months ]""}]
NCT00605826	A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence	Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial	10.1016/s0140-6736(10)62297-0	http://www.sciencedirect.com/science/article/pii/S0140673610622970?via%3Dihub	10	2008-01-30	Completed	2006-08-01	2009-10-01	2011-03-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of fecal incontinence episodes\n[ Time Frame: 6 months after last blinded treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of fecal incontinence episodes\n[ Time Frame: 6 months after last blinded treatment ]""}]	NA	[See Results Section.]	NA
NCT00610584	Acupuncture for Seasonal Allergic Rhinitis	Acupuncture in patients with seasonal allergic rhinitis: a randomized trial	10.7326/0003-4819-158-4-201302190-00002	https://www.ncbi.nlm.nih.gov/pubmed/23420231?dopt=Abstract	3	2008-01-28	Completed	2008-04-01	2011-04-01	2013-02-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score between weeks 6 and 8 of the first year (adjusted for baseline values).\n[ Time Frame: Weeks 6 and 8 of the first year (adjusted for baseline values). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score between weeks 6 and 8 of the first year (adjusted for baseline values).\n[ Time Frame: Weeks 6 and 8 of the first year (adjusted for baseline values). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score between weeks 6 and 8 of the first year (adjusted for baseline values).\n[ Time Frame: Weeks 6 and 8 of the first year (adjusted for baseline values). ]""}]	NA	NA
NCT00611910	Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial	10.1016/s0140-6736(11)61255-5	https://www.ncbi.nlm.nih.gov/pubmed/21872918	5	2008-01-29	Completed	2007-11-01	2011-02-01	2011-08-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00612092	Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol	Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study	10.1016/j.jcmg.2011.12.017	http://www.sciencedirect.com/science/article/pii/S1936878X12002744?via%3Dihub	3	2008-01-28	Unknown status	NA	NA	2012-05-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compared with a helical scan protocol the use of a sequential scan protocol is associated with a comparable diagnostic image quality, while the radiation dose estimates are significantly reduced.\n[ Time Frame: 1 month ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compared with a helical scan protocol the use of a sequential scan protocol is associated with a comparable diagnostic image quality, while the radiation dose estimates are significantly reduced.\n[ Time Frame: 1 month ]""}]
NCT00614224	Structural Neuroplasticity Associated With Aerobic Treadmill Training in Geriatric Chronic Stroke Survivors	Chronic stroke survivors benefit from high-intensity aerobic treadmill exercise: a randomized control trial	10.1177/1545968311418675	https://www.ncbi.nlm.nih.gov/pubmed/21885867	2	2008-01-31	Completed	2008-01-01	2010-01-01	2011-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""aerobic capacity (peak VO2)\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""gait velocity\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""aerobic capacity (peak VO2)\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""gait velocity\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""aerobic capacity (peak VO2)\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""gait velocity\n[ Time Frame: Baseline (timepoint 0) and after training (3 months) ]""}]	NA
NCT00615264	Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients	Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial	10.2337/dc13-1391	http://care.diabetesjournals.org/content/37/5/1392.long	6	2008-02-13	Completed	2005-09-01	2011-09-01	2013-05-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 2-hour MMTT\n[ Time Frame: 0, 6, 12, 18, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primaries: Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 20 minutes glucagon-stimulated test (GST) or a 2-hour MMTT\n[ Time Frame: 0, 6, 12, 18, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 20 minutes glucagon-stimulated test (GST)\n[ Time Frame: 0, to 24 months ]""}]	[See Results Section.]	NA
NCT00615732	Qigong and Exercise for Neck Pain in Adults (QENA)	Qigong versus exercise versus no therapy for patients with chronic neck pain: a randomized controlled trial	10.1097/brs.0b013e3181d51fca	https://www.ncbi.nlm.nih.gov/pubmed/21178832?dopt=Abstract	4	2008-02-01	Completed	2008-03-01	2008-09-01	2011-03-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6, 12, and 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6, 12, and 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6, 12, and 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6, 12, and 24 months ]""}]	NA
NCT00617175	Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III	Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial	10.1001/jama.2013.4598	NA	11	2008-02-14	Completed	2008-03-01	2011-12-01	2013-05-08	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate a 20% reduction of therapies (ATP and Shocks) delivered for treating spontaneous ventricular arrhythmia episodes with a fast cycle length (CL < 320 ms)\n[ Time Frame: end of study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is to demonstrate a 20% reduction of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL ≤ 320 ms)\n[ Time Frame: end of study ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00618280	Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail	Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms	10.1007/s00702-011-0743-1	NA	4	2008-02-08	Completed	2008-01-01	2010-06-01	2011-12-11	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of nicotine or placebo in healthy subjects and schizophrenic patients on attentional network activity in brain with functional magnetic resonance imaging and EEG\n[ Time Frame: after last subject out ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of nicotine or placebo in healthy subjects and schizophrenic patients on attentional network activity in brain with functional magnetic resonance imaging and EEG\n[ Time Frame: after last subject out ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of nicotine or placebo in healthy subjects and schizophrenic patients on attentional network activity in brain with functional magnetic resonance imaging and EEG\n[ Time Frame: after last subject out ]""}]	NA
NCT00625898	BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab	NA	10.1158/1538-7445.am2016-3269	http://cancerres.aacrjournals.org/content/76/14_Supplement/3269.short	22	2008-02-28	Terminated	2008-04-01	2012-08-01	2016-07-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	NA
NCT00626548	A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer	10.1016/j.juro.2012.03.008	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00626548	28	2008-02-21	Terminated	2008-01-01	2011-03-01	2012-05-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and Overall survival\n[ Time Frame: Assessed at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and Overall survival\n[ Time Frame: Assessed at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00626717	Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus	Prospective, randomized, double-blind trial to investigate the efficacy and safety of corneal cross-linking to halt the progression of keratoconus	10.1186/s12886-015-0070-7	https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-015-0070-7	5	2008-02-28	Completed	2007-08-01	2012-12-01	2015-07-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Keratoconus progression\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Endothelial cell loss\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Keratoconus progression\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Endothelial cell loss\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Keratoconus progression\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Endothelial cell loss\n[ Time Frame: 3 years ]""}]	NA	NA
NCT00627094	Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers	Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)	10.1161/circulationaha.109.931691	https://www.ncbi.nlm.nih.gov/pubmed/19128256	4	2008-02-20	Completed	2008-03-01	2009-04-01	2008-09-01	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[]	[]	NA	[See Results Section.]	NA
NCT00627523	Genotropin Treatment In Very Young Children Born Small For Gestational Age	A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin®) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study	10.1111/cen.12968	http://onlinelibrary.wiley.com/doi/10.1111/cen.12968/abstract	79	2008-02-22	Completed	2008-03-01	2013-12-01	2015-11-25	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the change from baseline in height SDS (Standard Deviation Score) and height velocity SDS, after 24 months of treatment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the change from baseline in height SDS (Standard Deviation Score) after 24 months of treatment.\n[ Time Frame: 24 months ]""}]	[See Results Section.]	NA	NA
NCT00627640	Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial	10.1001/jamaneurol.2016.4467	https://www.ncbi.nlm.nih.gov/pubmed/27942720?dopt=Abstract	15	2008-02-29	Completed	2008-02-01	2009-09-01	2017-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the change from baseline to W24 in daily \""on\"" time (\""on\"" time without dyskinesia plus \""on\"" time with minor dyskinesia)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the change from baseline to W24 in daily \""on\"" time (\""on\"" time without dyskinesia plus \""on\"" time with minor dyskinesia)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the change from baseline to W24 in daily \""on\"" time (\""on\"" time without dyskinesia plus \""on\"" time with minor dyskinesia)\n[ Time Frame: 24 weeks ]""}]	NA	NA
NCT00630812	Long Term Administration of Inhaled Mannitol in Cystic Fibrosis	Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study	10.1164/rccm.201109-1666oc	https://www.ncbi.nlm.nih.gov/pubmed/22198974?dopt=Abstract	9	2008-02-27	Completed	2008-05-01	2010-04-01	2011-12-28	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1\n[ Time Frame: 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 Absolute Change from baseline (mL)\n[ Time Frame: 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in absolute FEV1\n[ Time Frame: 26 weeks ]""}]	[See Results Section.]	NA
NCT00631371	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial	10.1200/jco.2013.50.5305	NA	101	2008-02-28	Completed	2008-03-01	2011-03-01	2013-12-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tumor measurements and survival status\n[ Time Frame: On going ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Independently assessed progression free survival (PFS)\n[ Time Frame: every 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00636181	Positive Pressure Treatment of Obstructive Sleep Apnea	Positive airway pressure initiation: a randomized controlled trial to assess the impact of therapy mode and titration process on efficacy, adherence, and outcomes	10.5665/sleep.1166	https://www.ncbi.nlm.nih.gov/pubmed/21804670	4	2008-03-13	Completed	2008-01-01	2009-03-01	2011-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 90 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 180 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 180 Days ]""}]	[See Results Section.]	NA
NCT00637169	Canadian Oxygen Trial (COT)	Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial	10.1001/jama.2013.5555	https://www.ncbi.nlm.nih.gov/pubmed/23644995?dopt=Abstract	11	2008-03-10	Completed	2006-12-01	2012-06-01	2013-05-22	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	NA
NCT00639743	PEITHO Pulmonary Embolism Thrombolysis Study	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism	10.1016/j.jacc.2016.12.039	https://pubmed.ncbi.nlm.nih.gov/28335835/	11	2008-03-19	Completed	2007-11-01	2012-07-01	2017-03-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: select one ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: select one ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	NA
NCT00640679	Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION	10.1160/th13-11-0900	https://www.ncbi.nlm.nih.gov/pubmed/24633406?dopt=Abstract	8	2008-03-20	Terminated	2008-03-01	2012-06-01	2014-03-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of cardiac death, myocardial infarction, stent thrombosis, stroke, major bleeding or rehospitalization due to acute coronary syndrome.\n[ Time Frame: 3 months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of cardiac death, myocardial infarction, stent thrombosis, stroke, major bleeding or rehospitalization due to acute coronary syndrome.\n[ Time Frame: 3 months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of cardiac death, myocardial infarction, stent thrombosis, stroke, major bleeding or rehospitalization due to acute coronary syndrome.\n[ Time Frame: 3 months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of cardiac death, myocardial infarction, stent thrombosis, stroke, major bleeding or rehospitalization due to acute coronary syndrome.\n[ Time Frame: 3 months after randomization ]""}]	NA
NCT00644059	Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines	Oil-in-water emulsion adjuvant with influenza vaccine in young children	10.1056/nejmoa1010331	https://www.ncbi.nlm.nih.gov/pubmed/21995388?dopt=Abstract	5	2008-03-25	Completed	2007-11-01	2010-04-01	2011-10-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one or two 0,25mL or 0,50mL IM injections of the study vaccine, compared to active control vaccine\n[ Time Frame: 181 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one or two 0,25mL or 0,50mL IM injections of the study vaccine, compared to active control vaccine\n[ Time Frame: 181 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one and two 0.25mL IM injections of the adjuvanted and non-adjuvanted influenza vaccines\n[ Time Frame: 7 days postvaccination ]\n\nSolicited local and systemic reactions were assessed and compared between adjuvanted and non-adjuvanted influenza vaccines in 6 to 36 month old subjects""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate efficacy of two 0.25mL IM injections of the adjuvanted influenza vaccine and non-influenza vaccines\n[ Time Frame: Each subject was assessed for one influenza season ]\n\nVirus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine and non-influenza vaccines in 6 to 36 month old subjects. This primary endpoint is only for homologous strains.""}]	[See Results Section.]	NA
NCT00646334	Comparative Study of AESCULAP Optilene® Mesh Elastic Versus Ethicon Ultrapro® Mesh in Incisional Hernia Repair	A randomised, multi-centre, prospective, observer and patient blind study to evaluate a non-absorbable polypropylene mesh vs. a partly absorbable mesh in incisional hernia repair	10.1007/s00423-012-1009-6	https://link.springer.com/article/10.1007%2Fs00423-012-1009-6	5	2008-03-25	Completed	2006-06-01	2009-06-01	2012-10-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical function score of the SF-36 questionnaire\n[ Time Frame: 21 days after insertion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical function score of the SF-36 questionnaire\n[ Time Frame: 21 days after insertion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical function score of the SF-36 questionnaire\n[ Time Frame: 21 days after insertion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical function score of the SF-36 questionnaire\n[ Time Frame: 21 days after insertion ]""}]	NA
NCT00647413	Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause]	Reducing tobacco smoke exposure in children aged below 4 years - a randomized controlled trial	10.1016/j.ypmed.2014.10.016	https://www.ncbi.nlm.nih.gov/pubmed/25456808?dopt=Abstract	1	2008-03-28	Unknown status	NA	NA	2014-10-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""exposure to environmental tobacco smoke\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""exposure to environmental tobacco smoke\n[ Time Frame: 6 months ]""}]
NCT00650078	Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)	10.1136/annrheumdis-2011-201067	https://www.ncbi.nlm.nih.gov/pubmed/22562974	17	2008-03-31	Completed	2008-03-01	2009-07-01	2012-05-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	NA
NCT00650143	Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction	Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial)	10.1016/j.ijcard.2015.11.180	https://www.ncbi.nlm.nih.gov/pubmed/26709136?dopt=Abstract	7	2008-03-31	Unknown status	2008-03-01	NA	2015-11-30	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of global myocardial function from baseline to 6 months of follow-up.\n[ Time Frame: Recruitment period: 1,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 3 years. ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of global myocardial function from baseline to 6 months of follow-up.\n[ Time Frame: Recruitment period: 4,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 6 years. ]""}]
NCT00656136	BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial	10.1016/s1470-2045(12)70087-6	https://www.ncbi.nlm.nih.gov/pubmed/22452896?dopt=Abstract	34	2008-04-09	Completed	NA	2010-03-01	2012-03-26	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]
NCT00659789	Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial	10.1016/s1473-3099(13)70343-8	https://www.ncbi.nlm.nih.gov/pubmed/24525316?dopt=Abstract	14	2008-04-15	Completed	2008-08-01	2010-07-01	2014-02-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52.\n[ Time Frame: Week 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52. To evaluate the % change in CD4 between week 28 and the last CD4 made prior to resumption of ART or week 52.\n[ Time Frame: Week 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52. To evaluate the % change in CD4 between week 28 and the last CD4 made prior to resumption of ART or week 52.\n[ Time Frame: Week 52 ]""}]	[See Results Section.]	NA
NCT00660179	Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension	Macitentan and morbidity and mortality in pulmonary arterial hypertension	10.1056/nejmoa1213917	NA	53	2008-04-16	Completed	2008-04-01	2012-02-01	2013-08-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[See Results Section.]	NA
NCT00661206	Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting	10.1093/eurheartj/ehu523	NA	11	2008-04-17	Unknown status	2008-09-01	NA	2015-01-23	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, stent thrombosis, stroke or TIMI major bleeding.\n[ Time Frame: 9 months after randomization ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, stent thrombosis, stroke or TIMI major bleeding.\n[ Time Frame: 9 months after randomization ]""}]
NCT00661830	Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)	Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme	10.1016/j.ejca.2014.09.013	NA	12	2008-04-15	Completed	2008-05-01	2010-06-01	2014-10-15	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: one year ]""}]	[See Results Section.]	NA	NA
NCT00661986	Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients	Low vs. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients	10.1038/ajh.2010.29	https://academic.oup.com/ajh/article/23/6/694/112955/Low-vs-Higher-Dose-Dark-Chocolate-and-Blood	2	2008-04-17	Completed	2008-02-01	2009-05-01	2010-03-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in mean ambulatory arterial blood pressure\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in mean ambulatory arterial blood pressure\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in mean ambulatory arterial blood pressure\n[ Time Frame: 3 months ]""}]	NA	NA
NCT00662428	Increasing Cost-effectiveness of Inpatient Treatment of Affective Disorders	[Length of hospitalization for inpatient treatment of depression. Results of a multicentre study on the effects of a new treatment model]	10.1007/s00115-012-3723-2	NA	5	2008-04-15	Completed	2008-05-01	2010-09-01	2014-03-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cost-effectiveness: ratio of treatment response and treatment costs\n[ Time Frame: one year after discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cost-effectiveness: ratio of treatment response and treatment costs\n[ Time Frame: one year after discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cost-effectiveness: ratio of treatment response and treatment costs\n[ Time Frame: one year after discharge ]""}]	NA	NA
NCT00662714	Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis	Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test	10.1016/j.jcf.2013.06.001	NA	6	2008-04-18	Completed	2001-09-01	2009-12-01	2013-06-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 2 years ]""}]	NA	NA
NCT00663104	Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause	Effect of block-periodized exercise training on bone and coronary heart disease risk factors in early post-menopausal women: a randomized controlled study	10.1111/j.1600-0838.2011.01335.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0838.2011.01335.x/abstract	4	2008-04-21	Terminated	2008-04-01	2009-06-01	2013-02-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: baseline, 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: baseline, 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: baseline, 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: baseline, 12 month ]""}]	NA
NCT00664963	YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study	Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial	10.1093/eurheartj/ehr144	https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehr144	3	2008-04-18	Completed	2006-04-01	2010-03-01	2011-05-26	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""}]	NA
NCT00665223	A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial	10.1016/s1474-4422(11)70233-2	https://www.ncbi.nlm.nih.gov/pubmed/22071279	19	2008-04-22	Completed	2008-04-01	2009-04-01	2011-11-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.\n[ Time Frame: last timepoint at which outcome is assessed is after 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.\n[ Time Frame: last timepoint at which outcome is assessed is after 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.\n[ Time Frame: last timepoint at which outcome is assessed is after 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.\n[ Time Frame: last timepoint at which outcome is assessed is after 26 weeks ]""}]	NA
NCT00665626	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents	10.1002/art.30114	http://onlinelibrary.wiley.com/doi/10.1002/art.30114/abstract	11	2008-04-23	Completed	2008-05-01	2009-08-01	2011-01-28	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.\n[ Time Frame: Month 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.\n[ Time Frame: Month 3 ]""}]	NA	[See Results Section.]	NA
NCT00666341	Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens	Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study	10.1111/j.1365-2222.2012.03971.x	https://www.ncbi.nlm.nih.gov/pubmed/22909165	8	2008-04-23	Completed	2007-11-01	NA	2012-06-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint of this study is the number of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the up-titration phase\n[ Time Frame: November 2007 - July 2008 ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systemic reaction (according to Tryba)\n[ Time Frame: uptitration phase ]\n\nNumber of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the uptitration phase.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety measured in terms of adverse events (AEs)""}]
NCT00667667	Effects of Whole Body Vibration on Postmenopausal Risk-factors in Elderly Women	[Effects of two different types of whole body vibration on neuromuscular performance and body composition in postmenopausal women]	10.1055/s-0031-1292023	NA	4	2008-04-24	Terminated	2008-04-01	2009-06-01	2011-10-11	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: Baseline, 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: Baseline, 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: Baseline, 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density\n[ Time Frame: Baseline, 12 months ]""}]	NA
NCT00667810	Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials	10.1186/s13195-016-0189-7	https://www.ncbi.nlm.nih.gov/pubmed/27176461?dopt=Abstract	43	2008-04-25	Terminated	2008-05-01	2012-10-01	2016-05-12	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale; Disability Assessment for Dementia\n[ Time Frame: 78 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale total score\n[ Time Frame: 78 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Disability Assessment for Dementia total score\n[ Time Frame: 78 weeks ]""}]	[See Results Section.]	NA	NA
NCT00668759	A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation	A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation	10.1016/j.jacc.2010.07.046	https://www.ncbi.nlm.nih.gov/pubmed/21232669	14	2008-04-28	Completed	2008-04-01	2009-10-01	2011-01-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.\n[ Time Frame: Conversion of AF to SR for a minimum duration of one minute within 90 minutes after start of infusion. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.\n[ Time Frame: Conversion of AF to SR for a minimum duration of one minute within 90 minutes after start of infusion. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.\n[ Time Frame: Conversion of AF to SR for a minimum duration of one minute within 90 minutes after start of infusion. ]""}]	NA	NA
NCT00670254	Hydrocortisone for Prevention of Septic Shock	Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial	10.1001/jama.2016.14799	http://jamanetwork.com/journals/jama/fullarticle/2565176	7	2008-04-29	Completed	2009-01-01	2013-08-01	2016-11-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Septic shock\n[ Time Frame: 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Septic shock\n[ Time Frame: 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Septic shock\n[ Time Frame: 14 days ]""}]	NA	NA
NCT00672334	Sodium Bicarbonate in Cardiac Surgery Study	Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial	10.1371/journal.pmed.1001426	https://www.ncbi.nlm.nih.gov/pubmed/23610561?dopt=Abstract	8	2008-05-01	Terminated	2008-04-01	2011-06-01	2013-04-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level\n[ Time Frame: within first two-five postoperative days. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level\n[ Time Frame: within first two-five postoperative days. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level after adjustment for relevant baseline characteristics\n[ Time Frame: within first two-five postoperative days. ]""}]	NA	NA
NCT00674700	Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis	Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy	10.1111/j.1365-2222.2012.04044.x	https://www.ncbi.nlm.nih.gov/pubmed/22994348/	4	2008-05-07	Completed	2007-10-01	2009-01-01	2012-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00676143	Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients	Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed	10.1016/j.jval.2015.03.1787	NA	37	2008-05-09	Terminated	2008-05-01	2013-06-01	2015-04-10	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale; Disability Assessment for Dementia\n[ Time Frame: 78 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale Total Score\n[ Time Frame: 78 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Disability Assessment for Dementia Total Score\n[ Time Frame: 78 weeks ]""}]	NA	[See Results Section.]	NA
NCT00678275	Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease	10.1056/nejmoa1506002	https://pubmed.ncbi.nlm.nih.gov/26735993/	5	2008-05-14	Completed	2006-10-01	2014-02-01	2016-01-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of cumulative incidence of chronic GvHD (limited or extensive) after allogeneic SCT from HLA-identical siblings with or without anti-T-lymphocyte-globulin at 2 years after transplantation\n[ Time Frame: 2 years after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of cumulative incidence of chronic GvHD (limited or extensive) after allogeneic SCT from HLA-identical siblings with or without anti-T-lymphocyte-globulin at 2 years after transplantation\n[ Time Frame: 2 years after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of cumulative incidence of chronic GvHD (limited or extensive) after allogeneic SCT from HLA-identical siblings with or without anti-T-lymphocyte-globulin at 2 years after transplantation\n[ Time Frame: 2 years after transplantation ]""}]	NA	NA
NCT00678392	Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial	10.1016/s0140-6736(11)61613-9	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(11)61613-9	130	2008-05-12	Completed	2008-06-01	2010-08-01	2011-11-04	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[See Results Section.]	NA
NCT00678535	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial	10.1016/s1470-2045(13)70102-5	https://www.ncbi.nlm.nih.gov/pubmed/23594786	9	2008-05-14	Completed	2008-06-01	2011-12-01	2013-04-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: Various Timepoints ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: Various Timepoints ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00681135	Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients	A randomized clinical trial comparing the impact of different oral hygiene protocols and sealant applications on plaque, gingival, and caries index scores	10.1093/ejo/cjt043	https://www.ncbi.nlm.nih.gov/pubmed/23825160	6	2008-05-19	Completed	2008-04-01	2010-10-01	2013-07-03	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quigley-Hein-Index (QHI), Papillen-Blutungs-Index (PBI)\n[ Time Frame: every 4 weeks for 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque Indices\n[ Time Frame: every 4 weeks for 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Gingival Indices\n[ Time Frame: every 4 weeks for 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque Indices\n[ Time Frame: every 4 weeks for 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Gingival Indices\n[ Time Frame: every 4 weeks for 3 months ]""}]	NA	NA
NCT00683696	Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex	10.1056/nejmoa1306687	https://www.ncbi.nlm.nih.gov/pubmed/23998714	26	2008-05-21	Terminated	2008-08-01	2013-12-01	2013-09-02	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.\n[ Time Frame: Full study duration (event driven trial). Minimum 1 year follow-up and expected median patient follow-up duration of 2 years. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.\n[ Time Frame: Full study duration (event driven trial). Minimum 1 year follow-up and expected median patient follow-up duration of 2 years. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.\n[ Time Frame: 6 months ]""}]	NA	[See Results Section.]	NA
NCT00686244	IT-Based Training in Metabolic Syndrome	An internet-delivered exercise intervention for workplace health promotion in overweight sedentary employees: a randomized trial	10.1016/j.ypmed.2010.07.008	https://www.ncbi.nlm.nih.gov/pubmed/20638409	3	2008-05-28	Completed	2008-04-01	2009-04-01	2010-07-16	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the effect of a combined personal and IT- based training on the performance at the metabolic anaerobe barrier of patients with impending or manifest metabolic syndrome compared to a control group with conventional consulting\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the effect of a combined personal and IT- based training on the performance at the metabolic anaerobe barrier of patients with impending or manifest metabolic syndrome compared to a control group with conventional consulting\n[ Time Frame: 12 months ]""}]	NA	NA	NA
NCT00687869	Participative Rehabilitation in Stroke Patients	Effect of a stroke support service in Germany: a randomized trial	10.1179/1074935714z.0000000047	https://www.ncbi.nlm.nih.gov/pubmed/25920942?dopt=Abstract	2	2008-05-28	Completed	2008-06-01	2012-03-01	2015-04-28	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical scale of the Stroke Impact Scale 3.0\n[ Time Frame: before discharge from acute care, four weeks after discharge from the hospital or rehabilitation (in case of referral to a medical rehabilitation) immediately before randomization (baseline assessment), and 12 months after randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical scale of the Stroke Impact Scale 3.0\n[ Time Frame: before discharge from acute care, four weeks after discharge from the hospital or rehabilitation (in case of referral to a medical rehabilitation) immediately before randomization (baseline assessment), and 12 months after randomization ]""}]	NA	NA
NCT00690118	Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis	A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis	10.1371/journal.pone.0037885	https://www.ncbi.nlm.nih.gov/pubmed/22715372?dopt=Abstract	5	2008-06-03	Terminated	2008-05-01	2011-01-01	2012-06-08	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in patients with ALS treated with pioglitazone compared to placebo\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in patients with ALS treated with pioglitazone compared to placebo\n[ Time Frame: 18 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in patients with ALS treated with pioglitazone compared to placebo\n[ Time Frame: 18 months ]""}]	NA
NCT00693888	Lighthouse Project on Dementia, Ulm, Germany	[Maintenance of health and relief for caregivers of elderly with dementia by using ""initial case management"": experiences from the Lighthouse Project on Dementia, Ulm, ULTDEM-study]	10.1007/s00391-012-0337-z	https://link.springer.com/article/10.1007/s00391-012-0337-z	4	2008-06-06	Unknown status	2008-06-01	NA	2012-04-28	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: six months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: six months ]""}]
NCT00697333	Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial	10.1016/s1470-2045(20)30013-9	https://pubmed.ncbi.nlm.nih.gov/32171429/	8	2008-06-12	Unknown status	2009-05-01	NA	2020-03-12	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""local progression free survival\n[ Time Frame: actuarial ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to local progression\n[ Time Frame: actuarial ]\n\nTime from randomization to first evidence of local progression or last follow up""}]
NCT00701142	Haemocomplettan® P During Aortic Replacement	Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial	10.1016/j.jtcvs.2012.12.083	https://linkinghub.elsevier.com/retrieve/pii/S0022-5223(13)00002-0	7	2008-06-18	Completed	2008-06-01	2010-03-01	2013-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs)administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	NA
NCT00705965	Effects of a Psychotherapy Intervention in Depressed Patients With Coronary Artery Disease	A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD): Results of an Observer-Blinded, Multicenter, Randomized Trial in Depressed Patients With Coronary Artery Disease	10.1097/psy.0000000000000332	https://insights.ovid.com/pubmed?pmid=27187851	6	2008-06-26	Completed	2008-11-01	2013-04-01	2016-07-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to year 1 in depressive symptoms (HADS-D)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	NA
NCT00707369	Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization	Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial	10.1111/jcpe.12441	https://www.ncbi.nlm.nih.gov/pubmed/26250060?dopt=Abstract	4	2008-06-27	Completed	2008-06-01	2011-12-01	2015-09-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of sites showing attachment loss ≥ 1.3 mm over a 27.5-months period\n[ Time Frame: 27.5-months period (six measurements) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of sites showing attachment loss ≥ 1.3 mm over a 27.5-months period\n[ Time Frame: 27.5-months period (six measurements) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of sites showing attachment loss ≥ 1.3 mm over a 27.5-months period\n[ Time Frame: 27.5-months period (six measurements) ]""}]	NA	NA
NCT00708162	Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study	10.1016/s1473-3099(11)70249-3	https://www.ncbi.nlm.nih.gov/pubmed/22015077	17	2008-06-30	Completed	2008-09-01	2010-10-01	2011-10-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	NA
NCT00708253	Single- Versus Double-balloon Enteroscopy in Small Bowel Diagnostics	Single- vs. double-balloon enteroscopy in small-bowel diagnostics: a randomized multicenter trial	10.1055/s-0030-1256247	https://www.ncbi.nlm.nih.gov/pubmed/?term=Single-+vs.+double-balloon+enteroscopy+in+small-bowel+diagnostics%3A+a+randomized+multicenter+trial	4	2008-07-01	Completed	2008-06-01	2010-04-01	2011-03-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary endpoint: Comparison of completeness of visualization of the small bowel by combination of upper and lower balloon enteroscopy\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary endpoint: Comparison of completeness of visualization of the small bowel by combination of upper and lower balloon enteroscopy\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary endpoint: Comparison of completeness of visualization of the small bowel by combination of upper and lower balloon enteroscopy\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00708942	Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1	Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia	10.1002/lsm.22255	https://www.ncbi.nlm.nih.gov/pubmed/24799181	7	2008-07-02	Terminated	2009-01-01	2012-01-01	2014-05-06	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 month ]""}]	[See Results Section.]	NA	NA
NCT00710541	Non-invasive Ventilation in Severe Chronic Obstructive Pulmonary Disease(COPD)	Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial	10.1016/s2213-2600(14)70153-5	https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(14)70153-5	3	2008-07-03	Terminated	2006-01-01	2011-07-01	2014-07-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all-cause mortality\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all-cause mortality\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all-cause mortality\n[ Time Frame: one year ]""}]	NA	NA
NCT00711230	NA	NA	NA	NA	9	2008-07-07	Completed	2008-04-01	2009-12-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of DermaVir Patch\n[ Time Frame: Throughout the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of DermaVir Patch\n[ Time Frame: Throughout the study ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent of participants with primary safety endpoint\n[ Time Frame: 24 weeks ]\n\nPrimary safety endpoint: occurrence of at least two > Grade 3 adverse event including signs/symptoms, lab toxicities, and/or clinical events that is possibly or definitely related to study treatment (as judged by the GIEU006 team, including site clinicians on the team, blinded to treatment arm) any time from the first day of study treatment until 42 days after the last study vaccine administration.""}]
NCT00711295	Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups	Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients	10.1128/cvi.00065-14	https://www.ncbi.nlm.nih.gov/pubmed/24739978	8	2008-07-07	Completed	2008-08-01	2009-03-01	2014-04-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	NA
NCT00711503	Anti-Interleukin-1 in Diabetes Action	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials	10.1016/s0140-6736(13)60023-9	https://www.ncbi.nlm.nih.gov/pubmed/23562090?dopt=Abstract	9	2008-07-03	Completed	2009-01-01	2012-01-01	2013-04-05	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	NA	NA
NCT00712101	Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction	Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial	10.1016/s0140-6736(11)61872-2	NA	6	2008-07-03	Completed	2008-07-01	2011-04-01	2012-02-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined clinical endpoint: death, reinfarction, new congestive heart failure\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined clinical endpoint: death, reinfarction, new congestive heart failure\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined clinical endpoint: death, reinfarction, new congestive heart failure\n[ Time Frame: 90 days ]""}]	NA	NA
NCT00712218	Lymphadenectomy In Ovarian Neoplasms	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms	10.1056/nejmoa1808424	https://pubmed.ncbi.nlm.nih.gov/30811909/	5	2008-07-08	Completed	2008-12-01	2017-12-01	2019-02-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: time from randomization until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: time from randomization until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: time from randomization until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: time from randomization until death ]""}]	NA
NCT00714311	Efficacy of Transference-Focused Psychotherapy for Borderline Personality Disorder	Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial	10.1192/bjp.bp.109.070177	https://pubmed.ncbi.nlm.nih.gov/20435966/	4	2008-07-09	Completed	2004-10-01	2009-02-01	2010-05-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission of borderline personality disorder according to the criteria of DSM-IV.\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drop-out\n[ Time Frame: 1 year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Suicidality (suicide attempts)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drop-out\n[ Time Frame: 1 year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Suicidality (suicide attempts)\n[ Time Frame: 1 year ]""}]	[See Results Section.]	NA
NCT00715091	Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)	10.1136/annrheumdis-2015-207897	https://www.ncbi.nlm.nih.gov/pubmed/26242443	4	2008-07-14	Completed	2008-09-01	2013-12-01	2015-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films\n[ Time Frame: 2 years ]""}]	NA	NA
NCT00715806	Claustrophobia and Magnetic Resonance Imaging	Reduction of claustrophobia with short-bore versus open magnetic resonance imaging: a randomized controlled trial	10.1371/journal.pone.0023494	https://www.ncbi.nlm.nih.gov/pubmed/21887259	5	2008-07-11	Completed	2008-07-01	2009-08-01	2011-08-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: During MRI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: During MRI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: Before or During MRI ]""}]	NA	NA
NCT00716079	The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial	Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage	10.1056/nejmoa1214609	https://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Abstract	11	2008-07-14	Completed	2008-09-01	2012-12-01	2013-05-29	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death or dependency, with dependency being defined by a score of 3 to 5 on the modified Rankin Scale (mRS)\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death or dependency, with dependency being defined by a score of 3 to 5 on the modified Rankin Scale (mRS)\n[ Time Frame: 90 days ]""}]	NA	[See Results Section.]	NA
NCT00716833	Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery	No effect of the cyclooxygenase-2 inhibitor etoricoxib on pre-emptive and post-operative analgesia in visceral surgery: results of a randomized controlled trial	10.1002/ejp.699	https://www.ncbi.nlm.nih.gov/pubmed/25828692?dopt=Abstract	6	2008-07-15	Terminated	2006-02-01	2010-12-01	2015-03-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative use of morphine as assessed within first 48 hours after surgery\n[ Time Frame: first 48 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative use of morphine as assessed within first 48 hours after surgery\n[ Time Frame: first 48 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative use of morphine as assessed within first 48 hours after surgery\n[ Time Frame: first 48 hours ]""}]	NA	NA
NCT00718939	Rheos® Diastolic Heart Failure Trial	Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study	10.1016/j.jacc.2010.03.089	http://www.sciencedirect.com/science/article/pii/S0735109710027221	8	2008-07-17	Completed	2008-07-01	2010-12-01	2010-10-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomizatiom. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomizatiom. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomization. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	NA
NCT00719667	German Off Pump Coronary Artery Bypass in Elderly Study	Off-pump versus on-pump coronary-artery bypass grafting in elderly patients	10.1056/nejmoa1211666	https://www.ncbi.nlm.nih.gov/pubmed/23477657?dopt=Abstract	2	2008-07-21	Completed	2008-07-01	2011-10-01	2013-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Myocardial infarction\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Stroke\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Any revascularisation\n[ Time Frame: 1 month and30 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""renal failure\n[ Time Frame: 1 month and 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Myocardial infarction\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Stroke\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Any revascularisation\n[ Time Frame: 1 month and30 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""renal failure\n[ Time Frame: 1 month and 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Myocardial infarction\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Stroke\n[ Time Frame: 1 month and 12 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Any revascularisation\n[ Time Frame: 1 month and30 month ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""renal failure\n[ Time Frame: 1 month and 12 month ]""}]	NA	NA
NCT00722566	A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study	10.1016/s1470-2045(11)70081-x	NA	14	2008-07-24	Completed	2008-06-01	2010-07-01	2011-04-18	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[See Results Section.]	NA
NCT00723411	A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)	GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus	10.1056/nejmoa1107096	https://www.ncbi.nlm.nih.gov/pubmed/22296077?dopt=Abstract	12	2008-07-25	Terminated	2008-07-01	2010-07-01	2012-02-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Meal stimulated C-peptide (area under the curve)\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Meal stimulated C-peptide (area under the curve)\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Meal stimulated C-peptide (area under the curve)\n[ Time Frame: 15 months ]""}]	NA	NA
NCT00724022	Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation	Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial	10.1016/s0140-6736(16)32187-0	https://pubmed.ncbi.nlm.nih.gov/27871759/	9	2008-07-28	Completed	2008-06-01	2010-09-01	2016-11-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The low dose tacrolimus study arm will be modified to further improve efficacy (prevention of BPAR, best possible renal function) and safety (adverse event profile) of immunosuppression.\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.\n[ Time Frame: one year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.\n[ Time Frame: one year after transplantation ]""}]	NA	NA
NCT00729703	Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications	Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study	10.1016/j.jchf.2014.05.015	https://www.ncbi.nlm.nih.gov/pubmed/25282033?dopt=Abstract	6	2008-08-06	Completed	2006-06-01	2008-12-01	2014-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first part is the time to first occurrence of inappropriate ICD shock therapy. The second part is the composite endpoint of time to first occurrence of death (all causes)or Hospitalizations due to cardio-vascular event.\n[ Time Frame: implant, 3 months, 9 months, 15 months, 21 months and 27 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first part is the time to first occurrence of inappropriate ICD shock therapy. The second part is the composite endpoint of time to first occurrence of death (all causes)or Hospitalizations due to cardio-vascular event.\n[ Time Frame: implant, 3 months, 9 months, 15 months, 21 months and 27 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first part is the time to first occurrence of inappropriate ICD shock therapy. The second part is the composite endpoint of time to first occurrence of death (all causes)or Hospitalizations due to cardio-vascular event.\n[ Time Frame: implant, 3 months, 9 months, 15 months, 21 months and 27 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first part is the time to first occurrence of inappropriate ICD shock therapy. The second part is the composite endpoint of time to first occurrence of death (all causes)or Hospitalizations due to cardio-vascular event.\n[ Time Frame: implant, 3 months, 9 months, 15 months, 21 months and 27 months ]""}]	NA
NCT00730548	Compare Remote Patient Management and Standard Care in CRT-D and ICD-patients to Assess the Effect on Heart Failure	A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices	10.1093/europace/euv039	https://www.ncbi.nlm.nih.gov/pubmed/25983310?dopt=Abstract	10	2008-08-04	Completed	2007-11-01	2011-04-01	2015-05-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hospital length of stay due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hospital length of stay due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first hospitalization due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first hospitalization due to worsened heart failure\n[ Time Frame: 15 months ]""}]	NA
NCT00732953	Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries	Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease	10.1136/hrt.2011.226563	https://heart.bmj.com/content/97/16/1338.long	5	2008-08-08	Completed	2009-01-01	2010-01-01	2011-07-20	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	NA
NCT00732979	Infrahepatic Inferior Vena Cava Clamping During Hepatectomy	Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial	10.1097/sla.0b013e318214bee5	http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2011&issue=06000&article=00009&type=abstract	2	2008-08-11	Completed	2008-03-01	2011-12-01	2011-06-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: End of operation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: End of operation ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: End of operation ]""}]	NA
NCT00733343	Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure	Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure	10.1056/nejmoa1506459	https://pubmed.ncbi.nlm.nih.gov/26323938/	23	2008-08-11	Completed	2008-01-01	2015-05-01	2015-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""1) all cause mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""2) cardiovascular mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""3) all cause mortality or all cause hospitalization\n[ Time Frame: time to first event ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""1) all cause mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""2) cardiovascular mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""3) all cause mortality or all cause hospitalization\n[ Time Frame: time to first event ]""}]	NA	[See Results Section.]	NA
NCT00734942	Development and Implementation of Evidence-Based Family-Oriented Support for Young Carers and Their Families in Germany	Germany's First Young Carers Project's Impact on the Children: Relieving the Entire Family. A Qualitative Evaluation	10.2174/1874434601105010086	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227871/	2	2008-08-12	Unknown status	NA	NA	2011-10-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""health-related Quality of Life in children\n[ Time Frame: study start and after 5 month of intervention ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""health-related Quality of Life in children\n[ Time Frame: study start and after 5 month of intervention ]""}]
NCT00735137	Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth	Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial	10.1016/j.ajog.2015.08.051	http://www.sciencedirect.com/science/article/pii/S0002937815009333	5	2008-08-13	Completed	2008-08-01	2012-02-01	2015-08-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be spontaneous delivery from randomization to 33 weeks and 6 days (237 days) of gestation.\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be spontaneous delivery from randomization to 33 weeks and 6 days (237 days) of gestation.\n[ Time Frame: 10 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be spontaneous delivery from randomization to 33 weeks and 6 days (237 days) of gestation.\n[ Time Frame: 10 weeks ]""}]	NA
NCT00740831	PGL4001 Versus GnRH-agonist in Uterine Myomas	Ulipristal acetate versus leuprolide acetate for uterine fibroids	10.1056/nejmoa1103180	https://www.ncbi.nlm.nih.gov/pubmed/22296076?dopt=Abstract	26	2008-08-22	Completed	2008-08-01	2010-01-01	2012-02-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[See Results Section.]	NA
NCT00742547	Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice	Effectiveness of a supportive telephone counseling intervention in type 2 diabetes patients: randomized controlled study	10.1371/journal.pone.0077954	https://www.ncbi.nlm.nih.gov/pubmed/24205043?dopt=Abstract	7	2008-08-26	Completed	2008-10-01	2012-07-01	2013-10-30	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 18 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c\n[ Time Frame: 18 months ]""}]	NA
NCT00742859	Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)	10.1093/eurheartj/eht039	https://academic.oup.com/eurheartj/article/34/20/1498/489785/Betrixaban-compared-with-warfarin-in-patients-with	8	2008-08-26	Completed	2008-10-01	2009-08-01	2013-03-13	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[See Results Section.]	NA
NCT00745745	Septal Positioning of Ventricular Implanted Cardioverter Defibrillator (ICD) Leads	Safety of mid-septal electrode placement in implantable cardioverter defibrillator recipients--results of the SPICE (Septal Positioning of ventricular ICD Electrodes) study	10.1016/j.ijcard.2014.04.229	https://www.ncbi.nlm.nih.gov/pubmed/24838056?dopt=Abstract	7	2008-09-02	Completed	2008-08-01	2010-12-01	2014-04-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival of RV-ICD-lead related complications\n[ Time Frame: 3 months after implantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival of RV-ICD-lead related complications\n[ Time Frame: 3 months after implantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival of RV-ICD-lead related complications\n[ Time Frame: 3 months after implantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival of RV-ICD-lead related complications\n[ Time Frame: 3 months after implantation ]""}]	NA
NCT00746720	Modulation of the Surgical Inflammatory Response by Etoricoxib	Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief	10.1002/j.1532-2149.2011.00062.x	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00746720	7	2008-09-03	Terminated	2006-05-01	2009-07-01	2011-12-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.\n[ Time Frame: within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.\n[ Time Frame: within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.\n[ Time Frame: within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.\n[ Time Frame: within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2) ]""}]	NA
NCT00747487	Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy	A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy	10.1093/brain/awr170	https://www.ncbi.nlm.nih.gov/pubmed/21788663?dopt=Abstract	9	2008-09-04	Completed	2007-11-01	NA	2011-07-25	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity\n[ Time Frame: 24 weeks ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity between baseline and Week 24 in either right or left eye\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity between baseline and Week 24 in either right or left eye\n[ Time Frame: 24 weeks ]""}]
NCT00748202	Berinert P Study of Subcutaneous Versus Intravenous Administration	Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study	10.1111/trf.12501	http://onlinelibrary.wiley.com/doi/10.1111/trf.12501/abstract	8	2008-09-04	Completed	2008-09-01	2010-12-01	2013-11-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120 and 168 hours. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120, 168, 336 an 504 hours. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120, 168, 336 an 504 hours. ]""}]	NA	NA
NCT00749996	Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease	Herniectomy versus herniectomy with the DIAM spinal stabilization system in patients with sciatica and concomitant low back pain: results of a prospective randomized controlled multicenter trial	10.1007/s00586-016-4796-6	NA	15	2008-09-09	Completed	2006-11-01	2011-03-01	2016-10-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate a statistically significant difference in the relief of back pain between both treatment groups. The endpoint will be the difference between baseline and 6-month of the patient's back-pain score on a Visual Analogue Scale (VAS).\n[ Time Frame: 6 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate a statistically significant difference in the relief of back pain between both treatment groups. The endpoint will be the difference between baseline and 6-month of the patient's back-pain score on a Visual Analogue Scale (VAS).\n[ Time Frame: 6 Months ]""}]	[See Results Section.]	NA	NA
NCT00751465	Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability	Can a one-weekend group therapy reduce fear of blushing? Results of an open trial	10.1080/10615800903075132	https://www.ncbi.nlm.nih.gov/pubmed/19557558?dopt=Abstract	7	2008-09-11	Completed	2008-11-01	2009-11-01	2010-05-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Liebowitz Social Anxiety Scale\n[ Time Frame: post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: within, post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: within, post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: pre, within, post, 6-months, and 12-months follow-up ]\n\nBrief Social Phobia Scale BSPS is an interview assessing fear and avoidance in seven social situations and severity of four bodily symptoms.""}]	NA
NCT00751959	Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks	Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial	10.1001/jamapediatrics.2015.0504	NA	5	2008-09-11	Completed	2009-04-01	2012-06-01	2015-08-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival until term without CLD\n[ Time Frame: 13-17 weeks after birth ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival until term without CLD\n[ Time Frame: 13-17 weeks after birth ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival until term without CLD\n[ Time Frame: 13-17 weeks after birth ]""}]	NA	NA
NCT00752336	Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation	Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: a prospective, comparative study	10.1016/j.healun.2010.08.030	http://www.sciencedirect.com/science/article/pii/S1053249810005383	1	2008-09-12	Unknown status	NA	NA	2011-02-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HRQoL,exercise capacity\n[ Time Frame: 36 mts ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HRQoL,exercise capacity\n[ Time Frame: 36 mts ]""}]
NCT00757159	Study on Regenerative Treatment of Intra-bony Defects	Clinical outcomes after treatment of periodontal intrabony defects with nanocrystalline hydroxyapatite (Ostim) or enamel matrix derivatives (Emdogain): a randomized controlled clinical trial	10.1155/2014/786353	https://www.ncbi.nlm.nih.gov/pubmed/24689056	5	2008-09-22	Completed	2008-08-01	2009-10-01	2014-02-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of bone fill after surgery\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of bone fill after surgery\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of bone fill after surgery\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00758017	Efficacy of Different Acupuncture Methods for Chronic Low Back Pain	Standardized versus Individualized Acupuncture for Chronic Low Back Pain: A Randomized Controlled Trial	10.1155/2013/125937	https://www.hindawi.com/journals/ecam/2013/125937/	5	2008-09-22	Completed	2009-01-01	2011-03-01	2013-10-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity over 8 weeks (area under the curve)\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity over 8 weeks (area under the curve)\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity over 8 weeks (area under the curve)\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT00758277	Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients	Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial	10.1097/jcp.0b013e31825e213e	https://www.ncbi.nlm.nih.gov/pubmed/22722516?dopt=Abstract	4	2008-09-23	Completed	2007-05-01	2009-07-01	2012-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison alcohol free \""surviving \""(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos\n[ Time Frame: During and after treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison alcohol free \""surviving \""(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos\n[ Time Frame: During and after treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison alcohol free \""surviving \""(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos\n[ Time Frame: During and after treatment ]""}]	NA	NA
NCT00761059	Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning	Oral glucose in preterm neonates during oropharyngeal suctioning: a randomized controlled cross-over trial	10.1007/s00431-014-2472-6	https://link.springer.com/article/10.1007/s00431-014-2472-6	2	2008-09-25	Unknown status	NA	NA	2014-12-19	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The PIPP-Score, a validated pain-score, is used to measure the patient's pain\n[ Time Frame: during nasopharyngeal suctioning ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The PIPP-Score, a validated pain-score, is used to measure the patient's pain\n[ Time Frame: during nasopharyngeal suctioning ]""}]
NCT00761475	Primary Mesh Closure of Abdominal Midline Wounds	Short-term results of a randomized controlled trial comparing primary suture with primary glued mesh augmentation to prevent incisional hernia	10.1097/sla.0000000000000798	https://www.ncbi.nlm.nih.gov/pubmed/24983993?dopt=Abstract	6	2008-09-26	Completed	2009-02-01	2012-12-01	2015-02-01	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incisional hernia occurence\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incisional hernia occurence\n[ Time Frame: 2 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incisional hernia occurence\n[ Time Frame: 2 years ]""}]	NA
NCT00763659	Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)	Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial	10.1001/jamaophthalmol.2013.2851	https://www.ncbi.nlm.nih.gov/pubmed/23519529?dopt=Abstract	6	2008-09-30	Completed	2008-05-01	2010-12-01	2013-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00763971	Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17	European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder	10.1016/j.euroneuro.2012.11.012	https://www.ncbi.nlm.nih.gov/pubmed/23332456?dopt=Abstract	24	2008-09-30	Completed	2008-10-01	2010-10-01	2013-01-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADHD Rating Scale\n[ Time Frame: Weekly for 7 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADHD Rating Scale\n[ Time Frame: Weekly for 7 weeks of treatment ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00764881	Effects of SH T00658ID on Libido	Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction	10.1111/jsm.12310	http://www.sciencedirect.com/science/article/pii/S1743609515302319?via%3Dihub	20	2008-10-01	Completed	2009-01-01	2010-08-01	2012-09-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in the not weighted sum of Female Sexual Function Index (FSFI) sexual desire and the sexual arousal component scores, defined as the total of questions 1 to 6 of the FSFI.\n[ Time Frame: Baseline to cycle 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in the not weighted sum of Female Sexual Function Index (FSFI) sexual desire and the sexual arousal component scores, defined as the total of questions 1 to 6 of the FSFI.\n[ Time Frame: Baseline to cycle 6 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00764933	Structured Information During the Intensive Care Unit Stay	Does an additional structured information program during the intensive care unit stay reduce anxiety in ICU patients?: a multicenter randomized controlled trial	10.1186/1471-2253-14-48	https://bmcanesthesiol.biomedcentral.com/articles/10.1186/1471-2253-14-48	4	2008-10-01	Completed	2008-01-01	2009-12-01	2014-06-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient self-reported anxiety\n[ Time Frame: First three days on ICU and/or within 24 hours after ICU discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient self-reported anxiety\n[ Time Frame: First three days on ICU and/or within 24 hours after ICU discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient self-reported anxiety\n[ Time Frame: First three days on ICU and/or within 24 hours after ICU discharge ]""}]	NA	NA
NCT00765323	Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly	Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly	10.1210/jc.2013-2262	https://www.ncbi.nlm.nih.gov/pubmed/23969184?dopt=Abstract	12	2008-10-01	Terminated	2008-09-01	2010-06-01	2013-08-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments\n[ Time Frame: 12 months ]""}]	NA
NCT00765830	Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)	One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment	10.1111/j.1463-1326.2012.01634.x	https://www.ncbi.nlm.nih.gov/pubmed/22690943	7	2008-10-02	Completed	2008-09-01	2010-04-01	2012-07-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment\n[ Time Frame: 52 weeks ]""}]	NA
NCT00769457	OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network	Fluid status telemedicine alerts for heart failure: a randomized controlled trial	10.1093/eurheartj/ehw099	https://pubmed.ncbi.nlm.nih.gov/26984864/	12	2008-10-08	Completed	2008-09-01	2014-11-01	2016-03-16	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day 35 after implantation\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	NA
NCT00769561	Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders	Biofeedback-based cognitive-behavioral treatment compared with occlusal splint for temporomandibular disorder: a randomized controlled trial	10.1097/ajp.0b013e3182850559	https://www.ncbi.nlm.nih.gov/pubmed/23446073?dopt=Abstract	3	2008-10-08	Completed	2008-06-01	2010-07-01	2013-12-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))\n[ Time Frame: Pre-Post-Design including 4 assessment points: pre-treatment, post-treatment, 3- and 6-month follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))\n[ Time Frame: Pre-Post-Design including 4 assessment points: pre-treatment, post-treatment, 3- and 6-month follow up ]""}]	NA	[See Results Section.]	NA
NCT00770783	Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression	Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects	10.1017/s0033291714002244	https://pubmed.ncbi.nlm.nih.gov/25420474/	7	2008-10-09	Completed	2005-02-01	2013-09-01	2014-11-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement (Hamilton Rating Scale for Depression)\n[ Time Frame: After each treatment and at followups up to 3 months after the treatment course ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement (Hamilton Rating Scale for Depression)\n[ Time Frame: After each treatment and at followups up to 3 months after the treatment course ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement (Hamilton Rating Scale for Depression)\n[ Time Frame: After each treatment and at followups up to 3 months after the treatment course ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement (Hamilton Rating Scale for Depression)\n[ Time Frame: After each treatment and at followups up to 3 months after the treatment course ]""}]	NA
NCT00774072	Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization	Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study	10.2147/dddt.s54064	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930477/	5	2008-10-16	Completed	2008-10-01	2010-11-01	2014-02-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid\n[ Time Frame: day -1, 1, 29, 30, 59, 60 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid\n[ Time Frame: day -1, 1, 29, 30, 59, 60 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid\n[ Time Frame: day -1, 1, 29, 30, 59, 60 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid\n[ Time Frame: day -1, 1, 29, 30, 59, 60 ]""}]	NA
NCT00776633	Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial	10.1016/j.jacc.2015.02.050	NA	9	2008-10-20	Unknown status	2008-09-01	2013-12-01	2015-04-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.\n[ Time Frame: 9 months ]""}]	NA
NCT00778648	Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms	NA	NA	https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/reduction-of-common-cold-symptoms-by-encapsulated-juice-powder-concentrate-of-fruits-and-vegetables-a-randomised-double-blind-placebo-controlled-trial/4E3A02A6D1E0EF0A17D0043394E843C4	3	2008-10-21	Completed	2008-09-01	2009-05-01	2010-08-23	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to determine the effect of an encapsulated juice powder concentrate on the number of days with at least moderate common cold symptoms\n[ Time Frame: Common cold symptoms will be documented by participants with the common cold questionnaire during the study period. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to determine the effect of an encapsulated juice powder concentrate on the number of days with at least moderate common cold symptoms\n[ Time Frame: The number of days with at least moderate common cold symptoms will be assessed with a common cold questionnaire over a period of eight months. ]""}]	NA	[See Results Section.]	NA
NCT00779597	Improvement of Self Management for Oncologic Patients With Pain	Improvement of pain-related self-management for cancer patients through a modular transitional nursing intervention: a cluster-randomized multicenter trial	10.1016/j.pain.2014.01.006	https://www.ncbi.nlm.nih.gov/pubmed/24434732	2	2008-10-23	Completed	2008-10-01	2009-12-01	2014-01-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient-related barriers to management of cancer pain (Barriers Questionnaire II)\n[ Time Frame: 7 days after discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient-related barriers to management of cancer pain (Barriers Questionnaire II)\n[ Time Frame: 7 days after discharge ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient-related barriers to management of cancer pain (Barriers Questionnaire II)\n[ Time Frame: 7 days after discharge ]""}]	NA	NA
NCT00783120	Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia	Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial	10.1016/j.biopsych.2014.10.009	https://www.ncbi.nlm.nih.gov/pubmed/25582269?dopt=Abstract	8	2008-10-30	Completed	2008-01-01	2012-01-01	2014-10-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in negative symptoms (baseline vs. day 21, PANNS negative sum score)\n[ Time Frame: 105 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in negative symptoms (baseline vs. day 21, PANNS negative sum score)\n[ Time Frame: 105 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in negative symptoms (baseline vs. day 21, PANNS negative sum score)\n[ Time Frame: 105 Days ]""}]	NA	NA
NCT00783159	Fit in the Aged by Professional Training	Effects of strength training versus power training on physical performance in prefrail community-dwelling older adults	10.1159/000332207	https://www.karger.com/Article/Abstract/332207	6	2008-10-30	Completed	2008-06-01	2009-12-01	2011-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short physical performance battery\n[ Time Frame: 3 months after intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short physical performance battery\n[ Time Frame: 3 months after intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short physical performance battery\n[ Time Frame: 3 months after intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short physical performance battery\n[ Time Frame: 3 months after intervention ]""}]	NA
NCT00784654	Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17	Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design	10.1016/j.jaac.2014.01.017	https://www.ncbi.nlm.nih.gov/pubmed/24839883?dopt=Abstract	22	2008-11-03	Completed	2009-01-01	2011-08-01	2014-03-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adverse Events and Vital Signs\n[ Time Frame: Weekly for the first 4 weeks of treatment; monthly for the final 48 weeks of treatment ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Laboratory Results\n[ Time Frame: Week 20 amd Week 52 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""ECGs\n[ Time Frame: Week 12, Week 24, Week 36 and Week 52 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Discontinuations\n[ Time Frame: Throughout the 52-week study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite endpoint based on the ADHD Rating Scale-IV (ADHD-RS-IV)and Clinical Global Impressions - Severity of Illness (CGI-S)rating scale\n[ Time Frame: Weekly for the 6-week double-blind treatment period (final 6 weeks of study treatment) ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00785109	Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification	Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study	10.1161/circulationaha.116.027011	https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.027011	11	2008-11-04	Completed	2010-01-01	2014-12-01	2017-05-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of aortic valve calcification by activation of the calcification inhibiting protein MGP by means of additional intake of vitamin K\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of aortic valve calcification by activation of the calcification inhibiting protein MGP by means of additional intake of vitamin K\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of aortic valve calcification by activation of the calcification inhibiting protein MGP by means of additional intake of vitamin K\n[ Time Frame: 18 months ]""}]	NA	NA
NCT00785330	Allo-hNHL (FluBuCy)	Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial	10.1016/s1470-2045(14)70161-5	https://www.ncbi.nlm.nih.gov/pubmed/24827808	3	2008-11-04	Completed	2004-04-01	2009-03-01	2014-05-11	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The specific measure that will be used to determine the effect of the intervention(s) or, for observational studies, related to core objectives of the study and receiving the most emphasis in assessment. (a) rate of acute GVHD grade II-IV after one year\n[ Time Frame: One year after allogeneic stem cell transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The specific measure that will be used to determine the effect of the intervention(s) or, for observational studies, related to core objectives of the study and receiving the most emphasis in assessment. (a) rate of acute GVHD grade II-IV after one year\n[ Time Frame: One year after allogeneic stem cell transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The specific measure that will be used to determine the effect of the intervention(s) or, for observational studies, related to core objectives of the study and receiving the most emphasis in assessment. (a) rate of acute GVHD grade II-IV after one year\n[ Time Frame: One year after allogeneic stem cell transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The specific measure that will be used to determine the effect of the intervention(s) or, for observational studies, related to core objectives of the study and receiving the most emphasis in assessment. (a) rate of acute GVHD grade II-IV after one year\n[ Time Frame: One year after allogeneic stem cell transplantation ]""}]	NA
NCT00786994	The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial	10.1111/bjd.13342	https://www.ncbi.nlm.nih.gov/pubmed/25124939?dopt=Abstract	7	2008-11-05	Completed	2008-10-01	2010-11-01	2015-02-25	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical clearance of all treated actinic keratoses\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance.\n[ Time Frame: 18 weeks ]\n\nObjective response of the marker actinic keratosis, defined as his-tologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance.\n[ Time Frame: 18 weeks ]\n\nObjective response of the marker actinic keratosis, defined as his-tologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy.""}]	[See Results Section.]	NA
NCT00792220	""Mobile Stroke-Unit"" for Reduction of the Response Time in Ischemic Stroke	Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial	10.1016/s1474-4422(12)70057-1	http://www.sciencedirect.com/science/article/pii/S1474442212700571	8	2008-11-14	Completed	2008-11-01	2011-07-01	2012-04-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision""}]	NA
NCT00794326	Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD	Low-Sodium Versus Standard-Sodium Peritoneal Dialysis Solution in Hypertensive Patients: A Randomized Controlled Trial	10.1053/j.ajkd.2015.07.031	https://pubmed.ncbi.nlm.nih.gov/26388284/	21	2008-11-19	Completed	2008-10-01	2014-12-01	2015-09-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.\n[ Time Frame: At the beginning and after 8 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.\n[ Time Frame: At the beginning and after 8 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.\n[ Time Frame: At the beginning and after 8 weeks of treatment ]""}]	NA	NA
NCT00795964	Influence of Tidal Volume on Postoperative Pulmonary Function	Ventilation with low tidal volumes during upper abdominal surgery does not improve postoperative lung function	10.1093/bja/aes140	NA	5	2008-11-20	Completed	2008-09-01	2010-09-01	2012-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lung function as assessed by spirometry\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lung function as assessed by spirometry\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lung function as assessed by spirometry\n[ Time Frame: 1 year ]""}]	NA	NA
NCT00796354	Constipation Associated With Irritable Bowel Syndrome (IBS-C)	Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome	10.1038/ajg.2013.197	NA	5	2008-11-21	Completed	2008-11-01	2009-04-01	2013-07-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.\n[ Time Frame: April 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.\n[ Time Frame: April 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.\n[ Time Frame: April 2009 ]""}]	NA	NA
NCT00798317	Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.	Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes	10.1056/nejmoa1110823	NA	17	2008-11-25	Completed	2008-12-01	2010-12-01	2012-08-16	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[See Results Section.]	NA
NCT00798525	Argatroban Versus Lepirudin in Critically Ill Patients	Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial	10.1186/s13054-014-0588-8	https://www.ncbi.nlm.nih.gov/pubmed/25344113	7	2008-11-25	Terminated	2009-01-01	2012-03-01	2014-10-25	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of a maximum of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	NA	NA
NCT00798967	Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects	Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure	10.1053/j.gastro.2012.09.007	https://www.ncbi.nlm.nih.gov/pubmed/22982184	15	2008-11-26	Completed	2008-11-01	2010-12-01	2012-09-11	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage who demonstrate a response at Week 20 and maintain that response through Week 24. A response is at least a 20% reduction from baseline in weekly PN volume.\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage who demonstrate a response at Week 20 and maintain that response through Week 24. A response is at least a 20% reduction from baseline in weekly PN volume.\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00800384	Shockless Implant Evaluation	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)	10.1016/s0140-6736(14)61903-6	NA	15	2008-12-01	Completed	2009-01-01	2012-04-01	2015-02-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 3 years ]""}]	[See Results Section.]	NA
NCT00802425	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss	Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study	10.1097/mao.0000000000000466	https://www.ncbi.nlm.nih.gov/pubmed/24979398	13	2008-12-03	Completed	2008-12-01	2012-07-01	2014-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hearing loss\n[ Time Frame: 7 days ]\n\nAverage change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry""}]	NA	NA
NCT00803205	Study of Ataluren (PTC124™) in Cystic Fibrosis	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial	10.1016/s2213-2600(14)70100-6	https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(14)70100-6	36	2008-12-04	Completed	2009-07-01	2012-03-01	2014-05-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	NA
NCT00803309	Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial	10.1371/journal.pone.0128069	https://www.ncbi.nlm.nih.gov/pubmed/26057627?dopt=Abstract	9	2008-12-04	Terminated	2008-11-01	2012-09-01	2015-06-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)\n[ Time Frame: 48 weeks (arm A) or 36 weeks (arm B) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)\n[ Time Frame: 48 weeks (arm A) or 36 weeks (arm B) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)\n[ Time Frame: 48 weeks (arm A) or 36 weeks (arm B) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)\n[ Time Frame: 48 weeks (arm A) or 36 weeks (arm B) ]""}]	NA
NCT00803634	Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO)	10.1016/j.ahj.2013.12.023	https://www.ncbi.nlm.nih.gov/pubmed/?term=Clevidipine+in+acute+heart+failure%3A+Results+of+the+A+Study+of+Blood+Pressure+Control+in+Acute+Heart+Failure%E2%80%94A+Pilot+Study+(PRONTO)	19	2008-12-04	Completed	2008-12-01	2010-12-01	2014-01-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[See Results Section.]	NA
NCT00804102	Transcorneal Electrical Stimulation Therapy for Retinal Disease	Phosphene thresholds elicited by transcorneal electrical stimulation in healthy subjects and patients with retinal diseases	10.1167/iovs.12-9612	https://www.ncbi.nlm.nih.gov/pubmed/23049087?dopt=Abstract	5	2008-12-05	Completed	2008-01-01	2010-07-01	2012-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, enhanced visual acuity, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	NA	NA
NCT00807300	Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial	10.1007/s00270-018-2127-5	https://pubmed.ncbi.nlm.nih.gov/30488303/	5	2008-12-10	Completed	2006-10-01	2015-12-01	2018-11-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to progression\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to untreatable progression\n[ Time Frame: the follow up period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to untreatable progression\n[ Time Frame: the follow up period ]""}]	NA	NA
NCT00808236	Pre-ROSC Intra-Nasal Cooling Effectiveness	Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)	10.1161/circulationaha.109.931691	https://www.ncbi.nlm.nih.gov/pubmed/20679548?dopt=Abstract	6	2008-12-11	Completed	2008-11-01	2009-06-01	2010-08-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ROSC rate\n[ Time Frame: within 1 hour of arrest ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ROSC rate\n[ Time Frame: within 1 hour of arrest ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00810043	Medtronic SCORE Study - Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty	A randomized trial comparing 2 techniques of balloon kyphoplasty and curette use for obtaining vertebral body height restoration and angular-deformity correction in vertebral compression fractures due to osteoporosis	10.3174/ajnr.a3363	https://www.ncbi.nlm.nih.gov/pubmed/23179647	10	2008-12-15	Completed	2009-02-01	2010-10-01	2012-11-22	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compare vertebral body anatomy height restoration obtained after balloon kyphoplasty when 1) curette is used first followed by an inflatable bone tamp (IBT) and 2) the IBT is used first, followed by the curette, and then an IBT\n[ Time Frame: 48 hours post procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compare vertebral body anatomy height restoration obtained after balloon kyphoplasty when 1) curette is used first followed by an inflatable bone tamp (IBT) and 2) the IBT is used first, followed by the curette, and then an IBT\n[ Time Frame: 48-hr post procedure; 30-day ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00810472	Functional Antigen Matching in Corneal Transplantation	Rejection Prophylaxis in Corneal Transplant	10.3238/arztebl.2018.0259	https://pubmed.ncbi.nlm.nih.gov/29735006/	8	2008-12-17	Completed	2009-09-01	2012-01-01	2018-04-13	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first endothelial graft rejection.\n[ Time Frame: Mostly within the first six months. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first endothelial graft rejection.\n[ Time Frame: Mostly within the first six months. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first endothelial graft rejection.\n[ Time Frame: Mostly within the first six months. ]""}]	NA	NA
NCT00810992	Traditional Tibetan Medicine for Patients With Coronary Artery Disease	Weight reduction in patients with coronary artery disease: comparison of Traditional Tibetan Medicine and Western diet	10.1016/j.ijcard.2013.07.034	https://www.ncbi.nlm.nih.gov/pubmed/23890855?dopt=Abstract	9	2008-12-17	Completed	2009-01-01	2010-11-01	2013-07-26	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body mass index\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body mass index\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body mass index\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00811291	Influence of Vitamin-B-complex on Cognitive Ability of Kindergarten Kids	Three-month B vitamin supplementation in pre-school children affects folate status and homocysteine, but not cognitive performance	10.1007/s00394-013-0647-y	https://www.ncbi.nlm.nih.gov/pubmed/24481688	4	2008-12-17	Completed	2008-09-01	2009-08-01	2014-01-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in outcome of cognitive testing of kindergarten kids after intervention\n[ Time Frame: August 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in outcome of cognitive testing of kindergarten kids after intervention\n[ Time Frame: August 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in outcome of cognitive testing of kindergarten kids after intervention\n[ Time Frame: August 2009 ]""}]	NA	NA
NCT00811421	Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy	Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial	10.1371/journal.pmed.1001733	NA	9	2008-12-18	Completed	2009-09-01	2012-09-01	2014-09-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.\n[ Time Frame: day 0, birth ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.\n[ Time Frame: day 0, delivery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.\n[ Time Frame: day 0, birth ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.\n[ Time Frame: day 0, delivery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.\n[ Time Frame: day 0, birth ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.\n[ Time Frame: day 0, delivery ]""}]	NA	NA
NCT00811668	Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR	Anticyclic modulated ventilation versus continuous positive airway pressure in patients with coexisting obstructive sleep apnea and Cheyne-Stokes respiration: a randomized crossover trial	10.1016/j.sleep.2014.02.012	https://www.ncbi.nlm.nih.gov/pubmed/24841107	6	2008-12-18	Completed	2008-05-01	2009-02-01	2014-04-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""central apnea-hypopnea-index\n[ Time Frame: February 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""central apnea-hypopnea-index\n[ Time Frame: February 2009 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""central apnea-hypopnea-index\n[ Time Frame: February 2009 ]""}]	NA	NA
NCT00816660	Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial	10.1182/blood-2013-01-479527	http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=23777763	16	2009-01-02	Completed	2008-12-01	2010-10-01	2013-06-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after various doses of rVWF:rFVIII.\n[ Time Frame: approximately up to 9 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	NA
NCT00819286	Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain	Sternal closure with rigid plate fixation versus wire closure: a randomized controlled multicenter trial	10.1016/j.athoracsur.2012.07.085	https://www.ncbi.nlm.nih.gov/pubmed/23103010	12	2009-01-07	Completed	2008-12-01	2011-01-01	2012-10-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in anterior chest wall pain\n[ Time Frame: 3-6 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in anterior chest wall pain\n[ Time Frame: 3-6 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00822068	Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation	Short-term anomia training and electrical brain stimulation	10.1161/strokeaha.110.609032	https://www.ncbi.nlm.nih.gov/pubmed/21636820	1	2009-01-13	Unknown status	NA	NA	2011-06-02	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of words correctly named after training plus tDCS\n[ Time Frame: 1 year ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of words correctly named after training plus tDCS\n[ Time Frame: 1 year ]""}]
NCT00822393	Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial	10.1016/s2352-3026(19)30157-7	https://pubmed.ncbi.nlm.nih.gov/31606445/	21	2009-01-13	Completed	2008-11-01	2012-03-01	2019-10-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 1 year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 1 year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 2 years after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 2 years after transplantation ]""}]	NA
NCT00823212	The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions	A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial	10.1016/j.jacc.2011.02.016	https://www.ncbi.nlm.nih.gov/pubmed/21470815	23	2009-01-13	Completed	2009-01-01	2010-10-01	2011-04-04	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Twelve-month target lesion failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.\n[ Time Frame: 12-month post index procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Twelve-month target lesion failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.\n[ Time Frame: 12-month post index procedure ]""}]	[See Results Section.]	NA
NCT00827983	Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)	Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study	10.1016/j.fertnstert.2013.09.010	https://www.ncbi.nlm.nih.gov/pubmed/24140033?dopt=Abstract	6	2009-01-22	Completed	2009-01-01	2010-11-01	2013-10-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ongoing pregnancy rate at the end of the study\n[ Time Frame: 10 weeks after treatment start ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ongoing pregnancy rate at the end of the study\n[ Time Frame: 10 weeks after treatment start ]""}]	[See Results Section.]	NA	NA
NCT00831233	Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)	10.1159/000345423	https://www.ncbi.nlm.nih.gov/pubmed/23258223	9	2009-01-27	Terminated	2009-04-01	2010-07-01	2012-12-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LUTS relief based on reduction in IPSS (questionnaire)\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LUTS relief based on reduction in IPSS (questionnaire)\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00831688	Efficacy of Local Overpressure Treatment for Meniere's Disease	Effect of transtympanic low-pressure therapy in patients with unilateral Menière's disease unresponsive to betahistine: a randomised, placebo-controlled, double-blinded, clinical trial	10.1017/s0022215112000102	https://www.ncbi.nlm.nih.gov/pubmed/22365373	2	2009-01-28	Completed	2005-08-01	2009-04-01	2012-02-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in vertigo score from pre-therapy to post-therapy. (Vertigo score = summation of daily vertigo severity over 4 weeks. Daily vertigo score = a number between = and 4.)\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in vertigo score from pre-therapy to post-therapy. (Vertigo score = summation of daily vertigo severity over 4 weeks. Daily vertigo score = a number between = and 4.)\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in vertigo score from pre-therapy to post-therapy. (Vertigo score = summation of daily vertigo severity over 4 weeks. Daily vertigo score = a number between = and 4.)\n[ Time Frame: 4 months ]""}]	NA	NA
NCT00832039	Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis	Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial	10.1001/jamainternmed.2016.2514	http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2534154	10	2009-01-28	Completed	2009-11-01	2013-03-01	2016-09-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 28 days ]""}]	NA	NA
NCT00833248	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide	10.1016/j.clon.2012.09.010	https://www.ncbi.nlm.nih.gov/pubmed/23257248?dopt=Abstract	13	2009-01-30	Completed	2009-04-01	2011-06-01	2012-12-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean percentage reduction in prostate volume\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean percentage reduction in prostate volume\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[See Results Section.]	NA	NA
NCT00833612	Counterpulsation Reduces Infarct Size Pre-PCI for AMI	Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial	10.1001/jama.2011.1280	https://www.ncbi.nlm.nih.gov/pubmed/21878431?dopt=Abstract	5	2009-01-30	Completed	2008-12-01	2010-10-01	2011-08-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine whether IABC before mechanical reperfusion decreases myocardial infarct (MI) size.\n[ Time Frame: 3-5 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine whether IABC before mechanical reperfusion decreases myocardial infarct (MI) size.\n[ Time Frame: 3-5 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine whether IABC before mechanical reperfusion decreases myocardial infarct (MI) size.\n[ Time Frame: 3-5 days ]""}]	NA	NA
NCT00833768	A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003885-16/results	5	2009-01-29	Terminated	2009-01-01	2009-09-01	2010-03-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the efficacy and safety of sevelamer carbonate and placebo dosed three times per day (TID) on serum phosphorus levels\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the efficacy and safety of sevelamer carbonate and placebo dosed three times per day (TID) on serum phosphorus levels\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the efficacy and safety of sevelamer carbonate and placebo dosed three times per day (TID) on serum phosphorus levels\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the efficacy and safety of sevelamer carbonate and placebo dosed three times per day (TID) on serum phosphorus levels\n[ Time Frame: 24 weeks ]""}]	NA
NCT00835978	Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial	10.1016/s1470-2045(13)70464-9	http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70464-9/fulltext	84	2009-02-02	Completed	2009-03-01	2012-10-01	2013-10-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[See Results Section.]	NA
NCT00837564	Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression	Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Chronic Major Depression	10.1159/000381957	https://www.ncbi.nlm.nih.gov/pubmed/?term=Cognitive+Behavioral+Analysis+System+of+Psychotherapy+versus+Escitalopram+in+Chronic+Major+Depression	2	2009-02-04	Unknown status	2009-02-01	NA	2015-05-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptomatology after 8 weeks after randomization as measured by the MADRS\n[ Time Frame: 8 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptomatology after 8 weeks after randomization as measured by the MADRS\n[ Time Frame: 8 weeks ]""}]
NCT00837603	Physical Training in Transposition of the Great Arteries	Symmetrical dimethylarginine is superior to NT-proBNP for detecting systemic ventricular dysfunction in adults after atrial repair for transposition of the great arteries	10.1016/j.ijcard.2013.05.030	NA	3	2009-02-04	Completed	2009-02-01	2010-09-01	2013-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""}]	NA	NA
NCT00841256	Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children	High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study	10.1016/j.jaci.2012.06.047	https://pubmed.ncbi.nlm.nih.gov/22939758/	11	2009-02-10	Completed	NA	2013-08-01	2012-08-29	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score\n[ Time Frame: After 1 year of treatment ]\n\nThe change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score\n[ Time Frame: After 1 year of treatment ]\n\nThe change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.""}]
NCT00843297	COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest	Invasive versus non-invasive cooling after in- and out-of-hospital cardiac arrest: a randomized trial	10.1007/s00392-013-0572-3	https://link.springer.com/article/10.1007/s00392-013-0572-3	2	2009-02-12	Completed	2008-04-01	2009-12-01	2013-05-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to reach the target temperature\n[ Time Frame: Twenty-four hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NSE as a parameter for cerebral damage\n[ Time Frame: Seventy-two hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to reach the target temperature\n[ Time Frame: Twenty-four hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NSE as a parameter for cerebral damage\n[ Time Frame: Seventy-two hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to reach the target temperature\n[ Time Frame: Twenty-four hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NSE as a parameter for cerebral damage\n[ Time Frame: Seventy-two hours ]""}]	NA	NA
NCT00844142	Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)	Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers	10.1186/ar4464	https://www.ncbi.nlm.nih.gov/pubmed/24476416?dopt=Abstract	1	2009-02-12	Unknown status	NA	NA	2014-01-30	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome: Reduction of active inflammatory lesions in MRI at 12 months.\n[ Time Frame: 108 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome: Reduction of active inflammatory lesions in MRI at 12 months.\n[ Time Frame: 108 weeks ]""}]
NCT00844649	Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine	10.1056/nejmoa1304369	https://www.ncbi.nlm.nih.gov/pubmed/24131140?dopt=Abstract	62	2009-02-13	Completed	2009-03-01	2012-12-01	2013-10-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""the primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and gemcitabine versus gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and Gemcitabine versus Gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and Gemcitabine versus Gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[See Results Section.]	NA
NCT00847444	Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer	10.1016/j.clbc.2016.11.008	https://www.sciencedirect.com/science/article/abs/pii/S1526820916302579	2	2009-02-17	Unknown status	2009-02-01	NA	2017-01-10	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary objective of this study is to compare disease free survival after randomisation in patients treated with a combination of 5-FU/Epirubicine/Cyclophosphamide followed by Docetaxel vs. Docetaxel/Cyclophosphamide\n[ Time Frame: 60 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary objective of this study is to compare disease free survival after randomisation in patients treated with a combination of 5-FU/Epirubicine/Cyclophosphamide followed by Docetaxel vs. Docetaxel/Cyclophosphamide\n[ Time Frame: 60 months ]""}]
NCT00849667	Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse	10.1200/jco.2015.63.2596	http://ascopubs.org/doi/full/10.1200/jco.2015.63.2596	63	2009-02-20	Completed	2009-03-01	2012-09-01	2016-07-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival using by RECIST\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival using by RECIST\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival using by RECIST\n[ Time Frame: 3 years ]""}]	NA	NA
NCT00850629	Hormonal Regulation of Body Weight Maintenance	Hormonal regulatory mechanisms in obese children and adolescents after previous weight reduction with a lifestyle intervention: maintain - paediatric part - a RCT from 2009-15	10.1186/s40608-016-0110-8	https://pubmed.ncbi.nlm.nih.gov/27298729/	4	2009-02-24	Completed	2009-10-01	2012-07-01	2016-06-10	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight regain during lifestyle intervention in children, adolescents and adults vs. placebo\n[ Time Frame: 18 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight regain during lifestyle intervention in children, adolescents and adults vs. placebo\n[ Time Frame: 18 month ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""BMI will be assessed during lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo\n[ Time Frame: 21 months ]\n\nBMI (kg/m2) will be analyzed after intentional weight loss in two comparable parts of a randomized controlled trial including (1) children and adolescents and (2) adults. Therefore effects of a multimodal lifestyle intervention will be compared to placebo.""}]	NA
NCT00852670	ACT-128800 in Psoriasis	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001443-19/results	4	2009-02-26	Completed	2008-10-01	2009-06-01	2011-01-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.\n[ Time Frame: Baseline to week 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.\n[ Time Frame: Baseline to week 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.\n[ Time Frame: Baseline to week 6 ]""}]	NA	NA
NCT00862511	Serum Metal Ion Concentration After Total Knee Arthroplasty (TKA)	Midterm Results After Coated and Uncoated TKA: A Randomized Controlled Study	10.3928/01477447-20160509-10	https://www.healio.com/orthopedics/journals/ortho/2016-5-39-3-supplemental/%7B690c5cdd-d69e-4f90-adcf-c896b76e81cf%7D/midterm-results-after-coated-and-uncoated-tka-a-randomized-controlled-study	5	2009-03-16	Completed	2009-03-01	2012-12-01	2016-05-26	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Metal ion concentration in serum after TKA (Cr, Co, Mb, Ni)\n[ Time Frame: 1 y and 5y ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Metal ion concentration in serum after TKA (Cr, Co, Mb, Ni)\n[ Time Frame: 1 y and 5y ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Metal ion concentration in serum after TKA (Cr, Co, Mb, Ni)\n[ Time Frame: 1 y and 5y ]""}]	NA
NCT00864253	A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma	10.1093/annonc/mdv324	https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv324	38	2009-03-17	Completed	2009-04-01	2011-06-01	2015-09-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is progression-free survival (PFS) based on a blinded radiology assessment of response using RECIST response guidelines.\n[ Time Frame: Every 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is progression-free survival (PFS) based on a blinded radiology assessment of response using RECIST response guidelines.\n[ Time Frame: Every 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00867672	Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial	10.1200/jco.19.01053	https://pubmed.ncbi.nlm.nih.gov/31794324/	8	2009-03-23	Completed	2011-11-01	2015-02-01	2019-12-03	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	NA	NA
NCT00867750	SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma	Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma	10.1111/liv.12750	https://www.ncbi.nlm.nih.gov/pubmed/25443863	4	2009-03-20	Completed	2006-03-01	2011-06-01	2015-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life (HRQL)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life (HRQL)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life (HRQL)\n[ Time Frame: 9 months ]""}]	NA	NA
NCT00868166	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS	A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis	10.1111/ene.12344	http://onlinelibrary.wiley.com/doi/10.1111/ene.12344/full	8	2009-03-23	Completed	2009-04-01	2011-04-01	2014-01-21	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[See Results Section.]	NA
NCT00869726	A Study for Patients With Secondary Progressive Multiple Sclerosis	A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS	10.1212/wnl.0b013e318233b240	NA	4	2009-03-24	Completed	2004-12-01	2009-06-01	2011-10-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).\n[ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).\n[ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).\n[ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos ]""}]	NA	NA
NCT00872612	Trial for the Diagnosis of Sarcoidosis	Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial	10.1001/jama.2013.5823	http://jamanetwork.com/journals/jama/fullarticle/1697962	6	2009-03-30	Completed	2009-03-01	2011-11-01	2013-06-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The role of endosonography (EBUS/ EUS - FNA) in demonstrating non-caseating granulomas in comparison with conventional bronchoscopy (TBLB + EBB)\n[ Time Frame: within a week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The role of endosonography (EBUS/ EUS - FNA) in demonstrating non-caseating granulomas in comparison with conventional bronchoscopy (TBLB + EBB)\n[ Time Frame: within a week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The role of endosonography (EBUS/ EUS - FNA) in demonstrating non-caseating granulomas in comparison with conventional bronchoscopy (TBLB + EBB)\n[ Time Frame: within a week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The role of endosonography (EBUS/ EUS - FNA) in demonstrating non-caseating granulomas in comparison with conventional bronchoscopy (TBLB + EBB)\n[ Time Frame: within a week ]""}]	NA
NCT00872716	Quetiapine in Specific Phobia	Acute anxiolytic effects of quetiapine during virtual reality exposure--a double-blind placebo-controlled trial in patients with specific phobia	10.1016/j.euroneuro.2013.01.001	https://www.ncbi.nlm.nih.gov/pubmed/23375006	6	2009-03-30	Completed	2009-04-01	2011-03-01	2013-01-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VAS-Anxiety\n[ Time Frame: on study day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VAS-Anxiety\n[ Time Frame: on study day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VAS-Anxiety\n[ Time Frame: on study day ]""}]	NA	NA
NCT00873119	Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial	10.1002/cncr.29229	http://onlinelibrary.wiley.com/doi/10.1002/cncr.29229/full	13	2009-03-31	Completed	2009-02-01	2012-02-01	2015-01-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival measured by RECIST criteria\n[ Time Frame: May 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival measured by RECIST criteria\n[ Time Frame: May 2010 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00874107	Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)	A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer	10.1186/s40425-018-0324-z	NA	18	2009-04-01	Completed	2009-06-01	2013-07-01	2018-02-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	NA	NA
NCT00874848	Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer	10.1007/s10637-017-0450-3	NA	18	2009-04-02	Completed	2009-08-01	2012-07-01	2017-03-16	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[See Results Section.]	NA	NA
NCT00875914	Magnetically Navigated vs. Manually Guided Radiofrequency in Atrioventricular-node-reentry-tachycardia	Multicenter, randomized comparison between magnetically navigated and manually guided radiofrequency ablation of atrioventricular nodal reentrant tachycardia (the MagMa-AVNRT-trial)	10.1007/s00392-017-1144-8	https://www.ncbi.nlm.nih.gov/pubmed/28849269	4	2009-04-03	Completed	2009-04-01	2012-03-01	2017-08-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total x-ray time and dose for patient\n[ Time Frame: electrophysiological examination ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total x-ray time and dose for patient\n[ Time Frame: electrophysiological examination ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total x-ray time and dose for patient\n[ Time Frame: electrophysiological examination ]""}]	NA	NA
NCT00875992	Trial to Evaluate the Effectiveness of Angular Stable Locking System (ASLS) in Patients With Distal Tibial Fractures	Evaluation of the effectiveness of the angular stable locking system in patients with distal tibial fractures treated with intramedullary nailing: a multicenter randomized controlled trial	10.2106/jbjs.m.01355	https://www.ncbi.nlm.nih.gov/pubmed/25410507?dopt=Abstract	5	2009-04-03	Completed	2009-06-01	2012-03-01	2014-11-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to pain free full weight bearing\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to pain free full weight bearing\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to pain free full weight bearing\n[ Time Frame: 1 year ]""}]	NA	NA
NCT00876720	Effectiveness Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus	Efficacy of different protocols of transcranial magnetic stimulation for the treatment of tinnitus: Pooled analysis of two randomized controlled studies	10.3109/15622975.2012.708438	https://www.ncbi.nlm.nih.gov/pubmed/22909265	3	2009-04-06	Completed	2009-04-01	2010-08-01	2012-08-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	NA	NA
NCT00879229	ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis	Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model	10.1016/j.rmed.2014.12.011	http://www.resmedjournal.com/article/S0954-6111(14)00449-1/fulltext	12	2009-04-08	Terminated	2009-07-01	2011-05-01	2015-01-03	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in six-minute walk distance (6MWD).\n[ Time Frame: 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in six-minute walk distance (6MWD).\n[ Time Frame: 16 weeks ]""}]	[See Results Section.]	NA	NA
NCT00880724	European Multi-center Post Market Study of the IBV Valve System	Multicentre European study for the treatment of advanced emphysema with bronchial valves	10.1183/09031936.00019711	http://erj.ersjournals.com/content/39/6/1319	3	2009-04-13	Completed	2007-03-01	2009-12-01	2012-06-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference between the response rates of the treatment and control groups.\n[ Time Frame: 3-months post randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference between the response rates of the treatment and control groups.\n[ Time Frame: 3-months post randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference between the response rates of the treatment and control groups.\n[ Time Frame: 3-months post randomization ]""}]	NA
NCT00882375	Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy	At 68 years, unrecognised sleep apnoea is associated with elevated ambulatory blood pressure	10.1183/09031936.00162710	https://www.ncbi.nlm.nih.gov/pubmed/22523363?dopt=Abstract	12	2009-04-15	Completed	2009-03-01	2010-06-01	2012-04-20	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.\n[ Time Frame: at weeks 2, 6, 24 and 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.\n[ Time Frame: at weeks 2, 6, 24 and 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.\n[ Time Frame: at weeks 2, 6, 24 and 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.\n[ Time Frame: at weeks 2, 6, 24 and 52 ]""}]	NA
NCT00886704	Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis	Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index	10.1017/s0007114510001054	https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-a-convenience-drink-fortified-with-n3-fatty-acids-on-the-n3-index/A283F41DD8F75D19ED12B14619561443	4	2009-04-22	Completed	2009-04-01	2009-08-01	2010-04-27	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Omega-3 Index\n[ Time Frame: day one and at 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Omega-3 Index\n[ Time Frame: day one and at 8 weeks ]""}]	NA	[See Results Section.]	NA
NCT00887978	Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial	10.1378/chest.12-2875	https://www.ncbi.nlm.nih.gov/pubmed/23669822?dopt=Abstract	9	2009-04-23	Completed	2009-06-01	2011-07-01	2013-09-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 6-minute walk distance from Baseline to Week 16""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 6-minute walk distance from Baseline to Week 16""}]	[See Results Section.]	NA	NA
NCT00888433	Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?	10.1097/hjh.0b013e328344db3a	NA	8	2009-04-24	Completed	2009-06-01	2010-09-01	2011-05-01	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood Pressure Reduction\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood Pressure Reduction\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00888940	Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery	A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)	10.1016/j.jtcvs.2011.06.001	https://linkinghub.elsevier.com/retrieve/pii/S0022-5223(11)00600-3	7	2009-04-26	Completed	2009-06-01	2010-01-01	2011-07-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate the relative efficacy of ecallantide and Cyklokapron(R) in the reduction of blood loss in subjects undergoing cardiac surgery including the use of CPB, associated with a high risk of bleeding.\n[ Time Frame: Over the duration of the study. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate the relative efficacy of ecallantide and Cyklokapron(R) in the reduction of blood loss in subjects undergoing cardiac surgery including the use of CPB, associated with a high risk of bleeding.\n[ Time Frame: Over the duration of the study. ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00889343	Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer	NA	10.1200/jco.2013.31.15_suppl.3586	http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3586	6	2009-04-27	Terminated	2009-03-01	2011-11-01	2013-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo\n[ Time Frame: 6 to 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo\n[ Time Frame: 6 to 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo\n[ Time Frame: 6 to 12 months ]""}]	NA	NA
NCT00891826	Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability	Heart rate variability and Omega-3 Index in euthymic patients with bipolar disorders	10.1016/j.eurpsy.2014.11.010	https://www.ncbi.nlm.nih.gov/pubmed/?term=Heart+rate+variability+and+Omega-3+Index+in+euthymic+patients+with+bipolar+disorders	3	2009-04-30	Completed	2009-04-01	2012-06-01	2014-12-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SDNN (msec)\n[ Time Frame: at baseline and after 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SDNN (msec)\n[ Time Frame: at baseline and after 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SDNN (msec)\n[ Time Frame: at baseline and after 12 weeks ]""}]	NA	NA
NCT00893373	Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial	10.1016/s1470-2045(15)00362-9	https://pubmed.ncbi.nlm.nih.gov/26549589/	4	2009-05-04	Completed	2009-03-01	2011-11-01	2015-11-06	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""}]	NA
NCT00893867	Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke	Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke	10.1161/strokeaha.111.000013	https://www.ncbi.nlm.nih.gov/pubmed/23391764	14	2009-05-05	Terminated	2009-12-01	2012-04-01	2013-02-07	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin Scale (mRS) categorical analysis (\""shift\"")\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin Scale (mRS) categorical analysis (\""shift\"")\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin Scale (mRS) categorical analysis (\""shift\"")\n[ Time Frame: 90 days ]""}]	NA	NA
NCT00895609	Sugammadex and Neostigmine at Shallow Neuromuscular Blockade	Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block	10.1097/aln.0b013e3181f4182a	http://anesthesiology.pubs.asahq.org/Article.aspx?articleid=1933132	3	2009-05-07	Completed	2009-03-01	2009-08-01	2010-11-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to TOF-ratio 0.9 following the investigational drug\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to TOF-ratio 0.9 following the investigational drug\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to TOF-ratio 0.9 following the investigational drug\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	NA
NCT00895778	Neuromuscular Blockade Improves Surgical Conditions	Neuromuscular blockade improves surgical conditions (NISCO)	10.1007/s00464-014-3711-7	https://www.ncbi.nlm.nih.gov/pubmed/25125097?dopt=Abstract	3	2009-05-07	Completed	2009-03-01	2010-12-01	2014-08-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative patient-controlled analgesic demand for adequate pain control\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative patient-controlled analgesic demand for adequate pain control\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative patient-controlled analgesic demand for adequate pain control\n[ Time Frame: Regular anesthesia time, approximately 1 hour ]""}]	NA	NA
NCT00895830	Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)	Intravenous buspirone for the prevention of postoperative nausea and vomiting	10.1007/s00228-012-1284-8	https://link.springer.com/article/10.1007%2Fs00228-012-1284-8	6	2009-05-07	Completed	2009-05-01	2009-11-01	2012-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[See Results Section.]	NA	NA
NCT00900146	Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients	Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial	10.1161/circulationaha.112.122556	NA	7	2009-05-11	Terminated	2009-04-01	2012-05-01	2012-11-05	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess safety and tolerability of four doses of ACZ885 vs. placebo over 4 months in patients with T2DM To assess the effect on HbA1c of four doses of ACZ885 vs. placebo as an add-on regimen over 4 months in patients with T2DM\n[ Time Frame: 4 months ]""}]	[See Results Section.]	NA	NA	NA
NCT00902876	A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions	Treatment of gingival recession defects with a coronally advanced flap and a xenogeneic collagen matrix: a multicenter randomized clinical trial	10.1111/jcpe.12019	https://www.ncbi.nlm.nih.gov/pubmed/23050490	5	2009-05-14	Completed	2009-03-01	2011-07-01	2012-10-10	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of root coverage\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of root coverage\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of root coverage\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of root coverage\n[ Time Frame: 6 month ]""}]	NA
NCT00902889	Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease	Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease	10.1007/s00429-014-0805-x	https://www.ncbi.nlm.nih.gov/pubmed/24878825	5	2009-05-14	Completed	2009-05-01	2010-04-01	2014-05-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of stimulation of GPI versus GPR (UHDRS Scale)\n[ Time Frame: 3 months after stimulation treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of stimulation of GPI versus GPR (UHDRS Scale)\n[ Time Frame: 3 months after stimulation treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of stimulation of GPI versus GPR (UHDRS Scale)\n[ Time Frame: 3 months after stimulation treatment ]""}]	NA	NA
NCT00902941	Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline	Effects of rasagiline on olfactory function in patients with Parkinson’s disease	10.1002/mds.25661	http://onlinelibrary.wiley.com/doi/10.1002/mds.25661/full	5	2009-05-14	Completed	2009-05-01	2012-02-01	2013-11-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""olfactory function\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""olfactory function\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""olfactory function\n[ Time Frame: 4 months ]""}]	NA	NA
NCT00903331	Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial	10.1183/09031936.00104612	NA	27	2009-05-15	Completed	2009-05-01	2011-06-01	2013-05-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[See Results Section.]	NA
NCT00905268	A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients	The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms	10.1161/circulationaha.111.059477	https://www.ncbi.nlm.nih.gov/pubmed/?term=MICONOS	4	2009-05-19	Completed	2006-04-01	2009-12-01	2012-02-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]\n\n(Where the patient populations are not normally distributed for ICARS the responder analysis will be used as the primary endpoint and a clinically relevant margin of 2.5 ICARS points will be applied)""}]	[See Results Section.]	NA
NCT00905840	A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants	A double-blind randomized controlled trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV small-diameter bone level implants in edentulous mandibles--results from a 1-year observation period	10.1111/j.1708-8208.2010.00324.x	https://www.ncbi.nlm.nih.gov/pubmed/21414131	7	2009-05-20	Completed	2007-11-01	2009-10-01	2011-03-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00906763	Effects of Chocolate on Motor Symptoms of Parkinson's Disease	Comparison of chocolate to cacao-free white chocolate in Parkinson's disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial	10.1007/s00415-012-6527-1	https://link.springer.com/article/10.1007/s00415-012-6527-1	2	2009-05-20	Unknown status	2009-05-01	NA	2012-05-15	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""UPDRS part III\n[ Time Frame: 1 h after intake of study intervention ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""UPDRS part III\n[ Time Frame: 1 h after intake of study intervention ]""}]
NCT00908362	Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers	Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial	10.1186/1465-9921-14-114	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00908362	2	2009-05-22	Completed	2009-05-01	2009-10-01	2013-10-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number and the CCR7 expression of DCs in bronchoalveolar lavage fluid before and after therapy with fluticasone or fluticasone/salmeterol, as compared to placebo.\n[ Time Frame: 2 time points (A and B). Time point A: day 0 (directly before the inhalation therapy). Time point B: day 29 (directly after the inhalation therapy). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number and the CCR7 expression of DCs in bronchoalveolar lavage fluid before and after therapy with fluticasone or fluticasone/salmeterol, as compared to placebo.\n[ Time Frame: 2 time points (A and B). Time point A: day 0 (directly before the inhalation therapy). Time point B: day 29 (directly after the inhalation therapy). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number and the CCR7 expression of DCs in bronchoalveolar lavage fluid before and after therapy with fluticasone or fluticasone/salmeterol, as compared to placebo.\n[ Time Frame: 2 time points (A and B). Time point A: day 0 (directly before the inhalation therapy). Time point B: day 29 (directly after the inhalation therapy). ]""}]	NA	NA
NCT00909532	Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation	10.1056/nejmoa1105185	NA	14	2009-05-26	Completed	2009-05-01	2010-07-01	2011-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	NA
NCT00909727	Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation	Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation	10.1164/rccm.201301-0153oc	http://www.atsjournals.org/doi/abs/10.1164/rccm.201301-0153OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&	16	2009-05-26	Completed	2009-06-01	2010-02-01	2013-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	NA	NA
NCT00913029	Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)	Prospective unmasked randomized evaluation of the iStent inject (®) versus two ocular hypotensive agents in patients with primary open-angle glaucoma	10.2147/opth.s59932	https://www.ncbi.nlm.nih.gov/pubmed/24855336?dopt=Abstract	6	2009-06-02	Completed	2009-05-01	2011-03-01	2014-05-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean intraocular pressure (IOP)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean intraocular pressure (IOP)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean intraocular pressure (IOP)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean intraocular pressure (IOP)\n[ Time Frame: 1 year ]""}]	NA
NCT00913744	Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion	Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration	10.1016/j.ophtha.2014.10.006	NA	13	2009-06-03	Completed	2009-12-01	2012-12-01	2014-11-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with release of focal vitreomacular adhesion by day 28 as determined by masked Central Reading Center\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with release of focal vitreomacular adhesion by day 28 as determined by masked Central Reading Center\n[ Time Frame: Day 28 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00915252	Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)	Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study	10.1371/journal.pone.0052695	https://www.ncbi.nlm.nih.gov/pubmed/23300745?dopt=Abstract	6	2009-06-04	Completed	2009-07-01	2012-12-01	2012-12-31	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Event Free Survival (EFS) of all AML patients\n[ Time Frame: continously up to 12 months after start of study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Event Free Survival (EFS) of all AML patients\n[ Time Frame: continously up to 12 months after start of study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Event Free Survival (EFS) of all AML patients\n[ Time Frame: continously up to 12 months after start of study ]""}]	NA	NA
NCT00916409	Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial	10.1001/jama.2017.18718	https://pubmed.ncbi.nlm.nih.gov/29260225/	123	2009-06-08	Completed	2009-06-01	2015-01-01	2017-12-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 5 years ]""}]	NA	NA
NCT00917046	The SMARTEX Heart Failure Study	High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction	10.1161/circulationaha.116.022924	https://www.ncbi.nlm.nih.gov/pubmed/28082387?dopt=Abstract	16	2009-06-09	Completed	2009-01-01	2013-06-01	2017-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac volumes and functions (reverse remodeling and improved left ventricular function)\n[ Time Frame: Baseline-12 weeks- 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac volumes and functions (reverse remodeling and improved left ventricular function)\n[ Time Frame: Baseline-12 weeks- 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks\n[ Time Frame: Baseline-12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks\n[ Time Frame: Baseline-12 weeks ]""}]	NA
NCT00918619	Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection	Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619)	10.1007/s00423-014-1203-9	https://www.ncbi.nlm.nih.gov/pubmed/24880345?dopt=Abstract	7	2009-06-09	Completed	2010-01-01	2010-11-01	2014-06-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with hemostasis 3 minutes after application of the haemostat product\n[ Time Frame: 3 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with hemostasis 3 minutes after application of the haemostat product\n[ Time Frame: 3 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with hemostasis 3 minutes after application of the haemostat product\n[ Time Frame: 3 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with hemostasis 3 minutes after application of the haemostat product\n[ Time Frame: 3 minutes ]""}]	NA
NCT00919295	Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome	Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study	10.1345/aph.1r725	http://journals.sagepub.com/doi/pdf/10.1345/aph.1R725	6	2009-06-11	Completed	2008-12-01	2011-10-01	2013-06-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"".\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"".\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"" and pain responders (>= 30% PVAS reduction).\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	NA	NA
NCT00920504	Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program	Results of a randomized controlled pilot study of a self-management intervention for cancer pain	10.1016/j.ejon.2012.08.002	http://www.sciencedirect.com/science/article/pii/S1462388912000828?via%3Dihub	4	2009-06-12	Completed	2009-06-01	2011-06-01	2013-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average and worst pain as reported daily by patients on a scale from 0 (no pain) to 10 (worst imaginable pain)\n[ Time Frame: measured daily for 10 weeks and in week 14 and 22 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average and worst pain as reported daily by patients on a scale from 0 (no pain) to 10 (worst imaginable pain)\n[ Time Frame: measured daily for 10 weeks and in week 14 and 22 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average and worst pain as reported daily by patients on a scale from 0 (no pain) to 10 (worst imaginable pain)\n[ Time Frame: measured daily for 10 weeks and in week 14 and 22 ]""}]	NA	NA
NCT00923793	Comparison of Individual Computer Aided Design/Manufactured (CAD/CAM) - Based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty	Cranioplasty using custom-made hydroxyapatite versus titanium: a randomized clinical trial	10.3171/2015.10.jns151245	https://pubmed.ncbi.nlm.nih.gov/26918471/	3	2009-06-17	Terminated	2009-06-01	2014-04-01	2016-02-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the rate of local and/or systemic infections (acute/chronic) in both study arms within the first 6 months after operation.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the rate of local and/or systemic infections (acute/chronic) in both study arms within the first 6 months after operation.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the rate of local and/or systemic infections (acute/chronic) in both study arms within the first 6 months after operation.\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00924638	Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke	Cryptogenic stroke and underlying atrial fibrillation	10.1056/nejmoa1313600	https://www.ncbi.nlm.nih.gov/pubmed/24963567	8	2009-06-18	Completed	2009-06-01	2013-05-01	2014-06-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00924989	A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study	10.1016/s1470-2045(15)70081-1	https://www.ncbi.nlm.nih.gov/pubmed/25795408?dopt=Abstract	34	2009-06-18	Completed	2009-08-01	2013-11-01	2015-03-18	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 vs placebo\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 versus placebo\n[ Time Frame: 33 months ]\n\nTime from date of randomization until time of documented death""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 versus placebo\n[ Time Frame: 33 months ]\n\nTime from date of randomization until time of documented death""}]	NA
NCT00925301	Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease	Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat	10.1056/nejmoa1510198	https://doi.org/10.1056/NEJMoa1510198	56	2009-06-19	Completed	2009-08-01	2012-07-01	2016-08-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00927173	Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder	Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial	10.1002/wps.20199	https://www.ncbi.nlm.nih.gov/pubmed/25655160	25	2009-06-23	Completed	2009-09-01	2011-12-01	2015-02-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 5 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 5 weeks ]""}]	NA
NCT00927836	AXIS 2: AX200 for the Treatment of Ischemic Stroke	Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial	10.1161/strokeaha.113.001531	https://www.ncbi.nlm.nih.gov/pubmed/23963331	12	2009-06-24	Completed	2009-05-01	2011-11-01	2013-08-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement on mRS relative to placebo-treated patients\n[ Time Frame: day 90 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement on mRS relative to placebo-treated patients\n[ Time Frame: day 90 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement on mRS relative to placebo-treated patients\n[ Time Frame: day 90 ]""}]	NA	NA
NCT00928915	International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage	Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial	10.1016/s1474-4422(16)00110-1	https://pubmed.ncbi.nlm.nih.gov/27302126/	7	2009-06-25	Completed	NA	NA	2016-04-11	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""INR ≤ 1.2 within 3 hours after start of drug infusion\n[ Time Frame: 3 hours ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""INR ≤ 1.2 within 3 hours after start of drug infusion\n[ Time Frame: 3 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""INR ≤ 1.2 within 3 hours after start of drug infusion\n[ Time Frame: 3 hours ]""}]
NCT00930813	LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis	The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty	10.1016/j.jcin.2013.05.022	http://www.sciencedirect.com/science/article/pii/S1936879813015306?via%3Dihub	9	2009-06-30	Completed	2009-06-01	2010-06-01	2014-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00931463	A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen	Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study	10.1016/s0140-6736(13)61164-2	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61164-2/abstract	9	2009-07-01	Completed	2009-09-01	2012-09-01	2013-06-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[See Results Section.]	NA
NCT00932100	A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study	10.4244/eijy14m06_01	https://www.ncbi.nlm.nih.gov/pubmed/24929350?dopt=Abstract	7	2009-07-02	Completed	2009-07-01	2011-01-01	2014-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The composite incidence of major and minor bleeding\n[ Time Frame: Through Day 30 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The composite incidence of major and minor bleeding\n[ Time Frame: Through Day 30 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The composite incidence of major and minor bleeding\n[ Time Frame: Through Day 30 ]""}]	NA	NA
NCT00932893	An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer	10.1056/nejmoa1214886	https://www.ncbi.nlm.nih.gov/pubmed/23724913?dopt=Abstract	86	2009-07-02	Completed	2009-09-01	2012-06-01	2013-06-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[See Results Section.]	NA
NCT00932971	HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial	10.1016/s1473-3099(18)30663-7	https://pubmed.ncbi.nlm.nih.gov/30833068/	10	2009-07-06	Completed	2009-06-01	2017-05-01	2019-02-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Negativation of HDV-RNA at the end of therapy\n[ Time Frame: week 96 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Negativation of HDV-RNA at the end of therapy\n[ Time Frame: week 96 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Negativation of HDV-RNA at the end of therapy\n[ Time Frame: week 96 ]""}]	NA	NA
NCT00933218	Beer, Marathon, Genetics, Inflammation and the Cardiovascular System: Be-MaGIC-Trial	72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon	10.1249/mss.0b013e31821b12eb	NA	2	2009-07-06	Completed	2009-06-01	2009-11-01	2011-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker: Interleukin 6 and Interleukin 10\n[ Time Frame: pre-, post-, one & three day follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker: Interleukin 6 and Interleukin 10\n[ Time Frame: pre-, post-, one & three day follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker: Interleukin 6 and Interleukin 10\n[ Time Frame: pre-, post-, one & three day follow-up ]""}]	NA	NA
NCT00934687	Botulinum Toxin for the Treatment of Depression	Facing depression with botulinum toxin: a randomized controlled trial	10.1016/j.jpsychires.2012.01.027	NA	5	2009-07-07	Completed	2009-08-01	2011-04-01	2012-02-24	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (reduction in Ham-D score by >30% compared to baseline)\n[ Time Frame: six weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (reduction in Ham-D score by >30% compared to baseline)\n[ Time Frame: six weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (reduction in Ham-D score by >30% compared to baseline)\n[ Time Frame: six weeks ]""}]	NA
NCT00938743	Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine	Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine	10.1016/j.eurpsy.2012.08.001	https://www.ncbi.nlm.nih.gov/pubmed/23062837	2	2009-07-13	Completed	2008-01-01	2009-12-01	2012-10-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standardized practical driving test\n[ Time Frame: 1/2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standardized practical driving test\n[ Time Frame: 1/2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standardized practical driving test\n[ Time Frame: 1/2010 ]""}]	NA	NA
NCT00940095	Clazosentan in Aneurysmal Subarachnoid Hemorrhage	Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling	10.1161/strokeaha.111.648980	https://www.ncbi.nlm.nih.gov/pubmed/22403047	26	2009-07-14	Terminated	2009-07-01	2010-10-01	2012-03-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol\n[ Time Frame: Within 6 weeks post-aSAH ]""}]	NA
NCT00941213	Monopolar Electrosurgery Versus Ultrasound Scissors in Thoracoscopic Ventral Spondylodesis	Blood loss and operative duration using monopolar electrosurgery versus ultrasound scissors for surgical preparation during thoracoscopic ventral spondylodesis: results of a randomized, blinded, controlled trial	10.1007/s00586-014-3303-1	https://www.ncbi.nlm.nih.gov/pubmed/24760465	2	2009-07-16	Unknown status	NA	NA	2014-04-24	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""duration of the operation\n[ Time Frame: end of the scin suture at the end of operation ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""duration of the operation\n[ Time Frame: end of the scin suture at the end of operation ]""}]
NCT00941460	Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial	10.1158/1078-0432.ccr-14-2737	https://www.ncbi.nlm.nih.gov/pubmed/25655102	5	2009-07-16	Completed	2009-09-01	2012-08-01	2015-02-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.\n[ Time Frame: up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.\n[ Time Frame: up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.\n[ Time Frame: up to one year ]""}]	NA	NA
NCT00941733	Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia	Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial	10.1016/j.jacc.2014.06.1198	https://pubmed.ncbi.nlm.nih.gov/25301459/	14	2009-07-17	Completed	2009-09-01	2013-08-01	2014-10-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00943111	A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)	Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial	10.1016/s0140-6736(14)61841-9	https://www.ncbi.nlm.nih.gov/pubmed/25819691	24	2009-07-21	Completed	2009-08-01	2012-09-01	2015-03-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study in patients with Gaucher disease type 1 who have been stabilized with Cerezyme is to demonstrate that, the majority of patients who receive Genz-112638 remain stable.\n[ Time Frame: 39 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The percentage of patients who remain stable for 52 weeks (the primary analysis period)\n[ Time Frame: 52 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00947414	Cellulite and Extracorporeal Shock Wave	Cellulite and focused extracorporeal shockwave therapy for non-invasive body contouring: a randomized trial	10.1007/s13555-013-0039-5	https://www.ncbi.nlm.nih.gov/pubmed/24297647	4	2009-07-27	Completed	2009-06-01	2011-10-01	2013-12-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Nuernberger Score based on photo of cellulite\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Nuernberger Score based on photo of cellulite\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Nuernberger Score based on photo of cellulite\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT00949975	A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium	A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium	10.3109/15412555.2011.641803	https://www.ncbi.nlm.nih.gov/pubmed/22458939?dopt=Abstract	9	2009-07-30	Completed	2009-07-01	2010-08-01	2012-04-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[See Results Section.]	NA
NCT00950274	Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery	Cardiac Function Improvement and Bone Marrow Response -: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133+ Application After Myocardial Infarction	10.1016/j.ebiom.2017.07.022	https://www.sciencedirect.com/science/article/pii/S2352396417302967?via%3Dihub	16	2009-07-30	Terminated	2009-07-01	2016-03-01	2017-07-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Left ventricular ejection fraction at rest, measured by MRI\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Left ventricular ejection fraction at rest, measured by MRI\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Left ventricular ejection fraction at rest, measured by MRI\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Left ventricular ejection fraction at rest, measured by MRI\n[ Time Frame: 6 months ]""}]	NA
NCT00950300	A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial	10.1016/s1470-2045(12)70329-7	https://www.ncbi.nlm.nih.gov/pubmed/22884505?dopt=Abstract	131	2009-07-30	Completed	NA	NA	2012-08-09	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""trastuzumab serum concentrations, comparing sc versus iv administration\n[ Time Frame: throughout cycles 1 to 8 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""pathologic complete response\n[ Time Frame: after surgery between cycles 8 and 9 ]""}]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""trastuzumab serum concentrations, comparing sc versus iv administration\n[ Time Frame: throughout cycles 1 to 8 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""pathologic complete response\n[ Time Frame: after surgery between cycles 8 and 9 ]""}]
NCT00952458	Bispectral Index Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography	Bispectral index monitoring of midazolam and propofol sedation during endoscopic retrograde cholangiopancreatography: a randomized clinical trial (the EndoBIS study)	10.1055/s-0031-1291485	NA	4	2009-08-03	Completed	2009-07-01	2010-05-01	2012-01-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary complications of sedation\n[ Time Frame: 1-4 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary complications of sedation\n[ Time Frame: 1-4 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary complications of sedation\n[ Time Frame: 1-4 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary complications of sedation\n[ Time Frame: 1-4 hours ]""}]	NA
NCT00953108	Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression	10.1016/j.psyneuen.2013.10.008	https://www.ncbi.nlm.nih.gov/pubmed/24275013?dopt=Abstract	6	2009-08-05	Completed	2009-09-01	2012-02-01	2013-10-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""serial dexamethasone/CRH tests\n[ Time Frame: week 0, 1, and 5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""serial dexamethasone/CRH tests\n[ Time Frame: week 0, 1, and 5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""serial dexamethasone/CRH tests\n[ Time Frame: week 0, 1, and 5 ]""}]	NA	NA
NCT00955565	Accuracy of Navigation in Placement of Sacroiliac Screw	Three-dimensional navigation is more accurate than two-dimensional navigation or conventional fluoroscopy for percutaneous sacroiliac screw fixation in the dysmorphic sacrum: a randomized multicenter study	10.1097/bot.0000000000000092	https://www.ncbi.nlm.nih.gov/pubmed/24694553	3	2009-08-07	Completed	2008-06-01	2010-01-01	2014-12-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of misplaced sacroiliac screws as evaluated by postop CT-scanning.\n[ Time Frame: 2 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of misplaced sacroiliac screws as evaluated by postop CT-scanning.\n[ Time Frame: 2 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of misplaced sacroiliac screws as evaluated by postop CT-scanning.\n[ Time Frame: 2 days ]""}]	NA	NA
NCT00956566	Comparison of Low Fat and Low Carbohydrate Diets With Respect to Weight Loss and Metabolic Effects	Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects	10.1002/hep.24242	http://onlinelibrary.wiley.com/doi/10.1002/hep.24242/abstract	3	2009-08-10	Completed	2007-04-01	2010-05-01	2011-03-11	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: Month 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: Month 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: Month 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: Month 6 ]""}]	NA
NCT00958750	Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia	A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women	10.1016/j.jaad.2010.09.724	http://www.sciencedirect.com/science/article/pii/S0190962210018116	2	2009-08-12	Completed	2008-06-01	NA	2011-06-23	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks\n[ Time Frame: 24 weeks ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks\n[ Time Frame: 24 weeks ]""}]
NCT00958776	A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza	Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients	10.1093/cid/ciu632	https://www.ncbi.nlm.nih.gov/pubmed/25115871?dopt=Abstract	85	2009-08-12	Terminated	2009-11-01	2012-11-01	2014-08-12	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the effect of treatment with peramivir plus standard of care (SOC) compared to placebo plus SOC on time to clinical resolution in adults and adolescents who are hospitalized with acute influenza.\n[ Time Frame: Day 5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measurement of vital signs and oxygen saturation will be summarized by visit, changes from baseline.\n[ Time Frame: Thru Day 10 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measurement of vital signs and oxygen saturation will be summarized by visit, changes from baseline.\n[ Time Frame: Thru Day 10 ]""}]	[See Results Section.]	NA
NCT00970437	A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression	Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial	10.1001/jamapsychiatry.2016.3880	https://pubmed.ncbi.nlm.nih.gov/28146251/	5	2009-09-01	Completed	2010-04-01	2013-02-01	2017-03-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression)\n[ Time Frame: 20 weeks after randomization (after acute treatment phase) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression)\n[ Time Frame: 20 weeks after randomization (after acute treatment phase) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression)\n[ Time Frame: 20 weeks after randomization (after acute treatment phase) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression)\n[ Time Frame: 20 weeks after randomization (after acute treatment phase) ]""}]	NA
NCT00973609	Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial	10.1016/s1470-2045(15)00042-x	https://pubmed.ncbi.nlm.nih.gov/26361971/	10	2009-09-08	Completed	2009-08-01	2013-12-01	2015-09-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to failure of maintenance and reinduction treatment strategy measured from randomization\n[ Time Frame: From randomization until second progression after reinduction treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to failure of maintenance and reinduction treatment strategy measured from randomization\n[ Time Frame: From randomization until second progression after reinduction treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to failure of maintenance and reinduction treatment strategy measured from randomization\n[ Time Frame: From randomization until second progression after reinduction treatment ]""}]	NA	NA
NCT00974077	Psychophysiological Correlates of Mindfulness Based Cognitive Therapy (MBCT) in Recurrent Depression	Event-related brain potentials reflect increased concentration ability after mindfulness-based cognitive therapy for depression: a randomized clinical trial	10.1016/j.psychres.2012.05.031	https://www.ncbi.nlm.nih.gov/pubmed/22771173	3	2009-09-09	Completed	2008-09-01	2011-07-01	2012-07-06	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse (MDE)\n[ Time Frame: 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse (MDE)\n[ Time Frame: 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse (MDE)\n[ Time Frame: 12 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse (MDE)\n[ Time Frame: 12 month ]""}]	NA
NCT00974155	The Early Medication Change (EMC) Trial	Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder	10.1371/journal.pone.0194574	https://pubmed.ncbi.nlm.nih.gov/29668746/	7	2009-09-09	Completed	2009-09-01	2014-05-01	2018-04-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14 (n=192)\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT00974506	Pilot Study: Complementary Therapies in Geriatric Patients	Effects and feasibility of an Integrative Medicine program for geriatric patients-a cluster-randomized pilot study	10.2147/cia.s45242	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724560/	2	2009-09-09	Completed	2009-08-01	2011-04-01	2013-07-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[]	[]	[]	NA	NA
NCT00974779	High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients	Randomized controlled pilot study of 2 weeks' treatment with high cutoff membrane for hemodialysis patients with elevated C-reactive protein	10.1111/j.1525-1594.2012.01479.x	https://www.ncbi.nlm.nih.gov/pubmed/22845695?dopt=Abstract	4	2009-09-09	Completed	2009-11-01	2011-08-01	2012-07-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammation: CRP plasma level and quantity of circulating CD14/16 positive monocytes\n[ Time Frame: 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammation: CRP plasma level and quantity of circulating CD14/16 positive monocytes\n[ Time Frame: 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammation: CRP plasma level and quantity of circulating CD14/16 positive monocytes\n[ Time Frame: 2 weeks ]""}]	NA	NA
NCT00976092	Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction	10.1093/eurheartj/ehu182	NA	4	2009-09-11	Unknown status	2009-09-01	NA	2014-05-09	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""composite of all-cause death, recurrent MI, unplanned IRA revascularization, stroke, definite stent thrombosis or major bleeding\n[ Time Frame: 30 days ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""composite of all-cause death, recurrent MI, unplanned IRA revascularization, stroke, definite stent thrombosis or major bleeding\n[ Time Frame: 30 days ]""}]
NCT00976521	The INFUSE - Anterior Myocardial Infarction (AMI) Study	Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial	10.1001/jama.2012.421	https://www.ncbi.nlm.nih.gov/pubmed/22447888?dopt=Abstract	17	2009-09-11	Completed	2009-09-01	2012-01-01	2012-03-25	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size (percentage of total LV mass) measured by cardiac MRI\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size (percentage of total LV mass) measured by cardiac MRI\n[ Time Frame: 30 days ]""}]	NA	[See Results Section.]	NA
NCT00976859	Efficacy of Cognitive Restructuring and Imagery Modification to Reduce the Feeling of Being Contaminated After Childhood Sexual Abuse	A randomized controlled trial on cognitive restructuring and imagery modification to reduce the feeling of being contaminated in adult survivors of childhood sexual abuse suffering from posttraumatic stress disorder	10.1159/000348450	NA	5	2009-09-14	Completed	2009-09-01	2011-10-01	2013-05-22	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Emotional held negative self-belief of being polluted(How much you feel this is true, regardless of how you think rationally)on 0-100 Likert scales anchored at \""I do not belief at all that I am polluted\"" and \""I am completely convinced that I am polluted\""\n[ Time Frame: at the beginning and at the end of the intervention session, after a week at the beginning of the third session ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Vividness of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Distress related to the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Vividness of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Distress associated to the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""}]	NA	NA
NCT00977925	The Severe Soft Tissue Bleeding Study	Safety and Hemostatic Effectiveness of the Fibrin Pad for Severe Soft-Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic (Non-cardiac) Surgery: A Randomized, Controlled, Superiority Trial	10.1007/s00268-015-3106-5	https://link.springer.com/article/10.1007%2Fs00268-015-3106-5	7	2009-09-15	Completed	2009-08-01	2011-01-01	2015-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site. Hemostasis is defined as no detectable bleeding at the TBS.\n[ Time Frame: Intra-operative ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site. Hemostasis is defined as no detectable bleeding at the TBS.\n[ Time Frame: Intra-operative ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site. Hemostasis is defined as no detectable bleeding at the TBS.\n[ Time Frame: Intra-operative ]""}]	NA	NA
NCT00979056	Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin	Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial	10.1016/s1473-3099(13)70221-4	https://www.ncbi.nlm.nih.gov/pubmed/24012319	5	2009-09-16	Completed	2009-10-01	2012-03-01	2013-09-04	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.\n[ Time Frame: From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.\n[ Time Frame: From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.\n[ Time Frame: From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.\n[ Time Frame: From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany ]""}]	NA
NCT00979719	Improvement of a Physically Active Lifestyle	Intervention effects of exercise self-regulation on physical exercise and eating fruits and vegetables: a longitudinal study in orthopedic and cardiac rehabilitation	10.1016/j.ypmed.2011.06.019	https://www.ncbi.nlm.nih.gov/pubmed/21784096?dopt=Abstract	6	2009-09-17	Completed	2009-10-01	2011-11-01	2011-07-14	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical activity\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical activity\n[ Time Frame: 18 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical activity\n[ Time Frame: 18 months ]""}]	NA
NCT00979745	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)	Afamelanotide for Erythropoietic Protoporphyria	10.1056/nejmoa1411481	https://www.ncbi.nlm.nih.gov/pubmed/26132941	6	2009-09-17	Completed	2009-09-01	2011-05-01	2015-07-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 9 months ]""}]	[See Results Section.]	NA
NCT00983151	Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation	A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes	10.1016/j.eururo.2011.08.039	http://www.europeanurology.com/article/S0302-2838(11)00907-9/pdf	7	2009-09-22	Terminated	2009-08-01	2010-09-01	2011-08-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in IELT (Intravaginal ejaculatory time)\n[ Time Frame: Per attempt at sexual intercourse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in IELT (Intravaginal ejaculatory time)\n[ Time Frame: Per attempt at sexual intercourse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in IELT (Intravaginal ejaculatory time)\n[ Time Frame: Per attempt at sexual intercourse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Increase in IELT (Intravaginal ejaculatory time)\n[ Time Frame: Per attempt at sexual intercourse ]""}]	NA
NCT00985634	Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops	Randomized clinical trial comparing a thermosensitive polymer (LeGoo) with conventional vessel loops for temporary coronary artery occlusion during off-pump coronary artery bypass surgery	10.1016/j.athoracsur.2011.07.003	https://www.ncbi.nlm.nih.gov/pubmed/22115228?dopt=Abstract	1	2009-09-25	Unknown status	NA	NA	2011-12-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.\n[ Time Frame: in operating room ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.\n[ Time Frame: in operating room ]""}]
NCT00986323	Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma	Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial	10.1136/thoraxjnl-2011-200665	https://www.ncbi.nlm.nih.gov/pubmed/22131290?dopt=Abstract	2	2009-09-28	Completed	2008-04-01	2010-01-01	2011-11-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.\n[ Time Frame: Week -2, 0, 4, 12, 24, 36 and 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.\n[ Time Frame: Week -2, 0, 4, 12, 24, 36 and 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.\n[ Time Frame: Week -2, 0, 4, 12, 24, 36 and 52 ]""}]	NA	NA
NCT00986752	Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease	Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH)	10.1161/circulationaha.116.025329	NA	4	2009-09-29	Unknown status	2009-07-01	NA	2017-04-19	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage diameter stenosis\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage diameter stenosis\n[ Time Frame: 6 months ]""}]
NCT00987077	Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy	Selective retina therapy for acute central serous chorioretinopathy	10.1136/bjo.2009.178327	http://bjo.bmj.com/content/95/1/83	1	2009-09-29	Completed	2007-04-01	2009-01-01	2010-06-15	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Serial changes in ETDRS letterscore\n[ Time Frame: 3 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Serial changes in ETDRS letterscore\n[ Time Frame: 3 months ]""}]	NA	NA
NCT00987324	Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial	10.1016/s0140-6736(12)61964-3	https://www.ncbi.nlm.nih.gov/pubmed/23206837	3	2009-09-29	Completed	2009-07-01	2012-07-01	2012-12-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent in-segment diameter stenosis at follow-up angiography\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent in-segment diameter stenosis at follow-up angiography\n[ Time Frame: 6-8 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent in-segment diameter stenosis at follow-up angiography\n[ Time Frame: 6-8 months ]""}]	NA
NCT00987532	A Participatory Parental Intervention Promoting Physical Activity in Preschools	A participatory physical activity intervention in preschools: a cluster randomized controlled trial	10.1016/j.amepre.2013.01.032	http://www.sciencedirect.com/science/article/pii/S0749379713001803	1	2009-09-30	Unknown status	NA	NA	2013-07-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in mean accelerometry counts over 6 days\n[ Time Frame: baseline, end of intervention, six months after end of intervention ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in mean accelerometry counts over 6 days\n[ Time Frame: baseline, end of intervention, six months after end of intervention ]""}]
NCT00988208	Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial	10.1016/s1470-2045(15)70025-2	http://www.sciencedirect.com/science/article/pii/S1470204515700252?via%3Dihub	51	2009-10-01	Completed	2009-11-01	2013-11-01	2015-03-03	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: Cycle 1 Day 1 until subject death ]""}]	[See Results Section.]	[See Results Section.]	[See Results Section.]	NA
NCT00988754	School Based Health Promotion Program in Secondary Schools	Retinal vessel diameter, obesity and metabolic risk factors in school children (JuvenTUM 3)	10.1016/j.atherosclerosis.2011.12.029	https://www.ncbi.nlm.nih.gov/pubmed/22244041?dopt=Abstract	3	2009-10-01	Completed	2008-07-01	2012-07-01	2011-12-27	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]\n\nnumber of days with physical activity > 60 minutes""}]	NA
NCT00991211	Bendamustine Plus Rituximab Versus CHOP Plus Rituximab	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial	10.1016/s0140-6736(12)61763-2	http://www.sciencedirect.com/science/article/pii/S0140673612617632?via%3Dihub	2	2009-10-06	Completed	2004-01-01	2009-08-01	2013-02-20	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: observation 3 years or significant differences between two arms ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: observation 3 years or significant differences between two arms ]""}]	NA	NA
NCT00993408	Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension	10.1183/09031936.00137511	http://erj.ersjournals.com/content/40/4/874	1	2009-10-09	Completed	2008-04-01	2009-06-01	2012-02-23	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of hemodynamic parameters after single oral dose of ACT-293987.\n[ Time Frame: 17 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proof-of-concept assessment of the efficacy of ACT-293987 in subjects with PAH by measuring the change from baseline in the PVR at Week 17 compared to placebo.\n[ Time Frame: 17 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of hemodynamic parameters after single oral dose of ACT-293987.\n[ Time Frame: 17 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proof-of-concept assessment of the efficacy of ACT-293987 in subjects with PAH by measuring the change from baseline in the PVR at Week 17 compared to placebo.\n[ Time Frame: 17 weeks ]""}]	NA	NA
NCT00993681	Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study	Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala	10.1016/s1473-3099(13)70297-4	https://www.sciencedirect.com/science/article/pii/S1473309913702974	4	2009-10-09	Completed	2009-10-01	2010-10-01	2013-11-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of cases with vaccine preventable outcome\n[ Time Frame: Day 17 (17 days after arrival in destination country) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of cases with vaccine preventable outcome\n[ Time Frame: Day 17 (17 days after arrival in destination country) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of cases with vaccine preventable outcome\n[ Time Frame: Day 17 (17 days after arrival in destination country) ]""}]	NA	NA
NCT00993980	Qigong and Exercise Therapy for Low Back Pain in Adults	Qigong versus exercise therapy for chronic low back pain in adults--a randomized controlled non-inferiority trial	10.1002/ejp.529	http://onlinelibrary.wiley.com/doi/10.1002/ejp.529/abstract	4	2009-10-13	Completed	2009-10-01	2010-03-01	2014-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average pain intensity during the last 7 days measured on a visual analogue scale (VAS)\n[ Time Frame: baseline, 3, 6 and 12 months ]""}]	NA	NA
NCT00995852	Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study	Complete unilateral vs partial bilateral endoscopic lung volume reduction in patients with bilateral lung emphysema	10.1378/chest.11-2886	NA	3	2009-10-14	Unknown status	2009-09-01	NA	2012-10-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in pulmonary function (FEV1) 6-minute walking test\n[ Time Frame: 3 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in pulmonary function (FEV1) 6-minute walking test\n[ Time Frame: 3 months ]""}]
NCT00996463	Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients	A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan	10.1186/s12879-014-0619-8	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-014-0619-8	4	2009-10-15	Completed	2010-01-01	2010-09-01	2014-11-25	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	NA	NA
NCT00996554	Randomized Study Comparing Two Established Gastrointestinal Suture Techniques - One-layer-continuous Versus Double-layer-continuous Suture	Single-Layer Continuous Versus Double-Layer Continuous Suture in Colonic Anastomoses-a Randomized Multicentre Trial (ANATECH Trial)	10.1007/s11605-015-3003-0	https://www.ncbi.nlm.nih.gov/pubmed/26525206?dopt=Abstract	3	2009-10-15	Terminated	2004-01-01	2012-01-01	2015-11-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: 3 months ]""}]	NA
NCT00997841	Conventional Versus Point-of-care Based Coagulation Management	Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients	10.1097/aln.0b013e318264c644	http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933881	3	2009-10-18	Completed	2009-06-01	2010-04-01	2012-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""amount of transfused red blood cell concentrates\n[ Time Frame: 24 h after begin of surgical intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""amount of transfused red blood cell concentrates\n[ Time Frame: 24 h after begin of surgical intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""amount of transfused red blood cell concentrates\n[ Time Frame: 24 h after begin of surgical intervention ]""}]	NA	NA
NCT00998439	Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter	A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study	10.1016/j.jacc.2012.01.015	https://www.ncbi.nlm.nih.gov/pubmed/22386286?dopt=Abstract	6	2009-10-19	Unknown status	2009-10-01	NA	2012-02-29	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]""}]
NCT00998556	Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study	10.1093/eurheartj/ehx355	https://pubmed.ncbi.nlm.nih.gov/28934837/	8	2009-10-19	Completed	2010-06-01	2016-03-01	2017-07-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up\n[ Time Frame: 6 months ]\n\nChange in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography""}]	NA
NCT00998907	PDS*Plus and Wound Infections After Laparotomy	Surgical-site infection after abdominal wall closure with triclosan-impregnated polydioxanone sutures: results of a randomized clinical pathway facilitated trial (NCT00998907)	10.1016/j.surg.2013.04.011	http://www.sciencedirect.com/science/article/pii/S003960601300158X	5	2009-10-20	Completed	2009-09-01	2011-11-01	2013-07-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of wound infections\n[ Time Frame: 30 days after the operation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of wound infections\n[ Time Frame: 30 days after the operation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of wound infections\n[ Time Frame: 30 days after the operation ]""}]	NA	NA
NCT00999856	Investigation of a Sub-Conjunctival Insert	Safety and accuracy of a new long-term subconjunctival glucose sensor	10.1111/j.1753-0407.2012.00192.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1753-0407.2012.00192.x/abstract	3	2009-10-21	Terminated	2008-08-01	2012-03-01	2012-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""short term and mid term performance of different versions of the insert\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""recovery from surgery (wound healing)\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""short term and mid term performance of different versions of the insert\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""recovery from surgery (wound healing)\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""short term and mid term performance of different versions of the insert\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""recovery from surgery (wound healing)\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement\n[ Time Frame: at 1 month, at 2 months, at 3 months ]""}]	NA
NCT01009138	Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression	The effect of a Diabetes-Specific Cognitive Behavioral Treatment Program (DIAMOS) for patients with diabetes and subclinical depression: results of a randomized controlled trial	10.2337/dc14-1416	https://www.ncbi.nlm.nih.gov/pubmed/25605812	10	2009-11-05	Completed	2009-11-01	2011-09-01	2015-01-20	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D)\n[ Time Frame: baseline, 2 weeks after treatment, 6 months-FU, 12 months-FU ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D-Score)\n[ Time Frame: Baseline, 12 months-FU ]\n\nThe Center for Epidemiologic Studies Depression Scale (CES-D) is used for the assessment of depressive symptoms. The decicive measurement of this primary outcome variable is conducted 12 month after termination of the treatment (12 month follow up). The difference of the CES-D scores between baseline and 12 months follow up is calculated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D-Score)\n[ Time Frame: Baseline, 12 months-FU ]\n\nThe Center for Epidemiologic Studies Depression Scale (CES-D) is used for the assessment of depressive symptoms. The decicive measurement of this primary outcome variable is conducted 12 month after termination of the treatment (12 month follow up). The difference of the CES-D scores between baseline and 12 months follow up is calculated.""}]	[See Results Section.]	NA
NCT01011322	A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis	First multicenter study of modified release phosphatidylcholine ""LT-02"" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses	10.1038/ajg.2014.104	https://www.ncbi.nlm.nih.gov/pubmed/24796768?dopt=Abstract	8	2009-11-10	Unknown status	2009-12-01	2011-07-01	2014-05-06	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the efficacy of IMP in mesalazine-refractory ulcerative colitis\n[ Time Frame: From day 1 of treatment until end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the efficacy of IMP in mesalazine-refractory ulcerative colitis\n[ Time Frame: From day 1 of treatment until end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the efficacy of IMP in mesalazine-refractory ulcerative colitis\n[ Time Frame: From day 1 of treatment until end of treatment ]""}]	NA	NA
NCT01011920	Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial	10.1016/s2352-3026(17)30174-6	https://pubmed.ncbi.nlm.nih.gov/29054815/	12	2009-11-10	Completed	2009-11-01	2012-09-01	2017-10-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""response rate after primary chemotherapy and 2 years failure free survival at second randomization\n[ Time Frame: 3 months, 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""response rate after primary chemotherapy and 2 years failure free survival at second randomization\n[ Time Frame: 3 months, 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""response rate after primary chemotherapy and 2 years failure free survival at second randomization\n[ Time Frame: 3 months, 2 years ]""}]	NA	NA
NCT01013259	Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis	Tolerability and clinical outcome of coseasonal treatment with Escherichia coli strain Nissle 1917 in grass pollen-allergic subjects	10.1159/000356328	https://www.ncbi.nlm.nih.gov/pubmed/?term=Tolerability+and+Clinical+Outcome+of+Coseasonal+Treatment+with+Escherichia+coli+Strain+Nissle+1917+in+Grass+Pollen-Allergic+Subjects	1	2009-11-12	Completed	2009-02-01	2009-09-01	2013-11-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptom-medication score\n[ Time Frame: 45 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptom-medication score\n[ Time Frame: 45 days ]""}]	NA	NA
NCT01014507	Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma	No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group	10.1093/annonc/mdq066	https://www.ncbi.nlm.nih.gov/pubmed/20305034?dopt=Abstract	5	2009-11-16	Completed	2004-01-01	NA	2010-10-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FSH level 6 month after end of treatment\n[ Time Frame: 6 month ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FSH level 6 month after end of treatment\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FSH level 6 month after end of treatment\n[ Time Frame: 6 month ]""}]
NCT01014767	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors	NA	10.1093/neuonc/nov229.01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639153/#__ffn_sectitle	14	2009-11-16	Terminated	2009-11-01	2012-11-01	2015-11-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Baseline to disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: Baseline to 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Till disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Till disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: 4 Months ]""}]	[See Results Section.]	NA
NCT01016873	INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study	10.1016/j.ophtha.2013.02.016	http://www.sciencedirect.com/science/article/pii/S0161642013001504	13	2009-11-19	Completed	2009-11-01	2012-05-01	2013-09-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[See Results Section.]	NA
NCT01019434	Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma	10.1158/1078-0432.ccr-14-0951-t	https://pubmed.ncbi.nlm.nih.gov/25338498/	9	2009-11-24	Completed	2009-10-01	2013-10-01	2014-10-22	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year\n[ Time Frame: 1 year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year\n[ Time Frame: 1 year ]""}]	NA
NCT01020630	Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program	10.1186/s12885-016-2736-9	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01020630	10	2009-11-23	Completed	2009-11-01	2012-11-01	2016-08-31	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: After first and second cycle, then after every second cycles or if clinically indicated until progress of disease ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: Average time period: up to one year (participants are followed until progression or death) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: Average time period: up to one year (participants are followed until progression or death) ]""}]	NA	NA
NCT01021423	A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).	Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation	10.1111/bjh.12449	https://www.ncbi.nlm.nih.gov/pubmed/23834234?dopt=Abstract	14	2009-11-25	Terminated	2009-11-01	2013-05-01	2013-07-09	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: Until 80% of subjects have died or 5 years after last subject randomized ]""}]	[See Results Section.]	NA	[See Results Section.]	NA
NCT01022242	Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery	PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial	10.1371/journal.pone.0110735	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110735	6	2009-11-30	Completed	2009-12-01	2012-05-01	2014-10-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary variable is Total Active Motion (TAM) at the proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints (i.e. TAM2) of the affected digit at actively made fist at 12 weeks after surgery.\n[ Time Frame: from administration until 12 months after. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary variable is Total Active Motion (TAM) at the proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints (i.e. TAM2) of the affected digit at actively made fist at 12 weeks after surgery.\n[ Time Frame: from administration until 12 months after. ]""}]	[See Results Section.]	NA	NA
NCT01025167	The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients	A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial	10.1002/cncr.28197	https://www.ncbi.nlm.nih.gov/pubmed/23765693?dopt=Abstract	2	2009-12-02	Completed	2006-09-01	2010-01-01	2013-06-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body cell mass measured by bioelectrical impedance spectroscopy (BIS)\n[ Time Frame: Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body cell mass measured by bioelectrical impedance spectroscopy (BIS)\n[ Time Frame: Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body cell mass measured by bioelectrical impedance spectroscopy (BIS)\n[ Time Frame: Baseline, mid of radio-/chemotherapy, end of radio-/chemotherapy, day 28 of convalescence period, day 49 of convalescence period ]""}]	NA	NA
NCT01027884	Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)	Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy	10.1016/j.nmd.2016.12.014	https://pubmed.ncbi.nlm.nih.gov/28189481/	21	2009-12-08	Completed	2009-07-01	2013-12-01	2017-01-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Objective: to assess the efficacy of idebenone, compared to placebo, in improving or delaying the loss of respiratory function in patients with DMD. Primary endpoint: percent predicted peak expiratory flow (PEF)\n[ Time Frame: Efficacy assessments: Baseline, Week 13, 26 , 39, 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Objective: to assess the efficacy of idebenone, compared to placebo, in improving or delaying the loss of respiratory function in patients with DMD. Primary endpoint: percent predicted peak expiratory flow (PEF)\n[ Time Frame: Efficacy assessments: Baseline, Week 13, 26 , 39, 52 ]""}]	[See Results Section.]	NA	NA
NCT01029067	Metacognitive Training in Schizophrenia	Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms	10.1017/s0033291710002618	NA	3	2009-12-08	Completed	2009-09-01	2010-05-01	2011-01-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""delusion severity as assessed with the Positive and Negative Syndrome Scale (PANSS); sum of item scores p1, p5, p6 and g9\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""delusion severity as assessed with the Positive and Negative Syndrome Scale (PANSS); sum of item scores p1, p5, p6 and g9\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""delusion severity as assessed with the Positive and Negative Syndrome Scale (PANSS); sum of item scores p1, p5, p6 and g9\n[ Time Frame: 4 weeks ]""}]	NA
NCT01030666	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Regenerative therapy of infrabony defects with or without systemic doxycycline. A randomized placebo-controlled trial	10.1111/j.1600-051x.2012.01861.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1600-051X.2012.01861.x/abstract	9	2009-12-10	Terminated	2007-04-01	2011-01-01	2012-03-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[See Results Section.]	NA
NCT01035190	Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia	Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia	10.1056/nejmoa1501917	https://www.nejm.org/doi/10.1056/NEJMoa1501917?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0www.ncbi.nlm.nih.gov	8	2009-12-17	Completed	2010-04-01	2013-10-01	2015-10-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without BPD at 36 weeks GA\n[ Time Frame: 36 weeks GA ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without BPD at 36 weeks GA\n[ Time Frame: 36 weeks GA ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without BPD at 36 weeks GA\n[ Time Frame: 36 weeks GA ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without BPD at 36 weeks GA\n[ Time Frame: 36 weeks GA ]""}]	NA
NCT01035242	""Association Splitting"" in Obsessive-Compulsive Disorder (OCD)	Further evidence for biased semantic networks in obsessive-compulsive disorder (OCD): when knives are no longer associated with buttering bread but only with stabbing people	10.1016/j.jbtep.2014.05.002	https://www.sciencedirect.com/science/article/pii/S000579161400041X	2	2009-12-17	Completed	2009-03-01	2012-07-01	2014-05-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)\n[ Time Frame: 8 weeks, 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)\n[ Time Frame: 8 weeks, 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)\n[ Time Frame: 8 weeks, 6 months ]""}]	NA
NCT01038804	A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer	Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer	10.1007/s10549-014-3238-6	NA	26	2009-12-22	Completed	2009-12-01	2012-09-01	2014-12-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival (PFS)\n[ Time Frame: At the time of progression or death or at 2 year follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival (PFS)\n[ Time Frame: At the time of progression or death or at 2 year follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival (PFS)\n[ Time Frame: At the time of progression or death or at 2 year follow up ]""}]	NA	NA
NCT01039103	Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)	Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration	10.1016/j.nano.2015.02.021	https://www.ncbi.nlm.nih.gov/pubmed/?term=Prednisolone-containing+liposomes+accumulate+in+human+atherosclerotic+macrophages+upon+intravenous+administration	7	2009-12-22	Terminated	2009-12-01	2011-11-01	2015-03-17	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 8.\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 8.\n[ Time Frame: 8 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 8.\n[ Time Frame: 8 weeks ]""}]	NA
NCT01041950	A Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage	Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis	10.1002/ana.24834	https://pubmed.ncbi.nlm.nih.gov/27888608/	7	2010-01-04	Completed	2009-11-01	2014-07-01	2017-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""modified Rankin scale and Barthel index\n[ Time Frame: 3 and 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirement of permanent VP-shunt\n[ Time Frame: 14 days ]\n\nif three attempts to clamp the EVD (control group) or LD (treatment group) fail, or overall extra-corporal drainage time exceeds 14 days, a VP-shunt is placed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirement of permanent VP-shunt\n[ Time Frame: 14 days ]\n\nif three attempts to clamp the EVD (control group) or LD (treatment group) fail, or overall extra-corporal drainage time exceeds 14 days, a VP-shunt is placed.""}]	NA	NA
NCT01045746	Effects of Whole-Body Vibration on Balance in the Elderly Population	Feasibility and effects of applying stochastic resonance whole-body vibration on untrained elderly: a randomized crossover pilot study	10.1186/s12877-015-0021-4	https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-015-0021-4	5	2010-01-08	Completed	2010-01-01	2010-08-01	2015-03-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static and dynamic Balance\n[ Time Frame: after on session, four and eight weeks, Follow up 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static and dynamic Balance\n[ Time Frame: after on session, four and eight weeks, Follow up 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static balance\n[ Time Frame: after one session, four and eight weeks ]""}]	NA	NA
NCT01047891	Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	10.1016/s1470-2045(18)30372-3	https://pubmed.ncbi.nlm.nih.gov/30100379/	3	2010-01-12	Completed	2010-01-01	2015-02-01	2018-08-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]\n\nThe primary target value of this study is the comparison of the median progression-free survival time between the two study arms. Progression-free survival time (PFS) of a patient is defined as the time in months from start of the first therapy cycle until PD or death is observed""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]\n\nThe primary target value of this study is the comparison of the median progression-free survival time between the two study arms. Progression-free survival time (PFS) of a patient is defined as the time in months from start of the first therapy cycle until PD or death is observed""}]	NA	NA
NCT01049100	Surgical Staging in Cervical Cancer Prior to Chemoradiation	Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group	10.1016/j.ijrobp.2015.10.027	https://pubmed.ncbi.nlm.nih.gov/26853333/	2	2010-01-13	Unknown status	2009-04-01	NA	2015-10-20	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DFS (disease-free survival)\n[ Time Frame: 4 years ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DFS (disease-free survival)\n[ Time Frame: 4 years ]""}]
NCT01049399	Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy	10.1002/mds.25824	https://www.ncbi.nlm.nih.gov/pubmed/24532007	7	2010-01-13	Completed	2009-12-01	2011-09-01	2014-02-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe\n[ Time Frame: 52 weeks ]""}]	NA	NA
NCT01049607	Stapler Hepatectomy for Elective Liver Resection	Randomized clinical trial of stapler versus clamp-crushing transection in elective liver resection	10.1002/bjs.9387	http://onlinelibrary.wiley.com/doi/10.1002/bjs.9387/abstract	3	2010-01-13	Completed	2010-01-01	2011-10-01	2014-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]	NA	NA
NCT01049971	REDWIL: Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors	Reduction of wound infections in laparoscopic-assisted colorectal resections by plastic wound ring drapes (REDWIL)?--A randomized controlled trial	10.1007/s00423-012-0954-4	https://link.springer.com/article/10.1007/s00423-012-0954-4	2	2010-01-14	Completed	2007-12-01	2010-06-01	2012-04-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 10 days, 3 months, 6 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 10 days, 3 months, 6 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 6 months postoperatively ]\n\nthe total percentage of wound infections within 6 months postoperatively will be analyzed""}]	NA	NA
NCT01050686	Need for Subcutaneous Wound Drains in Ileostomy Reversal	Necessity of subcutaneous suction drains in ileostomy reversal (DRASTAR)-a randomized, controlled bi-centered trial	10.1007/s00423-016-1436-x	https://pubmed.ncbi.nlm.nih.gov/27138020/	4	2010-01-14	Completed	2010-03-01	2014-11-01	2016-05-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	NA	NA
NCT01055119	Effect of Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder	Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial	10.1016/j.plefa.2014.04.004	https://www.ncbi.nlm.nih.gov/pubmed/24958525	3	2010-01-22	Completed	2009-04-01	2012-09-01	2014-05-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Behavior, Cognition\n[ Time Frame: Before intervention and 16 weeks after start of intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Behavior, Cognition\n[ Time Frame: Before intervention and 16 weeks after start of intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Behavior, Cognition\n[ Time Frame: Before intervention and 16 weeks after start of intervention ]""}]	NA	NA
NCT01055522	NA	NA	NA	NA	8	2010-01-22	Terminated	2008-06-01	2012-11-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine\n[ Time Frame: 21 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate Objective response rate (ORR) by CT or MRI\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine\n[ Time Frame: 21 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate Objective response rate (ORR) by CT or MRI\n[ Time Frame: 18 weeks ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine\n[ Time Frame: 21 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate Objective response rate (ORR) by CT or MRI\n[ Time Frame: 18 weeks ]""}]
NCT01056341	Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy	A randomized, controlled trial of oral propranolol in infantile hemangioma	10.1056/nejmoa1404710	http://www.nejm.org/doi/full/10.1056/NEJMoa1404710	28	2010-01-24	Completed	2010-01-01	2011-11-01	2015-02-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete/nearly complete resolution of the target IH at W24 compared to baseline based on the intra-patient blinded centralised independent qualitative assessments of W24 photographs.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete/nearly complete resolution of the target IH at W24 compared to baseline based on the intra-patient blinded centralised independent qualitative assessments of W24 photographs.\n[ Time Frame: 6 months ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01056744	Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents	Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up	10.1161/circinterventions.113.001146	http://circinterventions.ahajournals.org/cgi/pmidlookup?view=long&pmid=25371536	3	2010-01-25	Completed	2009-06-01	2011-05-01	2014-11-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial coverage of the stent struts assessed by optical coherence tomography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial coverage of the stent struts assessed by optical coherence tomography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial coverage of the stent struts assessed by optical coherence tomography\n[ Time Frame: 6 months ]""}]	NA	NA
NCT01057043	Cupping in Osteoarthritis of the Knee	Pulsatile dry cupping in patients with osteoarthritis of the knee - a randomized controlled exploratory trial	10.1186/1472-6882-12-184	https://www.ncbi.nlm.nih.gov/pubmed/23057611?dopt=Abstract	2	2010-01-26	Completed	2010-01-01	2010-07-01	2012-10-12	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster Universities Osteoarthritis (WOMAC) - Score\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster Universities Osteoarthritis (WOMAC) - Score\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster Universities Osteoarthritis (WOMAC) - Score\n[ Time Frame: 4 weeks ]""}]	NA
NCT01058343	Safety of IFNa Kinoid in Systemic Lupus Erythematosus	Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid	10.1002/art.37785	https://www.ncbi.nlm.nih.gov/pubmed/23203821?dopt=Abstract	12	2010-01-27	Completed	2010-03-01	2011-04-01	2013-02-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of adverse events\n[ Time Frame: study duration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of adverse events\n[ Time Frame: study duration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of adverse events\n[ Time Frame: study duration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of adverse events\n[ Time Frame: study duration ]""}]	NA
NCT01058980	ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial	10.1016/s0140-6736(15)60026-5	NA	9	2010-01-28	Completed	2009-12-01	2013-09-01	2015-07-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]\n\nThe primary outcome is time to first recurrence of symptomatic ECG-documented AF or atrial flutter/tachycardia between days 91 & 365 after ablation, or repeat ablation procedure during the first 90 days. AF or atrial flutter/tachycardia will qualify as an arrhythmia recurrence after ablation if it lasts 30 seconds or longer and is documented by 12-lead ECG, surface ECG rhythm strips, or TTM recordings. Documented episodes will be adjudicated by a blinded committee. Time 0 is defined as day 91 post ablation with FUp's extending 365 days post ablation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]\n\nThe primary outcome is time to first recurrence of symptomatic ECG-documented AF or atrial flutter/tachycardia between days 91 & 365 after ablation, or repeat ablation procedure during the first 90 days. AF or atrial flutter/tachycardia will qualify as an arrhythmia recurrence after ablation if it lasts 30 seconds or longer and is documented by 12-lead ECG, surface ECG rhythm strips, or TTM recordings. Documented episodes will be adjudicated by a blinded committee. Time 0 is defined as day 91 post ablation with FUp's extending 365 days post ablation.""}]	NA	NA
NCT01059266	PURETHAL Grasses Rush Study	Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation	10.1159/000343026	https://www.ncbi.nlm.nih.gov/pubmed/23183541?dopt=Abstract	6	2010-01-28	Completed	2010-02-01	2010-09-01	2012-11-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""systemic reactions > grade I or large local reactions related to injection\n[ Time Frame: 24 hrs after injection ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""systemic reactions > grade I or large local reactions related to injection\n[ Time Frame: 24 hrs after injection ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""systemic reactions > grade I or large local reactions related to injection\n[ Time Frame: 24 hrs after injection ]""}]	NA	NA
NCT01060501	Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer	Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment	10.1016/j.ejso.2008.01.019	http://www.sciencedirect.com/science/article/pii/S0748798308000358	1	2010-02-01	Completed	1992-07-01	2009-07-01	2008-12-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 5-year ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 5-year ]""}]	NA
NCT01061229	Homeopathic Drug Proving Trial	Homeopathic drug proving of Okoubaka aubrevillei: a randomised placebo-controlled trial	10.1186/1745-6215-14-96	https://www.ncbi.nlm.nih.gov/pubmed/23561008	3	2010-02-02	Completed	2010-03-01	2010-07-01	2013-04-05	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome parameter is the number of characteristic proving symptoms per subject, derived from the qualitative data analysis of the homeopathic proving drug compared to placebo.\n[ Time Frame: 3 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome parameter is the number of characteristic proving symptoms per subject, derived from the qualitative data analysis of the homeopathic proving drug compared to placebo.\n[ Time Frame: 3 weeks ]""}]	NA	NA
NCT01061931	Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation	Mesh ablator vs. cryoballoon pulmonary vein ablation of symptomatic paroxysmal atrial fibrillation: results of the MACPAF study	10.1093/europace/eus084	https://www.ncbi.nlm.nih.gov/pubmed/22523379	4	2010-02-02	Terminated	2009-03-01	2010-11-01	2012-04-20	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary veins per patient\n[ Time Frame: During ablation procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary veins per patient\n[ Time Frame: During ablation procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary veins per patient\n[ Time Frame: During ablation procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary veins per patient\n[ Time Frame: During ablation procedure ]""}]	NA
NCT01063829	Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients	Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation	10.1056/nejmoa1309533	http://www.nejm.org/doi/full/10.1056/NEJMoa1309533	16	2010-02-04	Completed	2010-02-01	2011-10-01	2014-05-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[See Results Section.]	NA
NCT01065311	Mindfulness-based Cognitive Therapy for Chronic Depression	A randomized controlled trial on the efficacy of mindfulness-based cognitive therapy and a group version of cognitive behavioral analysis system of psychotherapy for chronically depressed patients	10.1037/ccp0000042	https://www.ncbi.nlm.nih.gov/pubmed/26371617	4	2010-02-08	Completed	2010-10-01	2013-03-01	2015-08-10	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Post intervention and 6 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Post intervention and 6 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Change from Baseline in HAM-D at 8 weeks ]""}]	NA	NA
NCT01065337	Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia	Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients	10.1111/j.1742-1241.2011.02886.x	https://www.ncbi.nlm.nih.gov/pubmed/22284892	3	2010-02-08	Completed	2005-08-01	2009-02-01	2012-01-27	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""}]	NA
NCT01065935	Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)	ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients	10.1016/j.healun.2015.08.012	https://www.ncbi.nlm.nih.gov/pubmed/26452996	20	2010-02-08	Completed	2010-02-01	2012-06-01	2015-09-03	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The occurrence of new or progressive BOS grade 0p through 3 in RSV-infected lung transplant recipients\n[ Time Frame: 180 days after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The occurrence of new or progressive BOS grade 0p through 3 in RSV-infected lung transplant recipients\n[ Time Frame: 180 days after randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The occurrence of new or progressive BOS grade 0p through 3 in RSV-infected lung transplant recipients\n[ Time Frame: 180 days after randomization ]""}]	NA
NCT01066962	Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects	Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial	10.1016/s0140-6736(14)61170-3	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)611703/abstract	8	2010-02-09	Completed	2010-08-01	2013-08-01	2014-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined components\n[ Time Frame: minimum 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined components\n[ Time Frame: minimum 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined components\n[ Time Frame: minimum 2 years ]""}]	NA	NA
NCT01067703	Remote Ischaemic Preconditioning for Heart Surgery (RIPHeart-Study)	A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery	10.1056/nejmoa1413579	https://pubmed.ncbi.nlm.nih.gov/26436208/	5	2010-02-10	Terminated	2010-12-01	2014-05-01	2015-10-05	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	NA
NCT01068106	Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents	The Nobori biolimus-eluting stent: update of available evidence	10.1586/17434440.2014.894458	https://www.ncbi.nlm.nih.gov/pubmed/24579987?dopt=Abstract	4	2010-02-11	Unknown status	2010-02-01	NA	2014-03-03	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or revascularisation related to the target lesion.\n[ Time Frame: 12 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite endpoint of cardiac death, myocardial infarction related to the target vessel or revascularisation related to the target lesion.\n[ Time Frame: 12 months ]""}]
NCT01070849	A Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare	A bio-psycho-social exercise program (RÜCKGEWINN) for chronic low back pain in rehabilitation aftercare--study protocol for a randomised controlled trial	10.1186/1471-2474-11-266	https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-11-266	2	2010-02-17	Completed	2009-11-01	2011-10-01	2010-11-17	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perceived pain-related functional disability as measured with the Hanover Functional Ability Questionnaire (Kohlmann & Raspe, Rehabilitation. 1996;35:I-VIII.)\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perceived pain-related functional disability as measured with the Hanover Functional Ability Questionnaire (Kohlmann & Raspe, Rehabilitation. 1996;35:I-VIII.)\n[ Time Frame: one year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perceived pain-related functional disability as measured with the Hanover Functional Ability Questionnaire (Kohlmann & Raspe, Rehabilitation. 1996;35:I-VIII.)\n[ Time Frame: one year ]""}]	NA
NCT01071837	APG101 in Glioblastoma	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma	10.1158/1078-0432.ccr-14-0951-t	https://clincancerres.aacrjournals.org/content/20/24/6304	21	2010-02-18	Completed	2009-12-01	2011-08-01	2014-10-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""6 months rate of progression free survival (PFS6)\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""6 months rate of progression free survival (PFS6)\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""6 months rate of progression free survival (PFS6)\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""6 months rate of progression free survival (PFS6)\n[ Time Frame: 6 month ]""}]	NA
NCT01072305	Pneumatic Compression of the Legs to Reduce Fluid Demand in Minor Surgery	Peristaltic pneumatic compression of the legs reduces fluid demand and improves hemodynamic stability during surgery: a randomized, prospective study	10.1097/aln.0b013e31820c3973	https://www.ncbi.nlm.nih.gov/pubmed/?term=Peristaltic+Pneumatic+Compression+of+the+Legs+Reduces+Fluid+Demand+and+Improves+Hemodynamic+Stability+during+Surgery	1	2010-02-19	Completed	2009-02-01	2009-06-01	2011-03-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative fluid demand\n[ Time Frame: intraoperative ]\n\nIntraoperative = from induction of general anesthesia to end of the surgical procedure, length of procedure may vary (expected mean duration= 45 min)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative fluid demand\n[ Time Frame: intraoperative ]\n\nIntraoperative = from induction of general anesthesia to end of the surgical procedure, length of procedure may vary (expected mean duration= 45 min)""}]	NA	NA
NCT01072474	Capnography During ERCP	Capnographic monitoring of midazolam and propofol sedation during ERCP: a randomized controlled study (EndoBreath Study)	10.1055/s-0034-1393117	https://www.ncbi.nlm.nih.gov/pubmed/26415090?dopt=Abstract	3	2010-02-19	Completed	2010-02-01	2011-02-01	2015-09-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypoxemia\n[ Time Frame: From the beginning to the end of the ERCP procedure, i.e. from 0h to approximately 2h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypoxemia\n[ Time Frame: From the beginning to the end of the ERCP procedure, i.e. from 0h to approximately 2h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypoxemia\n[ Time Frame: From the beginning to the end of the ERCP procedure, i.e. from 0h to approximately 2h ]""}]	NA	NA
NCT01073917	Effects of Spontaneous Breathing Activity on Atelectasis Formation During General Anaesthesia	Spontaneous breathing during general anesthesia prevents the ventral redistribution of ventilation as detected by electrical impedance tomography: a randomized trial	10.1097/aln.0b013e318256ee08	http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933640	3	2010-02-22	Completed	2010-03-01	2010-10-01	2012-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Regional ventilation at the end of anaesthesia and at discharge from PACU compared to baseline values obtained before induction\n[ Time Frame: Before, during and after anesthesia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Regional ventilation at the end of anaesthesia and at discharge from PACU compared to baseline values obtained before induction\n[ Time Frame: Before, during and after anesthesia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Regional ventilation at the end of anaesthesia and at discharge from PACU compared to baseline values obtained before induction\n[ Time Frame: Before, during and after anesthesia ]""}]	NA	NA
NCT01074697	Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin	Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial	10.1016/s1470-2045(15)00615-4	https://pubmed.ncbi.nlm.nih.gov/26952945/	12	2010-02-23	Completed	2010-04-01	2015-04-01	2016-03-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.\n[ Time Frame: 35 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.\n[ Time Frame: 35 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.\n[ Time Frame: 35 days ]""}]	NA	NA
NCT01078168	Alzheimer's Disease Acitretin Medication	Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin	10.1212/wnl.0000000000001017	https://www.ncbi.nlm.nih.gov/pubmed/25344383	3	2010-03-01	Completed	2010-03-01	2013-01-01	2014-10-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in CSF APPSα concentration at Visit 3 compared to Baseline\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in CSF APPSα concentration at Visit 3 compared to Baseline\n[ Time Frame: 4 weeks ]""}]	NA	[See Results Section.]	NA
NCT01078298	Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression	Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial	10.7326/0003-4819-159-6-201309170-00005	https://www.ncbi.nlm.nih.gov/pubmed/24042367?dopt=Abstract	30	2010-02-26	Completed	2010-03-01	2011-09-01	2013-09-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the 4-week Continuous Quit Rate (CQR) for Weeks 9 through 12\n[ Time Frame: wk 9-12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the 4-week Continuous Quit Rate (CQR) for Weeks 9 through 12\n[ Time Frame: wk 9-12 ]""}]	[See Results Section.]	NA	NA
NCT01079104	Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units	First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis	10.1186/s12876-017-0569-x	https://www.ncbi.nlm.nih.gov/pubmed/28209134	6	2010-03-01	Terminated	2010-09-01	2013-08-01	2017-02-16	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]\n\nMortality 30 days after the first intervention""}]	NA
NCT01079442	Coffee Trial - Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?	Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy	10.1002/bjs.8885	http://onlinelibrary.wiley.com/doi/10.1002/bjs.8885/epdf	2	2010-03-02	Completed	2010-03-01	2011-03-01	2012-09-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of solid stool).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of solid stool).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of stool).""}]	NA	NA
NCT01080690	Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)	Endosonography For Right-sided and Acute Upper Intestinal Misery: the EFRAIM study: A prospective, randomized, controlled, blinded study	10.1177/2050640613498589	https://www.ncbi.nlm.nih.gov/pubmed/24917980	1	2010-03-03	Unknown status	NA	NA	2013-10-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Yield of the clinical diagnosis by EUS results alone will be compared to the yield by combined results of sonography, EGD and EUS.\n[ Time Frame: within the first week of complaints ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Yield of the clinical diagnosis by EUS results alone will be compared to the yield by combined results of sonography, EGD and EUS.\n[ Time Frame: within the first week of complaints ]""}]
NCT01081145	Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study	10.1111/jcpp.12492	https://www.ncbi.nlm.nih.gov/pubmed/26871297?dopt=Abstract	50	2010-03-04	Completed	2010-04-01	2013-06-01	2016-02-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)\n[ Time Frame: weekly ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Global Impressions- Severity of Illness Scale (CGI-S)\n[ Time Frame: weekly ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)\n[ Time Frame: weekly ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Global Impressions- Severity of Illness Scale (CGI-S)\n[ Time Frame: weekly ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01083030	Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis	Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial	10.1161/circinterventions.112.971630	http://circinterventions.ahajournals.org/content/5/6/831	3	2010-03-08	Completed	2010-03-01	2011-08-01	2012-11-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]\n\nEfficacy of paclitaxel coated percutaneous transluminal angioplasty (PTA) balloons in inhibiting restenosis of femoropopliteal arteries (late lumen loss)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]\n\nEfficacy of paclitaxel coated percutaneous transluminal angioplasty (PTA) balloons in inhibiting restenosis of femoropopliteal arteries (late lumen loss)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]\n\nEfficacy of paclitaxel coated percutaneous transluminal angioplasty (PTA) balloons in inhibiting restenosis of femoropopliteal arteries (late lumen loss)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss\n[ Time Frame: 6 months ]\n\nEfficacy of paclitaxel coated percutaneous transluminal angioplasty (PTA) balloons in inhibiting restenosis of femoropopliteal arteries (late lumen loss)""}]	NA
NCT01083394	Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery	ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial	10.1161/jaha.117.006321	NA	3	2010-03-08	Unknown status	2010-03-01	NA	2017-07-25	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage diameter stenosis\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage diameter stenosis\n[ Time Frame: 6 months ]""}]
NCT01084382	"" Arthrospira Platensis"" as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon	The effect of Arthrospira platensis capsules on CD4 T-cells and antioxidative capacity in a randomized pilot study of adult women infected with human immunodeficiency virus not under HAART in Yaoundé, Cameroon	10.3390/nu6072973	NA	2	2010-03-09	Completed	2010-04-01	2010-06-10	2014-07-23	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CD4 cell account\n[ Time Frame: 12 weeks ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CD4 cell account\n[ Time Frame: 12 weeks ]""}]	NA
NCT01086839	Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis	Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial	10.1016/j.jcf.2016.05.003	https://www.ncbi.nlm.nih.gov/pubmed/27267518	5	2010-03-12	Completed	2010-03-01	2013-04-01	2016-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Variations in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Variations in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	NA	NA
NCT01087723	European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial	Bivalirudin started during emergency transport for primary PCI	10.1056/nejmoa1311096	https://www.ncbi.nlm.nih.gov/pubmed/24171490?dopt=Abstract	6	2010-03-15	Completed	2010-02-01	2013-08-01	2013-10-30	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death , re-infarction (MI) or non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death and non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death and non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[See Results Section.]	NA
NCT01088620	Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer	CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status	10.1016/j.cllc.2015.05.009	https://linkinghub.elsevier.com/retrieve/pii/S1525-7304(15)00141-2	9	2010-03-16	Suspended	2010-04-01	NA	2015-06-02	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival rate at 6 months\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival rate at 6 months\n[ Time Frame: 6 months ]""}]
NCT01089231	Effects of Omega-3 Fatty Acids on the Human Gene Expression	Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men	10.1186/1743-7075-9-45	https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-9-45	5	2010-03-17	Completed	2010-03-01	2010-07-01	2012-03-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gene expression\n[ Time Frame: before, after four hours, after seven days and after three months ]\n\n\n\nto asses changes in gene expression patterns of male subjects (healthy vs. hyperlipidemic) after consumption of 3 g omega-3 fatty acids (2.5 g EPA/DHA) per day at different time points (four hours, seven days and three months)\n\nto detect differences in gene expression patterns between healthy subjects and subjects with hyperlipidemia""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gene expression\n[ Time Frame: before, after four hours, after seven days and after three months ]\n\n\n\nto asses changes in gene expression patterns of male subjects (healthy vs. hyperlipidemic) after consumption of 3 g omega-3 fatty acids (2.5 g EPA/DHA) per day at different time points (four hours, seven days and three months)\n\nto detect differences in gene expression patterns between healthy subjects and subjects with hyperlipidemia""}]	[See Results Section.]	NA	NA
NCT01092533	Myfortic for the Treatment of Non-infectious Intermediate Uveitis	Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial	10.1136/bjophthalmol-2017-310156	https://bjo.bmj.com/content/102/5/647.long	3	2010-03-24	Completed	2010-03-01	2015-10-01	2017-09-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from study entry to first relapse\n[ Time Frame: 6 months ]\n\nA log-rank test will be used to evaluate differences between the treatment and control group with the null hypothesis of no differences in the survival distributions between the two groups and the alternative hypothesis of different survival distributions. A two-sided log-rank test will be used at a significance level of 0.05.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from study entry to first relapse\n[ Time Frame: 6 months ]\n\nA log-rank test will be used to evaluate differences between the treatment and control group with the null hypothesis of no differences in the survival distributions between the two groups and the alternative hypothesis of different survival distributions. A two-sided log-rank test will be used at a significance level of 0.05.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from study entry to first relapse\n[ Time Frame: 6 months ]\n\nA log-rank test will be used to evaluate differences between the treatment and control group with the null hypothesis of no differences in the survival distributions between the two groups and the alternative hypothesis of different survival distributions. A two-sided log-rank test will be used at a significance level of 0.05.""}]	NA	NA
NCT01094080	Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health	Infant formula composition affects energetic efficiency for growth: the BeMIM study, a randomized controlled trial	10.1016/j.clnu.2013.12.007	NA	10	2010-03-25	Completed	2010-02-01	2011-08-01	2013-12-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: postnatal age 30 and 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: postnatal age 30 and 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight from day 30 to day 120\n[ Time Frame: postnatal age 30 to 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight from day 30 to day 120\n[ Time Frame: postnatal age 30 to 120 days ]""}]	NA
NCT01094145	Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease	Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia	10.1038/mp.2014.32	NA	4	2010-03-25	Completed	2010-01-01	2013-01-01	2014-05-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive improvement\n[ Time Frame: one- year ]\n\nimproving cognitive outcome parameters assessed by a series of standardized neuropsychological tests""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive improvement\n[ Time Frame: one- year ]\n\nimproving cognitive outcome parameters assessed by a series of standardized neuropsychological tests""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive improvement\n[ Time Frame: one- year ]\n\nimproving cognitive outcome parameters assessed by a series of standardized neuropsychological tests""}]	NA	NA
NCT01097434	Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography	10.1007/s10554-014-0376-1	https://www.ncbi.nlm.nih.gov/pubmed/24452729	4	2010-03-31	Completed	2010-04-01	2011-05-01	2014-01-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT for each evaluable strut segment\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT for each evaluable strut segment\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT\n[ Time Frame: 6-8 months ]""}]	NA	NA
NCT01097967	Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy	Longitudinal polysomnographic assessment from acute to subacute phase in infratentorial versus supratentorial stroke	10.1159/000356323	https://pubmed.ncbi.nlm.nih.gov/24435018/	7	2010-04-01	Unknown status	2010-07-01	NA	2014-01-16	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of new vascular events or death in stroke survivors (myocardial infarction, stroke, death) assessed by telephone or reported\n[ Time Frame: 24 monts after stroke ]\n\nNew vascular events will be assessed by regular telephone interviews at 6,12 and 24 months after stroke""}]	[]
NCT01098656	Lenalidomide Maintenance Post-debulking in Advanced CTCL	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs	10.1684/ejd.2017.3008	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01098656	11	2010-04-02	Terminated	2010-05-01	2016-04-01	2017-06-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	NA
NCT01101139	Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery	Postoperative impairment of motor function at train-of-four ratio ≥0.9 cannot be improved by sugammadex (1 mg kg-1)	10.1093/bja/aeu453	https://www.ncbi.nlm.nih.gov/pubmed/25586724?dopt=Abstract	2	2010-04-08	Completed	2010-04-01	2011-05-01	2015-01-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle functionMuscle function following the investigational drug""}]	NA	NA
NCT01101399	Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy	10.1007/s12032-014-0302-3	NA	6	2010-04-08	Completed	2010-05-01	2012-11-01	2014-11-06	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin from baseline to Week 4\n[ Time Frame: Weeks 4 post baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin from baseline to Week 4\n[ Time Frame: Weeks 4 post baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin from baseline to Week 4\n[ Time Frame: Weeks 4 post baseline ]""}]	NA	NA
NCT01103284	Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015929-37/results	13	2010-04-13	Completed	2010-04-01	2013-10-01	2016-07-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""beta-cell function, measured as change from baseline in stimulated C-peptide secretion (AUC) during a mixed-meal tolerance test\n[ Time Frame: 25 months after 1st administration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""beta-cell function, measured as change from baseline in stimulated C-peptide secretion (AUC) during a mixed-meal tolerance test\n[ Time Frame: 25 months after 1st administration ]""}]	[See Results Section.]	NA	NA
NCT01105143	Effects of Negative Energy Balance on Muscle Mass Regulation	Association between Subcutaneous Adipose Tissue Inflammation, Insulin Resistance, and Calorie Restriction in Obese Females	10.4049/jimmunol.2000108	https://pubmed.ncbi.nlm.nih.gov/32482712/	2	2010-04-15	Completed	2012-03-01	2015-05-01	2020-07-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg-1•min-1/(mU•L-1)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of muscle mass (in % of body weight)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg-1•min-1/(mU•L-1)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of muscle mass (in % of body weight)""}]	NA	NA
NCT01105351	Effect of Folic Acid on Primary Folate Forms in Relation to MTHFR	Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial	10.1007/s00394-015-0916-z	https://link.springer.com/article/10.1007%2Fs00394-015-0916-z	7	2010-04-15	Completed	2010-06-01	2012-12-01	2015-05-06	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood metabolic markers\n[ Time Frame: 18 months ]\n\nwe will measure primary folate forms after folic acid supplement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood metabolic markers\n[ Time Frame: 18 months ]\n\nwe will measure primary folate forms after folic acid supplement""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood metabolic markers\n[ Time Frame: 18 months ]\n\nwe will measure primary folate forms after folic acid supplement""}]	NA
NCT01106365	Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis	Effects of deep repetitive transcranial magnetic stimulation on brain-derived neurotrophic factor serum concentration in healthy volunteers	10.1159/000358088	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01106365	18	2010-04-16	Completed	2010-02-01	2013-02-01	2014-03-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 3x/week during treatment phase ]\n\nexamination by physician, assessement of adverse events""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 3x/week during treatment phase ]\n\nexamination by physician, assessement of adverse events""}]	NA
NCT01106430	Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate	Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study	10.1007/s40263-013-0104-8	NA	39	2010-04-16	Completed	2010-06-01	2014-01-01	2013-12-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical Global Impression-Improvement (CGI-I) Score\n[ Time Frame: 9 weeks ]\n\nClinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.""}]	[See Results Section.]	NA	[See Results Section.]	NA
NCT01106586	Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial	10.1016/s0140-6736(12)60918-0	https://www.ncbi.nlm.nih.gov/pubmed/22748590?dopt=Abstract	15	2010-04-19	Completed	2010-04-01	2011-11-01	2012-06-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	NA
NCT01106820	Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life	Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial	10.1002/ijc.29383	https://pubmed.ncbi.nlm.nih.gov/25484317/	6	2010-04-19	Completed	2010-04-01	2013-10-01	2014-12-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	NA
NCT01108146	Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder	No evidence for differential dose effects of hydrocortisone on intrusive memories in female patients with complex post-traumatic stress disorder--a randomized, double-blind, placebo-controlled, crossover study	10.1177/0269881115592339	https://www.ncbi.nlm.nih.gov/pubmed/26152322?dopt=Abstract	3	2010-04-20	Completed	2008-10-01	2012-10-01	2015-07-06	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the frequency and intensity of intrusions assessed with the subscale Intrusions of the Impact of Event Scale (IES-R)\n[ Time Frame: 4 Years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the frequency and intensity of intrusions assessed with the subscale Intrusions of the Impact of Event Scale (IES-R)\n[ Time Frame: 4 Years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the frequency and intensity of intrusions assessed with the subscale Intrusions of the Impact of Event Scale (IES-R)\n[ Time Frame: 4 Years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the frequency and intensity of intrusions assessed with the subscale Intrusions of the Impact of Event Scale (IES-R)\n[ Time Frame: 4 Years ]""}]	NA
NCT01108510	Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results	10.1093/infdis/jit122	https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jit122	11	2010-04-20	Completed	2010-04-01	2012-01-01	2013-03-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	NA
NCT01110720	Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial	10.1016/s1474-4422(14)70088-2	https://www.ncbi.nlm.nih.gov/pubmed/24873720	21	2010-04-26	Completed	2010-10-01	2012-10-01	2014-05-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy, as measured by the change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety, as measured by reported AEs, electrocardiograms (ECG), nasal examinations and clinical laboratory measures\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy, as measured by the change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety, as measured by reported AEs, electrocardiograms (ECG), nasal examinations and clinical laboratory measures\n[ Time Frame: 52 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy, as measured by the change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks\n[ Time Frame: 52 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety, as measured by reported AEs, electrocardiograms (ECG), nasal examinations and clinical laboratory measures\n[ Time Frame: 52 weeks ]""}]	NA	NA
NCT01110915	Advisa MRI Clinical Study	Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla	10.1016/j.hrthm.2013.01.022	https://www.ncbi.nlm.nih.gov/pubmed/23333721?dopt=Abstract	9	2010-04-23	Completed	2010-06-01	2012-03-01	2013-01-17	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.75V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.75V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[See Results Section.]	NA
NCT01112579	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study	10.1016/j.jchf.2015.10.006	https://pubmed.ncbi.nlm.nih.gov/26682789/	8	2010-04-27	Completed	2010-04-01	2014-09-01	2016-12-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular volumes as measured by cardiac echo\n[ Time Frame: Baseline and 6 months ]""}]	[See Results Section.]	NA	NA
NCT01112865	Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects	Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naïve children and adults	10.2147/mder.s59821	https://www.dovepress.com/results-from-an-international-multicenter-trial-evaluating-the-ease-of-peer-reviewed-article-MDER	27	2010-04-27	Completed	2010-07-01	2011-11-01	2014-04-11	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of dyads and adult subjects that reported the Genotropin Mark VII pen as no different or easier to use compared the current Genotropin Pen\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of dyads and adult subjects that reported the Genotropin Mark VII pen as no different or easier to use compared the current Genotropin Pen\n[ Time Frame: 4 months ]""}]	[See Results Section.]	NA	NA
NCT01114165	Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients	Impact of multiplex PCR on antimicrobial treatment in febrile neutropenia: a randomized controlled study	10.1007/s00430-014-0385-7	https://www.ncbi.nlm.nih.gov/pubmed/25573349	5	2010-04-30	Completed	2010-05-01	2012-09-01	2015-01-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of changes in empirical antimicrobial therapy\n[ Time Frame: up to the end of study participation ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to the change to the targeted antimicrobial therapy\n[ Time Frame: at time point of change to the targeted antimicrobial therapy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of changes in empirical antimicrobial therapy\n[ Time Frame: up to the end of study participation ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to the change to the targeted antimicrobial therapy\n[ Time Frame: at time point of change to the targeted antimicrobial therapy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The number of changes in empirical antimicrobial therapy\n[ Time Frame: up to the end of study participation ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to the change to the targeted antimicrobial therapy\n[ Time Frame: at time point of change to the targeted antimicrobial therapy ]""}]	NA	NA
NCT01115101	Superiority Study for Pain Treatment After Cesarean	Pain management after cesarean: a randomized controlled trial of oxycodone versus intravenous piritramide	10.1007/s00404-012-2384-5	https://www.ncbi.nlm.nih.gov/pubmed/22622852	4	2010-05-03	Completed	2009-07-01	2009-11-01	2012-05-24	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of Pain Scores on the Visual Analog Scale\n[ Time Frame: 6 month ]\n\n\n\nThe primary outcome measure was the change in patients assessment of pain after cesarean (CS) from baseline.\n\nFor pain assessment a visual analog scale (VAS) was used. Women were asked to quantify pain using an eleven point numerical rating score from 0 to 10, with 0 indicating no pain, and 10 the worst pain. Pain level was evaluated before therapy (2h after CS), 12h, 24h, 32h, 40h, 48 and 72h after CS.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of Pain Scores on the Visual Analog Scale\n[ Time Frame: 6 month ]\n\n\n\nThe primary outcome measure was the change in patients assessment of pain after cesarean (CS) from baseline.\n\nFor pain assessment a visual analog scale (VAS) was used. Women were asked to quantify pain using an eleven point numerical rating score from 0 to 10, with 0 indicating no pain, and 10 the worst pain. Pain level was evaluated before therapy (2h after CS), 12h, 24h, 32h, 40h, 48 and 72h after CS.""}]	[See Results Section.]	NA
NCT01115192	Blephacura Versus Baby Shampoo to Treat Blepharitis	[Eyelid hygiene for contact lens wearers with blepharitis. Comparative investigation of treatment with baby shampoo versus phospholipid solution]	10.1007/s00347-012-2725-6	https://link.springer.com/article/10.1007/s00347-012-2725-6	4	2010-05-03	Completed	2009-06-01	2010-12-01	2013-01-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[]	[]	[]	[]	NA
NCT01117519	Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery	Influence of goal-directed therapy with balanced crystalloid-colloid or unbalanced crystalloid solution on base excess	10.1177/0300060513509548	https://www.ncbi.nlm.nih.gov/pubmed/24514432	9	2010-05-04	Completed	2010-05-01	2011-06-01	2014-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: up to 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	NA	NA
NCT01117597	Terrestrial Trunked Radio (TETRA) and Cognitive Functions in Healthy Subjects	Do signals of a hand-held TETRA transmitter affect cognitive performance, well-being, mood or somatic complaints in healthy young men? Results of a randomized double-blind cross-over provocation study	10.1016/j.envres.2015.03.021	https://pubmed.ncbi.nlm.nih.gov/25839715/	4	2010-05-04	Completed	2010-04-01	2013-09-01	2015-03-31	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in cognitive tests\n[ Time Frame: acute effect under exposure will be assessed for a period of 3 hours for 9 test sessions (two weeks apart, three sessions for every exposure condition) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in cognitive tests\n[ Time Frame: acute effect under exposure will be assessed for a period of 3 hours for 9 test sessions (two weeks apart, three sessions for every exposure condition) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in cognitive tests\n[ Time Frame: acute effect under exposure will be assessed for a period of 3 hours for 9 test sessions (two weeks apart, three sessions for every exposure condition) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in cognitive tests\n[ Time Frame: acute effect under exposure will be assessed for a period of 3 hours for 9 test sessions (two weeks apart, three sessions for every exposure condition) ]""}]	NA
NCT01117818	Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease	Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales	10.14283/jpad.2015.67	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746013/	8	2010-05-04	Completed	2010-09-01	2013-12-01	2016-02-08	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 18 months ]""}]	NA	NA
NCT01119261	EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol	A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon	10.1056/nejmoa1311388	https://www.ncbi.nlm.nih.gov/pubmed/24251360?dopt=Abstract	6	2010-05-06	Completed	2010-11-01	2013-03-01	2013-11-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT01119274	EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon	A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon	10.1056/nejmoa1311388	https://www.ncbi.nlm.nih.gov/pubmed/24251360?dopt=Abstract	4	2010-05-06	Completed	2010-11-01	2013-01-01	2013-11-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of patients with INR > or = 4.0, which indicates overanticoagulation\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of patients with INR > or = 4.0, which indicates overanticoagulation\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of patients with INR > or = 4.0, which indicates overanticoagulation\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT01119300	EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin	A randomized trial of genotype-guided dosing of warfarin	10.1056/nejmoa1311386	https://www.ncbi.nlm.nih.gov/pubmed/24251363?dopt=Abstract	4	2010-05-06	Completed	2011-01-01	2013-01-01	2013-11-19	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy\n[ Time Frame: 12 weeks ]""}]	NA
NCT01119469	Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis	Cognitive therapy versus exposure therapy for hypochondriasis (health anxiety): A randomized controlled trial	10.1037/ccp0000013	https://pubmed.ncbi.nlm.nih.gov/25495359/	11	2010-05-06	Completed	2010-06-01	2013-06-01	2014-12-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Illness Attitude Scales (IAS)\n[ Time Frame: 3 months ]\n\nself-report measure that assesses attitudes, fears, and beliefs associated with the psychopathology of hypochondriasis and that of abnormal illness behavior""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""}]	NA	NA
NCT01121666	Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment	NA	NA	https://insights.ovid.com/human-reproduction/hurep/2013/06/001/108-phase-iii-assessor-blinded-randomised-multi/137/00004683	8	2010-05-11	Completed	2010-06-01	2011-12-01	2013-01-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[See Results Section.]	NA
NCT01123473	Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer	NA	10.1200/jco.2015.33.3_suppl.80	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.80	9	2010-05-13	Terminated	2010-09-01	2013-08-01	2015-01-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	NA
NCT01123512	The Kiva® System as a Vertebral Augmentation Treatment	KAST Study: The Kiva System As a Vertebral Augmentation Treatment-A Safety and Effectiveness Trial: A Randomized, Noninferiority Trial Comparing the Kiva System With Balloon Kyphoplasty in Treatment of Osteoporotic Vertebral Compression Fractures	10.1097/brs.0000000000000906	https://www.ncbi.nlm.nih.gov/pubmed/25822543	16	2010-05-12	Completed	2010-07-01	2012-08-01	2015-06-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm Visual Analog Scale (VAS)\n[ Time Frame: 12 Month Post-op ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI)\n[ Time Frame: 12 Month Post-op ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Absence of device-related serious adverse events, defined as device-related adverse events requiring surgical reintervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation\n[ Time Frame: 12 Month Post-op ]""}]	[See Results Section.]	NA	NA
NCT01124214	Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)	In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video)	10.1016/j.gie.2013.09.020	https://www.ncbi.nlm.nih.gov/pubmed/24219822?dopt=Abstract	22	2010-05-14	Completed	2010-04-01	2012-12-01	2013-11-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year, 6 months for early outcome analysis ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with High Grade Dysplasia (HGD) or Carcinoma (CA) divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	NA
NCT01124786	A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity	10.1200/jco.2013.51.0826	http://ascopubs.org/doi/full/10.1200/jco.2013.51.0826	35	2010-05-14	Completed	2010-05-01	2012-10-01	2013-11-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[See Results Section.]	NA
NCT01130493	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066	Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients	10.1016/j.parkreldis.2014.08.004	https://www.ncbi.nlm.nih.gov/pubmed/25306200	20	2010-05-24	Completed	2010-05-01	2011-03-01	2014-08-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[See Results Section.]	NA
NCT01137305	Soft Skills and Surgical Performance	Do soft skills predict surgical performance?: a single-center randomized controlled trial evaluating predictors of skill acquisition in virtual reality laparoscopy	10.1007/s00268-010-0933-2	https://www.ncbi.nlm.nih.gov/pubmed/21190109	2	2010-06-03	Completed	2008-06-01	2009-01-01	2010-12-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VR- performance after training\n[ Time Frame: Three months ]\n\nOutcome measurement comprised defined parameters of VR- performance including \""time to complete task\"", economy of instrument motion\"" and \""tissue damage\"" within the most complex module \""diathermy cutting\"" as primary endpoint.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VR- performance after training\n[ Time Frame: Three months ]\n\nOutcome measurement comprised defined parameters of VR- performance including \""time to complete task\"", economy of instrument motion\"" and \""tissue damage\"" within the most complex module \""diathermy cutting\"" as primary endpoint.""}]	NA	NA
NCT01137968	Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer	10.1093/annonc/mdu550	https://www.ncbi.nlm.nih.gov/pubmed/25467017	23	2010-06-04	Completed	2010-05-01	2012-05-01	2014-12-02	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression, as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	NA
NCT01143233	Low-protein Infant Formula With Partial or Extensive Proteinhydrolysate 4 Year Follow-up	Hydrolyzed Formula With Reduced Protein Content Supports Adequate Growth: A Randomized Controlled Noninferiority Trial	10.1097/mpg.0000000000001853	https://pubmed.ncbi.nlm.nih.gov/29216020/	9	2010-06-11	Completed	2010-04-01	2014-07-01	2018-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: 4 months ]\n\nThe intervention is to assess average weight gain in the first 4 months of life.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: 4 months ]\n\nThe intervention is to assess average weight gain in the first 4 months of life.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: 4 months ]\n\nThe intervention is to assess average weight gain in the first 4 months of life.""}]	NA	NA
NCT01143272	Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial	10.1093/ofid/ofw011	https://www.ncbi.nlm.nih.gov/pubmed/26973849?dopt=Abstract	9	2010-06-11	Terminated	2010-06-01	2012-11-01	2016-01-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative incidence of any antibiotic-associated diarrhoea\n[ Time Frame: 2 years ]\n\nCumulative incidence of any antibiotic-associated diarrhoea""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative incidence of any antibiotic-associated diarrhoea\n[ Time Frame: 2 years ]\n\nCumulative incidence of any antibiotic-associated diarrhoea""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hazard of any antibiotic-associated diarrhoea\n[ Time Frame: 29 months ]\n\nhazard of any antibiotic-associated diarrhoea""}]	[See Results Section.]	NA
NCT01145092	Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes	A single nucleotide polymorphism associates with the response of muscle ATP synthesis to long-term exercise training in relatives of type 2 diabetic humans	10.2337/dc11-1426	NA	1	2010-06-15	Completed	2006-02-01	2009-03-01	2011-12-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin Sensitivitymeasured by oral glucose tolerance test""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin Sensitivitymeasured by oral glucose tolerance test""}]	NA	NA
NCT01145404	Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer	Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie	10.1016/j.ejca.2015.01.059	https://www.ncbi.nlm.nih.gov/pubmed/25694417	11	2010-06-15	Terminated	2010-06-01	2013-06-01	2015-02-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate (ORR)\n[ Time Frame: about 10 month (until progression) ]\n\n\n\nObjective response rate (ORR, complete and partial remission according to RECIST criteria\n\n- all to be confirmed by at least two consecutive tumor response assessments within no shorter than 4 weeks)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate (ORR)\n[ Time Frame: about 10 month (until progression) ]\n\n\n\nObjective response rate (ORR, complete and partial remission according to RECIST criteria\n\n- all to be confirmed by at least two consecutive tumor response assessments within no shorter than 4 weeks)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate (ORR)\n[ Time Frame: about 10 month (until progression) ]\n\n\n\nObjective response rate (ORR, complete and partial remission according to RECIST criteria\n\n- all to be confirmed by at least two consecutive tumor response assessments within no shorter than 4 weeks)""}]	NA	NA
NCT01146444	Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)	Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus	10.1111/exd.12428	https://www.ncbi.nlm.nih.gov/pubmed/24758584	5	2010-06-16	Completed	2009-11-01	2011-09-01	2014-07-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE\n[ Time Frame: September 2011 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE\n[ Time Frame: September 2011 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE\n[ Time Frame: September 2011 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE\n[ Time Frame: September 2011 ]""}]	NA
NCT01147874	Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics	10.1016/j.jaad.2013.07.023	NA	10	2010-06-17	Completed	2010-08-01	2011-09-01	2013-08-24	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The prevalence of PsA in subjects with psoriasis based on a clinical rheumatology assessment.\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The prevalence of PsA in subjects with psoriasis as determined by clinical assessment by a rheumatologist including physical exam, medical history and results from laboratory analysis.\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	NA	NA
NCT01147939	Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)	International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia	10.1200/jco.2013.52.8562	https://www.ncbi.nlm.nih.gov/pubmed/24841975?dopt=Abstract	31	2010-06-21	Completed	2010-06-01	2013-06-01	2014-05-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until death or until 6 months follow-up is completed for all patients ]\n\nTime from date of randomisation until the date of death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until 300 events occur ]\n\nTime from date of randomisation until the date of death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until 300 events occur ]\n\nTime from date of randomisation until the date of death""}]	NA	NA
NCT01148264	Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis	NA	NA	https://d-nb.info/1117028305/34	5	2010-06-21	Terminated	2010-07-01	2013-10-01	2016-06-16	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical benefit rate\n[ Time Frame: three days ]\n\nno vomitus, no further rescue medication, nausea < 25mm on the visual analog scale (VAS) or reduction on the VAS of >50%""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical benefit rate\n[ Time Frame: three days ]\n\nno vomitus, no further rescue medication, nausea < 25mm on the visual analog scale (VAS) or reduction on the VAS of >50%""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical benefit rate\n[ Time Frame: three days ]\n\nno vomitus, no further rescue medication, nausea < 25mm on the visual analog scale (VAS) or reduction on the VAS of >50%""}]	NA	NA
NCT01149109	Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial	10.1016/s0140-6736(18)31791-4	https://pubmed.ncbi.nlm.nih.gov/30782343/	6	2010-06-22	Completed	2010-10-01	2015-02-01	2019-02-14	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: after follow up (4 years) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: after follow up (4 years) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: after follow up (4 years) ]""}]	NA	NA
NCT01153139	Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression	Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial	10.1016/j.jad.2013.12.025	https://www.ncbi.nlm.nih.gov/pubmed/24411682	4	2010-06-28	Completed	2010-04-01	2012-08-01	2013-12-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Montgomery-Åsberg Depression Rating Scale (MADRS) after 6 weeks of treatment\n[ Time Frame: baseline, after the end of treatment (week 6) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)\n[ Time Frame: after the end of treatment (week 6) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)\n[ Time Frame: after the end of treatment (week 6) ]""}]	NA	NA
NCT01154140	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung	First-line crizotinib versus chemotherapy in ALK-positive lung cancer	10.1056/nejmoa1408440	https://www.ncbi.nlm.nih.gov/pubmed/25470694	82	2010-06-29	Completed	2011-01-01	2013-11-01	2014-12-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)\n[ Time Frame: 35 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS)\n[ Time Frame: 35 months ]\n\nThe period from study entry until disease progression, death or date of last contact. Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS)\n[ Time Frame: 35 months ]\n\nThe period from study entry until disease progression, death or date of last contact. Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)""}]	[See Results Section.]	NA
NCT01159366	Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI	Incidence and distribution of occluded culprit arteries and impact of coronary collaterals on outcome in patients with non-ST-segment elevation myocardial infarction and early invasive treatment strategy	10.1007/s00392-010-0269-9	https://link.springer.com/article/10.1007/s00392-010-0269-9	2	2010-07-08	Completed	2006-07-01	2009-12-01	2010-12-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MACE\n[ Time Frame: 6 months ]\n\ncomposite of death, reinfarction and readmission for unstable angina within 6 months after inclusion""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MACE\n[ Time Frame: 6 months ]\n\ncomposite of death, reinfarction and readmission for unstable angina within 6 months after inclusion""}]	NA	NA
NCT01163032	Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder	Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials	10.1016/s0140-6736(15)60031-9	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60031-9/fulltext	28	2010-07-13	Completed	2010-08-01	2012-11-01	2015-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective average total night time sleep\n[ Time Frame: Weeks 3-6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the efficacy of tasimelteon in subjects with N24HSWD as measured by the proportion of entrainment.\n[ Time Frame: 4 weeks ]\n\nTo determine the efficacy of tasimelteon in entraining the endogenous circadian melatonin rhythm to the 24 hour period in patients with N24HSWD.""}]	[See Results Section.]	NA	NA
NCT01163734	Ranolazine in Diastolic Heart Failure	RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study	10.1016/j.jchf.2012.12.002	https://www.ncbi.nlm.nih.gov/pubmed/24621836?dopt=Abstract	3	2010-07-14	Completed	2010-04-01	2011-02-01	2013-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 30 minutes in cardiac catheterization hemodynamic parameters at both resting and paced conditions\n[ Time Frame: Baseline to 30 minutes ]\n\n\n\nChange from baseline to 30 minutes from initiation of study drug bolus No.1 in cardiac catheterization hemodynamic parameters at both resting and paced conditions:\n\nTime-constant of relaxation (tau)\n\nLeft ventricular end-diastolic pressure (LVEDP)\n\ndP/dtmin (minimal rate of LV pressure change)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 30 minutes in cardiac catheterization hemodynamic parameters at both resting and paced conditions\n[ Time Frame: Baseline to 30 minutes ]\n\n\n\nChange from baseline to 30 minutes from initiation of study drug bolus No.1 in cardiac catheterization hemodynamic parameters at both resting and paced conditions:\n\nTime-constant of relaxation (tau)\n\nLeft ventricular end-diastolic pressure (LVEDP)\n\ndP/dtmin (minimal rate of LV pressure change)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 30 minutes in cardiac catheterization hemodynamic parameters at both resting and paced conditions\n[ Time Frame: Baseline to 30 minutes ]\n\n\n\nChange from baseline to 30 minutes from initiation of study drug bolus No.1 in cardiac catheterization hemodynamic parameters at both resting and paced conditions:\n\nTime-constant of relaxation (tau)\n\nLeft ventricular end-diastolic pressure (LVEDP)\n\ndP/dtmin (minimal rate of LV pressure change)""}]	NA	NA
NCT01164059	Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study	10.1016/s2215-0366(16)00085-7	http://www.sciencedirect.com/science/article/pii/S2215036616000857?via%3Dihub	4	2010-07-15	Completed	2010-02-01	2013-08-01	2016-06-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Contentment with treatment: Patient (SF-36)\n[ Time Frame: 24 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Contentment with treatment: Psychiatrist (CGI)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Contentment with treatment: Patient (SF-36)\n[ Time Frame: 24 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Contentment with treatment: Psychiatrist (CGI)\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Contentment with treatment: Patient (SF-36)\n[ Time Frame: 24 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Contentment with treatment: Psychiatrist (CGI)\n[ Time Frame: 24 weeks ]""}]	NA	NA
NCT01166243	The Fibrin Pad Liver Study	A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery	10.1111/j.1477-2574.2012.00583.x	https://www.ncbi.nlm.nih.gov/pubmed/23216780?dopt=Abstract	11	2010-07-20	Completed	2010-07-01	2011-08-01	2012-10-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).\n[ Time Frame: Intra-operative ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).\n[ Time Frame: Intra-operative ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).\n[ Time Frame: Intra-operative ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).\n[ Time Frame: Intra-operative ]""}]	NA
NCT01166997	ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism	Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism	10.1161/circulationaha.113.005544	https://www.ncbi.nlm.nih.gov/pubmed/24226805?dopt=Abstract	10	2010-07-20	Completed	2010-07-01	2013-04-01	2013-11-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[See Results Section.]	NA
NCT01167075	A Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin)	Tolerability and efficacy of a low-volume enteral supplement containing key nutrients in the critically ill	10.1016/j.clnu.2011.04.003	http://www.sciencedirect.com/science/article/pii/S0261561411000689	1	2010-07-21	Completed	2006-02-01	2009-02-01	2011-05-31	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Length of stay in ICU\n[ Time Frame: 14 days ]\n\nThe primary endpoints were length of stay in ICU and sufficient enteral feed.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Length of stay in ICU\n[ Time Frame: 14 days ]\n\nThe primary endpoints were length of stay in ICU and sufficient enteral feed.""}]	NA	NA
NCT01168791	Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma	10.1200/jco.2016.67.6684	https://www.ncbi.nlm.nih.gov/pubmed/27621408	34	2010-07-21	Completed	2010-07-01	2012-07-01	2016-11-10	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months, then every 12 weeks until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival followed by Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival followed by Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death ]""}]	NA	NA
NCT01171274	Effects of Hatha Yoga on Chronic Neck Pain	Randomized-controlled trial comparing yoga and home-based exercise for chronic neck pain	10.1097/ajp.0b013e318251026c	https://www.ncbi.nlm.nih.gov/pubmed/?term=Randomized-controlled+Trial+Comparing+Yoga+and+Home-based+Exercise+for+Chronic+Neck+Pain	7	2010-07-27	Completed	2010-08-01	2010-12-01	2013-03-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 11 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 11 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 10 ]\n\n100mm visual analog scale""}]	NA	NA
NCT01171339	Prioritising and Optimising Multi-medication in Multimorbidity	NA	10.3205/11dkvf049	http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/29505	5	2010-07-27	Completed	2010-08-01	2011-11-01	2013-04-03	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Medication Appropriateness Index (MAI)-Score\n[ Time Frame: 6 months from baseline ]\n\nDifference in Medication Appropriateness Index (MAI)-Score 6 months from baseline minus baseline (MAI T1-T0)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Medication Appropriateness Index (MAI)-Score\n[ Time Frame: 6 months from baseline ]\n\nDifference in Medication Appropriateness Index (MAI)-Score 6 months from baseline minus baseline (MAI T1-T0)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Medication Appropriateness Index (MAI)-Score\n[ Time Frame: 6 months from baseline ]\n\nDifference in Medication Appropriateness Index (MAI)-Score 6 months from baseline minus baseline (MAI T1-T0)""}]	NA
NCT01171820	SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)	The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions	10.1016/j.ahj.2012.02.006	https://www.ncbi.nlm.nih.gov/pubmed/22607866	3	2010-07-27	Completed	2006-11-01	2009-07-01	2012-04-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-stent Late Loss(LL)\n[ Time Frame: 270 days ]""}]	NA	[See Results Section.]	[See Results Section.]	NA
NCT01172119	BioFreedom FIM Clinical Trial.	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial	10.1016/j.jcin.2015.09.008	http://www.sciencedirect.com/science/article/pii/S1936879815013928?via%3Dihub	2	2010-07-28	Completed	2008-08-01	2010-06-01	2016-01-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-Stent Late Lumen Loss at 12 months post-procedure.\n[ Time Frame: 12 Months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-Stent Late Lumen Loss at 12 months post-procedure.\n[ Time Frame: 12 Months ]""}]	NA	NA
NCT01172938	Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor	10.1136/annrheumdis-2013-205056	http://ard.bmj.com/content/73/6/1020.long	23	2010-07-28	Completed	2010-06-01	2012-04-01	2014-03-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline\n[ Time Frame: Weeks 0-24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline\n[ Time Frame: Weeks 0-24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""American College of Rheumatology 20 (ACR 20)\n[ Time Frame: 16 weeks ]\n\nProportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline after 16 weeks of treatment""}]	[See Results Section.]	NA
NCT01174420	Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany	Trabeculectomy using mitomycin C versus an atelocollagen implant: clinical results of a randomized trial and histopathologic findings	10.1159/000356400	https://www.ncbi.nlm.nih.gov/pubmed/24401481	3	2010-08-02	Unknown status	2009-11-01	NA	2013-12-24	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraocular pressure (IOP) reduction\n[ Time Frame: 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraocular pressure (IOP) reduction\n[ Time Frame: 6 months ]""}]
NCT01174498	Pilot Study of the Effect of Transcutaneous Stimulation of the Vagus Nerve on Pain Perception and Parameters of the Autonomic Nervous System	The effect of transcutaneous vagus nerve stimulation on pain perception--an experimental study	10.1016/j.brs.2012.04.006	https://www.ncbi.nlm.nih.gov/pubmed/22621941	3	2010-08-02	Completed	2009-11-01	2010-07-01	2012-05-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""QST- Quantitative Sensory Testing\n[ Time Frame: twice a day, two days in total ]\n\nmeasurement of pain with the qst method before and after the transcutaneous stimulation""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""QST- Quantitative Sensory Testing\n[ Time Frame: twice a day, two days in total ]\n\nmeasurement of pain with the qst method before and after the transcutaneous stimulation""}]	NA	NA
NCT01174992	A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair	A multicentre, prospective, randomized, controlled study to evaluate the use of a fibrin sealant as an adjunct to sutured dural repair	10.3109/02688697.2014.948808	NA	4	2010-08-03	Completed	2010-07-01	2011-09-01	2014-08-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of success\n[ Time Frame: Day 1 (intraoperative) ]\n\nProportion of success (intraoperative watertight closure) in the treatment of intraoperative CSF leakage.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of success\n[ Time Frame: Day 1 (intraoperative) ]\n\nProportion of success (intraoperative watertight closure) in the treatment of intraoperative CSF leakage.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of success\n[ Time Frame: Day 1 (intraoperative) ]\n\nProportion of success (intraoperative watertight closure) in the treatment of intraoperative CSF leakage.""}]	NA	NA
NCT01175265	Effects of Breathing Retraining in Patients With Chronic Obstructive Pulmonary Disease (COPD)	The effects of controlled breathing during pulmonary rehabilitation in patients with COPD	10.1159/000324449	https://www.ncbi.nlm.nih.gov/pubmed/21474911	1	2010-08-03	Completed	2008-11-01	2009-08-01	2011-04-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cardiopulmonary exercise capacity6-minute walking distance, 6MWD""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cardiopulmonary exercise capacity6-minute walking distance, 6MWD""}]	NA	NA
NCT01176721	Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia	Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study	10.1007/s00406-015-0618-9	https://www.ncbi.nlm.nih.gov/pubmed/26210303	7	2010-08-05	Completed	2010-03-01	2010-12-01	2015-07-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of t-VNS in schizophrenia\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of t-VNS in schizophrenia\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of t-VNS in schizophrenia\n[ Time Frame: 24 weeks ]""}]	NA	NA
NCT01176968	Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study	10.1093/eurheartj/ehu164	https://www.ncbi.nlm.nih.gov/pubmed/24780614	27	2010-08-04	Completed	2010-09-01	2012-10-01	2014-04-29	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation.\n[ Time Frame: 0-18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation.\n[ Time Frame: 0-18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality,re-hospitalization or extended initial hospital stay due to diagnosis of heart failure,sustained ventricular tachycardia or fibrillation,ejection fraction ≤40% or BNP above age adjusted cut off\n[ Time Frame: 0-23 months ]""}]	[See Results Section.]	NA
NCT01178255	Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)	Homeopathy for depression: a randomized, partially double-blind, placebo-controlled, four-armed study (DEP-HOM)	10.1371/journal.pone.0074537	https://www.ncbi.nlm.nih.gov/pubmed/24086352	4	2010-08-09	Terminated	2010-08-01	2011-11-01	2013-09-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the total score on the 17-item Hamilton Depression Rating Scale - (HAM-D)\n[ Time Frame: six weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the mean total depression score post treatment\n[ Time Frame: six weeks ]\n\ntotal score on the 17-item Hamilton Depression Rating Scale - (HAM-D)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the mean total depression score post treatment\n[ Time Frame: six weeks ]\n\ntotal score on the 17-item Hamilton Depression Rating Scale - (HAM-D)""}]	NA	NA
NCT01179789	New E-Service for a Dietary Approach to the Elderly	Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The ""RISTOMED project"": Randomized controlled trial in healthy older people	10.1016/j.clnu.2014.09.023	https://www.ncbi.nlm.nih.gov/pubmed/25453395?dopt=Abstract	2	2010-08-10	Completed	2009-10-01	2010-08-01	2014-10-08	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""High-sensitivity C-reactive protein (hs-CRP) as measure of systemic low-grade inflammation (cardiovascular risk)\n[ Time Frame: 2 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""High-sensitivity C-reactive protein (hs-CRP) as measure of systemic low-grade inflammation (cardiovascular risk)\n[ Time Frame: 2 months ]""}]	NA	NA
NCT01179971	n-3 and n-6 Fatty Acids in Rheumatoid Arthritis	Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial	10.1186/1476-511x-10-130	https://www.ncbi.nlm.nih.gov/pubmed/21816071?dopt=Abstract	2	2010-08-10	Completed	2008-12-01	2010-01-01	2011-08-04	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incorporation of eicosapentaenoic acid in plasma lipids\n[ Time Frame: 12 weeks ]\n\nratio of arachidonic acid/eicosapentaenoic acid in plasma lipids""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incorporation of eicosapentaenoic acid in plasma lipids\n[ Time Frame: 12 weeks ]\n\nratio of arachidonic acid/eicosapentaenoic acid in plasma lipids""}]	NA	NA
NCT01180322	Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine	Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine	10.1038/s41375-019-0395-y	https://www.nature.com/articles/s41375-019-0395-y	6	2010-08-11	Completed	2010-11-01	2013-01-01	2019-02-06	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rates of complete remission (CR) after induction therapy\n[ Time Frame: 56 days ]\n\nTo evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rates of complete remission (CR) after induction therapy\n[ Time Frame: 56 days ]\n\nTo evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rates of complete remission (CR) after induction therapy\n[ Time Frame: 56 days ]\n\nTo evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rates of complete remission (CR) after induction therapy\n[ Time Frame: 56 days ]\n\nTo evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate""}]	NA
NCT01180400	A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder	Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant	10.1016/j.euroneuro.2013.12.008	https://www.sciencedirect.com/science/article/pii/S0924977X13003532	13	2010-08-11	Completed	2010-08-01	2011-08-01	2013-12-21	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 8 (baseline) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 9 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 10 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 8 (baseline) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 9 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 10 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01181206	Covering of the Abdominal Wall in Laparotomies: Differences in Surgical Site Infections Between an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven Swabs at Technische Universität München	Multicenter double-blinded randomized controlled trial of standard abdominal wound edge protection with surgical dressings versus coverage with a sterile circular polyethylene drape for prevention of surgical site infections: a CHIR-Net trial (BaFO; NCT01181206)	10.1097/sla.0000000000000954	NA	5	2010-08-12	Completed	2010-08-01	2013-08-01	2014-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical site infections\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical site infections\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical site infections\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical site infections\n[ Time Frame: 3 years ]""}]	NA
NCT01181401	InductionChemo-Radio-Antibody-Treatment	NA	10.1200/jco.2016.34.15_suppl.6035	https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6035	3	2010-08-12	Completed	2010-08-01	2015-04-01	2016-05-20	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.\n[ Time Frame: August 2010- December 2012 ]\n\nacute hematological toxicity""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.\n[ Time Frame: August 2010- December 2012 ]\n\nacute hematological toxicity""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.\n[ Time Frame: August 2010- December 2012 ]\n\nacute hematological toxicity""}]	NA
NCT01186263	Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy	Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-Microspheres Used in Preradioembolization Dosimetry: Influence on the Liver-Lung Shunt	10.2967/jnumed.115.169987	NA	3	2010-08-20	Completed	2010-07-01	2011-07-01	2016-02-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy\n[ Time Frame: Tc-99m MAA scan one day prior to radioembolisation; Bremsstahlen-Scan after SIR spheres therapy ]\n\nThe percentage in liver volume for which the accumulation of SIR spheres during therapy was correctly predicted by Tc-99m MAA will be given by a blinded reader in categories by visual assessment (0-10%, >10-20%, >20-30%, …, >90-100%) (only patients who received Tc-99m MAA during evaluation.)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy\n[ Time Frame: Tc-99m MAA scan one day prior to radioembolisation; Bremsstahlen-Scan after SIR spheres therapy ]\n\nThe percentage in liver volume for which the accumulation of SIR spheres during therapy was correctly predicted by Tc-99m MAA will be given by a blinded reader in categories by visual assessment (0-10%, >10-20%, >20-30%, …, >90-100%) (only patients who received Tc-99m MAA during evaluation.)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy\n[ Time Frame: Tc-99m MAA scan one day prior to radioembolisation; Bremsstahlen-Scan after SIR spheres therapy ]\n\nThe percentage in liver volume for which the accumulation of SIR spheres during therapy was correctly predicted by Tc-99m MAA will be given by a blinded reader in categories by visual assessment (0-10%, >10-20%, >20-30%, …, >90-100%) (only patients who received Tc-99m MAA during evaluation.)""}]	NA	NA
NCT01186510	Lung Perfusion With Oxygenated Blood During Aortic Clamping	The influence of selective pulmonary perfusion on the inflammatory response and clinical outcome of patients with chronic obstructive pulmonary disease undergoing cardiopulmonary bypass	10.1093/icvts/ivu062	https://academic.oup.com/icvts/article-lookup/doi/10.1093/icvts/ivu062	4	2010-08-20	Completed	2010-08-01	2012-11-01	2014-03-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker\n[ Time Frame: 5 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker\n[ Time Frame: 5 days ]""}]	NA	NA
NCT01186861	Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer	10.1038/bjc.2017.226	https://www.ncbi.nlm.nih.gov/pubmed/28772281	33	2010-08-19	Completed	2010-11-01	2013-06-01	2017-08-03	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib (Arm A), or erlotinib and placebo (Arm B) in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC\n[ Time Frame: 22 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	NA
NCT01187134	Medical Education for Sepsis Source Control and Antibiotics	Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study	10.1186/cc13755	https://www.ncbi.nlm.nih.gov/pubmed/24589043?dopt=Abstract	10	2010-08-20	Completed	2011-07-01	2013-06-01	2014-03-03	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause mortality\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause mortality\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause mortality\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause mortality\n[ Time Frame: 28 days ]""}]	NA
NCT01187888	Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy	PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy	10.1007/s00415-016-8169-1	https://www.ncbi.nlm.nih.gov/pubmed/27230855	4	2010-08-23	Terminated	2010-01-01	2012-06-01	2016-05-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exerct a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exerct a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exert a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	NA	NA
NCT01188902	The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women	Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial	10.1016/j.metabol.2013.11.005	https://www.ncbi.nlm.nih.gov/pubmed/24360749	4	2010-08-25	Completed	2010-08-01	2012-04-01	2013-11-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT01189253	Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma	A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial	10.1016/j.ejca.2015.03.023	https://www.ncbi.nlm.nih.gov/pubmed/25912752	18	2010-08-25	Terminated	2010-12-01	2013-06-01	2015-04-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival as assessed by RECIST v 1.1 criteria (phase IIB and phase III)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety (phase IIB)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival as assessed by RECIST v 1.1 criteria (phase IIB and phase III)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety (phase IIB)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival as assessed by RECIST v 1.1 criteria (phase IIB and phase III)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety (phase IIB)""}]	NA	NA
NCT01191359	Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch	Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study	10.1016/j.jaci.2014.03.026	https://www.ncbi.nlm.nih.gov/pubmed/24794686	3	2010-08-27	Completed	2010-01-01	2010-12-01	2014-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch\n[ Time Frame: after 4, 8, 12, 24, 36 weeks of treatment ]\n\nspecific antibody determination""}]	NA	NA
NCT01194219	Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)	10.1016/j.jaad.2015.03.049	https://www.ncbi.nlm.nih.gov/pubmed/26089047	30	2010-09-01	Completed	2010-08-01	2012-02-01	2015-07-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving at least a 75% improvement in Psoriasis Area Severity Index (PASI) score.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving at least a 75% improvement in Psoriasis Area Severity Index (PASI) score.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01196195	KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)	Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children	10.1097/qad.0000000000000862	NA	6	2010-09-07	Completed	2010-08-01	2012-07-01	2015-11-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nAUC, Cmin and Cmax values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 Ribonucleic acid (RNA) ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmacokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nArea under the curve (AUC), minimum observed plasma concentration (Cmin) and maximum observed plasma concentration (Cmax) values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 Ribonucleic acid (RNA) ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmacokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nArea under the curve (AUC), minimum observed plasma concentration (Cmin) and maximum observed plasma concentration (Cmax) values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	NA	NA
NCT01197508	A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy	10.3109/15622975.2014.989261	https://www.ncbi.nlm.nih.gov/pubmed/25602163?dopt=Abstract	10	2010-09-08	Completed	2010-09-01	2012-02-01	2015-01-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery_Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16)\n[ Time Frame: Will be scored at Weeks 8 (baseline), 9, 10, 12, 14 and 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery_Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16)\n[ Time Frame: Will be scored at Weeks 8 (baseline), 9, 10, 12, 14 and 16 ]""}]	[See Results Section.]	NA	NA
NCT01199276	Hip Fracture Surgery in Elderly Patients	The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial	10.1016/j.bja.2017.11.015	https://pubmed.ncbi.nlm.nih.gov/29397119/	20	2010-09-09	Completed	2010-09-01	2011-09-01	2017-11-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post Operative Delirium diagnosed with the Confusion Assessment Method within four days post-surgery\n[ Time Frame: Four days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post Operative Delirium diagnosed with the Confusion Assessment Method within four days post-surgery\n[ Time Frame: Four days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post Operative Delirium diagnosed with the Confusion Assessment Method within four days post-surgery\n[ Time Frame: Four days ]""}]	NA	NA
NCT01200121	Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers	Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108	10.1016/j.ejca.2016.05.004	https://www.sciencedirect.com/science/article/abs/pii/S0959804916321268	9	2010-09-10	Completed	2010-02-01	2013-10-01	2016-06-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paracentesis-free survival (ParFS)\n[ Time Frame: one year ]\n\nThe first primary endpoint will consist of paracentesis-free survival (ParFS) which will be calculated as the time period between the initial puncture after randomization to the first subsequent paracentesis or other symptomatic treatments for ascites with the exception of diuretics or until death (whichever occurs first)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paracentesis-free survival (ParFS)\n[ Time Frame: one year ]\n\nThe first primary endpoint will consist of paracentesis-free survival (ParFS) which will be calculated as the time period between the initial puncture after randomization to the first subsequent paracentesis or other symptomatic treatments for ascites with the exception of diuretics or until death (whichever occurs first)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paracentesis-free survival (ParFS)\n[ Time Frame: one year ]\n\nThe first primary endpoint will consist of paracentesis-free survival (ParFS) which will be calculated as the time period between the initial puncture after randomization to the first subsequent paracentesis or other symptomatic treatments for ascites with the exception of diuretics or until death (whichever occurs first)""}]	NA	NA
NCT01200420	Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects	Treatment of HCV infection by targeting microRNA	10.1056/nejmoa1209026	http://www.nejm.org/doi/full/10.1056/NEJMoa1209026	6	2010-09-10	Completed	2010-09-01	2011-12-01	2013-03-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: regularly over 18 weeks ]\n\nSafety evaluation will study the adverse event (AE) profile, clinical laboratory safety tests, vital signs, 12 lead and ECG monitoring.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: regularly over 18 weeks ]\n\nSafety evaluation will study the adverse event (AE) profile, clinical laboratory safety tests, vital signs, 12 lead and ECG monitoring.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: regularly over 18 weeks ]\n\nSafety evaluation will study the adverse event (AE) profile, clinical laboratory safety tests, vital signs, 12 lead and ECG monitoring.""}]	NA	NA
NCT01203228	Dose-reduced Versus Standard Conditioning in MDS/sAML	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)	10.1200/jco.2016.70.7349	https://ascopubs.org/doi/full/10.1200/JCO.2016.70.7349	11	2010-09-15	Terminated	2004-05-01	2014-12-01	2017-05-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""non-relapse mortality\n[ Time Frame: every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""non-relapse mortality\n[ Time Frame: every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""non-relapse mortality\n[ Time Frame: every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation ]""}]	NA	NA
NCT01203254	Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease	Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study	10.1016/j.crohns.2014.05.009	https://www.ncbi.nlm.nih.gov/pubmed/24953836?dopt=Abstract	6	2010-09-15	Terminated	2010-10-01	2011-10-01	2014-06-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of fluid stool > 30 %\n[ Time Frame: 4 weeks after baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of fluid stool > 30 %\n[ Time Frame: 4 weeks after baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of fluid stool > 30 %\n[ Time Frame: 4 weeks after baseline ]""}]	NA	NA
NCT01205906	Comparison of an Internet-based Guided Self-help and a Group Therapy for Chronic Tinnitus	Internet-based guided self-help versus group cognitive behavioral therapy for chronic tinnitus: a randomized controlled trial	10.1159/000360705	NA	4	2010-09-20	Completed	2010-05-01	2011-03-01	2014-06-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress""}]	NA	NA
NCT01205919	Internet-based Guided Self-help for Chronic Tinnitus	Internet-Delivered Cognitive-Behavior Therapy for Tinnitus: A Randomized Controlled Trial	10.1097/psy.0000000000000310	https://www.ncbi.nlm.nih.gov/pubmed/26867083?dopt=Abstract	3	2010-09-20	Completed	2010-05-01	2010-10-01	2016-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Handicap Inventory (THI; Newman, Jacobson, & Spitzer, 1996; German version: Kleinjung et al., 2007)\n[ Time Frame: 18 months ]\n\nThe measure assesses tinnitus-related disability and handicap.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MINI-Tinnitus Questionnaire (Mini-TQ; Hiller & Goebel, 2004)\n[ Time Frame: 18 months ]\n\nThe measure is a short version of the Tinnitus Questionnaire (TQ, Goebel & Hiller, 1998), to assess tinnitus-related psychological distress.""}]	NA	NA
NCT01206790	Immunological Changes Through Narrative Treatment of Post-Traumatic Stress Disorder (PTSD) in Torture Victims	The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: evidence from a randomized controlled trial	10.1016/j.jpsychires.2014.03.016	https://www.ncbi.nlm.nih.gov/pubmed?term=10.1016%2Fj.jpsychires.2014.03.016	3	2010-09-21	Completed	2009-06-01	2011-05-01	2014-05-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTSD diagnosis and severity score according to the Clinicians Administered PTSD Scale (CAPS)\n[ Time Frame: 4 month after completion of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTSD diagnosis and severity score according to the Clinicians Administered PTSD Scale (CAPS)\n[ Time Frame: 4 month after completion of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTSD diagnosis and severity score according to the Clinicians Administered PTSD Scale (CAPS)\n[ Time Frame: 4 month after completion of treatment ]""}]	NA	NA
NCT01207960	Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Dental Phobia	Efficacy of a trauma-focused treatment approach for dental phobia: a randomized clinical trial	10.1111/eos.12090	https://www.ncbi.nlm.nih.gov/pubmed/24206075	3	2010-09-22	Completed	2010-01-01	2011-09-01	2013-09-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dental anxiety\n[ Time Frame: 4 weeks ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dental anxiety\n[ Time Frame: 3 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Dental anxiety\n[ Time Frame: 12 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dental anxiety\n[ Time Frame: 4 weeks ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dental anxiety\n[ Time Frame: 3 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Dental anxiety\n[ Time Frame: 12 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dental anxiety\n[ Time Frame: 4 weeks ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dental anxiety\n[ Time Frame: 3 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Dental anxiety\n[ Time Frame: 12 months ]\n\nDental anxiety is assessed by the Dental Anxiety Scale (DAS) and the Dental Fear Survey (DFS).""}]	NA	NA
NCT01208194	Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial	10.1007/s00432-014-1682-7	NA	4	2010-09-22	Completed	2010-06-01	2012-12-01	2014-05-10	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of median progression-free survival (PFS) in both treatment groups\n[ Time Frame: Measured on accrual time 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of median progression-free survival (PFS) in both treatment groups\n[ Time Frame: Measured on accrual time 3 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of median progression-free survival (PFS) in both treatment groups\n[ Time Frame: Measured on accrual time 3 years ]""}]	NA
NCT01208233	Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke	Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial	10.1016/j.jstrokecerebrovasdis.2015.11.026	https://www.ncbi.nlm.nih.gov/pubmed/26738812?dopt=Abstract	37	2010-09-22	Terminated	2010-12-01	2014-03-01	2015-12-28	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability assessed by an Independent Data and Safety Monitoring Board (DSMB) using data, including AEs , vital signs, brain MRI, ECG, physical (including neurological) examination, NIHSS scores, laboratory tests.\n[ Time Frame: Day 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects with Modified Rankin Scale (mRS) less than or equal to 2\n[ Time Frame: Day 90 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability assessed by an Independent Data and Safety Monitoring Board (DSMB) using data, including SAEs, AEs , vital signs, brain MRI, ECG, physical (including neurological) examination, NIHSS scores, laboratory tests.\n[ Time Frame: Day 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects with Modified Rankin Scale (mRS) less than or equal to 2\n[ Time Frame: Day 90 ]""}]	NA	[See Results Section.]	NA
NCT01209208	Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis	Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis	10.1053/j.gastro.2018.08.042	https://pubmed.ncbi.nlm.nih.gov/30195447/	11	2010-09-24	Completed	2010-05-01	2017-06-01	2018-09-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT01209377	Study of Eye Movement Desensitization and Reprocessing (EMDR) Working Mechanism	A Comparison of Dual Attention, Eye Movements, and Exposure Only during Eye Movement Desensitization and Reprocessing for Posttraumatic Stress Disorder: Results from a Randomized Clinical Trial	10.1159/000447671	NA	1	2010-09-24	Unknown status	NA	NA	2016-10-15	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CAPS-2: Clinical Administered PTSD Scale\n[ Time Frame: 30 minutes ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CAPS-2: Clinical Administered PTSD Scale\n[ Time Frame: 30 minutes ]""}]
NCT01209637	Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD	Coronary Collateral Growth Induced by Physical Exercise: Results of the Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable Coronary Artery Disease (EXCITE) Trial	10.1161/circulationaha.115.016442	https://www.ncbi.nlm.nih.gov/pubmed/26979085?dopt=Abstract	3	2010-09-24	Completed	2010-03-01	2012-12-01	2016-03-15	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""coronary collateral blod flow\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""coronary collateral blod flow\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""coronary collateral blod flow\n[ Time Frame: 4 weeks ]""}]	NA
NCT01212718	Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase	Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial	10.1016/j.ejca.2011.11.007	http://www.sciencedirect.com/science/article/pii/S0959804911009002	1	2010-09-30	Completed	2001-07-01	2010-06-01	2011-11-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best response to first-line chemotherapy (recist)\n[ Time Frame: 1 year ]\n\nResponse to chemotherapy was evaluated and documented according to the RECIST criteria after every therapy cycle (every two months).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best response to first-line chemotherapy (recist)\n[ Time Frame: 1 year ]\n\nResponse to chemotherapy was evaluated and documented according to the RECIST criteria after every therapy cycle (every two months).""}]	NA	NA
NCT01214278	Bioavailability of Different n-3 Fatty Acid Formulations	Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil	10.1186/1476-511x-10-145	https://www.ncbi.nlm.nih.gov/pubmed/21854650	4	2010-10-04	Completed	2010-10-01	2010-11-01	2011-08-22	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""EPA- and DHA levels\n[ Time Frame: baseline ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""EPA- and DHA levels\n[ Time Frame: two hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""EPA- and DHA levels\n[ Time Frame: four hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EPA- and DHA level\n[ Time Frame: six hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""EPA- and DHA levels\n[ Time Frame: eight hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""EPA- and DHA levels\n[ Time Frame: 24 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""EPA- and DHA levels\n[ Time Frame: 48 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""EPA- and DHA levels\n[ Time Frame: 72 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""EPA- and DHA levels\n[ Time Frame: baseline ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""EPA- and DHA levels\n[ Time Frame: two hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""EPA- and DHA levels\n[ Time Frame: four hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EPA- and DHA level\n[ Time Frame: six hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""EPA- and DHA levels\n[ Time Frame: eight hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""EPA- and DHA levels\n[ Time Frame: 24 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""EPA- and DHA levels\n[ Time Frame: 48 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""EPA- and DHA levels\n[ Time Frame: 72 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under concentration time curve (AUC)\n[ Time Frame: about 24 hours ]\n\nConcentration of eicosapentanoiec acid (EPA) and docosahexanoiec acid (DHA) was measured at baseline and after 2, 4, 6, 8 and 24 hours.""}]	NA
NCT01215071	Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA	Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy	10.1016/j.eururo.2014.07.046	http://www.sciencedirect.com/science/article/pii/S0302283814007362	4	2010-10-05	Completed	2006-03-01	2013-03-01	2014-08-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free Survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free Survival\n[ Time Frame: 5 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free Survival (RFS)\n[ Time Frame: 5 years ]\n\nDefinition Recurrence-free survival: Time from radical cystectomy to tumor reccurence or death from any cause up to 5 years""}]	NA
NCT01215266	Sorafenib in Urothelium Cancer of Bladder	Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)	10.1111/bju.12437	https://www.ncbi.nlm.nih.gov/pubmed/24053564	3	2010-10-05	Terminated	2006-10-01	2011-03-01	2014-03-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: 5 years ]""}]	NA	NA
NCT01216605	Oxytocin and Emotion Recognition	Oxytocin differentially modulates eye gaze to naturalistic social signals of happiness and anger	10.1016/j.psyneuen.2012.10.002	https://www.cambridge.org/core/services/aop-cambridge-core/content/view/A106EFEBD6EC4D83DE46C0C9694B778D/S0033291712002565a.pdf/intranasal_oxytocin_increases_covert_attention_to_positive_social_cues.pdf (maybe same data as the second publication?)

http://www.sciencedirect.com/science/article/pii/S030645301200337X?via%3Dihub

http://www.sciencedirect.com/science/article/pii/S0306453011002307?via%3Dihub	1	2010-10-06	Completed	2009-11-01	2010-01-01	2012-10-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance on a facial emotion recognition task\n[ Time Frame: 45 min. following drug administration ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance on a facial emotion recognition task\n[ Time Frame: 45 min. following drug administration ]""}]	NA	NA
NCT01217528	Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients	Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study	10.1007/s00392-015-0870-z	https://link.springer.com/article/10.1007%2Fs00392-015-0870-z	6	2010-10-07	Completed	2009-08-01	2012-07-01	2015-05-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEventfree survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEventfree survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEvent free survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEvent free survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	NA
NCT01218217	Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB	Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients	10.1093/jac/dku553	https://www.ncbi.nlm.nih.gov/pubmed/25630641	6	2010-10-08	Completed	2010-11-01	2011-09-01	2015-01-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.\n[ Time Frame: Daily during first two weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.\n[ Time Frame: Daily during first two weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.\n[ Time Frame: Daily during first two weeks ]""}]	NA	NA
NCT01219244	Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)	Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment	10.1016/j.neuroimage.2015.09.050	https://pubmed.ncbi.nlm.nih.gov/26433119/	11	2010-10-12	Completed	2010-08-01	2016-07-01	2015-10-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale - cognitive subscale\n[ Time Frame: Prior to intervention and after 6 months of intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale - cognitive subscale\n[ Time Frame: Prior to intervention and after 6 months of intervention ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale - cognitive subscale\n[ Time Frame: Prior to intervention and after 6 months of intervention ]""}]	NA
NCT01220856	NA	NA	NA	NA	6	2010-10-13	Completed	2010-07-01	2012-11-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of insulin-independent patients following a single donor-single islet cell transplantation\n[ Time Frame: day 75 +/- 5 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The proportion of insulin-independent patients after a single donor-single islet cell transplantation\n[ Time Frame: up to one year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Time to achieve insulin-independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Total time of insulin independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""13."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""14."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""15."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""16."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""17."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: monh 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""18."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""19."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""20."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""21."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""22."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""23."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""24."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""25."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""26."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""27."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""28."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 12 post-transplant ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of insulin-independent patients following a single donor-single islet cell transplantation\n[ Time Frame: day 75 +/- 5 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The proportion of insulin-independent patients after a single donor-single islet cell transplantation\n[ Time Frame: up to one year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Time to achieve insulin-independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Total time of insulin independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""13."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""14."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""15."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""16."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""17."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: monh 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""18."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""19."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""20."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""21."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""22."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""23."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""24."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""25."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""26."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""27."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""28."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 12 post-transplant ]""}]	NA	NA	[See Results Section.]
NCT01221610	BIOLUX P-I First in Man Study	Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial	10.1177/1526602814564383	http://journals.sagepub.com/doi/abs/10.1177/1526602814564383	6	2010-10-14	Completed	2010-10-01	NA	2015-02-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).\n[ Time Frame: 6 months ]""}]
NCT01221779	Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation	Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia	10.1093/brain/aww002	https://pubmed.ncbi.nlm.nih.gov/26912641/	3	2010-10-14	Unknown status	2011-01-01	NA	2016-02-16	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Boston Naming Test\n[ Time Frame: Change of naming score from baseline (day 1 of study) to immediately after 2-week intervention period (post-testing) ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Boston Naming Test\n[ Time Frame: Change of naming score from baseline (day 1 of study) to immediately after 2-week intervention period (post-testing) ]""}]
NCT01223352	Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension	A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3	10.1111/bcp.13267	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510076/	25	2010-10-15	Completed	2011-01-01	2013-08-01	2017-03-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure to bosentan (AUC over 24 hours)\n[ Time Frame: 24 hours ]\n\nDaily exposure to bosentan, i.e., AUC over a period of 24 h (AUC0-24h), and calculated as a multiple of the exposure over a dosing interval (AUCτ), 3 × AUCτ and 2 × AUCτ for three times and two times daily dosing, respectively.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure to bosentan (AUC over 24 hours)\n[ Time Frame: 24 hours ]\n\nDaily exposure to bosentan, i.e., AUC over a period of 24 h (AUC0-24h), and calculated as a multiple of the exposure over a dosing interval (AUCτ), 3 × AUCτ and 2 × AUCτ for three times and two times daily dosing, respectively.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure [AUC(0-24c)] to bosentan\n[ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment ]\n\n\n\nDaily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours [AUC(0-24)].\n\nConcentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau (i.e., the AUC over a dosing interval): AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen. As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].""}]	[See Results Section.]	NA
NCT01223677	Rumination-focused CBT Training for the Prevention of Depression and Anxiety	Prevention of anxiety disorders and depression by targeting excessive worry and rumination in adolescents and young adults: A randomized controlled trial	10.1016/j.brat.2016.12.015	https://pubmed.ncbi.nlm.nih.gov/28049069/	3	2010-10-18	Completed	2010-10-01	2013-07-01	2016-12-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II (BDI-II)\n[ Time Frame: 1 year after training has ended ]\n\nself-report questionnaire of depressive symptom severity""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II (BDI-II)\n[ Time Frame: 1 year after training has ended ]\n\nself-report questionnaire of depressive symptom severity""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II (BDI-II)\n[ Time Frame: 1 year after training has ended ]\n\nself-report questionnaire of depressive symptom severity""}]	NA	NA
NCT01224379	Comparison of Standard Fusion With ""Topping Off""-System in Lumbar Spine	Comparison of standard fusion with a ""topping off"" system in lumbar spine surgery: a protocol for a randomized controlled trial	10.1186/1471-2474-12-239	https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-12-239	1	2010-10-19	Unknown status	NA	NA	2011-10-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SF36\n[ Time Frame: 6 Month ]\n\n\n\nPrimary efficacy endpoint:\n\nThe baseline and follow-up values after 6 weeks after the operation as well as 6 and 12 months after baseline of the SF-36 (Short-Form-36)-Measured Outcome regarding the Physical Component Summary (PCS).""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SF36\n[ Time Frame: 6 Month ]\n\n\n\nPrimary efficacy endpoint:\n\nThe baseline and follow-up values after 6 weeks after the operation as well as 6 and 12 months after baseline of the SF-36 (Short-Form-36)-Measured Outcome regarding the Physical Component Summary (PCS).""}]
NCT01225133	Complex Āyurvedic Treatment in Osteoarthritis of the Knee Compared to Standard Care.	Effectiveness of an Ayurveda treatment approach in knee osteoarthritis - a randomized controlled trial	10.1016/j.joca.2018.01.022	https://pubmed.ncbi.nlm.nih.gov/29426006/	13	2010-10-19	Completed	2010-10-01	2013-03-01	2018-02-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster University Osteoarthritis Index (WOMAC)\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster University Osteoarthritis Index (WOMAC)\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Western Ontario and McMaster University Osteoarthritis Index (WOMAC)\n[ Time Frame: week 12 ]""}]	NA	NA
NCT01225380	A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C	Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed	10.1002/hep.27836	https://www.ncbi.nlm.nih.gov/pubmed/25847509	14	2010-10-19	Completed	2010-10-01	2012-09-01	2012-05-20	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""}]	NA
NCT01228149	COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy	Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma	10.1371/journal.pone.0171636	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310886/	7	2010-10-25	Completed	2010-08-01	2014-04-01	2017-02-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[See Results Section.]	NA
NCT01228799	Trabeculectomy Versus Canaloplasty	Trabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial	10.1111/aos.12722	http://onlinelibrary.wiley.com/doi/10.1111/aos.12722/full	3	2010-10-26	Completed	2010-06-01	2012-12-01	2015-04-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 1 year ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 2 years ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 1 year ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 2 years ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 1 year ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""success rate (complete and qualified success)\n[ Time Frame: 2 years ]\n\nSuccess is defined 1. IOP < 21 mmHg and at least 20% IOP reduction from baseline 2. IOP < 18 mmHg""}]	NA	NA
NCT01229306	Repeat Ablation Procedure in Patients With Relapse of Atrial Fibrillation	Recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation: is repeat pulmonary vein isolation enough? A prospective, randomized trial	10.1093/europace/euu389	NA	2	2010-10-26	Unknown status	2010-07-01	NA	2015-02-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Freedom of atrial arrhythmias""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Freedom of atrial arrhythmias""}]
NCT01229774	Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty	Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac	10.1007/s00264-015-3077-z	https://www.springermedizin.de/comparative-clinical-study-of-the-prophylaxis-of-heterotopic-oss/8241318	3	2010-10-27	Completed	2011-02-01	2014-08-01	2016-04-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perioperative blood loss after implantation of a hip joint endoprosthesis\n[ Time Frame: Three days ]\n\nThe primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac. The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.""}]	NA	NA
NCT01230086	Trop-Shock DFT-testing Versus None	ICD Shock, Not Ventricular Fibrillation, Causes Elevation of High Sensitive Troponin T after Defibrillation Threshold Testing--The Prospective, Randomized, Multicentre TropShock-Trial	10.1371/journal.pone.0131570	https://www.ncbi.nlm.nih.gov/pubmed/26208329?dopt=Abstract	5	2010-10-27	Completed	2010-08-01	2013-03-01	2015-07-24	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of hs Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	NA
NCT01230723	Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography	Tissue characterization after drug-eluting stent implantation using optical coherence tomography	10.1161/atvbaha.113.301227	https://www.ncbi.nlm.nih.gov/pubmed/23539216	2	2010-10-28	Unknown status	2010-10-01	NA	2013-03-28	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Degree of stent strut coverage assessed by OCT for each visible strut segment\n[ Time Frame: 6-8 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Degree of stent strut coverage assessed by OCT for each visible strut segment\n[ Time Frame: 6-8 months ]""}]
NCT01232283	Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)	10.1111/bjd.14164	https://www.ncbi.nlm.nih.gov/pubmed/26357944	25	2010-11-01	Completed	2010-11-01	2012-03-01	2015-11-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects who achieve at least a 75% reduction in Psoriasis Area Severity Index (PASI-75) at Week 16 from baseline.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects who achieve at least a 75% reduction in Psoriasis Area Severity Index (PASI-75) at Week 16 from baseline.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01233180	Effects of Gua Sha and Thermotherapy on Chronic Neck Pain	Effectiveness of traditional Chinese ""gua sha"" therapy in patients with chronic neck pain: a randomized controlled trial	10.1111/j.1526-4637.2011.01053.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2011.01053.x/full	3	2010-11-02	Completed	2010-09-01	2011-02-01	2011-01-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Day 4 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Day 4 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Day 4 ]""}]	NA
NCT01234194	Composite Variability Index and Propofol Remifentanil Anesthesia	The response of the composite variability index to a standardized noxious stimulus during propofol-remifentanil anesthesia	10.1213/ane.0b013e31827ced18	https://www.ncbi.nlm.nih.gov/pubmed/23400975	1	2010-11-03	Completed	2009-11-01	2010-07-01	2013-02-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prediction Probability of CVI versus remifentanil effect compartment concentration and versus movement after painful stimulus""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prediction Probability of CVI versus remifentanil effect compartment concentration and versus movement after painful stimulus""}]	NA	NA
NCT01234233	Effects of Preoperative Warming of Patients on Postoperative Hypothermia and Shivering	Correlation, accuracy, precision and practicability of perioperative measurement of sublingual temperature in comparison with tympanic membrane temperature in awake and anaesthetised patients	10.1097/eja.0b013e32834cd6de	http://journals.lww.com/ejanaesthesiology/pages/articleviewer.aspx?year=2012&issue=02000&article=00003&type=abstract	5	2010-11-03	Completed	2010-03-01	2011-03-01	2012-02-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic (body temperature < 36°C) patients at postoperative arrival at postoperative care unit (PACU)\n[ Time Frame: postoperative arrival at PACU (once) ]\n\nAfter surgery patients will be admitted to PACU. Body temperature will be evaluted here to study the number of hypothermic patients depended from duration of preoperative warming.Time frame for assessment of data: 5 min after postoperative arrival at PACU (one single measurement, duration: 30 sec).Afterwards patients will be observed for about 2h.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic (body temperature < 36°C) patients at postoperative arrival at postoperative care unit (PACU)\n[ Time Frame: postoperative arrival at PACU (once) ]\n\nAfter surgery patients will be admitted to PACU. Body temperature will be evaluted here to study the number of hypothermic patients depended from duration of preoperative warming.Time frame for assessment of data: 5 min after postoperative arrival at PACU (one single measurement, duration: 30 sec).Afterwards patients will be observed for about 2h.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic (body temperature < 36°C) patients at postoperative arrival at postoperative care unit (PACU)\n[ Time Frame: postoperative arrival at PACU (once) ]\n\nAfter surgery patients will be admitted to PACU. Body temperature will be evaluted here to study the number of hypothermic patients depended from duration of preoperative warming.Time frame for assessment of data: 5 min after postoperative arrival at PACU (one single measurement, duration: 30 sec).Afterwards patients will be observed for about 2h.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic (body temperature < 36°C) patients at postoperative arrival at postoperative care unit (PACU)\n[ Time Frame: postoperative arrival at PACU (once) ]\n\nAfter surgery patients will be admitted to PACU. Body temperature will be evaluted here to study the number of hypothermic patients depended from duration of preoperative warming.Time frame for assessment of data: 5 min after postoperative arrival at PACU (one single measurement, duration: 30 sec).Afterwards patients will be observed for about 2h.""}]	NA
NCT01234662	Influence of Surgical Regional Anesthesia on Postoperative Pain	Neuraxial anesthesia for pain control after cesarean section: a prospective randomized trial comparing three different neuraxial techniques in clinical practice	NA	https://www.ncbi.nlm.nih.gov/pubmed/26207431	5	2010-11-03	Unknown status	2010-11-01	NA	2015-07-24	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative pain levels during movement (cough)\n[ Time Frame: At nine hours after the end of surgery (closure time) ]\n\nPatient self-assessed postoperative pain levels during movement (cough) using an unmarked zero to one hundred mm visual analog scale (VAS)""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative pain levels during movement (cough)\n[ Time Frame: At nine hours after the end of surgery (closure time) ]\n\nPatient self-assessed postoperative pain levels during movement (cough) using an unmarked zero to one hundred mm visual analog scale (VAS)""}]
NCT01236807	MR INFORM - MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease	Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease	10.1056/nejmoa1716734	https://pubmed.ncbi.nlm.nih.gov/31216398/	4	2010-11-08	Completed	2010-12-01	2016-08-01	2019-06-20	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""}]	NA	NA
NCT01238107	A Clinical Study With MT-102 in Subjects With Cancer Cachexia	Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)	10.1002/jcsm.12126	http://onlinelibrary.wiley.com/doi/10.1002/jcsm.12126/full	8	2010-11-09	Completed	2011-04-01	2013-05-01	2016-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer\n[ Time Frame: 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer\n[ Time Frame: 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer\n[ Time Frame: 16 weeks ]""}]	NA	NA
NCT01240083	Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression	Bilateral prefrontal rTMS and theta burst TMS as an add-on treatment for depression: a randomized placebo controlled trial	10.3109/15622975.2014.964768	https://www.ncbi.nlm.nih.gov/pubmed/25430687	3	2010-11-12	Completed	2010-04-01	2011-09-01	2014-11-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: 19 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: 19 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: 19 days ]""}]	NA	NA
NCT01241591	A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial	10.1016/s0140-6736(14)62113-9	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962113-9/supplemental	26	2010-11-12	Completed	2010-11-01	2013-01-01	2015-06-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 12\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response ie, the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline, at Week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 12\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response ie, the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline, at Week 12.\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01244048	Intervention With n3 LC-PUFA-supplemented Yogurt	Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors	10.1016/j.clnu.2012.12.010	http://www.sciencedirect.com/science/article/pii/S026156141200283X	2	2010-11-18	Completed	2008-10-01	2008-11-01	2012-12-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)\n[ Time Frame: change from baseline after 5 weeks or 10 weeks ]\n\n\n\nchange from baseline after 5 weeks (first period) 10 weeks wash-out change from baseline after 10 weeks (second period)\n\nGroup 1: placebo (first and second period) Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day (first and second period) Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day (first and second period)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)\n[ Time Frame: change from baseline after 10 weeks ]\n\n\n\nchange from baseline after 10 weeks\n\nGroup 1: placebo Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day""}]	NA	NA
NCT01244061	A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider	Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial	10.1038/clpt.2014.124	https://www.ncbi.nlm.nih.gov/pubmed/24911368	30	2010-11-18	Completed	2010-12-01	2012-11-01	2014-06-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Continuous Abstinence Rate for Weeks 9-12 (CAR 9-12)\n[ Time Frame: Weeks 9-12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Continuous Abstinence Rate for Weeks 9-12 (CAR 9-12)\n[ Time Frame: Weeks 9-12 ]""}]	[See Results Section.]	NA	NA
NCT01244490	Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)	Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial	10.1016/j.euroneuro.2014.09.014	https://www.ncbi.nlm.nih.gov/pubmed/25453486?dopt=Abstract	25	2010-11-18	Completed	2010-12-01	2013-08-01	2014-10-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score\n[ Time Frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score\n[ Time Frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01245075	Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction	Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction	10.1038/mp.2012.196	https://www.nature.com/articles/mp2012196.pdf	3	2010-11-19	Unknown status	2011-01-01	NA	2013-01-22	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Levomethadone\n[ Time Frame: seven month ]\n\nReduction of the dosage of the substitute (in detail Levomethadone) comparing baseline and the particular ward rounds during and at the end of the crossover-design.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Levomethadone\n[ Time Frame: seven month ]\n\nReduction of the dosage of the substitute (in detail Levomethadone) comparing baseline and the particular ward rounds during and at the end of the crossover-design.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of Levomethadone\n[ Time Frame: seven month ]\n\nReduction of the dosage of the substitute (in detail Levomethadone) comparing baseline and the particular ward rounds during and at the end of the crossover-design.""}]
NCT01247051	Comparison of Two Different Heart-lung Machine Filling Methods: Precoating Versus Colloidal Fluids	Pre-filling of the extracorporeal circuit with autologous blood is safe, but not effective in optimizing biocompatibility in high-risk patients	10.1177/0267659112447654	NA	2	2010-11-23	Completed	NA	2011-08-01	2012-05-25	FALSE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss\n[ Time Frame: 24 hours ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss""}]
NCT01249638	Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC	NA	10.1200/jco.18.00052	NA	2	2010-11-29	Unknown status	NA	NA	2018-11-02	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TFS\n[ Time Frame: 9 months ]\n\nTime of Failure Strategy""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TFS\n[ Time Frame: 9 months ]\n\nTime of Failure Strategy""}]
NCT01250106	Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications	Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept	10.2337/dc14-2690	https://www.ncbi.nlm.nih.gov/pubmed/26084343	3	2010-11-29	Unknown status	2010-11-01	NA	2015-06-17	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin resistance\n[ Time Frame: 8 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin resistance\n[ Time Frame: 8 weeks ]""}]
NCT01251328	Near INfrared Spectroscopy in Aortic valvE ReplacemenT	Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcome†	10.1093/bja/aev294	https://www.ncbi.nlm.nih.gov/pubmed/26424178?dopt=Abstract	4	2010-11-30	Completed	2010-12-01	2012-04-01	2015-09-29	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period and periprocedural\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	NA	NA
NCT01252459	NA	NA	NA	NA	2	2010-12-02	Unknown status	NA	NA	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS)\n[ Time Frame: 6 months after randomization ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS)\n[ Time Frame: 6 months after randomization ]""}]
NCT01252940	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF	Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants	10.1097/qad.0000000000000087	http://journals.lww.com/aidsonline/Abstract/2014/01280/Simplification_to.6.aspx	12	2010-12-02	Completed	2010-11-01	2012-02-01	2014-01-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 24\n[ Time Frame: 24 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 24\n[ Time Frame: 24 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01255722	Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography	Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial	10.1007/s00330-016-4437-9	https://www.ncbi.nlm.nih.gov/pubmed/27271922	5	2010-12-06	Completed	2010-11-01	2012-09-01	2016-06-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluability of CT scans based upon segments assessment using a 5-point evaluation scale grading the quality and the interpretability of images.\n[ Time Frame: < 24h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluability of CT scans based upon segments assessment using a 5-point evaluation scale grading the quality and the interpretability of images.\n[ Time Frame: < 24h ]""}]	[See Results Section.]	NA	NA
NCT01255813	Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache	Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study	10.1177/0333102412473667	https://www.ncbi.nlm.nih.gov/pubmed/23314784	7	2010-12-06	Completed	2010-12-01	2012-06-01	2013-01-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related serious Adverse Events (AEs)\n[ Time Frame: 15 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute pain relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related Serious Adverse Events (SAEs)\n[ Time Frame: Implant through the Experimental Period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute Pain Relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related Serious Adverse Events (SAEs)\n[ Time Frame: Implant through the Experimental Period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute Pain Relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	NA
NCT01256424	Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia	A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2	10.1016/j.ajog.2014.10.1107	https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(14)02199-1	12	2010-12-07	Completed	2011-04-01	2012-07-01	2014-10-31	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare lesion response rates of three different doses of HAL PDT and placebo (no illumination) at 3 months after treatment.\n[ Time Frame: 3 months after last treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare lesion response rates of three different doses of HAL PDT and placebo (no illumination) at 3 months after treatment.\n[ Time Frame: 3 months after last treatment ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01256996	Therapy of Peri-implantitis: Scaling Versus Low Abrasive Powder	NA	10.1055/s-0034-1395621	https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0034-1395621	1	2010-12-08	Unknown status	NA	NA	2014-12-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pocket probing depth\n[ Time Frame: Twelve months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pocket probing depth\n[ Time Frame: Twelve months ]""}]
NCT01258153	Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic	NA	10.1016/s0016-5085(15)31431-1	https://www.gastrojournal.org/article/S0016-5085(15)31431-1/pdf	13	2010-12-09	Completed	2010-11-01	2013-12-01	2015-04-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[See Results Section.]	NA
NCT01258738	Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes	Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial	10.1002/art.38721	http://onlinelibrary.wiley.com/doi/10.1002/art.38721/abstract	22	2010-12-09	Completed	2011-02-01	2012-12-01	2014-08-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA
NCT01259739	Cocoa Flavanols and Exercise Capacity	Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning	10.1161/circresaha.114.303822	https://www.ncbi.nlm.nih.gov/pubmed/24643960	5	2010-12-13	Completed	2010-11-01	2013-10-01	2014-03-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary exercise capacity (time to complete time trail, lactate anaerobic threshold, cardio-pulmonary exercise capacity\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary exercise capacity (time to complete time trail, lactate anaerobic threshold, cardio-pulmonary exercise capacity\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiopulmonary exercise capacity (time to complete time trail, lactate anaerobic threshold, cardio-pulmonary exercise capacity\n[ Time Frame: 7 days ]""}]	NA	NA
NCT01261091	Early Tracheostomy in Ventilated Stroke Patients	Stroke-related Early Tracheostomy versus Prolonged Orotracheal Intubation in Neurocritical Care Trial (SETPOINT): a randomized pilot trial	10.1161/strokeaha.112.669895	https://www.ncbi.nlm.nih.gov/pubmed/23204058	2	2010-12-15	Completed	2009-09-01	2011-11-01	2012-11-29	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensive Care Unit Length of Stay (ICU-LOS)\n[ Time Frame: open ]\n\nThe primary endpoint is assessed as days from admission to until discharge from the intensive care unit.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensive Care Unit Length of Stay (ICU-LOS)\n[ Time Frame: open ]\n\nThe primary endpoint is assessed as days from admission to until discharge from the intensive care unit.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensive Care Unit Length of Stay (ICU-LOS)\n[ Time Frame: open ]\n\nThe primary endpoint is assessed as days from admission to until discharge from the intensive care unit.""}]	NA
NCT01261741	Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems	NA	NA	http://www.jns-journal.com/article/S0022-510X(13)01543-8/fulltext	5	2010-12-15	Completed	2010-11-01	2011-08-01	2013-10-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""Patient Global Impression of Change\"" (PGI-C) at visit 4\n[ Time Frame: 12 weeks ]\n\nIt is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""Patient Global Impression of Change\"" (PGI-C) at visit 4\n[ Time Frame: 12 weeks ]\n\nIt is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""Patient Global Impression of Change\"" (PGI-C) at visit 4\n[ Time Frame: 12 weeks ]\n\nIt is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""Patient Global Impression of Change\"" (PGI-C) at visit 4\n[ Time Frame: 12 weeks ]\n\nIt is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.""}]	NA
NCT01261949	Combined Low Frequency Frontal and Temporal rTMS Treatment in Chronic Tinnitus	Can Temporal Repetitive Transcranial Magnetic Stimulation be Enhanced by Targeting Affective Components of Tinnitus with Frontal rTMS? A Randomized Controlled Pilot Trial	10.3389/fnsys.2011.00088	https://www.ncbi.nlm.nih.gov/pubmed/22069382?dopt=Abstract	4	2010-12-16	Completed	2009-04-01	2010-12-01	2011-11-04	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller\n[ Time Frame: Baseline, Day 12 ]""}]	NA
NCT01262521	Dietary Nitrate and Cardiovascular Health	Dietary inorganic nitrate mobilizes circulating angiogenic cells	10.1016/j.freeradbiomed.2012.02.051	https://www.ncbi.nlm.nih.gov/pubmed/22406434	3	2010-12-16	Completed	2010-11-01	2012-10-01	2012-03-09	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Circulating angiogenic cells\n[ Time Frame: 4 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Circulating angiogenic cells\n[ Time Frame: 4 hours ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Circulating angiogenic cells\n[ Time Frame: 4 hours ]""}]	NA
NCT01262677	Once-A-Day Pregabalin For Partial Seizures	Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial	10.1111/epi.12690	http://onlinelibrary.wiley.com/doi/10.1111/epi.12690/full	28	2010-12-16	Completed	2011-02-01	2012-08-01	2014-06-24	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind maintenance treatment phase.\n[ Time Frame: Week 2 to week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind treatment phase.\n[ Time Frame: Week 0 to week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind treatment phase.\n[ Time Frame: Week 0 to week 14 ]""}]	[See Results Section.]	NA
NCT01263522	Optimization of Preventive Effects of Physical Training	Irisin and exercise training in humans - results from a randomized controlled training trial	10.1186/1741-7015-11-235	https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-235	2	2010-12-17	Completed	2010-12-01	2013-12-01	2013-11-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2 max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	NA
NCT01264549	Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)	The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke	10.3389/fneur.2017.00153	https://pubmed.ncbi.nlm.nih.gov/28484421/	18	2010-12-21	Completed	2010-12-01	2014-07-01	2017-04-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score\n[ Time Frame: 3 months after onset of symptoms (stroke) ]\n\nTo assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score\n[ Time Frame: 3 months after onset of symptoms (stroke) ]\n\nTo assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score\n[ Time Frame: 3 months after onset of symptoms (stroke) ]\n\nTo assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score\n[ Time Frame: 3 months after onset of symptoms (stroke) ]\n\nTo assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.""}]	NA
NCT01266655	Baclofen for the Treatment of Alcohol Dependence	Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study	10.1016/j.euroneuro.2018.08.507	https://pubmed.ncbi.nlm.nih.gov/30217552/	5	2010-12-23	Completed	2011-02-01	2014-08-01	2018-09-11	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total abstinence from alcohol and cumulative abstinence duration\n[ Time Frame: 13-16 weeks (depending on the individually tolerated baclofen dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total abstinence from alcohol and cumulative abstinence duration\n[ Time Frame: 13-16 weeks (depending on the individually tolerated baclofen dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total abstinence from alcohol and cumulative abstinence duration\n[ Time Frame: 13-16 weeks (depending on the individually tolerated baclofen dose) ]""}]	NA	NA
NCT01267838	Culotte Technique Versus TAP Stunting for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents	Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial	10.1093/eurheartj/ehw345	https://academic.oup.com/eurheartj/article/37/45/3399/2661742	2	2010-12-28	Completed	2010-02-01	2015-02-01	2016-08-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal percent diameter stenosis at the bifurcation (QCA)\n[ Time Frame: 9 months post index PCI ]\n\nMaximal percent diameter stenosis at the bifurcation (QCA)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal percent diameter stenosis at the bifurcation (QCA)\n[ Time Frame: 9 months post index PCI ]\n\nMaximal percent diameter stenosis at the bifurcation (QCA)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal percent diameter stenosis at the bifurcation (QCA)\n[ Time Frame: 9 months post index PCI ]\n\nMaximal percent diameter stenosis at the bifurcation (QCA)""}]	NA
NCT01270126	Trial of Alternating Current Stimulation in Optic Neuropathy	Non-invasive alternating current stimulation improves vision in optic neuropathy	10.3233/rnn-2011-0624	http://content.iospress.com/download/restorative-neurology-and-neuroscience/rnn624?id=restorative-neurology-and-neuroscience%2Frnn624	4	2011-01-04	Completed	2006-11-01	2010-12-01	2011-01-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Nov 2006 - Dec 2010 ]\n\nCentral visual fields were assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field were characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors was defined as the primary outcome criterion.""}]	NA	NA	[See Results Section.]	NA
NCT01271361	Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients	Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial	10.1093/eurheartj/ehs456	NA	2	2011-01-05	Completed	2010-11-01	2011-09-01	2013-02-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""minimal flow area assessed by OFDI\n[ Time Frame: at baseline procedure (post-stenting) ]\n\nFlow area is defined as: (Stent area + incomplete stent apposition area) - (intraluminal defect area attached to the wall + intraluminal defect area free from the wall)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""minimal flow area assessed by OFDI\n[ Time Frame: at baseline procedure (post-stenting) ]\n\nFlow area is defined as: (Stent area + incomplete stent apposition area) - (intraluminal defect area attached to the wall + intraluminal defect area free from the wall)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""minimal flow area assessed by OFDI\n[ Time Frame: at baseline procedure (post-stenting) ]\n\nFlow area is defined as: (Stent area + incomplete stent apposition area) - (intraluminal defect area attached to the wall + intraluminal defect area free from the wall)""}]	NA	NA
NCT01271790	A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection	10.1002/hep.27053	http://onlinelibrary.wiley.com/doi/10.1002/hep.27053/full	11	2011-01-06	Completed	2010-12-01	2012-11-01	2014-05-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable hepatitis C virus (HCV) RNA 24 weeks after treatment cessation""}]	NA	NA
NCT01272674	Adiponectin and Circulating Progenitor Cells (CPC) Function	Adiponectin promotes the migration of circulating angiogenic cells through p38-mediated induction of the CXCR4 receptor	10.1016/j.ijcard.2012.05.056	https://www.ncbi.nlm.nih.gov/pubmed/22682478	4	2011-01-07	Completed	2006-05-01	2010-11-01	2012-06-07	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""migratory capacity of endothelial progenitor cells towards an SDF-1 gradient\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""migratory capacity of endothelial progenitor cells towards an SDF-1 gradient\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""migratory capacity of endothelial progenitor cells towards an SDF-1 gradient\n[ Time Frame: 4 weeks ]""}]	NA
NCT01276639	A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials	10.1111/bjd.14018	http://onlinelibrary.wiley.com/doi/10.1111/bjd.14018/abstract	26	2011-01-12	Completed	2011-03-01	2013-04-01	2015-10-29	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response, ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 16.\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline at Week 16.\n[ Time Frame: Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician Global Assessment (PGA) response, ie, the proportion of participants achieving a PGA of \""clear\"" or \""almost clear\"" at week 16\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of participants achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline at Week 16\n[ Time Frame: Week 16 ]""}]	[See Results Section.]	NA	NA
NCT01277406	NA	NA	NA	NA	9	2011-01-13	Completed	2011-01-01	2013-12-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: MTD of 4SC-201 (Resminostat) in combination with FOLFIRI by investigating safety, tolerability and pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: Progression free survival (PFS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: MTD of 4SC-201 (Resminostat) in combination with FOLFIRI by investigating safety, tolerability and pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: Progression free survival (PFS)""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: MTD of 4SC-201 (Resminostat) in combination with FOLFIRI by investigating safety, tolerability and pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: Progression free survival (PFS)""}]
NCT01278537	Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Onco-surgery	Patient Empowerment Improved Perioperative Quality of Care in Cancer Patients Aged ≥ 65 Years - A Randomized Controlled Trial	10.1371/journal.pone.0137824	https://pubmed.ncbi.nlm.nih.gov/26378939/	7	2011-01-18	Completed	2011-02-01	2014-01-01	2015-09-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Length of hospital stay\n[ Time Frame: within the first month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of life\n[ Time Frame: within the first year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Length of hospital stay\n[ Time Frame: within the first month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of life\n[ Time Frame: within the first year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Length of hospital stay\n[ Time Frame: within the first month ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of life\n[ Time Frame: within the first year ]""}]	NA	NA
NCT01279577	Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease	A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease	10.1093/ecco-jcc/jjw184	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881737/	6	2011-01-18	Completed	2010-11-01	2014-02-01	2016-10-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT01280877	Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)	Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial	10.1371/journal.pone.0156134	https://www.ncbi.nlm.nih.gov/pubmed/27355577?dopt=Abstract	6	2011-01-19	Completed	2010-12-01	2012-02-01	2016-06-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	NA
NCT01281189	Phase 3 Study of Dexpramipexole in ALS	Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial	10.1016/s1474-4422(13)70221-7	https://linkinghub.elsevier.com/retrieve/pii/S1474-4422(13)70221-7	27	2011-01-20	Completed	2011-03-01	2013-01-01	2013-09-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT01282827	Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve)	Non-invasive alternating current stimulation improves vision in optic neuropathy	10.3233/rnn-2011-0624	NA	3	2011-01-24	Completed	2006-11-01	2010-03-01	2011-01-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: between baseline and 60 days after stimulation ]\n\nCentral visus fields were assessed with computer based high-resolution perimetry (HRP). Based on such plots, areas of the visual field were characterized as intact, partially damaged or absolutely impaired (blind).""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: between baseline and 60 days after stimulation ]\n\nCentral visus fields were assessed with computer based high-resolution perimetry (HRP). Based on such plots, areas of the visual field were characterized as intact, partially damaged or absolutely impaired (blind).""}]	NA
NCT01282918	NORDIC ICD (Cardioverter Defibrillator Implantation) Trial	Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial	10.1093/eurheartj/ehv292	https://academic.oup.com/eurheartj/article/36/37/2500/2466025	5	2011-01-24	Completed	2011-01-01	2014-07-01	2015-06-25	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 24 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 12 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 12 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	NA	NA
NCT01284062	Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients	Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study	10.1136/gutjnl-2014-308337	http://gut.bmj.com/content/64/6/894	29	2011-01-25	Completed	2011-03-01	2013-04-01	2015-01-07	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fold change from baseline in fecal calprotectin at Week 14.\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fold change from baseline in fecal calprotectin at Week 14.\n[ Time Frame: Week 14 ]""}]	[See Results Section.]	NA	NA
NCT01285271	A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon	Feasibility and safety of xenon compared with sevoflurane anaesthesia in coronary surgical patients: a randomized controlled pilot study	10.1093/bja/aet072	https://academic.oup.com/bja/article-lookup/doi/10.1093/bja/aet072	4	2011-01-26	Completed	2011-05-01	2011-09-01	2013-04-11	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	NA	NA
NCT01289964	The Effect of 5 Times Dry Cupping in the Treatment of Chronic Neck Pain	The influence of a series of five dry cupping treatments on pain and mechanical thresholds in patients with chronic non-specific neck pain--a randomised controlled pilot study	10.1186/1472-6882-11-63	https://www.ncbi.nlm.nih.gov/pubmed/21843336	2	2011-02-03	Completed	2009-07-01	2009-12-01	2011-08-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: at T2 (Day 25) ]\n\n100mm Visual Analogue Scale""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: at T2 (Day 25) ]\n\n100mm Visual Analogue Scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: at T2 (Day 25) ]\n\n100mm Visual Analogue Scale""}]	NA
NCT01291693	Testing Delivery Channels of Brief Motivational Alcohol Intervention	In-person alcohol counseling versus computer-generated feedback: Results from a randomized controlled trial	10.1037/hea0000556	https://pubmed.ncbi.nlm.nih.gov/28967769/	6	2011-02-07	Completed	2011-02-01	2013-03-01	2017-10-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6, 12, 18, 24 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) score""}]	NA	NA
NCT01293266	Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation	Effect of propofol and sevoflurane on acid-base balance during pediatric heart catheterization	NA	http://www.minervamedica.it/en/journals/minerva-anestesiologica/article.php?cod=R02Y2013N06A0626	2	2011-02-09	Completed	2009-05-01	2010-08-01	2013-03-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Serum Lactate\n[ Time Frame: 4 hours ]\n\nSerum lactate is measured during application of propofol and sevoflurane to examine the effect on metabolic acidosis.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Serum Lactate\n[ Time Frame: 4 hours ]\n\nSerum lactate is measured during application of propofol and sevoflurane to examine the effect on metabolic acidosis.""}]	NA	NA
NCT01294254	Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites	Accelerated reepithelialization by triterpenes: proof of concept in the healing of surgical skin lesions	10.1159/000357501	https://www.karger.com/Article/FullText/357501	2	2011-02-10	Completed	2010-04-01	2010-11-01	2014-07-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone during a treatment period of 14 days.\n[ Time Frame: 14 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone during a treatment period of 14 days.\n[ Time Frame: 14 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone during a treatment period of 14 days.\n[ Time Frame: 14 days ]""}]	NA
NCT01296776	Effect of Electromyostimulation on Bone	Whole-Body Electromyostimulation to Fight Osteopenia in Elderly Females: The Randomized Controlled Training and Electrostimulation Trial (TEST-III)	10.1155/2015/643520	NA	6	2011-02-14	Completed	2011-01-01	2012-11-01	2015-02-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density at the lumbar spine and femoral neck region\n[ Time Frame: baseline - after 12 months ]\n\nBone Mineral Density as assessed by Dual Energy X-ray Absorptiometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Falls\n[ Time Frame: throughout the 12 month study period ]\n\nFall frequency and fall related injuries as assessed by the calendar method""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density at the lumbar spine and femoral neck region\n[ Time Frame: baseline - after 12 months ]\n\nBone Mineral Density as assessed by Dual Energy X-ray Absorptiometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Falls\n[ Time Frame: throughout the 12 month study period ]\n\nFall frequency and fall related injuries as assessed by the calendar method""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density at the lumbar spine and femoral neck region\n[ Time Frame: baseline - after 12 months ]\n\nBone Mineral Density as assessed by Dual Energy X-ray Absorptiometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Falls\n[ Time Frame: throughout the 12 month study period ]\n\nFall frequency and fall related injuries as assessed by the calendar method""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bone Mineral Density at the lumbar spine and femoral neck region\n[ Time Frame: baseline - after 12 months ]\n\nBone Mineral Density as assessed by Dual Energy X-ray Absorptiometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Falls\n[ Time Frame: throughout the 12 month study period ]\n\nFall frequency and fall related injuries as assessed by the calendar method""}]	NA
NCT01296997	Calcium Phosphate and Incretins	Postprandial effects of calcium phosphate supplementation on plasma concentration-double-blind, placebo-controlled cross-over human study	10.1186/1475-2891-12-30	https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-12-30	2	2011-02-15	Completed	2010-07-01	2010-09-01	2013-03-08	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""secretion of incretins\n[ Time Frame: 3 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""secretion of incretins\n[ Time Frame: 3 weeks ]""}]	NA	NA
NCT01297023	Human Intervention Study With Calcium Phosphate and Vitamin D	Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron	10.1186/1475-2891-13-6	https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-6	2	2011-02-15	Completed	2011-01-01	2011-04-01	2014-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bone resorption and bone formation markers in blood and urine\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bone resorption and bone formation markers in blood and urine\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bone resorption and bone formation markers in blood and urine\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT01297712	Endoscopic Assessment of Polyp Histology	Endoscopic versus histological characterisation of polyps during screening colonoscopy	10.1136/gutjnl-2013-304562	http://gut.bmj.com/content/63/3/458.long	3	2011-02-15	Terminated	2009-09-01	2010-11-01	2013-06-28	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Accuracy (sensitivity/specificity) of HDTV/iScan image technology (Hi Line) versus conventional colonoscopy (classic Line) in the diagnosis of adenomas versus hyperplastic polyps\n[ Time Frame: 14 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Accuracy (sensitivity/specificity) of HDTV/iScan image technology (Hi Line) versus conventional colonoscopy (classic Line) in the diagnosis of adenomas versus hyperplastic polyps\n[ Time Frame: 14 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Accuracy (sensitivity/specificity) of HDTV/iScan image technology (Hi Line) versus conventional colonoscopy (classic Line) in the diagnosis of adenomas versus hyperplastic polyps\n[ Time Frame: 14 months ]""}]	NA
NCT01299324	Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure	REVIVE Trial: Retrograde Delivery of Autologous Bone Marrow in Patients With Heart Failure	10.5966/sctm.2015-0070	https://www.ncbi.nlm.nih.gov/pubmed/26217065	3	2011-02-17	Completed	2011-02-01	2013-08-01	2015-07-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of participants with adverse events as a measure of safety and tolerability\n[ Time Frame: 12 Months ]\n\nTo demonstrate that the infusion of bone marrow nucleated cells into the coronary sinus is safe as assessed by adverse event records.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of participants with adverse events as a measure of safety and tolerability\n[ Time Frame: 12 Months ]\n\nTo demonstrate that the infusion of bone marrow nucleated cells into the coronary sinus is safe as assessed by adverse event records.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of participants with adverse events as a measure of safety and tolerability\n[ Time Frame: 12 Months ]\n\nTo demonstrate that the infusion of bone marrow nucleated cells into the coronary sinus is safe as assessed by adverse event records.""}]	NA	NA
NCT01299480	A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years	Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents	10.1093/jpids/piv039	https://www.ncbi.nlm.nih.gov/pubmed/26407272	12	2011-02-16	Completed	2011-03-01	2012-05-01	2015-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint for the co-primary objectives are the proportion of subjects achieving an rLP2086-specific SBA titer >=1:4 , for each of the 4 primary strains, measured 1 month after the third vaccination with rLP2086 vaccine (in groups 1 and 2).\n[ Time Frame: 1 month after the third vaccination ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint for the co-primary objectives are the proportion of subjects achieving an rLP2086-specific SBA titer >=1:4 , for each of the 4 primary strains, measured 1 month after the third vaccination with rLP2086 vaccine (in groups 1\n[ Time Frame: 1 month after the third vaccination ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""and 2).\n[ Time Frame: 1 month after the third vaccination ]""}]	[See Results Section.]	NA	NA
NCT01299948	Progression of HIV-Disease Under Low Dose Corticosteroids	Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial	10.1371/journal.pone.0146678	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146678	3	2011-02-18	Completed	2007-06-01	2011-03-01	2016-01-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to progression of HIV disease\n[ Time Frame: 2 years ]\n\nThe primary objective of the study is to assess the effect of the low dose prednisolone therapy on the time to progression of HIV disease. The time to progression is defined as the time between the baseline and the change of staging to advanced disease (CDC stage A3, B3 or C) or death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to progression of HIV disease\n[ Time Frame: 2 years ]\n\nThe primary objective of the study is to assess the effect of the low dose prednisolone therapy on the time to progression of HIV disease. The time to progression is defined as the time between the baseline and the change of staging to advanced disease (CDC stage A3, B3 or C) or death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to progression of HIV disease\n[ Time Frame: 2 years ]\n\nThe primary objective of the study is to assess the effect of the low dose prednisolone therapy on the time to progression of HIV disease. The time to progression is defined as the time between the baseline and the change of staging to advanced disease (CDC stage A3, B3 or C) or death""}]	NA	NA
NCT01302600	Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial	10.1016/s1474-4422(17)30085-6	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01302600	5	2011-02-18	Completed	2010-11-01	2013-09-01	2017-04-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor fonction Measure (MFM) D1+D2 score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor fonction Measure (MFM) D1+D2 score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor function Measure (MFM) D1+D2 score""}]	NA	NA
NCT01303224	Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)	The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS	10.1136/gutjnl-2015-310683	http://gut.bmj.com/content/66/8/1403.long	13	2011-02-23	Completed	2010-10-01	2012-05-01	2016-04-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response for satisfactory relief of overall IBS symptoms and of abdominal pain/discomfort satisfactory relief during 8 weeks of treatment-(75% rule)\n[ Time Frame: Eight weeks ]\n\n\n\nWeekly binary questions (yes/no): \""Did you have satisfactory relief of your overall IBS symptoms during the last week?\"" and \""Did you have satisfactory relief of your abdominal pain or discomfort during the last week?\""\n\nResponder: Report of satisfactory overall IBS symptom relief =\""Yes\"" and of satisfacory abdominal pain/discomfort relief = \""Yes\"" 6/8 weeks (75% rule)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response for satisfactory relief of overall IBS symptoms and of abdominal pain/discomfort satisfactory relief during 8 weeks of treatment-(75% rule)\n[ Time Frame: Eight weeks ]\n\n\n\nWeekly binary questions (yes/no): \""Did you have satisfactory relief of your overall IBS symptoms during the last week?\"" and \""Did you have satisfactory relief of your abdominal pain or discomfort during the last week?\""\n\nResponder: Report of satisfactory overall IBS symptom relief =\""Yes\"" and of satisfacory abdominal pain/discomfort relief = \""Yes\"" 6/8 weeks (75% rule)""}]	[See Results Section.]	NA	NA
NCT01303588	Yoga and Qigong for Elderly Patients With Chronic Low Back Pain	NA	NA	http://www.sciencedirect.com/science/article/pii/S1526590016005939	2	2011-02-24	Completed	2011-05-01	2012-05-01	2016-03-30	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional rating Index (FRI)\n[ Time Frame: 3 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional rating Index (FRI)\n[ Time Frame: 3 months ]""}]	NA	NA
NCT01304368	Effects of Thermotherapy on Chronic Neck Pain	NA	10.1016/j.eujim.2012.04.001	http://www.sciencedirect.com/science/article/pii/S1876382012000509	1	2011-02-24	Completed	2009-08-01	2010-08-01	2012-12-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Day 14 ]\n\n100mm visual analog scale""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Day 14 ]\n\n100mm visual analog scale""}]	NA	NA
NCT01304992	Cholesterol-lowering Effects of Lupin Protein	Lupin protein positively affects plasma LDL cholesterol and LDL:HDL cholesterol ratio in hypercholesterolemic adults after four weeks of supplementation: a randomized, controlled crossover study	10.1186/1475-2891-12-107	https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-12-107	4	2011-02-25	Completed	2011-02-01	2011-08-01	2013-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cholesterol metabolism\n[ Time Frame: after 0,4,8,12,16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cholesterol metabolism\n[ Time Frame: After 0, 4, 8, 12, 16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cholesterol metabolism\n[ Time Frame: After 0, 4, 8, 12, 16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	NA	NA
NCT01306552	Evaluation of a Combined Parent-student Programme for Smoking Prevention in Berlin Schools	Berlin evaluates school tobacco prevention - BEST prevention: study design and methodology	10.1186/1471-2458-14-871	https://www.ncbi.nlm.nih.gov/pubmed/25150368?dopt=Abstract	1	2011-03-01	Unknown status	NA	NA	2014-08-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regular smokers among students at the 2 year follow-up assessment.\n[ Time Frame: 2 years ]\n\nThe primary study outcome is the percentage of regular smokers among students at the 2 year follow-up assessment.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regular smokers among students at the 2 year follow-up assessment.\n[ Time Frame: 2 years ]\n\nThe primary study outcome is the percentage of regular smokers among students at the 2 year follow-up assessment.""}]
NCT01307020	Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain	Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain	10.1186/s10194-015-0541-5	https://thejournalofheadacheandpain.springeropen.com/articles/10.1186/s10194-015-0541-5	19	2011-03-01	Completed	2011-02-01	2011-10-01	2015-06-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients achieving at least 50 % of the theoretical maximum total pain relief score at 6 hours post-dosing.\n[ Time Frame: 6 hours ]\n\nPain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients achieving at least 50 % of the theoretical maximum total pain relief score at 6 hours post-dosing.\n[ Time Frame: 6 hours ]\n\nPain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %""}]	[See Results Section.]	NA	NA
NCT01309178	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Therapy of CF-patients with amitriptyline and placebo--a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study	10.1159/000350071	https://www.ncbi.nlm.nih.gov/pubmed/23572075	1	2011-03-04	Unknown status	NA	NA	2013-04-02	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of the lung function parameter FEV1 (absolute and relative to baseline) under verum and placebo\n[ Time Frame: in 4 weeks ]\n\nThe primary aim is the change of the lung function parameter Forced Expiratory Volume in 1 second (FEV1) relative to baseline under verum and placebo""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of the lung function parameter FEV1 (absolute and relative to baseline) under verum and placebo\n[ Time Frame: in 4 weeks ]\n\nThe primary aim is the change of the lung function parameter Forced Expiratory Volume in 1 second (FEV1) relative to baseline under verum and placebo""}]
NCT01309243	Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110)	10.1097/qai.0000000000000017	NA	7	2011-03-03	Completed	2011-02-01	2012-11-01	2014-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who achieve HIV 1 RNA < 50 copies/mL at week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who achieve HIV 1 RNA < 50 copies/mL at week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01309737	A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials	10.1111/bjd.14018	http://onlinelibrary.wiley.com/doi/10.1111/bjd.14018/abstract	24	2011-03-04	Completed	2011-03-01	2013-04-01	2015-10-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA)response, ie, the proportion of subjects achieving a PGA of\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline at Week 16.\n[ Time Frame: Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA)response, ie, the proportion of participants achieving a PGA of \""clear\"" or \""almost clear\"" at week 16\n[ Time Frame: week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of participants achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline at Week 16\n[ Time Frame: week 16 ]""}]	[See Results Section.]	NA	NA
NCT01311245	Testing Alcohol Interventions Among Job-seekers	Does stage tailoring matter in brief alcohol interventions for job-seekers? A randomized controlled trial	10.1111/add.12677	https://www.ncbi.nlm.nih.gov/pubmed/24981701	3	2011-03-08	Completed	2008-07-01	2010-12-01	2014-08-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 and 15 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 and 15 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 and 15 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	NA
NCT01313013	A Question Prompt Sheet for Depressive Outpatients	Effects of a question prompt sheet on active patient behaviour: a randomized controlled trial with depressed outpatients	10.1177/0020764013482311	https://www.ncbi.nlm.nih.gov/pubmed/23632272	1	2011-03-09	Completed	2010-07-01	2011-03-01	2013-04-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[]	NA	[]	NA	NA
NCT01314716	Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials	10.1016/s2213-2600(14)70165-1	http://www.sciencedirect.com/science/article/pii/S2213260014701651?via%3Dihub	30	2011-03-11	Completed	2011-04-01	2013-07-01	2014-08-18	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in QOL-B Respiratory Symptoms Score\n[ Time Frame: Baseline to end of treatment course 1 (Day 28) ]\n\nChange in the Respiratory Symptoms score on the Quality of Life Questionaire-Bronchiectasis(QOL-B) from baseline to the end of the placebo-controlled course 1 treatment with AZLI or placebo (Day 28)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in QOL-B Respiratory Symptoms Score\n[ Time Frame: Baseline to end of treatment course 1 (Day 28) ]\n\nChange in the Respiratory Symptoms score on the Quality of Life Questionaire-Bronchiectasis(QOL-B) from baseline to the end of the placebo-controlled course 1 treatment with AZLI or placebo (Day 28)""}]	[See Results Section.]	NA	NA
NCT01315002	Nicotine Effects on Endophenotypes of Schizophrenia	The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism	10.1007/s00213-013-3081-1	https://www.ncbi.nlm.nih.gov/pubmed/?term=The+effect+of+nicotine+on+sensorimotor+gating+is+modulated+by+a+CHRNA3+polymorphism	4	2011-03-14	Completed	2008-07-01	2012-03-01	2013-04-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[See Results Section.]	NA
NCT01316198	Effects of Xanthophylls on Optical Density	Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study	10.1016/j.nut.2013.05.012	https://www.ncbi.nlm.nih.gov/pubmed/24103519	2	2011-03-15	Completed	2010-06-01	2011-06-01	2013-10-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment in AMD patients\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment in AMD patients\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Optical density of macular pigment in AMD patients\n[ Time Frame: 10 weeks ]""}]	NA	NA
NCT01317290	Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans	Cheek cell fatty acids reflect n-3 PUFA in blood fractions during linseed oil supplementation: a controlled human intervention study	10.1186/1476-511x-12-173	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842671/	4	2011-03-16	Completed	NA	NA	2013-11-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""increase of n-3 LC-PUFA in human lipids\n[ Time Frame: 0,7,56 days ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""n-3 LC-PUFA in human lipids (EPA)\n[ Time Frame: 0,7,56 days ]\n\nEPA (% of total identified fatty acid methyl esters)""}]
NCT01318395	Aliskiren on Retinal Vasculature Treatment Study	Effect of aliskiren on vascular remodelling in small retinal circulation	10.1097/hjh.0000000000000735	https://insights.ovid.com/pubmed?pmid=26398851	4	2011-03-17	Completed	2010-05-01	2013-06-01	2015-12-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.\n[ Time Frame: After 8 weeks of treatment with aliskiren versus placebo ]\n\nWLR = (outer diameter - inner diameter) / inner diameter) of retinal arterioles""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.\n[ Time Frame: After 8 weeks of treatment with aliskiren versus placebo ]\n\nWLR = (outer diameter - inner diameter) / inner diameter) of retinal arterioles""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.\n[ Time Frame: After 8 weeks of treatment with aliskiren versus placebo ]\n\nWLR = (outer diameter - inner diameter) / inner diameter) of retinal arterioles""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.\n[ Time Frame: After 8 weeks of treatment with aliskiren versus placebo ]\n\nWLR = (outer diameter - inner diameter) / inner diameter) of retinal arterioles""}]	NA
NCT01319357	Effects of Saxagliptin on Endothelial Function	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes	10.1186/1475-2840-13-19	https://cardiab.biomedcentral.com/articles/10.1186/1475-2840-13-19	5	2011-03-17	Completed	2010-10-01	2013-04-01	2014-01-14	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation\n[ Time Frame: after 6 weeks of treatment with saxagliptin vs. 6 weeks of treatment with placebo (12 weeks in all) ]\n\nretinal circulation. By applying Scanning-Laser-Doppler-Flowmetry, the change of retinal capillary flow after i.v. L-NMMA application""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation\n[ Time Frame: after 6 weeks of treatment with saxagliptin vs. 6 weeks of treatment with placebo (12 weeks in all) ]\n\nretinal circulation. By applying Scanning-Laser-Doppler-Flowmetry, the change of retinal capillary flow after i.v. L-NMMA application""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation\n[ Time Frame: after 6 weeks of treatment with saxagliptin vs. 6 weeks of treatment with placebo (12 weeks in all) ]\n\nretinal circulation. By applying Scanning-Laser-Doppler-Flowmetry, the change of retinal capillary flow after i.v. L-NMMA application""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation\n[ Time Frame: after 6 weeks of treatment with saxagliptin vs. 6 weeks of treatment with placebo (12 weeks in all) ]\n\nretinal circulation. By applying Scanning-Laser-Doppler-Flowmetry, the change of retinal capillary flow after i.v. L-NMMA application""}]	NA
NCT01320254	PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study	10.1016/j.ejca.2017.12.028	https://pubmed.ncbi.nlm.nih.gov/29413685/	6	2011-03-21	Completed	2011-06-01	2016-09-12	2018-02-03	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival rate\n[ Time Frame: 6 months ]\n\nThe progression-free survival rate at six months (primary endpoint) is defined as the number of patients recorded to be free of progression (according to RECIST) at this time point, divided by the number of patients randomized to the respective arm.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival rate\n[ Time Frame: 6 months ]\n\nThe progression-free survival rate at six months (primary endpoint) is defined as the number of patients recorded to be free of progression (according to RECIST) at this time point, divided by the number of patients randomized to the respective arm.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival rate\n[ Time Frame: 6 months ]\n\nThe progression-free survival rate at six months (primary endpoint) is defined as the number of patients recorded to be free of progression (according to RECIST) at this time point, divided by the number of patients randomized to the respective arm.""}]	NA	NA
NCT01321840	Cortical Plasticity in a Complex Intervention for Endometriosis	Psychotherapy With Somatosensory Stimulation for Endometriosis-Associated Pain: A Randomized Controlled Trial	10.1097/aog.0000000000001691	https://www.ncbi.nlm.nih.gov/pubmed/27741200?dopt=Abstract	3	2011-03-23	Completed	2010-03-01	2012-12-01	2016-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain function\n[ Time Frame: 12 weeks ]\n\nChanges in cortical thickness, functional connectivity and perfusion of brain areas related to the processing of pain and emotions.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain function\n[ Time Frame: 12 weeks ]\n\nChanges in cortical thickness, functional connectivity and perfusion of brain areas related to the processing of pain and emotions.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain function\n[ Time Frame: 12 weeks ]\n\nChanges in cortical thickness, functional connectivity and perfusion of brain areas related to the processing of pain and emotions.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain function\n[ Time Frame: 12 weeks ]\n\nChanges in cortical thickness, functional connectivity and perfusion of brain areas related to the processing of pain and emotions.""}]	NA
NCT01323270	A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.	Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents	10.1093/jpids/piv064	https://www.ncbi.nlm.nih.gov/pubmed/26803328?dopt=Abstract	18	2011-03-24	Completed	2011-03-01	2013-01-01	2016-01-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportions of subjects achieving prespecified criteria for the concomitant antigens 1 month after vaccination 1 (visit 2).\n[ Time Frame: 1 month after vaccination 1 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportions of subjects achieving prespecified criteria for the concomitant antigens 1 month after vaccination 1 (visit 2).\n[ Time Frame: 1 month after vaccination 1 ]""}]	[See Results Section.]	NA	NA
NCT01323556	Mechanisms of Panic Disorders Treatment	Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative	10.1111/psyp.12553	NA	2	2011-03-24	Unknown status	2010-03-01	NA	2016-03-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Anxiety Rating Scale (HARS)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nstructured clinician rating assessing the severity of an anxiety disorder""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinician Global Impression Scale (CGI)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nclinician rating assessing the severity of panic disorder and agoraphobia""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Panic and Agoraphobia Scale (PAS)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nPAS is self-rating assessing panic disorder and agoraphobia severity with five factor analytic derived subscale scores (panic attacks, anticipatory anxiety, agoraphobic avoidance, health concerns, functional impairment) and a total score indicating the global severity. The questionnaire was specifically developed for monitoring changes during psychotherapy or psychopharmacological treatments.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Mobility Inventory\n[ Time Frame: up to 32 weeks (follow up) ]\n\nSelf-rating assessing the extent of situational avoidance. The questionnaire comprises 27 situations that have to be evaluated in regard to frequency of avoidance, when alone or when accompanied.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Number of panic attacks\n[ Time Frame: up to 32 weeks (follow up) ]\n\nNumber of panic attacks experienced during the last week is assessed.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Anxiety Rating Scale (HARS)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nstructured clinician rating assessing the severity of an anxiety disorder""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinician Global Impression Scale (CGI)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nclinician rating assessing the severity of panic disorder and agoraphobia""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Panic and Agoraphobia Scale (PAS)\n[ Time Frame: up to 32 weeks (follow up) ]\n\nPAS is self-rating assessing panic disorder and agoraphobia severity with five factor analytic derived subscale scores (panic attacks, anticipatory anxiety, agoraphobic avoidance, health concerns, functional impairment) and a total score indicating the global severity. The questionnaire was specifically developed for monitoring changes during psychotherapy or psychopharmacological treatments.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Mobility Inventory\n[ Time Frame: up to 32 weeks (follow up) ]\n\nSelf-rating assessing the extent of situational avoidance. The questionnaire comprises 27 situations that have to be evaluated in regard to frequency of avoidance, when alone or when accompanied.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Number of panic attacks\n[ Time Frame: up to 32 weeks (follow up) ]\n\nNumber of panic attacks experienced during the last week is assessed.""}]
NCT01326520	Effect of Dietary Phospholipids on Atopic Dermatitis	Supplementation of a dairy drink enriched with milk phospholipids in patients with atopic dermatitis - a double-blind, placebo-controlled, randomized, cross-over study	10.1016/j.clnu.2014.01.014	https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(14)00039-9	4	2011-03-29	Completed	2011-03-01	2011-10-01	2014-01-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in skin texture from baseline and in comparison with placebo\n[ Time Frame: after 0,2,10,16, and 24 weeks ]\n\nSCORAD Index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in skin texture from baseline and in comparison with placebo\n[ Time Frame: after 0,2,10,16, and 24 weeks ]\n\nSCORAD Index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in skin texture from baseline and in comparison with placebo\n[ Time Frame: after 0,2,10,16, and 24 weeks ]\n\nSCORAD Index""}]	NA	NA
NCT01326767	Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)	10.1093/annonc/mdw290	https://www.sciencedirect.com/science/article/pii/S0923753419359186?via%3Dihub	5	2011-03-30	Completed	2011-03-01	2014-12-01	2016-08-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Grad 4 Neutropenia\n[ Time Frame: up to 6 weeks on treatment ]\n\nThe rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared. At the same time progression free survival and overall survival must not be affected.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Grad 4 Neutropenia\n[ Time Frame: up to 6 weeks on treatment ]\n\nThe rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared. At the same time progression free survival and overall survival must not be affected.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Grad 4 Neutropenia\n[ Time Frame: up to 6 weeks on treatment ]\n\nThe rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared. At the same time progression free survival and overall survival must not be affected.""}]	NA	NA
NCT01327534	Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI	Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction)	10.1016/j.jcin.2014.09.007	https://www.ncbi.nlm.nih.gov/pubmed/25616919?dopt=Abstract	6	2011-03-30	Completed	2011-05-01	2013-03-01	2014-11-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylisation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylisation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	NA
NCT01327547	A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents	10.1179/1528433614z.0000000011	NA	45	2011-03-31	Completed	2011-05-01	2013-04-01	2015-03-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities defined as >5x upper limit of normal (ULN) for subjects whose baseline ALT ≤ULN, or\n[ Time Frame: 48 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""or >3.5x baseline for subjects whose baseline ALT >ULN, at Week 48 in the maraviroc arm versus the placebo arm""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities.\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01328210	Effects of Blood Letting in Metabolic Syndrome	Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial	10.1186/1741-7015-10-54	https://www.ncbi.nlm.nih.gov/pubmed/22647517	2	2011-04-01	Completed	2008-07-01	2009-03-01	2012-05-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""insulin sensitivity\n[ Time Frame: change from baseline at 6 weeks ]\n\nGlucose and insulin are measured on the basis of overnight fasting blood samples and Insulin sensitivity calculated according to HOMA-Index""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""systolic blood pressure\n[ Time Frame: change from baseline at 6 weeks ]\n\nBlood pressure is measured twice after 5 minutes rest in the sitting position by sphygmomanometry""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""insulin sensitivity\n[ Time Frame: change from baseline at 6 weeks ]\n\nGlucose and insulin are measured on the basis of overnight fasting blood samples and Insulin sensitivity calculated according to HOMA-Index""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""systolic blood pressure\n[ Time Frame: change from baseline at 6 weeks ]\n\nBlood pressure is measured twice after 5 minutes rest in the sitting position by sphygmomanometry""}]	NA	NA
NCT01329731	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Changes in white spot lesions following post-orthodontic weekly application of 1.25 per cent fluoride gel over 6 months-a randomized placebo-controlled clinical trial. Part I: photographic data evaluation	10.1093/ejo/cjw060	NA	4	2011-04-05	Completed	2011-03-01	2013-10-01	2017-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks (lesion size to total labial tooth area, %)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks""}]	NA	NA
NCT01330394	Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Alcoholism	A randomized controlled trial of targeted prefrontal cortex modulation with tDCS in patients with alcohol dependence	10.1017/s1461145714000984	NA	5	2011-04-06	Completed	2011-06-01	2013-07-01	2014-07-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""use of alcohol\n[ Time Frame: one year and a half ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""use of alcohol\n[ Time Frame: one year and a half ]""}]	[See Results Section.]	NA	NA
NCT01330485	Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder	Affect regulation training reduces symptom severity in depression - A randomized controlled trial	10.1371/journal.pone.0220436	https://pubmed.ncbi.nlm.nih.gov/31465443/	8	2011-04-05	Completed	2010-11-01	2014-04-01	2019-08-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in depressive symptoms (BDI-II, HRSD)\n[ Time Frame: pre/post/follow-up design, including 10 points of measurement (before/during/after group based intervention and first 16 weeks of iCBT-D) ]\n\nInvestigating reciprocal associations between Depressive Symptom Severity (DSS) and General Emotion Regulation Skills (GEMS). Clarifying whether experimentally enhancing GEMS reduces DSS and whether fostering GEMS enhances outcome of subsequent individual CBT for depression (iCBT-D) on DSS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in depressive symptoms (Beck Depression Inventory, BDI-II; Hamilton Rating Scale for Depression, HRSD)\n[ Time Frame: pre/post/follow-up design, including 10 points of measurement (before/during/after group based intervention and first 16 weeks of iCBT-D) ]\n\nInvestigating reciprocal associations between Depressive Symptom Severity (DSS) and General Emotion Regulation Skills (GEMS). Clarifying whether experimentally enhancing GEMS reduces DSS and whether fostering GEMS enhances outcome of subsequent individual CBT for depression (iCBT-D) on DSS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depressive symptoms\n[ Time Frame: Pre to post ART, CFC or WLC; hence covering the ten week time period from the first assessment point (prior to randomization) to the assessment point 10 weeks later ]\n\nChange in depressive symptoms as assessed in Beck Depression Inventory (BDI-II) and Hamilton Rating Scale for Depression (HRSD) and aggregated to a composite score is possible""}]	NA	NA
NCT01330823	L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)	L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial	10.1186/1475-2891-11-52	NA	1	2011-04-06	Suspended	NA	NA	2012-07-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha\n[ Time Frame: 12 weeks ]\n\nInfluence of L-Carnitine on proinflammatory cytokine TNF-alpha""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha\n[ Time Frame: 12 weeks ]\n\nInfluence of L-Carnitine on proinflammatory cytokine TNF-alpha""}]
NCT01331473	PROximal Protection VErsus NON-Protection in Carotid Artery Stenting	NA	NA	https://www.researchgate.net/publication/327302891_Neue_DWI-Lasionen_beim_Carotisstent_mit_und_ohne_proximales_Protektionssystem	3	2011-04-06	Unknown status	2011-05-01	NA	2016-01-01	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Day 1-3 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Day 1-3 ]""}]
NCT01331798	Evaluation of Cohera TissuGlu in the Management of Wound Drainage Following Abdominoplasty	Randomized, prospective study of TissuGlu® surgical adhesive in the management of wound drainage following abdominoplasty	10.1007/s00266-011-9844-3	https://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+Cohera+TissuGlu+in+the+Management+of+Wound+Drainage+Following+Abdominoplasty	1	2011-04-07	Completed	2009-12-01	2010-05-01	2011-12-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""• Safety data will be gathered with respect to the number, timing, severity, duration and resolution of device and non-device related adverse events occurring among study subjects.\n[ Time Frame: Discharge, 14, 30, 60, 90 Day follow-up ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""• Safety data will be gathered with respect to the number, timing, severity, duration and resolution of device and non-device related adverse events occurring among study subjects.\n[ Time Frame: Discharge, 14, 30, 60, 90 Day follow-up ]""}]	NA	NA
NCT01337297	Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction	Bilateral transcranial direct current stimulation over dorsolateral prefrontal cortex changes the drug-cued reactivity in the anterior cingulate cortex of crack-cocaine addicts	10.1016/j.brs.2013.09.007	https://www.ncbi.nlm.nih.gov/pubmed/24139147?dopt=Abstract	5	2011-04-15	Completed	2011-06-01	2012-11-01	2013-10-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in the relapse frequencies to the use of crack-cocaine\n[ Time Frame: after two-weeks treatment with active-tDCS or sham-tDCS ]\n\nchanges in the number of relapses to the use of crack-cocaine after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in the relapse frequencies to the use of crack-cocaine\n[ Time Frame: after two-weeks treatment with active-tDCS or sham-tDCS ]\n\nchanges in the number of relapses to the use of crack-cocaine after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS.""}]	[See Results Section.]	[See Results Section.]	NA
NCT01338922	Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM)	Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial	10.1111/pedi.12777	https://pubmed.ncbi.nlm.nih.gov/30302877/	3	2011-04-19	Completed	2011-04-01	2015-07-01	2018-10-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R modular QOL questionnaire (Ravens-Sieberer, http://www.kindl.org. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R modular QOL questionnaire (Ravens-Sieberer, http://www.kindl.org. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (HRQOL) (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R (KINDL) modular questionnaire. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	NA	NA
NCT01339026	Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel	10.1371/journal.pone.0135037	https://www.ncbi.nlm.nih.gov/pubmed/26317618?dopt=Abstract	6	2011-04-19	Terminated	2012-02-01	2013-09-01	2015-08-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet Reactivity\n[ Time Frame: 4 hours post loading dose ]\n\nThe primary endpoint will compare the proportion of patients with improved platelet response (i.e. decreased platelet reactivity under the cut-off value of 400 Au.min) in the prasugrel re-loading arm compared to the clopidogrel re-loading arm at 4 hours after randomization in patients with initial high platelet reactivity""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet Reactivity\n[ Time Frame: 4 hours post loading dose ]\n\nThe primary endpoint will compare the proportion of patients with improved platelet response (i.e. decreased platelet reactivity under the cut-off value of 400 Au.min) in the prasugrel re-loading arm compared to the clopidogrel re-loading arm at 4 hours after randomization in patients with initial high platelet reactivity""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet Reactivity\n[ Time Frame: 4 hours post loading dose ]\n\nThe primary endpoint will compare the proportion of patients with improved platelet response (i.e. decreased platelet reactivity under the cut-off value of 400 Au.min) in the prasugrel re-loading arm compared to the clopidogrel re-loading arm at 4 hours after randomization in patients with initial high platelet reactivity""}]	NA	NA
NCT01339819	Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)	10.1155/2015/798486	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502273/	4	2011-04-20	Completed	2011-04-01	2012-05-01	2015-07-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	NA	NA
NCT01343602	Enhancing Participation of Chronic Stroke Patients by Constraint Induced Movement Therapy (HOMECIMT)	Home-based constraint-induced movement therapy for patients with upper limb dysfunction after stroke (HOMECIMT): a cluster-randomised, controlled trial	10.1016/s1474-4422(15)00147-7	http://www.sciencedirect.com/science/article/pii/S1474442215001477?via%3Dihub	5	2011-04-27	Completed	2011-10-01	2013-06-01	2015-07-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Activity Log - Quality Of Movement (MAL-QOM) and Wolf Motor Function Test - Performance Time (WMFT-PT)\n[ Time Frame: 4 weeks (post-treatment) relative to baseline performance ]\n\n\""Participation\"" defined as equal involvement in all aspects of society and daily living for people with disabilities is a composite outcome of the following two measures: The MAL-QOM is a self-administered measure of how well 30 daily activities are performed to assess the change in the quality of arm and hand use and the WMFT-PT, measured as the average time (in seconds) to complete 15 tasks, to evaluate the change in arm and hand function.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Activity Log - Quality Of Movement (MAL-QOM) and Wolf Motor Function Test - Performance Time (WMFT-PT)\n[ Time Frame: 4 weeks (post-treatment) relative to baseline performance ]\n\n\""Participation\"" defined as equal involvement in all aspects of society and daily living for people with disabilities is a composite outcome of the following two measures: The MAL-QOM is a self-administered measure of how well 30 daily activities are performed to assess the change in the quality of arm and hand use and the WMFT-PT, measured as the average time (in seconds) to complete 15 tasks, to evaluate the change in arm and hand function.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Activity Log - Quality Of Movement (MAL-QOM) and Wolf Motor Function Test - Performance Time (WMFT-PT)\n[ Time Frame: 4 weeks (post-treatment) relative to baseline performance ]\n\n\""Participation\"" defined as equal involvement in all aspects of society and daily living for people with disabilities is a composite outcome of the following two measures: The MAL-QOM is a self-administered measure of how well 30 daily activities are performed to assess the change in the quality of arm and hand use and the WMFT-PT, measured as the average time (in seconds) to complete 15 tasks, to evaluate the change in arm and hand function.""}]	NA	NA
NCT01345630	Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1	Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment	10.1097/qad.0000000000001058	NA	40	2011-04-28	Terminated	2011-09-01	2013-09-01	2016-05-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of patients with plasma HIV 1 RNA <50 copies/mL at Week 48.\n[ Time Frame: Week 48 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects with plasma HIV 1 RNA <50 copies/mL at Week 48.\n[ Time Frame: Week 48 ]\n\nNumber of subjects who meet the primary endpoint.""}]	[See Results Section.]	NA	NA
NCT01347567	Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study	10.1002/ejhf.1053	https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1053	3	2011-05-03	Completed	2011-04-01	2013-03-01	2018-01-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average number of \""hard' events per subject\n[ Time Frame: Over 180 days ]\n\n\n\nWith hard events defined as:\n\nHF related death,\nHF related readmissions to the hospitaL,\nIV treatment with diuretics or unusual oral diuretic change in ER\nUnplanned outpatient treatments for decompensated HF""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average number of \""hard' events per subject\n[ Time Frame: Over 180 days ]\n\n\n\nWith hard events defined as:\n\nHF related death,\nHF related readmissions to the hospitaL,\nIV treatment with diuretics or unusual oral diuretic change in ER\nUnplanned outpatient treatments for decompensated HF""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average number of \""hard' events per subject\n[ Time Frame: Over 180 days ]\n\n\n\nWith hard events defined as:\n\nHF related death,\nHF related readmissions to the hospitaL,\nIV treatment with diuretics or unusual oral diuretic change in ER\nUnplanned outpatient treatments for decompensated HF""}]	NA	NA
NCT01350986	Guided Self-Help for Parents of Children With Externalizing Problem Behavior	NA	10.1111/jcpp.12177	http://onlinelibrary.wiley.com/doi/10.1111/jcpp.12177/full	1	2011-05-09	Unknown status	NA	NA	2013-12-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change Oppositional Defiant Disorder subscale score of the Symptom Checklist Disruptive Behavior Disorder (SCL-ODD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nQuestionnaire considers the diagnostic criteria of DSM-IV and ICD-10 for ODD. Informant is participating parent.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change total score of the Symptom Checklist Attention-Deficit/Hyperactivity Disorder (SCL-ADHD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nQuestionnaire considers the diagnostic criteria of DSM-IV and ICD-10 for ADHD. Informant is participating parent.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change Oppositional Defiant Disorder subscale score of the Diagnostic Checklist Disruptive Behavior Disorder (DCL-ODD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nDiagnostic interview considers the criteria of DSM-IV and ICD-10 for ODD. Informant is mental health worker.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change total score of the Diagnostic Checklist Attention-Deficit/Hyperactivity Disorder (DCL-ADHD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nDiagnostic interview considers the criteria of DSM-IV and ICD-10 for ADHD. Informant is mental health worker.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change Oppositional Defiant Disorder subscale score of the Symptom Checklist Disruptive Behavior Disorder (SCL-ODD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nQuestionnaire considers the diagnostic criteria of DSM-IV and ICD-10 for ODD. Informant is participating parent.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change total score of the Symptom Checklist Attention-Deficit/Hyperactivity Disorder (SCL-ADHD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nQuestionnaire considers the diagnostic criteria of DSM-IV and ICD-10 for ADHD. Informant is participating parent.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change Oppositional Defiant Disorder subscale score of the Diagnostic Checklist Disruptive Behavior Disorder (DCL-ODD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nDiagnostic interview considers the criteria of DSM-IV and ICD-10 for ODD. Informant is mental health worker.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change total score of the Diagnostic Checklist Attention-Deficit/Hyperactivity Disorder (DCL-ADHD; Döpfner, Görtz-Dorten, & Lehmkuhl, 2008)\n[ Time Frame: pre, intermediate, post, 6-month FU, 12-month FU ]\n\nDiagnostic interview considers the criteria of DSM-IV and ICD-10 for ADHD. Informant is mental health worker.""}]
NCT01352325	Efficacy of System Constellations in a General Population	Improving experience in personal social systems through family constellation seminars: results of a randomized controlled trial	10.1111/famp.12051	http://onlinelibrary.wiley.com/doi/10.1111/famp.12051/full	4	2011-05-10	Completed	2011-02-01	2011-12-01	2013-11-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in psychological well-being at 2 weeks and four months\n[ Time Frame: Baseline, day of treatment, 2 weeks after treatment, 4 months after treatment ]\n\nPsychological well-being will be assessed using the 'Outcome Questionnaire' in its German version (EB-45). The EB-45 is a brief 45-item self report outcome/tracking instrument designed for repeated measurement of client progress through the course of psychotherapy and following termination. The scales of the EB-45 measure symptom distress, interpersonal functioning, and social role.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in psychological well-being at 2 weeks and four months\n[ Time Frame: Baseline, day of treatment, 2 weeks after treatment, 4 months after treatment ]\n\nPsychological well-being will be assessed using the 'Outcome Questionnaire' in its German version (EB-45). The EB-45 is a brief 45-item self report outcome/tracking instrument designed for repeated measurement of client progress through the course of psychotherapy and following termination. The scales of the EB-45 measure symptom distress, interpersonal functioning, and social role.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in psychological well-being at 2 weeks and four months\n[ Time Frame: Baseline, day of treatment, 2 weeks after treatment, 4 months after treatment ]\n\nPsychological well-being will be assessed using the 'Outcome Questionnaire' in its German version (EB-45). The EB-45 is a brief 45-item self report outcome/tracking instrument designed for repeated measurement of client progress through the course of psychotherapy and following termination. The scales of the EB-45 measure symptom distress, interpersonal functioning, and social role.""}]	NA	NA
NCT01352702	Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)	10.1155/2015/798486	https://pubmed.ncbi.nlm.nih.gov/26229963/	5	2011-05-11	Terminated	2011-05-01	2014-05-01	2015-07-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP induced platelet aggregation\n[ Time Frame: 2 weeks ]\n\nTo determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.""}]	NA	NA
NCT01355835	Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease	Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease	10.1007/s00415-011-5906-3	NA	4	2011-05-17	Completed	2011-02-01	2012-08-01	2011-02-02	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gait score\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\nThe 'gait score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'gait score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""'Axial score'\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\n\n\nThe composite 'axial score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'axial score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.\n\nSafety: falls""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""'Axial score'\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\n\n\nThe composite 'axial score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'axial score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.\n\nSafety: falls""}]	NA
NCT01357694	BRIA - Bridging Intervention in Anesthesiology	Readiness to change and therapy outcomes of an innovative psychotherapy program for surgical patients: results from a randomized controlled trial	10.1186/s12888-017-1579-5	https://pubmed.ncbi.nlm.nih.gov/29284443/	9	2011-05-19	Completed	2011-05-01	2013-02-01	2017-12-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""participation in psychosocial therapy\n[ Time Frame: six months after baseline assessment ]\n\nrate of patients who participate in succeeding outpatient or inpatient psychosocial treatment (psychotherapy, addiction therapy)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""participation in psychosocial therapy\n[ Time Frame: six months after baseline assessment ]\n\nrate of patients who participate in succeeding outpatient or inpatient psychosocial treatment (psychotherapy, addiction therapy)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""participation in psychosocial therapy\n[ Time Frame: six months after baseline assessment ]\n\nrate of patients who participate in succeeding outpatient or inpatient psychosocial treatment (psychotherapy, addiction therapy)""}]	NA	NA
NCT01357980	Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis	Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study	10.1002/nau.22954	http://onlinelibrary.wiley.com/doi/10.1002/nau.22954/full	16	2011-05-20	Completed	2011-05-01	2013-03-01	2017-02-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean change from baseline in daily incontinence episode frequency\n[ Time Frame: Day 84 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean change from baseline in daily incontinence episode frequency\n[ Time Frame: Day 84 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01360554	ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial	10.1016/s1470-2045(14)70452-8	NA	54	2011-05-24	Completed	2011-06-01	2013-08-01	2014-10-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[See Results Section.]	NA
NCT01360840	EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer	Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer	10.1158/1078-0432.ccr-15-2512	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01360840	12	2011-05-25	Completed	2011-04-01	2014-09-01	2016-02-02	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: anticipated average time frame of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical anti-tumor activity assessed as progression free survival (PFS)\n[ Time Frame: up to 3 months after last subject randomized ]""}]	[See Results Section.]	NA	NA
NCT01368471	Safety and Efficacy Study of MGuard Stent After a Heart Attack	Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial	10.1016/j.jacc.2012.09.004	NA	5	2011-06-07	Completed	2011-06-01	2012-06-01	2012-11-06	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST resolution) measured 60 to 90 minutes after the last angiogram.\n[ Time Frame: 60-90 minutes post-procedure ]\n\nWe will measure the incidence of complete ST segment resolution (defined as ≥70% ST resolution on an EKG) measured 60 to 90 minutes after the last angiogram.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	NA
NCT01370863	An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients	Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment	10.1111/nmo.12484	http://onlinelibrary.wiley.com/doi/10.1111/nmo.12484/abstract	8	2011-06-09	Terminated	2010-12-01	2012-06-01	2014-12-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24-h pH/MII monitoring (pre- and post- treatment)\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24-h pH/MII monitoring (pre- and post- treatment)\n[ Time Frame: 4 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01378078	Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia	Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study	10.1093/schbul/sbw041	https://www.ncbi.nlm.nih.gov/pubmed/27098066	3	2011-06-21	Completed	2011-06-01	2013-06-01	2016-04-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SANS reduction\n[ Time Frame: 4 weeks after baseline ]\n\ndecrease by 30%""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SANS reduction\n[ Time Frame: 4 weeks after baseline ]\n\ndecrease by 30%""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SANS reduction\n[ Time Frame: 4 weeks after baseline ]\n\ndecrease by 30%""}]	NA	NA
NCT01379248	Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset	Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset	10.1016/j.jcin.2015.09.010	https://pubmed.ncbi.nlm.nih.gov/26793952/	3	2011-06-21	Completed	2011-06-01	2014-11-01	2016-01-25	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microvascular obstruction (cardiac magnetic resonance imaging)\n[ Time Frame: 1-4 days after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microvascular obstruction (cardiac magnetic resonance imaging)\n[ Time Frame: 1-4 days after randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microvascular obstruction (cardiac magnetic resonance imaging)\n[ Time Frame: 1-4 days after randomization ]""}]	NA
NCT01381198	Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia	Distal rectus femoris transfer as part of multilevel surgery in children with spastic diplegia--a randomized clinical trial	10.1016/j.gaitpost.2012.02.017	http://www.sciencedirect.com/science/article/pii/S0966636212000689	2	2011-06-23	Completed	2007-06-01	2011-04-01	2012-03-15	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Range of knee flexion in swing phase\n[ Time Frame: prior intervention (baseline) and 1 year post intervention ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Range of knee flexion in swing phase\n[ Time Frame: prior intervention (baseline) and 1 year post intervention ]""}]	NA	NA
NCT01382017	Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study	Effects of lacosamide and carbamazepine on human motor cortex excitability: a double-blind, placebo-controlled transcranial magnetic stimulation study	10.1016/j.seizure.2013.05.010	https://www.ncbi.nlm.nih.gov/pubmed/23778157	2	2011-06-24	Completed	2011-06-01	2012-08-01	2013-06-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TMS measures of cortical excitability\n[ Time Frame: within 24h after intake of study medication ]\n\nTranscranial magnetic stimulation (TMS) measurements included resting motor thresholds (RMT) and active motor thresholds (AMT), the intensity to evoke MEP of ∼1mV peak-to-peak amplitude (SI1mV), short-interval intracortical inhibition/intracortical facilitation (SICI/ICF), long-interval intracortical inhibition (LICI), short-interval intracortical facilitation (SICF), recruitment curves, MEP under tonic activation (aMEP), and cortical silent period (CSP), and MEP changes in response to short trains of repetitive TMS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TMS measures of cortical excitability\n[ Time Frame: within 24h after intake of study medication ]\n\nTranscranial magnetic stimulation (TMS) measurements included resting motor thresholds (RMT) and active motor thresholds (AMT), the intensity to evoke MEP of ∼1mV peak-to-peak amplitude (SI1mV), short-interval intracortical inhibition/intracortical facilitation (SICI/ICF), long-interval intracortical inhibition (LICI), short-interval intracortical facilitation (SICF), recruitment curves, MEP under tonic activation (aMEP), and cortical silent period (CSP), and MEP changes in response to short trains of repetitive TMS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TMS measures of cortical excitability\n[ Time Frame: within 24h after intake of study medication ]\n\nTranscranial magnetic stimulation (TMS) measurements included resting motor thresholds (RMT) and active motor thresholds (AMT), the intensity to evoke MEP of ∼1mV peak-to-peak amplitude (SI1mV), short-interval intracortical inhibition/intracortical facilitation (SICI/ICF), long-interval intracortical inhibition (LICI), short-interval intracortical facilitation (SICF), recruitment curves, MEP under tonic activation (aMEP), and cortical silent period (CSP), and MEP changes in response to short trains of repetitive TMS.""}]	NA	NA
NCT01382680	Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide Wire	A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial	10.1055/s-0034-1377628	https://www.thieme-connect.com/DOI/DOI?10.1055/s-0034-1377628	3	2011-06-24	Completed	2010-10-01	2013-10-01	2014-09-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of guidewires per ERCP session\n[ Time Frame: Within the same ERCP session (day 1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of guidewires per ERCP session\n[ Time Frame: Within the same ERCP session (day 1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of guidewires per ERCP session\n[ Time Frame: Within the same ERCP session (day 1) ]""}]	NA	NA
NCT01384058	Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes	Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus	10.1016/j.atherosclerosis.2011.10.043	http://www.sciencedirect.com/science/article/pii/S0021915011010677?via%3Dihub	3	2011-06-27	Completed	2007-11-01	2010-05-01	2011-11-09	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Concentration of apoB in dLDL from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: 12 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Concentration of Apolipoprotein B (ApoB) in dense Low Density Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: 12 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: baseline and 6 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe 10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	NA
NCT01387048	Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin	A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne	10.1111/jdv.12823	NA	3	2011-07-01	Completed	2011-08-01	2012-08-01	2014-11-14	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	NA	NA
NCT01388231	Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice	Manualized cognitive therapy versus cognitive-behavioral treatment-as-usual for social anxiety disorder in routine practice: A cluster-randomized controlled trial	10.1016/j.brat.2017.05.012	NA	2	2011-07-04	Unknown status	2010-09-01	NA	2017-05-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of Social Phobia Symptoms\n[ Time Frame: Data will be collected for an expected treatment period of 30 weeks in average (corresponding to an expected average of n=25 sessions), at treatment completion, at 6 and 12 months post-treatment. ]\n\nSymptom severity will be assessed via the Liebowitz Social Anxiety Scale (LSAS).""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of Social Phobia Symptoms\n[ Time Frame: Data will be collected for an expected treatment period of 30 weeks in average (corresponding to an expected average of n=25 sessions), at treatment completion, at 6 and 12 months post-treatment. ]\n\nSymptom severity will be assessed via the Liebowitz Social Anxiety Scale (LSAS).""}]
NCT01389375	Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial	Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial	10.1001/jama.2014.15305	NA	5	2011-07-06	Completed	2011-07-01	2014-06-01	2014-11-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of arterial access related complications\n[ Time Frame: 30 days ]\n\n\n\nComposite of arterial access related complications, defined as the composite of:\n\nRate of ipsilateral groin hematomas with largest diameter exceeding 5 cm\nPseudoaneurysm\nAV-Fistula\nMajor bleeding\nCritical limb ischemia\nLocal infection\nSurgical repair\nRevascularisation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of arterial access related complications\n[ Time Frame: 30 days ]\n\n\n\nComposite of arterial access related complications, defined as the composite of:\n\nRate of ipsilateral groin hematomas with largest diameter exceeding 5 cm\nPseudoaneurysm\nAV-Fistula\nMajor bleeding\nCritical limb ischemia\nLocal infection\nSurgical repair\nRevascularisation""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of arterial access related complications\n[ Time Frame: 30 days ]\n\n\n\nComposite of arterial access related complications, defined as the composite of:\n\nRate of ipsilateral groin hematomas with largest diameter exceeding 5 cm\nPseudoaneurysm\nAV-Fistula\nMajor bleeding\nCritical limb ischemia\nLocal infection\nSurgical repair\nRevascularisation""}]	NA
NCT01389856	Persistent Pulmonary Hypertension of the Newborn	Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial	10.1016/j.jpeds.2016.06.078	https://www.ncbi.nlm.nih.gov/pubmed/27502103?dopt=Abstract	14	2011-07-07	Terminated	2011-09-01	2013-12-01	2016-08-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with treatment failure\n[ Time Frame: From baseline to up to 14 days ]\n\n\n\nExploratory Endpoint:\n\nProportion of patients with treatment failure:\n\nNeed for extra corporeal membrane oxygenation (ECMO) or\nInitiation of alternative pulmonary vasodilator""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with treatment failure\n[ Time Frame: From baseline to up to 14 days ]\n\n\n\nExploratory Endpoint:\n\nProportion of patients with treatment failure:\n\nNeed for extra corporeal membrane oxygenation (ECMO) or\nInitiation of alternative pulmonary vasodilator""}]	[See Results Section.]	NA	NA
NCT01391338	A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)	Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial	10.1016/j.urology.2017.02.029	NA	8	2011-07-08	Completed	2011-06-01	2013-02-01	2017-02-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), total score at 12 weeks\n[ Time Frame: Baseline and 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), total score at 12 weeks\n[ Time Frame: Baseline and 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), total score at 12 weeks\n[ Time Frame: Baseline and 12 weeks ]""}]	NA	NA
NCT01393067	cSEMS vs. NEPS in Stricture of Biliary Anastomosis After Liver Transplantation	Multiple plastic stents versus covered metal stent for treatment of anastomotic biliary strictures after liver transplantation: a prospective, randomized, multicenter trial	10.1016/j.gie.2017.03.009	https://pubmed.ncbi.nlm.nih.gov/28302527/	4	2011-07-12	Completed	2011-03-01	2015-03-01	2017-03-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of interventions (ERCP) to attain resolution of stenosis\n[ Time Frame: up to one year ]\n\nNumber of interventions (ERC) in study group cSEMS is compared to number of interventions (ERC) in study group NEPS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of interventions (ERCP) to attain resolution of stenosis\n[ Time Frame: up to one year ]\n\nNumber of interventions (ERC) in study group cSEMS is compared to number of interventions (ERC) in study group NEPS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of interventions (ERCP) to attain resolution of stenosis\n[ Time Frame: up to one year ]\n\nNumber of interventions (ERC) in study group cSEMS is compared to number of interventions (ERC) in study group NEPS""}]	NA	NA
NCT01394692	Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery	Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial	10.1016/s1470-2045(11)70196-6	https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(11)70196-6	2	2011-07-13	Completed	2007-10-01	2010-07-01	2011-08-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of Resection\n[ Time Frame: 72 hours ]\n\nThe extent of resection following surgery of a contrast-enhancing glioma according to postoperative high-field MRI within 72 hours""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of Resection\n[ Time Frame: 72 hours ]\n\nThe extent of resection following surgery of a contrast-enhancing glioma according to postoperative high-field MRI within 72 hours""}]	[See Results Section.]	NA
NCT01398488	Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education	Conventional vs. tablet computer-based patient education following lung transplantation--a randomized controlled trial	10.1371/journal.pone.0090828	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946627/	4	2011-07-19	Completed	2011-07-01	2012-07-01	2014-03-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Calcineurin trough levels\n[ Time Frame: 6 month ]\n\nImprovement of percentage of calcineurin inhibitor trough levels (Delta %) in target range 6 months after patient education compared to 6 months before patient education""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Calcineurin trough levels\n[ Time Frame: 6 month ]\n\nImprovement of percentage of calcineurin inhibitor trough levels (Delta %) in target range 6 months after patient education compared to 6 months before patient education""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Calcineurin trough levels\n[ Time Frame: 6 month ]\n\nImprovement of percentage of calcineurin inhibitor trough levels (Delta %) in target range 6 months after patient education compared to 6 months before patient education""}]	NA	NA
NCT01400022	Topical 0.05% Clobetasol Propionate in Vaseline Versus UVA-1 Phototherapy in Vulvar Lichen Sclerosus	UV-A1 phototherapy vs clobetasol propionate, 0.05%, in the treatment of vulvar lichen sclerosus: a randomized clinical trial	10.1001/jamadermatol.2013.7733	https://www.ncbi.nlm.nih.gov/pubmed/24696010	2	2011-07-21	Completed	2010-08-01	2013-01-01	2014-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement during UVA1/cortisone treatment\n[ Time Frame: 6 months follow-up ]\n\nClinical improvement during UVA1/cortisone treatment using an investigator score measuring hypopigmentation, sclerosis, atrophy, hyperkeratosis, erosions, edema, erythema in a numerical scale as to be rated followed: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The total score is then calculated respectively from the sum of individual scores (max. 21 points).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement during UVA1/cortisone treatment\n[ Time Frame: 6 months follow-up ]\n\nClinical improvement during UVA1/cortisone treatment using an investigator score measuring hypopigmentation, sclerosis, atrophy, hyperkeratosis, erosions, edema, erythema in a numerical scale as to be rated followed: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The total score is then calculated respectively from the sum of individual scores (max. 21 points).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical improvement during UVA1/cortisone treatment\n[ Time Frame: 6 months follow-up ]\n\nClinical improvement during UVA1/cortisone treatment using an investigator score measuring hypopigmentation, sclerosis, atrophy, hyperkeratosis, erosions, edema, erythema in a numerical scale as to be rated followed: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The total score is then calculated respectively from the sum of individual scores (max. 21 points).""}]	NA	NA
NCT01400100	Effects of Intraarterial Octreotide on Pancreatic Texture	Effects of intra-arterial octreotide on pancreatic texture: a randomized controlled trial	10.1177/1457496913490457	https://www.ncbi.nlm.nih.gov/pubmed/23963030	4	2011-07-21	Completed	2011-08-01	2012-02-01	2013-08-20	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pancreatic hardness\n[ Time Frame: 3 months postoperatively ]\n\nPancreatic hardness is a quantifiable parameter, measured by a Shore Durometer in Shore Units on a 0-100 SU scale.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pancreatic hardness\n[ Time Frame: 3 months postoperatively ]\n\nPancreatic hardness is a quantifiable parameter, measured by a Shore Durometer in Shore Units on a 0-100 SU scale.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pancreatic hardness\n[ Time Frame: 3 months postoperatively ]\n\nPancreatic hardness is a quantifiable parameter, measured by a Shore Durometer in Shore Units on a 0-100 SU scale.""}]	NA	NA
NCT01401283	GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery	Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: a multi-center, prospective, randomized study	10.1186/cc12885	https://ccforum.biomedcentral.com/articles/10.1186/cc12885	5	2011-07-22	Completed	2011-07-01	2012-06-01	2013-09-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hospital stay hospital stay\n[ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days ]\n\nlength of stay in the postoperative care unit length of hospital stay""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hospital stay hospital stay\n[ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days ]\n\nlength of stay in the postoperative care unit length of hospital stay""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postoperative complications\n[ Time Frame: Participants will be followed from end of surgery for the duration of stay in the recovery room, for the duration of the complete hospital stay, an expected average of ten 10 days ]\n\nCategories of postoperative complications: Infection (respiratory, abdominal, UTI, wound), Respiratory (prolonged need for ventilation), Cardiovascular (edema, arrythmia, hypotension, AMI, stroke), Abdominal (constipation), Renal (urine output <500ml/d, ARF)""}]	[See Results Section.]	NA
NCT01401296	Evaluation of the Effectiveness of a Web-based Treatment Program for Depression for the Reduction of Depressive Symptoms	A randomized controlled trial of internet-based therapy in depression	10.1016/j.brat.2012.04.006	NA	3	2011-07-22	Completed	2011-05-01	2012-09-01	2012-05-03	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	NA
NCT01402739	Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses	Why does a point of care guided transfusion algorithm not improve blood loss and transfusion practice in patients undergoing high-risk cardiac surgery? A prospective randomized controlled pilot study	10.1186/s12871-019-0689-7	https://pubmed.ncbi.nlm.nih.gov/30777015/	6	2011-07-25	Terminated	2011-08-01	2015-06-01	2019-02-18	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""chest tube output\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""chest tube output\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""chest tube output\n[ Time Frame: 24 hours ]""}]	NA	NA
NCT01405313	Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV	Performance of conventional and enhanced adaptive servoventilation (ASV) in heart failure patients with central sleep apnea who have adapted to conventional ASV	10.1007/s11325-014-1083-9	https://www.ncbi.nlm.nih.gov/pubmed/25413958?dopt=Abstract	4	2011-07-28	Completed	2011-07-01	2011-09-01	2014-11-21	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""AHI\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including SpO2, respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apnea/hypopnea index (AHI)\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apnea/hypopnea index (AHI)\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[See Results Section.]	NA
NCT01406067	Treatment of Children With Peer Related Aggressive Behavior	Efficacy of an individualized social competence training for children with Oppositional Defiant Disorders/Conduct Disorders	10.1080/10503307.2015.1094587	https://www.ncbi.nlm.nih.gov/pubmed/26522864	4	2011-07-28	Completed	2011-01-01	2012-09-01	2015-11-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Questionnaire for Aggressive Behavior of Children (FAVK) total score for peer related aggression\n[ Time Frame: Change from pre- assessment to post assessment 30 weeks after treatment begin and to follow up 3 months and 9 months after post assessment ]\n\nThe Questionnaire for Aggressive Behavior of Children (FAVK) is a newly developed parent rating scale which assesses several factors of peer related aggression: (1) disturbance of social cognitive information processing, (2) disturbance of social problem solving and social skills, (3) disturbance of impulse control, and (4) disturbance of social interaction. These scores a summed to a total score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Questionnaire for Aggressive Behavior of Children (FAVK) total score for peer related aggression\n[ Time Frame: Change from pre- assessment to post assessment 30 weeks after treatment begin and to follow up 3 months and 9 months after post assessment ]\n\nThe Questionnaire for Aggressive Behavior of Children (FAVK) is a newly developed parent rating scale which assesses several factors of peer related aggression: (1) disturbance of social cognitive information processing, (2) disturbance of social problem solving and social skills, (3) disturbance of impulse control, and (4) disturbance of social interaction. These scores a summed to a total score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Questionnaire for Aggressive Behavior of Children (FAVK) total score for peer related aggression\n[ Time Frame: Change from pre- assessment to post assessment 30 weeks after treatment begin and to follow up 3 months and 9 months after post assessment ]\n\nThe Questionnaire for Aggressive Behavior of Children (FAVK) is a newly developed parent rating scale which assesses several factors of peer related aggression: (1) disturbance of social cognitive information processing, (2) disturbance of social problem solving and social skills, (3) disturbance of impulse control, and (4) disturbance of social interaction. These scores a summed to a total score""}]	NA	NA
NCT01406730	Running Effect on Cardiovascular and Muscular Parameters	Myocardial adaptation to high-intensity (interval) training in previously untrained men with a longitudinal cardiovascular magnetic resonance imaging study (Running Study and Heart Trial)	10.1161/circimaging.114.002566	http://circimaging.ahajournals.org/content/8/4/e002566.long	4	2011-07-29	Completed	2011-07-01	2012-07-01	2015-04-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""myocardial mass/stroke volume\n[ Time Frame: 4 month ]\n\nAtrial and ventricular volume and mass indexes were assessed by magnetic resonance imaging (MRI)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""myocardial mass/stroke volume\n[ Time Frame: 4 month ]\n\nAtrial and ventricular volume and mass indexes were assessed by magnetic resonance imaging (MRI)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""myocardial mass/stroke volume\n[ Time Frame: 4 month ]\n\nAtrial and ventricular volume and mass indexes were assessed by magnetic resonance imaging (MRI)""}]	NA	NA
NCT01407055	Optimizing Expectations in Cardiac Surgery Patients	Effects of Preoperative Psychological Interventions on Catecholamine and Cortisol Levels After Surgery in Coronary Artery Bypass Graft Patients: The Randomized Controlled PSY-HEART Trial	10.1097/psy.0000000000000483	https://pubmed.ncbi.nlm.nih.gov/28846584/	7	2011-07-29	Completed	2011-07-01	2014-10-01	2017-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disability 6 months after surgery, controlled for baseline disability (Pain Disability Index; PDI)\n[ Time Frame: 6 months after surgery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disability 6 months after surgery, controlled for baseline disability (Pain Disability Index; PDI)\n[ Time Frame: 6 months after surgery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disability 6 months after surgery, controlled for baseline disability (Pain Disability Index; PDI)\n[ Time Frame: 6 months after surgery ]""}]	NA	NA
NCT01407887	Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children	Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso	10.1093/infdis/jiu540	https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiu540	2	2011-08-01	Completed	2011-08-01	2011-08-01	2014-09-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""P. falciparum gametocyte prevalence\n[ Time Frame: day 14 of follow-up ]\n\nP. falciparum gametocyte prevalence on day 14 of follow-up (PCR determination)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""P. falciparum gametocyte prevalence\n[ Time Frame: day 14 of follow-up ]\n\nP. falciparum gametocyte prevalence on day 14 of follow-up (PCR determination)""}]	NA	NA
NCT01409330	German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET)	Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial	10.1007/s00125-014-3457-8	NA	6	2011-08-03	Unknown status	2011-02-01	NA	2014-11-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""whole body insulin sensitivity\n[ Time Frame: 1 year ]\n\nmeasurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""whole body insulin sensitivity\n[ Time Frame: 8 weeks ]\n\nmeasurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp""}]
NCT01409720	Isometric Muscle Training in Patients With Spinal Bony Metastases Under Radiation Therapy	Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial	10.1186/1471-2407-14-67	https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-67	2	2011-08-03	Completed	2011-09-01	2012-09-01	2014-02-05	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""feasibility of isometric exercise in vertebral bony metastases\n[ Time Frame: 12 weeks post completion of radiotherapy ]\n\nsafety and feasibility of isometric exercise in vertebral bony metastases""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""feasibility of isometric exercise in vertebral bony metastases\n[ Time Frame: 12 weeks post completion of radiotherapy ]\n\nsafety and feasibility of isometric exercise in vertebral bony metastases""}]	NA
NCT01411566	Clinical Intervention Psychosis and Addiction	Trans-Sector Integrated Treatment in Psychosis and Addiction	10.3238/arztebl.2015.0683	https://www.ncbi.nlm.nih.gov/pubmed/?term=26554316	1	2011-08-05	Unknown status	NA	NA	2015-10-09	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Substance use\n[ Time Frame: one year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Substance use\n[ Time Frame: 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Substance use\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in drug use motivation\n[ Time Frame: 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in drug use motivation\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in drug use motivation\n[ Time Frame: 1 year ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Substance use\n[ Time Frame: one year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Substance use\n[ Time Frame: 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Substance use\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in drug use motivation\n[ Time Frame: 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in drug use motivation\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in drug use motivation\n[ Time Frame: 1 year ]""}]
NCT01412320	Cocoa Flavanols in Renal Disease	Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis	10.1371/journal.pone.0140215	https://www.ncbi.nlm.nih.gov/pubmed/26485680	4	2011-08-08	Completed	2011-08-01	2012-12-01	2015-10-20	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""An improvement of endothelial function as measured by flow-mediated dilation (FMD)\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The effect of flavanols on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.\n[ Time Frame: 30 days ]\n\nTo study the effect of flavanols on flow mediated dilation of the brachial artery after 5 minutes of forearm ischemia and reperfusion in patients with ESRD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The effect of flavanols on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.\n[ Time Frame: 30 days ]\n\nTo study the effect of flavanols on flow mediated dilation of the brachial artery after 5 minutes of forearm ischemia and reperfusion in patients with ESRD""}]	NA	NA
NCT01414231	Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a	Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup	10.1200/jco.2012.42.2907	https://pubmed.ncbi.nlm.nih.gov/22965967/	1	2011-08-10	Unknown status	NA	NA	2012-09-10	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: after 5 years ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: after 5 years ]""}]
NCT01415622	Feasibility, Efficacy, and Safety of Venous Ulcer Treatment Using a Hand Plasma Generator (PlasmaDerm) Chronisch venöser Ulzerationen (PlasmaDerm)	Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm(®) VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622)	10.1111/jdv.12490	https://www.ncbi.nlm.nih.gov/pubmed/24666170?dopt=Abstract	2	2011-08-11	Completed	2011-04-01	2012-07-01	2014-03-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of SAEs\n[ Time Frame: 2 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of SAEs\n[ Time Frame: 2 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of SAEs\n[ Time Frame: 2 months ]""}]	NA	NA
NCT01415804	Investigation of Stent-grafts in Aortic Dissection (INSTEAD)	Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial	10.1161/circinterventions.113.000463	https://www.ncbi.nlm.nih.gov/pubmed/23922146?dopt=Abstract	1	2011-08-11	Completed	2002-02-01	2010-10-01	2013-08-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 5 years post randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All cause mortality\n[ Time Frame: 5 years post randomization ]""}]	NA	NA
NCT01417312	Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients	Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial	10.3945/ajcn.113.075309	https://www.ncbi.nlm.nih.gov/pubmed/25733633	12	2011-08-15	Completed	2011-07-01	2012-10-01	2015-01-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systemic lipid oxidation\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	NA
NCT01417949	Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)	10.1186/s12981-019-0250-2	https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-019-0250-2	4	2011-08-15	Completed	2011-08-01	2016-10-01	2019-11-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death, all new/relapsing opportunistic infections and other grade 4 clinical endpoints within 24 weeks after randomization\n[ Time Frame: 24 weeks ]\n\nClinical Progression (death, all new or relapsing OI, other Grade 4 clinical endpoint) within 24 weeks. For abnormalities not found in the Toxicity Tables, a Grade 4 event will be defined as potentially life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable). Patients who drop out of study observation before end of week 12 are counted as clinical progression.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death, all new/relapsing opportunistic infections and other grade 4 clinical endpoints within 24 weeks after randomization\n[ Time Frame: 24 weeks ]\n\nClinical Progression (death, all new or relapsing OI, other Grade 4 clinical endpoint) within 24 weeks. For abnormalities not found in the Toxicity Tables, a Grade 4 event will be defined as potentially life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable). Patients who drop out of study observation before end of week 12 are counted as clinical progression.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death, all new/relapsing opportunistic infections and other grade 4 clinical endpoints within 24 weeks after randomization\n[ Time Frame: 24 weeks ]\n\nClinical Progression (death, all new or relapsing OI, other Grade 4 clinical endpoint) within 24 weeks. For abnormalities not found in the Toxicity Tables, a Grade 4 event will be defined as potentially life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable). Patients who drop out of study observation before end of week 12 are counted as clinical progression.""}]	NA	NA
NCT01418053	The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome	Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome--A Randomized Controlled Cross-Over Trial	10.1159/000398790	https://www.ncbi.nlm.nih.gov/pubmed/26044145?dopt=Abstract	7	2011-08-15	Completed	2011-08-01	2013-09-01	2015-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptome Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	NA
NCT01418066	Ayurvedic Herbs in Diarrhea Predominant Irritable Bowel Syndrome	Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial	10.1016/j.ctim.2016.04.002	http://www.sciencedirect.com/science/article/pii/S0965229916300528	4	2011-08-15	Completed	2011-08-01	2012-12-01	2016-04-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""irritable bowel syndrome- symptom severity score\n[ Time Frame: T2 (Day 28) ]\n\nIBS-SSS(Francis, 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""irritable bowel syndrome- symptom severity score\n[ Time Frame: T2 (Day 28) ]\n\nIBS-SSS(Francis, 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""irritable bowel syndrome- symptom severity score\n[ Time Frame: T2 (Day 28) ]\n\nIBS-SSS(Francis, 1997)""}]	NA	NA
NCT01420744	Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)	10.1007/s00134-018-5143-7	https://pubmed.ncbi.nlm.nih.gov/29632995/	5	2011-08-19	Completed	2011-08-01	2015-02-01	2018-04-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days (VFDs)\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days (VFDs)\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	NA	NA
NCT01425359	Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina	Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)	10.1016/j.jacc.2013.02.011	https://www.ncbi.nlm.nih.gov/pubmed/23500237	10	2011-08-26	Completed	2011-09-01	2013-03-01	2013-03-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The average weekly angina frequency over the last 6 weeks of treatment\n[ Time Frame: 6 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The average weekly angina frequency over the last 6 weeks of treatment\n[ Time Frame: 6 weeks ]""}]	NA	[See Results Section.]	NA
NCT01426880	Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial	10.1016/s1470-2045(14)70160-3	https://www.ncbi.nlm.nih.gov/pubmed/24794243?dopt=Abstract	9	2011-08-31	Completed	2011-08-01	2013-05-01	2014-04-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)\n[ Time Frame: 24 weeks (time window -3 weeks) ]\n\nPathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)\n[ Time Frame: 24 weeks (time window -3 weeks) ]\n\nPathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)\n[ Time Frame: 24 weeks (time window -3 weeks) ]\n\nPathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)\n[ Time Frame: 24 weeks (time window -3 weeks) ]\n\nPathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.""}]	NA
NCT01433523	House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma	Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial	10.1001/jama.2016.3964	https://jamanetwork.com/journals/jama/fullarticle/2516714	7	2011-09-13	Completed	2011-08-01	2013-04-01	2016-04-26	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the risk of an asthma exacerbation.\n[ Time Frame: Measured during the last 4 months of the trial (months 14-18) ]\n\nNumber of asthma exacerbations reported in the IMP treated groups compared to number of asthma exacerbations reported in the placebo group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	NA
NCT01433653	Cognitive Behavioral Therapy for Complicated Grief	Efficacy of an outpatient treatment for prolonged grief disorder: a randomized controlled clinical trial	10.1016/j.jad.2014.05.035	https://www.ncbi.nlm.nih.gov/pubmed/25082115?dopt=Abstract	2	2011-09-13	Completed	2005-05-01	2011-02-01	2014-06-02	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PG-13 (Prolonged Grief Interview - 13 Item version)\n[ Time Frame: Change between intake (t1) and end of treatment (t2) in complicated grief severity within 5 months. t1= before treatment or wait list begins, t2 = 4 months after t1 (end of treatment, end of waitlist), t3 = follow-up (1.5 years after t2) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PG-13 (Prolonged Grief Interview - 13 Item version)\n[ Time Frame: Change between intake (t1) and end of treatment (t2) in complicated grief severity within 5 months. t1= before treatment or wait list begins, t2 = 4 months after t1 (end of treatment, end of waitlist), t3 = follow-up (1.5 years after t2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PG-13 (Prolonged Grief Interview - 13 Item version)\n[ Time Frame: Change between intake (t1) and end of treatment (t2) in complicated grief severity within 5 months. t1= before treatment or wait list begins, t2 = 4 months after t1 (end of treatment, end of waitlist), t3 = follow-up (1.5 years after t2) ]""}]	NA
NCT01434589	Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction	Efficacy of Short-term Treatment of Internet and Computer Game Addiction: A Randomized Clinical Trial	10.1001/jamapsychiatry.2019.1676	https://pubmed.ncbi.nlm.nih.gov/31290948/	9	2011-09-14	Completed	2012-01-01	2017-06-01	2019-07-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in internet or computer game addiction (self-rating)\n[ Time Frame: 4 and 10 months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in internet or computer game addiction (self-rating)\n[ Time Frame: 4 and 10 months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in internet or computer game addiction (self-rating)\n[ Time Frame: 4 and 10 months after randomization ]""}]	NA	NA
NCT01435226	GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection	Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response	10.1093/infdis/jiu325	https://academic.oup.com/jid/article/210/12/1881/2908616/Interferon-Induced-Protein10-Kinetics-in-Treatment	11	2011-09-15	Completed	2011-09-01	2013-03-01	2014-06-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and Tolerability\n[ Time Frame: 24 weeks ]\n\n\n\nTo evaluate safety and tolerability of combination therapy with GS-5885, GS-9451, tegobuvir and ribavirin or GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and ribavirin.\n\nSafety will be assessed during the study through the reporting of adverse events, clinical laboratory tests, physical examinations, vital signs and 12-lead ECGs at various time points during the study.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Antiviral Activity\n[ Time Frame: 24 weeks ]\n\nTo evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < lower limit of quantitation [LLoQ] 24 weeks post-treatment) of combination therapy with GS-5885, GS-9451, tegobuvir and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in treatment-experienced subjects with chronic genotype 1a or 1b HCV infection""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and Tolerability\n[ Time Frame: 24 weeks ]\n\n\n\nTo evaluate safety and tolerability of combination therapy with GS-5885, GS-9451, tegobuvir and ribavirin or GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and ribavirin.\n\nSafety will be assessed during the study through the reporting of adverse events, clinical laboratory tests, physical examinations, vital signs and 12-lead ECGs at various time points during the study.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Antiviral Activity\n[ Time Frame: 24 weeks ]\n\nTo evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < lower limit of quantitation [LLoQ] 24 weeks post-treatment) of combination therapy with GS-5885, GS-9451, tegobuvir and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in treatment-experienced subjects with chronic genotype 1a or 1b HCV infection""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and Tolerability\n[ Time Frame: 24 weeks ]\n\n\n\nTo evaluate safety and tolerability of combination therapy with GS-5885, GS-9451, tegobuvir and ribavirin or GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and ribavirin.\n\nSafety will be assessed during the study through the reporting of adverse events, clinical laboratory tests, physical examinations, vital signs and 12-lead ECGs at various time points during the study.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Antiviral Activity\n[ Time Frame: 24 weeks ]\n\nTo evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < lower limit of quantitation [LLoQ] 24 weeks post-treatment) of combination therapy with GS-5885, GS-9451, tegobuvir and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in treatment-experienced subjects with chronic genotype 1a or 1b HCV infection""}]	NA	NA
NCT01436162	Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder	Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies	10.1016/j.jad.2016.07.006	NA	48	2011-09-16	Completed	2011-10-01	2013-12-01	2016-07-05	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks\n[ Time Frame: Baseline and up to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks\n[ Time Frame: Baseline and up to 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01437930	Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients	Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail	10.1007/s00394-014-0764-2	https://link.springer.com/article/10.1007%2Fs00394-014-0764-2	5	2011-09-20	Completed	2011-09-01	2012-04-01	2014-09-13	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, TAG)\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)\n[ Time Frame: 10 weeks ]""}]	NA	NA
NCT01438463	PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis	Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis	10.2500/ajra.2010.24.3508	https://www.ncbi.nlm.nih.gov/pubmed/?term=Efficacy+and+safety+of+a+glutaraldehyde-modified+house+dust+mite+extract+in+allergic+rhinitis	7	2011-09-21	Completed	2011-09-01	2013-03-01	2010-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test\n[ Time Frame: 12 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test\n[ Time Frame: 12 months ]""}]	NA
NCT01439100	A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain	Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial	10.1016/s1474-4422(15)00243-4	https://www.ncbi.nlm.nih.gov/pubmed/26494524	8	2011-09-21	Completed	2011-10-01	2013-08-01	2015-10-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[]	[]	[]	NA	NA
NCT01440062	Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)	High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial	10.1177/2055217320903474	https://pubmed.ncbi.nlm.nih.gov/32047645/	23	2011-09-23	Terminated	2011-12-01	2018-12-01	2020-01-24	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parameters\n[ Time Frame: 1 day ]\n\nefficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parameters\n[ Time Frame: 1 day ]\n\nefficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parameters\n[ Time Frame: 1 day ]\n\nefficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D""}]	NA
NCT01441791	PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery	Ventilation with high versus low peep levels during general anaesthesia for open abdominal surgery does not affect postoperative spirometry: A randomised clinical trial	10.1097/eja.0000000000000626	https://www.ncbi.nlm.nih.gov/pubmed/28306591	4	2011-09-26	Completed	2011-02-01	2013-01-01	2017-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative pulmonary complications (PPCs)\n[ Time Frame: first 5 days post-operative and on the day of discharge a final assessment is performed scoring endpoints occuring on day 6 and up. ]\n\nMild respiratory failure Severe respiratory failure ALI/ARDS (Acute Lung Injury and Acute Respiratory Distress Syndrome) Suspected pulmonary infection Pulmonary infiltrate Pleural effusion Atelectasis Pneumothorax Bronchospasm Aspiration pneumonitis Cardiopulmonary edema""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative pulmonary complications (PPCs)\n[ Time Frame: first 5 days post-operative and on the day of discharge a final assessment is performed scoring endpoints occuring on day 6 and up. ]\n\nMild respiratory failure Severe respiratory failure ALI/ARDS (Acute Lung Injury and Acute Respiratory Distress Syndrome) Suspected pulmonary infection Pulmonary infiltrate Pleural effusion Atelectasis Pneumothorax Bronchospasm Aspiration pneumonitis Cardiopulmonary edema""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative pulmonary complications (PPCs)\n[ Time Frame: first 5 days post-operative and on the day of discharge a final assessment is performed scoring endpoints occuring on day 6 and up. ]\n\nMild respiratory failure Severe respiratory failure ALI/ARDS (Acute Lung Injury and Acute Respiratory Distress Syndrome) Suspected pulmonary infection Pulmonary infiltrate Pleural effusion Atelectasis Pneumothorax Bronchospasm Aspiration pneumonitis Cardiopulmonary edema""}]	NA	NA
NCT01441986	Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects	Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment	10.1038/nm.3822	NA	2	2011-09-26	Completed	2011-09-01	2012-05-01	2015-03-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the blood glucose (BG) concentration-time profile\n[ Time Frame: from 1-3 hours post-dose (i.e. from 0-2 hours after an OGTT) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the blood glucose (BG) concentration-time profile\n[ Time Frame: from 1-3 hours post-dose (i.e. from 0-2 hours after an OGTT) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the blood glucose (BG) concentration-time profile\n[ Time Frame: from 1-3 hours post-dose (i.e. from 0-2 hours after an OGTT) ]""}]	NA	NA
NCT01442376	Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients	Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study	10.1016/s1470-2045(15)00520-3	http://www.sciencedirect.com/science/article/pii/S1470204515005203?via%3Dihub	20	2011-09-27	Completed	2011-09-01	2012-10-01	2016-01-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in proportion of patients with Complete Response (CR) defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 during first cycle\n[ Time Frame: 0 to 24 hours after T0 ]\n\nTime 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in proportion of patients with Complete Response (CR) defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 during first cycle\n[ Time Frame: 0 to 24 hours after T0 ]\n\nTime 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy""}]	[See Results Section.]	NA	NA
NCT01442610	Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease	Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial	10.1111/ene.13567	https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13567	2	2011-09-27	Completed	2011-10-01	2015-03-01	2016-01-11	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in sleep efficacy\n[ Time Frame: baseline and 8 weeks ]\n\nChange from baseline in sleep efficacy (% in time in bed (TIB) / sleep partial time (SPT)) in polysomnography at 8 weeks""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in PDSS-2\n[ Time Frame: Baseline and 8 weeks ]\n\nChange from baseline in sleep quality at 8 weeks""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in sleep efficacy\n[ Time Frame: baseline and 8 weeks ]\n\nChange from baseline in sleep efficacy (% in time in bed (TIB) / sleep partial time (SPT)) in polysomnography at 8 weeks""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in PDSS-2\n[ Time Frame: Baseline and 8 weeks ]\n\nChange from baseline in sleep quality at 8 weeks""}]	NA
NCT01448213	Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)	NA	NA	https://iovs.arvojournals.org/article.aspx?articleid=2272397	8	2011-10-05	Completed	2011-10-01	2014-10-01	2014-04-01	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of immunologic graft rejection episodes\n[ Time Frame: Within 1 year ]""}]	[See Results Section.]	NA	NA	NA
NCT01448785	Abiliti™ Treatment in Obese Subjects	NA	NA	https://www.nature.com/ijo/journal/v40/n12/full/ijo2016159a.html	4	2011-10-05	Unknown status	2011-04-01	NA	2016-09-16	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Non-inferiority of the abiliti therapy compared to adjustable gastric banding\n[ Time Frame: 12 months ]\n\n\n\nThe non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria:\n\nAchieve at least 20% excess weight loss (%EWL) from implant to end of the study period.\nExperience no serious or severe adverse events related to the device or the procedure\nNo significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Percentage of Responders\n[ Time Frame: 12 months ]\n\nFifty (50 %) of the subject population must obtain an EWL ≥ 25%""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety\n[ Time Frame: 12 months ]\n\n\nIncidence and seriousness of all adverse events.\nIncidence of device or procedure-related adverse events\nFrequency of clinically significant abnormal laboratory values as determined by the Investigator;""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Non-inferiority of the abiliti therapy compared to adjustable gastric banding\n[ Time Frame: 12 months ]\n\n\n\nThe non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria:\n\nAchieve at least 20% excess weight loss (%EWL) from implant to end of the study period.\nExperience no serious or severe adverse events related to the device or the procedure\nNo significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Percentage of Responders\n[ Time Frame: 12 months ]\n\nFifty (50 %) of the subject population must obtain an EWL ≥ 25%""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety\n[ Time Frame: 12 months ]\n\n\nIncidence and seriousness of all adverse events.\nIncidence of device or procedure-related adverse events\nFrequency of clinically significant abnormal laboratory values as determined by the Investigator;""}]
NCT01450865	Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo	Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial	10.1186/1479-5876-11-34	https://www.ncbi.nlm.nih.gov/pubmed/23394517?dopt=Abstract	3	2011-10-10	Completed	2009-10-01	2010-07-01	2013-02-08	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Before and two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Change of neuronal excitability from Baseline (before) to two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Change of neuronal excitability from Baseline (before) to two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	NA
NCT01450930	Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency	Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency	10.1530/eje-12-1057	http://www.eje-online.org/content/169/2/147.long	2	2011-10-12	Completed	2011-11-01	2012-07-01	2013-06-29	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioequivalence Study\n[ Time Frame: 4 hours ]\n\npharmakokinetic data (Cmax, time to Cmax, area under the curve of serum/salivary cortisol levels)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioequivalence Study\n[ Time Frame: 4 hours ]\n\npharmakokinetic data (Cmax, time to Cmax, area under the curve of serum/salivary cortisol levels)""}]	NA	NA
NCT01453179	Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)	Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials	10.1111/jdv.15868	https://pubmed.ncbi.nlm.nih.gov/31407414/	11	2011-10-12	Completed	2011-10-01	2016-01-01	2019-09-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Long-term outcome with respect to the risk of progression to SCC (in situ and/or invasive) of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) with increased precision (meta-analysis with study 3271).\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Long-term outcome with respect to the risk of progression to SCC (in situ and/or invasive) of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) with increased precision (meta-analysis with study 3271).\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Long-term outcome with respect to the risk of progression to SCC (in situ and/or invasive) of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) with increased precision (meta-analysis with study 3271).\n[ Time Frame: 3 years ]""}]	NA	NA
NCT01455675	Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000801-39/results	14	2011-10-19	Completed	2011-10-01	2016-12-01	2019-04-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction\n[ Time Frame: max. 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction\n[ Time Frame: max. 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction\n[ Time Frame: max. 24 months ]""}]	NA	NA
NCT01456364	Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study	10.1080/09537104.2016.1190007	NA	2	2011-10-18	Unknown status	2011-09-01	NA	2016-06-08	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP-induced platelet aggregation after randomized treatment with ticagrelor or prasugrel\n[ Time Frame: Day 2 post randomization ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADP-induced platelet aggregation after randomized treatment with ticagrelor or prasugrel\n[ Time Frame: Day 2 post randomization ]""}]
NCT01458457	Life Quality and Mental State in Patients With Breast Cancer	Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial	10.1007/s10549-014-3249-3	https://www.ncbi.nlm.nih.gov/pubmed/25555830?dopt=Abstract	5	2011-10-21	Completed	2011-05-01	2012-10-01	2015-01-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 months ]""}]	NA
NCT01460758	Effectiveness of rTMS With Double-Cone-Coil in Patients With Major Depression	The ACDC pilot trial: targeting the anterior cingulate by double cone coil rTMS for the treatment of depression	10.1016/j.brs.2014.11.014	https://www.ncbi.nlm.nih.gov/pubmed/25541389	5	2011-10-26	Completed	2011-04-01	2013-10-01	2014-11-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: Day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: Day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)\n[ Time Frame: Day 19 ]""}]	NA	NA
NCT01466387	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study	10.1016/j.tmaid.2014.04.011	NA	7	2011-11-07	Completed	2011-11-01	2012-05-01	2014-05-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GMTs/GMCs of antibodies to typhoid Vi polysaccharide and yellow fever virus on Day 29.\n[ Time Frame: 28 Days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GMTs/GMCs of antibodies to Japanese encephalitis and rabies virus on Day 29.\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GMTs/GMCs of antibodies to typhoid Vi polysaccharide and yellow fever virus on Day 29.\n[ Time Frame: 28 Days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GMTs/GMCs of antibodies to Japanese encephalitis and rabies virus on Day 29.\n[ Time Frame: 28 days ]""}]	[See Results Section.]	NA	NA
NCT01468766	Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy	Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life	10.1093/annonc/mdu374	https://pubmed.ncbi.nlm.nih.gov/25096607/	5	2011-11-07	Completed	2011-02-01	2013-06-01	2014-08-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fatigue measured by Fatigue Assessment Questionnaire (FAQ)\n[ Time Frame: change between baseline and week 13 (end of intervention) ]""}]	NA
NCT01470677	Tachosil for the Prevention of Symptomatic Lymph Cysts	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial	10.1186/1471-2407-14-635	https://pubmed.ncbi.nlm.nih.gov/25175029/	6	2011-11-09	Completed	2011-11-01	2016-01-01	2014-08-30	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of sonographically detected pelvic lymphoceles of at least 2cm in the largest diameter within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptomatic lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of symptomatic pelvic lymphoceles defined by CTCAE 4.03 grade >2 within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptomatic lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of symptomatic pelvic lymphoceles defined by CTCAE 4.03 grade >2 within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	NA
NCT01472939	Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)	Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy	10.1111/apt.13115	http://onlinelibrary.wiley.com/doi/10.1111/apt.13115/abstract	12	2011-11-16	Completed	2012-03-01	2013-05-01	2015-02-19	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regurgitation-free days compared to placebo\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regurgitation-free days compared to placebo\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01474109	Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials	10.1001/jama.2016.5258	https://www.ncbi.nlm.nih.gov/pubmed/27163986?dopt=Abstract	25	2011-11-15	Completed	2011-12-01	2014-04-01	2016-05-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cumulative number of digital ulcers up to week 16\n[ Time Frame: Period1: baseline (visit 2) to week 16. Period2: week 16 to end of study (which will occur when the last randomized patient, not prematurely withdrawn, has completed Period 1 and a 30 day safety follow-up period) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cumulative number of digital ulcers up to week 16\n[ Time Frame: Period1: baseline (visit 2) to week 16. Period2: week 16 to end of study (which will occur when the last randomized patient, not prematurely withdrawn, has completed Period 1 and a 30 day safety follow-up period) ]""}]	[See Results Section.]	NA	NA
NCT01474265	Sympathovagal Balance in Smoking Cessation	Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial	10.1186/s12971-016-0091-x	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977756/	4	2011-11-15	Completed	2011-11-01	2012-12-01	2016-08-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.\n[ Time Frame: 33 weeks ]\n\nPatients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.\n[ Time Frame: 33 weeks ]\n\nPatients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.\n[ Time Frame: 33 weeks ]\n\nPatients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.\n[ Time Frame: 33 weeks ]\n\nPatients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.""}]	NA
NCT01475669	Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery	Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy	10.1093/bja/aew169	https://pubmed.ncbi.nlm.nih.gov/27317703/	34	2011-11-17	Completed	2011-12-01	2014-07-01	2017-12-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	NA	NA
NCT01475838	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients	Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial	10.1016/s1473-3099(14)70782-0	NA	12	2011-11-18	Completed	2011-11-01	2013-12-01	2014-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the FDA snapshot analysis\n[ Time Frame: Week 48 ]""}]	[See Results Section.]	NA
NCT01475994	Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis	Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber	10.1016/j.jaci.2015.04.015	https://www.ncbi.nlm.nih.gov/pubmed/?term=Exacerbation+of+atopic+dermatitis+on+grass+pollen+exposure+in+an+environmental+challenge+chamber	2	2011-11-17	Completed	2011-11-01	2012-03-01	2015-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SCORAD\n[ Time Frame: Day 1/Baseline vs. Day 3 ]\n\nChange in SCORAD between Day 1/ baseline (assessed 60 minutes prior to challenge) and Day 3 (assessed post-challenge)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SCORAD\n[ Time Frame: Day 1/Baseline vs. Day 3 ]\n\nChange in SCORAD between Day 1/ baseline (assessed 60 minutes prior to challenge) and Day 3 (assessed post-challenge)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""SCORAD\n[ Time Frame: Day 1/Baseline vs. Day 3 ]\n\nChange in SCORAD between Day 1/ baseline (assessed 60 minutes prior to challenge) and Day 3 (assessed post-challenge)""}]	NA	NA
NCT01478880	Efficacy and Safety of Bilateral Theta Burst Stimulation for the Treatment of Auditory Hallucinations	Treatment of auditory hallucinations with bilateral theta burst stimulation: a randomized controlled pilot trial	10.1016/j.brs.2014.01.001	https://www.ncbi.nlm.nih.gov/pubmed/24495662	4	2011-11-21	Completed	2011-05-01	2013-07-01	2014-01-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psychotic Symptom Rating Scales (PSYRATS), subscale for auditory hallucinations\n[ Time Frame: 3 weeks ]\n\nChange of PSYRATS AH score compared to baseline after 3 weeks of treatment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psychotic Symptom Rating Scales (PSYRATS), subscale for auditory hallucinations\n[ Time Frame: 3 weeks ]\n\nChange of PSYRATS AH score compared to baseline after 3 weeks of treatment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Psychotic Symptom Rating Scales (PSYRATS), subscale for auditory hallucinations\n[ Time Frame: 3 weeks ]\n\nChange of PSYRATS AH score compared to baseline after 3 weeks of treatment""}]	NA	NA
NCT01480362	Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds	Negative pressure wound therapy compared with standard moist wound care on diabetic foot ulcers in real-life clinical practice: results of the German DiaFu-RCT	10.1136/bmjopen-2018-026345	https://bmjopen.bmj.com/content/10/3/e026345	9	2011-11-25	Completed	2011-11-01	2015-02-01	2020-03-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound Closure\n[ Time Frame: within a maximum treatment time of 16 weeks ]\n\n\n\nNumber of achieved and confirmed wound closures plus the time until complete wound closure (in days) The wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\n\nThe closure must remain at least for a period of 14 days.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound Closure\n[ Time Frame: within a maximum treatment time of 16 weeks ]\n\n\n\nNumber of achieved and confirmed wound closures plus the time until complete wound closure (in days) The wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\n\nThe closure must remain at least for a period of 14 days.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of achieved and confirmed wound closures within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time until wound closure within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of achieved and confirmed wound closures within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time until wound closure within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""}]	NA
NCT01481584	Nutritional Evaluation of Canola Protein in Comparison With Soy Protein	Nutritional evaluation of rapeseed protein compared to soy protein for quality, plasma amino acids, and nitrogen balance--a randomized cross-over intervention study in humans	10.1016/j.clnu.2012.11.005	https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(12)00237-3	2	2011-11-24	Completed	2010-05-01	2010-07-01	2012-11-14	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma amino acids\n[ Time Frame: At Day 1 (Intervention day); After 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes ]\n\nFree proteinogenic amino acids""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma amino acids\n[ Time Frame: At Day 1 (Intervention day); After 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes ]\n\nFree proteinogenic amino acids""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma amino acids\n[ Time Frame: At Day 1 (Intervention day); After 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes ]\n\nFree proteinogenic amino acids""}]	NA
NCT01481909	Study on Mastocytosis for Rupatadine Treatment	Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial	10.1111/all.12159	http://onlinelibrary.wiley.com/doi/10.1111/all.12159/full	2	2011-11-28	Completed	2010-09-01	2011-08-01	2013-06-04	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pruritus\n[ Time Frame: 10 weeks ]\n\nReduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pruritus\n[ Time Frame: 10 weeks ]\n\nReduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pruritus\n[ Time Frame: 10 weeks ]\n\nReduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.""}]	NA
NCT01484418	Exposure-based Treatment for Avoidant Back Pain Patients	Exposure and CBT for chronic back pain: An RCT on differential efficacy and optimal length of treatment	10.1037/ccp0000298	https://pubmed.ncbi.nlm.nih.gov/29781651/	4	2011-12-01	Completed	2011-08-01	2015-08-01	2018-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in pain severity at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nNumeric Rating Scale (NRS)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in pain disability at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nPain Disability Index (PDI) Quebec Back Pain Disability Scale (QBPDS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in pain severity at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nNumeric Rating Scale (NRS)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in pain disability at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nPain Disability Index (PDI) Quebec Back Pain Disability Scale (QBPDS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in pain severity at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nNumeric Rating Scale (NRS)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in pain disability at 3 and 6 months after admission\n[ Time Frame: from Pretest (admission) to Posttest (an expected average of 3 months after admission) to Follow-up (an expected average of 6 months after admission) ]\n\nPain Disability Index (PDI) Quebec Back Pain Disability Scale (QBPDS)""}]	NA	NA
NCT01485952	An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196	An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease	10.1111/bcp.12512	https://www.ncbi.nlm.nih.gov/pubmed/25223731	3	2011-12-02	Completed	2011-03-01	2011-11-01	2015-03-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells\n[ Time Frame: Baseline, Day 7, Day 14, Follow-Up ]\n\nCollection of peripheral blood mononuclear cells for biomarker investigations, specifically acetylation status of mutant huntingtin, levels of circulating huntingtin, innate immune markers and transcriptional profiles""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells\n[ Time Frame: Baseline, Day 7, Day 14, Follow-Up ]\n\nCollection of peripheral blood mononuclear cells for biomarker investigations, specifically acetylation status of mutant huntingtin, levels of circulating huntingtin, innate immune markers and transcriptional profiles""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells\n[ Time Frame: Baseline, Day 7, Day 14, Follow-Up ]\n\nCollection of peripheral blood mononuclear cells for biomarker investigations, specifically acetylation status of mutant huntingtin, levels of circulating huntingtin, innate immune markers and transcriptional profiles""}]	NA
NCT01486329	VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer	Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial	10.1080/2162402x.2014.1001217	https://pubmed.ncbi.nlm.nih.gov/26137397/	6	2011-12-05	Completed	2011-12-01	2014-10-01	2015-04-27	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""}]	NA
NCT01488955	Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI	Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial	10.1136/bmj.h6544	https://pubmed.ncbi.nlm.nih.gov/26698878/	7	2011-12-07	Completed	2012-02-01	2014-02-01	2015-12-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of additional treatments with antibiotics combined with number of symptoms\n[ Time Frame: day 0-28 ]\n\nThe study outcome is considered as positive, if the interventional group where only symptoms were treated has less additional treatments with antibiotics as the interventional group, where antibiotics are given from day 0 on. Additionally, the interventional group where only symptoms were treated has to be non inferior with respect to number of symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of additional treatments with antibiotics combined with number of symptoms\n[ Time Frame: day 0-28 ]\n\nThe study outcome is considered as positive, if the interventional group where only symptoms were treated has less additional treatments with antibiotics as the interventional group, where antibiotics are given from day 0 on. Additionally, the interventional group where only symptoms were treated has to be non inferior with respect to number of symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of additional treatments with antibiotics combined with number of symptoms\n[ Time Frame: day 0-28 ]\n\nThe study outcome is considered as positive, if the interventional group where only symptoms were treated has less additional treatments with antibiotics as the interventional group, where antibiotics are given from day 0 on. Additionally, the interventional group where only symptoms were treated has to be non inferior with respect to number of symptoms.""}]	NA	NA
NCT01490268	Pain Therapy After Elective Cardiac Surgery	Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC-MS/MS: application to clinical trial in patients undergoing open heart surgery	10.1016/j.jpba.2012.07.025	NA	3	2011-12-08	Completed	2011-11-01	2012-09-01	2012-07-31	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessements of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessements of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessments of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	NA
NCT01491152	Pilot Study of Whole Body Vibration for Children With Cerebral Palsy (CP) From 12 Months of Age	NA	NA	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114341/	4	2011-12-12	Completed	2012-01-01	2014-02-01	2016-09-07	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of gross motor function (GMFM-66)\n[ Time Frame: Baseline (T0), week 14 (T1, after training) und week 28 (T2, after follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of gross motor function (GMFM-66)\n[ Time Frame: Baseline (T0), week 14 (T1, after training) und week 28 (T2, after follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of gross motor function (GMFM-66)\n[ Time Frame: Baseline (T0), week 14 (T1, after training) und week 28 (T2, after follow-up) ]""}]	NA	NA
NCT01495533	Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter	A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial	10.1002/ccd.26216	https://pubmed.ncbi.nlm.nih.gov/26331782/	4	2011-12-15	Completed	2011-12-01	2013-12-01	2015-09-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late lumen loss in-segment\n[ Time Frame: 6 months ]\n\nangiographic late lumen loss in-segment assessed by quantitative coronary angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late lumen loss in-segment\n[ Time Frame: 6 months ]\n\nangiographic late lumen loss in-segment assessed by quantitative coronary angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late lumen loss in-segment\n[ Time Frame: 6 months ]\n\nangiographic late lumen loss in-segment assessed by quantitative coronary angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late lumen loss in-segment\n[ Time Frame: 6 months ]\n\nangiographic late lumen loss in-segment assessed by quantitative coronary angiography""}]	NA
NCT01495702	Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial	10.1016/s1473-3099(14)70796-0	http://www.sciencedirect.com/science/article/pii/S1473309914707960?via%3Dihub	11	2011-12-16	Completed	2011-11-01	2013-12-01	2014-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the FDA snapshot analysis\n[ Time Frame: Week 48 ]""}]	[See Results Section.]	NA
NCT01498731	Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)	NA	NA	https://academic.oup.com/eurheartj/article/36/6/369/445340	3	2011-12-21	Completed	2011-04-01	2013-06-01	2014-04-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.\n[ Time Frame: 30 days after discharge ]\n\nRate of MACE (all- cause death or survived sudden cardiac arrest, myocardial infarction, re-hospitalisation for acute coronary syndrome, acute unplanned PCI, coronary artery bypass grafting (CABG) and documented life-threatening arrhythmias (VF, VT, AV-block III)) within 30 days Copeptin vs. Control arm (non-inferiority).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.\n[ Time Frame: 30 days after discharge ]\n\nRate of MACE (all- cause death or survived sudden cardiac arrest, myocardial infarction, re-hospitalisation for acute coronary syndrome, acute unplanned PCI, coronary artery bypass grafting (CABG) and documented life-threatening arrhythmias (VF, VT, AV-block III)) within 30 days Copeptin vs. Control arm (non-inferiority).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.\n[ Time Frame: 30 days after discharge ]\n\nRate of MACE (all- cause death or survived sudden cardiac arrest, myocardial infarction, re-hospitalisation for acute coronary syndrome, acute unplanned PCI, coronary artery bypass grafting (CABG) and documented life-threatening arrhythmias (VF, VT, AV-block III)) within 30 days Copeptin vs. Control arm (non-inferiority).""}]	NA	NA
NCT01500330	Home Use of Cupping Massage in Chronic Neck Pain	Effectiveness of home-based cupping massage compared to progressive muscle relaxation in patients with chronic neck pain--a randomized controlled trial	10.1371/journal.pone.0065378	https://www.ncbi.nlm.nih.gov/pubmed/23762355	4	2011-12-22	Completed	2012-01-01	2012-05-01	2013-06-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: T2 (84 days) ]\n\nPain intensity on a 100mm visual analogue scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: T2 (84 days) ]\n\nPain intensity on a 100mm visual analogue scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: T2 (84 days) ]\n\nPain intensity on a 100mm visual analogue scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: T2 (84 days) ]\n\nPain intensity on a 100mm visual analogue scale""}]	NA
NCT01500993	Capecitabine in the Perioperative Treatment of Rectal Cancer	Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial	10.1016/s1470-2045(12)70116-x	https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(12)70116-X	3	2011-12-26	Completed	2002-03-01	2011-03-01	2012-04-13	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 5-year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 5-year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 5-year ]""}]	NA
NCT01502163	Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia	Efficacy of a novel prewarming system in the prevention of perioperative hypothermia. A prospective, randomized, multicenter study	NA	NA	2	2011-12-29	Completed	2011-10-01	2012-02-01	2013-10-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Core Temperature at end of surgery\n[ Time Frame: Approximatly 120 minutes (at end of surgery) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Core Temperature at end of surgery\n[ Time Frame: Approximatly 120 minutes (at end of surgery) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Core Temperature at end of surgery\n[ Time Frame: Approximatly 120 minutes (at end of surgery) ]""}]	NA	NA
NCT01502241	Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial	10.1016/s1470-2045(12)70164-x	https://www.sciencedirect.com/science/article/pii/S147020451270164X	1	2011-12-29	Completed	2005-01-01	2010-11-01	2012-05-10	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 12 months ]\n\nThe primary endpoint was overall survival, measured in days from surgery to death for any reason. Patients alive at the day of the last contact were censored.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 12 months ]\n\nThe primary endpoint was overall survival, measured in days from surgery to death for any reason. Patients alive at the day of the last contact were censored.""}]	NA	NA
NCT01503216	Safety and Bioefficacy of Vitamin D2 and Vitamin D3	Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial	10.1210/jc.2012-4287	https://www.ncbi.nlm.nih.gov/pubmed/24001747?dopt=Abstract	2	2011-12-30	Completed	2012-01-01	2012-05-01	2013-09-03	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of 25-hydroxvitamin D\n[ Time Frame: after 4 and 8 weeks of supplementation ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of 25-hydroxvitamin D\n[ Time Frame: after 4 and 8 weeks of supplementation ]""}]	NA	NA
NCT01504256	Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas	Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer	10.1038/s41416-018-0150-6	https://pubmed.ncbi.nlm.nih.gov/29988111/	15	2012-01-04	Completed	2011-10-01	2015-10-01	2018-07-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of macroscopic complete remissions of peritoneal carcinomatosis\n[ Time Frame: Assessment after 14 - 18 weeks after start of treatment ]\n\nMacroscopic complete response (mCR) rate of the peritoneal lesions, as resulting from the second diagnostic laparoscopy or laparotomy performed after chemotherapy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of macroscopic complete remissions of peritoneal carcinomatosis\n[ Time Frame: Assessment after 14 - 18 weeks after start of treatment ]\n\nMacroscopic complete response (mCR) rate of the peritoneal lesions, as resulting from the second diagnostic laparoscopy or laparotomy performed after chemotherapy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of macroscopic complete remissions of peritoneal carcinomatosis\n[ Time Frame: Assessment after 14 - 18 weeks after start of treatment ]\n\nMacroscopic complete response (mCR) rate of the peritoneal lesions, as resulting from the second diagnostic laparoscopy or laparotomy performed after chemotherapy.""}]	NA	NA
NCT01504347	Phase 1/2 Lyme Vaccine Study	Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial	10.1016/s1473-3099(13)70110-5	NA	8	2012-01-03	Completed	2011-03-01	2012-07-01	2013-05-10	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Antibody response to the vaccine\n[ Time Frame: 28 days after the third vaccination (= Day 85) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Frequency and severity of injection site and systemic reactions\n[ Time Frame: Within 7 days after each vaccination (i.e. Days 8, 36 and 64) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Antibody response to the vaccine\n[ Time Frame: 28 days after the third vaccination (= Day 85) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Frequency and severity of injection site and systemic reactions\n[ Time Frame: Within 7 days after each vaccination (i.e. Days 8, 36 and 64) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Antibody response to the vaccine\n[ Time Frame: 28 days after the third vaccination (= Day 85) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Frequency and severity of injection site and systemic reactions\n[ Time Frame: Within 7 days after each vaccination (i.e. Days 8, 36 and 64) ]""}]	NA
NCT01510080	Acceptance and Efficacy of Live Supervision	The Effects of Bug-in-the-Eye Supervision on Therapeutic Alliance and Therapist Competence in Cognitive-Behavioural Therapy: A Randomized Controlled Trial	10.1002/cpp.1968	https://onlinelibrary.wiley.com/doi/abs/10.1002/cpp.1968	7	2012-01-10	Completed	2012-01-01	2014-07-01	2016-10-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Supervisory Questionnaire (SQ)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses nondisclosure of the supervisee during supervision""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Supervisee Levels Questionnaire (SLQ-R)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Counseling Self-Estimate Inventory (COSE)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self efficacy of the supervisee""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses level of development and supervision needs of the therapist""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Supervisory Questionnaire (SQ)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses nondisclosure of the supervisee during supervision""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Supervisee Levels Questionnaire (SLQ-R)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Counseling Self-Estimate Inventory (COSE)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self efficacy of the supervisee""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses level of development and supervision needs of the therapist""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Supervisory Questionnaire (SQ)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses nondisclosure of the supervisee during supervision""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Supervisee Levels Questionnaire (SLQ-R)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Counseling Self-Estimate Inventory (COSE)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses self efficacy of the supervisee""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks ]\n\nself-report measure that assesses level of development and supervision needs of the therapist""}]	NA	NA
NCT01510704	Phase II Dose-ranging Study of APD421 in PONV	I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial	10.1093/bja/aet251	https://academic.oup.com/bja/article-lookup/doi/10.1093/bja/aet251	5	2012-01-12	Completed	2012-01-01	2012-04-01	2013-07-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01510860	Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis	Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis	10.1002/cpdd.24	https://www.ncbi.nlm.nih.gov/pubmed/27121784	2	2012-01-17	Completed	2008-11-01	2010-07-01	2013-04-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of liver enzymes between baseline and the end of the treatment-period with Ursofalk 250 mg capsules and the end of treatment-period with Ursofalk 500 mg tablets.\n[ Time Frame: Between baseline and week 24 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of liver enzymes between baseline and the end of the treatment-period with Ursofalk 250 mg capsules and the end of treatment-period with Ursofalk 500 mg tablets.\n[ Time Frame: Between baseline and week 24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of liver enzymes between baseline and the end of the treatment-period with Ursofalk 250 mg capsules and the end of treatment-period with Ursofalk 500 mg tablets.\n[ Time Frame: Between baseline and week 24 ]""}]	NA
NCT01515852	General Anesthesia vs. Local Anesthesia in Stereotaxy	General Anesthesia Versus Local Anesthesia in Stereotactic Biopsies of Brain Lesions: A Prospective Randomized Study	10.1016/j.wneu.2016.09.064	https://pubmed.ncbi.nlm.nih.gov/27671885/	2	2012-01-23	Unknown status	NA	NA	2016-09-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTSS-10\n[ Time Frame: Three days after operation ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTSS-10\n[ Time Frame: Three days after operation ]""}]
NCT01516021	How Fat Influences the Brain	Fat intake modulates cerebral blood flow in homeostatic and gustatory brain areas in humans	10.3945/ajcn.111.031492	https://www.ncbi.nlm.nih.gov/pubmed/22572644?dopt=Abstract	1	2012-01-18	Completed	2011-01-01	2011-03-01	2012-05-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in Cerebral Blood Flow due to the high or low fat yoghurt intake after 30 minutes and 120 minutes compared to a baseline measurement 30 minutes before yoghurt intake.\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after fat intake ]\n\n\n\nWe were interested in differential brain activations due to the high or low fat meal. To assess this, the mentioned time points are suitable.\n\nThe Cerebral Blood Flow is measured using Arterial Spin Labeling sequences in a functional magnetic resonance tomography.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in Cerebral Blood Flow due to the high or low fat yoghurt intake after 30 minutes and 120 minutes compared to a baseline measurement 30 minutes before yoghurt intake.\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after fat intake ]\n\n\n\nWe were interested in differential brain activations due to the high or low fat meal. To assess this, the mentioned time points are suitable.\n\nThe Cerebral Blood Flow is measured using Arterial Spin Labeling sequences in a functional magnetic resonance tomography.""}]	NA	NA
NCT01516827	Effectiveness of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for Children With Post-traumatic Stress Disorder (TreatChildTrauma)	Complex PTSD as proposed for ICD-11: validation of a new disorder in children and adolescents and their response to Trauma-Focused Cognitive Behavioral Therapy	10.1111/jcpp.12640	https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/jcpp.12640	5	2012-01-19	Completed	2012-02-01	2016-05-01	2016-09-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""}]	NA
NCT01519466	Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study	Abstracts of the 50th EASD Annual Meeting, September 15-19, 2014, Vienna, Austria	10.1007/s00125-014-3355-0	https://link.springer.com/article/10.1007/s00125-014-3355-0	8	2012-01-24	Completed	2012-01-01	2012-10-01	2014-08-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[See Results Section.]	NA
NCT01520103	Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer	VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer	10.1007/s10549-019-05280-2	https://pubmed.ncbi.nlm.nih.gov/31115844/	9	2012-01-26	Completed	2012-01-01	2016-12-01	2019-05-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: Assessment over 36 months, minimum 12 month ]\n\nProgression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse or death.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: Assessment over 36 months, minimum 12 month ]\n\nProgression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse or death.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: Assessment over 36 months, minimum 12 month ]\n\nProgression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse or death.""}]	NA	NA
NCT01521585	A Phase II Safety and Tolerability Study With SEN0014196	NA	10.1136/jnnp-2014-309032.294	http://jnnp.bmj.com/content/85/Suppl_1/A102.1	5	2012-01-26	Completed	2011-11-01	2012-10-01	2014-09-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 12 weeks ]\n\nAdverse event (AE) reporting, 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and laboratory safety tests. Suicide risk (Columbia Suicide Severity Rating Scale,C-SSRS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 12 weeks ]\n\nAdverse event (AE) reporting, 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and laboratory safety tests. Suicide risk (Columbia Suicide Severity Rating Scale,C-SSRS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 12 weeks ]\n\nAdverse event (AE) reporting, 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and laboratory safety tests. Suicide risk (Columbia Suicide Severity Rating Scale,C-SSRS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 12 weeks ]\n\nAdverse event (AE) reporting, 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and laboratory safety tests. Suicide risk (Columbia Suicide Severity Rating Scale,C-SSRS).""}]	NA
NCT01523743	Quality of Life Intermittent Catheter Study	A prospective, randomized, crossover, multicenter study comparing quality of life using compact versus standard catheters for intermittent self-catheterization	10.1016/j.juro.2013.04.026	https://www.ncbi.nlm.nih.gov/pubmed/23587630	4	2012-01-30	Completed	2011-11-01	2012-04-01	2013-04-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[See Results Section.]	NA
NCT01524055	CO2 Insufflation During Single-Balloon-Enteroscopy	CO2 insufflation during single-balloon enteroscopy: a multicenter randomized controlled trial	10.1055/s-0033-1359041	https://www.ncbi.nlm.nih.gov/pubmed/24353124?dopt=Abstract	5	2012-01-27	Completed	2011-12-01	2013-02-01	2013-12-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation depth\n[ Time Frame: 2h ]\n\nThe endoscopists estimate the depth of intubation during each examination using a recently described and validated technique.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation depth\n[ Time Frame: 2h ]\n\nThe endoscopists estimate the depth of intubation during each examination using a recently described and validated technique.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation depth\n[ Time Frame: 2h ]\n\nThe endoscopists estimate the depth of intubation during each examination using a recently described and validated technique.""}]	NA	NA
NCT01525537	Surgical Pleth Index (SPI) Guided Analgesia During Sevoflurane Anesthesia	Sufentanil administration guided by surgical pleth index vs standard practice during sevoflurane anaesthesia: a randomized controlled pilot study	10.1093/bja/aet485	https://academic.oup.com/bja/article-lookup/doi/10.1093/bja/aet485	2	2012-02-02	Completed	2009-03-01	2010-02-01	2014-02-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sufentanil consumption\n[ Time Frame: during induction and end of anesthesia (1-3 hours) ]\n\nWe will measure the sufentanil consumption during beginning of anesthesia and extubation in microgram per hour.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sufentanil consumption\n[ Time Frame: during induction and end of anesthesia (1-3 hours) ]\n\nWe will measure the sufentanil consumption during beginning of anesthesia and extubation in microgram per hour.""}]	NA	NA
NCT01525667	Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty	Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty	10.1002/jcsm.12316	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204595/	10	2012-02-02	Completed	2012-11-01	2014-03-01	2018-09-19	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 12 months ]\n\n\nAdverse events\nSafety laboratory values and ECG findings\nImmunological reaction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Efficacy\n[ Time Frame: 12 months ]\n\n• Function of the GM assessing maximal contraction force""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy End-Point\n[ Time Frame: 26 weeks ]\n\nFunction of the GM assessing maximal contraction force""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety End-Point\n[ Time Frame: 104 weeks ]\n\nAdverse Event, Laboratory Values, ECG Findings and Immunological Reaction""}]	[See Results Section.]	NA	NA
NCT01526447	Effects of Craniosacral Therapy on Chronic Neck Pain	Credibility of a comparative sham control intervention for Craniosacral Therapy in patients with chronic neck pain	10.1016/j.ctim.2014.09.007	NA	7	2012-02-01	Completed	2012-02-01	2012-11-01	2014-10-06	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: week 8 ]\n\nPain intensity on a 100mm visual analogue scale (VAS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: week 8 ]\n\nPain intensity on a 100mm visual analogue scale (VAS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: week 8 ]\n\nPain intensity on a 100mm visual analogue scale (VAS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: week 8 ]\n\nPain intensity on a 100mm visual analogue scale (VAS)""}]	NA
NCT01530139	Strategies for Personalised Nutrition	Effects of a Web-Based Personalized Intervention on Physical Activity in European Adults: A Randomized Controlled Trial	10.2196/jmir.4660	NA	5	2012-02-08	Completed	2012-08-01	2014-12-01	2015-10-14	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line version of the EPIC Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	NA
NCT01530399	Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery	NA	NA	http://www.themedicinescompany.com/investors/news/medicines-company-discontinues-phase-2b-trial-mdco-2010	6	2012-02-07	Terminated	2012-03-01	2012-11-01	2012-10-04	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chest tube drainage at 12 hours after surgery\n[ Time Frame: 12 hours post CABG ]\n\nChest tube drainage at 12 hours after surgery""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chest tube drainage at 12 hours after surgery\n[ Time Frame: 12 hours post CABG ]\n\nChest tube drainage at 12 hours after surgery""}]	NA	[See Results Section.]	NA
NCT01534364	Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery	Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial	10.1161/jaha.117.008181	https://pubmed.ncbi.nlm.nih.gov/29535139/	7	2012-02-15	Completed	2012-01-01	2015-02-01	2018-03-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (\""cross clamping\"") in comparison to baseline value obtained in the morning of the day of surgery (day 0).\n[ Time Frame: baseline and 24 hours after induction of ischemia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (\""cross clamping\"") in comparison to baseline value obtained in the morning of the day of surgery (day 0).\n[ Time Frame: baseline and 24 hours after induction of ischemia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (\""cross clamping\"") in comparison to baseline value obtained in the morning of the day of surgery (day 0).\n[ Time Frame: baseline and 24 hours after induction of ischemia ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Increase of serum creatinine in mg/dl 24 h after induction of ischemia (\""cross clamping\"") in comparison to baseline value obtained in the morning of the day of surgery (day 0).\n[ Time Frame: baseline and 24 hours after induction of ischemia ]""}]	NA
NCT01534455	Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)	10.1097/cad.0000000000000722	https://pubmed.ncbi.nlm.nih.gov/30875348/	5	2012-02-13	Terminated	2012-02-01	2015-02-01	2019-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percent of patients who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percent of patients with Adverse Events (any Grade and Grade 3/4).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants with Adverse Events (any Grade and Grade 3/4).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants with Adverse Events (any Grade and Grade 3/4).""}]	NA	NA
NCT01534962	Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study	10.1016/j.hrthm.2015.01.021	https://www.ncbi.nlm.nih.gov/pubmed/25602175?dopt=Abstract	11	2012-02-16	Completed	2012-01-01	2013-09-01	2015-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the efficacy of 3 doses of Ranolazine (low, intermediate and high) versus placebo, given for up to 16 weeks, in maintaining sinus rhythm after successful DCC in patients with non-permanent atrial fibrillation (AFib).\n[ Time Frame: 16 weeks (112 days) ]\n\nTime (median; days) from randomisation (Day 1) to first documented AF recurrence.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the efficacy of 3 doses of Ranolazine (low, intermediate and high) versus placebo, given for up to 16 weeks, in maintaining sinus rhythm after successful DCC in patients with non-permanent atrial fibrillation (AFib).\n[ Time Frame: 16 weeks (112 days) ]\n\nTime (median; days) from randomisation (Day 1) to first documented AF recurrence.""}]	[See Results Section.]	NA	NA
NCT01538173	Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty	The role of hydroxyethyl starch in preventing surgical-site infections and nipple necrosis in patients undergoing reduction mammaplasty: a prospective case-control study of 334 patients	10.1007/s00266-013-0113-5	https://www.ncbi.nlm.nih.gov/pubmed/23571784	4	2012-02-22	Completed	2007-01-01	NA	2013-04-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical side infection\n[ Time Frame: 4 weeks ]\n\nPrimary end point was the development of surgical side infection""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical side infection\n[ Time Frame: 4 weeks ]\n\nPrimary end point was the development of surgical side infection""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Surgical side infection\n[ Time Frame: 4 weeks ]\n\nPrimary end point was the development of surgical side infection""}]
NCT01538355	A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis	Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis	10.1016/j.ebiom.2018.08.057	https://pubmed.ncbi.nlm.nih.gov/30292675/	7	2012-02-23	Completed	2011-12-01	2013-02-01	2018-10-03	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life and tolerability12 subscales with two summary scores physical health und mental health""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life and tolerability\n[ Time Frame: 5 Visits ]\n\n12 subscales with two summary scores physical health und mental health""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.\n[ Time Frame: Visit: Baseline, month 1, month 3 and month 6 ]\n\nTwo summary scores: physical health und mental health, 12 subscales and 2 single item scales.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.\n[ Time Frame: Visit: Baseline, month 1, month 3 and month 6 ]\n\nTwo summary scores: physical health und mental health, 12 subscales and 2 single item scales.""}]	NA
NCT01538979	Phase II Study of Grass Pollen Allergy Vaccine BM32	Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32	10.1016/j.jaci.2017.09.052	NA	3	2012-02-24	Completed	2012-03-01	2014-12-01	2018-01-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean daily combined symptom medication score (SMS)during the peak of the pollen season.\n[ Time Frame: Up to 3 months ]\n\nThe score will be recorded daily for the 30-45 days with the highest pollen count in each center""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean daily combined symptom medication score (SMS)during the peak of the pollen season.\n[ Time Frame: Up to 3 months ]\n\nThe score will be recorded daily for the 30-45 days with the highest pollen count in each center""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean daily combined symptom medication score (SMS)during the peak of the pollen season.\n[ Time Frame: Up to 3 months ]\n\nThe score will be recorded daily for the 30-45 days with the highest pollen count in each center""}]	NA	NA
NCT01539512	A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia	10.1056/nejmoa1315226	https://www.ncbi.nlm.nih.gov/pubmed/24450857	26	2012-02-24	Completed	2012-02-01	2014-02-01	2014-01-22	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: Baseline to Month 18 ]\n\nProgression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause.""}]	NA	[See Results Section.]	NA
NCT01540357	Mindfulness-based Therapy in Chronic Tinnitus	Mindfulness-and body-psychotherapy-based group treatment of chronic tinnitus: a randomized controlled pilot study	10.1186/1472-6882-12-235	https://www.ncbi.nlm.nih.gov/pubmed/23186556?dopt=Abstract	2	2012-02-27	Completed	2010-05-01	2010-10-01	2012-11-28	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus complaints as measured by the German version of the Tinnitus Questionnaire (TQ)(Baseline versus week 9)\n[ Time Frame: Baseline to Week 9 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus complaints as measured by the German version of the Tinnitus Questionnaire (TQ)(Baseline versus week 9)\n[ Time Frame: Baseline to Week 9 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus complaints as measured by the German version of the Tinnitus Questionnaire (TQ)(Baseline versus week 9)\n[ Time Frame: Baseline to Week 9 ]""}]	NA
NCT01540383	Effectiveness of Intensive Aphasia Therapy Under Routine Clinical Conditions	Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting	10.1016/s0140-6736(17)30067-3	https://pubmed.ncbi.nlm.nih.gov/28256356/	9	2012-02-22	Completed	2012-04-01	2014-07-01	2017-04-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes on the Amsterdam Nijmegen Everyday Language Test (ANELT) - A-scale\n[ Time Frame: Baseline is compared to performance immediately and 6 months post 3 weeks of intensive language therapy. Patients with at least 5 weeks of therapy, performance will also be assessed after therapy completion (on average 6 weeks) ]\n\nMean gain in ANELT understandability scores (ANELT A-scale; using the parallel versions ANELT-I and ANELT-II)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes on the Amsterdam Nijmegen Everyday Language Test (ANELT) - A-scale\n[ Time Frame: Baseline is compared to performance immediately and 6 months post 3 weeks of intensive language therapy. Patients with at least 5 weeks of therapy, performance will also be assessed after therapy completion (on average 6 weeks) ]\n\nMean gain in ANELT understandability scores (ANELT A-scale; using the parallel versions ANELT-I and ANELT-II)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes on the Amsterdam Nijmegen Everyday Language Test (ANELT) - A-scale\n[ Time Frame: Baseline is compared to performance immediately and 6 months post 3 weeks of intensive language therapy. Patients with at least 5 weeks of therapy, performance will also be assessed after therapy completion (on average 6 weeks) ]\n\nMean gain in ANELT understandability scores (ANELT A-scale; using the parallel versions ANELT-I and ANELT-II)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes on the Amsterdam Nijmegen Everyday Language Test (ANELT) - A-scale\n[ Time Frame: Baseline is compared to performance immediately and 6 months post 3 weeks of intensive language therapy. Patients with at least 5 weeks of therapy, performance will also be assessed after therapy completion (on average 6 weeks) ]\n\nMean gain in ANELT understandability scores (ANELT A-scale; using the parallel versions ANELT-I and ANELT-II)""}]	NA
NCT01541579	Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial	10.1016/s0140-6736(16)31203-x	https://pubmed.ncbi.nlm.nih.gov/27477896/	11	2012-02-29	Completed	2012-07-01	2016-01-01	2016-07-29	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""}]	NA
NCT01541605	Methylphenidate for the Treatment of Acute Mania	A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)	10.1016/j.euroneuro.2017.11.003	https://pubmed.ncbi.nlm.nih.gov/29174864/	3	2012-02-23	Completed	2012-03-01	2016-05-01	2017-11-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""manic symptoms as assessed by the Young Mania Rating Scale (YMRS)\n[ Time Frame: after 2.5 days of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""manic symptoms as assessed by the Young Mania Rating Scale (YMRS)\n[ Time Frame: after 2.5 days of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""manic symptoms as assessed by the Young Mania Rating Scale (YMRS)\n[ Time Frame: after 2.5 days of treatment ]""}]	NA	NA
NCT01543243	Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control	Preliminary inconclusive results of a randomised double blinded cross-over pilot trial in long-term-care dwelling elderly assessing the feasibility of stochastic resonance whole-body vibration	10.1186/s11556-015-0150-y	https://eurapa.biomedcentral.com/articles/10.1186/s11556-015-0150-y	5	2012-02-27	Completed	2011-11-01	2012-08-01	2015-10-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dynamic body balance\n[ Time Frame: effects after 4 weeks ]\n\nThe Expanded Timed Get Up-and-Go (ETGUG) will be used for measuring dynamic body balance. At 2, 8 and 10 meters along the walkway, markers were set, allowing to the measurement the change of the split times.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dynamic body balance\n[ Time Frame: effects after 4 weeks ]\n\nThe Expanded Timed Get Up-and-Go (ETGUG) will be used for measuring dynamic body balance. At 2, 8 and 10 meters along the walkway, markers were set, allowing to the measurement the change of the split times.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dynamic body balance\n[ Time Frame: effects after 4 weeks ]\n\nThe Expanded Timed Get Up-and-Go (ETGUG) will be used for measuring dynamic body balance. At 2, 8 and 10 meters along the walkway, markers were set, allowing to the measurement the change of the split times.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dynamic body balance\n[ Time Frame: effects after 4 weeks ]\n\nThe Expanded Timed Get Up-and-Go (ETGUG) will be used for measuring dynamic body balance. At 2, 8 and 10 meters along the walkway, markers were set, allowing to the measurement the change of the split times.""}]	NA
NCT01544686	Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients	A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients	10.1093/annonc/mdw275	https://pubmed.ncbi.nlm.nih.gov/27456299/	5	2012-02-28	Completed	2012-02-01	2015-10-01	2016-07-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter\n[ Time Frame: 14 days ]\n\nIncidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter\n[ Time Frame: 14 days ]\n\nIncidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter\n[ Time Frame: 14 days ]\n\nIncidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter""}]	NA	NA
NCT01554709	Safety and Performance Study of the CardioGard Cannula	Novel emboli protection system during cardiac surgery: a multi-center, randomized, clinical trial	10.1016/j.athoracsur.2014.06.061	https://www.ncbi.nlm.nih.gov/pubmed/25258158	2	2012-03-13	Completed	2012-03-01	2013-12-01	2014-09-23	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DWI- Diffusion Weighted Imaging\n[ Time Frame: The outcome measure is assessed in average a week after the surgery ]\n\ndiffusion weighted magnetic resonance imaging (DW-MRI)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DWI- Diffusion Weighted Imaging\n[ Time Frame: The outcome measure is assessed in average a week after the surgery ]\n\ndiffusion weighted magnetic resonance imaging (DW-MRI)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DWI- Diffusion Weighted Imaging\n[ Time Frame: The outcome measure is assessed in average a week after the surgery ]\n\ndiffusion weighted magnetic resonance imaging (DW-MRI)""}]	NA
NCT01556529	CDRM Study: Computer-assisted Diabetes Risk Management-for Secondary and Tertiary Prevention of T2DM Complications	Testosterone and type 2 diabetes in men	10.3109/13685538.2013.879113	https://www.ncbi.nlm.nih.gov/pubmed/?term=Testosterone+and+type+2+diabetes+in+men+AND+Mazur	2	2012-03-14	Completed	2007-06-01	2011-05-01	2014-01-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c, incidence of typical diabetes complications\n[ Time Frame: 36 months (max) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HbA1c, incidence of typical diabetes complications\n[ Time Frame: 36 months (max) ]""}]	NA	NA
NCT01564004	Clinical Hypnosis Before External Cephalic Version (ECV)	The Effects of Clinical Hypnosis versus Neurolinguistic Programming (NLP) before External Cephalic Version (ECV): A Prospective Off-Centre Randomised, Double-Blind, Controlled Trial	10.1155/2012/626740	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388481/	1	2012-03-26	Unknown status	NA	NA	2012-06-21	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful ECV\n[ Time Frame: 3 hours after ECV treatment ]\n\nRate of cephalic presentation three hours after external cephalic version.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful ECV\n[ Time Frame: 3 hours after ECV treatment ]\n\nRate of cephalic presentation three hours after external cephalic version.""}]
NCT01564095	TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion	Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers	10.1097/txd.0000000000000588	https://www.ncbi.nlm.nih.gov/pubmed/27500266	3	2012-03-23	Terminated	2011-10-01	2013-07-01	2016-05-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum serum ALT-level\n[ Time Frame: 48 hrs following liver transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum serum ALT-level\n[ Time Frame: 48 hrs following liver transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum serum ALT-level\n[ Time Frame: 48 hrs following liver transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum serum ALT-level\n[ Time Frame: 48 hrs following liver transplantation ]""}]	NA
NCT01566708	Neuro-Music Therapy for Recent Onset Tinnitus: Evaluation of a Therapy Concept	Cortical reorganization in recent-onset tinnitus patients by the Heidelberg Model of Music Therapy	10.3389/fnins.2015.00049	https://www.ncbi.nlm.nih.gov/pubmed/25745385	4	2012-03-27	Unknown status	2012-01-01	NA	2015-02-19	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Questionnaire (TQ, Goebel and Hiller 1998) total score change from baseline to end of treatment\n[ Time Frame: baseline to week 1 and 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Tinnitus-Beeinträchtigungs-Fragebogen (TBF-12, Greimel et al. 2000) total score change from baseline to end of treatment\n[ Time Frame: baseline to week 1 and 12 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tinnitus Questionnaire (TQ, Goebel and Hiller 1998) total score change from baseline to end of treatment\n[ Time Frame: baseline to week 1 and 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Tinnitus-Beeinträchtigungs-Fragebogen (TBF-12, Greimel et al. 2000) total score change from baseline to end of treatment\n[ Time Frame: baseline to week 1 and 12 ]""}]
NCT01567956	Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study	Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment	10.1111/j.1365-2036.2011.04844.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2011.04844.x/full	4	2012-03-29	Terminated	2012-04-01	2013-10-01	2011-09-19	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of clinical/endoscopic remissions\n[ Time Frame: End of treatment (week 8) ]\n\nRemission will be defined according with the overall modified Mayo score (Disease Activity Index). A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1 will be considered necessary to classify the patient in remission state.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of clinical/endoscopic remissions\n[ Time Frame: End of treatment (week 8) ]\n\nRemission will be defined according with the overall modified Mayo score (Disease Activity Index). A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1 will be considered necessary to classify the patient in remission state.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of clinical/endoscopic remissions\n[ Time Frame: End of treatment (week 8) ]\n\nRemission will be defined according with the overall modified Mayo score (Disease Activity Index). A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1 will be considered necessary to classify the patient in remission state.""}]	NA
NCT01569204	Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma	Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group	10.1016/s1470-2045(17)30696-4	https://pubmed.ncbi.nlm.nih.gov/29133014/	6	2012-04-02	Completed	2012-10-01	2014-03-01	2017-11-10	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (RR) after six cycles of chemotherapy\n[ Time Frame: 18 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (RR) after six cycles of chemotherapy\n[ Time Frame: 18 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (RR) after six cycles of chemotherapy\n[ Time Frame: 18 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response rate (RR) after six cycles of chemotherapy\n[ Time Frame: 18 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment\n[ Time Frame: 18 weeks ]""}]	NA
NCT01575704	Physical Exercise Therapy in Pediatric Stem Cell Transplantation	NA	NA	http://d-nb.info/1119887003/34	3	2012-04-10	Completed	2011-01-01	2013-01-01	2016-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle strength\n[ Time Frame: change between hospital admission and discharge (approximately 4-6 weeks) and 3 months and 6 months after transplantation ]\n\nUpper limb: hand grip strength with JAMAR dynamometry; Lower limb: maximal isometric voluntary strength of M. quadriceps femoris""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle strength\n[ Time Frame: change between hospital admission and discharge (approximately 4-6 weeks) and 3 months and 6 months after transplantation ]\n\nUpper limb: hand grip strength with JAMAR dynamometry; Lower limb: maximal isometric voluntary strength of M. quadriceps femoris""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle strength\n[ Time Frame: change between hospital admission and discharge (approximately 4-6 weeks) and 3 months and 6 months after transplantation ]\n\nUpper limb: hand grip strength with JAMAR dynamometry; Lower limb: maximal isometric voluntary strength of M. quadriceps femoris""}]	NA	NA
NCT01576107	MOTIVACTION - Study	Physical Activity Enjoyment and Self-Efficacy As Predictors of Cancer Patients' Physical Activity Level	10.3389/fpsyg.2016.00898	http://journal.frontiersin.org/article/10.3389/fpsyg.2016.00898/full	3	2012-04-10	Completed	2012-04-01	2012-11-01	2016-06-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical activity (accelerometer, Actigraph)\n[ Time Frame: 4 weeks ]\n\nmeasured for 7 days""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical activity (accelerometer, Actigraph)\n[ Time Frame: 4 weeks ]\n\nmeasured for 7 days""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical activity (accelerometer, Actigraph)\n[ Time Frame: 4 weeks ]\n\nmeasured for 7 days""}]	NA	NA
NCT01577134	Personal Resources of Elderly People With Multimorbidity	Revisiting self-regulatory techniques to promote physical activity in older adults: null-findings from a randomised controlled trial	10.1080/08870446.2016.1185523	http://www.tandfonline.com/doi/full/10.1080/08870446.2016.1185523?scroll=top&needAccess=true	3	2012-04-12	Completed	2012-04-01	2013-08-01	2016-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity (self-report)\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months ]""}]	NA	NA
NCT01578525	Medication Safety of Elderly Patients in Hospital and Ambulatory Setting	Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial	10.1186/s12877-018-0814-3	https://pubmed.ncbi.nlm.nih.gov/29898670/	3	2012-04-13	Completed	2012-04-01	2014-04-01	2018-06-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission\n[ Time Frame: one year after discharge from the cooperating ward ]""}]	NA	NA
NCT01580124	CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study	Pulmonary Vein Isolation Versus Defragmentation: The CHASE-AF Clinical Trial	10.1016/j.jacc.2015.09.088	https://pubmed.ncbi.nlm.nih.gov/26700836/	5	2012-04-17	Completed	2010-11-01	2014-02-01	2015-12-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence of atrial arrhythmia during 12 months follow up\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence of atrial arrhythmia during 12 months follow up\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence of atrial arrhythmia during 12 months follow up\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence of atrial arrhythmia during 12 months follow up\n[ Time Frame: 12 months ]""}]	NA
NCT01580592	Cold Urticaria Treatment With Xolair	Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial	10.1016/j.jaci.2017.01.043	https://pubmed.ncbi.nlm.nih.gov/28389393/	10	2012-04-18	Completed	2012-04-01	2015-05-01	2017-04-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in critical temperature thresholds (CTT) from baseline to day 70 after treatment with omalizumab compared to placebo\n[ Time Frame: day 70 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in critical temperature thresholds (CTT) from baseline to day 70 after treatment with omalizumab compared to placebo\n[ Time Frame: day 70 ]""}]	[See Results Section.]	NA	NA
NCT01582724	Effectiveness of Additional Self-care Acupressure for Women With Menstrual Pain Compared to Usual Care Alone	Effectiveness of additional self-care acupressure for women with menstrual pain compared to usual care alone: using stakeholder engagement to design a pragmatic randomized trial and study protocol	10.1186/1745-6215-14-99	https://pubmed.ncbi.nlm.nih.gov/24499425/	7	2012-04-19	Completed	2012-12-01	2014-09-01	2013-04-11	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pain intensity at the days of pain during the 3rd cycle after therapy start (Numeric Rating Scale, NRS)\n[ Time Frame: 3rd menstruation after therapy start ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pain intensity at the days of pain during the 3rd cycle after therapy start (Numeric Rating Scale, NRS)\n[ Time Frame: 3rd menstruation after therapy start ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pain intensity at the days of pain during the 3rd cycle after therapy start (Numeric Rating Scale, NRS)\n[ Time Frame: 3rd menstruation after therapy start ]""}]	NA
NCT01582893	Permeability Enhancement to Reduce Chronic Inflammation	High cut-off dialysis in chronic haemodialysis patients	10.1111/eci.12559	http://onlinelibrary.wiley.com/doi/10.1111/hdi.12494/full	5	2012-04-19	Completed	2012-04-01	2013-02-01	2015-11-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of CD162 expression on monocytes\n[ Time Frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase) ]\n\nchange of CD162 expression on monocytes, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of CD162 expression on monocytes\n[ Time Frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase) ]\n\nchange of CD162 expression on monocytes, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of CD162 expression on monocytes\n[ Time Frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase) ]\n\nchange of CD162 expression on monocytes, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of CD162 expression on monocytes\n[ Time Frame: 8 weeks (3 weeks treatment phase, 2 weeks wash out phase, 3 weeks treatment phase) ]\n\nchange of CD162 expression on monocytes, timepoints in each treatment phase: 1.)1st.day (prae dialysis) 2.)1st.day (post dialysis) 3.)2nd.day (prae dialysis) 4.)8th.day (prae dialysis) 5.)15th.day (prae dialysis) 6.)22nd.day (prae dialysis)""}]	NA
NCT01586091	Safety Study of Levocetirizine and Fexofenadine	The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers	10.2340/00015555-1490	https://www.ncbi.nlm.nih.gov/pubmed/23147964?dopt=Abstract	2	2012-04-24	Completed	2011-02-01	2011-11-01	2013-05-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response\n[ Time Frame: 24 hours per treatment - two visits ]\n\nThe comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response\n[ Time Frame: 24 hours per treatment - two visits ]\n\nThe comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.""}]	[See Results Section.]	NA
NCT01589913	REmote Web Assisted Care for Heart Failure Patients With Implantable Cardioverter Defibrillators	Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial	10.1093/eurheartj/ehz134	https://pubmed.ncbi.nlm.nih.gov/30957867/	11	2012-05-01	Completed	2012-05-01	2015-11-01	2020-03-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of psychosocial well-being (combined score for measures of anxiety, depression, and quality of life) from week 1 (T1) to one week after (T2) the 6-weeks prevention program\n[ Time Frame: up to 1 week before ICD-implantation (T0), in week 1 (T1) and within one week after (T2) the 6-weeks prevention program, and 12 months after T0 (T3) ]\n\nassessment tools for aspects of psychosocial well-being (German versions will be used): Anxiety: Cardiac Fear Questionnaire (Hoyer & Eifert, 2001); Depression: Hospital Anxiety and Depression Scale (Hinz & Brähler, 2011); QoL: MOS 36-item short-form health survey (Ware & Sherbourne, 1992)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of psychosocial well-being (combined score for measures of anxiety, depression, and quality of life) from week 1 (T1) to one week after (T2) the 6-weeks prevention program\n[ Time Frame: up to 1 week before ICD-implantation (T0), in week 1 (T1) and within one week after (T2) the 6-weeks prevention program, and 12 months after T0 (T3) ]\n\nassessment tools for aspects of psychosocial well-being (German versions will be used): Anxiety: Cardiac Fear Questionnaire (Hoyer & Eifert, 2001); Depression: Hospital Anxiety and Depression Scale (Hinz & Brähler, 2011); QoL: MOS 36-item short-form health survey (Ware & Sherbourne, 1992)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of psychosocial well-being (combined score for measures of anxiety, depression, and quality of life) from week 1 (T1) to one week after (T2) the 6-weeks prevention program\n[ Time Frame: up to 1 week before ICD-implantation (T0), in week 1 (T1) and within one week after (T2) the 6-weeks prevention program, and 12 months after T0 (T3) ]\n\nassessment tools for aspects of psychosocial well-being (German versions will be used): Anxiety: Cardiac Fear Questionnaire (Hoyer & Eifert, 2001); Depression: Hospital Anxiety and Depression Scale (Hinz & Brähler, 2011); QoL: MOS 36-item short-form health survey (Ware & Sherbourne, 1992)""}]	NA	NA
NCT01591031	Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium	Intubating conditions and side effects of propofol, remifentanil and sevoflurane compared with propofol, remifentanil and rocuronium: a randomised, prospective, clinical trial	10.1186/1471-2253-14-39	https://www.ncbi.nlm.nih.gov/pubmed/24860256?dopt=Abstract	2	2012-05-02	Completed	2012-04-01	2013-02-01	2014-05-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 h after tracheal intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 h after tracheal intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 h after tracheal intubation ]""}]	NA	NA
NCT01593540	Clinical Examination of Metal Free Interdental Brushes	Clinical efficacy and patients' acceptance of a rubber interdental bristle. A randomized controlled trial	10.1007/s00784-013-1164-3	NA	1	2012-05-07	Completed	2010-09-01	2011-08-01	2014-01-10	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Analysis of the differences between both groups. Measurements in form of Plaque-Index (Quigley und Hein, Tureskey Mod. 1970)\n[ Time Frame: Beginning and after four weeks of use ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Analysis of the differences between both groups. Measurements in form of Plaque-Index (Quigley und Hein, Tureskey Mod. 1970)\n[ Time Frame: Beginning and after four weeks of use ]""}]	NA	NA
NCT01595997	Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris	The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis	10.1111/exd.12927	https://www.ncbi.nlm.nih.gov/pubmed/?term=The+single-chain+anti-TNF-%CE%B1+antibody+DLX105+induces+clinical+and+biomarker+responses+upon+local+administration+in+patients+with+chronic+plaque-type+psoriasis	3	2012-05-09	Completed	2012-02-01	2012-08-01	2016-02-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Local tolerability: Investigator's assessment of local tolerability using a validated score for each treatment area. Patient's assessment of subjective tolerability sensations (burning, itching, pain) recorded on a visual analogue scale (VAS) (0-10\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Local tolerability: Investigator's assessment of local tolerability using a validated score for each treatment area. Patient's assessment of subjective tolerability sensations (burning, itching, pain) recorded on a visual analogue scale (VAS) (0-10\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Local tolerability: Investigator's assessment of local tolerability using a validated score for each treatment area. Patient's assessment of subjective tolerability sensations (burning, itching, pain) recorded on a visual analogue scale (VAS) (0-10\n[ Time Frame: 28 days ]""}]	NA	NA
NCT01598649	Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects	Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: a randomized controlled trial	10.1016/j.clnu.2014.03.008	https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(14)00083-1	5	2012-05-10	Completed	2012-06-01	2012-12-01	2014-04-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in cholesterol metabolism\n[ Time Frame: After 0, 4, 10, 14, 20, and 24 weeks ]\n\nBlood lipids (total cholesterol, LDL cholesterol, HDL cholesterol, cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in cholesterol metabolism\n[ Time Frame: After 0, 4, 10, 14, 20, and 24 weeks ]\n\nBlood lipids (total cholesterol, LDL cholesterol, HDL cholesterol, cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in cholesterol metabolism\n[ Time Frame: After 0, 4, 10, 14, 20, and 24 weeks ]\n\nBlood lipids (total cholesterol, LDL cholesterol, HDL cholesterol, cholesterol, triacylglyceroles)""}]	NA	NA
NCT01598948	Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis	Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)	10.1016/j.atherosclerosis.2017.02.019	NA	7	2012-05-12	Completed	2012-08-01	2015-04-01	2017-02-24	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pre-apheresis LDL-cholesterol (phase 1 of the study)\n[ Time Frame: 6 months ]\n\npre-apheresis LDL-cholesterol concentration will be averaged from 3 subsequent aphereses (exactly 1 week apart) before initiation of mipomersen therapy and after 6 months of weekly apheresis therapy; apheresis conditions will not be changed.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fraction of patients in whom apheresis conditions can be modified (phase 2 of the study)\n[ Time Frame: 3 months ]\n\nIn phase 2 of the study mipomersen will be given weekly. It will be evaluated in what fraction of patients this results in a decrease of apheresis time, apheresis frequency or stopping of apheresis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pre-apheresis LDL-cholesterol (phase 1 of the study)\n[ Time Frame: 6 months ]\n\npre-apheresis LDL-cholesterol concentration will be averaged from 3 subsequent aphereses (exactly 1 week apart) before initiation of mipomersen therapy and after 6 months of weekly apheresis therapy; apheresis conditions will not be changed.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fraction of patients in whom apheresis conditions can be modified (phase 2 of the study)\n[ Time Frame: 3 months ]\n\nIn phase 2 of the study mipomersen will be given weekly. It will be evaluated in what fraction of patients this results in a decrease of apheresis time, apheresis frequency or stopping of apheresis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pre-apheresis LDL-cholesterol (phase 1 of the study)\n[ Time Frame: 6 months ]\n\npre-apheresis LDL-cholesterol concentration will be averaged from 3 subsequent aphereses (exactly 1 week apart) before initiation of mipomersen therapy and after 6 months of weekly apheresis therapy; apheresis conditions will not be changed.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fraction of patients in whom apheresis conditions can be modified (phase 2 of the study)\n[ Time Frame: 3 months ]\n\nIn phase 2 of the study mipomersen will be given weekly. It will be evaluated in what fraction of patients this results in a decrease of apheresis time, apheresis frequency or stopping of apheresis.""}]	NA	NA
NCT01600014	Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp	Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study	10.1111/bjd.14222	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14222	9	2012-05-15	Completed	2012-05-01	2013-12-01	2015-10-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[See Results Section.]	NA
NCT01601769	Tissue Sparing Therapy of Female Precancerous Genital Lesions With VITOM	A multicentric randomized study comparing two techniques of magnification assisted loop excision of high-grade cervical intraepithelial neoplasia: video exoscopy and colposcopy	10.1007/s00404-013-3134-z	https://link.springer.com/article/10.1007/s00404-013-3134-z	1	2012-05-16	Unknown status	NA	NA	2013-12-27	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cervical volume removed\n[ Time Frame: İmmediately after surgery ]\n\nCervical volume removed during the operation is recorded""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""İntraoperative Complications\n[ Time Frame: During the intraoperative ]\n\nComplications encountered during the prodecure""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Short term complications\n[ Time Frame: Within 48 hours after operation ]\n\nComplications within 48 hours after operation""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Late complications\n[ Time Frame: After 48 hours ]\n\nComplications occuring after 48 hours""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cervical volume removed\n[ Time Frame: İmmediately after surgery ]\n\nCervical volume removed during the operation is recorded""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""İntraoperative Complications\n[ Time Frame: During the intraoperative ]\n\nComplications encountered during the prodecure""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Short term complications\n[ Time Frame: Within 48 hours after operation ]\n\nComplications within 48 hours after operation""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Late complications\n[ Time Frame: After 48 hours ]\n\nComplications occuring after 48 hours""}]
NCT01605487	Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria	NA	NA	https://refubium.fu-berlin.de/handle/fub188/23549	19	2012-05-21	Completed	2012-06-01	2013-07-01	2018-12-07	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Critical stimulation time threshold(CSTT) after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical stimulation time threshold (CSTT) determines the shortest stimulation time sufficient for inducing a wheal-and-flare reaction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Critical temperature threshold (CTT)after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical temperature threshold (CTT) determines the highest temperature sufficient for inducing a wheal-and-flare reaction""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Critical stimulation time threshold(CSTT) after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical stimulation time threshold (CSTT) determines the shortest stimulation time sufficient for inducing a wheal-and-flare reaction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Critical temperature threshold (CTT)after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical temperature threshold (CTT) determines the highest temperature sufficient for inducing a wheal-and-flare reaction""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Critical stimulation time threshold(CSTT) after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical stimulation time threshold (CSTT) determines the shortest stimulation time sufficient for inducing a wheal-and-flare reaction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Critical temperature threshold (CTT)after challenge with cold\n[ Time Frame: Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49) ]\n\nCritical temperature threshold (CTT) determines the highest temperature sufficient for inducing a wheal-and-flare reaction""}]	NA	NA
NCT01606462	Oxytocin and Social Cognition	Oxytocin facilitates protective responses to aversive social stimuli in males	10.1073/pnas.1208852109	https://www.ncbi.nlm.nih.gov/pubmed/?term=Oxytocin+facilitates+protective+responses+to+aversive+social+stimuli+in+males	4	2012-05-24	Completed	2011-06-01	2013-06-01	2012-10-16	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli\n[ Time Frame: two years ]\n\nMRI data are analyzed using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK). In the first level analysis the following conditions are modeled: 'neutral: subsequently remembered', 'neutral: subsequently forgotten', 'aversive: subsequently remembered', and 'aversive: subsequently forgotten'.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli\n[ Time Frame: two years ]\n\nMRI data are analyzed using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK). In the first level analysis the following conditions are modeled: 'neutral: subsequently remembered', 'neutral: subsequently forgotten', 'aversive: subsequently remembered', and 'aversive: subsequently forgotten'.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli\n[ Time Frame: two years ]\n\nMRI data are analyzed using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK). In the first level analysis the following conditions are modeled: 'neutral: subsequently remembered', 'neutral: subsequently forgotten', 'aversive: subsequently remembered', and 'aversive: subsequently forgotten'.""}]	NA
NCT01607099	Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility	Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial	10.1111/jgh.13010	NA	4	2012-05-25	Completed	2012-09-01	2014-02-01	2015-05-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress initated by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress triggered by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress triggered by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	NA	NA
NCT01607775	In-house Produced PMMA- Versus PEEK-cages	Influence of cervical bone mineral density on cage subsidence in patients following stand-alone anterior cervical discectomy and fusion	10.1007/s00586-014-3725-9	https://link.springer.com/article/10.1007/s00586-014-3725-9	2	2012-05-24	Completed	2009-02-01	2012-02-01	2014-12-18	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical outcome (NDI)\n[ Time Frame: 12 months postoperative ]\n\nNDI (Neck disability index) will be measured prior to surgery and 12 months after surgery. A difference of 20% between both groups is considered to be clinically significant, which is proposed for the experimental implant (PMMA-cage).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical outcome (NDI)\n[ Time Frame: 12 months postoperative ]\n\nNDI (Neck disability index) will be measured prior to surgery and 12 months after surgery. A difference of 20% between both groups is considered to be clinically significant, which is proposed for the experimental implant (PMMA-cage).""}]	NA	NA
NCT01607970	Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making	Oxytocin facilitates protective responses to aversive social stimuli in males	10.1073/pnas.1208852109	https://www.ncbi.nlm.nih.gov/pubmed/?term=Oxytocin+facilitates+protective+responses+to+aversive+social+stimuli+in+males	1	2012-05-25	Completed	2011-08-01	2012-05-01	2012-10-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""baseline startle magnitude and affective modulation of the startle magnitude after oxytocin and placebo administration\n[ Time Frame: 24 Months ]\n\nThe experimental tasks started 45 min after intranasal OXT/PLC administration. The STARTLE-paradigm features 20 negative (mostly threatening), 20 neutral, and 20 positive pictures, presented for 5 s each. The startle stimulus consists of a single 50-ms burst of white noise (100 dB) with nearly instantaneous rise and was delivered binaurally via headphones during 60% of the pictures (i.e. 12 from each category) at 2 - 4 s after picture onset. We examined the baseline startle magnitude as well as the affective modulation of the startle magnitude.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""baseline startle magnitude and affective modulation of the startle magnitude after oxytocin and placebo administration\n[ Time Frame: 24 Months ]\n\nThe experimental tasks started 45 min after intranasal OXT/PLC administration. The STARTLE-paradigm features 20 negative (mostly threatening), 20 neutral, and 20 positive pictures, presented for 5 s each. The startle stimulus consists of a single 50-ms burst of white noise (100 dB) with nearly instantaneous rise and was delivered binaurally via headphones during 60% of the pictures (i.e. 12 from each category) at 2 - 4 s after picture onset. We examined the baseline startle magnitude as well as the affective modulation of the startle magnitude.""}]	NA	NA
NCT01612312	Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI)	Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial	10.1016/j.jacc.2014.05.064	https://pubmed.ncbi.nlm.nih.gov/25212646/	6	2012-06-01	Completed	2011-03-01	2013-06-01	2014-09-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of late microvascular obstruction assessed by cardiac magnetic resonance imaging (CMR)\n[ Time Frame: CMR performed within day 1 to 4 after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of late microvascular obstruction assessed by cardiac magnetic resonance imaging (CMR)\n[ Time Frame: CMR performed within day 1 to 4 after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of late microvascular obstruction assessed by cardiac magnetic resonance imaging (CMR)\n[ Time Frame: CMR performed within day 1 to 4 after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of late microvascular obstruction assessed by cardiac magnetic resonance imaging (CMR)\n[ Time Frame: CMR performed within day 1 to 4 after randomization ]""}]	NA
NCT01614301	Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma	Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial	10.1111/jdv.13391	https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.13391	1	2012-06-05	Unknown status	NA	NA	2015-09-29	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""response rate\n[ Time Frame: 2014 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""response rate\n[ Time Frame: 2014 ]""}]
NCT01616966	Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Sevoflurane and Propofol	Anesthesia with Propofol versus Sevoflurane: Does the Longer Neuromuscular Block under Sevoflurane Anesthesia Reduce Laryngeal Injuries?	10.1155/2013/723168	https://www.ncbi.nlm.nih.gov/pubmed/?term=Anesthesia+with+Propofol+versus+Sevoflurane%3A+Does+the+Longer+Neuromuscular+Block+under+Sevoflurane+Anesthesia+Reduce+Laryngeal+Injuries%3F	2	2012-06-11	Completed	2010-08-01	2011-10-01	2013-02-13	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24h after surgery ]\n\nassessed by stroboscopy""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24h after surgery ]\n\nassessed by stroboscopy""}]	NA	NA
NCT01617343	The HEP-OKS Study - Hemifield Eye Patching and Optokinetic Stimulation to Treat Hemispatial Neglect in Stroke Patients	Randomized controlled trial on hemifield eye patching and optokinetic stimulation in acute spatial neglect	10.1161/strokeaha.114.006059	https://pubmed.ncbi.nlm.nih.gov/24923723/	3	2012-06-11	Completed	2012-08-01	2014-02-01	2014-06-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score in a neglect test battery\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nPerformance in a neglect test battery (score between 0 and 100%) consisting of standard neglect tests including two cancellation tasks, line bisection, figure copying and text reading""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Functional independence score\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nLevel of functional independence (score between 0 and 100%) as measured by the Barthel-Index and the Catherine-Bergego-Scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score in a neglect test battery\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nPerformance in a neglect test battery (score between 0 and 100%) consisting of standard neglect tests including two cancellation tasks, line bisection, figure copying and text reading""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Functional independence score\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nLevel of functional independence (score between 0 and 100%) as measured by the Barthel-Index and the Catherine-Bergego-Scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total score in a neglect test battery\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nPerformance in a neglect test battery (score between 0 and 100%) consisting of standard neglect tests including two cancellation tasks, line bisection, figure copying and text reading""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Functional independence score\n[ Time Frame: Change from baseline at Day 8 (post-treatment) ]\n\nLevel of functional independence (score between 0 and 100%) as measured by the Barthel-Index and the Catherine-Bergego-Scale""}]	NA	NA
NCT01618565	Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Shoulder Dystocia Management	Objective structured assessment of technical skills evaluation of theoretical compared with hands-on training of shoulder dystocia management: a randomized controlled trial	10.1097/aog.0b013e31826af9a9	https://www.ncbi.nlm.nih.gov/pubmed/22996098?dopt=Abstract	2	2012-06-12	Completed	2012-04-01	2012-12-01	2012-10-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: 30 minutes ]\n\nProbands are tested with a 22 item Objective Structured Assessment of Technical Skills (OSATS) scoring system after training and 72 hours thereafter.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: 30 minutes ]\n\nProbands are tested with a 22 item Objective Structured Assessment of Technical Skills (OSATS) scoring system after training and 72 hours thereafter.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: 30 minutes ]\n\nProbands are tested with a 22 item Objective Structured Assessment of Technical Skills (OSATS) scoring system after training and 72 hours thereafter.""}]	NA
NCT01619657	Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis	Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study	10.1164/rccm.201807-1203oc	https://pubmed.ncbi.nlm.nih.gov/30409023/	6	2012-06-12	Completed	2012-06-01	2016-11-01	2019-05-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients in both treatment groups with adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: during the 52 week treatment period ]\n\nSafety of inhalation with HS and IS in newborns and infants with CF assessed by proportion of adverse events (AEs) and serious adverse events (SAEs)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients in both treatment groups with adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: during the 52 week treatment period ]\n\nSafety of inhalation with HS and IS in newborns and infants with CF assessed by proportion of adverse events (AEs) and serious adverse events (SAEs)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients in both treatment groups with adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: during the 52 week treatment period ]\n\nSafety of inhalation with HS and IS in newborns and infants with CF assessed by proportion of adverse events (AEs) and serious adverse events (SAEs)""}]	NA	NA
NCT01624961	Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults	Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres	10.1186/s12936-015-0628-0	https://www.ncbi.nlm.nih.gov/pubmed/25889522?dopt=Abstract	6	2012-06-19	Completed	2012-06-01	2012-10-01	2015-03-18	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The infectivity of the administration regimens will be assessed by thick film microscopy and PCR for P. falciparum DNA.\n[ Time Frame: Day 5 until day 21 or until treatment ]\n\nParasitology and parasite molecular biology tests: These tests are used to determine malaria parasites (thick blood smear and PCR). Both tests are performed at screening and then approximately every 12 hours during the period of intense observation from day 5 until day 21 or until treatment. Thereafter, these tests are performed during safety follow-ups at Days 28, 84, and 168. Turn over time for thick blood smear microscopy is < 2 hours to ensure timely treatment in case of a positive result. PCR results are available only after study completion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The infectivity of the administration regimens will be assessed by thick film microscopy and PCR for P. falciparum DNA.\n[ Time Frame: Day 5 until day 21 or until treatment ]\n\nParasitology and parasite molecular biology tests: These tests are used to determine malaria parasites (thick blood smear and PCR). Both tests are performed at screening and then approximately every 12 hours during the period of intense observation from day 5 until day 21 or until treatment. Thereafter, these tests are performed during safety follow-ups at Days 28, 84, and 168. Turn over time for thick blood smear microscopy is < 2 hours to ensure timely treatment in case of a positive result. PCR results are available only after study completion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The infectivity of the administration regimens will be assessed by thick film microscopy and PCR for P. falciparum DNA.\n[ Time Frame: Day 5 until day 21 or until treatment ]\n\nParasitology and parasite molecular biology tests: These tests are used to determine malaria parasites (thick blood smear and PCR). Both tests are performed at screening and then approximately every 12 hours during the period of intense observation from day 5 until day 21 or until treatment. Thereafter, these tests are performed during safety follow-ups at Days 28, 84, and 168. Turn over time for thick blood smear microscopy is < 2 hours to ensure timely treatment in case of a positive result. PCR results are available only after study completion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The infectivity of the administration regimens will be assessed by thick film microscopy and PCR for P. falciparum DNA.\n[ Time Frame: Day 5 until day 21 or until treatment ]\n\nParasitology and parasite molecular biology tests: These tests are used to determine malaria parasites (thick blood smear and PCR). Both tests are performed at screening and then approximately every 12 hours during the period of intense observation from day 5 until day 21 or until treatment. Thereafter, these tests are performed during safety follow-ups at Days 28, 84, and 168. Turn over time for thick blood smear microscopy is < 2 hours to ensure timely treatment in case of a positive result. PCR results are available only after study completion.""}]	NA
NCT01627015	Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula	Effects of a Follow-On Formula Containing Isomaltulose (Palatinose™) on Metabolic Response, Acceptance, Tolerance and Safety in Infants: A Randomized-Controlled Trial	10.1371/journal.pone.0151614	NA	5	2012-06-21	Completed	2012-06-01	2014-04-01	2016-03-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nPrimary hypothesis to be tested is: After 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nAfter 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nAfter 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	NA	NA
NCT01627379	Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)	10.1016/j.annonc.2019.10.018	https://pubmed.ncbi.nlm.nih.gov/31959339/	7	2012-06-21	Terminated	2012-05-01	2015-05-01	2019-12-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 3 years ]\n\n\n\nKaplan-Meier estimate of the median time between date of randomization and the date of death from any cause or the date of last follow-up in case of no documentation of death.\n\nComparison of Overall survival of treatment arms \""Panitumumab + Chemotherapy\"" and \""Chemotherapy only\"" in patients with nonresectable, advanced or metastatic ESCC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 3 years ]\n\n\n\nKaplan-Meier estimate of the median time between date of randomization and the date of death from any cause or the date of last follow-up in case of no documentation of death.\n\nComparison of Overall survival of treatment arms \""Panitumumab + Chemotherapy\"" and \""Chemotherapy only\"" in patients with nonresectable, advanced or metastatic ESCC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 3 years ]\n\n\n\nKaplan-Meier estimate of the median time between date of randomization and the date of death from any cause or the date of last follow-up in case of no documentation of death.\n\nComparison of Overall survival of treatment arms \""Panitumumab + Chemotherapy\"" and \""Chemotherapy only\"" in patients with nonresectable, advanced or metastatic ESCC.""}]	NA	NA
NCT01628627	Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy	Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial	10.1007/s00125-012-2795-7	https://www.ncbi.nlm.nih.gov/pubmed/23238789	1	2012-06-26	Completed	2006-05-01	2010-04-01	2012-12-13	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Nerve Conduction Velocity of the Deep Peroneal, Tibial, or Sural Nerve\n[ Time Frame: baseline and 51 weeks ]\n\nChange in Nerve Conduction Velocity of the Deep Peroneal , Tibial, or Sural Nerve at 51 weeks (i.e., after three cycles of FREMS treatment) versus baseline""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Nerve Conduction Velocity of the Deep Peroneal, Tibial, or Sural Nerve\n[ Time Frame: baseline and 51 weeks ]\n\nChange in Nerve Conduction Velocity of the Deep Peroneal , Tibial, or Sural Nerve at 51 weeks (i.e., after three cycles of FREMS treatment) versus baseline""}]	NA	NA
NCT01630434	International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation	Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study	10.1016/s2213-2600(18)30136-x	https://pubmed.ncbi.nlm.nih.gov/29650408/	13	2012-06-26	Completed	2011-11-01	2014-08-01	2018-04-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study endpoint is a composite of patient and graft survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 at 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	NA
NCT01631799	Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia	NA	NA	http://purl.uni-rostock.de/fodb/pub/49779	1	2012-06-27	Completed	2008-10-01	2011-09-01	2015-12-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Function\n[ Time Frame: 3 months after surgery ]\n\n3 months after surgery the function of the total knee replacement is testd""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Function\n[ Time Frame: 3 months after surgery ]\n\n3 months after surgery the function of the total knee replacement is testd""}]	NA	NA
NCT01632371	Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial	10.1016/j.jcin.2017.04.024	NA	4	2012-06-28	Completed	2012-06-01	2015-08-01	2017-07-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-segment percent diameter stenosis\n[ Time Frame: 6-8 months ]\n\nIn-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-segment percent diameter stenosis\n[ Time Frame: 6-8 months ]\n\nIn-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-segment percent diameter stenosis\n[ Time Frame: 6-8 months ]\n\nIn-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography""}]	NA	NA
NCT01634958	Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma	Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study	10.1111/j.1365-2222.2010.03521.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2010.03521.x/full	5	2012-07-03	Completed	2012-10-01	2013-04-01	2010-06-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Conjunctival Provocation Test (CPT)\n[ Time Frame: At screening and after approx. 22 weeks (EoS) ]\n\n\n\nComparison between dosage groups: percentage of patients who need an increased amount of allergen to provoke a positive CPT at the end of the treatment (comparison slope of efficacy). It is expected that at the end of the study higher doses are necessary to provoke a positive CPT.\n\nAccording to the EMA \""Guideline on clinical development of products for specific immunotherapy for the treatment of allergic diseases\"" provocation tests are accepted as primary outcomes for dose-finding studies.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Conjunctival Provocation Test (CPT)\n[ Time Frame: At screening and after approx. 22 weeks (EoS) ]\n\n\n\nComparison between dosage groups: percentage of patients who need an increased amount of allergen to provoke a positive CPT at the end of the treatment (comparison slope of efficacy). It is expected that at the end of the study higher doses are necessary to provoke a positive CPT.\n\nAccording to the EMA \""Guideline on clinical development of products for specific immunotherapy for the treatment of allergic diseases\"" provocation tests are accepted as primary outcomes for dose-finding studies.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Conjunctival Provocation Test (CPT)\n[ Time Frame: At screening and after approx. 22 weeks (EoS) ]\n\n\n\nComparison between dosage groups: percentage of patients who need an increased amount of allergen to provoke a positive CPT at the end of the treatment (comparison slope of efficacy). It is expected that at the end of the study higher doses are necessary to provoke a positive CPT.\n\nAccording to the EMA \""Guideline on clinical development of products for specific immunotherapy for the treatment of allergic diseases\"" provocation tests are accepted as primary outcomes for dose-finding studies.""}]	NA
NCT01635114	Effect of resVida on Liver Fat Content	Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial	10.1111/dom.13268	https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.13268	5	2012-07-03	Completed	2012-06-01	2013-12-01	2018-02-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Liver fat content\n[ Time Frame: 3 months ]\n\nMeasured by 1H-MRS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Liver fat content\n[ Time Frame: 3 months ]\n\nMeasured by 1H-MRS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Liver fat content\n[ Time Frame: 3 months ]\n\nMeasured by 1H-MRS""}]	NA	NA
NCT01635634	Cupping in Fibromyalgia	Efficacy of cupping therapy in patients with the fibromyalgia syndrome-a randomised placebo controlled trial	10.1038/srep37316	https://pubmed.ncbi.nlm.nih.gov/27853272/	7	2012-07-06	Completed	2012-06-01	2014-07-01	2016-11-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: Day 18 ]\n\nPain on a 100mm visual analog scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: Day 18 ]\n\nPain on a 100mm visual analog scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: Day 18 ]\n\nPain on a 100mm visual analog scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain Intensity\n[ Time Frame: Day 18 ]\n\nPain on a 100mm visual analog scale""}]	NA
NCT01635660	Out-of-Hospital Randomized Comparison of Video-assisted Endotracheal Intubation	Videolaryngoscopy for Physician-Based, Prehospital Emergency Intubation: A Prospective, Randomized, Multicenter Comparison of Different Blade Types Using A.P. Advance, C-MAC System, and KingVision	10.1213/ane.0000000000002735	https://pubmed.ncbi.nlm.nih.gov/29239965/	3	2012-07-06	Completed	2011-10-01	2014-07-01	2018-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation success\n[ Time Frame: Immediately after intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation success\n[ Time Frame: Immediately after intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intubation success\n[ Time Frame: Immediately after intubation ]""}]	NA	NA
NCT01636752	Effectiveness of Internet-based Depression Treatment	Effects of a Psychological Internet Intervention in the Treatment of Mild to Moderate Depressive Symptoms: Results of the EVIDENT Study, a Randomized Controlled Trial	10.1159/000445355	https://pubmed.ncbi.nlm.nih.gov/27230863/	5	2012-07-05	Completed	2012-07-01	2015-03-01	2016-05-27	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PHQ-9\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	NA
NCT01638793	Capnographic Monitoring of Propofol-sedation During Colonoscopy	Capnographic monitoring of propofol-based sedation during colonoscopy	10.1055/s-0033-1359149	NA	3	2012-07-11	Completed	2012-06-01	2013-12-01	2013-12-11	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypoxia (SO2 <90%)Study objective is to evaluate if a reduction of hypoxic events (SO2 <90% for ≥ 15 sec) can be obtained with capnographic monitoring as compared to standard monitoring of respiration with pulse-oxymetry in patients receiving colonoscopy under Propofol-based sedation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypoxia (SO2 <90%)Study objective is to evaluate if a reduction of hypoxic events (SO2 <90% for ≥ 15 sec) can be obtained with capnographic monitoring as compared to standard monitoring of respiration with pulse-oxymetry in patients receiving colonoscopy under Propofol-based sedation""}]	NA	NA	NA
NCT01639781	Age-dependent Effects of Flavanols on Vascular Status	Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial	10.1007/s11357-015-9794-9	https://pubmed.ncbi.nlm.nih.gov/26013912/	4	2012-07-10	Completed	2011-11-01	2014-08-01	2015-05-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14 ]\n\nFlow mediated dilatation (FMD)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14 ]\n\nFlow mediated dilatation (FMD)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14 ]\n\nFlow mediated dilatation (FMD)""}]	NA	NA
NCT01641185	Ion Prostate Irradiation	Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial	10.1016/j.ijrobp.2016.02.025	https://pubmed.ncbi.nlm.nih.gov/27084659/	5	2012-07-13	Completed	2012-05-01	2015-12-01	2016-02-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proctitis and cystitis\n[ Time Frame: 3 years ]\n\nvia incidence grade 3-4 toxicity (NCI-CTC-AE)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proctitis and cystitis\n[ Time Frame: 3 years ]\n\nvia incidence grade 3-4 toxicity (NCI-CTC-AE)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proctitis and cystitis\n[ Time Frame: 3 years ]\n\nvia incidence grade 3-4 toxicity (NCI-CTC-AE)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proctitis and cystitis\n[ Time Frame: 3 years ]\n\nvia incidence grade 3-4 toxicity (NCI-CTC-AE)""}]	NA
NCT01647880	MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial	10.1186/s12883-020-01645-z	https://pubmed.ncbi.nlm.nih.gov/32126977/	16	2012-07-23	Terminated	2013-03-01	2016-04-01	2020-03-03	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parametersDecrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parametersDecrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parametersDecrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy parametersDecrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline""}]	NA
NCT01650805	Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial	10.1016/s1470-2045(16)00080-2	http://www.sciencedirect.com/science/article/pii/S1470204516000802?via%3Dihub	33	2012-07-24	Terminated	2012-06-01	2021-06-01	2016-04-12	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Molecular response (MMR) rate\n[ Time Frame: 12 months after first dose ]\n\nTo compare the efficacy of ponatinib with imatinib as measured by major molecular response (MMR) rate at 12 months (1 month or cycle = 28 days)""}]	[See Results Section.]	NA	NA	NA
NCT01651780	Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial	10.1016/j.jacc.2015.10.003	https://pubmed.ncbi.nlm.nih.gov/26477635/	11	2012-07-26	Completed	2012-10-01	2015-08-01	2015-10-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Bleeding\n[ Time Frame: 48h post or discharge ]\n\nMajor bleeding defined as Bleeding Academic Research Consortium (BARC) type ≥3 at 48 hours or hospital discharge whichever occurs first.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Bleeding\n[ Time Frame: 48 hours post-procedure or discharge ]\n\nThe primary end point will be major bleeding defined as Bleeding Academic Research Consortium (BARC) type ≥3b at 48 hours or hospital discharge whichever occurs first.""}]	NA	[See Results Section.]	NA
NCT01651832	Supportive Cancer Care Networkers (SCAN)	[Trans-sectoral care for patients with colorectal cancer: Design of a prospective randomized controlled multi-center trial (FKZ 01GY1143)]	10.1016/j.zefq.2014.06.012	https://zefq-journal.com/article/S1865921714001330/abstract	4	2012-07-25	Completed	2012-07-01	2015-12-01	2015-01-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""}]	NA
NCT01652391	Modulation of Cognitive Control by Transcranial Direct Current Stimulation	Amelioration of cognitive control in depression by transcranial direct current stimulation	10.1016/j.biopsych.2012.10.010	https://www.ncbi.nlm.nih.gov/pubmed/23219367	2	2012-07-25	Completed	2010-07-01	2011-06-01	2012-12-06	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Correctness of response\n[ Time Frame: The primary outcome measure is obtained during the intervention (20min tDCS or sham stimulation). ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Correctness of response\n[ Time Frame: The primary outcome measure is obtained during the intervention (20min tDCS or sham stimulation). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Correctness of response\n[ Time Frame: The primary outcome measure is obtained during the intervention (20min tDCS or sham stimulation). ]""}]	NA
NCT01654679	Impact of Preoperative Local Water-Filtered Infrared-A (wIRA) Irradiation on Postoperative Wound Healing	Impact of preoperative local water-filtered infrared A irradiation on postoperative wound healing: a randomized patient- and observer-blinded controlled clinical trial	10.1097/sla.0000000000000235	https://www.ncbi.nlm.nih.gov/pubmed/24169161?dopt=Abstract	2	2012-07-28	Completed	2008-08-01	2010-06-01	2013-12-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative wound infection rate\n[ Time Frame: day 2 to 8 and day 30 ]\n\n\n\nThe rate of wound infection was assessed from day 2 to 8 and day 30 post surgery.\n\nThe wound infection rate was assessed by a visual analogue scale (VAS) Group A: irradiated with local water-filtered infrared A (wIRA) irradiation Group B: irriadiate with conventional visible light""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative wound infection rate\n[ Time Frame: day 2 to 8 and day 30 ]\n\n\n\nThe rate of wound infection was assessed from day 2 to 8 and day 30 post surgery.\n\nThe wound infection rate was assessed by a visual analogue scale (VAS) Group A: irradiated with local water-filtered infrared A (wIRA) irradiation Group B: irriadiate with conventional visible light""}]	NA	NA
NCT01655290	Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI	Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T	10.1097/rli.0000000000000076	NA	7	2012-07-30	Completed	2012-08-01	2013-05-01	2014-10-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy (contrast-to-noise ratio)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy (contrast-to-noise ratio)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy (contrast-to-noise ratio)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy (contrast-to-noise ratio)""}]	NA
NCT01655368	Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)	Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT	10.1007/s00406-019-01064-3	https://pubmed.ncbi.nlm.nih.gov/31520149/	7	2012-07-30	Completed	2012-05-01	2015-04-01	2019-09-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective quality of life\n[ Time Frame: 12 months after intervention ]\n\n\n\nsubjective quality of life 12 months after intervention determined by WHOQOL-BREF total score.\n\nTo impart coping-strategies in handling stigmatization and to develop empowerment by embedding a psychotherapeutic module in psychoeducational groups.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective quality of life\n[ Time Frame: 12 months after intervention ]\n\n\n\nsubjective quality of life 12 months after intervention determined by WHOQOL-BREF total score.\n\nTo impart coping-strategies in handling stigmatization and to develop empowerment by embedding a psychotherapeutic module in psychoeducational groups.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective quality of life\n[ Time Frame: 12 months after intervention ]\n\n\n\nsubjective quality of life 12 months after intervention determined by WHOQOL-BREF total score.\n\nTo impart coping-strategies in handling stigmatization and to develop empowerment by embedding a psychotherapeutic module in psychoeducational groups.""}]	NA	NA
NCT01656096	Renal Sympathetic Denervation in Mild Refractory Hypertension	Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension	10.1161/hypertensionaha.115.05283	https://pubmed.ncbi.nlm.nih.gov/25824248/	4	2012-07-31	Completed	2012-07-01	2014-07-01	2015-03-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in systolic blood pressure (ABPM mean value)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in systolic blood pressure (ABPM mean value)\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in systolic blood pressure (ABPM mean value)\n[ Time Frame: 6 months ]""}]	NA
NCT01656720	A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period	Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response	10.1007/s00384-016-2585-7	NA	4	2012-08-01	Completed	2012-02-01	2013-12-01	2016-04-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score\n[ Time Frame: Up to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score\n[ Time Frame: Up to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score\n[ Time Frame: Up to 8 weeks ]""}]	NA	NA
NCT01656928	Effects of a Pre-school-based Nutritional Intervention on Children's Eating Behavior and Anthropometric Parameters	Positive impact of a pre-school-based nutritional intervention on children's fruit and vegetable intake: results of a cluster-randomized trial	10.1017/s136898001100200x	https://www.ncbi.nlm.nih.gov/pubmed/21859516?dopt=Abstract	1	2012-08-02	Completed	2008-09-01	2010-09-01	2011-08-23	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Fruit- and vegetable consumption\n[ Time Frame: 0, 6, 12 months ]\n\nBefore intervention (0 months), at the end of intervention (6 months), six months after intervention (12 months)""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Fruit- and vegetable consumption\n[ Time Frame: 0, 6, 12 months ]\n\nBefore intervention (0 months), at the end of intervention (6 months), six months after intervention (12 months)""}]	NA
NCT01657305	Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)	Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program	10.1016/j.burns.2017.03.005	https://www.sciencedirect.com/science/article/pii/S0305417917301493	13	2012-08-03	Completed	2012-08-01	2013-08-01	2017-04-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[See Results Section.]	NA
NCT01660425	Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support	Telephone-assisted self-help for parents of children with attention-deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial	10.1111/jcpp.12661	https://pubmed.ncbi.nlm.nih.gov/27878809/	5	2012-08-07	Unknown status	2012-05-01	NA	2016-11-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Weiss Functional Impairment Rating Scale (WFIRS-P), parent rating\n[ Time Frame: beginning, six months, 12 months; 16 months (control group) ]\n\nThe WFIRS-P is used for the assessment of psychosocial functioning of children diagnosed with ADHD.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Weiss Functional Impairment Rating Scale (WFIRS-P), parent rating\n[ Time Frame: baseline, six months, 12 months; 16 months (control group) ]\n\nThe WFIRS-P is used for the assessment of psychosocial functioning of children diagnosed with ADHD.""}]
NCT01662232	Improvement of Endothelial Function by EGCG	Tea-induced improvement of endothelial function in humans: No role for epigallocatechin gallate (EGCG)	10.1038/s41598-017-02384-x	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442103/	4	2012-08-09	Completed	2012-08-01	2013-09-01	2017-05-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Flow-mediated dilation of the arteria brachialis\n[ Time Frame: 2 hours after ingestion ]\n\nChange in flow-mediated dilation (in %) of the arteria brachialis after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG is assessed by vascular ultrasound.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Flow-mediated dilation of the arteria brachialis\n[ Time Frame: 2 hours after ingestion ]\n\nChange in flow-mediated dilation (in %) of the arteria brachialis after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG is assessed by vascular ultrasound.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Flow-mediated dilation of the arteria brachialis\n[ Time Frame: 2 hours after ingestion ]\n\nChange in flow-mediated dilation (in %) of the arteria brachialis after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG is assessed by vascular ultrasound.""}]	NA	NA
NCT01663311	Repetitive Transcranial Magnetic Stimulation With Double Cone Coil in Chronic Tinnitus	Combined rTMS treatment targeting the Anterior Cingulate and the Temporal Cortex for the Treatment of Chronic Tinnitus	10.1038/srep18028	https://www.ncbi.nlm.nih.gov/pubmed/?term=Combined+rTMS+treatment+targeting+the+Anterior+Cingulate+and+the+Temporal+Cortex+for+the+Treatment+of+Chronic+Tinnitus	3	2012-08-08	Completed	2012-07-01	2013-11-01	2015-12-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction > 5, contrast Baseline versus end of treatment/ day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction > 5, contrast Baseline versus end of treatment/ day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction > 5, contrast Baseline versus end of treatment/ day 12)\n[ Time Frame: Day 12 ]""}]	NA	NA
NCT01663324	rTMS for the Treatment of Chronic Tinnitus: Optimization by Simulation of the Cortical Tinnitus Network	Triple-site rTMS for the treatment of chronic tinnitus: a randomized controlled trial	10.1038/srep22302	https://pubmed.ncbi.nlm.nih.gov/26927363/	6	2012-08-08	Completed	2012-07-01	2014-08-01	2016-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast Baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	NA
NCT01663649	Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders	Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial	10.1111/epi.12833	https://pubmed.ncbi.nlm.nih.gov/25410633/	2	2012-08-08	Completed	2012-06-01	2013-12-01	2014-11-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of depressive symptoms\n[ Time Frame: 7 Days ]\n\nSeverity of depressive symptoms as assessed with the Beck Depression Inventory (BDI)""}]	NA
NCT01668485	Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation	Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes	10.1007/s00125-013-3120-9	https://link.springer.com/article/10.1007%2Fs00125-013-3120-9	2	2012-08-15	Completed	2001-11-01	2010-11-01	2014-12-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Whole body glucose counterregulation\n[ Time Frame: 6-8 weeks ]\n\nWhole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the euglycemic and hypoglycemic clamp tests.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Whole body glucose counterregulation\n[ Time Frame: 6-8 weeks ]\n\nWhole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests.""}]	NA	NA
NCT01668498	Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer	AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer	10.18632/oncotarget.21249	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739620/	11	2012-08-17	Completed	2011-05-01	2014-12-01	2017-09-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients developing no skin toxicity ≥ grade 2\n[ Time Frame: 8 weeks ]\n\nPercentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients developing no skin toxicity ≥ grade 2\n[ Time Frame: 8 weeks ]\n\nPercentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients developing no skin toxicity ≥ grade 2\n[ Time Frame: 8 weeks ]\n\nPercentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab.""}]	NA	NA
NCT01669109	Hatha Yoga for Patients With Colorectal Cancer	A randomized controlled bicenter trial of yoga for patients with colorectal cancer	10.1002/pon.3927	https://www.ncbi.nlm.nih.gov/pubmed/26228466?dopt=Abstract	6	2012-08-16	Completed	2012-09-01	2013-12-01	2015-07-29	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life\n[ Time Frame: Week 10 ]\n\nFunctional Assessment of Cancer Therapy - Colorectal Cancer (FACT-C)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life\n[ Time Frame: Week 10 ]\n\nFunctional Assessment of Cancer Therapy - Colorectal Cancer (FACT-C)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health-related quality of life\n[ Time Frame: Week 10 ]\n\nFunctional Assessment of Cancer Therapy - Colorectal Cancer (FACT-C)""}]	NA	NA
NCT01669382	Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites	Comparison of Exo-Seal(®) and Angio-Seal (®) for arterial puncture site closure: A randomized, multicenter, single-blind trial	10.1007/s00059-015-4306-3	NA	2	2012-08-20	Completed	2012-01-01	2012-09-01	2015-06-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bleeding, need for vascular surgery and device failure\n[ Time Frame: 24 hours ]\n\nbleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bleeding, need for vascular surgery and device failure\n[ Time Frame: 24 hours ]\n\nbleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bleeding, need for vascular surgery and device failure\n[ Time Frame: 24 hours ]\n\nbleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.""}]	NA	NA
NCT01673763	Post-ERCP Pancreatitis Prevention by Stent Insertion	Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial	10.1055/a-0886-6384	NA	2	2012-08-27	Completed	2010-07-01	2016-06-01	2019-07-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of post-ERCP pancreatitis\n[ Time Frame: up to 1 week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of post-ERCP pancreatitis\n[ Time Frame: up to 1 week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of post-ERCP pancreatitis\n[ Time Frame: up to 1 week ]""}]	NA	NA
NCT01673776	Multimodal Approach to Improve the Outcome of Patients With a Proximal Femoral Fracture	Perioperative multi-system optimization protocol in elderly hip fracture patients: a randomized-controlled trial	10.1007/s12630-019-01475-9	NA	4	2012-08-23	Completed	2012-03-01	2016-10-01	2019-09-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postoperative complications\n[ Time Frame: The participants will be followed for the duration of hospital stay, an expected average of 14 days ]\n\npostoperative complications: cardiovascular, cerebrovascular, pulmonal, renal and surgical complications""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postoperative complications\n[ Time Frame: The participants will be followed for the duration of hospital stay, an expected average of 14 days ]\n\npostoperative complications: cardiovascular, cerebrovascular, pulmonal, renal and surgical complications""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postoperative complications\n[ Time Frame: The participants will be followed for the duration of hospital stay, an expected average of 14 days ]\n\npostoperative complications: cardiovascular, cerebrovascular, pulmonal, renal and surgical complications""}]	NA	NA
NCT01682720	Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection	Sofosbuvir and ribavirin in HCV genotypes 2 and 3	10.1056/nejmoa1316145	NA	8	2012-09-06	Completed	2012-09-01	2013-10-01	2014-05-04	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy 12 weeks after discontinuation of therapy.\n[ Time Frame: 24 weeks ]\n\nTo determine the efficacy of treatment with GS-7977 + Ribavarin (RBV) compared to treatment with GS-7977 placebo + RBV placebo as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR 12).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety and tolerability of GS-7977 + RBV.\n[ Time Frame: 12 weeks ]\n\nTo assess the safety and tolerability of GS-7977 + RBV compared to placebo control as measured by review of the accumulated safety data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy 12 weeks after discontinuation of therapy.\n[ Time Frame: 24 weeks ]\n\n•To determine the efficacy of treatment with GS 7977+ ribavirin (RBV) as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR12)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety and tolerability of GS-7977 + RBV.\n[ Time Frame: 12 weeks ]\n\n•To assess the safety and tolerability of GS-7977+RBV as measured by review of the accumulated safety data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)\n[ Time Frame: Posttreatment Week 12 ]\n\nSVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Any adverse events leading to permanent discontinuation of study drug(s)\n[ Time Frame: Up to 24 weeks ]""}]	[See Results Section.]	NA
NCT01683578	Protective Variable Ventilation for Open Abdominal Surgery	Variable versus conventional lung protective mechanical ventilation during open abdominal surgery: study protocol for a randomized controlled trial	10.1186/1745-6215-15-155	https://www.ncbi.nlm.nih.gov/pubmed/24885921?dopt=Abstract	2	2012-09-10	Completed	2012-09-01	2013-09-01	2014-05-02	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced vital capacity\n[ Time Frame: Preoperative until 5th postoperative day ]\n\nForced vital capacity is assessed on the first postoperative day""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced vital capacity\n[ Time Frame: Preoperative until 5th postoperative day ]\n\nForced vital capacity is assessed on the first postoperative day""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced vital capacity\n[ Time Frame: Preoperative until 5th postoperative day ]\n\nForced vital capacity is assessed on the first postoperative day""}]	NA
NCT01685775	Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy	Transvaginal/transumbilical hybrid--NOTES--versus 3-trocar needlescopic cholecystectomy: short-term results of a randomized clinical trial	10.1097/sla.0000000000000218	https://www.ncbi.nlm.nih.gov/pubmed/24108196?dopt=Abstract	2	2012-09-11	Completed	2010-02-01	2012-07-01	2015-03-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of pain in motion\n[ Time Frame: at the operation day ]\n\nPain Scores on the Visual Analog Scale (0-10)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Intensity of pain in motion\n[ Time Frame: at postoperative day 1 ]\n\n2 measures (in the morning and in the evening) Pain Scores on the Visual Analog Scale (0-10)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Intensity of pain in motion\n[ Time Frame: at postoperative day 2 ]\n\nPain Scores on the Visual Analog Scale (0-10)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of pain in motion\n[ Time Frame: at the operation day ]\n\nPain Scores on the Visual Analog Scale (0-10)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Intensity of pain in motion\n[ Time Frame: at postoperative day 1 ]\n\n2 measures (in the morning and in the evening) Pain Scores on the Visual Analog Scale (0-10)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Intensity of pain in motion\n[ Time Frame: at postoperative day 2 ]\n\nPain Scores on the Visual Analog Scale (0-10)""}]	NA	NA
NCT01690117	German Adaptation of REACH II	Individualized support for informal caregivers of people with dementia - effectiveness of the German adaptation of REACH II	10.1186/s12877-017-0678-y	https://pubmed.ncbi.nlm.nih.gov/29233097/	3	2012-09-20	Completed	2012-10-01	2015-01-01	2017-12-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Zarit Caregiver Burden Interview (ZBI)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Zarit Caregiver Burden Interview (ZBI)\n[ Time Frame: 9 months ]""}]	[See Results Section.]	NA	NA
NCT01692041	Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma	Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma	10.1016/j.phymed.2014.05.006	http://www.sciencedirect.com/science/article/pii/S094471131400227X?via%3Dihub	1	2012-09-24	Unknown status	NA	NA	2014-06-07	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MEF75-25 before bronchodilation - relative change\n[ Time Frame: every 4 weeks ]\n\nMEF75-25 will be measured at every time point of the study and relative changes will be followed""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""FEV1 before bronchodilation - relative change\n[ Time Frame: every 4 weeks ]\n\nFEV1 before bronchodilation will be measured at every study visit and changes will be documented""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MEF75-25 before bronchodilation - relative change\n[ Time Frame: every 4 weeks ]\n\nMEF75-25 will be measured at every time point of the study and relative changes will be followed""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""FEV1 before bronchodilation - relative change\n[ Time Frame: every 4 weeks ]\n\nFEV1 before bronchodilation will be measured at every study visit and changes will be documented""}]
NCT01693497	Comparison of Cognitive Processing Therapy (CPT) and Dialogical Exposure Therapy (DET) for Posttraumatic Stress Disorder	A Randomized Controlled Clinical Trial of Dialogical Exposure Therapy versus Cognitive Processing Therapy for Adult Outpatients Suffering from PTSD after Type I Trauma in Adulthood	10.1159/000440726	https://www.ncbi.nlm.nih.gov/pubmed/26610167?dopt=Abstract	1	2012-09-24	Completed	2002-09-01	2011-09-01	2015-11-27	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTBS Symptom Severity\n[ Time Frame: change from pretreatment to posttreatment (planned duration 12 weeks on average) to follow-up (six months after posttreatment) ]\n\nEven though participants are assessed by a clinical interview before entering the study, the primary outcome measure is the PDS which is applied before and after treatment as well as at 6-month follow-up.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PTBS Symptom Severity\n[ Time Frame: change from pretreatment to posttreatment (planned duration 12 weeks on average) to follow-up (six months after posttreatment) ]\n\nEven though participants are assessed by a clinical interview before entering the study, the primary outcome measure is the PDS which is applied before and after treatment as well as at 6-month follow-up.""}]	NA	NA
NCT01694849	Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening	10.1053/j.gastro.2016.01.038	https://pubmed.ncbi.nlm.nih.gov/26874076/	17	2012-09-26	Completed	2012-09-01	2014-10-01	2016-02-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of responders defined by the disappearance of steatohepatitis without worsening of fibrosis\n[ Time Frame: 52 weeks ]\n\n\n\nTo evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the percentage of responders from baseline to Week 52, defined by the disappearance of steatohepatitis (i.e. patients no longer meeting the criteria for steatohepatitis) without worsening of fibrosis.\n\nWorsening of fibrosis is evaluated using NASH CRN (Clinical Research Network) fibrosis staging system and defined as:\n\nProgression to stage 3 or 4 for patients at stage 0, 1 or 2 on diagnostic liver biopsy\nProgression to stage 4 for patients at stage 3 on diagnostic liver biopsy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of responders defined by the disappearance of steatohepatitis without worsening of fibrosis\n[ Time Frame: 52 weeks ]\n\n\n\nTo evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the percentage of responders from baseline to Week 52, defined by the disappearance of steatohepatitis (i.e. patients no longer meeting the criteria for steatohepatitis) without worsening of fibrosis.\n\nWorsening of fibrosis is evaluated using NASH CRN (Clinical Research Network) fibrosis staging system and defined as:\n\nProgression to stage 3 or 4 for patients at stage 0, 1 or 2 on diagnostic liver biopsy\nProgression to stage 4 for patients at stage 3 on diagnostic liver biopsy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of responders defined by the disappearance of steatohepatitis without worsening of fibrosis\n[ Time Frame: 52 weeks ]\n\n\n\nTo evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the percentage of responders from baseline to Week 52, defined by the disappearance of steatohepatitis (i.e. patients no longer meeting the criteria for steatohepatitis) without worsening of fibrosis.\n\nWorsening of fibrosis is evaluated using NASH CRN (Clinical Research Network) fibrosis staging system and defined as:\n\nProgression to stage 3 or 4 for patients at stage 0, 1 or 2 on diagnostic liver biopsy\nProgression to stage 4 for patients at stage 3 on diagnostic liver biopsy""}]	NA	NA
NCT01696526	Bioefficiency of of Conventional Fish and Vitamin D Fortified Fish	Efficacy of fish intake on vitamin D status: a meta-analysis of randomized controlled trials	10.3945/ajcn.114.105395	http://ajcn.nutrition.org/content/102/4/837.full	5	2012-09-28	Completed	2012-10-01	2012-12-01	2015-09-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of 25-hydroxvitamin D\n[ Time Frame: after 4 weeks of consumption ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of 25-hydroxvitamin D\n[ Time Frame: after 4 weeks of consumption ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of 25-hydroxvitamin D\n[ Time Frame: after 4 weeks of consumption ]""}]	NA	NA
NCT01697306	The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer	The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial	10.1016/j.juro.2013.03.097	http://www.sciencedirect.com/science/article/pii/S0022534713038901	1	2012-09-27	Completed	2006-09-01	2011-03-01	2013-03-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""quality of life of intermediate-risk NMIBC patients treated with intravesical Gemcitabine chemotherapy or BCG\n[ Time Frame: 1 year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""quality of life of intermediate-risk NMIBC patients treated with intravesical Gemcitabine chemotherapy or BCG\n[ Time Frame: 1 year ]""}]	NA	NA
NCT01700322	Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study	Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study	10.1136/bmjopen-2014-005268	https://pubmed.ncbi.nlm.nih.gov/24801283/	6	2012-10-03	Completed	2012-08-01	2016-07-01	2014-05-06	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in FMD\n[ Time Frame: baseline and 1 month ]\n\nThe primary endpoint is the change in flow-mediated dilation (FMD) (comparison before treatment versus after treatment and stenting) in the three study groups. The mean FMD across the three measurements (1 day, 1 week, 1 month) performed after coronary artery stenting will be compared to the FMD value before drug administration and stenting.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in FMD\n[ Time Frame: baseline and 1 month ]\n\nThe primary endpoint is the change in flow-mediated dilation (FMD) (comparison before treatment versus after treatment and stenting) in the three study groups. The mean FMD across the three measurements (1 day, 1 week, 1 month) performed after coronary artery stenting will be compared to the FMD value before drug administration and stenting.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in FMD\n[ Time Frame: baseline and 1 month ]\n\nThe primary endpoint is the change in flow-mediated dilation (FMD) (comparison before treatment versus after treatment and stenting) in the three study groups. The mean FMD across the three measurements (1 day, 1 week, 1 month) performed after coronary artery stenting will be compared to the FMD value before drug administration and stenting.""}]	NA
NCT01701479	Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)	NA	10.1200/jco.2016.34.15_suppl.10562	http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.10562	4	2012-10-03	Active, not recruiting	2010-11-01	2020-12-01	2016-05-01	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy endpoint\n[ Time Frame: day 15 of first cycle ]\n\n\n\nOn day 15 of the first cycle in ≥ 80% of patients:\n\nan increase of 500% and/or an absolute minimum increase to ≥100 cells/mcLof the CD16/CD56 positive activated NK cells, AND\na measurable ch14.18/CHO level of at least 1 µg/ml.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Pain-toxicity endpoint\n[ Time Frame: Day 5 of ch14.18/CHO infusion cycle 1 ]\n\ni.v. morphine free ch14.18/CHO infusion schedule after the first 5 days during the first cycle in >= 80% of patients""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: through study completion, an average of 1 year ]\n\n\n\nThe primary endpoint is event free survival calculated from the date of randomisation. The following will be considered as events:\n\ndisease progression or relapse\ndeath from any cause\nsecond neoplasm""}]	NA	NA	NA
NCT01703273	Low-level Intervention for Adolescents With Extreme Obesity	A Structured, Manual-Based Low-Level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents with Extreme Obesity - the STEREO Trial	10.1159/000475717	https://pubmed.ncbi.nlm.nih.gov/28787738/	6	2012-10-09	Completed	2012-08-01	2014-12-01	2017-08-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint(tested hirarchically) of a) Compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint(tested hirarchically) of a) Compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint (tested hierarchically) of a) compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint (tested hierarchically) of a) compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	NA
NCT01703819	Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects	Effects of Neurexan ® in an experimental acute stress setting--An explorative double-blind study in healthy volunteers	10.1016/j.lfs.2015.12.058	https://www.ncbi.nlm.nih.gov/pubmed/26772822	4	2012-10-10	Completed	2012-10-01	2013-04-01	2016-01-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[See Results Section.]	NA	NA
NCT01703832	Explorative Open Label Study of Efficacy Profile of Neurexan® in Experimental Acute Stress Setting in Healthy Subjects	Effects of Neurexan ® in an experimental acute stress setting--An explorative double-blind study in healthy volunteers	10.1016/j.lfs.2015.12.058	https://www.ncbi.nlm.nih.gov/pubmed/26772822	5	2012-10-10	Completed	2012-10-01	2013-04-01	2016-01-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[See Results Section.]	NA	NA
NCT01711905	Study on the Effects of a Recommendation Based Supply of Vitamin D3 in Healthy Volunteers	Vitamin D3 supplementation: Response and predictors of vitamin D3 metabolites - A randomized controlled trial	10.1016/j.clnu.2015.04.021	https://www.ncbi.nlm.nih.gov/pubmed/26037521?dopt=Abstract	4	2012-10-18	Completed	2012-11-01	2013-04-01	2015-05-19	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""25-hydroxyvitamin D3\n[ Time Frame: after 12 weeks of supplementation ]\n\nmajor outcome variable is the increase of 25-hydroxyvitamin D3 in the treatment group in comparison with the placebo group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""25-hydroxyvitamin D3\n[ Time Frame: after 12 weeks of supplementation ]\n\nmajor outcome variable is the increase of 25-hydroxyvitamin D3 in the treatment group in comparison with the placebo group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""25-hydroxyvitamin D3\n[ Time Frame: after 12 weeks of supplementation ]\n\nmajor outcome variable is the increase of 25-hydroxyvitamin D3 in the treatment group in comparison with the placebo group""}]	NA	NA
NCT01712464	Modulation of Reinforcement Learning	Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial	10.1038/s41386-018-0258-7	https://pubmed.ncbi.nlm.nih.gov/30390065/	4	2012-10-19	Completed	2012-10-01	2014-04-01	2018-11-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bold Signal in nucleus accumbens\n[ Time Frame: 1 Day ]\n\nduring social learning at one treatment with oxytocin vs placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bold Signal in nucleus accumbens\n[ Time Frame: 1 Day ]\n\nduring social learning at one treatment with oxytocin vs placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bold Signal in nucleus accumbens\n[ Time Frame: 1 Day ]\n\nduring social learning at one treatment with oxytocin vs placebo""}]	NA	NA
NCT01713426	A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment	NA	NA	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738436/	6	2012-10-22	Completed	2012-07-01	2013-09-01	2015-11-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8, without change to background chronic pain medication\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8, without change to background chronic pain medication\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8\n[ Time Frame: Baseline and week 8 ]""}]	NA
NCT01714414	A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen	Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire	10.1097/qad.0000000000001362	NA	13	2012-10-25	Completed	2012-12-01	2014-06-01	2017-02-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with plasma HIV RNA < 50 copies/ml\n[ Time Frame: at week 24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with plasma HIV RNA < 50 copies/ml\n[ Time Frame: at week 24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with plasma HIV RNA < 50 copies/ml\n[ Time Frame: at week 24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with plasma HIV RNA < 50 copies/ml\n[ Time Frame: at week 24 ]""}]	NA
NCT01716286	Neural Correlates of an Olive Oil Essence	Olive oil aroma extract modulates cerebral blood flow in gustatory brain areas in humans	10.3945/ajcn.113.062679	https://www.ncbi.nlm.nih.gov/pubmed/24025630?dopt=Abstract	2	2012-10-24	Completed	2012-02-01	2012-03-01	2013-09-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity (cerebral blood flow change after yogurt intake)\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	NA
NCT01716832	Walking for Stress Reduction	Mindful walking in psychologically distressed individuals: a randomized controlled trial	10.1155/2013/489856	https://www.hindawi.com/journals/ecam/2013/489856/abs/	2	2012-10-29	Completed	2011-03-01	2011-09-01	2013-07-31	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cohens Perceived Stress Scale 14 Items\n[ Time Frame: 4 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cohens Perceived Stress Scale 14 Items\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cohens Perceived Stress Scale 14 Items\n[ Time Frame: 4 weeks ]""}]	NA
NCT01716923	Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia	Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery	10.1111/trf.14528	https://pubmed.ncbi.nlm.nih.gov/29498049/	5	2012-10-29	Completed	2013-04-01	2014-07-01	2018-03-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy Endpoint - mean hemoglobin content\n[ Time Frame: Day 2 ]\n\nThe mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety Endpoint - Adverse events\n[ Time Frame: 90 days ]\n\nThe frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy Endpoint - mean hemoglobin content\n[ Time Frame: Day 2 ]\n\nThe mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety Endpoint - Adverse events\n[ Time Frame: 90 days ]\n\nThe frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy Endpoint - mean hemoglobin content\n[ Time Frame: Day 2 ]\n\nThe mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety Endpoint - Adverse events\n[ Time Frame: 90 days ]\n\nThe frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.""}]	NA	NA
NCT01719263	Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study	Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial	10.1016/s2213-2600(16)00045-x	https://pubmed.ncbi.nlm.nih.gov/26899390/	10	2012-10-29	Completed	2012-06-01	2015-03-01	2016-02-16	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in pulmonary function\n[ Time Frame: Months 1, 3, 6, 12, 24, 36 ]\n\nChange in spirometry and/or lung volume measurements from baseline to months 1,3,6,12,24, and 36""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1-second (FEV1) compared to active comparator\n[ Time Frame: Year 1 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of Life (SGRQ)\n[ Time Frame: Year 1 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1-second (FEV1) compared to active comparator\n[ Time Frame: Year 1 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of Life (SGRQ)\n[ Time Frame: Year 1 ]""}]	NA	NA
NCT01724437	Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation	Benefit of pulmonary vein isolation guided by loss of pace capture on the ablation line: results from a prospective 2-center randomized trial	10.1016/j.jacc.2013.03.059	http://www.sciencedirect.com/science/article/pii/S0735109713017269?via%3Dihub	2	2012-11-06	Completed	2009-11-01	2010-11-01	2013-05-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to AF recurrence\n[ Time Frame: 12 months ]\n\nrecurrence of AF as assessed by 3 day holter monitoring""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""time to AT recurrence\n[ Time Frame: 12 months ]\n\nassessment of AT recurrence using 3 day holter monitoring""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to AF recurrence\n[ Time Frame: 12 months ]\n\nrecurrence of AF as assessed by 3 day holter monitoring""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""time to AT recurrence\n[ Time Frame: 12 months ]\n\nassessment of AT recurrence using 3 day holter monitoring""}]	NA	NA
NCT01726387	Self-Management for Anxiety, Depression and Somatoform Disorders	Collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: Cluster-randomised controlled trial (findings of the SMADS study)	10.1016/j.ijnurstu.2016.08.007	https://pubmed.ncbi.nlm.nih.gov/27611093/	15	2012-11-13	Completed	2013-03-01	2015-06-01	2016-08-21	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	NA
NCT01726933	LAS41008 in Moderate to Severe Chronic Plaque Psoriasis	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE)	10.1111/bjd.14947	https://pubmed.ncbi.nlm.nih.gov/27515097/	7	2012-11-12	Completed	2012-11-01	2014-10-01	2016-11-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PASI 75\n[ Time Frame: 16 weeks ]\n\nReduction of PASI by 75% from baseline to week 16""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Physician Global Assessment, PGA\n[ Time Frame: 16 weeks ]\n\nChange in PGA from baseline to week 16""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PASI 75\n[ Time Frame: 16 weeks ]\n\nReduction of PASI by 75% from baseline to week 16""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Physician Global Assessment, PGA\n[ Time Frame: 16 weeks ]\n\nChange in PGA from baseline to week 16""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PASI 75\n[ Time Frame: 16 weeks ]\n\nReduction of PASI by 75% from baseline to week 16""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Physician Global Assessment, PGA\n[ Time Frame: 16 weeks ]\n\nChange in PGA from baseline to week 16""}]	NA	NA
NCT01727362	Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy	Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study	10.1007/s10549-019-05431-5	https://pubmed.ncbi.nlm.nih.gov/31520284/	9	2012-11-12	Completed	2012-10-01	2015-10-01	2019-09-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)\n[ Time Frame: 6 month ]""}]	NA	NA
NCT01728441	Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery	Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease	10.1016/j.jacc.2018.11.039	https://pubmed.ncbi.nlm.nih.gov/30765033/	6	2012-11-13	Completed	2012-10-01	2014-04-01	2019-02-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PSVR\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""TLR\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Peak Systolic Velocity Ratio (PSVR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""target lesion revascularization (TLR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Peak Systolic Velocity Ratio (PSVR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""target lesion revascularization (TLR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	NA	NA
NCT01729234	Effects of Dietary Nitrate on Age-related Vascular Function	Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk	10.1016/j.jacc.2013.08.691	NA	2	2012-11-14	Completed	2012-10-01	2013-05-01	2013-08-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function measured by flow-mediated dilation (FMD)\n[ Time Frame: 30 days ]\n\nThe effect of dietary nitrate on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function measured by flow-mediated dilation (FMD)\n[ Time Frame: 30 days ]\n\nThe effect of dietary nitrate on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function measured by flow-mediated dilation (FMD)\n[ Time Frame: 30 days ]\n\nThe effect of dietary nitrate on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.""}]	NA
NCT01731158	Sequential Therapy in Metastatic Renal Cell Carinoma	Circulating Tumor Cell Composition in Renal Cell Carcinoma	10.1371/journal.pone.0153018	https://pubmed.ncbi.nlm.nih.gov/27101285/	4	2012-11-16	Completed	2012-10-01	2016-05-01	2016-04-21	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]\n\nPFS rate""}]	NA
NCT01731249	Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis	Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study	10.1186/2045-7022-4-7	https://www.ncbi.nlm.nih.gov/pubmed/24517417?dopt=Abstract	2	2012-11-15	Completed	2010-11-01	2012-07-01	2014-02-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average Adjusted Symptom Score\n[ Time Frame: Year 2 of treatment ]\n\nSymptom score adjusted on patient's rescue medication usage""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average Adjusted Symptom Score\n[ Time Frame: Year 2 of treatment ]\n\nSymptom score adjusted on patient's rescue medication usage""}]	NA	NA
NCT01735513	Intraprocedural Intraaortic Embolic Protection With the EmbolX Device in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation	Intraaortic Protection From Embolization in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation	10.1016/j.athoracsur.2015.03.119	https://pubmed.ncbi.nlm.nih.gov/26234838/	2	2012-11-27	Completed	2012-07-01	2014-04-01	2015-08-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection of new morphological brain injury with new hyper-intense DW-MRI cerebral lesions on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Postoperative day 1-3 ]\n\nMRI of the brain is obtained at the same time as clinical exams. Scans are performed on a 1.5-T MR unit and a circular polarized head coil. The imaging protocol includes a transversal DW, single shot echo-planar sequence of the whole brain. Diffusion images are processed to generate isotopic apparent diffusion coefficient maps using dedicated software allowing for proper classification of the lesions. Transversal fluid-attenuated inversion recovery and transversal T2-weighted turbo spin-echo sequences are also performed. Slice thickness is 5mm for all sequences. Scans are read by an experienced neuroradiologist blinded to the clinical data. The presence, number, volume and location of all new focal diffusion abnormalities were recorded.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection of new morphological brain injury with new hyper-intense DW-MRI cerebral lesions on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Postoperative day 1-3 ]\n\nMRI of the brain is obtained at the same time as clinical exams. Scans are performed on a 1.5-T MR unit and a circular polarized head coil. The imaging protocol includes a transversal DW, single shot echo-planar sequence of the whole brain. Diffusion images are processed to generate isotopic apparent diffusion coefficient maps using dedicated software allowing for proper classification of the lesions. Transversal fluid-attenuated inversion recovery and transversal T2-weighted turbo spin-echo sequences are also performed. Slice thickness is 5mm for all sequences. Scans are read by an experienced neuroradiologist blinded to the clinical data. The presence, number, volume and location of all new focal diffusion abnormalities were recorded.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection of new morphological brain injury with new hyper-intense DW-MRI cerebral lesions on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Postoperative day 1-3 ]\n\nMRI of the brain is obtained at the same time as clinical exams. Scans are performed on a 1.5-T MR unit and a circular polarized head coil. The imaging protocol includes a transversal DW, single shot echo-planar sequence of the whole brain. Diffusion images are processed to generate isotopic apparent diffusion coefficient maps using dedicated software allowing for proper classification of the lesions. Transversal fluid-attenuated inversion recovery and transversal T2-weighted turbo spin-echo sequences are also performed. Slice thickness is 5mm for all sequences. Scans are read by an experienced neuroradiologist blinded to the clinical data. The presence, number, volume and location of all new focal diffusion abnormalities were recorded.""}]	NA
NCT01737034	A Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon	Carbohydrate quality and quantity affect glucose and lipid metabolism during weight regain in healthy men	10.3945/jn.113.179390	http://jn.nutrition.org/content/143/10/1593	2	2012-11-26	Completed	2011-01-01	2012-08-01	2013-08-14	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon\n[ Time Frame: Body composition measurement after 4 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon\n[ Time Frame: Body composition measurement after 6 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in body composition and energy metabolism after 3 weeks of underfeeding and 2 following weeks of refeeding\n[ Time Frame: Body composition measurement after 4 and 6 study weeks ]\n\nBody composition measurement including BODPOD, QMR, BIA Energy Metabolism measurement using indirect calorimetry""}]	NA	NA
NCT01741532	Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)	Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study	10.1016/s1474-4422(19)30142-5	NA	14	2012-12-03	Completed	2012-12-01	2016-09-01	2019-07-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in severity of dystonia (using BAD scale) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: 18 months ]\n\nThe Barry-Albright Dystonia Scale (BAD) will be completed at baseline, months 6, 12 and 18 visits and will be assessed by central raters.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in patient's global impression of condition's improvement (using PGI-I) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: 18 months ]\n\nPatient Global Impression of Improvement (PGI-I) will be completed at months 6, 12 and 18 visits.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in severity of dystonia (using BAD scale) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: Baseline to 18 Months ]\n\nThe Barry-Albright Dystonia Scale (BAD) will be completed at baseline, months 6, 12 and 18 visits and will be assessed by central raters.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in patient's global impression of condition's improvement (using PGI-I) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: Baseline to 18 months ]\n\nPatient Global Impression of Improvement (PGI-I) will be completed at months 6, 12 and 18 visits.""}]	[See Results Section.]	NA	NA
NCT01742468	Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis	Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil	10.1016/j.clnu.2017.02.021	https://www.ncbi.nlm.nih.gov/pubmed/28302406	7	2012-12-04	Completed	2012-09-01	2012-12-01	2017-03-06	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""arachidonic acid/docosahexaenoic acid ratio in plasmal lipids and erythrocyte membranes\n[ Time Frame: 10 weeks ]\n\narachidonic acid is a precursor of eicosanoids (leukotriens 4 series, prostaglandins 2 series) docosahexaenoic acid is a precursor of (resolvins and protectins (pro-resolving)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sum of tender and swollen joints (68/66), disease activity score DAS 28, ultrasound score US-7\n[ Time Frame: 10 weeks ]\n\nDisease activity parameters""}]	NA	NA
NCT01743768	Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)	Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme	10.1056/nejmoa1411776	https://www.ncbi.nlm.nih.gov/pubmed/25981191?dopt=Abstract	4	2012-12-04	Completed	2012-12-01	2013-11-01	2015-05-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in late phase response after allergen challenge (AC), following multiple doses of inhaled SB010\n[ Time Frame: Day -1 and Day 28 (monitoring for 7 h after AC). ]\n\n\n\nAfter 28 days of treatment with SB010 or placebo, patients will undergo allergen bronchoprovocation [allergen challenge (AC)]. The results from AC on Day 28 will be compared to results obtained on Enrolment (Day -1).\n\nAllergen for AC will be selected based on skin prick test performed at Screening. The dose of selected allergen will be determined based on skin prick dilution test.\n\nAfter the AC, serial spirometry will be used to assess the influence of inhaled SB010 on the area under the Forced Expiratory Volume in 1 second (FEV1) curve during the late asthma response (LAR, 4 - 7 hours); measurement time points will be at 4, 5, 6, and 7 hours after AC.\n\nThe spirometric parameters FEV1 and forced vital capacity (FVC), obtained during pulmonary function testing, will be used to derive the primary efficacy variable AUC4-7 FEV1.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in late phase response after allergen challenge (AC), following multiple doses of inhaled SB010\n[ Time Frame: Day -1 and Day 28 (monitoring for 7 h after AC). ]\n\n\n\nAfter 28 days of treatment with SB010 or placebo, patients will undergo allergen bronchoprovocation [allergen challenge (AC)]. The results from AC on Day 28 will be compared to results obtained on Enrolment (Day -1).\n\nAllergen for AC will be selected based on skin prick test performed at Screening. The dose of selected allergen will be determined based on skin prick dilution test.\n\nAfter the AC, serial spirometry will be used to assess the influence of inhaled SB010 on the area under the Forced Expiratory Volume in 1 second (FEV1) curve during the late asthma response (LAR, 4 - 7 hours); measurement time points will be at 4, 5, 6, and 7 hours after AC.\n\nThe spirometric parameters FEV1 and forced vital capacity (FVC), obtained during pulmonary function testing, will be used to derive the primary efficacy variable AUC4-7 FEV1.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in late phase response after allergen challenge (AC), following multiple doses of inhaled SB010\n[ Time Frame: Day -1 and Day 28 (monitoring for 7 h after AC). ]\n\n\n\nAfter 28 days of treatment with SB010 or placebo, patients will undergo allergen bronchoprovocation [allergen challenge (AC)]. The results from AC on Day 28 will be compared to results obtained on Enrolment (Day -1).\n\nAllergen for AC will be selected based on skin prick test performed at Screening. The dose of selected allergen will be determined based on skin prick dilution test.\n\nAfter the AC, serial spirometry will be used to assess the influence of inhaled SB010 on the area under the Forced Expiratory Volume in 1 second (FEV1) curve during the late asthma response (LAR, 4 - 7 hours); measurement time points will be at 4, 5, 6, and 7 hours after AC.\n\nThe spirometric parameters FEV1 and forced vital capacity (FVC), obtained during pulmonary function testing, will be used to derive the primary efficacy variable AUC4-7 FEV1.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in late phase response after allergen challenge (AC), following multiple doses of inhaled SB010\n[ Time Frame: Day -1 and Day 28 (monitoring for 7 h after AC). ]\n\n\n\nAfter 28 days of treatment with SB010 or placebo, patients will undergo allergen bronchoprovocation [allergen challenge (AC)]. The results from AC on Day 28 will be compared to results obtained on Enrolment (Day -1).\n\nAllergen for AC will be selected based on skin prick test performed at Screening. The dose of selected allergen will be determined based on skin prick dilution test.\n\nAfter the AC, serial spirometry will be used to assess the influence of inhaled SB010 on the area under the Forced Expiratory Volume in 1 second (FEV1) curve during the late asthma response (LAR, 4 - 7 hours); measurement time points will be at 4, 5, 6, and 7 hours after AC.\n\nThe spirometric parameters FEV1 and forced vital capacity (FVC), obtained during pulmonary function testing, will be used to derive the primary efficacy variable AUC4-7 FEV1.""}]	NA
NCT01755143	Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment	MRI scanning in patients with new and existing CapSureFix Novus 5076 pacemaker leads: randomized trial results	10.1016/j.hrthm.2014.12.035	http://www.sciencedirect.com/science/article/pii/S1547527114015537	4	2012-12-18	Completed	2012-12-01	2014-04-01	2014-12-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication free rate\n[ Time Frame: MRI scan to one month later ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication free rate\n[ Time Frame: MRI scan to one month later ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""}]	NA	[See Results Section.]	NA
NCT01755507	Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis	10.1016/j.jhep.2017.05.009	https://pubmed.ncbi.nlm.nih.gov/28529147/	3	2012-12-21	Completed	2012-12-01	2015-10-01	2017-05-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in serum AP levels during treatment\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in serum AP levels during treatment\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in serum AP levels during treatment\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT01763112	Training With Whole Body Vibration Device in Patients With PAH	Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study	10.1136/heartjnl-2016-309852	https://pubmed.ncbi.nlm.nih.gov/28100544/	2	2013-01-07	Unknown status	2013-01-01	NA	2017-01-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in 6-Minute Walk Distance (6MWD)\n[ Time Frame: baseline and week 4 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in 6-Minute Walk Distance (6MWD)\n[ Time Frame: baseline and week 4 ]""}]
NCT01763294	A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy	Transcranial Direct Current Stimulation in Mesial Temporal Lobe Epilepsy and Hippocampal Sclerosis	10.1016/j.brs.2016.08.013	NA	2	2013-01-05	Completed	2012-02-01	2012-12-01	2016-08-31	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of seizures\n[ Time Frame: 2 months ]\n\nThe number of the seizures monthly for 2 months""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of seizures\n[ Time Frame: 2 months ]\n\nThe number of the seizures monthly for 2 months""}]	NA	NA
NCT01766791	Resistance Exercise, Muscle Mass, Strength and Body Composition	Myocardial adaption to HI(R)T in previously untrained men with a randomized, longitudinal cardiac MR imaging study (Physical adaptions in Untrained on Strength and Heart trial, PUSH-trial)	10.1371/journal.pone.0189204	https://pubmed.ncbi.nlm.nih.gov/29216285/	4	2013-01-10	Completed	2013-01-01	2014-02-01	2017-12-07	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at midfemur via Quantitative Computed Tomography (QCT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at mid-femur via Quantitative Computed Tomography (QCT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at mid-femur via Quantitative Computed Tomography (QCT)""}]	NA	NA
NCT01767181	Light and Exercise in Night-shift Workers	Exercise training prior to night shift work improves physical work capacity and arterial stiffness	10.1177/2047487319848196	https://journals.sagepub.com/doi/10.1177/2047487319848196	6	2013-01-11	Completed	2013-02-01	2016-03-01	2019-05-08	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 12 weeks ]\n\nThe difference of the expression pattern of the CLOCK gene in peripheral blood mononuclear cells (PBMCs) after 12 weeks between intervention and control group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 12 weeks ]\n\nThe difference of the expression pattern of the CLOCK gene in peripheral blood mononuclear cells (PBMCs) after 12 weeks between intervention and control group""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 12 weeks ]\n\nThe difference of the expression pattern of the CLOCK gene in peripheral blood mononuclear cells (PBMCs) after 12 weeks between intervention and control group""}]	NA	NA
NCT01768585	Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease	Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease	10.1097/hjh.0000000000001984	https://pubmed.ncbi.nlm.nih.gov/30672832/	1	2013-01-14	Unknown status	NA	NA	2019-05-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Aortic distensibility (MRI), pulse wave velocity (SphygmoCor®), flow-mediated dilatation (A. brachialis)\n[ Time Frame: Decembre 2014 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Aortic distensibility (MRI), pulse wave velocity (SphygmoCor®), flow-mediated dilatation (A. brachialis)\n[ Time Frame: Decembre 2014 ]""}]
NCT01769105	Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime	Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial	10.1016/j.jtos.2013.12.001	https://www.ncbi.nlm.nih.gov/pubmed/24725326	5	2013-01-15	Completed	2012-03-01	2013-07-01	2014-01-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome mearure (OSDI)""}]	[See Results Section.]	NA
NCT01770080	Efficacy of Euminz® for Tension-Type Headache	NA	10.1055/s-0037-1607119	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0037-1607119	4	2013-01-15	Completed	2013-02-01	2015-09-01	2017-09-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First primary objective of the first headache episode is \""pain-free\"" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS).\n[ Time Frame: 2 hours ]\n\nAcute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First primary objective of the first headache episode is \""pain-free\"" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS).\n[ Time Frame: 2 hours ]\n\nAcute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First primary objective of the first headache episode is \""pain-free\"" (0 or 1) after 2 hours measured on a six-step verbal pain rating scale (VPRS).\n[ Time Frame: 2 hours ]\n\nAcute treatment (3 to 5 time topical use of Euminz®) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).""}]	NA	NA
NCT01770990	Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive Mail	Effectiveness of Telephone-Administered Cognitive-Behavioral Psychotherapy for Depression With Versus Without Additional Letters: A Randomized Controlled Trial	10.1089/tmj.2018.0311	https://www.liebertpub.com/doi/abs/10.1089/tmj.2018.0311	4	2013-01-15	Completed	2012-09-01	2015-05-01	2020-03-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression symptom severity (PHQ-D-9)\n[ Time Frame: Baseline, approximately 3 months (end of treatment) ]\n\nChange in patient-rated depression symptom severity: Patient Health Questionnaire 9, German version (PHQ-D-9; Löwe, Zipfel & Herzog, 2002)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression symptom severity (PHQ-D-9)\n[ Time Frame: Baseline, approximately 3 months (end of treatment) ]\n\nChange in patient-rated depression symptom severity: Patient Health Questionnaire 9, German version (PHQ-D-9; Löwe, Zipfel & Herzog, 2002)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression symptom severity (PHQ-D-9)\n[ Time Frame: Baseline, approximately 3 months (end of treatment) ]\n\nChange in patient-rated depression symptom severity: Patient Health Questionnaire 9, German version (PHQ-D-9; Löwe, Zipfel & Herzog, 2002)""}]	NA	NA
NCT01773902	Protein for Premies	Effect of Increased Enteral Protein Intake on Growth in Human Milk-Fed Preterm Infants: A Randomized Clinical Trial	10.1001/jamapediatrics.2016.2681	https://jamanetwork.com/journals/jamapediatrics/fullarticle/2587682	5	2013-01-18	Completed	2012-10-01	2014-12-01	2016-11-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight gain\n[ Time Frame: From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight gain\n[ Time Frame: From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight gain\n[ Time Frame: From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight gain\n[ Time Frame: From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA) ]""}]	NA
NCT01774838	Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome	Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial	10.1016/j.ijcard.2017.06.099	https://pubmed.ncbi.nlm.nih.gov/28709700/	3	2013-01-21	Completed	2014-10-01	2015-06-01	2017-07-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer\n[ Time Frame: baseline and after 3 months ]\n\nThe primary endpoint is the change of endothelial function given in % from baseline to 3 months after therapy with prasugrel versus clopidogrel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer\n[ Time Frame: baseline and after 3 months ]\n\nThe primary endpoint is the change of endothelial function given in % from baseline to 3 months after therapy with prasugrel versus clopidogrel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer\n[ Time Frame: baseline and after 3 months ]\n\nThe primary endpoint is the change of endothelial function given in % from baseline to 3 months after therapy with prasugrel versus clopidogrel.""}]	NA	NA
NCT01776112	Enhancing Synaptic Plasticity and Cognition in Schizophrenia	Hippocampal plasticity in response to exercise in schizophrenia	10.1001/archgenpsychiatry.2009.193	https://pubmed.ncbi.nlm.nih.gov/20124113/	3	2013-01-22	Completed	2011-01-01	2014-03-01	2010-02-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hippocampal volume\n[ Time Frame: after three months of exercise ]\n\nMeasurement of hippocampal volume before and after the exercise intervention, 3T-MRI MPRAGE-Sequence, manual and automated delineation of hippocampal borders""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hippocampal volume\n[ Time Frame: after three months of exercise ]\n\nMeasurement of hippocampal volume before and after the exercise intervention, 3T-MRI MPRAGE-Sequence, manual and automated delineation of hippocampal borders""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hippocampal volume\n[ Time Frame: after three months of exercise ]\n\nMeasurement of hippocampal volume before and after the exercise intervention, 3T-MRI MPRAGE-Sequence, manual and automated delineation of hippocampal borders""}]	NA
NCT01782365	Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Patients With Mild Cognitive Impairment	Promoting Sleep Oscillations and Their Functional Coupling by Transcranial Stimulation Enhances Memory Consolidation in Mild Cognitive Impairment	10.1523/jneurosci.0260-17.2017	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705731/	9	2013-01-31	Completed	2013-04-01	2016-08-01	2017-07-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 Weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 Weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 Weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 Weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	NA
NCT01782391	Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Patients With Mild Cognitive Impairments	Promoting Sleep Oscillations and Their Functional Coupling by Transcranial Stimulation Enhances Memory Consolidation in Mild Cognitive Impairment	10.1523/jneurosci.0260-17.2017	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705731/	9	2013-01-31	Withdrawn	2013-01-01	NA	2017-07-26	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]
NCT01785082	Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test	Randomized clinical trial comparing liver resection with and without perioperative assessment of liver function	10.1002/bjs5.81	https://pubmed.ncbi.nlm.nih.gov/30263981/	3	2013-02-04	Completed	2013-01-01	2015-09-01	2018-06-14	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of correctly determined positive patients in each trial group\n[ Time Frame: no later than day 30 after surgery ]\n\nCorrectly determined positive patients are patients which are transferred to general ward after surgery because of the result of the LiMAx-test (LiMAx-group) or general diagnosis (control group). Patients have to stay at general ward until discharge no later than day 30 after surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of correctly determined positive patients in each trial group\n[ Time Frame: no later than day 30 after surgery ]\n\nCorrectly determined positive patients are patients which are transferred to general ward after surgery because of the result of the LiMAx-test (LiMAx-group) or general diagnosis (control group). Patients have to stay at general ward until discharge no later than day 30 after surgery.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of correctly determined positive patients in each trial group\n[ Time Frame: no later than day 30 after surgery ]\n\nCorrectly determined positive patients are patients which are transferred to general ward after surgery because of the result of the LiMAx-test (LiMAx-group) or general diagnosis (control group). Patients have to stay at general ward until discharge no later than day 30 after surgery.""}]	NA
NCT01785186	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial	10.1016/s1473-3099(16)30274-2	NA	8	2013-02-04	Completed	2013-04-01	2014-09-01	2016-10-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[See Results Section.]	NA
NCT01788800	Physical Activity and Cognitive Behavioural Therapy in Panic Disorder	NA	NA	http://www.sciencedirect.com/science/article/pii/S0022395614002052	2	2013-02-08	Completed	2009-01-01	2013-03-01	2014-07-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: up to 28 weeks (follow up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: up to 28 weeks (follow up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: up to 28 weeks (follow up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	NA	NA
NCT01791790	Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Elderly Healthy Subjects	Boosting Slow Oscillatory Activity Using tDCS during Early Nocturnal Slow Wave Sleep Does Not Improve Memory Consolidation in Healthy Older Adults	10.1016/j.brs.2016.04.016	https://pubmed.ncbi.nlm.nih.gov/27247261/	9	2013-02-13	Completed	2013-01-01	2017-12-01	2016-04-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	NA
NCT01792713	Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis	Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability	10.2340/00015555-2268	https://www.ncbi.nlm.nih.gov/pubmed/26527564	2	2013-02-14	Completed	2013-02-01	2013-09-01	2016-08-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Patient Global Assessment (PGA)\n[ Time Frame: day 1, day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Patient Global Assessment (PGA)\n[ Time Frame: day 1, day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Patient Global Assessment (PGA)\n[ Time Frame: day 1, day 28 ]""}]	NA	NA
NCT01793558	Incidence and Prevention of Hypothermia in Newborns Bonding During Caesarean Section	The incidence and prevention of hypothermia in newborn bonding after cesarean delivery: a randomized controlled trial	10.1213/ane.0000000000000160	https://www.ncbi.nlm.nih.gov/pubmed/24681658	3	2013-02-14	Completed	2013-02-01	2013-04-01	2014-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body core temperature of the newborn\n[ Time Frame: 20 min after birth ]\n\nCore temperature of the infants will be measured with specific probes 20 min after birth (end of bonding period)by a rectal temperature probe.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body core temperature of the newborn\n[ Time Frame: 20 min after birth ]\n\nCore temperature of the infants will be measured with specific probes 20 min after birth (end of bonding period)by a rectal temperature probe.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body core temperature of the newborn\n[ Time Frame: 20 min after birth ]\n\nCore temperature of the infants will be measured with specific probes 20 min after birth (end of bonding period)by a rectal temperature probe.""}]	NA	NA
NCT01795040	Efficacy of Omega-3/Omega-6 Fatty Acids in Pre-school Children at Risk for ADHD	Efficacy of Omega-3/Omega-6 Fatty Acids in Preschool Children at Risk of ADHD: A Randomized Placebo-Controlled Trial	10.1177/1087054719883023	https://journals.sagepub.com/doi/abs/10.1177/1087054719883023	3	2013-02-16	Unknown status	2010-09-01	NA	2019-11-02	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Symptom Checklist for pre-school children with ADHD symptoms (FBB-ADHS-V) total score rated by parents and teachers\n[ Time Frame: Change from pre- assessment to post assessment four months after treatment begin and to post assessment eight months after treatment begin ]\n\nThe FBB-ADHS-V Questionnaire is a developed parent and teacher rating scale which assesses several factors of hyperactivity, impulsivity and inattention problems in pre-school or at home.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Symptom Checklist for pre-school children with ADHD symptoms (FBB-ADHS-V) total score rated by parents and teachers\n[ Time Frame: Change from pre- assessment to post assessment four months after treatment begin and to post assessment eight months after treatment begin ]\n\nThe FBB-ADHS-V Questionnaire is a developed parent and teacher rating scale which assesses several factors of hyperactivity, impulsivity and inattention problems in pre-school or at home.""}]
NCT01795482	Preoperative Patient Warming for Prevention of Perioperative Hypothermia in Major Abdominal Surgery	Warming before and after epidural block before general anaesthesia for major abdominal surgery prevents perioperative hypothermia: A randomised controlled trial	10.1097/eja.0000000000000369	https://pubmed.ncbi.nlm.nih.gov/26555870/	4	2013-02-19	Completed	2013-02-01	2014-08-01	2016-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic patients at arrival at PACU\n[ Time Frame: 2 hours ]\n\nAfter the operation patients will be admitted to the PACU. Here, body temperature will be assessed and the incidence of hypothermic patients (body temperature < 36°C)will be measured.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic patients at arrival at PACU\n[ Time Frame: 2 hours ]\n\nAfter the operation patients will be admitted to the PACU. Here, body temperature will be assessed and the incidence of hypothermic patients (body temperature < 36°C)will be measured.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of hypothermic patients at arrival at PACU\n[ Time Frame: 2 hours ]\n\nAfter the operation patients will be admitted to the PACU. Here, body temperature will be assessed and the incidence of hypothermic patients (body temperature < 36°C)will be measured.""}]	NA	NA
NCT01797458	European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth	Alternative Caries Management Options for Primary Molars: 2.5-Year Outcomes of a Randomised Clinical Trial	10.1159/000477855	https://pubmed.ncbi.nlm.nih.gov/29258064/	3	2013-02-21	Completed	2011-05-01	2013-12-01	2017-12-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Failure rate of the three treatment arms judged clinically\n[ Time Frame: up to 2 years ]\n\nFailure rate of the three treatment arms judged clinically after 1 and 2 years such as clear caries progression, secondary caries, loss of restoration, reversible pulpitis treated without requiring pulpotomy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Failure rate of the three treatment arms judged clinically\n[ Time Frame: up to 2 years ]\n\nFailure rate of the three treatment arms judged clinically after 1 and 2 years such as clear caries progression, secondary caries, loss of restoration, reversible pulpitis treated without requiring pulpotomy""}]	[See Results Section.]	NA	NA
NCT01797484	Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia	Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial	10.1177/1074248418784290	https://journals.sagepub.com/doi/10.1177/1074248418784290	6	2013-02-20	Completed	2013-07-01	2015-06-01	2018-06-24	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area of ischemic myocardium/cm² (longitudinal strain, radial/circumferential strain)\n[ Time Frame: 42 days after first dose of Ranolazine ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area of ischemic myocardium/cm² (longitudinal strain, radial/circumferential strain)\n[ Time Frame: 42 days after first dose of Ranolazine ]""}]	[See Results Section.]	NA	NA
NCT01797601	Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application	Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults	10.2337/dc14-2319	https://care.diabetesjournals.org/content/38/6/1044.long	3	2013-02-20	Completed	2013-02-01	2014-04-01	2015-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin effect on regional brain activity assessed by fMRI\n[ Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin effect on regional brain activity assessed by fMRI\n[ Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin effect on regional brain activity assessed by fMRI\n[ Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Insulin effect on regional brain activity assessed by fMRI\n[ Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application ]""}]	NA
NCT01797861	Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy	Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol	10.1111/aos.12938	https://pubmed.ncbi.nlm.nih.gov/26670630/	7	2013-02-21	Completed	2013-12-01	2017-05-01	2015-12-15	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of subretinal fluid on OCT scan\n[ Time Frame: 6-8 weeks after treatment ]\n\nThe primary endpoint of this study is to assess if there is a difference between the efficacy of half-dose photodynamic therapy treatment versus micropulse laser treatment in patients with chronic central serous chorioretinopathy. The assessment of this efficacy will be based on the anatomical effect on optical coherence tomography (OCT): absence of subretinal fluid versus persistent subretinal fluid, 6-8 weeks after treatment. After all, the absence or presence of fluid under the retina on the OCT scan is a direct reflection of the activity of the disease in these patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of subretinal fluid on OCT scan\n[ Time Frame: 6-8 weeks after treatment ]\n\nThe primary endpoint of this study is to assess if there is a difference between the efficacy of half-dose photodynamic therapy treatment versus micropulse laser treatment in patients with chronic central serous chorioretinopathy. The assessment of this efficacy will be based on the anatomical effect on optical coherence tomography (OCT): absence of subretinal fluid versus persistent subretinal fluid, 6-8 weeks after treatment. After all, the absence or presence of fluid under the retina on the OCT scan is a direct reflection of the activity of the disease in these patients.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of subretinal fluid on OCT scan\n[ Time Frame: 6-8 weeks after treatment ]\n\nThe primary endpoint of this study is to assess if there is a difference between the efficacy of half-dose photodynamic therapy treatment versus micropulse laser treatment in patients with chronic central serous chorioretinopathy. The assessment of this efficacy will be based on the anatomical effect on optical coherence tomography (OCT): absence of subretinal fluid versus persistent subretinal fluid, 6-8 weeks after treatment. After all, the absence or presence of fluid under the retina on the OCT scan is a direct reflection of the activity of the disease in these patients.""}]	NA
NCT01797887	Ayurvedic Versus Conventional Counseling in Mothers With Burnout-Syndrome	Ayurvedic versus conventional dietary and lifestyle counseling for mothers with burnout-syndrome: A randomized controlled pilot study including a qualitative evaluation	10.1016/j.ctim.2017.07.005	https://pubmed.ncbi.nlm.nih.gov/28917376/	5	2013-02-22	Completed	2013-05-01	2014-12-01	2017-07-16	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maslach-Burnout-Inventory (MBI)\n[ Time Frame: 3 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maslach-Burnout-Inventory (MBI)\n[ Time Frame: 3 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maslach-Burnout-Inventory (MBI)\n[ Time Frame: 3 month ]""}]	NA	NA
NCT01798160	Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).	Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma	10.1007/s00270-014-1012-0	https://www.ncbi.nlm.nih.gov/pubmed/25373796	2	2013-02-21	Completed	2010-02-01	2013-03-01	2014-11-07	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free-Survival\n[ Time Frame: up to three years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Overall-Survival\n[ Time Frame: up to three years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free-Survival\n[ Time Frame: up to three years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Overall-Survival\n[ Time Frame: up to three years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free-Survival\n[ Time Frame: up to three years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Overall-Survival\n[ Time Frame: up to three years ]""}]	NA
NCT01799005	FLAVIOLA Health Study	Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study	10.1017/s0007114515002822	https://pubmed.ncbi.nlm.nih.gov/26348767/	7	2013-02-24	Completed	2012-08-01	2014-08-01	2015-10-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Time points: day 0 [baseline], and day 30 each 0 and 2h. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Time points: day 0 [baseline], and day 30 each 0 and 2h. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Time points: day 0 [baseline], and day 30 each 0 and 2h. ]""}]	NA	NA
NCT01801280	Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study	10.1111/bcp.12664	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.12664	3	2013-02-26	Completed	2012-01-01	2013-03-01	2015-04-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioavailability of mycophenolic acid (measured by AUC)\n[ Time Frame: Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours. ]\n\n\n\nEvaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with Pantozol®; Myfortic® alone or in combination with Pantozol®.\n\nFor pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioavailability of mycophenolic acid (measured by AUC)\n[ Time Frame: Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours. ]\n\n\n\nEvaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with Pantozol®; Myfortic® alone or in combination with Pantozol®.\n\nFor pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.""}]	NA	[See Results Section.]	NA
NCT01803789	Single Versus Double Kirschner Wires for Intramedullary Fixation of Metacarpal V Fractures	Single versus dual Kirschner wires for closed reduction and intramedullary nailing of displaced fractures of the fifth metacarpal neck (1-2 KiWi): a randomized controlled trial	10.1302/0301-620x.101b10.bjj-2019-0410.r1	https://pubmed.ncbi.nlm.nih.gov/31564142/	5	2013-03-01	Completed	2013-05-01	2017-06-01	2019-10-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences in functional outcome of the therapy with single or double Kirschner wires measured with the DASH score\n[ Time Frame: 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences in functional outcome of the therapy with single or double Kirschner wires measured with the DASH score\n[ Time Frame: 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Differences in functional outcome of the therapy with single or double Kirschner wires measured with the DASH score\n[ Time Frame: 6 months after randomisation ]""}]	NA	NA
NCT01806012	Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy	A prospective, randomized clinical comparison between UltraCision and the novel sealing and cutting device BiCision in patients with laparoscopic supracervical hysterectomy	10.1007/s00464-013-2994-4	NA	1	2013-03-05	Completed	2010-08-01	2011-08-01	2013-05-14	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Operation time\n[ Time Frame: Day 1 ]\n\nThe following times were documented: total operation time; T1 = start of the operation until cornual structures were ready to be dissected; T2 = the time from the first coagulation and cutting of the cornual structures until the complete preparation of each parametrial side directly before cervical detachment; T3 = time needed for the cervical detachment and subsequent steps (morcellation, closure of trocar sites) until the end of the surgical procedure.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Operation time\n[ Time Frame: Day 1 ]\n\nThe following times were documented: total operation time; T1 = start of the operation until cornual structures were ready to be dissected; T2 = the time from the first coagulation and cutting of the cornual structures until the complete preparation of each parametrial side directly before cervical detachment; T3 = time needed for the cervical detachment and subsequent steps (morcellation, closure of trocar sites) until the end of the surgical procedure.""}]	NA	NA
NCT01811589	Guided Application of Ventricular Catheters	GAVCA Study: Randomized, Multicenter Trial to Evaluate the Quality of Ventricular Catheter Placement with a Mobile Health Assisted Guidance Technique	10.1093/neuros/nyx420	https://pubmed.ncbi.nlm.nih.gov/28973670/	7	2013-03-13	Completed	2013-05-01	2015-01-01	2018-08-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of he primary successful ventricular catheter placement with a Grade I or Grade I b and location in the ipsilateral ventricle\n[ Time Frame: Within the first 40 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of he primary successful ventricular catheter placement with a Grade I or Grade I b and location in the ipsilateral ventricle\n[ Time Frame: Within the first 40 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of he primary successful ventricular catheter placement with a Grade I or Grade I b and location in the ipsilateral ventricle\n[ Time Frame: Within the first 40 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of he primary successful ventricular catheter placement with a Grade I or Grade I b and location in the ipsilateral ventricle\n[ Time Frame: Within the first 40 days ]""}]	NA
NCT01811966	Preoperative Volume Substitution in Elective Surgery Patients	Pre-operative fluid bolus for improved haemodynamic stability during minor surgery: A prospectively randomized clinical trial	10.1111/aas.13157	https://pubmed.ncbi.nlm.nih.gov/29851024/	3	2013-03-14	Completed	2013-03-01	2015-02-01	2018-05-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hemodynamic instability\n[ Time Frame: at time of introduction of anesthesia ]\n\n\n\nHemodynamic instability during induction of anesthesia (0-10 min), defined as at least one of the following:\n\nSystolic blood pressure < 80 mmHg or decrease of 20% in preexistent hypertension\nMean blood pressure < 50 mmHg or decrease of 20% or > 20 mmHg in preexistent hypertension\nBradycardia < 45/min or decrease of 20% in preexistent bradycardia < 60/min.\nTachycardia > 120/min\nCardiac index < 2.0 l/min/m²""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hemodynamic instability\n[ Time Frame: at time of introduction of anesthesia ]\n\n\n\nHemodynamic instability during induction of anesthesia (0-10 min), defined as at least one of the following:\n\nSystolic blood pressure < 80 mmHg or decrease of 20% in preexistent hypertension\nMean blood pressure < 50 mmHg or decrease of 20% or > 20 mmHg in preexistent hypertension\nBradycardia < 45/min or decrease of 20% in preexistent bradycardia < 60/min.\nTachycardia > 120/min\nCardiac index < 2.0 l/min/m²""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hemodynamic instability\n[ Time Frame: at time of introduction of anesthesia ]\n\n\n\nHemodynamic instability during induction of anesthesia (0-10 min), defined as at least one of the following:\n\nSystolic blood pressure < 80 mmHg or decrease of 20% in preexistent hypertension\nMean blood pressure < 50 mmHg or decrease of 20% or > 20 mmHg in preexistent hypertension\nBradycardia < 45/min or decrease of 20% in preexistent bradycardia < 60/min.\nTachycardia > 120/min\nCardiac index < 2.0 l/min/m²""}]	NA	NA
NCT01812291	Evaluation of a Stepped Care Approach to Manage Depression in Diabetes	Assessment of diabetes acceptance can help identify patients with ineffective diabetes self-care and poor diabetes control	10.1111/dme.12553	https://pubmed.ncbi.nlm.nih.gov/25047992/	5	2013-03-14	Completed	2012-02-01	2015-10-01	2014-08-02	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood (HAMD)\n[ Time Frame: Baseline, 12 month follow up ]\n\nThe Hamilton Rating Scale for Depression (HAMD) is used to assess levels of depressive mood. The decisive measurement of this primary outcome variable is conducted 12 months after the treatment (12 month follow up). The difference of the HAMD scores between baseline and 12 month follow up is calculated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood - Hamilton Rating Scale for Depression (HAMD)\n[ Time Frame: 12 month ]\n\nMean difference between HAMD scores at baseline and at 12 month follow up""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood - Hamilton Rating Scale for Depression (HAMD)\n[ Time Frame: 12 month ]\n\nMean difference between HAMD scores at baseline and at 12 month follow up""}]	NA
NCT01812304	Theoretical Compared With hands-on Training of Vaginal Breech Management	Objective Structured Assessment of Technical Skills (OSATS) evaluation of theoretical versus hands-on training of vaginal breech delivery management: a randomized trial	10.1016/j.ejogrb.2013.09.015	https://www.ncbi.nlm.nih.gov/pubmed/24103530	2	2013-03-13	Completed	2011-10-01	2013-10-01	2013-09-25	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: probands are tested after training within an hour ]\n\nOSATS Scores are assessed on a pelvic model by a blinded assessor immediately after training (1 arm hands-on, 1 arm forntal teaching)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: probands are tested after training within an hour ]\n\nOSATS Scores are assessed on a pelvic model by a blinded assessor immediately after training (1 arm hands-on, 1 arm forntal teaching)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS Score\n[ Time Frame: probands are tested after training within an hour ]\n\nOSATS Scores are assessed on a pelvic model by a blinded assessor immediately after training (1 arm hands-on, 1 arm forntal teaching)""}]	NA
NCT01812616	A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients	NA	10.1200/jco.2017.35.15_suppl.2046	https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2046	10	2013-03-14	Completed	2013-09-01	2015-10-01	2017-05-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of Adverse Events as a Measure of Patient Safety.\n[ Time Frame: Study Day 1 - Day 358 ]\n\nAdverse events will be coded according to the current medical dictionary for regular activities graded using the Common Terminology Criteria for Adverse Events criteria. The number of patients who experienced an adverse event whilst on treatment will be presented.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of Adverse Events as a Measure of Patient Safety.\n[ Time Frame: Study Day 1 - Day 358 ]\n\nAdverse events will be coded according to the current medical dictionary for regular activities graded using the Common Terminology Criteria for Adverse Events criteria. The number of patients who experienced an adverse event whilst on treatment will be presented.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of Adverse Events as a Measure of Patient Safety.\n[ Time Frame: Study Day 1 - Day 358 ]\n\nAdverse events will be coded according to the current medical dictionary for regular activities graded using the Common Terminology Criteria for Adverse Events criteria. The number of patients who experienced an adverse event whilst on treatment will be presented.""}]	NA	NA
NCT01816386	Acupuncture Trial for Post Anaesthetic Recovery and Postoperative Pain	NA	10.1038/s41598-018-33459-y	NA	2	2013-03-21	Completed	2012-06-01	2014-06-01	2018-10-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is the assessment of the effects of permanent needle acupuncture at 12 acupuncture points for improving post anaesthetic recovery.\n[ Time Frame: The time from extubation to \""Ready for discharge\"" (in minutes) will followed for the duration in the recovery unit, an expected average of 1 hour ]\n\nTime from extubation to \""Ready for discharge\"" (in minutes) from the PACU as assessed by the Aldrete score, the Post Anaesthetic Discharge Scoring System (PADSS) and our 'in-house' scoring system when comparing the acupuncture group and the standard treatment group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is the assessment of the effects of permanent needle acupuncture at 12 acupuncture points for improving post anaesthetic recovery.\n[ Time Frame: The time from extubation to \""Ready for discharge\"" (in minutes) will followed for the duration in the recovery unit, an expected average of 1 hour ]\n\nTime from extubation to \""Ready for discharge\"" (in minutes) from the PACU as assessed by the Aldrete score, the Post Anaesthetic Discharge Scoring System (PADSS) and our 'in-house' scoring system when comparing the acupuncture group and the standard treatment group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is the assessment of the effects of permanent needle acupuncture at 12 acupuncture points for improving post anaesthetic recovery.\n[ Time Frame: The time from extubation to \""Ready for discharge\"" (in minutes) will followed for the duration in the recovery unit, an expected average of 1 hour ]\n\nTime from extubation to \""Ready for discharge\"" (in minutes) from the PACU as assessed by the Aldrete score, the Post Anaesthetic Discharge Scoring System (PADSS) and our 'in-house' scoring system when comparing the acupuncture group and the standard treatment group.""}]	NA	NA
NCT01817738	Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006314-14/results	7	2013-03-22	Terminated	2012-08-01	2016-09-01	2018-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	NA	NA
NCT01818115	Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.	A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma	10.1016/j.ophtha.2015.03.031	https://pubmed.ncbi.nlm.nih.gov/25972254/	5	2013-03-25	Completed	2011-01-01	2013-04-01	2015-05-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.\n[ Time Frame: 12 months ]\n\nA 24 month visit will be conducted to confirm 12 month findings.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.\n[ Time Frame: 12 months ]\n\nA 24 month visit will be conducted to confirm 12 month findings.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in proportion of subjects with 20% reduction in mean diurnal Intraocular Pressure (IOP) at 24 months following the wash-out of all glaucoma medications.\n[ Time Frame: 24 months ]\n\nThe 24 month diurnal IOP will be compared to the baseline value and a % change will be determined for each subject. A 20% drop in diurnal IOP is a successful response to treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in proportion of subjects with 20% reduction in mean diurnal Intraocular Pressure (IOP) at 24 months following the wash-out of all glaucoma medications.\n[ Time Frame: 24 months ]\n\nThe 24 month diurnal IOP will be compared to the baseline value and a % change will be determined for each subject. A 20% drop in diurnal IOP is a successful response to treatment.""}]	NA
NCT01820702	Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation	Musculoskeletal effects of 5 days of bed rest with and without locomotion replacement training	10.1007/s00421-014-3045-0	https://www.ncbi.nlm.nih.gov/pubmed/25425257	1	2013-03-26	Completed	2010-11-01	2011-05-01	2014-11-26	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal knee extensor and plantar flexor muscle force\n[ Time Frame: Baseline, after 5 days of bed rest ]\n\nThe maximal voluntary isometric force (MVC) was assessed before and following bed rest. MVC measurements were obtained from the left leg using the Biodex 3 system (Biodex Medical Systems, Shirley, New York, USA).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal knee extensor and plantar flexor muscle force\n[ Time Frame: Baseline, after 5 days of bed rest ]\n\nThe maximal voluntary isometric force (MVC) was assessed before and following bed rest. MVC measurements were obtained from the left leg using the Biodex 3 system (Biodex Medical Systems, Shirley, New York, USA).""}]	NA	NA
NCT01831947	Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.	Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial	10.1007/s00417-017-3589-x	NA	1	2013-04-11	Completed	2010-04-01	2013-03-01	2017-01-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""best-corrected visual acuity\n[ Time Frame: 12 months after start of treatment ]\n\nChange of best-corrected visual acuity before and 12 months after start of treatment with respect to number of letters read on ETDRS-sheets (Early Treatment Diabetes Retinopathy Study Sheets).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""best-corrected visual acuity\n[ Time Frame: 12 months after start of treatment ]\n\nChange of best-corrected visual acuity before and 12 months after start of treatment with respect to number of letters read on ETDRS-sheets (Early Treatment Diabetes Retinopathy Study Sheets).""}]	NA	NA
NCT01832389	Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage	Impact of Goal-Directed Therapy on Delayed Ischemia After Aneurysmal Subarachnoid Hemorrhage: Randomized Controlled Trial	10.1161/strokeaha.120.029279	NA	4	2013-04-11	Completed	2013-03-01	2015-11-01	2020-07-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours or a ≥ 2-point decrease in the Glasgow Coma Scale (GCS) lasting for at least 8 hours (as signs of a new focal neurological deficit); and/or radiologic signs of cerebral infarction in presence of vasospasm. other causes of neurological aggravation (e.g. hydrocephalus, re-bleeding etc) had to be excluded.""}]	NA	NA
NCT01833052	CLaret Embolic Protection ANd TAVI - Trial	Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial	10.1001/jama.2016.10302	https://pubmed.ncbi.nlm.nih.gov/27532914/	2	2013-04-15	Unknown status	2013-04-01	NA	2016-08-09	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate and Size of Cerebral Embolism\n[ Time Frame: 2 days after Intervention ]\n\nPrimary endpoint ist the rate and the size of cerebral embolism in postinterventional Magnetic Resonance Imaging (MRI).""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate and Size of Cerebral Embolism\n[ Time Frame: 2 days after Intervention ]\n\nPrimary endpoint ist the rate and the size of cerebral embolism in postinterventional Magnetic Resonance Imaging (MRI).""}]
NCT01834547	Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players	Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial	10.1016/j.euroneuro.2017.01.006	https://www.ncbi.nlm.nih.gov/pubmed/28119083	1	2013-04-17	Completed	2011-05-01	2013-04-01	2017-01-22	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chess games (win/ lose/ tie)\n[ Time Frame: two years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chess games (win/ lose/ tie)\n[ Time Frame: two years ]""}]	NA	NA
NCT01834573	Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.	The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial	10.1159/000371795	https://www.ncbi.nlm.nih.gov/pubmed/25823689	2	2013-04-17	Completed	2013-04-01	2013-09-01	2015-03-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 10 weeks ]""}]	NA	NA
NCT01835678	Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial	10.1007/s00125-016-4083-4	https://pubmed.ncbi.nlm.nih.gov/27586249/	4	2013-04-18	Completed	2012-10-01	2014-02-01	2016-09-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature\n[ Time Frame: Changes from baseline after 4 weeks of treatment with linagliptin and placebo ]\n\nThe primary objective of the study is the change of renal plasma flow to LNMMA infusion from baseline (given in ml/min) to determine the effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature\n[ Time Frame: Changes from baseline after 4 weeks of treatment with linagliptin and placebo ]\n\nThe primary objective of the study is the change of renal plasma flow to LNMMA infusion from baseline (given in ml/min) to determine the effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature\n[ Time Frame: Changes from baseline after 4 weeks of treatment with linagliptin and placebo ]\n\nThe primary objective of the study is the change of renal plasma flow to LNMMA infusion from baseline (given in ml/min) to determine the effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature\n[ Time Frame: Changes from baseline after 4 weeks of treatment with linagliptin and placebo ]\n\nThe primary objective of the study is the change of renal plasma flow to LNMMA infusion from baseline (given in ml/min) to determine the effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature.""}]	NA
NCT01837901	Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa	Transcorneal Electrical Stimulation for Patients With Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year	10.1167/iovs.16-19906	https://iovs.arvojournals.org/article.aspx?articleid=2599022	3	2013-04-22	Completed	2011-07-01	2013-08-01	2017-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[See Results Section.]	NA
NCT01839084	PaNeX: Partial Nephrectomy Under Xenon	Better haemodynamic stability under xenon anaesthesia than under isoflurane anaesthesia during partial nephrectomy - a secondary analysis of a randomised controlled trial	10.1186/s12871-019-0799-2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617591/	7	2013-04-19	Completed	2013-07-01	2016-03-01	2019-07-09	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the impact of xenon-anesthesia on the renal function after partial nephrectomy, compared to an isoflurane-anesthesia.\n[ Time Frame: Within the first 7 postoperative days ]\n\nEvaluation of the maximum decrease of glomerular filtration rate (GFR) within 7 days after partial nephrectomy surgery. Maximum decrease will be assessed by the difference between the baseline value of GFR and the minimum value of GFR after surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the impact of xenon-anesthesia on the renal function after partial nephrectomy, compared to an isoflurane-anesthesia.\n[ Time Frame: Within the first 7 postoperative days ]\n\nEvaluation of the maximum decrease of glomerular filtration rate (GFR) within 7 days after partial nephrectomy surgery. Maximum decrease will be assessed by the difference between the baseline value of GFR and the minimum value of GFR after surgery.""}]	NA	NA	NA
NCT01840839	Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults	Brain stimulation during an afternoon nap boosts slow oscillatory activity and memory consolidation in older adults	10.1016/j.neuroimage.2016.06.057	https://pubmed.ncbi.nlm.nih.gov/27381076/	8	2013-04-25	Completed	2013-03-01	2015-05-01	2016-07-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS\n[ Time Frame: 4 weeks ]\n\nRetention between stimulation conditions (0.75 Hz during SWS, vs sham stimulation during SWS) in the declarative memory task.""}]	NA
NCT01845129	Impact of Transcranial Direct Current Stimulation of the Motor Cortex on Language Functions in Residual Aphasia	Transcranial direct current stimulation effects on neural processing in post-stroke aphasia	10.1002/hbm.23469	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6866985/	1	2013-04-30	Unknown status	NA	NA	2016-11-11	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response latency during picture naming task (max. 80)\n[ Time Frame: Change in response latency between assessment 1 (week 1) and assessment 2 (week 2), assessments 1 and 2 are seperated by one week ]\n\nSubjects are assessed in a cross-over design. The primary outcome measure will be assessed twice in each subject, either during placebo (\""sham) stimulation or active (anodal) stimulation with transcranial direct current stimulation. Order of stimulation will be counterbalanced across the group.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response latency during picture naming task (max. 80)\n[ Time Frame: Change in response latency between assessment 1 (week 1) and assessment 2 (week 2), assessments 1 and 2 are seperated by one week ]\n\nSubjects are assessed in a cross-over design. The primary outcome measure will be assessed twice in each subject, either during placebo (\""sham) stimulation or active (anodal) stimulation with transcranial direct current stimulation. Order of stimulation will be counterbalanced across the group.""}]
NCT01845142	Immunologic Action of a Single Dose Cholecalciferol	Pharmacokinetic Evaluation of a Single Intramuscular High Dose versus an Oral Long-Term Supplementation of Cholecalciferol	10.1371/journal.pone.0169620	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256876/	4	2013-05-02	Completed	2013-02-01	2013-05-01	2017-01-23	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the numbers of vitamin D-responsive B cells after vitamin D administration.\n[ Time Frame: up to 3 months ]\n\nPeripheral B cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry. Vitamin D-responsive B cells will be quantified before and 1 week, 1 month and 3 months after vitamin D administration.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the numbers of vitamin D-responsive B cells after vitamin D administration.\n[ Time Frame: up to 3 months ]\n\nPeripheral B cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry. Vitamin D-responsive B cells will be quantified before and 1 week, 1 month and 3 months after vitamin D administration.""}]	NA	NA
NCT01850875	Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain	Eye Movement Desensitization and Reprocessing vs. Treatment-as-Usual for Non-Specific Chronic Back Pain Patients with Psychological Trauma: A Randomized Controlled Pilot Study	10.3389/fpsyt.2016.00201	https://pubmed.ncbi.nlm.nih.gov/28066274/	5	2013-05-07	Completed	2013-05-01	2014-11-01	2016-12-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pain intensity\n[ Time Frame: Change from Baseline Pain intensity at average 6 months ]\n\nNumerical rating scale 0-10""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pain intensity\n[ Time Frame: Change from Baseline Pain intensity at average 6 months ]\n\nNumerical rating scale 0-10""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pain intensity\n[ Time Frame: Change from Baseline Pain intensity at average 6 months ]\n\nNumerical rating scale 0-10""}]	NA	NA
NCT01852526	Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Lumbar-spine Fusion	Material failure in dynamic spine implants: are the standardized implant tests before market launch sufficient?	10.1007/s00586-019-05880-y	https://pubmed.ncbi.nlm.nih.gov/30649613/	3	2013-05-08	Terminated	2013-03-01	2017-02-01	2019-01-16	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Oswestry Disability Index\n[ Time Frame: 6 month ]\n\nODI (cross-cultural adaption of the ODI version 2.1 for use with German-speaking patients) - this is one of the condition-specific questionnaires recommended for use with back pain patients. The ODI is a standardized, patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living for those rehabilitating from low back pain. The questionnaire examines perceived level of disability in 10 everyday activities of daily living""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Oswestry Disability Index\n[ Time Frame: 6 month ]\n\nODI (cross-cultural adaption of the ODI version 2.1 for use with German-speaking patients) - this is one of the condition-specific questionnaires recommended for use with back pain patients. The ODI is a standardized, patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living for those rehabilitating from low back pain. The questionnaire examines perceived level of disability in 10 everyday activities of daily living""}]	NA	NA	NA
NCT01853384	Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers	Baseline factors affecting closure of venous leg ulcers	10.1016/j.jvsv.2017.06.017	https://pubmed.ncbi.nlm.nih.gov/29037354/	10	2013-05-10	Terminated	2013-11-01	2015-12-01	2017-11-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with complete wound closure over the treatment period.\n[ Time Frame: 12 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with complete wound closure over the treatment period.\n[ Time Frame: 12 Weeks ]""}]	[See Results Section.]	NA	NA
NCT01855035	Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring	Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial	10.1016/s1474-4422(17)30002-9	https://pubmed.ncbi.nlm.nih.gov/28187920/	8	2013-05-15	Completed	2013-05-01	2014-08-01	2017-02-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""}]	NA
NCT01856179	Supplementation of Land-based Stearidonic Acid (SDA)-Rich Oils in Humans	Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome	10.3945/jn.113.180802	http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=24553695	1	2013-05-14	Completed	2011-03-01	2011-08-01	2014-02-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""eicosapentaenic acid\n[ Time Frame: after 0,7, 56 days ]\n\neicosapentaenic acid in lipids of plasma, erythrocytes and peripheral mononuclear cells (% of total identified fatty acid methyl esters)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""eicosapentaenic acid\n[ Time Frame: after 0,7, 56 days ]\n\neicosapentaenic acid in lipids of plasma, erythrocytes and peripheral mononuclear cells (% of total identified fatty acid methyl esters)""}]	NA	NA
NCT01856244	Stability and Balance in Locomotion Through Exercise	Immediate effects of perturbation treadmill training on gait and postural control in patients with Parkinson's disease	10.1016/j.gaitpost.2016.08.020	https://pubmed.ncbi.nlm.nih.gov/27591395/	7	2013-05-16	Completed	2013-06-01	2016-06-01	2016-08-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nBerg Balance Scale (BBS), Postural Sway in the Romberg Test with eyes open and eyes closed for 10 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	NA
NCT01858987	Stapler vs. LigaSure in Elective Hepatic Resection	Randomized clinical trial of stapler hepatectomy versus LigaSure™ transection in elective hepatic resection	10.1002/bjs.10902	https://pubmed.ncbi.nlm.nih.gov/30069876/	2	2013-05-20	Completed	2011-11-01	2014-07-17	2018-07-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative Blood loss\n[ Time Frame: Beginning to end of surgical procedure ]\n\nIntraoperative blood loss represents the primary efficacy endpoint of the CRUNSH II-Trial. To obtain a more precise estimate for the individual patient patient's individual transection area will be considered as a continuous covariate in the analysis of covariance (ANOVA). The transection area will be assessed using an imprint of the resected specimen on a paper sheet with a known density of 80 mg/m2. The marked paper area will be cut and weight to calculate the transection area. Intraoperative blood loss will be measured according to the blood collected in the suction containers. Spilling water and ascites will be subtracted. Furthermore, swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers. Central venous pressure will be lowered below 5 cmH2O for the transection period.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative Blood loss\n[ Time Frame: Beginning to end of surgical procedure ]\n\nIntraoperative blood loss represents the primary efficacy endpoint of the CRUNSH II-Trial. To obtain a more precise estimate for the individual patient patient's individual transection area will be considered as a continuous covariate in the analysis of covariance (ANOVA). The transection area will be assessed using an imprint of the resected specimen on a paper sheet with a known density of 80 mg/m2. The marked paper area will be cut and weight to calculate the transection area. Intraoperative blood loss will be measured according to the blood collected in the suction containers. Spilling water and ascites will be subtracted. Furthermore, swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers. Central venous pressure will be lowered below 5 cmH2O for the transection period.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative Blood loss\n[ Time Frame: Beginning to end of surgical procedure ]\n\nIntraoperative blood loss represents the primary efficacy endpoint of the CRUNSH II-Trial. To obtain a more precise estimate for the individual patient patient's individual transection area will be considered as a continuous covariate in the analysis of covariance (ANOVA). The transection area will be assessed using an imprint of the resected specimen on a paper sheet with a known density of 80 mg/m2. The marked paper area will be cut and weight to calculate the transection area. Intraoperative blood loss will be measured according to the blood collected in the suction containers. Spilling water and ascites will be subtracted. Furthermore, swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers. Central venous pressure will be lowered below 5 cmH2O for the transection period.""}]	NA	NA
NCT01859416	Effects of Oral Nutritional Supplements in Nursing Home Residents	Effects of a low-volume, nutrient- and energy-dense oral nutritional supplement on nutritional and functional status: a randomized, controlled trial in nursing home residents	10.1016/j.jamda.2013.05.011	http://www.sciencedirect.com/science/article/pii/S152586101300282X?via%3Dihub	1	2013-05-17	Completed	2009-03-01	2010-07-01	2013-08-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight\n[ Time Frame: 12 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT01859429	Stepped Care - Optimising Psycho-oncological Care Provision by Structured Screening and Diagnosis	Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial	10.1002/pon.4492	https://pubmed.ncbi.nlm.nih.gov/28665542/	3	2013-05-17	Completed	2012-04-01	2014-12-01	2017-07-20	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental condition\n[ Time Frame: from baseline until 6 months ]\n\nHospital Anxiety and Depression Scale, HADS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental condition\n[ Time Frame: from baseline until 6 months ]\n\nHospital Anxiety and Depression Scale, HADS""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental condition\n[ Time Frame: from baseline until 6 months ]\n\nHospital Anxiety and Depression Scale, HADS""}]	NA
NCT01861951	A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma	A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial	10.1186/s13063-016-1434-x	https://pubmed.ncbi.nlm.nih.gov/27387325/	7	2013-05-22	Completed	2012-10-01	2017-01-01	2016-07-07	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months\n[ Time Frame: 10 to 40 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months\n[ Time Frame: 10 to 40 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months\n[ Time Frame: 10 to 40 months ]""}]	NA
NCT01865604	Impact of tDCS on Cerebral Autoregulation	Impact of tDCS on cerebral autoregulation in aging and in patients with cerebrovascular diseases	10.1212/wnl.0000000000001230	https://pubmed.ncbi.nlm.nih.gov/25576632/	5	2013-05-28	Completed	2012-04-01	2014-03-01	2015-01-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasomotor reactivity assessed by transcranial Dopplersonography\n[ Time Frame: on 3 days within 12 weeks ]\n\ncomparing cerebral vasomotor reactivity at baseline and after anodal/cathodal/sham stimulation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasomotor reactivity assessed by transcranial Dopplersonography\n[ Time Frame: on 3 days within 12 weeks ]\n\ncomparing cerebral vasomotor reactivity at baseline and after anodal/cathodal/sham stimulation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasomotor reactivity assessed by transcranial Dopplersonography\n[ Time Frame: on 3 days within 12 weeks ]\n\ncomparing cerebral vasomotor reactivity at baseline and after anodal/cathodal/sham stimulation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral vasomotor reactivity assessed by transcranial Dopplersonography\n[ Time Frame: on 3 days within 12 weeks ]\n\ncomparing cerebral vasomotor reactivity at baseline and after anodal/cathodal/sham stimulation""}]	NA
NCT01867736	BIOLUX P-II First-in-Man Study to Compare the Passeo-18 Lux DRB Against POBA in Infrapopliteal Arteries	Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries)	10.1016/j.jcin.2015.07.011	https://www.sciencedirect.com/science/article/pii/S1936879815011395	4	2013-05-30	Completed	2012-07-01	2014-01-01	2015-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety: Major adverse event rate (MAE), defined as all cause death, major amputation of target extremity, target lesion thrombosis, target lesion revascularisation (TLR)and target vessel revascularization (TVR) at 30 days.\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety: Major adverse event rate (MAE), defined as all cause death, major amputation of target extremity, target lesion thrombosis, target lesion revascularisation (TLR)and target vessel revascularization (TVR) at 30 days.\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety: Major adverse event rate (MAE), defined as all cause death, major amputation of target extremity, target lesion thrombosis, target lesion revascularisation (TLR)and target vessel revascularization (TVR) at 30 days.\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).\n[ Time Frame: 6 months ]""}]	NA	NA
NCT01879111	Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback	Depression screening with patient-targeted feedback in cardiology: DEPSCREEN-INFO randomised clinical trial	10.1192/bjp.bp.116.184168	https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/depression-screening-with-patienttargeted-feedback-in-cardiology-depscreeninfo-randomised-clinical-trial/51576167758C2532B495D52DCE083DAA	6	2013-06-14	Completed	2012-07-01	2013-10-01	2018-01-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Level of depression one month after screening (Patient Health Questionnaire-9)\n[ Time Frame: One month after depression screening ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Level of depression one month after screening (Patient Health Questionnaire-9)\n[ Time Frame: One month after depression screening ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Level of depression one month after screening (Patient Health Questionnaire-9)\n[ Time Frame: One month after depression screening ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Level of depression one month after screening (Patient Health Questionnaire-9)\n[ Time Frame: One month after depression screening ]""}]	NA
NCT01879241	Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis	Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial	10.1016/s1474-4422(18)30176-5	https://www.sciencedirect.com/science/article/pii/S1474442218301765?via%3Dihub	6	2013-06-12	Completed	2013-06-01	2016-03-01	2018-06-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in ALS-Patients with Rasagiline compared to placebo\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in ALS-Patients with Rasagiline compared to placebo\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival in ALS-Patients with Rasagiline compared to placebo\n[ Time Frame: 18 Months ]""}]	NA	NA
NCT01879839	Effect of a Pre-interventional Diet on Renal Function After Administration of Contrast Agent in Patients at Risk	Dietary restriction for prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary angiography: a randomized controlled trial	10.1038/s41598-020-61895-2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089976/	9	2013-06-13	Completed	2013-07-01	2016-09-01	2020-03-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rise of serum creatinine in mg/dl 48 hours after begin of coronary intervention (contrast agent administration)\n[ Time Frame: Baseline to 48 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rise of serum creatinine in mg/dl 48 hours after begin of coronary intervention (contrast agent administration)\n[ Time Frame: Baseline to 48 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rise of serum creatinine in mg/dl 48 hours after begin of coronary intervention (contrast agent administration)\n[ Time Frame: Baseline to 48 hours ]""}]	NA	NA
NCT01879878	Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]	Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study	10.1007/s10637-019-00826-z	https://pubmed.ncbi.nlm.nih.gov/31250356/	5	2013-06-17	Unknown status	2013-12-01	NA	2019-06-27	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""feasibility of a randomized controlled trial\n[ Time Frame: one year ]\n\nMain objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility of a randomized controlled trial\n[ Time Frame: One year ]\n\nMain objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy""}]
NCT01880970	Effect of Starter Formula on Infection Prevention	Starter formula enriched in prebiotics and probiotics ensures normal growth of infants and promotes gut health: a randomized clinical trial	10.1038/pr.2016.270	https://www.ncbi.nlm.nih.gov/pubmed/28002391	3	2013-06-17	Completed	2008-10-01	2013-10-01	2016-12-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Diarrhea and all infections with fever\n[ Time Frame: over 6 months and 1 year ]\n\nMean event rate of diarrhea and all infections with fever per child over 6 months and 1 year""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Diarrhea and all infections with fever\n[ Time Frame: over 6 months and 1 year ]\n\nMean event rate of diarrhea and all infections with fever per child over 6 months and 1 year""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Diarrhea and all infections with fever\n[ Time Frame: over 6 months and 1 year ]\n\nMean event rate of diarrhea and all infections with fever per child over 6 months and 1 year""}]	NA	NA
NCT01883531	Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years	Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial	10.1016/j.jcf.2017.02.003	https://www.sciencedirect.com/science/article/pii/S1569199317300280?via%3Dihub	7	2013-06-19	Completed	2013-06-01	2015-12-01	2017-03-01	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect on lung function (FEV1)\n[ Time Frame: The absolute change from each treatment period baseline to week 8 of each treatment period in percentage of predicted FEV1. ]\n\nTo determine the effect of eight weeks of twice-daily treatment with inhaled dry powder mannitol on lung function (FEV1) in subjects with CF who are aged six to seventeen years.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect on lung function (FEV1)\n[ Time Frame: The absolute change from each treatment period baseline to week 8 of each treatment period in percentage of predicted FEV1. ]\n\nTo determine the effect of eight weeks of twice-daily treatment with inhaled dry powder mannitol on lung function (FEV1) in subjects with CF who are aged six to seventeen years.""}]	NA	NA	NA
NCT01883765	Efficacy of Neurofeedback Training in Adults With ADHD	Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial	10.1016/s2215-0366(17)30291-2	https://www.sciencedirect.com/science/article/pii/S2215036617302912?via%3Dihub	2	2013-06-18	Completed	2013-02-01	2015-12-01	2017-08-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: pre-treatment, after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]\n\nConners' Adult ADHD Rating Scale (CAARS) Scores""}]	NA	NA
NCT01885000	Patient-Reported Outcome Of Facial Erythema (PROOF)	Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study	10.1111/jdv.13305	http://onlinelibrary.wiley.com/doi/10.1111/jdv.13305/abstract	8	2013-06-21	Completed	2013-07-01	2013-11-01	2015-09-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Dermatology Life Quality Index score\n[ Time Frame: baseline and 8 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Dermatology Life Quality Index score\n[ Time Frame: baseline and 8 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""satisfaction with the overall study treatment\n[ Time Frame: Day 8 ]""}]	[See Results Section.]	NA
NCT01886014	The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers	Effect of oxytocin on placebo analgesia: a randomized study	10.1001/jama.2013.277446	https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2013.277446	2	2013-06-24	Completed	2012-01-01	2012-09-01	2013-10-23	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Placebo analgesic responses\n[ Time Frame: ~ 45 min after appliction of oxytocin or saline ]\n\nIn this study the placebo analgesic response is defined as the difference in pain rating (visual analogue scale [0-100]) to thermal painful stimulation on the forearm on the placebo site compared to a control site.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Placebo analgesic responses\n[ Time Frame: ~ 45 min after appliction of oxytocin or saline ]\n\nIn this study the placebo analgesic response is defined as the difference in pain rating (visual analogue scale [0-100]) to thermal painful stimulation on the forearm on the placebo site compared to a control site.""}]	NA	NA
NCT01886365	Computerized Tight Glycemic Control in Cardiac Surgery	Perioperative glycemic control with a computerized algorithm versus conventional glycemic control in cardiac surgical patients undergoing cardiopulmonary bypass with blood cardioplegia	10.1053/j.jvca.2014.04.017	http://www.sciencedirect.com/science/article/pii/S105307701400175X	1	2013-06-24	Completed	2011-10-01	2012-10-01	2014-10-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time within a blood glucose corridor of 80 - 150 mg/dl\n[ Time Frame: From start of cardiopulmonary bypass during surgery until discharge from ICU, which is approximately after 48 -72 hrs. ]\n\nThe primary endpoint was defined as the time within a given blood glucose corridor from 80 - 150 mg/dl during therapy""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time within a blood glucose corridor of 80 - 150 mg/dl\n[ Time Frame: From start of cardiopulmonary bypass during surgery until discharge from ICU, which is approximately after 48 -72 hrs. ]\n\nThe primary endpoint was defined as the time within a given blood glucose corridor from 80 - 150 mg/dl during therapy""}]	NA	NA
NCT01890317	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction	10.1161/circulationaha.117.032722	https://pubmed.ncbi.nlm.nih.gov/30026282/	4	2013-06-26	Completed	2012-08-01	2015-11-01	2019-01-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac Power Index after 24 hr.\n[ Time Frame: 24 hours ]\n\nCardiac Power Index after 24 hours as surrogate endpoint.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac Power Index after 24 hr.\n[ Time Frame: 24 hours ]\n\nCardiac Power Index after 24 hours as surrogate endpoint.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac Power Index after 24 hr.\n[ Time Frame: 24 hours ]\n\nCardiac Power Index after 24 hours as surrogate endpoint.""}]	NA	NA
NCT01891864	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis	10.1111/bjd.15152	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15152	21	2013-06-28	Completed	2013-06-01	2015-04-01	2016-10-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	NA
NCT01896245	Laryngeal Injuries After Anesthesia Induction With Three Different Sevoflurane Concentrations (Without Muscle Relaxant)	Sevoflurane at 1.0 MAC together with remifentanil and propofol produces clinically acceptable intubation conditions at the vocal cords: A prospective randomized study	10.1177/0300060517701355	https://journals.sagepub.com/doi/10.1177/0300060517701355?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov	4	2013-07-05	Completed	2013-07-01	2014-08-01	2017-04-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 hours after tracheal intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 hours after tracheal intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of vocal cord injuries\n[ Time Frame: 24 hours after tracheal intubation ]""}]	NA	NA
NCT01897558	Myocardial Micro-damage in Relation to Active and Passive Fixation Pacemaker Electrodes	Pacemaker Implantation Associated Myocardial Micro-Damage: A Randomised Comparison between Active and Passive Fixation Leads	10.1038/s41598-018-23209-5	NA	3	2013-07-11	Completed	2013-04-01	2014-08-01	2018-03-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""high-sensitive Troponin T\n[ Time Frame: 1 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""high-sensitive Troponin T\n[ Time Frame: 1 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""high-sensitive Troponin T\n[ Time Frame: 1 day ]""}]	NA	NA
NCT01899456	Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation	Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve)	10.1093/ndt/gfv311	NA	4	2013-07-12	Completed	2013-07-01	2014-08-01	2015-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of renal denervation in patients after renal transplantation\n[ Time Frame: Baseline to 6 months ]\n\nEffect on blood pressure including office, ABPM, and home-based measurements. Number of adverse events. Changes of antihypertensive medications. Effects on renal function assessed with glomerular filtration rate. Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of renal denervation in patients after renal transplantation\n[ Time Frame: Baseline to 6 months ]\n\nEffect on blood pressure including office, ABPM, and home-based measurements. Number of adverse events. Changes of antihypertensive medications. Effects on renal function assessed with glomerular filtration rate. Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and efficacy of renal denervation in patients after renal transplantation\n[ Time Frame: Baseline to 6 months ]\n\nEffect on blood pressure including office, ABPM, and home-based measurements. Number of adverse events. Changes of antihypertensive medications. Effects on renal function assessed with glomerular filtration rate. Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.""}]	NA
NCT01900067	Study to Evaluate Safety and Efficacy of Blanket Used to Prevent Anesthesia Induced Hypothermia	Active perioperative patient warming using a self-warming blanket (BARRIER EasyWarm) is superior to passive thermal insulation: a multinational, multicenter, randomized trial	10.1016/j.jclinane.2016.06.030	NA	2	2013-07-15	Completed	2012-11-01	2013-03-01	2016-06-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the arithmetic mean of core body temperature measurements during the perioperative phase between the interventional treatment group and the control treatment group\n[ Time Frame: temperature measurments during pre,-intra and postoperative period, on average 1-5 hours, depending on the surgical intervention. ]\n\nThe subject's core body temperature at any time point is approximated by the arithmetic mean of three repeated tympanic temperature measurements every 15 minutes during the perioperative period""}]	NA	[See Results Section.]	NA	NA
NCT01900327	Neoadjuvant Treatment in Resectable Pancreatic Cancer	Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)	10.1186/1471-2407-14-411	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057592/	5	2013-07-11	Terminated	2014-02-01	2016-11-22	2014-06-07	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""3-Year Survival Rate\n[ Time Frame: 3 years after last patient in ]\n\nPrimary outcome measure is the efficacy of neoadjuvant CRT in improving 3-year survival probability from 30% in the control arm undergoing upfront surgery without neoadjuvant CRT to 42% (relative increase of 40%) in the study arm undergoing CRT. The underlying guess of a 30% 3-year survival probability in the control group derives from an assumed median overall survival (MOS) of 20.7 months which corresponds with a MOS of 17.9 months to 23.6 months reported in several randomized trials.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""3-Year Survival Rate\n[ Time Frame: 3 years after last patient in ]\n\nPrimary outcome measure is the efficacy of neoadjuvant CRT in improving 3-year survival probability from 30% in the control arm undergoing upfront surgery without neoadjuvant CRT to 42% (relative increase of 40%) in the study arm undergoing CRT. The underlying guess of a 30% 3-year survival probability in the control group derives from an assumed median overall survival (MOS) of 20.7 months which corresponds with a MOS of 17.9 months to 23.6 months reported in several randomized trials.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""3-Year Survival Rate\n[ Time Frame: 3 years after last patient in ]\n\nPrimary outcome measure is the efficacy of neoadjuvant CRT in improving 3-year survival probability from 30% in the control arm undergoing upfront surgery without neoadjuvant CRT to 42% (relative increase of 40%) in the study arm undergoing CRT. The underlying guess of a 30% 3-year survival probability in the control group derives from an assumed median overall survival (MOS) of 20.7 months which corresponds with a MOS of 17.9 months to 23.6 months reported in several randomized trials.""}]	NA
NCT01903538	Interference With Cognitive Control by Transcranial Direct Current Stimulation	Keep calm and carry on: improved frustration tolerance and processing speed by transcranial direct current stimulation (tDCS)	10.1371/journal.pone.0122578	https://www.ncbi.nlm.nih.gov/pubmed/25837520	1	2013-07-16	Completed	2011-07-01	2012-07-01	2015-04-02	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Correctness and reaction time of response\n[ Time Frame: Within 30 min starting 5 min after the initiation of stimulation ]\n\nCorrectness is defined as the percentage of correct responses in the DWM and AIT""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Correctness and reaction time of response\n[ Time Frame: Within 30 min starting 5 min after the initiation of stimulation ]\n\nCorrectness is defined as the percentage of correct responses in the DWM and AIT""}]	NA	NA
NCT01905475	CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003229-91/results	13	2013-07-22	Completed	2013-07-01	2015-10-01	2016-08-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in LVEF (left ventricular ejection fraction) as determined by MRI\n[ Time Frame: 4 months ]\n\nDifference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in LVEF (left ventricular ejection fraction) as determined by MRI\n[ Time Frame: 4 months ]\n\nDifference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in LVEF (left ventricular ejection fraction) as determined by MRI\n[ Time Frame: 4 months ]\n\nDifference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months""}]	NA	NA
NCT01908270	Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer	Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial	10.1002/cncr.29330	https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.29330	4	2013-07-24	Completed	2013-08-01	2013-11-01	2015-03-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Menopausal symptoms\n[ Time Frame: Week 12 ]\n\nMenopause Rating Scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Menopausal symptoms\n[ Time Frame: Week 12 ]\n\nMenopause Rating Scale""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Menopausal symptoms\n[ Time Frame: Week 12 ]\n\nMenopause Rating Scale""}]	NA	NA
NCT01908855	Cognitive-Behavioral Therapy Enriched With Emotion Regulation Training for Multiple Somatoform Symptoms	Negative affect as mediator between emotion regulation and medically unexplained symptoms	10.1016/j.jpsychores.2017.08.010	https://pubmed.ncbi.nlm.nih.gov/28867416/	5	2013-07-25	Completed	2013-10-01	2016-01-01	2017-08-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in somatic symptom severity (Screening of Somatoform Disorders, SOMS-7T) from pre-assessment to four in-between assessments to post-assessment to follow-up\n[ Time Frame: From pre-assessment (admission) to four in-between assessments (9, 13, 17, 21 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ]\n\nAssessment of somatic symptom severity during the last 7 days (self-rating)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in somatic symptom severity (Screening of Somatoform Disorders, SOMS-7T) from pre-assessment to four in-between assessments to post-assessment to follow-up\n[ Time Frame: From pre-assessment (admission) to four in-between assessments (9, 13, 17, 21 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ]\n\nAssessment of somatic symptom severity during the last 7 days (self-rating)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in somatic symptom severity (Screening of Somatoform Disorders, SOMS-7T) from pre-assessment to four in-between assessments to post-assessment to follow-up\n[ Time Frame: From pre-assessment (admission) to four in-between assessments (9, 13, 17, 21 weeks after admission) to post-assessment (25 weeks after admission) to follow-up (12 months after admission) ]\n\nAssessment of somatic symptom severity during the last 7 days (self-rating)""}]	NA	NA
NCT01914341	Short Term Effects of Live Music in Newborn Infants	NA	10.15496/publikation-9460	http://dx.doi.org/10.15496/publikation-9460	3	2013-07-31	Completed	2013-07-01	2014-01-01	2016-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""heartrate\n[ Time Frame: physiological parameters are measured twice over a period of 45 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""heartrate\n[ Time Frame: physiological parameters are measured twice over a period of 45 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""heartrate\n[ Time Frame: physiological parameters are measured twice over a period of 45 minutes ]""}]	NA	NA
NCT01914783	Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects	Effect of acute ozone induced airway inflammation on human sympathetic nerve traffic: a randomized, placebo controlled, crossover study	10.1371/journal.pone.0018737	https://pubmed.ncbi.nlm.nih.gov/21494635/	1	2013-07-31	Unknown status	NA	NA	2011-04-08	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle sympathetic nerve activity (MSNA)\n[ Time Frame: 2.5 hours after exposure to clean air, to ultrafine particles, or to a combination of ultrafine particles and ozone ]\n\nChange of sympathetic vasoconstrictor nerve activity directed to skeletal muscle expressed as sympathetic bursts per minute. The primary hypothesis of the study is that in healthy elderly subjects experimental exposure to air pollutants increases sympathetic nervous system activity compared with sham (clean air) exposure.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle sympathetic nerve activity (MSNA)\n[ Time Frame: 2.5 hours after exposure to clean air, to ultrafine particles, or to a combination of ultrafine particles and ozone ]\n\nChange of sympathetic vasoconstrictor nerve activity directed to skeletal muscle expressed as sympathetic bursts per minute. The primary hypothesis of the study is that in healthy elderly subjects experimental exposure to air pollutants increases sympathetic nervous system activity compared with sham (clean air) exposure.""}]	NA
NCT01914965	Apathy Cure Through Bupropion in Huntington's Disease	Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial	10.1371/journal.pone.0173872	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360242/	3	2013-07-31	Completed	2012-06-01	2014-04-01	2017-03-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apathy Evaluation Scale (AES-I)\n[ Time Frame: 10 weeks ]\n\nThe influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apathy Evaluation Scale (AES-I)\n[ Time Frame: 10 weeks ]\n\nThe influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apathy Evaluation Scale (AES-I)\n[ Time Frame: 10 weeks ]\n\nThe influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.""}]	NA	NA
NCT01916408	The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon	Decreased prevalence of cardiac arrhythmias during and after vigorous and prolonged exercise in healthy male marathon runners	10.1016/j.ahj.2015.04.001	NA	3	2013-08-01	Completed	2013-08-01	2014-01-01	2015-04-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers after Marathon Running\n[ Time Frame: one months ]\n\nChange of the inflammatory marker (IL-6) before and after a marathon in relation to the consumption of oral hydrolytic enzymes and bioflavonoids.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers after Marathon Running\n[ Time Frame: one months ]\n\nChange of the inflammatory marker (IL-6) before and after a marathon in relation to the consumption of oral hydrolytic enzymes and bioflavonoids.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers after Marathon Running\n[ Time Frame: one months ]\n\nChange of the inflammatory marker (IL-6) before and after a marathon in relation to the consumption of oral hydrolytic enzymes and bioflavonoids.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers after Marathon Running\n[ Time Frame: one months ]\n\nChange of the inflammatory marker (IL-6) before and after a marathon in relation to the consumption of oral hydrolytic enzymes and bioflavonoids.""}]	NA
NCT01921036	The Effects of Combined Exercise Training on Exercise Capacity in Cardiac Rehabilitation	Individualized vs. group exercise in improving quality of life and physical activity in patients with cardiac disease and low exercise capacity: results from the DOPPELHERZ trial	10.1080/09638288.2016.1242174	NA	3	2013-08-08	Completed	2011-02-01	2013-12-01	2016-10-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in maximal exercise capacity (watt/kgBW)\n[ Time Frame: six months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in maximal exercise capacity (watt/kgBW)\n[ Time Frame: six months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in maximal exercise capacity (watt/kgBW)\n[ Time Frame: six months ]""}]	NA	NA
NCT01921777	Effects of Traumeel®S Tablets on Recovery and Inflammatory Immune Response After Repeated Bouts of Exercise	Effects of Traumeel (Tr14) on recovery and inflammatory immune response after repeated bouts of exercise: a double-blind RCT	10.1007/s00421-017-3554-8	NA	3	2013-08-09	Completed	2010-01-01	2013-12-01	2017-02-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin-1 receptor antagonist (IL-1ra)\n[ Time Frame: 72 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin 6 (IL-6)\n[ Time Frame: 72 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin-1 receptor antagonist (IL-1ra)\n[ Time Frame: 72 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin 6 (IL-6)\n[ Time Frame: 72 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin-1 receptor antagonist (IL-1ra)\n[ Time Frame: 72 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in post-exercise two baseline levels up to 72-hours of Interleukin 6 (IL-6)\n[ Time Frame: 72 hours ]""}]	NA	NA
NCT01923493	Tuina for Patients With Chronic Neck Pain	Effectiveness and Cost-Effectiveness of Tuina for Chronic Neck Pain: A Randomized Controlled Trial Comparing Tuina with a No-Intervention Waiting List	10.1089/acm.2017.0209	https://www.liebertpub.com/doi/abs/10.1089/acm.2017.0209	3	2013-08-13	Completed	2013-08-01	2014-04-01	2018-03-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean neck pain intensity of the last seven days\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean neck pain intensity of the last seven days\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean neck pain intensity of the last seven days\n[ Time Frame: 4 weeks ]""}]	NA	NA
NCT01923961	Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration	Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal	10.1111/apha.12730	NA	2	2013-08-14	Completed	2013-08-01	2015-03-30	2016-06-22	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of para-cresylsulfate and indoxylsulfate\n[ Time Frame: 4 hours ]\n\nDetermination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of para-cresylsulfate and indoxylsulfate\n[ Time Frame: 4 hours ]\n\nDetermination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins""}]	NA	[See Results Section.]	NA
NCT01924702	Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)	Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia	10.1093/brain/aww002	https://academic.oup.com/brain/article/139/4/1152/2464226	4	2013-08-15	Unknown status	2011-01-01	NA	2016-02-16	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""naming performance\n[ Time Frame: Change of naming score from baseline (day 1 of study) to immediately after 2-week intervention period (post-testing) ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""naming performance\n[ Time Frame: Change of naming score from baseline (day 1 of study) to immediately after 2-week intervention period (post-testing) ]""}]
NCT01924962	Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries	A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial	10.1016/j.jcin.2018.05.041	https://www.sciencedirect.com/science/article/pii/S1936879818312111	3	2013-08-16	Completed	2011-08-01	2016-08-14	2018-10-08	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Regional left ventricular function\n[ Time Frame: 9 months ]\n\nimprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in regional left ventricular function at 9 months\n[ Time Frame: 9 months ]\n\nImprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in regional left ventricular function at 9 months\n[ Time Frame: 9 months ]\n\nImprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.""}]	NA	NA
NCT01927549	Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock	10.1056/nejmoa1710261	https://pubmed.ncbi.nlm.nih.gov/29083953/	5	2013-08-19	Completed	2013-04-01	2017-07-01	2017-10-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality and/or severe renal failure requiring renal replacement therapy\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality and/or severe renal failure requiring renal replacement therapy\n[ Time Frame: 30 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality and/or severe renal failure requiring renal replacement therapy\n[ Time Frame: 30 days ]""}]	NA
NCT01927991	Internet-based Self-help for Tinnitus: The Role of Support	NA	10.1016/j.invent.2015.03.007	https://www.sciencedirect.com/science/article/pii/S2214782915000184	4	2013-08-20	Completed	2012-09-01	2013-12-01	2015-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus distress\n[ Time Frame: 1 year; pre, post, 6-mo-follow-up ]\n\n\n\nAssessment of tinnitus distress with the Tinnitus Handicap Inventory (THI) and the Mini-Tinnitus Questionnaire (Mini-TQ)\n\nNewman, C. W., Jacobson, G. P., & Spitzer, J. B. (1996). Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg, 122(2), 143-148.\n\nHiller, W., & Goebel, G. (2004). Rapid assessment of tinnitus-related psychological distress using the Mini-TQ. Int J Audiol, 43(10), 600-604.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus distress\n[ Time Frame: 1 year; pre, post, 6-mo-follow-up ]\n\n\n\nAssessment of tinnitus distress with the Tinnitus Handicap Inventory (THI) and the Mini-Tinnitus Questionnaire (Mini-TQ)\n\nNewman, C. W., Jacobson, G. P., & Spitzer, J. B. (1996). Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg, 122(2), 143-148.\n\nHiller, W., & Goebel, G. (2004). Rapid assessment of tinnitus-related psychological distress using the Mini-TQ. Int J Audiol, 43(10), 600-604.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus distress\n[ Time Frame: 1 year; pre, post, 6-mo-follow-up ]\n\n\n\nAssessment of tinnitus distress with the Tinnitus Handicap Inventory (THI) and the Mini-Tinnitus Questionnaire (Mini-TQ)\n\nNewman, C. W., Jacobson, G. P., & Spitzer, J. B. (1996). Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg, 122(2), 143-148.\n\nHiller, W., & Goebel, G. (2004). Rapid assessment of tinnitus-related psychological distress using the Mini-TQ. Int J Audiol, 43(10), 600-604.""}]	NA	NA
NCT01928433	Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis	Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections	10.1128/aac.02317-17	https://pubmed.ncbi.nlm.nih.gov/29339395/	4	2013-08-20	Completed	2012-12-01	2014-06-01	2018-03-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical and microbiological response of patients with cUTI or pyelonephritis.\n[ Time Frame: Day 17 ]\n\n\n\nThe primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).\n\nClinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as Elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group.\n\nThe micro-ITT population is composed of all randomized patients who have a baseline bacterial pathogen on culture of urine or blood that causes UTI against which the investigational drug has antibacterial activity.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical and microbiological response of patients with cUTI or pyelonephritis.\n[ Time Frame: Day 17 ]\n\n\n\nThe primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).\n\nClinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as Elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group.\n\nThe micro-ITT population is composed of all randomized patients who have a baseline bacterial pathogen on culture of urine or blood that causes UTI against which the investigational drug has antibacterial activity.""}]	[See Results Section.]	NA	NA
NCT01928810	Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia	Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia	10.1016/j.jpsychires.2018.03.001	https://www.sciencedirect.com/science/article/abs/pii/S0022395617313560	4	2013-08-26	Completed	2011-03-01	2013-10-01	2018-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mobility Inventory (Chambless 1984)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nA 27-item inventory for the measurement of self-reported agoraphobic avoidance behavior""}]	NA	NA
NCT01931592	Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E	Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR)	10.1093/jac/dkz124	https://pubmed.ncbi.nlm.nih.gov/31220256/	5	2013-08-26	Terminated	2014-01-01	2016-10-01	2019-04-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short-term intestinal eradication\n[ Time Frame: 11 days ]\n\nShort-term intestinal eradication, defined as a fecal sample , negative for ESBL-E on day 6+/-1 and day 11+/-2""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short-term intestinal eradication\n[ Time Frame: 11 days ]\n\nShort-term intestinal eradication, defined as a fecal sample , negative for ESBL-E on day 6+/-1 and day 11+/-2""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short-term intestinal eradication\n[ Time Frame: 11 days ]\n\nShort-term intestinal eradication, defined as a fecal sample , negative for ESBL-E on day 6+/-1 and day 11+/-2""}]	NA	NA
NCT01933191	Exercise Treatment of Dental Anxiety	Clinical and neurobiological effects of aerobic exercise in dental phobia: A randomized controlled trial	10.1002/da.22659	http://onlinelibrary.wiley.com/doi/10.1002/da.22659/full	2	2013-08-30	Completed	2011-08-01	2013-09-01	2017-05-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in VAS - visual analog scale\n[ Time Frame: Baseline and one hour after dental intervention ]\n\nChange in the visual analogue scale (VAS) for anxiety""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in VAS - visual analog scale\n[ Time Frame: Baseline and one hour after dental intervention ]\n\nChange in the visual analogue scale (VAS) for anxiety""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in VAS - visual analog scale\n[ Time Frame: Baseline and one hour after dental intervention ]\n\nChange in the visual analogue scale (VAS) for anxiety""}]	NA	NA
NCT01934699	Intraprocedural Determination of Myocardial Vitality Using 2 Different Imaging Methods	Intra-procedural determination of viability by myocardial deformation imaging: a randomized prospective study in the cardiac catheter laboratory	10.1007/s00392-017-1099-9	https://link.springer.com/article/10.1007/s00392-017-1099-9?shared-article-renderer	4	2013-08-29	Unknown status	2011-06-01	NA	2017-03-20	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""State of health score\n[ Time Frame: 6 month after diagnistics ]\n\nState of health score will be determinated by all patients for the evaluation of clinical outcomes (using the standardized questionnaire on state of health (SF-36))6 months after clinical diagnostics.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""State of health score\n[ Time Frame: 6 month after diagnistics ]\n\nState of health score will be determinated by all patients for the evaluation of clinical outcomes (using the standardized questionnaire on state of health (SF-36))6 months after clinical diagnostics.""}]
NCT01935297	Exercise Training After Transcatheter Aortic Valve Implantation	Exercise training improves exercise capacity and quality of life after transcatheter aortic valve implantation: A randomized pilot trial	10.1016/j.ahj.2016.08.007	NA	3	2013-08-30	Completed	2013-06-01	2015-01-01	2016-08-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peak oxygen uptake\n[ Time Frame: Baseline to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peak oxygen uptake\n[ Time Frame: Baseline to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peak oxygen uptake\n[ Time Frame: Baseline to 8 weeks ]""}]	NA	NA
NCT01939639	The Influence of Oxytocin on the Processing of Social Contact	An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits	10.1038/npp.2014.78	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104346/	1	2013-09-05	Completed	2013-03-01	2013-06-01	2014-08-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pleasantness ratings of social touch\n[ Time Frame: 30 minutes after the nasal spray administration ]\n\nAfter each trial, subjects are asked to use a visual analog scale to rate the pleasantness of the administered touch.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Blood-oxygen-level dependent signal in response to social touch\n[ Time Frame: 30 minutes after the nasal spray administration ]\n\nBy using functional magnetic resonance imaging we want to examine oxytocin's effects on the neural correlates (BOLD signal) of social touch.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pleasantness ratings of social touch\n[ Time Frame: 30 minutes after the nasal spray administration ]\n\nAfter each trial, subjects are asked to use a visual analog scale to rate the pleasantness of the administered touch.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Blood-oxygen-level dependent signal in response to social touch\n[ Time Frame: 30 minutes after the nasal spray administration ]\n\nBy using functional magnetic resonance imaging we want to examine oxytocin's effects on the neural correlates (BOLD signal) of social touch.""}]	NA	NA
NCT01942473	Effects of Automated Adjustment of FiO2 on Cerebral and Arterial Oxygenation in Preterm Infants	Effects of automated adjustment of the inspired oxygen on fluctuations of arterial and regional cerebral tissue oxygenation in preterm infants with frequent desaturations	10.1016/j.jpeds.2014.10.007	https://www.sciencedirect.com/science/article/pii/S0022347614009524?via%3Dihub	2	2013-09-10	Completed	2012-08-01	2013-09-01	2014-11-18	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral tissue oxygen saturation\n[ Time Frame: 48 hours ]\n\nmean cerebral tissue oxygen saturation as well als distribution of cerebral tissue oxygen saturation over time will be assessed""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral tissue oxygen saturation\n[ Time Frame: 48 hours ]\n\nmean cerebral tissue oxygen saturation as well als distribution of cerebral tissue oxygen saturation over time will be assessed""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral tissue oxygen saturation\n[ Time Frame: 48 hours ]\n\nmean cerebral tissue oxygen saturation as well als distribution of cerebral tissue oxygen saturation over time will be assessed""}]	NA
NCT01947595	Individualized Lifestyle Intervention in Subjects With Prediabetes	A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes	10.1007/s00125-015-3760-z	https://link.springer.com/article/10.1007/s00125-015-3760-z	3	2013-09-17	Completed	2012-03-01	2017-08-01	2015-09-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))\n[ Time Frame: one year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))\n[ Time Frame: one year ]""}]	NA
NCT01953549	Physical Fitness Training in Subacute Stroke (PHYS-Stroke)	Physical Fitness Training in Patients with Subacute Stroke (PHYS-STROKE): multicentre, randomised controlled, endpoint blinded trial	10.1136/bmj.l5101	https://pubmed.ncbi.nlm.nih.gov/31533934/	10	2013-09-26	Completed	2013-10-01	2017-07-01	2019-09-18	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gait speed and Barthel Index (BI) (co-primary endpoint)\n[ Time Frame: 3 months post stroke vs baseline ]\n\ncomparing gait speed (m/s) and points achieved in BARTHEL Index in aerobic and non-aroebic training group 3 months after stroke vs baseline (before intervention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gait speed and Barthel Index (BI) (co-primary endpoint)\n[ Time Frame: 3 months post stroke vs baseline ]\n\ncomparing gait speed (m/s) and points achieved in BARTHEL Index in aerobic and non-aroebic training group 3 months after stroke vs baseline (before intervention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gait speed and Barthel Index (BI) (co-primary endpoint)\n[ Time Frame: 3 months post stroke vs baseline ]\n\ncomparing gait speed (m/s) and points achieved in BARTHEL Index in aerobic and non-aroebic training group 3 months after stroke vs baseline (before intervention)""}]	NA	NA
NCT01954836	Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial	The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study	10.1186/s12885-018-4353-2	https://pubmed.ncbi.nlm.nih.gov/29699509/	5	2013-09-29	Completed	2013-10-01	2015-03-01	2018-04-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life, modified FACT-O\n[ Time Frame: 24 h and 7 days after chemotherapy cycle ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life, modified FACT-O\n[ Time Frame: 24 h and 7 days after chemotherapy cycle ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life, modified FACT-O\n[ Time Frame: 24 h and 7 days after chemotherapy cycle ]""}]	NA	NA
NCT01956175	Electrical Pharyngeal Stimulation for Dysphagia Therapy in Tracheostomized Stroke Patients	Electrical pharyngeal stimulation for dysphagia treatment in tracheotomized stroke patients: a randomized controlled trial	10.1007/s00134-015-3897-8	https://pubmed.ncbi.nlm.nih.gov/26077087/	2	2013-10-01	Completed	2013-06-01	2014-08-01	2015-06-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 5 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol post-treatment between real and sham treatment groups""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 5 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol post-treatment between real and sham treatment groups""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 3 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol after three days of treatment between real and sham treatment groups""}]	NA	NA
NCT01959451	Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial	10.1016/s0140-6736(17)32155-4	NA	10	2013-10-08	Completed	2013-09-01	2016-05-01	2017-08-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria\n[ Time Frame: 12 months ]""}]	NA
NCT01959737	Delivery Room Skin-to-skin Study	Delivery room skin-to-skin contact for preterm infants-A randomized clinical trial	10.1111/apa.14975	https://onlinelibrary.wiley.com/doi/abs/10.1111/apa.14975	5	2013-10-09	Completed	2012-02-01	2015-07-01	2018-08-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maternal sensitivity and responsiveness\n[ Time Frame: 4 to 6 moinths corrected age ]\n\nMaternal sensitivity and responsiveness are assessed with the \""Mannheimer Method\"" for the analysis of mother child interaction. At the infants corrected age of 4 to 6 months a videotape of the mother changing the infants diapers and playing with the infant is used for analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maternal sensitivity and responsiveness\n[ Time Frame: 4 to 6 moinths corrected age ]\n\nMaternal sensitivity and responsiveness are assessed with the \""Mannheimer Method\"" for the analysis of mother child interaction. At the infants corrected age of 4 to 6 months a videotape of the mother changing the infants diapers and playing with the infant is used for analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maternal sensitivity and responsiveness\n[ Time Frame: 4 to 6 moinths corrected age ]\n\nMaternal sensitivity and responsiveness are assessed with the \""Mannheimer Method\"" for the analysis of mother child interaction. At the infants corrected age of 4 to 6 months a videotape of the mother changing the infants diapers and playing with the infant is used for analysis.""}]	NA	NA
NCT01963793	Topical Aprepitant in Prurigo Patients	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant	10.2340/00015555-2780	https://pubmed.ncbi.nlm.nih.gov/28853492/	6	2013-10-11	Completed	2013-10-01	2014-07-01	2018-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[See Results Section.]	NA
NCT01966783	Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis	Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis	10.1016/j.cgh.2018.04.027	https://pubmed.ncbi.nlm.nih.gov/29702300/	6	2013-10-21	Completed	2013-09-01	2015-12-01	2018-04-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Resolution of clinical symptoms\n[ Time Frame: 8 weeks ]\n\nSymptoms as reported in the diary""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Resolution of clinical symptoms\n[ Time Frame: 8 weeks ]\n\nSymptoms as reported in the diary""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Resolution of clinical symptoms\n[ Time Frame: 8 weeks ]\n\nSymptoms as reported in the diary""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Resolution of clinical symptoms\n[ Time Frame: 8 weeks ]\n\nSymptoms as reported in the diary""}]	NA
NCT01969929	Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy	A Randomized Controlled Clinical Trial Comparing 20 Gauge and 23 Gauge Vitrectomy for Patients with Macular Hole or Macular Pucker	10.1007/s12325-018-0826-6	https://pubmed.ncbi.nlm.nih.gov/30448886/	2	2013-10-21	Unknown status	2013-10-01	NA	2018-11-17	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alteration of aqueous flare between preoperative and 3-week-postoperative time point\n[ Time Frame: 3 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alteration of aqueous flare between preoperative and 3-week-postoperative time point\n[ Time Frame: 3 weeks ]""}]
NCT01970384	Transcranial Direct Current Stimulation for Dysphagia Therapy in Acute Stroke Patients	Randomized trial of transcranial direct current stimulation for poststroke dysphagia	10.1002/ana.25151	https://pubmed.ncbi.nlm.nih.gov/29350775/	3	2013-10-22	Completed	2012-01-01	2014-12-01	2018-02-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEDSS (Fiberoptic Endoscopic Dysphagia Severity Scale) Score\n[ Time Frame: Within three days after the last stimulation session ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEDSS (Fiberoptic Endoscopic Dysphagia Severity Scale) Score\n[ Time Frame: Within three days after the last stimulation session ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEDSS (Fiberoptic Endoscopic Dysphagia Severity Scale) Score\n[ Time Frame: Within three days after the last stimulation session ]""}]	NA	NA
NCT01984788	Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE	NA	NA	https://www.jacionline.org/article/S0091-6749(16)30270-6/pdf	5	2013-11-14	Completed	2013-11-01	2014-06-01	2016-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of acute angioedema attacks\n[ Time Frame: Over 28 days of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of acute angioedema attacks\n[ Time Frame: Over 28 days of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of acute angioedema attacks\n[ Time Frame: Over 28 days of treatment ]""}]	NA	NA
NCT01986517	Feedback and Psychotherapeutic Competencies	Competence feedback improves CBT competence in trainee therapists: A randomized controlled pilot study	10.1080/10503307.2015.1132857	https://www.tandfonline.com/doi/full/10.1080/10503307.2015.1132857	4	2013-11-11	Completed	2013-11-01	2014-07-01	2016-11-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive Therapy Scale (CTS)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 20 weeks ]\n\nexternal-assessment measure that assesses psychotherapeutic competency during a cognitive therapy session. CTS will be used by two trained raters licensed as psychological psychotherapists.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive Therapy Scale (CTS)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 20 weeks ]\n\nexternal-assessment measure that assesses psychotherapeutic competency during a cognitive therapy session. CTS will be used by two trained raters licensed as psychological psychotherapists.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cognitive Therapy Scale (CTS)\n[ Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 20 weeks ]\n\nexternal-assessment measure that assesses psychotherapeutic competency during a cognitive therapy session. CTS will be used by two trained raters licensed as psychological psychotherapists.""}]	NA	NA
NCT01988818	Prospective, Randomized Study of 2 Different Wound Dressings	Evaluation of Absorbent Versus Conventional Wound Dressing	10.3238/arztebl.2018.0213	https://pubmed.ncbi.nlm.nih.gov/29669676/	3	2013-11-13	Completed	2014-04-01	2015-12-01	2018-03-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blistering\n[ Time Frame: 0-6 days ]\n\nDevelopment of blistering from day 0 to day 6 post surgery Photo documentation will be evaluated in a blinded manner by the Clinical Evaluation Committee (CEC).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blistering\n[ Time Frame: 0-6 days ]\n\nDevelopment of blistering from day 0 to day 6 post surgery Photo documentation will be evaluated in a blinded manner by the Clinical Evaluation Committee (CEC).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blistering\n[ Time Frame: 0-6 days ]\n\nDevelopment of blistering from day 0 to day 6 post surgery Photo documentation will be evaluated in a blinded manner by the Clinical Evaluation Committee (CEC).""}]	NA	NA
NCT01993056	The Influence of 11+ on Injury Incidence and FMS-Score in Veteran Soccer Players	Injury prevention in male veteran football players - a randomised controlled trial using ""FIFA 11+""	10.1080/02640414.2014.975736	http://www.tandfonline.com/doi/abs/10.1080/02640414.2014.975736	1	2013-11-22	Completed	2011-08-01	2012-06-01	2014-11-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""injury incidence\n[ Time Frame: August 2011 - June 2012 ]\n\ninjury incidence (injuries per 1000h of soccer)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""injury incidence\n[ Time Frame: August 2011 - June 2012 ]\n\ninjury incidence (injuries per 1000h of soccer)""}]	NA	NA
NCT01994928	Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.	High-Flow Nasal Cannula Versus Bag-Valve-Mask for Preoxygenation Before Intubation in Subjects With Hypoxemic Respiratory Failure	10.4187/respcare.04413	https://pubmed.ncbi.nlm.nih.gov/27274092/	4	2013-11-20	Completed	2013-11-01	2014-11-01	2016-06-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]\n\nMean decrease in the saturation of oxygen measured by pulse oximetry (SpO2 [%]) during intubation.""}]	NA
NCT01995292	Comparison of Two Different Types of ""Spray as You go"" Technique for Awake Fiberoptic Intubation	A comparison of the Enk Fiberoptic Atomizer Set(™) with boluses of topical anaesthesia for awake fibreoptic intubation	10.1111/anae.13496	https://onlinelibrary.wiley.com/doi/full/10.1111/anae.13496	2	2013-11-21	Completed	2013-10-01	2014-10-01	2016-05-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comfort evaluation by the patient\n[ Time Frame: up to 4 weeks ]\n\nComparison of conventional and modified \""spray as you go\"" technique""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comfort evaluation by the patient\n[ Time Frame: up to 4 weeks ]\n\nComparison of conventional and modified \""spray as you go\"" technique""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comfort evaluation by the patient\n[ Time Frame: up to 4 weeks ]\n\nComparison of conventional and modified \""spray as you go\"" technique""}]	NA	NA
NCT02001636	Effect of Protein Supplementation After Bariatric Surgery	Impact of protein supplementation after bariatric surgery: A randomized controlled double-blind pilot study	10.1016/j.nut.2015.08.005	https://www.ncbi.nlm.nih.gov/pubmed/26691769	1	2013-11-27	Completed	2011-11-01	2012-12-01	2015-09-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Excess weight loss [%]\n[ Time Frame: At month 6 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Excess weight loss [%]\n[ Time Frame: At month 6 ]""}]	NA	NA
NCT02001792	Patient Positioning During Colonoscopy: Effects on Safety and Diagnostic Outcome	Patient position and hypoxemia during propofol sedation for colonoscopy: a randomized trial	10.1055/s-0034-1392329	NA	2	2013-12-04	Completed	2012-04-01	2014-02-01	2015-06-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""frequency of breathing and cardiac problems (decrease of saturation, hypotension, bradycardia) during colonoscopy\n[ Time Frame: participants will be followed for the duration of colonoscopy during hospital stay an expected average of 1 hour ]\n\nsaturation and heart rate will be measured continuously, blood pressure will be measures all 3 minutes""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""frequency of breathing and cardiac problems (decrease of saturation, hypotension, bradycardia) during colonoscopy\n[ Time Frame: participants will be followed for the duration of colonoscopy during hospital stay an expected average of 1 hour ]\n\nsaturation and heart rate will be measured continuously, blood pressure will be measures all 3 minutes""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""frequency of breathing and cardiac problems (decrease of saturation, hypotension, bradycardia) during colonoscopy\n[ Time Frame: participants will be followed for the duration of colonoscopy during hospital stay an expected average of 1 hour ]\n\nsaturation and heart rate will be measured continuously, blood pressure will be measures all 3 minutes""}]	NA	NA
NCT02002871	Blue Light for Treating Eczema	Prospective, Randomized Study on the Efficacy and Safety of Local UV-Free Blue Light Treatment of Eczema	10.1159/000448000	https://www.karger.com/Article/FullText/448000	5	2013-12-02	Completed	2013-10-01	2014-03-01	2016-08-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the sum score of local Eczema rating of the target area as compared to the control area at end of treatment\n[ Time Frame: at week 4 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the sum score of local Eczema rating of the target area as compared to the control area at end of treatment\n[ Time Frame: at week 4 ]""}]	[See Results Section.]	NA	NA
NCT02004847	Blue Light for Treating Psoriasis Vulgaris	Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris	10.1159/000430495	https://pubmed.ncbi.nlm.nih.gov/26044167/	6	2013-12-03	Completed	2013-09-01	2014-04-01	2015-06-02	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PASI of the target area (HI group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local Psoriasis area severity index (PASI) of the target area (High Intensity (HI) group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local Psoriasis area severity index (PASI) of the target area (High Intensity (HI) group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[See Results Section.]	NA
NCT02005237	Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity	Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis-a randomized controlled trial	10.7717/peerj.6037	https://peerj.com/articles/6037/	6	2013-12-03	Completed	2013-12-01	2016-04-01	2018-12-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Verbal Learning and Memory\n[ Time Frame: Baseline and at Month 3 (end of intervention) ]\n\nVerbal Learning and Memory will be assessed with the Verbal Learning and Memory Test (VLMT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Verbal Learning and Memory\n[ Time Frame: Baseline and at Month 3 (end of intervention) ]\n\nVerbal Learning and Memory will be assessed with the Verbal Learning and Memory Test (VLMT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Verbal Learning and Memory\n[ Time Frame: Baseline and at Month 3 (end of intervention) ]\n\nVerbal Learning and Memory will be assessed with the Verbal Learning and Memory Test (VLMT)""}]	NA	NA
NCT02007772	Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients	Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD	10.2147/copd.s206111	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615713/	8	2013-12-06	Completed	2009-11-01	2017-07-01	2019-07-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the relative decrease of capillary pC02 after the treatment with nasal high-flow compared with the baseline value and the relative decrease of the capillary pCO2 after treatment with BiPAP compared with the baseline value.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the capillary pC02 between the treatment with nasal high-flow compared with the baseline value.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the capillary pC02 between the treatment with nasal high-flow compared with the baseline value.""}]	NA	NA
NCT02008721	Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial	10.1016/s1474-4422(19)30141-3	NA	7	2013-12-08	Completed	2014-01-01	2016-09-01	2019-07-02	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME)\n[ Time Frame: 52 weeks ]\n\nTo assess the efficacy of EGCG vs. Placebo to reduce the progression in the motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) from V1 to V7, (80% power, 5% P-level, 50% effect size, i.e. an expected mean yearly UMSARS-ME increase of 3.9 under verum treatment compared to 7.8 ± 6.8 (mean ± standard deviation) under Placebo-treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME)\n[ Time Frame: 52 weeks ]\n\nTo assess the efficacy of EGCG vs. Placebo to reduce the progression in the motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) from V1 to V7, (80% power, 5% P-level, 50% effect size, i.e. an expected mean yearly UMSARS-ME increase of 3.9 under verum treatment compared to 7.8 ± 6.8 (mean ± standard deviation) under Placebo-treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME)\n[ Time Frame: 52 weeks ]\n\nTo assess the efficacy of EGCG vs. Placebo to reduce the progression in the motor examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) from V1 to V7, (80% power, 5% P-level, 50% effect size, i.e. an expected mean yearly UMSARS-ME increase of 3.9 under verum treatment compared to 7.8 ± 6.8 (mean ± standard deviation) under Placebo-treatment.""}]	NA	NA
NCT02012985	Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria	A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria	10.1007/s00467-016-3553-8	https://link.springer.com/article/10.1007/s00467-016-3553-8	5	2013-12-11	Completed	2013-12-01	2015-01-01	2016-12-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in urinary oxalate levels from Baseline to week 8 of treatment.\n[ Time Frame: 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in urinary oxalate levels from Baseline to week 8 of treatment.\n[ Time Frame: 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in urinary oxalate levels from Baseline to week 8 of treatment.\n[ Time Frame: 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) ]""}]	NA	NA
NCT02025205	Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study	Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study	10.1164/rccm.201607-1383oc	https://pubmed.ncbi.nlm.nih.gov/27580428/	12	2013-12-27	Completed	2014-08-01	2016-12-01	2016-11-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage change in Forced Expiratory Volume in 1 s (FEV1)\n[ Time Frame: At baseline and after 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage change in Forced Expiratory Volume in 1 s (FEV1)\n[ Time Frame: At baseline and after 3 months ]""}]	NA	[See Results Section.]	NA
NCT02027792	Cabbage Leaf Wraps in Osteoarthritis of the Knee	Efficacy of Cabbage Leaf Wraps in the Treatment of Symptomatic Osteoarthritis of the Knee: A Randomized Controlled Trial	10.1097/ajp.0000000000000352	https://pubmed.ncbi.nlm.nih.gov/26889617/	4	2014-01-03	Completed	2014-01-01	2014-08-01	2016-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: 4 weeks ]\n\npain intensity measured on three 0-100mm visual analog scales (actual, mean, worst pain)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: 4 weeks ]\n\npain intensity measured on three 0-100mm visual analog scales (actual, mean, worst pain)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: 4 weeks ]\n\npain intensity measured on three 0-100mm visual analog scales (actual, mean, worst pain)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity\n[ Time Frame: 4 weeks ]\n\npain intensity measured on three 0-100mm visual analog scales (actual, mean, worst pain)""}]	NA
NCT02029131	Exercise and Low Back Pain	Low-dose, non-supervised, health insurance initiated exercise for the treatment and prevention of chronic low back pain in employees. Results from a randomized controlled trial	10.1371/journal.pone.0178585	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490969/	5	2014-01-06	Completed	2014-01-01	2014-08-01	2017-06-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Back strength (kg)\n[ Time Frame: At baseline and after 20 weeks ]\n\nAssessed with the back-check 607 (Dr. WOLFF Sports and Prevention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Back strength (kg)\n[ Time Frame: At baseline and after 20 weeks ]\n\nAssessed with the back-check 607 (Dr. WOLFF Sports and Prevention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Back strength (kg)\n[ Time Frame: At baseline and after 20 weeks ]\n\nAssessed with the back-check 607 (Dr. WOLFF Sports and Prevention)""}]	NA	NA
NCT02034279	The INFECIR-2 Albumin Prevention Study	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	10.1016/j.cgh.2019.07.055	https://pubmed.ncbi.nlm.nih.gov/31394283/	4	2014-01-10	Terminated	2014-05-01	2016-12-31	2019-08-05	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: 28-day survival ]\n\n28-day survival and in hospital survival (expected average 2 weeks) will be the primary outcome""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: hospitalization ]\n\nHospital survival will be the primary outcome""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: hospitalization ]\n\nHospital survival will be the primary outcome""}]	NA	NA
NCT02035709	Postoperative Pain Therapy With Hydromorphone Using TCI-PCA	Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy	10.1097/aln.0b013e3182a76d05	https://pubmed.ncbi.nlm.nih.gov/23958818/	3	2014-01-13	Completed	2013-12-01	2015-04-01	2014-02-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hydromorphone Plasma Concentrations\n[ Time Frame: Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour for the following 17 hours after extubation ]\n\nPredictive accuracy of the \""Erlanger pharmacokinetic model\"" of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hydromorphone Plasma Concentrations\n[ Time Frame: Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour for the following 17 hours after extubation ]\n\nPredictive accuracy of the \""Erlanger pharmacokinetic model\"" of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hydromorphone Plasma Concentrations\n[ Time Frame: Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour for the following 17 hours after extubation ]\n\nPredictive accuracy of the \""Erlanger pharmacokinetic model\"" of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage""}]	NA
NCT02038062	Tissue Oxygenation of the Tibial Anterior Muscle After Clamping of the Femoral Artery	Effect of ischemic and pharmacological preconditioning of lower limb muscle tissue on tissue oxygenation measured by near-infrared spectroscopy--a pilot study	10.1186/1471-2253-14-54	https://bmcanesthesiol.biomedcentral.com/articles/10.1186/1471-2253-14-54	3	2014-01-15	Completed	2010-05-01	2012-01-01	2014-07-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of tissue oxygen saturation below 95 % of baseline\n[ Time Frame: 4 hours ]\n\nDecrease of tissue oxygen saturation below 95 % of baseline""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of tissue oxygen saturation below 95 % of baseline\n[ Time Frame: 4 hours ]\n\nDecrease of tissue oxygen saturation below 95 % of baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease of tissue oxygen saturation below 95 % of baseline\n[ Time Frame: 4 hours ]\n\nDecrease of tissue oxygen saturation below 95 % of baseline""}]	NA
NCT02039648	The Influence of Rumex Acetosa L on the Intraoral Colonization With Porphyromonas Gingivalis	Extract from Rumex acetosa L. for prophylaxis of periodontitis: inhibition of bacterial in vitro adhesion and of gingipains of Porphyromonas gingivalis by epicatechin-3-O-(4β→8)-epicatechin-3-O-gallate (procyanidin-B2-Di-gallate)	10.1371/journal.pone.0120130	NA	1	2014-01-16	Completed	2012-03-01	2013-04-01	2015-03-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of the intraoral prevalence of Porphyromonas gingivalis\n[ Time Frame: change from baseline to 2, 4, 7 and 14 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of the intraoral prevalence of Porphyromonas gingivalis\n[ Time Frame: change from baseline to 2, 4, 7 and 14 days ]""}]	NA	NA
NCT02043600	Randomized-controlled Trial of Yoga for Ulcerative Colitis	Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis	10.1111/apt.14062	https://pubmed.ncbi.nlm.nih.gov/28378342/	6	2014-01-21	Completed	2014-02-01	2015-05-01	2017-04-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-specific quality of life\n[ Time Frame: 3 months ]\n\nInflammatory Bowel Disease Questionnaire (IBDQ)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-specific quality of life\n[ Time Frame: 3 months ]\n\nInflammatory Bowel Disease Questionnaire (IBDQ)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-specific quality of life\n[ Time Frame: 3 months ]\n\nInflammatory Bowel Disease Questionnaire (IBDQ)""}]	NA	NA
NCT02044913	Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety	Effectiveness of telephone-based aftercare case management for adult patients with unipolar depression compared to usual care: A randomized controlled trial	10.1371/journal.pone.0186967	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186967	5	2014-01-22	Completed	2013-12-01	2015-06-01	2017-10-27	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI)\n[ Time Frame: Change in the BDI and BAI from baseline (beginning of inpatient treatment) to follow up (6 months after termination of the intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI)\n[ Time Frame: Change in the BDI from the beginning of the intervention to follow up (6 months after termination of the intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI)\n[ Time Frame: Change in the BDI from the beginning of the intervention to follow up (6 months after termination of the intervention) ]""}]	NA	NA
NCT02051621	Therapy of Atrial Flutter by Afib Ablation	Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial	10.1016/j.hrthm.2015.01.040	https://www.sciencedirect.com/science/article/pii/S1547527115001393?via%3Dihub	1	2014-01-30	Unknown status	NA	NA	2015-01-31	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number or patients with a recurrence of any atrial arrhythmia\n[ Time Frame: 2 years ]\n\nNumber (percentage) of patients with any atrial arrhythmia lasting longer than 30 s after ablation assessed by implantable loop recorder or 7-day-holter-ECG: AFL after AF ablation compared to the AFL ablation group and AF in both ablation groups""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number or patients with a recurrence of any atrial arrhythmia\n[ Time Frame: 2 years ]\n\nNumber (percentage) of patients with any atrial arrhythmia lasting longer than 30 s after ablation assessed by implantable loop recorder or 7-day-holter-ECG: AFL after AF ablation compared to the AFL ablation group and AF in both ablation groups""}]
NCT02051660	German Evaluation of the Effectiveness of the Psychological Intervention Managing Cancer and Living Meaningfully (CALM)	Spiritual well-being mediates the association between attachment insecurity and psychological distress in advanced cancer patients	10.1007/s00520-019-04744-x	https://pubmed.ncbi.nlm.nih.gov/30887126/	6	2014-01-29	Completed	2013-03-01	2017-06-01	2019-03-18	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient Health Questionnaire-9 (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depression module of the Patient Health Questionnaire (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Beck Depression-Inventory II (BDI-II)\n[ Time Frame: 6-months ]\n\nA reliable and valid 21-item self-report instrument for evaluating the severity of depression.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depression module of the Patient Health Questionnaire (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Beck Depression-Inventory II (BDI-II)\n[ Time Frame: 6-months ]\n\nA reliable and valid 21-item self-report instrument for evaluating the severity of depression.""}]	NA
NCT02052193	Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study	NA	10.1200/jco.2016.34.15_suppl.e21077	https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e21077	4	2014-01-30	Terminated	2014-01-01	2017-01-01	2017-05-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib\n[ Time Frame: day 2-5 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib or Vemurafenib\n[ Time Frame: day 2-5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib\n[ Time Frame: day 2-5 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib or Vemurafenib\n[ Time Frame: day 2-5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib\n[ Time Frame: day 2-5 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib or Vemurafenib\n[ Time Frame: day 2-5 ]""}]	NA	NA
NCT02052960	CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer	NA	10.1200/jco.2018.36.5_suppl.61	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.61	10	2014-01-31	Completed	2014-01-01	2017-07-01	2018-02-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy of CetuGEX™ in terms of progression-free survival\n[ Time Frame: up to 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy of CetuGEX™ in terms of progression-free survival\n[ Time Frame: up to 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of CetuGEX™ (Tomuzotuximab) as compared to Cetuximab in terms of progression-free survival\n[ Time Frame: up to 24 months ]\n\nThe primary objective of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in terms of PFS""}]	[See Results Section.]	NA
NCT02054468	Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia	Effects of single-shot and steady-state propofol anaesthesia on rocuronium dose-response relationship: a randomised trial	10.1111/aas.12523	NA	2	2014-02-03	Completed	2012-03-01	2014-02-01	2015-05-12	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ED-50 of rocuronium\n[ Time Frame: Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min ]\n\nThe primary outcome measure is the 1) ED-50 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""ED-95 of rocuronium\n[ Time Frame: Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min ]\n\nThe primary outcome measure is 2) the ED-95 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ED-50 of rocuronium\n[ Time Frame: Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min ]\n\nThe primary outcome measure is the 1) ED-50 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""ED-95 of rocuronium\n[ Time Frame: Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min ]\n\nThe primary outcome measure is 2) the ED-95 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia""}]	NA	NA
NCT02059369	Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation	Ablation of Complex Fractionated Electrograms With or Without ADditional LINEar Lesions for Persistent Atrial Fibrillation (The ADLINE Trial)	10.1111/jce.13206	NA	3	2014-02-07	Completed	2012-08-01	2014-07-01	2017-04-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Freedom from atrial arrhythmia\n[ Time Frame: 12 months ]\n\nDocumented freedom from atrial arrhythmia (AF or AT) recurrence""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Freedom from atrial arrhythmia\n[ Time Frame: 12 months ]\n\nDocumented freedom from atrial arrhythmia (AF or AT) recurrence""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Freedom from atrial arrhythmia\n[ Time Frame: 12 months ]\n\nDocumented freedom from atrial arrhythmia (AF or AT) recurrence""}]	NA	NA
NCT02066246	Lung Function After Robot-assisted Radical Prostate Ectomy	Perioperative assessment of regional ventilation during changing body positions and ventilation conditions by electrical impedance tomography	10.1093/bja/aew188	https://bjanaesthesia.org/article/S0007-0912(17)33839-4/fulltext	2	2014-02-18	Completed	2013-08-01	2014-09-01	2016-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""forced vital capacity (FVC)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""forced expiratory volume in one second (FEV1)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""forced vital capacity (FVC)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""forced expiratory volume in one second (FEV1)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""forced vital capacity (FVC)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""forced expiratory volume in one second (FEV1)\n[ Time Frame: before operation, 1, 24, 120 hours after surgery ]""}]	NA	NA
NCT02076646	A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma	NA	10.1007/s00262-019-02383-z	https://link.springer.com/article/10.1007/s00262-019-02383-z#citeas	4	2014-02-26	Unknown status	2013-10-01	2016-10-01	2019-09-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: Establish the maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: 21 days ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: evaluation of the antitumor activity\n[ Time Frame: 36 months ]\n\nevaluation of the best objective response rate (BORR)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: Establish the maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: 21 days ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: evaluation of the antitumor activity\n[ Time Frame: 36 months ]\n\nevaluation of the best objective response rate (BORR)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: From day 1 to day 21 of Cycle 1 (each cycle is 21-days) ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: best objective response rate (BORR)\n[ Time Frame: Up to 1 year ]\n\nEvaluation of antitumor activity""}]	NA	NA
NCT02078986	Effectiveness of WB-EMS Versus HIT-Resistance Training (RT)	NA	10.5960/dzsm.2015.209	https://www.germanjournalsportsmedicine.com/index.php?id=53995&L=0Prof	4	2014-03-04	Terminated	2014-02-01	2015-02-01	2015-12-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lean Body mass\n[ Time Frame: 14 weeks (baseline to 14 week follow-up assessment) ]\n\nLean Body Mass as assessed by Dual Energy x-Ray Absorptiometry (DXA) was determined twice, at baseline and after 14 weeks of exercise (WB-EMS or HIT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lean Body mass\n[ Time Frame: 14 weeks (baseline to 14 week follow-up assessment) ]\n\nLean Body Mass as assessed by Dual Energy x-Ray Absorptiometry (DXA) was determined twice, at baseline and after 14 weeks of exercise (WB-EMS or HIT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lean Body mass\n[ Time Frame: 14 weeks (baseline to 14 week follow-up assessment) ]\n\nLean Body Mass as assessed by Dual Energy x-Ray Absorptiometry (DXA) was determined twice, at baseline and after 14 weeks of exercise (WB-EMS or HIT)""}]	NA	NA
NCT02079311	Evaluation of Core Body Temperature When Using Forced Air Warming or an Active Blanket to Prevent Perioperative Hypothermia	Active perioperative patient warming using a self-warming blanket (BARRIER EasyWarm) is superior to passive thermal insulation: a multinational, multicenter, randomized trial	10.1016/j.jclinane.2016.06.030	https://www.sciencedirect.com/science/article/pii/S0952818016303051	3	2014-03-04	Completed	2014-01-01	2014-04-01	2016-07-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in core body temperature in the two treatment groups.\n[ Time Frame: Subjects will be followed for one day of hospital stay, data to be collected during the perioperative phase. Expected to be between 5-8 hours. ]\n\nTemperature assessments will be made using an oesophageal temperature probe when the subject is under general anaesthesia and by oral thermometer for all other temperature assessments performed in pre-, intra- and post-op.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in core body temperature in the two treatment groups.\n[ Time Frame: Subjects will be followed for one day of hospital stay, data to be collected during the perioperative phase. Expected to be between 5-8 hours. ]\n\nTemperature assessments will be made using an oesophageal temperature probe when the subject is under general anaesthesia and by oral thermometer for all other temperature assessments performed in pre-, intra- and post-op.""}]	[See Results Section.]	NA	NA
NCT02080299	Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation	No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial	10.1016/j.ijcard.2016.12.005	https://pubmed.ncbi.nlm.nih.gov/27940009/	4	2014-03-04	Unknown status	2013-09-01	2016-08-01	2016-12-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of periinterventional myocardial injury as reflected by the geometric mean of the area under the curve (AUC) for troponin I serum concentrations\n[ Time Frame: 72 hours postinterventionally after TAVI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of periinterventional myocardial injury as reflected by the geometric mean of the area under the curve (AUC) for troponin I serum concentrations\n[ Time Frame: 72 hours postinterventionally after TAVI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of periinterventional myocardial injury as reflected by the geometric mean of the area under the curve (AUC) for troponin I serum concentrations\n[ Time Frame: 72 hours postinterventionally after TAVI ]""}]	NA	NA
NCT02084381	PERCI- Medium Cut Off (MCO)	Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial	10.1371/journal.pone.0169024	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234772/	3	2014-03-07	Completed	2014-02-01	2014-07-01	2017-01-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha mRNA\n[ Time Frame: 4 weeks treatment time ]\n\nSignificant lower pre- dialytic TNF-α mRNA expression level in circulating peripheral blood mononuclear cells""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha mRNA\n[ Time Frame: 4 weeks treatment time ]\n\nSignificant lower pre- dialytic TNF-α mRNA expression level in circulating peripheral blood mononuclear cells""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha mRNA\n[ Time Frame: 4 weeks treatment time ]\n\nSignificant lower pre- dialytic TNF-α mRNA expression level in circulating peripheral blood mononuclear cells""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TNF-alpha mRNA\n[ Time Frame: 4 weeks treatment time ]\n\nSignificant lower pre- dialytic TNF-α mRNA expression level in circulating peripheral blood mononuclear cells""}]	NA
NCT02090686	Pulsatile Cupping in Low Back Pain	Pulsatile dry cupping in chronic low back pain - a randomized three-armed controlled clinical trial	10.1186/s12906-018-2187-8	https://pubmed.ncbi.nlm.nih.gov/29609566/	2	2014-03-17	Completed	2014-03-01	2014-10-01	2018-04-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of pain on visual analogues scale\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of pain on visual analogues scale\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of pain on visual analogues scale\n[ Time Frame: 4 weeks ]""}]	NA	NA
NCT02092974	Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin	Effects of Anodal Transcranial Direct Current Stimulation and Serotonergic Enhancement on Memory Performance in Young and Older Adults	10.1038/npp.2016.170	https://pubmed.ncbi.nlm.nih.gov/27555381/	7	2014-03-19	Completed	2014-03-01	2014-12-01	2016-08-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.\n[ Time Frame: immediately after end of learning phase (approx. 1 hour) ]\n\nRecall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.\n[ Time Frame: immediately after end of learning phase (approx. 1 hour) ]\n\nRecall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.\n[ Time Frame: immediately after end of learning phase (approx. 1 hour) ]\n\nRecall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.\n[ Time Frame: immediately after end of learning phase (approx. 1 hour) ]\n\nRecall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.""}]	NA
NCT02096562	Knee Swelling Under Use of Compression Stockings After Outpatient Surgery	NA	10.1186/s12891-019-2540-1	https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-019-2540-1	4	2014-03-23	Completed	2013-07-01	2015-03-01	2019-04-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling (circumference and volume)\n[ Time Frame: 10 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling of lower Extremity (circumference in mm and volume in ml)\n[ Time Frame: 10 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling of lower Extremity (circumference in mm and volume in ml)\n[ Time Frame: 10 days ]""}]	NA	NA
NCT02099968	Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial	NA	10.1101/2020.02.23.20027029	https://www.medrxiv.org/content/10.1101/2020.02.23.20027029v1	7	2014-03-26	Completed	2014-04-01	2014-12-01	2020-02-25	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systolic blood pressure\n[ Time Frame: 3 months ]\n\n24-hour ambulatory blood pressure""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""HOMA Index\n[ Time Frame: 3 months ]\n\nHomeostatic Model Assessment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systolic blood pressure\n[ Time Frame: 3 months ]\n\n24-hour ambulatory blood pressure""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""HOMA Index\n[ Time Frame: 3 months ]\n\nHomeostatic Model Assessment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systolic blood pressure\n[ Time Frame: 3 months ]\n\n24-hour ambulatory blood pressure""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""HOMA Index\n[ Time Frame: 3 months ]\n\nHomeostatic Model Assessment""}]	NA	NA
NCT02102919	Innovative Training Program for Elderly in Need of Care Individuals	Sensory-motor training targeting motor dysfunction and muscle weakness in long-term care elderly combined with motivational strategies: a single blind randomized controlled study	10.1186/s11556-016-0164-0	https://pubmed.ncbi.nlm.nih.gov/27239241/	6	2014-03-31	Completed	2013-01-01	2015-01-01	2016-05-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical functional performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	NA
NCT02107534	Group-based Training for Parents of Children With Dyslexia	NA	10.1007/s11145-016-9632-1	https://link.springer.com/article/10.1007%2Fs11145-016-9632-1	1	2014-04-03	Unknown status	NA	NA	2016-02-02	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Parenting Stress Index at 12 weeks\n[ Time Frame: 20 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Parenting Stress Index at 12 weeks\n[ Time Frame: 20 weeks ]""}]
NCT02110043	Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS	Impact of 3-Day Combined Anodal Transcranial Direct Current Stimulation-Visuospatial Training on Object-Location Memory in Healthy Older Adults and Patients with Mild Cognitive Impairment	10.3233/jad-191234	https://pubmed.ncbi.nlm.nih.gov/32280093/	8	2014-04-08	Completed	2014-03-01	2017-08-01	2020-05-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3-day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3-day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3-day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	NA
NCT02110056	Modulation of Visual-Spatial Learning in Healthy Older Adults by tDCS	Hippocampal Pathway Plasticity Is Associated with the Ability to Form Novel Memories in Older Adults	10.3389/fnagi.2016.00061	https://pubmed.ncbi.nlm.nih.gov/27047376/	6	2014-04-08	Completed	2014-03-01	2015-11-01	2016-03-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-Spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after the end of a 3 day training period in tDCS condition compared to sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to an improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day training period compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-Spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after the end of a 3 day training period in tDCS condition compared to sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to an improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day training period compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-Spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after the end of a 3 day training period in tDCS condition compared to sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to an improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day training period compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Performance in LOCATO task (Visual-Spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after the end of a 3 day training period in tDCS condition compared to sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to an improvement of visual-spatial learning and memory measured by performance in LOCATO task after end of a 3 day training period compared to sham stimulation.""}]	NA
NCT02110407	Modulation of Visual-Spatial Learning in Healthy Young Adults by tDCS	Effects of Anodal Transcranial Direct Current Stimulation and Serotonergic Enhancement on Memory Performance in Young and Older Adults	10.1038/npp.2016.170	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399237/	6	2014-04-08	Completed	2014-03-01	2017-01-01	2016-09-21	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""performance in LOCATO task (visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3 day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by the performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""performance in LOCATO task (visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3 day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by the performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""performance in LOCATO task (visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS\n[ Time Frame: immediately after end of a 3 day period of training in tDCS condition vs sham condition ]\n\nInvestigation whether the combination of intensive visual-spatial training (LOCATO task) and tDCS leads to improvement of visual-spatial learning and memory measured by the performance in LOCATO task after end of a 3 day period of training compared to sham stimulation.""}]	NA
NCT02112396	Community Reinforcement and Family Training (CRAFT) for Treatment-resistant Individuals With Alcohol Use Disorders	Efficacy of the Community Reinforcement and Family Training for concerned significant others of treatment-refusing individuals with alcohol dependence: A randomized controlled trial	10.1016/j.drugalcdep.2016.04.015	https://www.ncbi.nlm.nih.gov/pubmed/27141840	1	2014-04-09	Completed	2008-08-01	2011-03-01	2016-04-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment Utilization of relative with AUD\n[ Time Frame: 3 months ]\n\nTreatment utilization rates of the individual holding an AUD were assessed at 3-months follow-up""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment Utilization of relative with AUD\n[ Time Frame: 3 months ]\n\nTreatment utilization rates of the individual holding an AUD were assessed at 3-months follow-up""}]	NA	NA
NCT02115516	Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine	10.1038/nature21060	https://www.nature.com/articles/nature21060	7	2014-04-14	Completed	2014-04-01	2015-12-01	2017-02-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of volunteers who become parasitemic, detected by thick blood film microscopy, within 21 days following CHMI after immunization using PfSPZ Challenge or placebo under chemoprophylaxis [PfSPZ Challenge Vaccine (PfSPZ-CVac) approach].\n[ Time Frame: Within 21 days following CHMI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Occurrence of related Grade 3 adverse events (AEs) and SAEs from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study.\n[ Time Frame: 19 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of volunteers who become parasitemic, detected by thick blood film microscopy, within 21 days following CHMI after immunization using PfSPZ Challenge or placebo under chemoprophylaxis [PfSPZ Challenge Vaccine (PfSPZ-CVac) approach].\n[ Time Frame: Within 21 days following CHMI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Occurrence of related Grade 3 adverse events (AEs) and SAEs from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study.\n[ Time Frame: 19 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of volunteers who become parasitemic, detected by thick blood film microscopy, within 21 days following CHMI after immunization using PfSPZ Challenge or placebo under chemoprophylaxis [PfSPZ Challenge Vaccine (PfSPZ-CVac) approach].\n[ Time Frame: Within 21 days following CHMI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Occurrence of related Grade 3 adverse events (AEs) and SAEs from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study.\n[ Time Frame: 19 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of volunteers who become parasitemic, detected by thick blood film microscopy, within 21 days following CHMI after immunization using PfSPZ Challenge or placebo under chemoprophylaxis [PfSPZ Challenge Vaccine (PfSPZ-CVac) approach].\n[ Time Frame: Within 21 days following CHMI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Occurrence of related Grade 3 adverse events (AEs) and SAEs from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study.\n[ Time Frame: 19 months ]""}]	NA
NCT02115880	PRimary Prevention Of Depression in Offspring of Depressed Parents	Qualitative evaluation of a preventive intervention for the offspring of parents with a history of depression	10.1186/s12888-019-2273-6	NA	2	2014-04-14	Unknown status	NA	NA	2019-09-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Presence or absence of a depressive episode (child)\n[ Time Frame: T4 (9 months after completion of the programme) ]\n\nThe German version of the Diagnostic Interview for Psychiatric Disorders in Children and Adolescents (Kinder DIPS) will be used to assess whether the child meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for a depressive episode.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Presence or absence of a depressive episode (child)\n[ Time Frame: T4 (9 months after completion of the programme) ]\n\nThe German version of the Diagnostic Interview for Psychiatric Disorders in Children and Adolescents (Kinder DIPS) will be used to assess whether the child meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for a depressive episode.""}]
NCT02116088	Prevention and Intervention of Externalizing Problem Behavior in School: Development and Evaluation of a Teacher Coaching.	NA	10.1177/0143034320958743	https://journals.sagepub.com/doi/10.1177/0143034320958743	2	2014-04-14	Unknown status	2012-10-01	2015-07-01	2020-09-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Questionnaire on Behavior in School Lessons (FVU)\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Questionnaire on Behavior in School Lessons (FVU)\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Questionnaire on Behavior in School Lessons (FVU)\n[ Time Frame: one year ]""}]	NA	NA
NCT02118779	Observational Prolonged Trial in Myotonic Dystrophy Type 1	Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial	10.1016/s1474-4422(18)30203-5	NA	7	2014-04-18	Completed	2014-04-01	2016-03-01	2018-06-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DM1-Activ\n[ Time Frame: Baseline and 10 months ]\n\nThe primary outcome measure will be the change in DM1-Activ score. DM1-Activ is a specific outcome measure of activity and participation for patients with DM1.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DM1-Activ\n[ Time Frame: Baseline and 10 months ]\n\nThe primary outcome measure will be the change in DM1-Activ score. DM1-Activ is a specific outcome measure of activity and participation for patients with DM1.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""DM1-Activ\n[ Time Frame: Baseline and 10 months ]\n\nThe primary outcome measure will be the change in DM1-Activ score. DM1-Activ is a specific outcome measure of activity and participation for patients with DM1.""}]	NA	NA
NCT02121704	Magnetic Endoscope Imaging in Colonoscopy: Influence on Propofol Dosage	Magnetic endoscope imaging for routine colonoscopy: impact on propofol dosage and patient safety - a randomized trial	10.1055/s-0042-110933	NA	3	2014-04-22	Completed	2014-05-01	2015-08-01	2016-07-21	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Propofol dose\n[ Time Frame: up to one day (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 1 day) ]\n\nAt the end of colonoscopy total dose of Propofol applicated will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Propofol dose\n[ Time Frame: up to one day (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 1 day) ]\n\nAt the end of colonoscopy total dose of Propofol applicated will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Propofol dose\n[ Time Frame: up to one day (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 1 day) ]\n\nAt the end of colonoscopy total dose of Propofol applicated will be assessed.""}]	NA	NA
NCT02125344	A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial	10.1016/j.ejca.2018.10.015	https://pubmed.ncbi.nlm.nih.gov/30528802/	4	2014-04-25	Completed	2014-12-01	2016-11-01	2018-12-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pathological complete response (pCR= ypT0/is ypN0)\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nTo compare the pathological complete response (pCR= ypT0/is ypN0) rates of neoadjuvant treatment with sequential, dose-dense, dose-intensified ETC(+HP) vs. weekly PM(Cb)(+HP) in patients with high-risk operable or locally advanced breast cancer.\n\nMasked role for assessor.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nOnly for those patients randomized for the supportive anemia treatment:\n\nTo compare the frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2 (Hb < 10g/dl) between patients receiving supportive treatment for iron deficiency with parental ferric carboxymaltose versus physician's choice (no supportive treatment, oral iron substitution, erythropoiesis-stimulating agent (ESA), or both).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pathological complete response (pCR= ypT0/is ypN0)\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nTo compare the pathological complete response (pCR= ypT0/is ypN0) rates of neoadjuvant treatment with sequential, dose-dense, dose-intensified ETC(+HP) vs. weekly PM(Cb)(+HP) in patients with high-risk operable or locally advanced breast cancer.\n\nMasked role for assessor.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nOnly for those patients randomized for the supportive anemia treatment:\n\nTo compare the frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2 (Hb < 10g/dl) between patients receiving supportive treatment for iron deficiency with parental ferric carboxymaltose versus physician's choice (no supportive treatment, oral iron substitution, erythropoiesis-stimulating agent (ESA), or both).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pathological complete response (pCR= ypT0/is ypN0)\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nTo compare the pathological complete response (pCR= ypT0/is ypN0) rates of neoadjuvant treatment with sequential, dose-dense, dose-intensified ETC(+HP) vs. weekly PM(Cb)(+HP) in patients with high-risk operable or locally advanced breast cancer.\n\nMasked role for assessor.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2\n[ Time Frame: 18 weeks (time window + 3 weeks) ]\n\n\n\nOnly for those patients randomized for the supportive anemia treatment:\n\nTo compare the frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2 (Hb < 10g/dl) between patients receiving supportive treatment for iron deficiency with parental ferric carboxymaltose versus physician's choice (no supportive treatment, oral iron substitution, erythropoiesis-stimulating agent (ESA), or both).""}]	NA	NA
NCT02125669	Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas	The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial	10.1111/bjd.13266	NA	1	2014-04-27	Completed	2012-11-01	2013-09-01	2015-01-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""complete response\n[ Time Frame: 9 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""complete response\n[ Time Frame: 9 months ]""}]	NA	NA
NCT02125903	Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy	Continuous adductor canal block versus continuous femoral nerve block after total knee arthroplasty for mobilisation capability and pain treatment: a randomised and blinded clinical trial	10.1007/s00402-015-2403-7	https://pubmed.ncbi.nlm.nih.gov/26754752/	2	2014-04-28	Completed	2013-05-01	2014-05-01	2016-01-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Timed-Up and Go-test for mobility evaluation\n[ Time Frame: third postoperative day ]\n\nThe patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Timed-Up and Go-test for mobility evaluation\n[ Time Frame: third postoperative day ]\n\nThe patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Timed-Up and Go-test for mobility evaluation\n[ Time Frame: third postoperative day ]\n\nThe patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.""}]	NA	NA
NCT02126085	Sedation vs. Intubation for Endovascular Stroke TreAtment	Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy: A Randomized Clinical Trial	10.1001/jama.2016.16623	https://pubmed.ncbi.nlm.nih.gov/27785516/	7	2014-04-28	Completed	2014-04-01	2016-02-01	2016-10-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""National Institutes of Health Stroke Scale (NIHSS) after 24 hours\n[ Time Frame: 24 hours ]\n\nNeurological improvement of NIHSS 24 hours after intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""National Institutes of Health Stroke Scale (NIHSS) after 24 hours\n[ Time Frame: 24 hours ]\n\nNeurological improvement of NIHSS 24 hours after intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""National Institutes of Health Stroke Scale (NIHSS) after 24 hours\n[ Time Frame: 24 hours ]\n\nNeurological improvement of NIHSS 24 hours after intervention""}]	NA	NA
NCT02126852	Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia	NA	NA	https://mediatum.ub.tum.de/1304544	3	2014-04-28	Completed	2014-04-01	2016-04-01	2017-09-04	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of TOF-ratios obtained with acceleromyography and electromyography\n[ Time Frame: during surgery (2 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""This study evaluates the precision and agreement of TOF-ratios obtained with acceleromyography and electromyography during residual neuromuscular paralysis\n[ Time Frame: during surgery (2 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""This study evaluates the precision and agreement of TOF-ratios obtained with acceleromyography and electromyography during residual neuromuscular paralysis\n[ Time Frame: during surgery (2 hours) ]""}]	NA	NA
NCT02129400	Influence on Erythropoetin-level by Xenon	Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial	10.1007/s40279-016-0505-1	https://pubmed.ncbi.nlm.nih.gov/26939898/	3	2014-04-30	Terminated	2014-05-01	2015-01-01	2016-11-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total\n[ Time Frame: up to 216 hrs after first xenon-application ]\n\n\n\nChange from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total.\n\nTimepoints of measurement:\n\nBefore each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total\n[ Time Frame: up to 216 hrs after first xenon-application ]\n\n\n\nChange from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total.\n\nTimepoints of measurement:\n\nBefore each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total\n[ Time Frame: up to 216 hrs after first xenon-application ]\n\n\n\nChange from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total.\n\nTimepoints of measurement:\n\nBefore each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation""}]	NA	NA
NCT02134457	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial	10.1001/jamapediatrics.2017.4838	https://pubmed.ncbi.nlm.nih.gov/29309486/	6	2014-05-06	Completed	2014-08-01	2017-01-01	2018-03-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of treatment\n[ Time Frame: Up to 24 weeks post first injection ]\n\n\n\nEfficacy is determined by the number of infants without need for rescue treatment up to week 24 post first injection.\n\nRe-injection of study dose is not considered rescue treatment if applied after an initial response to treatment and after at least 4 weeks post injection.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of treatment\n[ Time Frame: Up to 24 weeks post first injection ]\n\n\n\nEfficacy is determined by the number of infants without need for rescue treatment up to week 24 post first injection.\n\nRe-injection of study dose is not considered rescue treatment if applied after an initial response to treatment and after at least 4 weeks post injection.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of treatment\n[ Time Frame: Up to 24 weeks post first injection ]\n\n\n\nEfficacy is determined by the number of infants without need for rescue treatment up to week 24 post first injection.\n\nRe-injection of study dose is not considered rescue treatment if applied after an initial response to treatment and after at least 4 weeks post injection.""}]	NA	NA
NCT02134769	Influence of Bionecteurs on Catheter-associated Infection	Needle-free connectors catheter-related bloodstream infections: a prospective randomized controlled trial	10.1186/s40635-019-0277-7	https://icm-experimental.springeropen.com/articles/10.1186/s40635-019-0277-7	3	2014-05-07	Completed	2014-05-01	2015-11-01	2019-12-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of catheter-related bloodstream infections using Bionecteurs\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of catheter-related bloodstream infections using Bionecteurs\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of catheter-related bloodstream infections using Bionecteurs\n[ Time Frame: 1 year ]""}]	NA	NA
NCT02135926	Thrombectomy in Patients Ineligible for iv tPA	Early termination of THRILL, a prospective study of mechanical thrombectomy in patients with acute ischemic stroke ineligible for i.v. thrombolysis	10.1007/s00062-016-0538-8	https://link.springer.com/article/10.1007/s00062-016-0538-8	7	2014-05-06	Terminated	2014-03-01	2018-02-01	2016-09-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mRS Shift\n[ Time Frame: 90 (+/-14) days after treatment ]\n\nThe primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days poststroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days postprocedure between treatment groups (\""mRS shift analysis\""). The null and alternative hypotheses are β ≥ 0 and β < 0, respectively, where β is the treatment arm parameter in a proportional-odds logistic model with mRS category as response variable.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mRS Shift\n[ Time Frame: 90 (+/-14) days after treatment ]\n\nThe primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days poststroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days postprocedure between treatment groups (\""mRS shift analysis\""). The null and alternative hypotheses are β ≥ 0 and β < 0, respectively, where β is the treatment arm parameter in a proportional-odds logistic model with mRS category as response variable.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mRS Shift\n[ Time Frame: 90 (+/-14) days after treatment ]\n\nThe primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days poststroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days postprocedure between treatment groups (\""mRS shift analysis\""). The null and alternative hypotheses are β ≥ 0 and β < 0, respectively, where β is the treatment arm parameter in a proportional-odds logistic model with mRS category as response variable.""}]	NA
NCT02137798	Reduction of Fluoroscopy Exposure During Atrial Fibrillation Ablation	Reduction of radiation exposure during atrial fibrillation ablation using a novel fluoroscopy image integrated 3-dimensional electroanatomic mapping system: A prospective, randomized, single-blind, and controlled study	10.1016/j.hrthm.2015.05.018	https://pubmed.ncbi.nlm.nih.gov/26001508/	2	2014-05-13	Completed	2014-03-01	2014-09-01	2015-05-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fluoroscopy time for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy time will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fluoroscopy doses for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy doses will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fluoroscopy time for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy time will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fluoroscopy doses for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy doses will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fluoroscopy time for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy time will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fluoroscopy doses for each step of atrial fibrillation ablation procedure\n[ Time Frame: 1 day ( at the end of each step of atrial fibrillation ablation procedure) ]\n\nFluoroscopy doses will be recorded at the end of each step of atrial fibrillation ablation, including femoral vein puncture, placement of catheters, transseptal puncture, system registration, reconstruction of left atrium, PV-Angiography, acquirement of voltage map, PV-isolation, confirmation of complete PV isolation and linear ablations.""}]	NA	NA
NCT02138552	Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo	Impact of different concentrations of an octenidine dihydrochloride mouthwash on salivary bacterial counts: a randomized, placebo-controlled cross-over trial	10.1007/s00784-018-2379-0	https://pubmed.ncbi.nlm.nih.gov/29500541/	1	2014-05-12	Completed	2013-10-01	2014-04-01	2018-05-02	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bacterial count reduction in saliva after a single application of OML in comparison to placebo application\n[ Time Frame: After 1 minute of rinsing ]\n\nBacterial count reduction is measured at V1 (Verum/Placebo) and V3 (Placebo/Verum) in a blinded cross-over design""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bacterial count reduction in saliva after a single application of OML in comparison to placebo application\n[ Time Frame: After 1 minute of rinsing ]\n\nBacterial count reduction is measured at V1 (Verum/Placebo) and V3 (Placebo/Verum) in a blinded cross-over design""}]	NA	NA
NCT02142231	AcuTA: Acupuncture in Test Anxiety	Effects of single-point acupuncture (HT7) in the prevention of test anxiety: Results of a RCT	10.1371/journal.pone.0202659	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116988/	2	2014-05-19	Completed	2014-04-01	2014-06-01	2018-08-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cortisol in saliva\n[ Time Frame: 8 timepoints (in minutes: -40;-10;+10;+20;+30;+40;+55;+70) ]\n\nSaliva samples will be obtained at above mentioned intervals for subsequent analysis of cortisol a in saliva. The stress model used in this trial is supposed to elevate cortisol in saliva 3-5 fold in controls.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cortisol in saliva\n[ Time Frame: 8 timepoints (in minutes: -40;-10;+10;+20;+30;+40;+55;+70) ]\n\nSaliva samples will be obtained at above mentioned intervals for subsequent analysis of cortisol a in saliva. The stress model used in this trial is supposed to elevate cortisol in saliva 3-5 fold in controls.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cortisol in saliva\n[ Time Frame: 8 timepoints (in minutes: -40;-10;+10;+20;+30;+40;+55;+70) ]\n\nSaliva samples will be obtained at above mentioned intervals for subsequent analysis of cortisol a in saliva. The stress model used in this trial is supposed to elevate cortisol in saliva 3-5 fold in controls.""}]	NA	NA
NCT02143427	Treatment of Children With Peer Related Aggressive Behavior (ScouT)	Efficacy of an Individualized Computer-Assisted Social Competence Training Program for Children With Oppositional Defiant Disorders/Conduct Disorders	10.3389/fpsyt.2019.00682	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759956/	2	2014-05-20	Unknown status	2014-05-01	NA	2019-09-18	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""total score for peer related aggression in the Questionnaire for Aggressive Behavior of Children (FAVK) parent rating\n[ Time Frame: change from pre- to post1-assessment (24 weeks after pre-assessment), from post1- to post2-assessment (16 weeks after post1-assessment), and to follow up (12 months after post2-assessment) ]\n\nThe Questionnaire for Aggressive Behavior of Children (FAVK) is a newly developed parent rating scale which assesses several factors of peer related aggression: (1) disturbance of social cognitive information processing, (2) disturbance of social problem solving and social skills, (3) disturbance of impulse control, and (4) disturbance of social interaction. These scores a summed to a total score.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""total score for peer related aggression in the Questionnaire for Aggressive Behavior of Children (FAVK) parent rating\n[ Time Frame: change from pre- to post1-assessment (24 weeks after pre-assessment), from post1- to post2-assessment (16 weeks after post1-assessment), and to follow up (12 months after post2-assessment) ]\n\nThe Questionnaire for Aggressive Behavior of Children (FAVK) is a newly developed parent rating scale which assesses several factors of peer related aggression: (1) disturbance of social cognitive information processing, (2) disturbance of social problem solving and social skills, (3) disturbance of impulse control, and (4) disturbance of social interaction. These scores a summed to a total score.""}]
NCT02144870	Efficacy of Psychotherapy Treatment of Children With Tics	Efficacy of Habit Reversal Training in Children With Chronic Tic Disorders: A Within-Subject Analysis	10.1177/0145445518796203	https://journals.sagepub.com/doi/10.1177/0145445518796203	2	2014-05-19	Unknown status	2013-11-01	NA	2018-08-27	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Symptom Checklist for Tic-Symptoms (FBB-TIC, parent rating) at week 8, 16 and 24\n[ Time Frame: eight weeks (T1), sixteen weeks (T2) and 24 weeks (T3) ]\n\nThe FBB-TIC is used to assess Tic-Symptoms according to DSM-IV and ICD-10 rated by parents""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in Quality of Life (Tic-HRQoL-FBB)(parent rating)\n[ Time Frame: eight weeks (T1) and twenty-four weeks (T3) ]\n\nThe Tic-HRQoL-FBB is used to assess impairment and quality of life through tic symptoms and other comorbid symptoms rated by parents""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Symptom Checklist for Tic-Symptoms (FBB-TIC, parent rating) at week 8, 16 and 24\n[ Time Frame: eight weeks (T1), sixteen weeks (T2) and 24 weeks (T3) ]\n\nThe FBB-TIC is used to assess Tic-Symptoms according to DSM-IV and ICD-10 rated by parents""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in Quality of Life (Tic-HRQoL-FBB)(parent rating)\n[ Time Frame: eight weeks (T1) and twenty-four weeks (T3) ]\n\nThe Tic-HRQoL-FBB is used to assess impairment and quality of life through tic symptoms and other comorbid symptoms rated by parents""}]
NCT02148770	The Effect of Neurofeedback on Eating Behaviour	Volitional regulation of brain responses to food stimuli in overweight and obese subjects: A real-time fMRI feedback study	10.1016/j.appet.2017.01.032	https://www.sciencedirect.com/science/article/abs/pii/S0195666316305220?via%3Dihub	3	2014-05-27	Unknown status	2014-11-01	NA	2017-01-25	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Connectivity\n[ Time Frame: 3 weeks ]\n\nDifference in functional connectivity between the ventral medial prefrontal cortex and the dorsal lateral prefrontal cortex before and after the training sessions during food choice task inside the scanner""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Activity in the dlPFC during the training-session\n[ Time Frame: 1 day ]\n\nDifferences in dlPFC activity between baseline and after up-regulation during the neurofeedback training session, as well as the difference between the treatment and the sham groups (ANCOVA approach).""}]
NCT02148835	Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals	Bioavailability of Dietary Omega-3 Fatty Acids Added to a Variety of Sausages in Healthy Individuals	10.3390/nu9060629	NA	3	2014-05-23	Completed	2014-05-01	2014-12-01	2017-06-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[See Results Section.]	NA
NCT02149238	Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects	Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies	10.3945/ajcn.116.140046	https://pubmed.ncbi.nlm.nih.gov/28003203/	2	2014-05-26	Completed	2011-02-01	2014-12-01	2016-12-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: 2 hours ]\n\nFlow mediated dilatation (FMD)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Plasma flavanol metabolites\n[ Time Frame: 2 hours ]\n\nMeasured by HPLC""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: 2 hours ]\n\nFlow mediated dilatation (FMD)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Plasma flavanol metabolites\n[ Time Frame: 2 hours ]\n\nMeasured by HPLC""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: 2 hours ]\n\nFlow mediated dilatation (FMD)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Plasma flavanol metabolites\n[ Time Frame: 2 hours ]\n\nMeasured by HPLC""}]	NA	NA
NCT02153294	PRotective VENTilation in Patients Without ARDS	Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial	10.1001/jama.2018.14280	https://pubmed.ncbi.nlm.nih.gov/30357256/	9	2014-06-02	Completed	2014-08-01	2017-09-20	2018-11-13	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator-free days\n[ Time Frame: first 28 days after start of ventilation ]\n\nThe number of ventilator-free days, defined as the number of days from day 1 to day 28 on which a patient breathes without assistance, if the period of unassisted breathing lasted at least 24 consecutive hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator-free days\n[ Time Frame: first 28 days after start of ventilation ]\n\nThe number of ventilator-free days, defined as the number of days from day 1 to day 28 on which a patient breathes without assistance, if the period of unassisted breathing lasted at least 24 consecutive hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator-free days\n[ Time Frame: first 28 days after start of ventilation ]\n\nThe number of ventilator-free days, defined as the number of days from day 1 to day 28 on which a patient breathes without assistance, if the period of unassisted breathing lasted at least 24 consecutive hours.""}]	NA	NA
NCT02156661	Oxytocin and Emotion Processing	The influence of oxytocin on volitional and emotional ambivalence	10.1093/scan/nsu147	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483569/	3	2014-06-04	Completed	2013-05-01	2014-06-01	2014-12-10	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain activity\n[ Time Frame: During emotion processing ]\n\nfMRI""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain activity\n[ Time Frame: During emotion processing ]\n\nfMRI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain activity\n[ Time Frame: During emotion processing ]\n\nfMRI""}]	NA
NCT02158468	Effect of Conditioning on Myocardial Damage in STEMI	Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial	10.1093/eurheartj/ehv463	https://pubmed.ncbi.nlm.nih.gov/26385956/	2	2014-06-04	Completed	2011-10-01	2014-08-01	2015-09-17	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Myocardial salvage assessed by MRI\n[ Time Frame: 1 week after infarction ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Myocardial salvage assessed by MRI\n[ Time Frame: 1 week after infarction ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Myocardial salvage assessed by MRI\n[ Time Frame: 1 week after infarction ]""}]	NA
NCT02163863	BioMimics 3D Stent Clinical Investigation: The Mimics Study	Helical Centerline Stent Improves Patency: Two-Year Results From the Randomized Mimics Trial	10.1161/circinterventions.115.002930	https://pubmed.ncbi.nlm.nih.gov/27208046/	3	2014-06-13	Completed	2010-02-01	2012-10-01	2016-06-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary safety endpoint\n[ Time Frame: 30 days ]\n\nFreedom from major adverse events defined as death, amputation and target lesion revascularization (TLR)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary performance endpoint\n[ Time Frame: 6 months ]\n\nFreedom from clinically driven TLR""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary safety endpoint\n[ Time Frame: 30 days ]\n\nFreedom from major adverse events defined as death, amputation and target lesion revascularization (TLR)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary performance endpoint\n[ Time Frame: 6 months ]\n\nFreedom from clinically driven TLR""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary safety endpoint\n[ Time Frame: 30 days ]\n\nFreedom from major adverse events defined as death, amputation and target lesion revascularization (TLR)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary performance endpoint\n[ Time Frame: 6 months ]\n\nFreedom from clinically driven TLR""}]	NA
NCT02169115	Urticaria Facticia Treatment With Omalizumab (UFO)	Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial	10.1016/j.jaci.2017.01.042	https://pubmed.ncbi.nlm.nih.gov/28389391/	5	2014-06-18	Completed	2012-12-01	2014-12-01	2017-04-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in provocation thresholds from baseline to day 70 in urticaria factitia patients after treatment with omalizumab compared to placebo\n[ Time Frame: 70 days ]\n\nPatients receive provocation test by FricTest (standardized stroking of the skin). The development of wheals within 30 minutes after provocation is monitored.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in provocation thresholds from baseline to day 70 in urticaria factitia patients after treatment with omalizumab compared to placebo\n[ Time Frame: 70 days ]\n\nPatients receive provocation test by FricTest (standardized stroking of the skin). The development of wheals within 30 minutes after provocation is monitored.""}]	[See Results Section.]	[See Results Section.]	NA
NCT02175953	Short-term Caregiver Psychotherapy	NA	10.1007/s00391-018-01501-3	https://link.springer.com/article/10.1007/s00391-018-01501-3	5	2014-06-25	Completed	2014-06-01	2015-11-01	2019-01-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in caregiver burden directly and 3 month after psychotherapeutical intervention\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nZarid Burden Interview will be used to measure caregiver burden""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in perceived self-efficacy directly and 3 month after psychotherapeutical intervention and reduction of symptoms of depression\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nSWE, a german self-efficacy self-rating scale, will be used for self-efficacy measurement AND ADS (German Version of the CES-D Scale) for measurement for symptoms of depression""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in perceived self-efficacy directly and 3 month after psychotherapeutical intervention and reduction of symptoms of depression\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nSWE, a german self-efficacy self-rating scale, will be used for self-efficacy measurement AND ADS (German Version of the CES-D Scale) for measurement for symptoms of depression""}]	NA	NA
NCT02178631	Effectiveness of Internet-based Depression Treatment (EVIDENT) in Severe Depression	NA	10.1016/j.invent.2014.12.003	https://www.sciencedirect.com/science/article/pii/S2214782914000402	2	2014-06-27	Completed	2013-02-01	2014-05-01	2015-03-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient Health Questionnaire - 9 items (PHQ-9)\n[ Time Frame: Change from Baseline to post (3mths). ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient Health Questionnaire - 9 items (PHQ-9)\n[ Time Frame: Change from Baseline to post (3mths). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient Health Questionnaire - 9 items (PHQ-9)\n[ Time Frame: Change from Baseline to post (3mths). ]""}]	NA
NCT02181101	Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial	10.1186/s13058-015-0639-3	NA	1	2014-07-01	Completed	2005-09-01	2013-09-01	2015-09-18	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival\n[ Time Frame: 5 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival\n[ Time Frame: 5 years ]""}]	NA	NA
NCT02189408	Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration	Does intraoperative application of leukocyte-poor platelet-rich plasma during arthroscopy for knee degeneration affect postoperative pain, function and quality of life? A 12-month randomized controlled double-blind trial	10.1007/s00402-015-2227-5	https://link.springer.com/article/10.1007%2Fs00402-015-2227-5	1	2014-07-11	Completed	2010-07-01	2012-12-01	2015-05-10	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain ( VAS )\n[ Time Frame: 6 months ]\n\nmeasurement of pain using a 100 mm VAS as platelet- rich-plasma demonstrated temporarily analgetic effects up to 6-9 months after application.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain ( VAS )\n[ Time Frame: 6 months ]\n\nmeasurement of pain using a 100 mm VAS as platelet- rich-plasma demonstrated temporarily analgetic effects up to 6-9 months after application.""}]	NA	NA
NCT02189473	Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression	Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01)	10.1200/jco.2015.64.0862	https://pubmed.ncbi.nlm.nih.gov/26729431/	8	2014-07-10	Completed	2010-09-01	2015-07-01	2016-01-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[See Results Section.]	NA
NCT02196324	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial	10.1016/j.jaad.2019.01.052	https://www.jaad.org/article/S0190-9622(19)30161-6/fulltext	5	2014-07-21	Completed	2014-07-01	2016-05-01	2019-03-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of VPD-737 5-mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of VPD-737 5-mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of serlopitant 5 mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	NA
NCT02196545	Physical Activity Training Program for Patients With Alzheimer's Dementia	Effects of physical activity training in patients with Alzheimer's dementia: results of a pilot RCT study	10.1371/journal.pone.0121478	https://www.ncbi.nlm.nih.gov/pubmed/25884637?dopt=Abstract	1	2014-07-18	Completed	2011-08-01	2013-07-01	2015-04-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""activities of daily living\n[ Time Frame: change from baseline after 12 weeks ]\n\nAlzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""activities of daily living\n[ Time Frame: change from baseline after 12 weeks ]\n\nAlzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL)""}]	NA	NA
NCT02196896	Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy	Online Self-Help as an Add-On to Inpatient Psychotherapy: Efficacy of a New Blended Treatment Approach	10.1159/000481177	https://www.karger.com/Article/Abstract/481177	8	2014-07-21	Completed	2014-06-01	2016-11-01	2017-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Six months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Three months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Three months after randomization ]""}]	NA	NA
NCT02197546	Acupuncture for Pain During Injection of Local Anaesthetic	Acupuncture Reduces Pain and Autonomic Distress During Injection of Local Anesthetic in Children: A Pragmatic Crossover Investigation	10.1097/ajp.0000000000000222	NA	1	2014-07-21	Completed	2010-07-01	2011-06-01	2016-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: 3 time points during one day of investigation ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: 3 time points during one day of investigation ]""}]	NA	NA
NCT02199106	Effectiveness of Neuronavigated Continuous Theta Burst Stimulation of the Left Heschl's Gyrus in Chronic Tinnitus	Neuronavigated left temporal continuous theta burst stimulation in chronic tinnitus	10.3233/rnn-150518	NA	1	2014-07-23	Completed	2009-01-01	2011-03-01	2016-03-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus questionnaire total score (contrast baseline (-day 3) versus end of treatment (day 10))\n[ Time Frame: -day 3; day 10 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in tinnitus questionnaire total score (contrast baseline (-day 3) versus end of treatment (day 10))\n[ Time Frame: -day 3; day 10 ]""}]	NA	NA
NCT02203461	Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication	Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study	10.3851/imp3049	NA	2	2014-07-28	Completed	2014-07-01	2014-10-01	2016-04-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin resistance, measured by hyperinsulinemic euglycemic clamp\n[ Time Frame: Day 14 ]\n\nChanges in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin resistance, measured by hyperinsulinemic euglycemic clamp\n[ Time Frame: Day 14 ]\n\nChanges in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin resistance, measured by hyperinsulinemic euglycemic clamp\n[ Time Frame: Day 14 ]\n\nChanges in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.""}]	NA	NA
NCT02207582	Prefrontal Transcranial Random Noise Stimulation in Patients With Depression	Bifrontal high-frequency transcranial random noise stimulation is not effective as an add-on treatment in depression	10.1016/j.jpsychires.2020.10.011	https://www.sciencedirect.com/science/article/pii/S0022395620310141	5	2014-08-01	Terminated	2014-07-01	2017-01-01	2020-10-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]\n\nChange in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))""}]	NA	NA
NCT02213367	Bilastine Updosing in Chronic Spontaneous Urticaria	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study	10.1111/all.13494	https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.13494	3	2014-08-08	Completed	2014-07-01	2016-03-01	2018-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on disease activity in patients with chronic spontaneous urticaria.\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on disease activity in patients with chronic spontaneous urticaria.\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on disease activity in patients with chronic spontaneous urticaria.\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT02216526	Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents	The effectiveness of standardized skin care regimens on skin dryness in nursing home residents: A randomized controlled parallel-group pragmatic trial	10.1016/j.ijnurstu.2017.02.006	https://pubmed.ncbi.nlm.nih.gov/28214613/	4	2014-08-13	Completed	2014-09-01	2015-04-01	2017-02-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[See Results Section.]	NA
NCT02217657	SmartTouch Catheter for Left Anterior Line - SmarT Line Study	Benefit of Contact Force Sensing Catheter Technology for Successful Left Atrial Anterior Line Formation: A Prospective Randomized Trial	10.1155/2018/9784259	NA	3	2014-08-14	Completed	2013-08-01	2016-12-01	2018-09-18	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of total RF application until bidirectional conduction block across the anterior line is achieved (including a waiting period of 30 minutes)\n[ Time Frame: 30 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of total RF application until bidirectional conduction block across the anterior line is achieved (including a waiting period of 30 minutes)\n[ Time Frame: 30 minutes ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of total RF application until bidirectional conduction block across the anterior line is achieved (including a waiting period of 30 minutes)\n[ Time Frame: 30 minutes ]""}]	NA
NCT02220517	Randomized Study Comparing MR-guided in Bore Versus MRI/US Fusion-guided Prostate Biopsy	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial	10.1007/s00345-015-1612-6	https://link.springer.com/article/10.1007/s00345-015-1612-6	2	2014-08-18	Completed	2011-11-01	2014-08-01	2015-06-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prostate cancer detection rate\n[ Time Frame: 1 week after biopsy ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Prostate cancer detection rate\n[ Time Frame: 1 week after biopsy ]""}]	NA	NA
NCT02222051	Tai Chi for Chronic Non-specific Neck Pain	The Effects of Tai Chi and Neck Exercises in the Treatment of Chronic Nonspecific Neck Pain: A Randomized Controlled Trial	10.1016/j.jpain.2016.06.004	https://pubmed.ncbi.nlm.nih.gov/27345663/	4	2014-08-20	Completed	2014-08-01	2014-12-01	2016-06-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: week 12 ]\n\npain intensity on a visual analogue scale (0-100mm)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: week 12 ]\n\npain intensity on a visual analogue scale (0-100mm)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: week 12 ]\n\npain intensity on a visual analogue scale (0-100mm)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain intensity\n[ Time Frame: week 12 ]\n\npain intensity on a visual analogue scale (0-100mm)""}]	NA
NCT02222675	Conserving Breast Surgery - Comparison of Conventional With Sonography	Ultrasound-Assisted Tumor Surgery in Breast Cancer - A Prospective, Randomized, Single-Center Study (MAC 001)	10.1055/a-0637-1725	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-0637-1725	2	2014-08-20	Completed	2009-04-01	2015-04-01	2018-07-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of second tumor resections\n[ Time Frame: Five years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of second tumor resections\n[ Time Frame: Five years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of second tumor resections\n[ Time Frame: Five years ]""}]	NA	NA
NCT02223091	KOKON Consultation on Complementary Medicine in Oncology - a Pilot Study	A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study	10.1186/s12885-016-2884-y	https://pubmed.ncbi.nlm.nih.gov/27809814/	5	2014-08-21	Completed	2014-09-01	2015-02-01	2016-11-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effectiveness of the training program\n[ Time Frame: day 1-7 ]\n\nThis is an exploratory study. The main aim is to evaluate the effectiveness of the training program which will be achieved using the different outcome measures defined here as secondary outcome measures.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effectiveness of the training program\n[ Time Frame: day 1-7 ]\n\nThis is an exploratory study. The main aim is to evaluate the effectiveness of the training program which will be achieved using the different outcome measures defined here as secondary outcome measures.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effectiveness of the training program\n[ Time Frame: day 1-7 ]\n\nThis is an exploratory study. The main aim is to evaluate the effectiveness of the training program which will be achieved using the different outcome measures defined here as secondary outcome measures.""}]	NA	NA
NCT02223767	TMS Augmented Exposure Therapy	Medial prefrontal cortex stimulation accelerates therapy response of exposure therapy in acrophobia	10.1016/j.brs.2016.11.007	https://www.sciencedirect.com/science/article/abs/pii/S1935861X16303084	4	2014-08-21	Completed	2014-08-01	2015-04-01	2016-11-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Questionaires\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Behavioral approach test\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective anxiety symptoms\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Subjective anxiety in height situation\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement by an behavioral approach test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective anxiety symptoms\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Subjective anxiety in height situation\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement by an behavioral approach test""}]	NA	NA
NCT02227550	Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation	10.1093/eurheartj/ehy176	https://pubmed.ncbi.nlm.nih.gov/29579168/	13	2014-08-27	Completed	2014-12-01	2017-04-01	2018-08-21	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""death and serious cardiovascular events\n[ Time Frame: appr. 4 months ]\n\nA composite of all-cause death, stroke (ischemic stroke, subarachnoid haemorrhage and haemorrhagic stroke), and major bleeding events, def.as BARC 2 or higher""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""death and serious cardiovascular events\n[ Time Frame: appr. 4 months ]\n\nA composite of all-cause death, stroke (ischemic stroke, subarachnoid haemorrhage and haemorrhagic stroke), and major bleeding events, def.as BARC 2 or higher""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""death and serious cardiovascular events\n[ Time Frame: appr. 4 months ]\n\nA composite of all-cause death, stroke (ischemic stroke, subarachnoid haemorrhage and haemorrhagic stroke), and major bleeding events, def.as BARC 2 or higher""}]	NA	NA
NCT02238392	Adenosine vs AF Termination for Paroxysmal AF Ablation	Arrhythmia Termination Versus Elimination of Dormant Pulmonary Vein Conduction as a Procedural End Point of Catheter Ablation for Paroxysmal Atrial Fibrillation: A Prospective Randomized Trial	10.1161/circep.115.002786	https://pubmed.ncbi.nlm.nih.gov/26297786/	1	2014-09-10	Completed	2012-01-01	2014-06-01	2015-08-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Arrhythmia-free survival\n[ Time Frame: 1 year ]\n\narrhythmia-free outcome during 1 year after the procedure""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Arrhythmia-free survival\n[ Time Frame: 1 year ]\n\narrhythmia-free outcome during 1 year after the procedure""}]	NA	NA
NCT02247180	Cognitive Rehabilitation in Alzheimer's Disease	Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial	10.3233/jad-160771	https://content.iospress.com/articles/journal-of-alzheimers-disease/jad160771	1	2014-09-18	Unknown status	NA	NA	2017-04-19	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in activities of daily living measured by a test for action regulation and planning skills (HOTAP) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in activities of daily living measured by an ADL-scale (Bayer-ADL) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change from baseline in behavioural memory abilities measured by a behavioural memory test (RBMT) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in activities of daily living measured by a test for action regulation and planning skills (HOTAP) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in activities of daily living measured by an ADL-scale (Bayer-ADL) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change from baseline in behavioural memory abilities measured by a behavioural memory test (RBMT) to the end of intervention and to follow-up (6 months later)\n[ Time Frame: prior intervention, after intervention (3 months), after 6 months ]""}]
NCT02251470	Home-based Balance Training Using Wii Fit After Stroke: A Feasibility Study	Home-based balance training using Wii Fit™: a pilot randomised controlled trial with mobile older stroke survivors	10.1186/s40814-018-0334-0	https://pilotfeasibilitystudies.biomedcentral.com/articles/10.1186/s40814-018-0334-0	4	2014-09-26	Completed	2014-10-01	2015-06-01	2018-08-25	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility\n[ Time Frame: 12-weeks ]\n\nRecruiting potential, the participants' acceptance/satisfaction of the intervention and economic aspects""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility\n[ Time Frame: 12-weeks ]\n\nRecruiting potential, the participants' acceptance/satisfaction of the intervention and economic aspects""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility\n[ Time Frame: 12-weeks ]\n\nRecruiting potential, the participants' acceptance/satisfaction of the intervention and economic aspects""}]	NA	NA
NCT02253563	Resistance Versus Balance Training in Parkinson's Disease	Resistance versus Balance Training to Improve Postural Control in Parkinson's Disease: A Randomized Rater Blinded Controlled Study	10.1371/journal.pone.0140584	https://pubmed.ncbi.nlm.nih.gov/26501562/	3	2014-09-26	Completed	2011-06-01	2014-02-01	2015-10-26	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fullerton Advanced Balance scale\n[ Time Frame: up to 2 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fullerton Advanced Balance scale\n[ Time Frame: up to 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fullerton Advanced Balance scale\n[ Time Frame: up to 2 years ]""}]	NA
NCT02260115	A Randomized Multi-centre Study to Assess the Safety and Manageability of a Laparoscopic Adhesion Barrier in Women Undergoing Gynecologic Laparoscopic Surgery Followed by Second Look Laparoscopy	A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier	10.1007/s00404-016-4211-x	https://link.springer.com/article/10.1007%2Fs00404-016-4211-x	2	2014-10-08	Completed	2013-11-01	2014-06-01	2016-11-14	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of adverse events, abnormal changes in vital signs and/or clinical laboratory measures\n[ Time Frame: Between baseline initial surgery and second look laparoscopy (4-12 weeks) ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of adverse events, abnormal changes in vital signs and/or clinical laboratory measures\n[ Time Frame: Between baseline initial surgery and second look laparoscopy (4-12 weeks) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of adverse events, abnormal changes in vital signs and/or clinical laboratory measures\n[ Time Frame: Between baseline initial surgery and second look laparoscopy (4-12 weeks) ]""}]	NA
NCT02262442	Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer During the Bronchoscopy	Nebulization versus standard application for topical anaesthesia during flexible bronchoscopy under moderate sedation - a randomized controlled trial	10.1186/s12931-018-0926-5	https://pubmed.ncbi.nlm.nih.gov/30463577/	3	2014-10-10	Unknown status	2014-10-01	NA	2018-11-21	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of anaesthetics during flexible bronchoscopy\n[ Time Frame: one hour ]\n\n\n\nValidation of the total amount of administered propofol (mg) during the flexible bronchoscopy.\n\nUsage of sedatives other than propofol (midazolam), total amount of administered lidocaine, duration of bronchoscopy.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of anaesthetics during flexible bronchoscopy\n[ Time Frame: one hour ]\n\n\n\nValidation of the total amount of administered propofol (mg) during the flexible bronchoscopy.\n\nUsage of sedatives other than propofol (midazolam), total amount of administered lidocaine, duration of bronchoscopy.""}]
NCT02272036	Short Message Service in Colonoscopy Preparation (PERICLES-II-SMS)	Improving the quality and acceptance of colonoscopy preparation by reinforced patient education with short message service: results from a randomized, multicenter study (PERICLES-II)	10.1016/j.gie.2018.08.014	NA	6	2014-10-21	Completed	2014-09-01	2017-02-01	2018-08-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bowel cleanness measured by Boston Bowel preparation Scale\n[ Time Frame: 1 day ]\n\nBoston bowel preparation scale (BBPS) is measured by the endoscopist during colonoscopy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bowel cleanness measured by Boston Bowel preparation Scale\n[ Time Frame: 1 day ]\n\nBoston bowel preparation scale (BBPS) is measured by the endoscopist during colonoscopy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bowel cleanness measured by Boston Bowel preparation Scale\n[ Time Frame: 1 day ]\n\nBoston bowel preparation scale (BBPS) is measured by the endoscopist during colonoscopy""}]	NA	NA
NCT02273141	Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.	Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial	10.1055/a-0639-5070	https://www.thieme-connect.de/products/ejournals/html/10.1055/a-0639-5070	6	2014-10-22	Completed	2014-10-01	2015-08-01	2018-07-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Use of Harefield Cleansing Scale to grade bowel cleansing efficacy\n[ Time Frame: Day of colonoscopy (Day 2) ]\n\nTo evaluate the overall bowel cleansing efficacy of NER1006 compared to SP+MS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Use of Harefield Cleansing Scale to grade bowel cleansing efficacy\n[ Time Frame: Day of colonoscopy (Day 2) ]\n\nTo evaluate the overall bowel cleansing efficacy of NER1006 compared to SP+MS.""}]	[See Results Section.]	NA	NA
NCT02290613	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)	10.1186/s13075-019-1981-0	https://pubmed.ncbi.nlm.nih.gov/31655622/	4	2014-11-10	Completed	2014-12-01	2017-12-01	2019-10-26	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pulmonary arterial pressure change from baseline\n[ Time Frame: baseline, 6 months ]\n\nDetermine whether mean pulmonary arterial pressure of SSc patients with borderline - PAH (mPAP 21 24 mmHg, TPG >11 mmHg) can be reduced by 3 mm Hg (absolute change baseline vs. 6 months; equals 15%) following treatment with ambrisentan 10 mg/die (initiated with 5 mg/die and elevated up to 10 mg/die) over 6 months (primary endpoint) compared to baseline and placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pulmonary arterial pressure change from baseline\n[ Time Frame: baseline, 6 months ]\n\nDetermine whether mean pulmonary arterial pressure of SSc patients with borderline - PAH (mPAP 21 24 mmHg, TPG >11 mmHg) can be reduced by 3 mm Hg (absolute change baseline vs. 6 months; equals 15%) following treatment with ambrisentan 10 mg/die (initiated with 5 mg/die and elevated up to 10 mg/die) over 6 months (primary endpoint) compared to baseline and placebo.""}]	NA	[See Results Section.]	NA
NCT02295462	Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial	Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): a cluster-randomised controlled trial	10.1093/ageing/afz016	https://academic.oup.com/ageing/article/48/3/419/5365248	6	2014-11-17	Completed	2014-12-01	2017-02-01	2019-02-26	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents receiving at least one antipsychotic medication after 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents receiving at least one antipsychotic medication after 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents receiving at least one antipsychotic medication after 12 months\n[ Time Frame: 12 months ]""}]	NA	NA
NCT02297334	Removal of Cytokines During Extracorporeal Circulation in Cardiac Surgery	NA	NA	https://ediss.sub.uni-hamburg.de/volltexte/2019/9543/pdf/Dissertation.pdf	4	2014-11-18	Completed	2013-09-01	2015-10-01	2019-01-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of levels of cytokines during procedure compared to baseline\n[ Time Frame: 1) 5 minutes before bypass 2) 2 hours after begin of bypass, 3) at the end of bypass, approximately 3 hours after begin of bypass, 4) 6 hours after bypass 5) 24 hours after bypass ]\n\nparameters to be measured are: interleukin (IL) 1, interleukin 6, interleukin 8, interleukin 10, tumor necrosis factor-alpha""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of levels of cytokines during procedure compared to baseline\n[ Time Frame: 1) 5 minutes before bypass 2) 2 hours after begin of bypass, 3) at the end of bypass, approximately 3 hours after begin of bypass, 4) 6 hours after bypass 5) 24 hours after bypass ]\n\nparameters to be measured are: interleukin (IL) 1, interleukin 6, interleukin 8, interleukin 10, tumor necrosis factor-alpha""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of levels of cytokines during procedure compared to baseline\n[ Time Frame: 1) 5 minutes before bypass 2) 2 hours after begin of bypass, 3) at the end of bypass, approximately 3 hours after begin of bypass, 4) 6 hours after bypass 5) 24 hours after bypass ]\n\nparameters to be measured are: interleukin (IL) 1, interleukin 6, interleukin 8, interleukin 10, tumor necrosis factor-alpha""}]	NA	NA
NCT02297646	Influencing Factors on Training Efficacy in Healthy Adults	Carbohydrate intake and training efficacy - a randomized cross-over study	10.1080/02640414.2017.1346276	https://www.ncbi.nlm.nih.gov/pubmed/28657863	1	2014-11-20	Completed	2012-08-01	2013-12-01	2017-06-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum oxygen consumption (VO2max)\n[ Time Frame: 24 weeks ]\n\nVO2max""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum oxygen consumption (VO2max)\n[ Time Frame: 24 weeks ]\n\nVO2max""}]	NA	NA
NCT02299089	Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study	10.1007/s00280-018-3734-1	https://pubmed.ncbi.nlm.nih.gov/30535537/	9	2014-11-21	Completed	2015-01-01	2016-02-01	2018-12-08	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared with baseline PK for Sandostatin® Long-acting Release (LAR®)\n[ Time Frame: Baseline, Day 84 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared with baseline PK for Sandostatin® Long-acting Release (LAR®)\n[ Time Frame: Baseline, Day 84 ]""}]	[See Results Section.]	NA	NA
NCT02307396	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial	10.1007/s00406-020-01109-y	NA	3	2014-12-01	Completed	2014-11-01	2016-05-01	2020-02-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""}]	NA	NA
NCT02313493	Efficacy and Feasibility of Baby Triple P - a Pilot Study	The Relevance of Infant Outcome Measures: A Pilot-RCT Comparing Baby Triple P Positive Parenting Program With Care as Usual	10.3389/fpsyg.2019.02425	https://pubmed.ncbi.nlm.nih.gov/31736826/	2	2014-12-07	Unknown status	2012-09-01	2015-07-01	2019-10-29	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of symptoms on the BSI 18 and the PFB-K\n[ Time Frame: Before birth (T1), two months after birth (T2) ]\n\nThe BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders. The relationship questionnaire (PFB-K) assess partnership satisfaction.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Severity rating (0-8) of regulatory problems in infants\n[ Time Frame: six months after birth (T3) ]\n\nRegulatory difficulties in crying, sleeping and feeding behavior in infants are assessed with a diagnostic interview (Baby-DIPS). The severity rating ranges from 0-8 (> 4 indicates a clinical referred disorder).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of symptoms on the BSI 18 and the PFB-K\n[ Time Frame: Before birth (T1), two months after birth (T2) ]\n\nThe BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders. The relationship questionnaire (PFB-K) assess partnership satisfaction.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Severity rating (0-8) of regulatory problems in infants\n[ Time Frame: six months after birth (T3) ]\n\nRegulatory difficulties in crying, sleeping and feeding behavior in infants are assessed with a diagnostic interview (Baby-DIPS). The severity rating ranges from 0-8 (> 4 indicates a clinical referred disorder).""}]	NA	NA	NA
NCT02318810	Influence of the Neuromuscular Blockade on Mask Ventilation	The effect of neuromuscular blockade on the efficiency of facemask ventilation in patients difficult to facemask ventilate: a prospective trial	10.1111/anae.14035	https://pubmed.ncbi.nlm.nih.gov/28913862/	5	2014-12-12	Completed	2015-03-01	2016-05-01	2017-09-14	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of improved mask ventilation after rocuronium administration\n[ Time Frame: Two minutes after rocuronium administration ]\n\nGraded with various scores""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of improved mask ventilation after rocuronium administration\n[ Time Frame: Two minutes after rocuronium administration ]\n\nGraded with various scores""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of improved mask ventilation after rocuronium administration\n[ Time Frame: Two minutes after rocuronium administration ]\n\nGraded with various scores""}]	NA	NA
NCT02321813	Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients	Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer	10.1016/j.ejca.2020.01.025	https://pubmed.ncbi.nlm.nih.gov/32179445/	4	2014-12-16	Completed	2014-01-01	2016-10-01	2020-03-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension)\n[ Time Frame: 1 year after the date of primary surgery for colorectal cancer ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension)\n[ Time Frame: 1 year after the date of primary surgery for colorectal cancer ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension)\n[ Time Frame: 1 year after the date of primary surgery for colorectal cancer ]""}]	NA	NA
NCT02322502	Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia	Emergence times and airway reactions during general anaesthesia with remifentanil and a laryngeal mask airway: A multicentre randomised controlled trial	10.1097/eja.0000000000000852	https://journals.lww.com/ejanaesthesiology/Fulltext/2018/08000/Emergence_times_and_airway_reactions_during.7.aspx	4	2014-12-22	Completed	2015-02-01	2016-02-01	2018-08-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time of emergence from anesthesia\n[ Time Frame: up to 15 minutes ]\n\ntime of emergence from anesthesia defined as time between cessation of anesthesia until patient is able to state his/her date of birth on command""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time of emergence from anesthesia\n[ Time Frame: up to 15 minutes ]\n\ntime of emergence from anesthesia defined as time between cessation of anesthesia until patient is able to state his/her date of birth on command""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time of emergence from anesthesia\n[ Time Frame: up to 15 minutes ]\n\ntime of emergence from anesthesia defined as time between cessation of anesthesia until patient is able to state his/her date of birth on command""}]	NA	NA
NCT02329067	The Metabolic Effect of Walnuts in Healthy Subjects	A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial	10.3390/nu9101097	NA	7	2014-12-29	Completed	2014-12-01	2016-06-01	2017-10-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Non-HDL-cholesterol\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT02330471	Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial	Spray Versus Forced Coagulation in Large Loop Excision of the Transformation Zone: A Randomized Trial	10.1097/lgt.0000000000000177	https://pubmed.ncbi.nlm.nih.gov/26796660/	2	2014-12-31	Completed	2014-01-01	2015-03-01	2016-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to complete intraoperative hemostasis\n[ Time Frame: 120 seconds ]\n\nthe time until complete hemostasis as judged by the surgeon has been achieved, will be measured in seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to complete intraoperative hemostasis\n[ Time Frame: 120 seconds ]\n\nthe time until complete hemostasis as judged by the surgeon has been achieved, will be measured in seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to complete intraoperative hemostasis\n[ Time Frame: 120 seconds ]\n\nthe time until complete hemostasis as judged by the surgeon has been achieved, will be measured in seconds""}]	NA	NA
NCT02334813	Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia	A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study	10.1159/000445420	https://pubmed.ncbi.nlm.nih.gov/27189086/	2	2015-01-07	Completed	2002-07-01	2015-01-01	2016-05-19	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission duration\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission duration\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT02336334	Evaluation of Posturing-Adherence in Patients After Intraocular Surgery	PROSPECTIVE RANDOMIZED TRIAL ASSESSING THE IMPACT OF FEEDBACK MECHANISMS ON PATIENT POSITIONING	10.1097/iae.0000000000002006	https://journals.lww.com/retinajournal/Abstract/2019/04000/PROSPECTIVE_RANDOMIZED_TRIAL_ASSESSING_THE_IMPACT.14.aspx	3	2015-01-12	Completed	2014-10-01	2016-04-01	2019-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effective time of ideal posturing with different sensors-systems\n[ Time Frame: up to 12 month ]\n\nTime (measured in minutes and in percent of 24h) with correct posturing in relation to the used sensor-type (with and without feedback)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effective time of ideal posturing with different sensors-systems\n[ Time Frame: up to 12 month ]\n\nTime (measured in minutes and in percent of 24h) with correct posturing in relation to the used sensor-type (with and without feedback)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effective time of ideal posturing with different sensors-systems\n[ Time Frame: up to 12 month ]\n\nTime (measured in minutes and in percent of 24h) with correct posturing in relation to the used sensor-type (with and without feedback)""}]	NA	NA
NCT02337062	Phase IIIb Study of APD421 in Combination as PONV Prophylaxis	Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial	10.1097/aln.0000000000002133	https://pubs.asahq.org/anesthesiology/article/128/6/1099/19881/Amisulpride-Prevents-Postoperative-Nausea-and	6	2015-01-12	Completed	2015-02-01	2015-09-01	2018-01-09	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete Response (protection from PONV)\n[ Time Frame: 24 hours ]\n\nProportion of patients with no PONV in the 24-hour period after end of surgery""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete Response (protection from PONV)\n[ Time Frame: 24 hours ]\n\nProportion of patients with no PONV in the 24-hour period after end of surgery""}]	[See Results Section.]	[See Results Section.]	NA
NCT02337400	Evaluation of a Cognitive Behavioral Smoking Reduction Program	Evaluation of the cognitive behavioral smoking reduction program ""Smoke_less"": a randomized controlled trial	10.1007/s00406-017-0818-6	NA	3	2015-01-09	Completed	2015-01-01	2016-02-01	2017-06-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in number of smoked cigarettes/day at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in percentage of carbon monoxide in exhalation air at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in number of smoked cigarettes/day at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in percentage of carbon monoxide in exhalation air at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in number of smoked cigarettes/day at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in percentage of carbon monoxide in exhalation air at 6, 17 and 29 weeks\n[ Time Frame: 6, 17 and 29 weeks ]""}]	NA	NA
NCT02338388	Cesarean-scar Thickness and Closure Technique	Longitudinal transvaginal ultrasound evaluation of cesarean scar niche incidence and depth in the first two years after single- or double-layer uterotomy closure: a randomized controlled trial	10.1111/aogs.13213	https://pubmed.ncbi.nlm.nih.gov/28832909/	2	2015-01-12	Completed	2012-01-01	2014-04-01	2017-09-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cesarean scar-thickness\n[ Time Frame: 24 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cesarean scar-thickness\n[ Time Frame: 24 months ]""}]	NA	NA
NCT02340299	Nasal HFOV Versus Nasal CPAP to Reduce Post-extubation pCO2	Hazards to avoid in future neonatal studies of nasal high-frequency oscillatory ventilation: lessons from an early terminated trial	10.1186/s13104-019-4268-2	https://pubmed.ncbi.nlm.nih.gov/31023363/	4	2015-01-13	Terminated	2015-01-01	2017-12-31	2019-04-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[See Results Section.]	NA
NCT02341898	Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents (IMPRINT)	Implementation of a multicomponent intervention to prevent physical restraints in nursing homes (IMPRINT): A pragmatic cluster randomized controlled trial	10.1016/j.ijnurstu.2019.03.017	https://pubmed.ncbi.nlm.nih.gov/31014546/	4	2015-01-16	Completed	2015-03-01	2017-03-01	2019-04-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents with at least one physical restraint assessed through direct observation by blinded research assistants\n[ Time Frame: 12 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents with at least one physical restraint assessed through direct observation by blinded research assistants\n[ Time Frame: 12 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of residents with at least one physical restraint assessed through direct observation by blinded research assistants\n[ Time Frame: 12 Months ]""}]	NA	NA
NCT02342509	Automated Control of End-tidal Volatile Anesthetic Concentration	NA	10.1186/cc14575	https://link.springer.com/article/10.1186/cc14575	1	2015-01-14	Completed	2014-09-01	2014-12-01	2015-03-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""volatile anaesthetics (VA) consumption\n[ Time Frame: duration of anesthesia: max. 3 h ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""volatile anaesthetics (VA) consumption\n[ Time Frame: duration of anesthesia: max. 3 h ]""}]	NA	NA
NCT02343029	Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial	Effects of aerobic exercise on brain metabolism and grey matter volume in older adults: results of the randomised controlled SMART trial	10.1038/tp.2017.135	https://www.nature.com/articles/tp2017135	2	2015-01-20	Completed	2014-06-01	2015-08-01	2017-07-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cerebral metabolism (assessed by MRSI)\n[ Time Frame: 6 month ]\n\n\n\nassessed by MRSI, Primary hypothesis is that aerobic exercise leads to an increase of cerebral N-acetyl-aspartate (NAA; mediated by plasma neurotrophins).\n\nSecondary hypothesis stipulates an increase of markers of neuronal energy reserve: i.e. the ratio of phosphocreatinin to creatinine and of adenosine-tri-phosphate (ATP) to ~di-phosphate (ADP).\n\nThird hypothesis is an increase in the volume of cortical grey matter""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cerebral metabolism (assessed by MRSI)\n[ Time Frame: 6 month ]\n\n\n\nassessed by MRSI, Primary hypothesis is that aerobic exercise leads to an increase of cerebral N-acetyl-aspartate (NAA; mediated by plasma neurotrophins).\n\nSecondary hypothesis stipulates an increase of markers of neuronal energy reserve: i.e. the ratio of phosphocreatinin to creatinine and of adenosine-tri-phosphate (ATP) to ~di-phosphate (ADP).\n\nThird hypothesis is an increase in the volume of cortical grey matter""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cerebral metabolism (assessed by MRSI)\n[ Time Frame: 6 month ]\n\n\n\nassessed by MRSI, Primary hypothesis is that aerobic exercise leads to an increase of cerebral N-acetyl-aspartate (NAA; mediated by plasma neurotrophins).\n\nSecondary hypothesis stipulates an increase of markers of neuronal energy reserve: i.e. the ratio of phosphocreatinin to creatinine and of adenosine-tri-phosphate (ATP) to ~di-phosphate (ADP).\n\nThird hypothesis is an increase in the volume of cortical grey matter""}]	NA	NA
NCT02344030	Comparsion of King Vision® Standard Blade and King Vision® Channeled Blade in Patients Scheduled for Tracheal Intubation	Using King Vision video laryngoscope with a channeled blade prolongs time for tracheal intubation in different training levels, compared to non-channeled blade	10.1371/journal.pone.0183382	https://pubmed.ncbi.nlm.nih.gov/28859114/	4	2015-01-21	Completed	2015-01-01	2015-02-01	2017-08-31	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\nWe want to measure the time for tracheal intubation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\nWe want to measure the time for tracheal intubation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\nWe want to measure the time for tracheal intubation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\nWe want to measure the time for tracheal intubation""}]	NA
NCT02348736	Comparison of SensaScope Intuboscope and McGrath Series 5 for Endotracheal Intubation	NA	10.1016/j.tacc.2018.01.003	https://www.sciencedirect.com/science/article/abs/pii/S2210844017302654	4	2015-01-22	Completed	2015-01-01	2015-04-01	2018-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\ntimes for tracheal intubation, View of the glottic, experience in anesthesia""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\ntimes for tracheal intubation, View of the glottic, experience in anesthesia""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison of different time for tracheal intubation\n[ Time Frame: <2min ]\n\ntimes for tracheal intubation, View of the glottic, experience in anesthesia""}]	NA	NA
NCT02349880	A Shared Decision-making Training for Inpatients With Schizophrenia	Training patients with schizophrenia to share decisions with their psychiatrists: a randomized-controlled trial	10.1007/s00127-016-1327-z	NA	2	2015-01-23	Completed	2011-10-01	2014-12-01	2016-12-31	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""adherence to antipsychotic medication\n[ Time Frame: 12 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""adherence to antipsychotic medication\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""adherence to antipsychotic medication\n[ Time Frame: 12 months ]""}]	NA
NCT02356016	Effects of Whole-body Electromyostimulation and Dietary Supplements on ""Sarcopenic Obesity""	Whole-body electromyostimulation to fight sarcopenic obesity in community-dwelling older women at risk. Resultsof the randomized controlled FORMOsA-sarcopenic obesity study	10.1007/s00198-016-3662-z	https://pubmed.ncbi.nlm.nih.gov/27289534/	4	2015-02-04	Completed	2015-01-01	2015-12-01	2016-06-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Appendicular skeletal muscle mass\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of appendicular skeletal muscle mass from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle density of the medial thigh\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of muscle density (thigh) from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Intramuscular fat content\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of Intramuscular fat content (thigh) from baseline to 6 month follow-up""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Appendicular skeletal muscle mass\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of appendicular skeletal muscle mass from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle density of the medial thigh\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of muscle density (thigh) from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Intramuscular fat content\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of Intramuscular fat content (thigh) from baseline to 6 month follow-up""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Appendicular skeletal muscle mass\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of appendicular skeletal muscle mass from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle density of the medial thigh\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of muscle density (thigh) from baseline to 6 month follow-up""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Intramuscular fat content\n[ Time Frame: baseline - 6 months follow-up ]\n\nchanges of Intramuscular fat content (thigh) from baseline to 6 month follow-up""}]	NA	NA
NCT02358720	Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases	Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy	10.1016/j.radonc.2018.04.030	https://pubmed.ncbi.nlm.nih.gov/29843899/	1	2015-02-06	Unknown status	NA	NA	2018-05-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain relief, as measured by visual analog scale (VAS)\n[ Time Frame: 3 months after therapy completed ]\n\nThe primary endpoint was defined as pain relief > 2 points according to visual analog scale (VAS) measured at the irradiated region up to three months after the end of RT""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""pain relief, as measured by visual analog scale (VAS)\n[ Time Frame: 3 months after therapy completed ]\n\nThe primary endpoint was defined as pain relief > 2 points according to visual analog scale (VAS) measured at the irradiated region up to three months after the end of RT""}]
NCT02360033	Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders	Comparing Cognitive Behavioral Therapy and Systemic Therapy for Social Anxiety Disorder: Randomized Controlled Pilot Trial (SOPHO-CBT/ST)	10.1111/famp.12492	https://pubmed.ncbi.nlm.nih.gov/31657011/	3	2015-02-04	Completed	2015-01-01	2017-01-01	2019-10-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Liebowitz Social Anxiety Scale (LSAS-SR)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nSocial Anxiety will be assessed using the Liebowitz Social Anxiety Scale (LSAS-SR) in its German version. The LSAS-SR is a brief 24-item self report instrument with 13 items relating to performance anxiety and 11 concerning social situations. Its purpose is to assess the range of social interaction and performance situations feared and the degree of avoidance by a patient in order to assist in the diagnosis of social anxiety disorder, 24 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Social Interaction Anxiety Scale (SIAS)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nMeasure of social interaction anxiety, 20 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change of Social Phobia Scale (SPS)\n[ Time Frame: Baseline, 8th,15th and 20th hour of therapy, end of treatment; 6, 9 and 12 months after randomization ]\n\nMeasure of anxiety while being observed by others, 20 items, German version""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Liebowitz Social Anxiety Scale (LSAS-SR)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nSocial Anxiety will be assessed using the Liebowitz Social Anxiety Scale (LSAS-SR) in its German version. The LSAS-SR is a brief 24-item self report instrument with 13 items relating to performance anxiety and 11 concerning social situations. Its purpose is to assess the range of social interaction and performance situations feared and the degree of avoidance by a patient in order to assist in the diagnosis of social anxiety disorder, 24 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Social Interaction Anxiety Scale (SIAS)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nMeasure of social interaction anxiety, 20 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change of Social Phobia Scale (SPS)\n[ Time Frame: Baseline, 8th,15th and 20th hour of therapy, end of treatment; 6, 9 and 12 months after randomization ]\n\nMeasure of anxiety while being observed by others, 20 items, German version""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Liebowitz Social Anxiety Scale (LSAS-SR)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nSocial Anxiety will be assessed using the Liebowitz Social Anxiety Scale (LSAS-SR) in its German version. The LSAS-SR is a brief 24-item self report instrument with 13 items relating to performance anxiety and 11 concerning social situations. Its purpose is to assess the range of social interaction and performance situations feared and the degree of avoidance by a patient in order to assist in the diagnosis of social anxiety disorder, 24 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Social Interaction Anxiety Scale (SIAS)\n[ Time Frame: Baseline, 8th,15th, 20th and 26th hour of therapy; 6, 9 and 12 months after randomization ]\n\nMeasure of social interaction anxiety, 20 items, German version""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change of Social Phobia Scale (SPS)\n[ Time Frame: Baseline, 8th,15th and 20th hour of therapy, end of treatment; 6, 9 and 12 months after randomization ]\n\nMeasure of anxiety while being observed by others, 20 items, German version""}]	NA	NA
NCT02362802	Myocardial Minimal Damage After Rapid Ventricular Pacing	Myocardial Minimal Damage After Rapid Ventricular Pacing - the prospective randomized multicentre MyDate-Trial	10.1038/s41598-020-61625-8	NA	4	2015-02-12	Unknown status	2014-09-01	2017-05-31	2020-03-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""High sensitive Troponin\n[ Time Frame: 14-20 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""High sensitive Troponin\n[ Time Frame: 14-20 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""High sensitive Troponin\n[ Time Frame: 14-20 hours ]""}]	NA	NA
NCT02364219	Impact of Prewarming on Perioperative Body Core Temperature and the Outcomes of Cytoreductive- and Major Open Abdominal Surgery: A Randomised Trial	Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial	10.1186/s12871-019-0828-1	https://pubmed.ncbi.nlm.nih.gov/31438849/	3	2015-02-16	Unknown status	NA	NA	2019-08-22	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body core temperature drop from induction of anesthesia to start of surgery\n[ Time Frame: approximately 30-40 minutes ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body core temperature drop from induction of anesthesia to start of surgery\n[ Time Frame: approximately 30-40 minutes ]""}]
NCT02365350	Randomized Clinical Trial on Follicular Flushing in IVF	Randomized, open trial comparing a modified double-lumen needle follicular flushing system with a single-lumen aspiration needle in IVF patients with poor ovarian response	10.1093/humrep/dex019	https://pubmed.ncbi.nlm.nih.gov/28333185/	2	2015-02-10	Completed	2015-01-01	2016-08-01	2017-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean number of COSs per patient randomized.\n[ Time Frame: 1 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean number of COSs per patient randomized.\n[ Time Frame: 1 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean number of COSs per patient randomized.\n[ Time Frame: 1 day ]""}]	NA	NA
NCT02372318	Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity	The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study	10.1016/j.euroneuro.2019.10.014	https://pubmed.ncbi.nlm.nih.gov/31740271/	3	2015-02-19	Terminated	2015-04-01	2016-05-01	2019-11-15	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in cue-induced brain activation between two fMRI scans (randomization to an intake of nalmefene (18 mg) or placebo).\n[ Time Frame: Primary outcome measures will be assessed on day 2 and day3 after fMRI scan, data collection will take up to 12 months ]\n\nThis difference will be extracted from whole-brain contrast images in the VS and DS using the percentage of activated voxels in these regions of interest (ROI).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in cue-induced brain activation between two fMRI scans (randomization to an intake of nalmefene (18 mg) or placebo).\n[ Time Frame: Primary outcome measures will be assessed on day 2 and day3 after fMRI scan, data collection will take up to 12 months ]\n\nThis difference will be extracted from whole-brain contrast images in the VS and DS using the percentage of activated voxels in these regions of interest (ROI).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in cue-induced brain activation between two fMRI scans (randomization to an intake of nalmefene (18 mg) or placebo).\n[ Time Frame: Primary outcome measures will be assessed on day 2 and day3 after fMRI scan, data collection will take up to 12 months ]\n\nThis difference will be extracted from whole-brain contrast images in the VS and DS using the percentage of activated voxels in these regions of interest (ROI).""}]	NA	NA
NCT02383238	Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation	10.1186/s12933-017-0510-1	https://pubmed.ncbi.nlm.nih.gov/28231831/	5	2015-03-02	Completed	2014-03-01	2015-10-01	2017-02-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microcirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effects after 6 weeks of treatment with dapagliflozin on retinal capillary flow (given as AU) as the key measurement of vascular remodeling in the microcirculation compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microcirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effects after 6 weeks of treatment with dapagliflozin on retinal capillary flow (given as AU) as the key measurement of vascular remodeling in the microcirculation compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microcirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effects after 6 weeks of treatment with dapagliflozin on retinal capillary flow (given as AU) as the key measurement of vascular remodeling in the microcirculation compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Microcirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effects after 6 weeks of treatment with dapagliflozin on retinal capillary flow (given as AU) as the key measurement of vascular remodeling in the microcirculation compared to placebo.""}]	NA
NCT02395159	Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)	Closed Incision Negative Pressure Therapy Reduces Surgical Site Infections in Vascular Surgery: A Prospective Randomised Trial (AIMS Trial)	10.1016/j.ejvs.2018.05.018	https://www.sciencedirect.com/science/article/pii/S1078588418303137	6	2015-03-19	Completed	2015-07-01	2017-07-01	2018-06-30	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""wound infections\n[ Time Frame: 7 days after the surgery ]\n\nThe primary objective is the occurrence of inguinal wound infections following surgery. Wound infections will be classified according to Szilagyi.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""wound infections\n[ Time Frame: 7 days after the surgery ]\n\nThe primary objective is the occurrence of inguinal wound infections following surgery. Wound infections will be classified according to Szilagyi.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""wound infections\n[ Time Frame: 7 days after the surgery ]\n\nThe primary objective is the occurrence of inguinal wound infections following surgery. Wound infections will be classified according to Szilagyi.""}]	NA	NA
NCT02406014	Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp	Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp	10.1111/bjd.16048	https://pubmed.ncbi.nlm.nih.gov/29030864/	7	2015-03-31	Completed	2015-04-01	2016-06-01	2015-01-15	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of all AKs\n[ Time Frame: 11 Months ]\n\nComplete clearance of all AKs in the treatment field at Week 8 for ingenol mebutate gel 0.015% and Week 17 for diclofenac sodium gel 3%""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of all AKs\n[ Time Frame: 11 Months ]\n\nComplete clearance of all AKs in the treatment field at Week 8 for ingenol mebutate gel 0.015% and Week 17 for diclofenac sodium gel 3%""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of all AKs\n[ Time Frame: 11 Months ]\n\nComplete clearance of all AKs in the treatment field at Week 8 for ingenol mebutate gel 0.015% and Week 17 for diclofenac sodium gel 3%""}]	NA
NCT02410096	Bronchial Inflammation and Hyperresponsiveness After Oil Supplementation	Oil supplementation with a special combination of n-3 and n-6 long-chain polyunsaturated fatty acids does not protect for exercise induced asthma: a double-blind placebo-controlled trial	10.1186/s12944-020-01343-2	https://pubmed.ncbi.nlm.nih.gov/32660564/	3	2015-04-01	Completed	2015-03-01	2016-02-01	2020-07-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease in FEV1 after exercise challenge in cold air as measured by spirometry (FEV1, percent predicted) - comparison verum vs placebo\n[ Time Frame: 4 weeks ]\n\nThe exercise challenge in cold air will be done on two timepoints. Before and after oil supplementation versus placebo supplementation. After exercise challenge spirometry will be measured. Decrease in FEV1 in verum and control group will be compared with t-test and Wilcoxon-Mann-Whitney-Test.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease in FEV1 after exercise challenge in cold air as measured by spirometry (FEV1, percent predicted) - comparison verum vs placebo\n[ Time Frame: 4 weeks ]\n\nThe exercise challenge in cold air will be done on two timepoints. Before and after oil supplementation versus placebo supplementation. After exercise challenge spirometry will be measured. Decrease in FEV1 in verum and control group will be compared with t-test and Wilcoxon-Mann-Whitney-Test.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Decrease in FEV1 after exercise challenge in cold air as measured by spirometry (FEV1, percent predicted) - comparison verum vs placebo\n[ Time Frame: 4 weeks ]\n\nThe exercise challenge in cold air will be done on two timepoints. Before and after oil supplementation versus placebo supplementation. After exercise challenge spirometry will be measured. Decrease in FEV1 in verum and control group will be compared with t-test and Wilcoxon-Mann-Whitney-Test.""}]	NA	NA
NCT02420145	Yoga for Abdominal Obesity	Yoga in Women With Abdominal Obesityߞa Randomized Controlled Trial	10.3238/arztebl.2016.0645	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098025/	2	2015-04-14	Completed	2015-04-01	2015-08-01	2016-09-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waist circumference\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waist circumference\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waist circumference\n[ Time Frame: Week 12 ]""}]	NA	NA
NCT02424552	Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma	Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily	10.1093/eurheartj/ehx235	https://pubmed.ncbi.nlm.nih.gov/28498942/	8	2015-04-20	Terminated	2015-06-01	2017-03-01	2017-08-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""relative dose reduction of ICS or OCS at week 24 as assessed by total ICS or OCS dose\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""relative dose reduction of ICS or OCS at week 24 as assessed by total ICS or OCS dose\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""relative dose reduction of ICS or OCS at week 24 as assessed by total ICS or OCS dose\n[ Time Frame: 24 weeks ]""}]	NA	NA
NCT02436083	Antibiotics in Free Flaps Reconstructions	The value of perioperative antibiotics on the success of oral free flap reconstructions	10.1002/micr.22470	NA	1	2015-05-05	Completed	2007-07-01	2012-06-01	2015-08-07	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequencies of wound infection detected by clinical examinations (daily for 2 weeks, 2 times per week afterwards)\n[ Time Frame: participants will be followed for the duration of hospital stay (2 weeks) and a total of 12 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequencies of wound infection detected by clinical examinations (daily for 2 weeks, 2 times per week afterwards)\n[ Time Frame: participants will be followed for the duration of hospital stay (2 weeks) and a total of 12 weeks ]""}]	NA	NA
NCT02437357	A Trial on Metacognitive Training for Depression (D-MCT)	NA	10.1024/1661-4747/a000167	https://econtent.hogrefe.com/doi/10.1024/1661-4747/a000167	2	2015-05-04	Completed	2015-03-01	2016-06-01	2015-02-28	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Hamilton Depression Rating Scale (HDRS), total score from pre to post treatment (4 weeks) and follow-up (3months)\n[ Time Frame: 4 months ]\n\nClinician-rated severity of depressive symptoms, 17-item version, most commonly used interview-based measure of depression""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Hamilton Depression Rating Scale (HDRS), total score from pre to post treatment (4 weeks) and follow-up (3months)\n[ Time Frame: 4 months ]\n\nClinician-rated severity of depressive symptoms, 17-item version, most commonly used interview-based measure of depression""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Hamilton Depression Rating Scale (HDRS), total score from pre to post treatment (4 weeks) and follow-up (3months)\n[ Time Frame: 4 months ]\n\nClinician-rated severity of depressive symptoms, 17-item version, most commonly used interview-based measure of depression""}]	NA
NCT02450578	DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria	DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection	10.1016/s1473-3099(17)30139-1	https://www.sciencedirect.com/science/article/pii/S1473309917301391?via%3Dihub	15	2015-05-18	Completed	2015-10-01	2017-01-01	2017-03-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[See Results Section.]	NA
NCT02453906	XNKQ Acupuncture Compared to Control Interventions Measured With EEG and fMRI	Somatosensory Stimulation With XNKQ Acupuncture Modulates Functional Connectivity of Motor Areas	10.3389/fnins.2019.00147	https://pubmed.ncbi.nlm.nih.gov/30914909/	2	2015-05-21	Completed	2015-05-01	2015-09-01	2019-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in brain background rhythms (mu-alpha and beta activity) [assessed using EEG and MRI] after one intervention (baseline vs. post stimulation) in comparison between the four different interventions.\n[ Time Frame: 60 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in resting state functional connectivity [assessed using EEG and MRI] after one intervention (baseline vs. post-stimulation) in comparison between the four different interventions\n[ Time Frame: 60 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in brain background rhythms (mu-alpha and beta activity) [assessed using EEG and MRI] after one intervention (baseline vs. post stimulation) in comparison between the four different interventions.\n[ Time Frame: 60 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in resting state functional connectivity [assessed using EEG and MRI] after one intervention (baseline vs. post-stimulation) in comparison between the four different interventions\n[ Time Frame: 60 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in brain background rhythms (mu-alpha and beta activity) [assessed using EEG and MRI] after one intervention (baseline vs. post stimulation) in comparison between the four different interventions.\n[ Time Frame: 60 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in resting state functional connectivity [assessed using EEG and MRI] after one intervention (baseline vs. post-stimulation) in comparison between the four different interventions\n[ Time Frame: 60 minutes ]""}]	NA	NA
NCT02468427	Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Delivery by Vacuum Extraction	A randomized comparison of video demonstration versus hands-on training of medical students for vacuum delivery using Objective Structured Assessment of Technical Skills (OSATS)	10.1097/md.0000000000006355	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369926/	2	2015-06-09	Completed	2015-03-01	2015-10-01	2017-03-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS scores\n[ Time Frame: 5 min after the training ]\n\n24 predefined OSATS items""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS scores\n[ Time Frame: 5 min after the training ]\n\n24 predefined OSATS items""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""OSATS scores\n[ Time Frame: 5 min after the training ]\n\n24 predefined OSATS items""}]	NA	NA
NCT02468999	Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans	Hypothalamic and Striatal Insulin Action Suppresses Endogenous Glucose Production and May Stimulate Glucose Uptake During Hyperinsulinemia in Lean but Not in Overweight Men	10.2337/db16-1380	https://diabetes.diabetesjournals.org/content/66/7/1797.long	2	2015-06-08	Completed	2015-01-01	2015-12-01	2017-02-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in glucose infusion rate during hyperinsulinemic euglycemic glucose clamp from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in endogenous glucose production from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]\n\nWill be assessed by tracer dilution technique.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Differences in insulin response between lean and overweight persons\n[ Time Frame: up to 210 minutes post nasal spray administration ]\n\nWill be assessed as plasma insulin and C-peptide concentrations.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in glucose infusion rate during hyperinsulinemic euglycemic glucose clamp from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in endogenous glucose production from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]\n\nWill be assessed by tracer dilution technique.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Differences in insulin response between lean and overweight persons\n[ Time Frame: up to 210 minutes post nasal spray administration ]\n\nWill be assessed as plasma insulin and C-peptide concentrations.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in glucose infusion rate during hyperinsulinemic euglycemic glucose clamp from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in endogenous glucose production from before to after nasal spray application in lean persons\n[ Time Frame: Change from 70-90 min (before spray) to 170-210 min and to 280-300 min ]\n\nWill be assessed by tracer dilution technique.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Differences in insulin response between lean and overweight persons\n[ Time Frame: up to 210 minutes post nasal spray administration ]\n\nWill be assessed as plasma insulin and C-peptide concentrations.""}]	NA	NA
NCT02471963	Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus	10.1161/circulationaha.117.029529	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029529	4	2015-06-10	Completed	2014-12-01	2015-11-01	2017-09-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of empagliflozin after 6 weeks of treatment on macrocirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effect of empagliflozin after 6 weeks of treatment on macrocirculation as assessed by the pulse wave reflection in the peripheral arterial tree with the composite parameters: central (aortic) systolic pressure, central (aortic) pulse pressure, augmentation pressure, forward wave amplitude, backward wave amplitude and the ratio of forward and backward (pulse wave velocity) compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of empagliflozin after 6 weeks of treatment on macrocirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effect of empagliflozin after 6 weeks of treatment on macrocirculation as assessed by the pulse wave reflection in the peripheral arterial tree with the composite parameters: central (aortic) systolic pressure, central (aortic) pulse pressure, augmentation pressure, forward wave amplitude, backward wave amplitude and the ratio of forward and backward (pulse wave velocity) compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of empagliflozin after 6 weeks of treatment on macrocirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effect of empagliflozin after 6 weeks of treatment on macrocirculation as assessed by the pulse wave reflection in the peripheral arterial tree with the composite parameters: central (aortic) systolic pressure, central (aortic) pulse pressure, augmentation pressure, forward wave amplitude, backward wave amplitude and the ratio of forward and backward (pulse wave velocity) compared to placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Effect of empagliflozin after 6 weeks of treatment on macrocirculation\n[ Time Frame: 6 weeks ]\n\nTo analyse the effect of empagliflozin after 6 weeks of treatment on macrocirculation as assessed by the pulse wave reflection in the peripheral arterial tree with the composite parameters: central (aortic) systolic pressure, central (aortic) pulse pressure, augmentation pressure, forward wave amplitude, backward wave amplitude and the ratio of forward and backward (pulse wave velocity) compared to placebo.""}]	NA
NCT02475603	Clinical, Biochemical and Neurophysiological Consequences of Intraoperative Tourniquet During Total Knee Arthroplasty	Tourniquet application during TKA did not affect the accuracy of implant positioning: a randomized clinical trial	10.1007/s00167-017-4760-y	https://pubmed.ncbi.nlm.nih.gov/29058023/	1	2015-06-15	Unknown status	NA	NA	2017-10-20	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Biochemical Data\n[ Time Frame: During operation 60 min Ischemia/Shame-Ischemia Time ]\n\nMeasurement of intracellular proteolytic activity""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Biochemical Data\n[ Time Frame: During operation 60 min Ischemia/Shame-Ischemia Time ]\n\nMeasurement of intracellular proteolytic activity""}]
NCT02479412	A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma	Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial	10.1186/s12931-019-1000-7	https://pubmed.ncbi.nlm.nih.gov/30777086/	9	2015-06-19	Completed	2015-06-01	2016-03-01	2019-02-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of AZD7594 by assessment of the change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15\n[ Time Frame: On Day 1 (pre-dose) and on Day 15 in each period ]\n\nComparison of the efficacy of AZD7594 in terms of change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15 (defined as the average of the values at 23:00 and 23:30 hours after last dose of investigational medicinal product [IMP] on Day 14) compared to placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of AZD7594 by assessment of the change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15\n[ Time Frame: On Day 1 (pre-dose) and on Day 15 in each period ]\n\nComparison of the efficacy of AZD7594 in terms of change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15 (defined as the average of the values at 23:00 and 23:30 hours after last dose of investigational medicinal product [IMP] on Day 14) compared to placebo""}]	[See Results Section.]	NA	NA
NCT02480608	Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)	NA	NA	https://ash.confex.com/ash/2017/webprogram/Paper99881.html	1	2015-06-23	Completed	2004-04-01	2011-08-01	2017-11-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of participants with complete molecular response as a measure of efficacy\n[ Time Frame: 18 months ]\n\ncomplete molecular response is achieved if BCR-ABL (breakpoint cluster region-Abelson murine leukemia) transcripts became undetectable""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of participants with complete molecular response as a measure of efficacy\n[ Time Frame: 18 months ]\n\ncomplete molecular response is achieved if BCR-ABL (breakpoint cluster region-Abelson murine leukemia) transcripts became undetectable""}]	NA	NA
NCT02500394	Biomarker Guided Intervention for Prevention of Acute Kidney Injury	Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study	10.1097/sla.0000000000002485	https://pubmed.ncbi.nlm.nih.gov/28857811/	4	2015-07-14	Completed	2015-06-01	2016-12-01	2018-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of AKI in both group\n[ Time Frame: 90 days ]\n\nincidence and severity of AKI according to AKI network definition within 90 days will be monitored""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of AKI in both group\n[ Time Frame: 90 days ]\n\nincidence and severity of AKI according to AKI network definition within 90 days will be monitored""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of AKI in both group\n[ Time Frame: 90 days ]\n\nincidence and severity of AKI according to AKI network definition within 90 days will be monitored""}]	NA	NA
NCT02501577	Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation	A comparison of various supraglottic airway devices for fiberoptical guided tracheal intubation	10.1016/j.bjane.2015.09.007	https://pubmed.ncbi.nlm.nih.gov/28236864/	1	2015-07-16	Unknown status	NA	NA	2016-05-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visibility of vocal cords\n[ Time Frame: intraoperative ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visibility of vocal cords\n[ Time Frame: intraoperative ]""}]
NCT02503293	A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003746-27/results	8	2015-07-17	Completed	2014-11-01	2017-12-11	2019-02-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL by delivery device used.\n[ Time Frame: Participants will be followed for a total of 6 months ]\n\nEach patient will be treated for two consecutive periods of three months each according to the sequence assigned based on the cross-over design (syringe and then pump, or pump and then syringe) without any intermediate washout period. The total duration of study treatment will therefore be 6 months for each patient. Assessment will be conducted via the LQI scale.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL by delivery device used.\n[ Time Frame: Participants will be followed for a total of 6 months ]\n\nEach patient will be treated for two consecutive periods of three months each according to the sequence assigned based on the cross-over design (syringe and then pump, or pump and then syringe) without any intermediate washout period. The total duration of study treatment will therefore be 6 months for each patient. Assessment will be conducted via the LQI scale.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL by delivery device used.\n[ Time Frame: Participants will be followed for a total of 6 months ]\n\nEach patient will be treated for two consecutive periods of three months each according to the sequence assigned based on the cross-over design (syringe and then pump, or pump and then syringe) without any intermediate washout period. The total duration of study treatment will therefore be 6 months for each patient. Assessment will be conducted via the LQI scale.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL by delivery device used.\n[ Time Frame: Participants will be followed for a total of 6 months ]\n\nEach patient will be treated for two consecutive periods of three months each according to the sequence assigned based on the cross-over design (syringe and then pump, or pump and then syringe) without any intermediate washout period. The total duration of study treatment will therefore be 6 months for each patient. Assessment will be conducted via the LQI scale.""}]	NA
NCT02508220	Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus	Tinnitus Treatment with Oxytocin: A Pilot Study	10.3389/fneur.2017.00494	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613090/	2	2015-07-23	Completed	2015-07-01	2015-09-01	2017-09-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus on VAS\n[ Time Frame: 30 minutes after intervention ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Clinical global impression scale\n[ Time Frame: 30 minutes after intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus on VAS\n[ Time Frame: 30 minutes after intervention ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Clinical global impression scale\n[ Time Frame: 30 minutes after intervention ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of tinnitus on VAS\n[ Time Frame: 30 minutes after intervention ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Clinical global impression scale\n[ Time Frame: 30 minutes after intervention ]""}]	NA	NA
NCT02509728	Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants	Combined choline and DHA supplementation: a randomized controlled trial	10.1007/s00394-019-01940-7	https://link.springer.com/article/10.1007%2Fs00394-019-01940-7	3	2015-07-27	Completed	2015-07-01	2017-10-31	2019-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""plasma concentrations of choline\n[ Time Frame: following 7 days of supplementation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""plasma concentrations of choline\n[ Time Frame: following 7 days of supplementation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""plasma concentrations of choline\n[ Time Frame: following 7 days of supplementation ]""}]	NA	NA
NCT02515526	Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein	Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?	10.1002/cpt.1083	https://pubmed.ncbi.nlm.nih.gov/29633238/	3	2015-08-03	Completed	2015-06-01	2015-08-01	2018-05-10	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CYP1A2: AUC0-t of caffeine in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NAT2 activity: (AFMU + AAMU) / (AFMU + AAMU + 1X + 1U)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""CYP2C9: AUC0-t of tolbutamide in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""CYP2C19: Molar omeprazole / 5-OH-omepazole AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""CYP2D6: Molar dextromethorphan / dextrorphan AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Hepatic CYP3A4: hepatic clearance of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Intestinal CYP3A4: intestinal extraction of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Intestinal p-glycoprotein: absolute bioavailability of digoxin (calculated as Ae)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Renal p-glycoprotein: renal secretion of digoxin\n[ Time Frame: 2 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CYP1A2: AUC0-t of caffeine in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NAT2 activity: (AFMU + AAMU) / (AFMU + AAMU + 1X + 1U)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""CYP2C9: AUC0-t of tolbutamide in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""CYP2C19: Molar omeprazole / 5-OH-omepazole AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""CYP2D6: Molar dextromethorphan / dextrorphan AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Hepatic CYP3A4: hepatic clearance of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Intestinal CYP3A4: intestinal extraction of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Intestinal p-glycoprotein: absolute bioavailability of digoxin (calculated as Ae)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Renal p-glycoprotein: renal secretion of digoxin\n[ Time Frame: 2 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CYP1A2: AUC0-t of caffeine in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""NAT2 activity: (AFMU + AAMU) / (AFMU + AAMU + 1X + 1U)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""CYP2C9: AUC0-t of tolbutamide in plasma\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""CYP2C19: Molar omeprazole / 5-OH-omepazole AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""CYP2D6: Molar dextromethorphan / dextrorphan AUC0-t ratio\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Hepatic CYP3A4: hepatic clearance of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Intestinal CYP3A4: intestinal extraction of midazolam\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Intestinal p-glycoprotein: absolute bioavailability of digoxin (calculated as Ae)\n[ Time Frame: 2 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Renal p-glycoprotein: renal secretion of digoxin\n[ Time Frame: 2 months ]""}]	NA
NCT02517775	Effects of Cranberry Consumption in Vascular Function in Healthy Individuals	Absorption, Metabolism and Excretion of Cranberry (Poly)phenols in Humans: A Dose Response Study and Assessment of Inter-Individual Variability	10.3390/nu9030268	https://www.mdpi.com/2072-6643/9/3/268	2	2015-08-04	Completed	2014-10-01	2015-09-01	2018-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption ]\n\nmeasured by Flow mediated dilation at 1, 2, 4, 6 and 8 hours after intake""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption ]\n\nmeasured by Flow mediated dilation at 1, 2, 4, 6 and 8 hours after intake""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption ]\n\nmeasured by Flow mediated dilation at 1, 2, 4, 6 and 8 hours after intake""}]	NA	NA
NCT02517801	Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women	NA	NA	https://docserv.uni-duesseldorf.de/servlets/DerivateServlet/Derivate-50771/Boschek%2C%20Lisa%20Charlotte_Dissertation.pdf	2	2015-08-06	Completed	2015-01-01	2015-09-01	2018-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline and on day 30 ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline and on day 30 ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: Baseline and on day 30 ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption""}]	NA	NA
NCT02519101	Effects of Continuous Noninvasive Arterial Pressure Measurement on Anaesthesia	The impact of continuous non-invasive arterial blood pressure monitoring on blood pressure stability during general anaesthesia in orthopaedic patients: A randomised trial	10.1097/eja.0000000000000690	NA	2	2015-08-07	Completed	2015-06-01	2016-05-01	2017-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Patients with Hypotensive Events in comparison between both groups\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dosage of Norepinephrine given to the patient to maintain blood pressure normotensive\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Patients with Hypotensive Events in comparison between both groups\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dosage of Norepinephrine given to the patient to maintain blood pressure normotensive\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Patients with Hypotensive Events in comparison between both groups\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Dosage of Norepinephrine given to the patient to maintain blood pressure normotensive\n[ Time Frame: During induction and maintainance of general anaesthesia (average estimated time = 3 hours) ]""}]	NA	NA
NCT02520830	Effects of Blueberry-polyphenols on Endothelial Function, Absorption and Metabolism	Circulating Anthocyanin Metabolites Mediate Vascular Benefits of Blueberries: Insights From Randomized Controlled Trials, Metabolomics, and Nutrigenomics	10.1093/gerona/glz047	https://pubmed.ncbi.nlm.nih.gov/30772905/	2	2015-08-07	Completed	2014-03-01	2015-09-01	2019-02-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: baseline and 1 month ]\n\nDetermination of endothelial function by Flow mediated dilation (FMD) 0 and 2 hours postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: baseline and 1 month ]\n\nDetermination of endothelial function by Flow mediated dilation (FMD) 0 and 2 hours postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Endothelial function\n[ Time Frame: baseline and 1 month ]\n\nDetermination of endothelial function by Flow mediated dilation (FMD) 0 and 2 hours postconsumption""}]	NA	NA
NCT02529358	Text Message Based Maintenance Intervention	Evaluation of a text-message-based maintenance intervention for Major Depressive Disorder after inpatient cognitive behavioral therapy	10.1016/j.jad.2017.10.047	NA	1	2015-08-19	Completed	2012-02-01	2013-10-01	2017-10-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptom load\n[ Time Frame: 6 weeks post treatment (after intervention) ]\n\nMeasurement of depressive symptom severity with Beck Depression Inventory""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Emotion Regulation Competence\n[ Time Frame: 6 weeks post treatment (after intervention) ]\n\nEmotion Regulation Competence measured by SERSA""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptom load\n[ Time Frame: 6 weeks post treatment (after intervention) ]\n\nMeasurement of depressive symptom severity with Beck Depression Inventory""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Emotion Regulation Competence\n[ Time Frame: 6 weeks post treatment (after intervention) ]\n\nEmotion Regulation Competence measured by SERSA""}]	NA	NA
NCT02534285	the Impact of Noise on Requirements of Anesthetics During General Anesthesia	NA	10.19224/ai2020.196	https://www.ai-online.info/archiv/2020/06-2020/laermabschirmung-senkt-nicht-den-desfluranbedarf-waehrend-allgemein-anaesthesien-fuehrt-aber-zu-einer-verminderung-von-bis-werten-60.html	4	2015-08-26	Completed	2015-08-01	2016-11-01	2020-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[See Results Section.]	NA
NCT02541071	Influence of the Noradrenergic System on the Formation of Intrusive Memories	Influence of the noradrenergic system on the formation of intrusive memories in women: an experimental approach with a trauma film paradigm	10.1017/s0033291716001379	https://www.cambridge.org/core/journals/psychological-medicine/article/influence-of-the-noradrenergic-system-on-the-formation-of-intrusive-memories-in-women-an-experimental-approach-with-a-trauma-film-paradigm/1116B707F29736D26005865ACAA9FF27	1	2015-09-03	Completed	2013-11-01	2014-10-01	2016-06-23	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of intrusive memories\n[ Time Frame: four consecutive days ]\n\nMeasured with an intrusion diary""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of intrusive memories\n[ Time Frame: four consecutive days ]\n\nMeasured with an intrusion diary""}]	NA	NA
NCT02547519	Pre-POINT-Early Study	NA	10.1101/2020.06.12.20129189	https://www.medrxiv.org/content/10.1101/2020.06.12.20129189v3	6	2015-09-09	Completed	2015-08-01	2017-08-01	2020-07-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The activation of a CD4+ T cell immune response against insulin\n[ Time Frame: change from baseline (visit 1) in CD4+ T cell response measured as a stimulation index at 12 months of treatment ]\n\nThe primary outcome for immune efficacy is the activation of an immune response (antibody or CD4+ T cell) against insulin. Each participant will be categorized as reaching a response or not. A response is defined as a >2-fold increase that reaches a stimulation index of >3.0.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The activation of an antibody response against insulin.\n[ Time Frame: change from baseline (visit 1) in antibodies measured as serum IgG binding to insulin (unit of measure, cpm) and salivary IgA binding to insulin (unit of measure, cpm) at 12 months of treatment ]\n\nAn antibody response is defined as an increase from baseline of >10 cpm in serum IgG binding to insulin from baseline to 12 months, or a positive salivary IgA binding to insulin at 12 months.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The activation of a CD4+ T cell immune response against insulin\n[ Time Frame: change from baseline (visit 1) in CD4+ T cell response measured as a stimulation index at 12 months of treatment ]\n\nThe primary outcome for immune efficacy is the activation of an immune response (antibody or CD4+ T cell) against insulin. Each participant will be categorized as reaching a response or not. A response is defined as a >2-fold increase that reaches a stimulation index of >3.0.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The activation of an antibody response against insulin.\n[ Time Frame: change from baseline (visit 1) in antibodies measured as serum IgG binding to insulin (unit of measure, cpm) and salivary IgA binding to insulin (unit of measure, cpm) at 12 months of treatment ]\n\nAn antibody response is defined as an increase from baseline of >10 cpm in serum IgG binding to insulin from baseline to 12 months, or a positive salivary IgA binding to insulin at 12 months.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The activation of a CD4+ T cell immune response against insulin\n[ Time Frame: change from baseline (visit 1) in CD4+ T cell response measured as a stimulation index at 12 months of treatment ]\n\nThe primary outcome for immune efficacy is the activation of an immune response (antibody or CD4+ T cell) against insulin. Each participant will be categorized as reaching a response or not. A response is defined as a >2-fold increase that reaches a stimulation index of >3.0.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The activation of an antibody response against insulin.\n[ Time Frame: change from baseline (visit 1) in antibodies measured as serum IgG binding to insulin (unit of measure, cpm) and salivary IgA binding to insulin (unit of measure, cpm) at 12 months of treatment ]\n\nAn antibody response is defined as an increase from baseline of >10 cpm in serum IgG binding to insulin from baseline to 12 months, or a positive salivary IgA binding to insulin at 12 months.""}]	NA	NA
NCT02548585	A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study	10.1016/s0140-6736(18)30726-8	https://pubmed.ncbi.nlm.nih.gov/29945727/	9	2015-09-10	Completed	2015-10-01	2017-02-24	2018-06-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[See Results Section.]	NA
NCT02551302	""Efficacy of Hybrid Systems (""Topping Off"") Versus Rigid Spinal Fusion in Lumbar Fusion Surgery: A Dual-center, Prospective, Randomized Pilot Study (""CD Horizon BalanC"")""	Material failure in dynamic spine implants: are the standardized implant tests before market launch sufficient?	10.1007/s00586-019-05880-y	https://pubmed.ncbi.nlm.nih.gov/30649613/	1	2015-09-15	Unknown status	NA	NA	2019-01-16	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in the subscores of physical pain and physical function in the ODI Questionaire\n[ Time Frame: Baseline to 6 month ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in the subscores of physical pain and physical function in the ODI Questionaire\n[ Time Frame: Baseline to 6 month ]""}]
NCT02551978	Kids Obesity Prevention Program - Study (KOP)	The Kids Obesity Prevention Program: Cluster Randomized Controlled Trial to Evaluate a Serious Game for the Prevention and Treatment of Childhood Obesity	10.2196/15725	https://www.jmir.org/2020/4/e15725/	2	2015-09-15	Completed	2015-09-01	2015-10-01	2020-04-24	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Knowledge of the children about nutrition and psychosocial aspects by a self-developed questionnaire specific for the serious game\n[ Time Frame: Change between baseline and two weeks after the baseline measurement ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Knowledge of the children about nutrition and psychosocial aspects by a self-developed questionnaire specific for the serious game\n[ Time Frame: Change between baseline and two weeks after the baseline measurement ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Knowledge of the children about nutrition and psychosocial aspects by a self-developed questionnaire specific for the serious game\n[ Time Frame: Change between baseline and two weeks after the baseline measurement ]""}]	NA	NA
NCT02552589	Effect of Toothpaste on the Reduction of Plaque and Inflammation	NA	10.1111/idh.12392	https://onlinelibrary.wiley.com/doi/abs/10.1111/idh.12392	4	2015-09-16	Completed	2015-09-01	2016-01-01	2019-02-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque index (Silness and Loe 1964)\n[ Time Frame: Change in plaque index from baseline at 12 weeks ]\n\nDifference of plaque index, compared between test group and control group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque index (Silness and Loe 1964)\n[ Time Frame: Change in plaque index from baseline at 12 weeks ]\n\nDifference of plaque index, compared between test group and control group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque index (Silness and Loe 1964)\n[ Time Frame: Change in plaque index from baseline at 12 weeks ]\n\nDifference of plaque index, compared between test group and control group.""}]	NA	NA
NCT02552654	Cortisol and the Formation of Intrusive Memories	Impact of exogenous cortisol on the formation of intrusive memories in healthy women	10.1016/j.jpsychires.2016.08.005	https://pubmed.ncbi.nlm.nih.gov/27569651/	2	2015-09-16	Completed	2015-09-01	2015-11-01	2016-08-13	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of intrusive memories\n[ Time Frame: seven consecutive days ]\n\nMeasured with an intrusion diary""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of intrusive memories\n[ Time Frame: seven consecutive days ]\n\nMeasured with an intrusion diary""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of intrusive memories\n[ Time Frame: seven consecutive days ]\n\nMeasured with an intrusion diary""}]	NA
NCT02552875	Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults	Shortening of the twitch stabilization period by tetanic stimulation in acceleromyography in infants, children and young adults (STSTS-Study): a prospective randomised, controlled trial	10.1007/s10877-019-00435-4	https://pubmed.ncbi.nlm.nih.gov/31786715/	1	2015-09-16	Completed	2014-09-01	2015-09-01	2019-11-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""T1% measurement\n[ Time Frame: 30 minutes ]\n\nT1% increase dependent on stimulation with and without a 50 Hz tetanic stimulation""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""T1% measurement\n[ Time Frame: 30 minutes ]\n\nT1% increase dependent on stimulation with and without a 50 Hz tetanic stimulation""}]	NA	NA
NCT02554318	Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia	NA	NA	http://geb.uni-giessen.de/geb/volltexte/2016/12027/pdf/SetiawanBudhi_2016_03_24.pdf	1	2015-09-17	Completed	2013-10-01	2015-02-01	2016-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight on a digital weight scale\n[ Time Frame: Baseline, 2 months ]\n\nThe change of body weight to the participants over the two months intervention period as measured in kilograms scale.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight on a digital weight scale\n[ Time Frame: Baseline, 2 months ]\n\nThe change of body weight to the participants over the two months intervention period as measured in kilograms scale.""}]	NA	NA
NCT02557113	Creation of a Small Cavity Reduces the Rate of Cement Leakage During Vertebral Body Augmentation	Small cavity creation in the vertebral body reduces the rate of cement leakage during vertebroplasty	10.1002/jor.23215	NA	1	2015-09-21	Completed	2011-01-01	2012-09-01	2016-03-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CT-Scan evaluation\n[ Time Frame: One week ]\n\nNumber of Cement Extravasation in each Vertebral Body""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CT-Scan evaluation\n[ Time Frame: One week ]\n\nNumber of Cement Extravasation in each Vertebral Body""}]	NA	NA
NCT02557698	Effectiveness of Using an Oil Bath Additive	The effectiveness of using a bath oil to reduce signs of dry skin: A randomized controlled pragmatic study	10.1016/j.ijnurstu.2016.10.010	https://pubmed.ncbi.nlm.nih.gov/27815985/	3	2015-09-22	Completed	2014-11-01	2015-04-01	2016-10-26	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Transepidermal water loss (TEWL) in g/m2/h at the left mid volar forearm\n[ Time Frame: Day 28 +/- 3 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Transepidermal water loss (TEWL) in g/m2/h at the left mid volar forearm\n[ Time Frame: Day 28 +/- 3 ]""}]	[See Results Section.]	NA
NCT02559141	Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study	Non-invasive hemodynamic optimization in major abdominal surgery: a feasibility study	NA	https://pubmed.ncbi.nlm.nih.gov/27352070/	2	2015-09-23	Completed	2014-03-01	2015-10-01	2016-06-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative complications\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative complications\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative complications\n[ Time Frame: 28 days ]""}]	NA	NA
NCT02564081	Remote Effects of Lower Limb Stretching	Remote effects of lower limb stretching: preliminary evidence for myofascial connectivity?	10.1080/02640414.2016.1179776	https://www.tandfonline.com/doi/abs/10.1080/02640414.2016.1179776	4	2015-09-29	Completed	2015-08-01	2015-11-01	2016-04-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	NA	NA
NCT02566369	Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris	Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne	10.1016/j.jaad.2019.02.044	https://pubmed.ncbi.nlm.nih.gov/30802558/	15	2015-10-01	Completed	2015-11-01	2018-01-01	2019-02-22	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[See Results Section.]	NA
NCT02569619	Evaluation of an Intervention to Promote Physical Activity in Outpatients With Mental Disorders	Increasing physical activity and healthy diet in outpatients with mental disorders: a randomized-controlled evaluation of two psychological interventions	10.1007/s00406-018-0941-z	https://link.springer.com/article/10.1007/s00406-018-0941-z	3	2015-10-05	Completed	2014-04-01	2016-02-01	2018-09-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity - objective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is objectively measured using accelerometry (ActiGraph GT1M)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in physical activity - subjective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is subjectively measured with the International Physical Activity Questionaire (IPAQ)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity - objective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is objectively measured using accelerometry (ActiGraph GT1M)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in physical activity - subjective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is subjectively measured with the International Physical Activity Questionaire (IPAQ)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity - objective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is objectively measured using accelerometry (ActiGraph GT1M)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in physical activity - subjective\n[ Time Frame: From baseline (T1) to 3 month after the intervention (T3) ]\n\nPhysical activity is subjectively measured with the International Physical Activity Questionaire (IPAQ)""}]	NA	NA
NCT02585882	Preventive Effect of Salt Fluoridation	Caries-Preventive Effect of Salt Fluoridation in Preschool Children in The Gambia: A Prospective, Controlled, Interventional Study	10.1159/000479892	https://www.karger.com/Article/FullText/479892	2	2015-10-22	Completed	2012-03-01	2013-08-01	2017-11-15	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""caries increment\n[ Time Frame: 12 months ]\n\ndifference of incidence of cavitated carious lesions (Δd3/4mft)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""caries increment\n[ Time Frame: 12 months ]\n\ndifference of incidence of cavitated carious lesions (Δd3/4mft)""}]	NA	NA
NCT02586181	Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People (KnoVIB)	One year B and D vitamins supplementation improves metabolic bone markers	10.1515/cclm-2012-0599	NA	2	2015-10-22	Completed	2009-08-01	2011-07-01	2013-03-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in bone formation markers\n[ Time Frame: baseline, 6 and 12 months ]\n\nConcentrations of bone formation markers in plasma [OC (ng/ml), BAP (U/L)]: are measured: if all are increased indicate enhanced bone formation""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in bone formation markers\n[ Time Frame: baseline, 6 and 12 months ]\n\nConcentrations of bone formation markers in plasma [OC (ng/ml), BAP (U/L)]: are measured: if all are increased indicate enhanced bone formation""}]	NA
NCT02587533	Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation	Efficacy of Electrical Baroreflex Activation Is Independent of Peripheral Chemoreceptor Modulation	10.1161/hypertensionaha.119.13925	https://pubmed.ncbi.nlm.nih.gov/31786986/	4	2015-10-23	Completed	2015-11-01	2017-12-01	2019-12-02	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle sympathetic nerve activity (MSNA)\n[ Time Frame: Over 24 minutes of stable de/oxygenation +/- dopamine infusion. ]\n\nMuscle sympathetic nerve activity (MSNA) will be determined as burst frequency, i. e. as the number of bursts per minute [bursts/min]. In responders, electrical carotid sinus stimulation will lead to a decline in MSNA: [-]MSNA. According to our primary hypothesis, [-]MSNA during hyperoxic conditions ([-]MSNA_hyperoxia) is larger than during hypoxia ([-]MSNA_hypoxia). Therefore, the primary endpoint of the study is the difference [-]MSNA_hyperoxia - [-]MSNA_hypoxia. The study is successful as soon as the difference between the reduction in the hyperoxic and the hypoxic condition is significantly different from zero. A positive value would confirm our primary hypothesis. In case of a negative difference, we would conclude that the potency of electrical baroreflex stimulation to lower sympathetic activity is larger under conditions of an activated chemoreflex.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle sympathetic nerve activity (MSNA)\n[ Time Frame: Over 24 minutes of stable de/oxygenation +/- dopamine infusion. ]\n\nMuscle sympathetic nerve activity (MSNA) will be determined as burst frequency, i. e. as the number of bursts per minute [bursts/min]. In responders, electrical carotid sinus stimulation will lead to a decline in MSNA: [-]MSNA. According to our primary hypothesis, [-]MSNA during hyperoxic conditions ([-]MSNA_hyperoxia) is larger than during hypoxia ([-]MSNA_hypoxia). Therefore, the primary endpoint of the study is the difference [-]MSNA_hyperoxia - [-]MSNA_hypoxia. The study is successful as soon as the difference between the reduction in the hyperoxic and the hypoxic condition is significantly different from zero. A positive value would confirm our primary hypothesis. In case of a negative difference, we would conclude that the potency of electrical baroreflex stimulation to lower sympathetic activity is larger under conditions of an activated chemoreflex.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle sympathetic nerve activity (MSNA)\n[ Time Frame: Over 24 minutes of stable de/oxygenation +/- dopamine infusion. ]\n\nMuscle sympathetic nerve activity (MSNA) will be determined as burst frequency, i. e. as the number of bursts per minute [bursts/min]. In responders, electrical carotid sinus stimulation will lead to a decline in MSNA: [-]MSNA. According to our primary hypothesis, [-]MSNA during hyperoxic conditions ([-]MSNA_hyperoxia) is larger than during hypoxia ([-]MSNA_hypoxia). Therefore, the primary endpoint of the study is the difference [-]MSNA_hyperoxia - [-]MSNA_hypoxia. The study is successful as soon as the difference between the reduction in the hyperoxic and the hypoxic condition is significantly different from zero. A positive value would confirm our primary hypothesis. In case of a negative difference, we would conclude that the potency of electrical baroreflex stimulation to lower sympathetic activity is larger under conditions of an activated chemoreflex.""}]	NA	NA
NCT02595229	Pronator Quadratus Repair After Volar Plating of Distal Radius Fractures	Pronator quadratus repair after volar plating of distal radius fractures or not? Results of a prospective randomized trial	10.1186/s40001-015-0187-4	https://www.ncbi.nlm.nih.gov/pubmed/26607745?dopt=Abstract	1	2015-11-01	Completed	2010-05-01	2013-03-01	2015-11-25	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Isometric forearm pronation strength (N)\n[ Time Frame: 6 weeks postoperative ]\n\nMeasurement of the isometric forearm pronation strength (N) using the IsoForce-Control EVO 2 dynamometer (MDS AG, Oberburg, Switzerland)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Isometric forearm pronation strength (N)\n[ Time Frame: 12 weeks postoperative ]\n\nMeasurement of the isometric forearm pronation strength (N) using the IsoForce-Control EVO 2 dynamometer (MDS AG, Oberburg, Switzerland)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Isometric forearm pronation strength (N)\n[ Time Frame: 6 weeks postoperative ]\n\nMeasurement of the isometric forearm pronation strength (N) using the IsoForce-Control EVO 2 dynamometer (MDS AG, Oberburg, Switzerland)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Isometric forearm pronation strength (N)\n[ Time Frame: 12 weeks postoperative ]\n\nMeasurement of the isometric forearm pronation strength (N) using the IsoForce-Control EVO 2 dynamometer (MDS AG, Oberburg, Switzerland)""}]	NA	NA
NCT02601963	Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea	A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea	10.1007/s40257-017-0339-0	https://pubmed.ncbi.nlm.nih.gov/29396702/	5	2015-11-10	Completed	2015-09-01	2016-09-01	2018-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""the absolute change in inflammatory lesion count at Week 12 compared to Baseline.\n[ Time Frame: Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""the absolute change in inflammatory lesion count at Week 12 compared to Baseline.\n[ Time Frame: Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""the absolute change in inflammatory lesion count at Week 12 compared to Baseline.\n[ Time Frame: Baseline to Week 12 ]""}]	NA	NA
NCT02602275	Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands	fMRI Revealed Reduced Amygdala Activation after Nx4 in Mildly to Moderately Stressed Healthy Volunteers in a Randomized, Placebo-Controlled, Cross-Over Trial	10.1038/s41598-020-60392-w	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052227/	3	2015-11-09	Completed	2015-08-01	2015-12-01	2020-03-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduced amygdala responsiveness measured by negative face to form contrasts in the Hariri task (Hariri et. al., 2000; Hariri et. al., 2003) after verum versus placebo condition\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 1: Effect of drug, driven by significantly smaller amygdala activations in the contrast (negative faces vs forms) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduced functional connectivity density (FCD) in amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 2: Interaction of time and drug, driven by significantly greater reductions of amygdala functional connectivity density (FCD) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Reduced whole brain functional connectivity of amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 3: Interaction of time and drug, driven by significantly greater changes (smaller and greater, two sided effects because of inclusion of top down and bottom up processes in different regions) of amygdala seeded connectivities in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the whole brain.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Reduced local resting state activity of amygdala after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 4: Interaction of time and drug, driven by significantly greater reductions of amygdala ALFF in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Increased effective connectivity from frontal cortex to amygdala during Hariri experiment after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 5: Influence of drug on directed connectivity in an effective connectivity model (DCM) from ventral prefrontal cortex (vPFC) towards amygdala, driven by positive effects of verum on directed negative effective (top down) connectivity from vPFC to amygdala. Significance for the modulating effect of drug on effective connectivity is accepted for a p level of 0.05, for a winning model selected based on Bayesian information criterion (BIC) across all subjects and scans (verum and placebo) (Sladky et al 2013).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Reduced stress network activation during stress (MIST) in verum relative to placebo.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 6: Effect of drug, driven by significantly smaller activations in anterior cingulate cortex, medio-orbitofrontal cortex, hippocampus, amygdala, and hypothalamus in the contrast (hard vs easy) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduced amygdala responsiveness measured by negative face to form contrasts in the Hariri task (Hariri et. al., 2000; Hariri et. al., 2003) after verum versus placebo condition\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 1: Effect of drug, driven by significantly smaller amygdala activations in the contrast (negative faces vs forms) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduced functional connectivity density (FCD) in amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 2: Interaction of time and drug, driven by significantly greater reductions of amygdala functional connectivity density (FCD) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Reduced whole brain functional connectivity of amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 3: Interaction of time and drug, driven by significantly greater changes (smaller and greater, two sided effects because of inclusion of top down and bottom up processes in different regions) of amygdala seeded connectivities in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the whole brain.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Reduced local resting state activity of amygdala after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 4: Interaction of time and drug, driven by significantly greater reductions of amygdala ALFF in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Increased effective connectivity from frontal cortex to amygdala during Hariri experiment after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 5: Influence of drug on directed connectivity in an effective connectivity model (DCM) from ventral prefrontal cortex (vPFC) towards amygdala, driven by positive effects of verum on directed negative effective (top down) connectivity from vPFC to amygdala. Significance for the modulating effect of drug on effective connectivity is accepted for a p level of 0.05, for a winning model selected based on Bayesian information criterion (BIC) across all subjects and scans (verum and placebo) (Sladky et al 2013).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Reduced stress network activation during stress (MIST) in verum relative to placebo.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 6: Effect of drug, driven by significantly smaller activations in anterior cingulate cortex, medio-orbitofrontal cortex, hippocampus, amygdala, and hypothalamus in the contrast (hard vs easy) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduced amygdala responsiveness measured by negative face to form contrasts in the Hariri task (Hariri et. al., 2000; Hariri et. al., 2003) after verum versus placebo condition\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 1: Effect of drug, driven by significantly smaller amygdala activations in the contrast (negative faces vs forms) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduced functional connectivity density (FCD) in amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 2: Interaction of time and drug, driven by significantly greater reductions of amygdala functional connectivity density (FCD) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Reduced whole brain functional connectivity of amygdala after verum versus placebo condition during rest.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 3: Interaction of time and drug, driven by significantly greater changes (smaller and greater, two sided effects because of inclusion of top down and bottom up processes in different regions) of amygdala seeded connectivities in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the whole brain.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Reduced local resting state activity of amygdala after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 4: Interaction of time and drug, driven by significantly greater reductions of amygdala ALFF in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Increased effective connectivity from frontal cortex to amygdala during Hariri experiment after verum versus placebo condition.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 5: Influence of drug on directed connectivity in an effective connectivity model (DCM) from ventral prefrontal cortex (vPFC) towards amygdala, driven by positive effects of verum on directed negative effective (top down) connectivity from vPFC to amygdala. Significance for the modulating effect of drug on effective connectivity is accepted for a p level of 0.05, for a winning model selected based on Bayesian information criterion (BIC) across all subjects and scans (verum and placebo) (Sladky et al 2013).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Reduced stress network activation during stress (MIST) in verum relative to placebo.\n[ Time Frame: Day 1 and Day 2 ]\n\nPrimary Outcome 6: Effect of drug, driven by significantly smaller activations in anterior cingulate cortex, medio-orbitofrontal cortex, hippocampus, amygdala, and hypothalamus in the contrast (hard vs easy) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.""}]	NA	NA
NCT02609412	Immediate Effects of Self-myofascial Release on Latent Trigger Point Sensitivity	Immediate effects of self-myofascial release on latent trigger point sensitivity: a randomized, placebo-controlled trial	10.5114/biolsport.2018.78055	https://pubmed.ncbi.nlm.nih.gov/30765920/	3	2015-11-18	Completed	2015-05-01	2016-05-01	2018-08-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pressure pain threshold [kg/cm²] assessed by pressure algometer\n[ Time Frame: Baseline (M1) - 3 minutes (M2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pressure pain threshold [kg/cm²] assessed by pressure algometer\n[ Time Frame: Baseline (M1) - 3 minutes (M2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in pressure pain threshold [kg/cm²] assessed by pressure algometer\n[ Time Frame: Baseline (M1) - 3 minutes (M2) ]""}]	NA	NA
NCT02612220	Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection	Randomized clinical trial of BioFoam® Surgical Matrix to achieve hemostasis after liver resection	10.1016/j.hpb.2019.10.1529	https://pubmed.ncbi.nlm.nih.gov/31680010/	5	2015-11-20	Completed	2015-12-01	2017-09-06	2019-11-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time-to-complete hemostasis\n[ Time Frame: 3 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time-to-complete hemostasis\n[ Time Frame: 3 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time-to-complete hemostasis\n[ Time Frame: 3 minutes ]""}]	NA	NA
NCT02620553	Primary Intervention With Mucosal Insulin	Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial	10.1001/jama.2015.2928	https://pubmed.ncbi.nlm.nih.gov/25898052/	2	2015-11-30	Completed	2007-09-01	2013-06-01	2015-04-21	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Blood Glucose Levels\n[ Time Frame: Day 1 ]\n\nEvaluation for hypoglycemia will be measured prior to administration of the insulin (baseline), then at 30, 60, and 120 minutes after administration of the insulin.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Daily Evaluation of Blood Glucose Levels\n[ Time Frame: Days 2 through 7 ]\n\nBlood glucose will be measured 60 minutes after the administration of the Insulin.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Evaluation of Blood Glucose Levels\n[ Time Frame: Measured 60 minutes after oral insulin dosing, every day during each 4th week, as long as the subject is given oral insulin. ]\n\nAfter treatment day 7, Insulin will be administered and measured on a monthly basis.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Blood Glucose Levels\n[ Time Frame: Day 1 ]\n\nEvaluation for hypoglycemia will be measured prior to administration of the insulin (baseline), then at 30, 60, and 120 minutes after administration of the insulin.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Daily Evaluation of Blood Glucose Levels\n[ Time Frame: Days 2 through 7 ]\n\nBlood glucose will be measured 60 minutes after the administration of the Insulin.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Evaluation of Blood Glucose Levels\n[ Time Frame: Measured 60 minutes after oral insulin dosing, every day during each 4th week, as long as the subject is given oral insulin. ]\n\nAfter treatment day 7, Insulin will be administered and measured on a monthly basis.""}]	NA
NCT02637544	Treatment Efficiency of Acupuncture in Non Chronified Pain Patients With TMDs	Comparison of acupuncture on specific and non-specific points for the treatment of painful temporomandibular disorders: A randomised controlled trial	10.1111/joor.12952	https://pubmed.ncbi.nlm.nih.gov/32077514/	2	2015-12-21	Unknown status	2014-04-01	NA	2020-03-09	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""current pain measured on Numerical Rating Scale\n[ Time Frame: 4 weeks ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""current pain measured on Numerical Rating Scale\n[ Time Frame: 4 weeks ]""}]
NCT02637778	Modulation of Cardiovascular Risk Factors by the Diet	Functional Biomarkers for the Selenium Status in a Human Nutritional Intervention Study	10.3390/nu12030676	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146433/	6	2015-12-17	Completed	2016-02-01	2016-06-01	2020-03-02	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids\n[ Time Frame: change from baseline at 20 weeks ]\n\ntotal cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerides (TAG) [mmol/L]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids\n[ Time Frame: change from baseline at 20 weeks ]\n\ntotal cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerides (TAG) [mmol/L]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids\n[ Time Frame: change from baseline at 20 weeks ]\n\ntotal cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerides (TAG) [mmol/L]""}]	NA	NA
NCT02639520	Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs	Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial	10.1159/000493368	https://www.karger.com/Article/FullText/493368	6	2015-12-21	Completed	2015-12-01	2017-06-01	2018-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\n\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.\n\nThe primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\n\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.\n\nThe primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).""}]	NA	NA
NCT02640703	Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial	Randomized Controlled Trial on the Effects of Morning versus Evening Primary Vaccination on Episodes of Hypoxemia and Bradycardia in Very Preterm Infants	10.1159/000501338	https://www.karger.com/Article/Abstract/501338	3	2015-12-22	Completed	2015-03-01	2016-12-01	2019-08-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of hypoxia and bradycardia events\n[ Time Frame: 72 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of hypoxia and bradycardia events\n[ Time Frame: 72 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of hypoxia and bradycardia events\n[ Time Frame: 72 hours ]""}]	NA	NA
NCT02643602	Does Bicarbonate in Addition to Theophylline Reduce CIN?	Sodium Bicarbonate Prevents Contrast-Induced Nephropathy in Addition to Theophylline: A Randomized Controlled Trial	10.1097/md.0000000000003720	https://www.ncbi.nlm.nih.gov/pubmed/27227933	2	2015-12-29	Completed	2005-12-01	2012-06-01	2016-05-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Contrast induced nephropathy\n[ Time Frame: 48 hours ]\n\nRaise in serum creatinine of ≥25% or ≥0.5 mg/dl""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Contrast induced nephropathy\n[ Time Frame: 48 hours ]\n\nRaise in serum creatinine of ≥25% or ≥0.5 mg/dl""}]	NA	NA
NCT02647489	Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted	First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria	10.1093/cid/ciy1140	https://academic.oup.com/cid/article/69/9/1509/5281109	7	2016-01-05	Completed	2016-05-01	2016-08-01	2019-01-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number and grade of adverse events (Grade 1-3 and serious adverse events) possibly, likely and definitely related to vaccination\n[ Time Frame: From the first administration of the interventions through study completion, an average of 1 and a half years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number and grade of adverse events (Grade 1-3 and serious adverse events) possibly, likely and definitely related to vaccination\n[ Time Frame: From the first administration of the interventions through study completion, an average of 1 and a half years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number and grade of adverse events (Grade 1-3 and serious adverse events) possibly, likely and definitely related to vaccination\n[ Time Frame: From the first administration of the interventions through study completion, an average of 1 and a half years ]""}]	NA	NA
NCT02647801	Self-control and Mindfulness Within Ambulatorily Assessed Network Systems Across Health Related Domains	A mind full of happiness: How mindfulness shapes affect dynamics in daily life	10.1037/emo0000562	https://pubmed.ncbi.nlm.nih.gov/30570315/	6	2016-01-04	Completed	2015-09-01	2016-12-01	2018-12-20	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 2 till day 41, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Three items from the Mindfulness Attention Awareness Scale (MAAS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nItems from the German version of the MAAS. Self-report on current mindfulness of participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Three items from the Mindfulness Attention Awareness Scale (MAAS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nItems from the German version of the MAAS. Self-report on current mindfulness of participants.""}]	NA	NA
NCT02664805	Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema	Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study	10.1111/bjd.18469	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.18469	8	2016-01-22	Completed	2016-02-01	2016-09-01	2019-08-29	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)\n[ Time Frame: 56 days ]\n\nTreatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)\n[ Time Frame: 56 days ]\n\nTreatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)\n[ Time Frame: 56 days ]\n\nTreatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear""}]	NA	NA
NCT02670265	Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions	Early Parenteral Nutrition in Patients with Biliopancreatic Mass Lesions, a Prospective, Randomized Intervention Trial	10.1371/journal.pone.0166513	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166513	1	2016-01-28	Completed	2012-06-01	2014-02-01	2016-11-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight loss\n[ Time Frame: ≥ 3 days ]\n\nInfluence of Olimel Peri 2.%% ® on body weight""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight loss\n[ Time Frame: ≥ 3 days ]\n\nInfluence of Olimel Peri 2.%% ® on body weight""}]	NA	NA
NCT02671929	Translation and Development of an Online Self-help Intervention With Subsequent Feasibility Study	Transdiagnostic, Psychodynamic Web-Based Self-Help Intervention Following Inpatient Psychotherapy: Results of a Feasibility Study and Randomized Controlled Trial	10.2196/mental.7889	https://pubmed.ncbi.nlm.nih.gov/29038094/	5	2016-01-29	Completed	2015-09-01	2016-05-01	2017-10-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Satisfaction of the intervention group with the internet-based self-help program measured with an reworded version of the \""patient satisfaction questionnaire\"" (ZUF-8)\n[ Time Frame: 10 weeks after study inclusion (T1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Satisfaction of the intervention group with the internet-based self-help program measured with an reworded version of the \""patient satisfaction questionnaire\"" (ZUF-8)\n[ Time Frame: 10 weeks after study inclusion (T1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Satisfaction of the intervention group with the internet-based self-help program measured with an reworded version of the \""patient satisfaction questionnaire\"" (ZUF-8)\n[ Time Frame: 10 weeks after study inclusion (T1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Satisfaction of the intervention group with the internet-based self-help program measured with an reworded version of the \""patient satisfaction questionnaire\"" (ZUF-8)\n[ Time Frame: 10 weeks after study inclusion (T1) ]""}]	NA
NCT02672553	EDWARDS INTUITY Valve System CADENCE-MIS Study	A randomized multicenter trial of minimally invasive rapid deployment versus conventional full sternotomy aortic valve replacement	10.1016/j.athoracsur.2014.09.022	https://pubmed.ncbi.nlm.nih.gov/25441065/	2	2016-01-29	Completed	2012-05-01	2015-03-01	2014-11-20	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cross-clamp time\n[ Time Frame: At time of surgery ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary bypass time\n[ Time Frame: At time of surgery ]""}]	NA	NA	[See Results Section.]	NA
NCT02675660	Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects	Oral supplementation with L-homoarginine in young volunteers	10.1111/bcp.13068	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13068	2	2016-02-02	Completed	2014-04-01	2015-04-01	2016-07-19	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the plasma concentration versus time curve (AUC)\n[ Time Frame: 1 Month ]\n\nTo determine the AUC of L-homoarginine (a) following a single oral dose and (b) following administration of multiple oral doses of L-homoarginine.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the plasma concentration versus time curve (AUC)\n[ Time Frame: 1 Month ]\n\nTo determine the AUC of L-homoarginine (a) following a single oral dose and (b) following administration of multiple oral doses of L-homoarginine.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the plasma concentration versus time curve (AUC)\n[ Time Frame: 1 Month ]\n\nTo determine the AUC of L-homoarginine (a) following a single oral dose and (b) following administration of multiple oral doses of L-homoarginine.""}]	NA
NCT02677129	Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy	NA	10.1007/s00520-018-4478-5	https://link.springer.com/article/10.1007/s00520-018-4478-5#citeas	4	2016-02-04	Completed	2014-08-01	2016-09-01	2018-10-04	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Activities of daily living\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nFunctional Independence Measurement (FIM) Questionnaire""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Activities of daily living\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\n- instrumental Activity of Daily Living (iADL)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short Physical Performance Battery\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nShort battery of physical performance tests used to assess lower extremity function. Balance, gait, strength, and endurance are evaluated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short Physical Performance Battery\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nShort battery of physical performance tests used to assess lower extremity function. Balance, gait, strength, and endurance are evaluated.""}]	NA	NA
NCT02679833	Effect of Toothpaste Fortified With Cyanocobalamin on Vitamin B12 Status	Vitamin B-12-fortified toothpaste improves vitamin status in vegans: a 12-wk randomized placebo-controlled study	10.3945/ajcn.116.141978	https://pubmed.ncbi.nlm.nih.gov/28052884/	4	2016-02-09	Completed	2014-11-01	2015-12-01	2017-01-04	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in plasma concentrations of methylmalonic acid\n[ Time Frame: Baseline, 3 months ]\n\nLowering methylmalonic acid in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The change in plasma concentrations of holotranscobalamin\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing holotranscobalamin in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""The change in plasma concentrations of homocysteine\n[ Time Frame: Baseline, 3 months ]\n\nLowering homocysteine in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""The change in plasma concentrations of vitamin B12\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing plasma vitamin B12 in the B12 arm compared with the placebo arm""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in plasma concentrations of methylmalonic acid\n[ Time Frame: Baseline, 3 months ]\n\nLowering methylmalonic acid in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The change in plasma concentrations of holotranscobalamin\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing holotranscobalamin in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""The change in plasma concentrations of homocysteine\n[ Time Frame: Baseline, 3 months ]\n\nLowering homocysteine in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""The change in plasma concentrations of vitamin B12\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing plasma vitamin B12 in the B12 arm compared with the placebo arm""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in plasma concentrations of methylmalonic acid\n[ Time Frame: Baseline, 3 months ]\n\nLowering methylmalonic acid in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The change in plasma concentrations of holotranscobalamin\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing holotranscobalamin in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""The change in plasma concentrations of homocysteine\n[ Time Frame: Baseline, 3 months ]\n\nLowering homocysteine in the B12 arm compared with the placebo arm""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""The change in plasma concentrations of vitamin B12\n[ Time Frame: Baseline, 3 months ]\n\nThe effect on increasing plasma vitamin B12 in the B12 arm compared with the placebo arm""}]	NA
NCT02685696	Surgical Site Infection in Caesarean Section Using Alexis O Compared to Metal Retractors	NA	10.17169/refubium-13320	https://refubium.fu-berlin.de/handle/fub188/9121	1	2016-02-14	Completed	2013-10-01	2016-02-01	2016-11-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of surgical site infection in low risk women having a first time planned Caesarean Section using the Alexis O Retractor compared to the traditional Metal Retractor.\n[ Time Frame: 6-8 Weeks after Surgery ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of surgical site infection in low risk women having a first time planned Caesarean Section using the Alexis O Retractor compared to the traditional Metal Retractor.\n[ Time Frame: 6-8 Weeks after Surgery ]""}]	NA	NA
NCT02689960	Vaginal Prednisone Administration for Prevention of Adrenal Crisis	Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease	10.1530/ec-19-0024	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454300/	4	2016-02-18	Completed	2017-01-01	2017-04-01	2019-03-18	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioequivalence of vaginal prednisone administration compared to rectal application, assessed by repeated determination of prednisolon levels (in blood)\n[ Time Frame: up to 12 months ]\n\nThe hypothesis is that the same prednisolone levels can be achieved within the same time frame after vaginale administration compared to rectal application.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioequivalence of vaginal prednisone administration compared to rectal application, assessed by repeated determination of prednisolon levels (in blood)\n[ Time Frame: up to 12 months ]\n\nThe hypothesis is that the same prednisolone levels can be achieved within the same time frame after vaginale administration compared to rectal application.""}]	NA	NA
NCT02695940	Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002098-40/results	7	2016-03-01	Completed	2016-03-01	2016-08-01	2017-10-14	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The total sign score (TSS) at Week 6 (Visit 6)\n[ Time Frame: after 6 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The total sign score (TSS) at Week 6 (Visit 6)\n[ Time Frame: after 6 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The total sign score (TSS) at Week 6 (Visit 6)\n[ Time Frame: after 6 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The total sign score (TSS) at Week 6 (Visit 6)\n[ Time Frame: after 6 weeks of treatment ]""}]	NA
NCT02697539	Plaque Formation Rate and Toothpaste	Impact of the Daily Use of a Microcrystal Hydroxyapatite Dentifrice on De Novo Plaque Formation and Clinical/Microbiological Parameters of Periodontal Health. A Randomized Trial	10.1371/journal.pone.0160142	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160142	1	2016-02-26	Completed	2011-03-01	2011-09-01	2016-07-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome plaque formation rate (PFR) was measured 24 hours after all teeth were treated mechanically.\n[ Time Frame: Measured 24 hours after all teeth were treated mechanically . ]\n\nFor the recording of PFR,all teeth were stained with a plaque revealer (Mira 2-Ton® Miradent, Hager & Werken GmbH, Duisburg, Germany).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome plaque formation rate (PFR) was measured 24 hours after all teeth were treated mechanically.\n[ Time Frame: Measured 24 hours after all teeth were treated mechanically . ]\n\nFor the recording of PFR,all teeth were stained with a plaque revealer (Mira 2-Ton® Miradent, Hager & Werken GmbH, Duisburg, Germany).""}]	NA	NA
NCT02701933	Effects of Ketamine on Eye Movements, Perception and Brain Function	Effects of ketamine on brain function during smooth pursuit eye movements	10.1002/hbm.23294	https://onlinelibrary.wiley.com/doi/full/10.1002/hbm.23294	1	2016-03-02	Completed	2014-04-01	2014-12-01	2016-10-26	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain activity in cortical and subcortical areas as assessed using BOLD (blood oxygen level dependent) functional magnetic resonance imaging (fMRI) at 3 Tesla field strength\n[ Time Frame: within 1 hour of start of IV infusion ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brain activity in cortical and subcortical areas as assessed using BOLD (blood oxygen level dependent) functional magnetic resonance imaging (fMRI) at 3 Tesla field strength\n[ Time Frame: within 1 hour of start of IV infusion ]""}]	NA	NA
NCT02705456	Enamel Caries in Orthodontic Patients	Impact of a non-fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries-susceptible orthodontic patients: A randomized, controlled 6-month trial	10.1111/jicd.12399	https://pubmed.ncbi.nlm.nih.gov/30701704/	3	2016-03-04	Completed	2014-10-01	2016-08-01	2019-01-30	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of developing enamel caries lesions\n[ Time Frame: 168 days (24 weeks) ]\n\nRecording of newly developing enamel caries lesions according to the International Caries Detection and Assessment System (ICDAS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of developing enamel caries lesions\n[ Time Frame: 168 days (24 weeks) ]\n\nRecording of newly developing enamel caries lesions according to the International Caries Detection and Assessment System (ICDAS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of developing enamel caries lesions\n[ Time Frame: 168 days (24 weeks) ]\n\nRecording of newly developing enamel caries lesions according to the International Caries Detection and Assessment System (ICDAS)""}]	NA	NA
NCT02716389	Cervical Kinematics' Reliability: Zero Positioning Using a 3-D-bulls Eye Spirit Level	Reliability of measuring half-cycle cervical range of motion may be increased using a spirit level for calibration	10.1016/j.msksp.2017.08.006	https://www.sciencedirect.com/science/article/abs/pii/S2468781217301388?via%3Dihub	2	2016-03-17	Completed	2016-03-01	2016-04-01	2018-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximal cervical range of motion in flexion/extension\n[ Time Frame: 2 min. ]""}]	NA	NA
NCT02721836	Yoga for Patients With Irritable Bowel Syndrome	Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome	10.1111/apt.14400	https://pubmed.ncbi.nlm.nih.gov/29076171/	4	2016-03-22	Completed	2016-04-01	2016-12-01	2017-10-27	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome Symptoms\n[ Time Frame: Week 12 ]\n\nIrritable Bowel Syndrome Severity Scoring System (IBS-SSS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome Symptoms\n[ Time Frame: Week 12 ]\n\nIrritable Bowel Syndrome Severity Scoring System (IBS-SSS)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome Symptoms\n[ Time Frame: Week 12 ]\n\nIrritable Bowel Syndrome Severity Scoring System (IBS-SSS)""}]	NA	NA
NCT02724592	Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions	Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel	10.1177/0022034517730531	https://pubmed.ncbi.nlm.nih.gov/28892645/	2	2016-03-24	Completed	2013-02-01	2014-04-01	2017-09-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ICDAS (International Caries Detection and Assessment System) index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.\n[ Time Frame: 6 months ]\n\nEvaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using ICDAS caries index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ICDAS (International Caries Detection and Assessment System) index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.\n[ Time Frame: 6 months ]\n\nEvaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using ICDAS caries index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.""}]	[See Results Section.]	NA
NCT02727140	Yoga as a Supportive Therapy for Patients With Hypertension	NA	10.3238/arztebl.2018.0833	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375068/	4	2016-04-01	Completed	2016-05-01	2017-01-01	2018-12-14	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24 h mean value of systolic and diastolic blood pressure\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24 h mean value of systolic and diastolic blood pressure\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24 h mean value of systolic and diastolic blood pressure\n[ Time Frame: 12 weeks ]""}]	NA	NA
NCT02728466	Effects of Cocoa Procyanidins on Vascular Function	Assessing the respective contributions of dietary flavanol monomers and procyanidins in mediating cardiovascular effects in humans: randomized, controlled, double-masked intervention trial	10.1093/ajcn/nqy229	https://pubmed.ncbi.nlm.nih.gov/30358831/	2	2016-03-30	Completed	2014-10-01	2016-05-01	2018-12-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change form Baseline Endothelial function at 1 month\n[ Time Frame: Baseline and 1 month ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption on baseline and on 1 month""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change form Baseline Endothelial function at 1 month\n[ Time Frame: Baseline and 1 month ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption on baseline and on 1 month""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change form Baseline Endothelial function at 1 month\n[ Time Frame: Baseline and 1 month ]\n\nMeasured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption on baseline and on 1 month""}]	NA	NA
NCT02734901	Effects of Acute Red Raspberry Consumption on Vascular Function in Healthy Individuals	Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: A double-blind randomized controlled trial	10.1016/j.abb.2018.05.016	https://pubmed.ncbi.nlm.nih.gov/29802820/	3	2016-04-11	Completed	2016-03-01	2016-09-01	2018-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 h and 24 h in Endothelial function\n[ Time Frame: Baseline, 2 h and 24 h ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 h postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 hour and 24 hour in Endothelial function\n[ Time Frame: Baseline, 2 hour and 24 hour ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 hour postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 hour and 24 hour in Endothelial function\n[ Time Frame: Baseline, 2 hour and 24 hour ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 hour postconsumption""}]	NA	NA
NCT02735187	Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.	NA	NA	https://pdfs.semanticscholar.org/b3a6/c8239a9c030a1c7a3af8acbafc77c9a8ecc2.pdf?_ga=2.264204238.316868046.1597691860-1172082013.1597691860	4	2016-04-11	Completed	2016-03-01	2016-08-01	2019-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[See Results Section.]	NA
NCT02743260	Drug Transporter Interaction Study PHENTRA_2015_KPUK	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin	10.1002/cpt.1564	https://pubmed.ncbi.nlm.nih.gov/31247117/	3	2016-04-13	Completed	2016-04-01	2017-12-01	2019-08-12	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavialability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]\n\nPK parameter""}]	NA
NCT02744638	Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis	Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial	10.3920/bm2017.0018	https://pubmed.ncbi.nlm.nih.gov/29065710/	3	2016-04-15	Completed	2015-02-01	2016-08-01	2017-10-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Amsel criteria.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Amsel criteria.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Nugent score""}]	NA	NA
NCT02751229	Honest Open Proud for Adolescents With Mental Illness	Honest, Open, Proud for adolescents with mental illness: pilot randomized controlled trial	10.1111/jcpp.12853	https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/jcpp.12853	4	2016-04-21	Completed	2016-05-01	2017-05-01	2017-12-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stigma Stress Scale, 8 items (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)\n[ Time Frame: 3 weeks (T1) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Health-Related Quality of Life Questionnaire KIDSCREEN-10 Index, 10 items (Deighton et al., 2014; Ravens-Sieberer et al., 2010)\n[ Time Frame: 6 weeks (T2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stigma Stress Scale, 8 items (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)\n[ Time Frame: 3 weeks (T1) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Health-Related Quality of Life Questionnaire KIDSCREEN-10 Index, 10 items (Deighton et al., 2014; Ravens-Sieberer et al., 2010)\n[ Time Frame: 6 weeks (T2) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stigma Stress Scale, 8 items (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)\n[ Time Frame: 3 weeks (T1) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Health-Related Quality of Life Questionnaire KIDSCREEN-10 Index, 10 items (Deighton et al., 2014; Ravens-Sieberer et al., 2010)\n[ Time Frame: 6 weeks (T2) ]""}]	NA	NA
NCT02752802	DyeVert System RCT	Impact of a novel contrast reduction system on contrast savings in coronary angiography - The DyeVert randomised controlled trial	10.1016/j.ijcard.2017.12.107	https://pubmed.ncbi.nlm.nih.gov/29373136/	4	2016-04-22	Completed	2016-04-01	2016-05-01	2018-01-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the total volume (percentage) of CM used comparing the DyeVert group to the control group.\n[ Time Frame: All data will be collected on the day of the procedure. ]\n\nDyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the total volume (percentage) of CM used comparing the DyeVert group to the control group.\n[ Time Frame: All data will be collected on the day of the procedure. ]\n\nDyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)""}]	[See Results Section.]	NA	NA
NCT02754167	Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis	10.1371/journal.pone.0212023	NA	4	2016-04-27	Unknown status	2016-04-01	2017-06-01	2019-03-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients with adverse events\n[ Time Frame: 28 days ]\n\nComposite measure including signs and symptoms, changes from baseline heart rate and blood pressure, ECG, body temperature, respiratory rate clinical chemistry and hematology""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients with adverse events\n[ Time Frame: 28 days ]\n\nComposite measure including signs and symptoms, changes from baseline heart rate and blood pressure, ECG, body temperature, respiratory rate clinical chemistry and hematology""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of patients with adverse events\n[ Time Frame: 28 days ]\n\nComposite measure including signs and symptoms, changes from baseline heart rate and blood pressure, ECG, body temperature, respiratory rate clinical chemistry and hematology""}]	NA	NA
NCT02755246	Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline	The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial	10.1016/j.cortex.2018.09.014	https://pubmed.ncbi.nlm.nih.gov/30388439/	3	2016-04-26	Completed	2016-04-01	2016-08-01	2018-10-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Cognitive Function (from neuropsychological test battery)\n[ Time Frame: Prior to intervention (baseline) and after 3 months of intervention ]\n\nComparing changes in cognitive function in subjects with polyamine intake and placebo treatment (pre vs. post intervention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Cognitive Function (from neuropsychological test battery)\n[ Time Frame: Prior to intervention (baseline) and after 3 months of intervention ]\n\nComparing changes in cognitive function in subjects with polyamine intake and placebo treatment (pre vs. post intervention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Cognitive Function (from neuropsychological test battery)\n[ Time Frame: Prior to intervention (baseline) and after 3 months of intervention ]\n\nComparing changes in cognitive function in subjects with polyamine intake and placebo treatment (pre vs. post intervention)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Cognitive Function (from neuropsychological test battery)\n[ Time Frame: Prior to intervention (baseline) and after 3 months of intervention ]\n\nComparing changes in cognitive function in subjects with polyamine intake and placebo treatment (pre vs. post intervention)""}]	NA
NCT02771535	Long-term Efficacy of Metacognitive Training for Depression (D-MCT)	Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial	10.1159/000443699	https://www.karger.com/Article/Abstract/443699	3	2016-05-12	Completed	2016-03-01	2017-05-01	2016-06-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Depression Rating Scale\n[ Time Frame: 3 years from baseline (t0) to 3-year follow up (t3) ]\n\nPrimary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t3)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Depression Rating Scale\n[ Time Frame: 3 years from baseline (t0) to 3-year follow up (t3) ]\n\nPrimary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t3)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Depression Rating Scale\n[ Time Frame: 3 years from baseline (t0) to 3-year follow up (t3) ]\n\nPrimary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t3)""}]	NA
NCT02771652	Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients	Internet-Supported Physical Exercise Training for Persons with Multiple Sclerosis-A Randomised, Controlled Study	10.3390/ijms17101667	NA	2	2016-05-10	Completed	2010-02-01	2011-06-01	2016-09-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS)\n[ Time Frame: Assessments took place at baseline and at 3 months ]\n\n38 items generate the subscales of fatigue/thinking, mobility of the lower/upper extremities, communication and mood. The HAQUAMS total score is calculated from a mean of the subscales, providing a total score between 1 and 5. Higher scores in HAQUAMS indicate lower levels in HRQoL. The primary outcome will be the change over time from baseline to month 3.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS)\n[ Time Frame: Assessments took place at baseline and at 3 months ]\n\n38 items generate the subscales of fatigue/thinking, mobility of the lower/upper extremities, communication and mood. The HAQUAMS total score is calculated from a mean of the subscales, providing a total score between 1 and 5. Higher scores in HAQUAMS indicate lower levels in HRQoL. The primary outcome will be the change over time from baseline to month 3.""}]	NA	NA
NCT02775019	Health Impact of L.Reuteri Consumption in Crew Members of a Naval Ship at Sea	Consumption of Lactobacillus reuteri-containing lozenges improves periodontal health in navy sailors at sea: A randomized controlled trial	10.1002/jper.19-0393	https://aap.onlinelibrary.wiley.com/doi/full/10.1002/JPER.19-0393	3	2016-05-13	Completed	2016-05-01	2016-08-01	2020-02-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bleeding on Probing\n[ Time Frame: 42 days ]\n\nNumber of sites being positive for bleeding on probing on the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44) with 6 probing sites per tooth""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bleeding on Probing\n[ Time Frame: 42 days ]\n\nNumber of sites being positive for bleeding on probing on the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44) with 6 probing sites per tooth""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bleeding on Probing\n[ Time Frame: 42 days ]\n\nNumber of sites being positive for bleeding on probing on the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44) with 6 probing sites per tooth""}]	NA	NA
NCT02794259	tDCS Effects on GABA Concentration and Brain Functional Connectivity in Older Adults of Retirement Age	tDCS-Induced Modulation of GABA Levels and Resting-State Functional Connectivity in Older Adults	10.1523/jneurosci.0079-17.2017	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596583/	2	2016-06-03	Completed	2016-04-01	2016-07-01	2017-04-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	NA	NA
NCT02794272	tDCS Effects on GABA Concentration and Brain Functional Connectivity in Older Adults Of Working Age	tDCS-Induced Modulation of GABA Levels and Resting-State Functional Connectivity in Older Adults	10.1523/jneurosci.0079-17.2017	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596583/	2	2016-06-03	Completed	2016-04-01	2016-07-01	2017-04-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) before and after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) before and after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GABA concentration assessed by magnetic resonance spectroscopy (MRS) before and after anodal tDCS adjusted for baseline levels\n[ Time Frame: assessed immediately before and after a 15-min stimulation time ]\n\nInvestigation whether anodal tDCS leads to a significant reduction of M1-GABA concentration in older adults compared to sham stimulation.""}]	NA	NA
NCT02799069	Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy	Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo	10.1111/j.1365-2133.2011.10613.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2011.10613.x/full	3	2016-06-09	Completed	2008-04-01	2009-08-01	2011-12-21	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall subject complete response\n[ Time Frame: 12 weeks after the last photodynamic therapy (PDT) ]\n\nAn overall complete responder was defined as a subject in whom all treated lesions were cleared 12 weeks after either the first PDT or re-treatment.""}]	NA	NA	[See Results Section.]	NA
NCT02804412	Aphasia Therapy: Factors of Efficacy	Constraint-Induced Aphasia Therapy in the Acute Stage: What Is the Key Factor for Efficacy? A Randomized Controlled Study	10.1177/1545968316662707	https://www.ncbi.nlm.nih.gov/pubmed/27506677	1	2016-06-14	Completed	2005-03-01	2013-01-01	2016-08-09	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of aphasia by Aachener Aphasia Test (AAT)\n[ Time Frame: pretreatment and within 24 h post intervention ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of aphasia by Aachener Aphasia Test (AAT)\n[ Time Frame: pretreatment and within 24 h post intervention ]""}]	NA	NA
NCT02806583	Talking Time: Telephone Support Groups for Informal Caregivers of People With Dementia	NA	NA	https://www.gkv-spitzenverband.de/media/dokumente/pflegeversicherung/forschung/projekte_unterseiten/redezeit/11-2017_REDEZEIT-Endbericht-final.pdf	6	2016-06-15	Completed	2015-11-01	2017-03-13	2017-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental Component Summary of the General Health Questionaires Short Form 12 (SF-12)\n[ Time Frame: 3 months ]\n\npsychological quality of life of the caregivers""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental Component Summary of the General Health Questionaires Short Form 12 (SF-12)\n[ Time Frame: 3 months ]\n\npsychological quality of life of the caregivers""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mental Component Summary of the General Health Questionaires Short Form 12 (SF-12)\n[ Time Frame: 3 months ]\n\npsychological quality of life of the caregivers""}]	NA	NA
NCT02810535	Local IgE in Subjects With Allergic or Non-allergic Rhinitis	Nasal IgE in subjects with allergic and non-allergic rhinitis	10.1016/j.waojou.2020.100129	https://pubmed.ncbi.nlm.nih.gov/32612737/	2	2016-06-20	Completed	2016-05-01	2017-08-01	2020-06-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of IgE between 24 subjects with non-allergic rhinitis, 24 subjects with allergic rhinitis and 20 healthy subjects.\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of IgE between 24 subjects with non-allergic rhinitis, 24 subjects with allergic rhinitis and 20 healthy subjects.\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of IgE between 24 subjects with non-allergic rhinitis, 24 subjects with allergic rhinitis and 20 healthy subjects.\n[ Time Frame: one year ]""}]	NA	NA
NCT02834338	Enhanced Perioperative Mobilization (EPM) Trial	Use of Activity Tracking in Major Visceral Surgery-the Enhanced Perioperative Mobilization Trial: a Randomized Controlled Trial	10.1007/s11605-018-3998-0	https://pubmed.ncbi.nlm.nih.gov/30298422/	4	2016-07-12	Completed	2016-07-01	2017-07-20	2018-10-08	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Step count\n[ Time Frame: First to fifth postoperative day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Step count\n[ Time Frame: First to fifth postoperative day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median Step count\n[ Time Frame: First to fifth postoperative day ]""}]	NA	NA
NCT02834377	Personalized Hemodynamic Therapy in Patients Undergoing High-risk Surgery	Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial	10.1016/j.bja.2020.04.094	https://pubmed.ncbi.nlm.nih.gov/32711724/	5	2016-07-12	Completed	2016-05-01	2017-06-30	2020-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of study participants with at least one complication of a composite of 30-day postinterventional complications\n[ Time Frame: up tp 90 days after study enrollment ]\n\ncomposite of 30-day postinterventional complications defined according to the ESA-ESICM guidelines for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine (acute kidney injury stage 1 or higher [KIDGO]; ARDS; anastomotic breakdown [moderate and severe]; arrhythmia [severe]; cardiac arrest; cardiogenic pulmonary oedema [severe]; deep vein thrombosis [moderate and severe]; delirium; GI bleeding [severe]; Infection, source uncertain [severe]; bloodstream infection [severe]; myocardial infarction [severe]; pneumonia [severe]; paralytic ileus [severe]; postoperative haemorrhage [severe]; pulmonary embolism [severe]; stroke [severe]; superficial, deep, organ/space surgical site infection [severe]; urinary tract infection [severe]; death)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of study participants with at least one complication of a composite of 30-day postinterventional complications\n[ Time Frame: up tp 90 days after study enrollment ]\n\ncomposite of 30-day postinterventional complications defined according to the ESA-ESICM guidelines for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine (acute kidney injury stage 1 or higher [KIDGO]; ARDS; anastomotic breakdown [moderate and severe]; arrhythmia [severe]; cardiac arrest; cardiogenic pulmonary oedema [severe]; deep vein thrombosis [moderate and severe]; delirium; GI bleeding [severe]; Infection, source uncertain [severe]; bloodstream infection [severe]; myocardial infarction [severe]; pneumonia [severe]; paralytic ileus [severe]; postoperative haemorrhage [severe]; pulmonary embolism [severe]; stroke [severe]; superficial, deep, organ/space surgical site infection [severe]; urinary tract infection [severe]; death)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of study participants with at least one complication of a composite of 30-day postinterventional complications\n[ Time Frame: up tp 90 days after study enrollment ]\n\ncomposite of 30-day postinterventional complications defined according to the ESA-ESICM guidelines for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine (acute kidney injury stage 1 or higher [KIDGO]; ARDS; anastomotic breakdown [moderate and severe]; arrhythmia [severe]; cardiac arrest; cardiogenic pulmonary oedema [severe]; deep vein thrombosis [moderate and severe]; delirium; GI bleeding [severe]; Infection, source uncertain [severe]; bloodstream infection [severe]; myocardial infarction [severe]; pneumonia [severe]; paralytic ileus [severe]; postoperative haemorrhage [severe]; pulmonary embolism [severe]; stroke [severe]; superficial, deep, organ/space surgical site infection [severe]; urinary tract infection [severe]; death)""}]	NA	NA
NCT02836665	Application of Telemedicine for Dermatological Emergency Patients	The assessment of dermatological emergencies in the emergency department via telemedicine is safe: a prospective pilot study	10.1007/s11739-020-02323-1	https://link.springer.com/article/10.1007/s11739-020-02323-1	3	2016-07-14	Completed	2016-08-01	2017-07-14	2020-04-04	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waiting time [min]\n[ Time Frame: 1 emergency visit [approximately 2 hours] ]\n\nTime is measured from the patients admission to the emergency room up to the personnel/telemedical diagnosis and therapy by the dermatological investigator in charge.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waiting time [min]\n[ Time Frame: 1 emergency visit [approximately 2 hours] ]\n\nTime is measured from the patients admission to the emergency room up to the personnel/telemedical diagnosis and therapy by the dermatological investigator in charge.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Waiting time [min]\n[ Time Frame: 1 emergency visit [approximately 2 hours] ]\n\nTime is measured from the patients admission to the emergency room up to the personnel/telemedical diagnosis and therapy by the dermatological investigator in charge.""}]	NA	NA
NCT02848014	The Effects of Interventions Aiming at Optimizing Expectations and Inducing Positive Emotions After an Acute Stressor	Optimizing expectations and distraction leads to lower cortisol levels after acute stress	10.1016/j.psyneuen.2017.12.011	https://www.sciencedirect.com/science/article/abs/pii/S0306453017313331	2	2016-07-25	Completed	2016-07-01	2016-11-01	2018-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in personal control expectation (Item of the Brief IPQ)\n[ Time Frame: Pre-intervention (baseline; T0) vs. Post-intervention (25 minutes after baseline assessment; T1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in personal control expectation (Item of the Brief IPQ)\n[ Time Frame: Pre-intervention (baseline; T0) vs. Post-intervention (25 minutes after baseline assessment; T1) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in personal control expectation (Item of the Brief IPQ)\n[ Time Frame: Pre-intervention (baseline; T0) vs. Post-intervention (25 minutes after baseline assessment; T1) ]""}]	NA	NA
NCT02848352	The Role of Expectations in Experimentally Induced Sadness	Expectation-induced placebo effect on acute sadness in women with major depression: An experimental investigation	10.1016/j.jad.2020.05.056	https://www.sciencedirect.com/science/article/abs/pii/S0165032720302500	2	2016-07-25	Completed	2016-06-01	2016-10-01	2020-05-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sadness (PANAS-X)\n[ Time Frame: Directly after watching the film sequence, no follow-up assessments ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sadness (PANAS-X)\n[ Time Frame: Directly after watching the film sequence, no follow-up assessments ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sadness (PANAS-X)\n[ Time Frame: Directly after watching the film sequence, no follow-up assessments ]""}]	NA	NA
NCT02851108	Methylene Blue Against Falciparum Malaria in Burkina Faso	Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial	10.1371/journal.pone.0222993	https://pubmed.ncbi.nlm.nih.gov/31600221/	4	2016-07-29	Completed	2016-10-01	2016-12-01	2019-10-10	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[See Results Section.]	NA
NCT02857660	Effect of Whole Body Electromyostimulation and/or Protein Supplementation on Sarcopenic Obesity in 70+	Effect of whole-body electromyostimulation and / or protein supplementation on obesity and cardiometabolic risk in older men with sarcopenic obesity: the randomized controlled FranSO trial	10.1186/s12877-018-0759-6	https://pubmed.ncbi.nlm.nih.gov/29523089/	4	2016-08-02	Completed	2016-07-01	2017-02-01	2018-03-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Sarcopenia Z-Score\n[ Time Frame: Change from Baseline Sarcopenia Z-Score at 16 weeks ]\n\nie. Z-Score generated by skeletal muscle index, gait speed and grip-strength according to the Sarcopenia Definition of the European Working Group on Sarcopenia in Older People""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Obesity\n[ Time Frame: Change from Baseline Obesity at 16 weeks ]\n\nAssessment of body fat content and body mass index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Sarcopenia Z-Score\n[ Time Frame: Change from Baseline Sarcopenia Z-Score at 16 weeks ]\n\nie. Z-Score generated by skeletal muscle index, gait speed and grip-strength according to the Sarcopenia Definition of the European Working Group on Sarcopenia in Older People""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Obesity\n[ Time Frame: Change from Baseline Obesity at 16 weeks ]\n\nAssessment of body fat content and body mass index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Sarcopenia Z-Score\n[ Time Frame: Change from Baseline Sarcopenia Z-Score at 16 weeks ]\n\nie. Z-Score generated by skeletal muscle index, gait speed and grip-strength according to the Sarcopenia Definition of the European Working Group on Sarcopenia in Older People""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of Obesity\n[ Time Frame: Change from Baseline Obesity at 16 weeks ]\n\nAssessment of body fat content and body mass index""}]	NA	NA
NCT02858817	Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine	10.1038/nature21060	https://pubmed.ncbi.nlm.nih.gov/28199305/	3	2016-08-05	Completed	2016-11-28	2018-03-01	2017-02-15	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number or occurrence of related Grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: from time of first administration of A/P until the last follow up visit, 414 days after first administration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number or occurrence of related Grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: from time of first administration of A/P until the last follow up visit, 414 days after first administration ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number or occurrence of related Grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs)\n[ Time Frame: from time of first administration of A/P until the last follow up visit, 414 days after first administration ]""}]	NA
NCT02861001	VivaSight-SL™ Versus Bronchoscopy for Percutaneous Tracheotomy	Bronchoscopy versus an endotracheal tube mounted camera for the peri-interventional visualization of percutaneous dilatational tracheostomy - a prospective, randomized trial (VivaPDT)	10.1186/s13054-017-1901-0	https://pubmed.ncbi.nlm.nih.gov/29284503/	3	2016-08-04	Completed	2016-04-01	2017-01-13	2017-12-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]\n\nfor score see detailed description""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]""}]	NA	NA
NCT02868320	SMS Technology for the Promotion of Diabetes Education and Self-Management in Egypt	SMS education for the promotion of diabetes self-management in low & middle income countries: a pilot randomized controlled trial in Egypt	10.1186/s12889-017-4973-5	https://pubmed.ncbi.nlm.nih.gov/29258499/	1	2016-08-11	Completed	2014-04-01	2015-06-01	2017-12-19	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in HbA1c\n[ Time Frame: baseline and 12 weeks ]\n\nmeasured by the difference between endpoint and baseline values and by the number of patients who experienced a reduction of at least 1% from baseline to endpoint""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in HbA1c\n[ Time Frame: baseline and 12 weeks ]\n\nmeasured by the difference between endpoint and baseline values and by the number of patients who experienced a reduction of at least 1% from baseline to endpoint""}]	NA	NA
NCT02870972	Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema	Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema	10.1056/nejmoa1716995	https://pubmed.ncbi.nlm.nih.gov/30044938/	9	2016-08-17	Completed	2016-08-01	2017-08-01	2018-07-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[See Results Section.]	NA
NCT02877797	Cap Assisted Upper Endoscopy to Visualize the Major Duodenal Papilla	Cap Assisted Upper Endoscopy for Examination of the Major Duodenal Papilla: A Randomized, Blinded, Controlled Crossover Study (CAPPA Study)	10.1038/ajg.2017.47	NA	1	2016-08-19	Completed	2016-02-01	2016-05-01	2017-03-14	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of complete visualisation of papilla duodeni major\n[ Time Frame: 120 seconds ]\n\nvisualisation: none, incomplete, complete""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of complete visualisation of papilla duodeni major\n[ Time Frame: 120 seconds ]\n\nvisualisation: none, incomplete, complete""}]	NA	NA
NCT02883608	Cap Assisted Forward-Viewing Endoscope vs Side-Viewing Endoscope for Examination of Major Duodenal Papilla	Comparison of cap-assisted endoscopy vs. side-viewing endoscopy for examination of the major duodenal papilla: a randomized, controlled, noninferiority crossover study	10.1055/a-0662-5445	NA	4	2016-08-24	Completed	2016-07-01	2016-10-01	2018-09-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of complete visualisation of papilla duodeni major\n[ Time Frame: within 5 minutes after intubation of the esophagus ]\n\ncomplete visualization is defined by visualization of both proximal and distal ends together with the orifice of the papilla""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of complete visualisation of papilla duodeni major\n[ Time Frame: within 5 minutes after intubation of the esophagus ]\n\ncomplete visualization is defined by visualization of both proximal and distal ends together with the orifice of the papilla""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of complete visualisation of papilla duodeni major\n[ Time Frame: within 5 minutes after intubation of the esophagus ]\n\ncomplete visualization is defined by visualization of both proximal and distal ends together with the orifice of the papilla""}]	NA	NA
NCT02885103	Combination of NHF and Nebulizer on Lung Function in COPD	Oral Versus Nasal High-Flow Bronchodilator Inhalation in Chronic Obstructive Pulmonary Disease	10.1089/jamp.2017.1432	https://pubmed.ncbi.nlm.nih.gov/29261402/	4	2016-08-25	Completed	2016-08-01	2017-11-01	2017-12-20	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in forced expiratory volume in 1s (FEV1)\n[ Time Frame: 45 minutes ]\n\nlitre""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""changes in breath way resistance (Rtot)\n[ Time Frame: 45 min ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in forced expiratory volume in 1s (FEV1)\n[ Time Frame: 45 minutes ]\n\nlitre""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""changes in breath way resistance (Rtot)\n[ Time Frame: 45 min ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in forced expiratory volume in 1s (FEV1)\n[ Time Frame: 45 minutes ]\n\nlitre""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""changes in breath way resistance (Rtot)\n[ Time Frame: 45 min ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in forced expiratory volume in 1s (FEV1)\n[ Time Frame: 45 minutes ]\n\nlitre""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""changes in breath way resistance (Rtot)\n[ Time Frame: 45 min ]""}]	NA
NCT02893800	Validation and Optimization of the Individual Benefits of Locating Systems in Dementia Care	User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care	10.1016/j.trci.2018.10.002	https://www.sciencedirect.com/science/article/pii/S2352873718300635	2	2016-09-02	Completed	2016-05-01	2016-11-01	2018-11-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Usability\n[ Time Frame: 8 weeks ]\n\nISONORM 9241/10 questionnaire (Prümper, 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Usability\n[ Time Frame: 8 weeks ]\n\nISONORM 9241/10 questionnaire (Prümper, 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Usability\n[ Time Frame: 8 weeks ]\n\nISONORM 9241/10 questionnaire (Prümper, 1997)""}]	NA	NA
NCT02896062	Development and Evaluation of a Sleep-coaching Program	Effects of a Workplace-Based Sleep Health Program on Sleep in Members of the German Armed Forces	10.5664/jcsm.7666	https://pubmed.ncbi.nlm.nih.gov/30853042/	2	2016-09-06	Completed	2014-10-01	2016-10-01	2019-03-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]\n\nPSQI total score""}]	NA	NA
NCT02902861	Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	10.1016/s0140-6736(16)32127-4	https://pubmed.ncbi.nlm.nih.gov/28012564/	1	2016-09-15	Completed	2013-02-01	2014-09-01	2016-12-22	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in 75% reduction of Psoriasis Area Severity Index (PASI75) responder rate between treatment arms\n[ Time Frame: week 16 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in 75% reduction of Psoriasis Area Severity Index (PASI75) responder rate between treatment arms\n[ Time Frame: week 16 ]""}]	NA	NA
NCT02912598	Lung Isolation in Thoracic Surgery - a Randomized Trial Comparing the VivaSight™ EB Endobronchial Blocker With Established Devices	NA	NA	https://d-nb.info/1141230399/34	1	2016-09-22	Completed	2015-01-01	2015-11-01	2016-12-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to initial lung isolation\n[ Time Frame: intraoperative ]\n\nDuration of initial bronchoscopy-guided placement of the endobronchial ballon. Start: Beginning of direct laryngoscopy. End: Initial inflation of the endobronchially placed cuff.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to initial lung isolation\n[ Time Frame: intraoperative ]\n\nDuration of initial bronchoscopy-guided placement of the endobronchial ballon. Start: Beginning of direct laryngoscopy. End: Initial inflation of the endobronchially placed cuff.""}]	NA	NA
NCT02919527	Acute Effects of Foam Rolling on Viscoelastic Tissue Properties and Fascial Sliding	NA	NA	https://d-nb.info/117425162X/34	3	2016-09-28	Completed	2016-09-01	2017-06-01	2018-11-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Passive-Resistive-Torque, Biodex System 3 Professional\n[ Time Frame: 1 minute ]\n\nIn passive mode, the lower leg is moved from full knee extension (0°) to the point of maximal knee flexion with a velocity of 5°/s. Torque and angle are recorded at 100 Hz, and passive stiffness can be calculated from the torque-angle relationship.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fascial-Sliding, Siemens Acuson X300, Cross correlation\n[ Time Frame: 1 minute ]\n\nSliding of fascial layers is quantified with a frame-by-frame cross correlation algorithm of high-resolution ultrasound images. The cross-correlation method calculates the correlation coefficient between the pixel grey levels for selected rectangle-shaped regions of interest (ROIs) in two adjacent images. The pixel shift that gives the maximum correlation coefficient corresponds to the relative movement between two frames.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Passive-Resistive-Torque, Biodex System 3 Professional\n[ Time Frame: 1 minute ]\n\nIn passive mode, the lower leg is moved from full knee extension (0°) to the point of maximal knee flexion with a velocity of 5°/s. Torque and angle are recorded at 100 Hz, and passive stiffness can be calculated from the torque-angle relationship.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fascial-Sliding, Siemens Acuson X300, Cross correlation\n[ Time Frame: 1 minute ]\n\nSliding of fascial layers is quantified with a frame-by-frame cross correlation algorithm of high-resolution ultrasound images. The cross-correlation method calculates the correlation coefficient between the pixel grey levels for selected rectangle-shaped regions of interest (ROIs) in two adjacent images. The pixel shift that gives the maximum correlation coefficient corresponds to the relative movement between two frames.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Passive-Resistive-Torque, Biodex System 3 Professional\n[ Time Frame: 1 minute ]\n\nIn passive mode, the lower leg is moved from full knee extension (0°) to the point of maximal knee flexion with a velocity of 5°/s. Torque and angle are recorded at 100 Hz, and passive stiffness can be calculated from the torque-angle relationship.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Fascial-Sliding, Siemens Acuson X300, Cross correlation\n[ Time Frame: 1 minute ]\n\nSliding of fascial layers is quantified with a frame-by-frame cross correlation algorithm of high-resolution ultrasound images. The cross-correlation method calculates the correlation coefficient between the pixel grey levels for selected rectangle-shaped regions of interest (ROIs) in two adjacent images. The pixel shift that gives the maximum correlation coefficient corresponds to the relative movement between two frames.""}]	NA	NA
NCT02920164	Auricular Acupuncture for Exam Anxiety in Medical Students	Auricular Acupuncture for Exam Anxiety in Medical Students-A Randomized Crossover Investigation	10.1371/journal.pone.0168338	NA	1	2016-09-29	Completed	2012-04-01	2012-07-01	2016-12-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of anxiety\n[ Time Frame: 2 days ]\n\nState-Trait-Anxiety Inventory""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of anxiety\n[ Time Frame: 2 days ]\n\nState-Trait-Anxiety Inventory""}]	NA	NA
NCT02920840	Brain-oscillation Synchronised Stimulation of the Prefrontal Cortex	Brain oscillation-synchronized stimulation of the left dorsolateral prefrontal cortex in depression using real-time EEG-triggered TMS	10.1016/j.brs.2019.10.007	https://www.sciencedirect.com/science/article/pii/S1935861X19304140	2	2016-09-28	Completed	2016-09-01	2017-04-01	2019-10-12	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in cortical excitability 30 minutes after the intervention\n[ Time Frame: 30 minutes ]\n\nTMS-evoked EEG potentials from left dlPFC""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in cortical excitability 30 minutes after the intervention\n[ Time Frame: 30 minutes ]\n\nTMS-evoked EEG potentials from left dlPFC""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in cortical excitability 30 minutes after the intervention\n[ Time Frame: 30 minutes ]\n\nTMS-evoked EEG potentials from left dlPFC""}]	NA
NCT02930525	Effect of High Flow Nasal Cannula vs. Standard Care on Respiratory Stability in Pediatric Procedural Sedation	High-flow nasal cannula vs standard respiratory care in pediatric procedural sedation: A randomized controlled pilot trial	10.1002/ppul.24975	https://onlinelibrary.wiley.com/doi/full/10.1002/ppul.24975	2	2016-10-11	Completed	2016-09-01	2017-12-01	2020-07-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Respiratory instability\n[ Time Frame: Time frame from first applications of intravenous sedatives until finishing the intended procedure ]\n\nNumber of episodes longer than 15 seconds with SpO2 < 93% and/ or pCO2 > 45 mmHg and/ or apnea (defined as cessation of airflow for > 15 seconds)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Respiratory instability\n[ Time Frame: Time frame from first applications of intravenous sedatives until finishing the intended procedure ]\n\nNumber of episodes longer than 15 seconds with SpO2 < 93% and/ or pCO2 > 45 mmHg and/ or apnea (defined as cessation of airflow for > 15 seconds)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Respiratory instability\n[ Time Frame: Time frame from first applications of intravenous sedatives until finishing the intended procedure ]\n\nNumber of episodes longer than 15 seconds with SpO2 < 93% and/ or pCO2 > 45 mmHg and/ or apnea (defined as cessation of airflow for > 15 seconds)""}]	NA	NA
NCT02930590	Effects of Different Support Surfaces on the Properties Skin After Loading	Comparing the effects of 3 different pressure ulcer prevention support surfaces on the structure and function of heel and sacral skin: An exploratory cross-over trial	10.1111/iwj.12883	https://onlinelibrary.wiley.com/doi/abs/10.1111/iwj.12883	3	2016-10-10	Completed	2016-09-01	2017-03-01	2017-12-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[See Results Section.]	NA
NCT02947542	Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial	Performance of One- Compared With Two-Catheter Concepts in Transradial Coronary Angiography (from the Randomized Use of Different Diagnostic Catheters-Radial-Trial)	10.1016/j.amjcard.2018.07.039	https://www.sciencedirect.com/science/article/abs/pii/S0002914918316230	4	2016-10-26	Completed	2016-04-01	2016-11-01	2018-08-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography duration\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography duration\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography Duration (sec)\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]\n\nassessed by Intention-to-treat analysis (IIT)""}]	NA	NA
NCT02951000	Platysma Trial - Platysma Suturing Versus no Sutures for Wound Closure After Primary Thyroid Surgery	Randomized clinical trial of platysma muscle suture versus no suture for wound closure after thyroid surgery	10.1002/bjs.10829	https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.10829	3	2016-10-31	Completed	2016-02-01	2016-11-01	2018-03-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative Pain\n[ Time Frame: Pain at morning of the first postoperative day ]\n\nvisual analogue pain scale (0-10)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative Pain\n[ Time Frame: Pain at morning of the first postoperative day ]\n\nvisual analogue pain scale (0-10)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Postoperative Pain\n[ Time Frame: Pain at morning of the first postoperative day ]\n\nvisual analogue pain scale (0-10)""}]	NA	NA
NCT02957838	Mitochondrial Effects of C18:0 Supplementation in Humans	Dietary stearic acid regulates mitochondria in vivo in humans	10.1038/s41467-018-05614-6	https://pubmed.ncbi.nlm.nih.gov/30087348/	2	2016-11-03	Completed	2016-11-01	2017-10-06	2018-08-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in Mitochondrial Morphology\n[ Time Frame: 2 days before supplementation, on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondria of neutrophils are stained and scored via immunofluorescence microcsopy, either as \""fragmented\"", \""intermediate\"" or \""fused\"". Statistical calculations will be performed on changes in fragmentation status after treatment.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in Mitochondrial Function\n[ Time Frame: on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondrial membrane potential and ROS production in neutrophils will be analyzed via FACS. Statistical calculations will be performed on changes in the respective levels after treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in Mitochondrial Morphology\n[ Time Frame: 2 days before supplementation, on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondria of neutrophils are stained and scored via immunofluorescence microcsopy, either as \""fragmented\"", \""intermediate\"" or \""fused\"". Statistical calculations will be performed on changes in fragmentation status after treatment.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in Mitochondrial Function\n[ Time Frame: on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondrial membrane potential and ROS production in neutrophils will be analyzed via FACS. Statistical calculations will be performed on changes in the respective levels after treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in Mitochondrial Morphology\n[ Time Frame: 2 days before supplementation, on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondria of neutrophils are stained and scored via immunofluorescence microcsopy, either as \""fragmented\"", \""intermediate\"" or \""fused\"". Statistical calculations will be performed on changes in fragmentation status after treatment.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes in Mitochondrial Function\n[ Time Frame: on the day of supplementation at 0, 3 and 6 h ]\n\nMitochondrial membrane potential and ROS production in neutrophils will be analyzed via FACS. Statistical calculations will be performed on changes in the respective levels after treatment.""}]	NA	NA
NCT02962518	Pressure Device in the Treatment of Ear Keloids	Treatment of ear keloids: algorithm for a multimodal therapy regimen	10.1007/s00405-017-4714-5	https://link.springer.com/article/10.1007%2Fs00405-017-4714-5	1	2016-11-08	Completed	2014-07-01	2016-10-01	2017-08-20	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence\n[ Time Frame: 12 months ]\n\nKeloid recurrence""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence\n[ Time Frame: 12 months ]\n\nKeloid recurrence""}]	NA	NA
NCT02963298	CRRT for Glutamate Elimination After Cardiac Arrest	Elimination of glutamate using CRRT for 72 h in patients with post-cardiac arrest syndrome: A randomized clinical pilot trial	10.1016/j.resuscitation.2019.09.020	https://pubmed.ncbi.nlm.nih.gov/31557520/	3	2016-11-10	Completed	2016-10-01	2017-09-06	2019-09-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Glutamate blood concentration in intervention arm over the time\n[ Time Frame: 72 hours ]\n\nReduction of blood Glutamate concentration by renal replacement therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Glutamate blood concentration in intervention arm over the time\n[ Time Frame: 72 hours ]\n\nReduction of blood Glutamate concentration by renal replacement therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Glutamate blood concentration in intervention arm over the time\n[ Time Frame: 72 hours ]\n\nReduction of blood Glutamate concentration by renal replacement therapy""}]	NA	NA
NCT02964520	EEG Alpha/Theta Neurofeedback to Reduce Trait Anxiety	NA	10.15496/publikation-24421	https://publikationen.uni-tuebingen.de/xmlui/handle/10900/83030	2	2016-11-10	Completed	2015-07-01	2017-01-01	2019-07-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the State-Trait Anxiety Inventory (STAI) Scale\n[ Time Frame: 1-2 weeks pre-treatment and at post treatment at end of last treatment session (4-5 weeks) ]\n\nChange from baseline of symptoms of anxiety to end of treatment after 4-5 weeks. The STAI scale consists of total 40 items on separate scales measuring state (20 items) and trait (20 items) anxiety. The participant reports how they feel right now at this moment for state anxiety and how they generally feel for trait anxiety. The state items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very true). The trait items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). The total scores range from 4-80 for each scale. Higher scores indicate more anxious participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the State-Trait Anxiety Inventory (STAI) Scale\n[ Time Frame: 1-2 weeks pre-treatment and at post treatment at end of last treatment session (4-5 weeks) ]\n\nChange from baseline of symptoms of anxiety to end of treatment after 4-5 weeks. The STAI scale consists of total 40 items on separate scales measuring state (20 items) and trait (20 items) anxiety. The participant reports how they feel right now at this moment for state anxiety and how they generally feel for trait anxiety. The state items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very true). The trait items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). The total scores range from 4-80 for each scale. Higher scores indicate more anxious participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in the State-Trait Anxiety Inventory (STAI) Scale\n[ Time Frame: 1-2 weeks pre-treatment and at post treatment at end of last treatment session (4-5 weeks) ]\n\nChange from baseline of symptoms of anxiety to end of treatment after 4-5 weeks. The STAI scale consists of total 40 items on separate scales measuring state (20 items) and trait (20 items) anxiety. The participant reports how they feel right now at this moment for state anxiety and how they generally feel for trait anxiety. The state items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very true). The trait items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). The total scores range from 4-80 for each scale. Higher scores indicate more anxious participants.""}]	NA	NA
NCT02975154	Microcurrent Therapy in the Treatment of Osteoarthritis of the Knee	NA	10.23736/s1973-9087.20.05921-3	NA	3	2016-11-23	Completed	2016-11-01	2017-09-04	2020-04-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]\n\nnumerical Rating scale""}]	NA	NA
NCT02990039	A Tailored Feasibility Study to Increase Physical Activity and to Reduce Sedentary Time	Do sociodemographic variables and cardiometabolic risk factors moderate the mere-measurement effect on physical activity and sedentary time?	10.1186/s12872-020-01551-9	https://pubmed.ncbi.nlm.nih.gov/32503441/	2	2016-12-07	Completed	2015-02-01	2016-09-01	2020-06-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adherence: Drop-out rates in control and intervention group\n[ Time Frame: up to 12 month ]\n\nMeasures: Analyses of drop-out rates (%) in control and intervention group""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adherence: Drop-out rates in control and intervention group\n[ Time Frame: up to 12 month ]\n\nMeasures: Analyses of drop-out rates (%) in control and intervention group""}]	NA	NA
NCT02990208	Diaphragmatic Breathing During Virtual Reality Exposure Therapy for Aviophobia	Diaphragmatic breathing during virtual reality exposure therapy for aviophobia: functional coping strategy or avoidance behavior? a pilot study	10.1186/s12888-016-1181-2	https://pubmed.ncbi.nlm.nih.gov/28100203/	1	2016-12-07	Completed	2014-01-01	2015-10-01	2017-01-18	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in FFS (Fear of Flying Scale) scores\n[ Time Frame: immediately before the exposure session, immediately after the exposure session, immediately before the test session (which took place one week after the exposure session), immediately after the test session, in a follow up (one year later) ]\n\nThe Fear of Flying Scale (FFS; German version (Mühlberger & Pauli, 2011)) covers 21 flight situations (e.g., planning the trip, boarding a plane, turbulence during the flight) rated on a 5-point Likert scale""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in FFS (Fear of Flying Scale) scores\n[ Time Frame: immediately before the exposure session, immediately after the exposure session, immediately before the test session (which took place one week after the exposure session), immediately after the test session, in a follow up (one year later) ]\n\nThe Fear of Flying Scale (FFS; German version (Mühlberger & Pauli, 2011)) covers 21 flight situations (e.g., planning the trip, boarding a plane, turbulence during the flight) rated on a 5-point Likert scale""}]	NA	NA
NCT02992236	Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers	10.1111/bcp.13870	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475696/	2	2016-12-09	Completed	2015-08-01	2016-05-01	2019-02-28	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Renal plasma flow\n[ Time Frame: 2 days ]\n\nRenal plasma flow measurement by PAH-Method""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Glomerular Filtration Rate\n[ Time Frame: 2 days ]\n\nby PAH-Method""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Renal plasma flow\n[ Time Frame: 2 days ]\n\nRenal plasma flow measurement by PAH-Method""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Glomerular Filtration Rate\n[ Time Frame: 2 days ]\n\nby PAH-Method""}]	[See Results Section.]	NA
NCT02993510	A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects.	A Randomized, Controlled Trial Comparing Autologous Matrix-Induced Chondrogenesis (AMIC®) to Microfracture: Analysis of 1- and 2-Year Follow-Up Data of 2 Centers	10.2174/1874325001307010133	https://pubmed.ncbi.nlm.nih.gov/23730377/	2	2016-12-12	Completed	2003-12-01	2015-12-01	2013-05-03	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histological evaluation of structural repair of evaluable biopsies harvested from the core of the index lesion during arthroscopy at 2 years\n[ Time Frame: 2 years post-surgery ]\n\nThe macroscopically assessed integration, surface properties and extent of filling of the defect and the microscopically assessed using the International Cartilage Repair Society (ICRS) score""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MRI (magnetic resonance imaging) assessment of structural repair parameters.\n[ Time Frame: 6 months and 1,2 and 5 years post-surgery ]\n\nStructural repair is assessed with magnetic resonance imaging (MRI, 1.5T) by an independent and blinded radiologist, with a focus on the extent, signal intensity and surface of the defect filling, integration to adjacent cartilage, and bone marrow lesion (BML).""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histological evaluation of structural repair of evaluable biopsies harvested from the core of the index lesion during arthroscopy at 2 years\n[ Time Frame: 2 years post-surgery ]\n\nThe macroscopically assessed integration, surface properties and extent of filling of the defect and the microscopically assessed using the International Cartilage Repair Society (ICRS) score""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""MRI (magnetic resonance imaging) assessment of structural repair parameters.\n[ Time Frame: 6 months and 1,2 and 5 years post-surgery ]\n\nStructural repair is assessed with magnetic resonance imaging (MRI, 1.5T) by an independent and blinded radiologist, with a focus on the extent, signal intensity and surface of the defect filling, integration to adjacent cartilage, and bone marrow lesion (BML).""}]	NA
NCT02997137	Impact of an Amino Acid Composition With Micronutrients on Wellbeing of Patients With Chronic Exhaustion Conditions	Impact of a Specific Amino Acid Composition with Micronutrients on Well-Being in Subjects with Chronic Psychological Stress and Exhaustion Conditions: A Pilot Study	10.3390/nu10050551	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986431/	1	2016-12-15	Completed	2014-10-01	2016-02-01	2018-04-29	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perceived Stress Questionnaire (PSQ30)\n[ Time Frame: 12-week dietary intervention ]\n\nIntervention changes in the total PSQ30 score at baseline and after 12 weeks""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Perceived Stress Questionnaire (PSQ30)\n[ Time Frame: 8-week dietary intervention ]\n\nIntervention changes in the total PSQ30 score at baseline and after 8 weeks""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perceived Stress Questionnaire (PSQ30)\n[ Time Frame: 12-week dietary intervention ]\n\nIntervention changes in the total PSQ30 score at baseline and after 12 weeks""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Perceived Stress Questionnaire (PSQ30)\n[ Time Frame: 8-week dietary intervention ]\n\nIntervention changes in the total PSQ30 score at baseline and after 8 weeks""}]	NA	NA
NCT03011463	Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1	Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects	10.1002/jcph.1523	https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.1523	2	2017-01-02	Completed	2016-11-01	2017-03-01	2019-09-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""absolute bioavailability\n[ Time Frame: up to 36 h after drug administration ]\n\nratio oral over intravenous area under the concentration time curve normalized by given dose""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""absolute bioavailability\n[ Time Frame: up to 36 h after drug administration ]\n\nratio oral over intravenous area under the concentration time curve normalized by given dose""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""absolute bioavailability\n[ Time Frame: up to 36 h after drug administration ]\n\nratio oral over intravenous area under the concentration time curve normalized by given dose""}]	NA	NA
NCT03011970	Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin	Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity	10.1016/j.biopsych.2017.04.015	https://www.sciencedirect.com/science/article/abs/pii/S0006322317315585	1	2017-01-03	Completed	2014-09-01	2015-12-01	2017-12-15	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in the amygdala\n[ Time Frame: 45min after nasal spray administration ]\n\n\n\nMagnetic resonance imaging (MRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli of varying intensity. The investigators specifically plan to investigate amygdala response to fearful faces, as this subcortical region has repeatedly been reported to show activation changes after OXT treatment.\n\nDose-test latency varies between the different treatment arms (i.e. imaging starts 15min [arm 1], 45min [arm 2,4 and 5] or 75min [arm 3] after nasal spray administration).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in the amygdala\n[ Time Frame: 45min after nasal spray administration ]\n\n\n\nMagnetic resonance imaging (MRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli of varying intensity. The investigators specifically plan to investigate amygdala response to fearful faces, as this subcortical region has repeatedly been reported to show activation changes after OXT treatment.\n\nDose-test latency varies between the different treatment arms (i.e. imaging starts 15min [arm 1], 45min [arm 2,4 and 5] or 75min [arm 3] after nasal spray administration).""}]	NA	NA
NCT03013322	Anticholium® Per Se	Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se)	10.1016/j.jcrc.2019.04.012	https://pubmed.ncbi.nlm.nih.gov/31035187/	2	2017-01-04	Completed	2014-08-01	2017-02-18	2019-04-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean Sequential Organ Failure Assessment (SOFA) score\n[ Time Frame: up to 14 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h after continuous infusion is commenced ]\n\nThe mean SOFA score (at least two individual values) during treatment and subsequent intensive care of up to 14 days is used as surrogate outcome in critically ill patients with perioperative sepsis and septic shock due to intra-abdominal infection.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean Sequential Organ Failure Assessment (SOFA) score\n[ Time Frame: up to 14 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h after continuous infusion is commenced ]\n\nThe mean SOFA score (at least two individual values) during treatment and subsequent intensive care of up to 14 days is used as surrogate outcome in critically ill patients with perioperative sepsis and septic shock due to intra-abdominal infection.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""mean Sequential Organ Failure Assessment (SOFA) score\n[ Time Frame: up to 14 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h after continuous infusion is commenced ]\n\nThe mean SOFA score (at least two individual values) during treatment and subsequent intensive care of up to 14 days is used as surrogate outcome in critically ill patients with perioperative sepsis and septic shock due to intra-abdominal infection.""}]	NA	NA
NCT03039387	Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	NA	NA	https://www.nature.com/articles/s41598-019-43234-2	1	2017-01-30	Unknown status	NA	NA	2019-05-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Interstimulusintervall and number of correct trials in the PASAT\n[ Time Frame: Assessment during stimulation/ sham stimulation in two sessions through study completion, on average 10 days. ]\n\nTo measure the performance in the PASAT the number of correct trials as well as the mean Interstimulusintervall will be assessed.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of positive and negative affect\n[ Time Frame: The positive and negative affect is assessed (a) right before and after the PASAT in two sessions through study completion, on average 10 days. And (b) also after the resting phase in two sessions through study completion, on average 10 days. ]\n\nChange of positive and negative affect after, compared to before performing the PASAT and also change of the affect during the resting phase.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Heart rate variability\n[ Time Frame: in two sessions through study completion, on average 10 days ]\n\nThe Heart Rate Variability will be measured during the resting phase right after the measurement of the affect.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Score in state rumination questionnaire\n[ Time Frame: in two sessions through study completion, on average 10 days ]\n\nThe state rumination will be measured after the resting phase""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Interstimulusintervall and number of correct trials in the PASAT\n[ Time Frame: Assessment during stimulation/ sham stimulation in two sessions through study completion, on average 10 days. ]\n\nTo measure the performance in the PASAT the number of correct trials as well as the mean Interstimulusintervall will be assessed.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of positive and negative affect\n[ Time Frame: The positive and negative affect is assessed (a) right before and after the PASAT in two sessions through study completion, on average 10 days. And (b) also after the resting phase in two sessions through study completion, on average 10 days. ]\n\nChange of positive and negative affect after, compared to before performing the PASAT and also change of the affect during the resting phase.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Heart rate variability\n[ Time Frame: in two sessions through study completion, on average 10 days ]\n\nThe Heart Rate Variability will be measured during the resting phase right after the measurement of the affect.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Score in state rumination questionnaire\n[ Time Frame: in two sessions through study completion, on average 10 days ]\n\nThe state rumination will be measured after the resting phase""}]
NCT03042429	Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients	Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials	10.1002/pbc.22693	https://pubmed.ncbi.nlm.nih.gov/21298742/	2	2017-02-01	Completed	2007-01-01	2016-12-31	2010-12-09	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: up to 9 years ]\n\ntime from diagnosis to Event or last follow-up""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: up to 9 years ]\n\ndays from diagnosis to Event or last follow-up""}]	NA
NCT03046940	The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication	NA	10.13140/rg.2.2.19672.85765	https://www.researchgate.net/publication/337734613_Patient-centered_communication_results_in_better_medication_adherence_A_randomized_controlled_trial	3	2017-02-06	Completed	2017-03-15	2017-06-08	2018-11-14	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pill intake\n[ Time Frame: Within 10 minutes after doctor-patient communication ]\n\nBehavioural test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pill intake\n[ Time Frame: Within 10 minutes after doctor-patient communication ]\n\nBehavioural test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pill intake\n[ Time Frame: Within 10 minutes after doctor-patient communication ]\n\nBehavioural test""}]	NA	NA
NCT03063008	Transforaminal Lumbar Interbody Fusion in PEEK Oblique Cages With and Without Titanium Coating	Transforaminal lumbar interbody fusion using polyetheretherketone oblique cages with and without a titanium coating: a randomised clinical pilot study	10.1302/0301-620x.99b10.bjj-2016-1292.r2	NA	1	2017-02-23	Completed	2012-01-16	2013-09-01	2017-10-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical outcome assessed by Oswestry Disability Index (ODI) after instrumented transforaminal lumbar fusion with TiPEEK or common PEEK\n[ Time Frame: 12 months ]\n\nOswestry Disability Index (ODI) after instrumented transforaminal lumbar fusion with TiPEEK or common PEEK""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical outcome assessed by Oswestry Disability Index (ODI) after instrumented transforaminal lumbar fusion with TiPEEK or common PEEK\n[ Time Frame: 12 months ]\n\nOswestry Disability Index (ODI) after instrumented transforaminal lumbar fusion with TiPEEK or common PEEK""}]	NA	NA
NCT03092206	Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication	Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study	10.3851/imp3271	https://www.intmedpress.com/journals/avt/abstract.cfm?id=3271&pid=48	4	2017-03-21	Completed	2017-04-01	2017-07-28	2018-10-03	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin sensitivity\n[ Time Frame: 14±2 days ]\n\nTo assess changes in insulin sensitivity (mean glucose disposal rate normalized to body weight (MBW [mg glucose/min*kg]) in HIV-negative, healthy, non-obese (BMI 18-25) male volunteers following 14±2 days of treatment with group 1 or group 2 or group 3, as measured by HEGC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin sensitivity\n[ Time Frame: 14±2 days ]\n\nTo assess changes in insulin sensitivity (mean glucose disposal rate normalized to body weight (MBW [mg glucose/min*kg]) in HIV-negative, healthy, non-obese (BMI 18-25) male volunteers following 14±2 days of treatment with group 1 or group 2 or group 3, as measured by HEGC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in insulin sensitivity\n[ Time Frame: 14±2 days ]\n\nTo assess changes in insulin sensitivity (mean glucose disposal rate normalized to body weight (MBW [mg glucose/min*kg]) in HIV-negative, healthy, non-obese (BMI 18-25) male volunteers following 14±2 days of treatment with group 1 or group 2 or group 3, as measured by HEGC.""}]	NA	NA
NCT03105024	Self-efficacy Enhancement and Exposure Therapy	Low Perceived Self-Efficacy Impedes Discriminative Fear Learning	10.3389/fpsyg.2019.01191	https://pubmed.ncbi.nlm.nih.gov/31275188/	3	2017-04-03	Completed	2017-03-22	2017-11-29	2019-06-18	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after, 1 month after) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]""}]	NA	NA
NCT03114293	Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS	Feasibility of a smartphone app to enhance physical activity in progressive MS: a pilot randomized controlled pilot trial over three months	10.7717/peerj.9303	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319035/	3	2017-04-13	Unknown status	2016-04-01	2017-04-30	2020-06-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of responders\n[ Time Frame: 3 Months ]\n\nRate of responders as defined by a 20% increase of steps or 20% increase in physical activity as measured with the actigraph""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of responders\n[ Time Frame: 3 Months ]\n\nRate of responders as defined by a 20% increase of steps or 20% increase in physical activity as measured with the actigraph""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of responders\n[ Time Frame: 3 Months ]\n\nRate of responders as defined by a 20% increase of steps or 20% increase in physical activity as measured with the actigraph""}]	NA	NA
NCT03114306	Evaluation of a Fast-track Knee Arthroplasty Concept	Local infiltration anaesthesia versus sciatic nerve and adductor canal block for fast-track knee arthroplasty: A randomised controlled clinical trial	10.1097/eja.0000000000000929	https://pubmed.ncbi.nlm.nih.gov/30562225/	3	2017-04-10	Completed	2017-04-06	2017-08-30	2019-04-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to first mobilisation (standing)\n[ Time Frame: up to 48h postoperatively ]\n\ntime from end of surgery until patients is able to stand""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to first mobilisation (standing)\n[ Time Frame: up to 48h postoperatively ]\n\ntime from end of surgery until patients is able to stand""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to first mobilisation (standing)\n[ Time Frame: up to 48h postoperatively ]\n\ntime from end of surgery until patients is able to stand""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to first mobilisation (standing)\n[ Time Frame: up to 48h postoperatively ]\n\ntime from end of surgery until patients is able to stand""}]	NA
NCT03120156	Effects of Sensomotoric Insoles on Postural Control in Elderly People	NA	NA	https://www.ostechnik.de/91-onlineartikel/5252-sensomotorische-schuheinlagen-zur-reduktion-der-sturzgefahr-bei-sturzgefaehrdeten-aelteren-menschen	3	2017-04-18	Completed	2017-07-01	2017-10-27	2019-06-05	TRUE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Posturographic measurement with Kistler's measuring plate\n[ Time Frame: 30 min. ]\n\na validated posturgraphy plate is measuring the balance ability""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Posturographic measurement with Kistler's measuring plate\n[ Time Frame: 30 min. ]\n\na validated posturgraphy plate is measuring the balance ability""}]	NA	NA
NCT03134144	Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities	Influence of a passive lower-limb exoskeleton during simulated industrial work tasks on physical load, upper body posture, postural control and discomfort	10.1016/j.apergo.2019.05.018	https://www.sciencedirect.com/science/article/abs/pii/S0003687019300985?via%3Dihub	4	2017-04-25	Completed	2017-05-01	2017-10-15	2019-05-30	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Center of Pressure\n[ Time Frame: 2 hours ]\n\nIndicator for the balance of the study participants""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle activity\n[ Time Frame: 2 hours ]\n\nIndicator for the muscular load that may change when wearing the passive exoskeleton""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Center of Pressure\n[ Time Frame: 2 hours ]\n\nIndicator for the balance of the study participants""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle activity\n[ Time Frame: 2 hours ]\n\nIndicator for the muscular load that may change when wearing the passive exoskeleton""}]	[See Results Section.]	NA
NCT03140397	Oral Bioavailability and Bioactivity of Prenylflavonoids From Hops	The Oral Bioavailability of 8-Prenylnaringenin from Hops (Humulus Lupulus L.) in Healthy Women and Men is Significantly Higher than that of its Positional Isomer 6-Prenylnaringenin in a Randomized Crossover Trial	10.1002/mnfr.201700838	https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.201700838	3	2017-05-03	Completed	2016-01-01	2017-04-01	2018-01-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal 6-PN after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Cell viability of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Cell viability of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal 6-PN after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Cell viability of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Cell viability of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal 6-PN after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]\n[ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose ]\n\nTotal trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Cell viability of PBMCs after 6-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Cell viability of PBMCs after 8-PN administration\n[ Time Frame: 0, 6, and 24 h post dose ]""}]	NA
NCT03141697	The Use of CO2 in Routine-Colonoscopy	Is CO2 insufflation an amelioration of routine colonoscopy?	10.23736/s1121-421x.18.02478-9	https://pubmed.ncbi.nlm.nih.gov/30008194/	1	2017-05-04	Completed	2012-04-01	2014-08-31	2018-09-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-procedural pain\n[ Time Frame: 0 - 24 hrs after colonoscopy ]\n\nPain after Colonoscopy, assessed by visual analog scale (VAS)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-procedural pain\n[ Time Frame: 0 - 24 hrs after colonoscopy ]\n\nPain after Colonoscopy, assessed by visual analog scale (VAS)""}]	NA	NA
NCT03146832	Therapeutic Strategies During Exposure to Pain in an Experimental Design	NA	10.1007/s10608-019-10070-7	https://www.springermedizin.de/evaluation-of-exposure-instructions-to-pain-should-therapist-foc/17955584	2	2017-05-09	Completed	2017-04-01	2017-06-15	2020-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain tolerance\n[ Time Frame: 5 minutes prior and 5 minutes after three exposure practice trials ]\n\nDetermined by the temperature at which the participant stopped the heat stimulus""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain tolerance\n[ Time Frame: 5 minutes prior and 5 minutes after three exposure practice trials ]\n\nDetermined by the temperature at which the participant stopped the heat stimulus""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain tolerance\n[ Time Frame: 5 minutes prior and 5 minutes after three exposure practice trials ]\n\nDetermined by the temperature at which the participant stopped the heat stimulus""}]	NA	NA
NCT03147131	Periprosthetic Bone Mineral Density Changes After Implantation Of A Short Hip Stem Compared To A Straight Stem	Bone remodelling after femoral short stem implantation in total hip arthroplasty: 1-year results from a randomized DEXA study	10.1007/s00402-015-2370-z	https://link.springer.com/article/10.1007%2Fs00402-015-2370-z	2	2017-05-05	Unknown status	2010-08-01	2012-02-01	2015-11-27	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	FALSE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stem specific stress shielding of a short compared to a straight hip stem\n[ Time Frame: Five years postoperatively ]\n\nPeriprosthetic Bone Mineral Density changes around a total hip arthroplasty stem""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stem specific stress shielding of a short compared to a straight hip stem\n[ Time Frame: Five years postoperatively ]\n\nPeriprosthetic Bone Mineral Density changes around a total hip arthroplasty stem""}]	NA
NCT03157622	Single-Case Study on Therapeutic Change in Chronic Low Back Pain	Treatment processes during exposure and cognitive-behavioral therapy for chronic back pain: A single-case experimental design with multiple baselines	10.1016/j.brat.2018.07.002	https://www.sciencedirect.com/science/article/abs/pii/S0005796718301050	2	2017-05-16	Completed	2015-06-01	2017-06-01	2018-07-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Therapeutic changes during the course of treatment compared to baseline\n[ Time Frame: from baseline phase (1-3 weeks) to intervention phase (5 weeks) ]\n\nSpecifically developed questionnaire on therapeutic change processes""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Therapeutic changes during the course of treatment compared to baseline\n[ Time Frame: from baseline phase (1-3 weeks) to intervention phase (5 weeks) ]\n\nSpecifically developed questionnaire on therapeutic change processes""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Therapeutic changes during the course of treatment compared to baseline\n[ Time Frame: from baseline phase (1-3 weeks) to intervention phase (5 weeks) ]\n\nSpecifically developed questionnaire on therapeutic change processes""}]	NA	NA
NCT03226587	Acute Effects of Whole Body Blue Light Exposure on Blood Pressure	Blue light exposure decreases systolic blood pressure, arterial stiffness, and improves endothelial function in humans	10.1177/2047487318800072	https://journals.sagepub.com/doi/abs/10.1177/2047487318800072	2	2017-07-20	Completed	2016-08-01	2017-08-01	2018-09-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peripheral blood pressure\n[ Time Frame: baseline, during 30 min exposure and 2 hours thereafter ]\n\nChange of peripheral blood pressure as measured before, during and up to 2 hours after 30 min blue light as compared to control""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peripheral blood pressure\n[ Time Frame: baseline, during 30 min exposure and 2 hours thereafter ]\n\nChange of peripheral blood pressure as measured before, during and up to 2 hours after 30 min blue light as compared to control""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of peripheral blood pressure\n[ Time Frame: baseline, during 30 min exposure and 2 hours thereafter ]\n\nChange of peripheral blood pressure as measured before, during and up to 2 hours after 30 min blue light as compared to control""}]	NA	NA
NCT03230422	A Comparison of Video Laryngoscopes and the Direct Laryngoscope in Simulated Normal and Difficult Infant Airway.	A comparison of two hyperangulated video laryngoscope blades to direct laryngoscopy in a simulated infant airway: a bicentric, comparative, randomized manikin study	10.1186/s12871-018-0580-y	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119241/	2	2017-07-25	Completed	2017-07-24	2017-07-31	2018-08-31	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to ventilation (seconds)\n[ Time Frame: Assessed intraoperatively at time of intubation (seconds) ]\n\nThree timepoints will be recorded, beginning with the insertion of the device past the theeth/gum into the mouth. These will inlcude time to best view, time to removal of device from the mouth, and the time to the first chest raising of the simulator""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to ventilation (seconds)\n[ Time Frame: Assessed intraoperatively at time of intubation (seconds) ]\n\nThree timepoints will be recorded, beginning with the insertion of the device past the theeth/gum into the mouth. These will inlcude time to best view, time to removal of device from the mouth, and the time to the first chest raising of the simulator""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to ventilation (seconds)\n[ Time Frame: Assessed intraoperatively at time of intubation (seconds) ]\n\nThree timepoints will be recorded, beginning with the insertion of the device past the theeth/gum into the mouth. These will inlcude time to best view, time to removal of device from the mouth, and the time to the first chest raising of the simulator""}]	NA	NA
NCT03231839	Nutritional Prevention of Diabetes Mellitus Type 2	NA	10.1093/ajcn/nqy307	https://academic.oup.com/ajcn/article/109/2/288/5307117	1	2017-07-24	Completed	2009-02-01	2012-06-30	2019-02-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in glucose metabolism\n[ Time Frame: baseline and six months ]\n\nglucose metabolism measured during the oral glucose tolerance test (OGTT)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in glucose metabolism\n[ Time Frame: baseline and six months ]\n\nglucose metabolism measured during the oral glucose tolerance test (OGTT)""}]	NA	NA
NCT03265899	Oxytocin and the Processing of Social Stress-Associated Chemosignals	Oxytocin reduces a chemosensory-induced stress bias in social perception	10.1038/s41386-018-0063-3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300531/	1	2017-08-25	Completed	2015-07-01	2016-11-30	2018-04-12	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced-choice ratings of morphed emotional faces with varying intensities (neutral to fearful).\n[ Time Frame: 30 min after nasal spray administration ]\n\nAfter each trial, subjects were asked to use a button response grip to indicate whether they perceived the depicted face as neutral or fearful.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Response time for facial stimuli ratings.\n[ Time Frame: 30 min after nasal spray administration ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Blood-oxygen-level dependent signal in response to chemosensory cues.\n[ Time Frame: 30 minutes after nasal spray administration ]\n\nThe modulatory effect of oxytocin on neural correlates Using functional magnetic resonance imaging, signal changes in the amygdala, hippocampus and the anterior cingulate cortex in response to olfactory cues of stress and sport (axillary sweat obtained from an unrelated sample of 30 healthy men undergoing the Trier Social Stress Test and ergometer training as control).""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced-choice ratings of morphed emotional faces with varying intensities (neutral to fearful).\n[ Time Frame: 30 min after nasal spray administration ]\n\nAfter each trial, subjects were asked to use a button response grip to indicate whether they perceived the depicted face as neutral or fearful.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Response time for facial stimuli ratings.\n[ Time Frame: 30 min after nasal spray administration ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Blood-oxygen-level dependent signal in response to chemosensory cues.\n[ Time Frame: 30 minutes after nasal spray administration ]\n\nThe modulatory effect of oxytocin on neural correlates Using functional magnetic resonance imaging, signal changes in the amygdala, hippocampus and the anterior cingulate cortex in response to olfactory cues of stress and sport (axillary sweat obtained from an unrelated sample of 30 healthy men undergoing the Trier Social Stress Test and ergometer training as control).""}]	NA	NA
NCT03272490	Polyaxial Locking Plates in Treating Distal Humeral Fractures	Polyaxial locking plates in treating distal humeral fractures: a comparative randomized trial for clinical outcome	10.1186/s12891-017-1910-9	NA	1	2017-09-01	Completed	2014-02-05	2017-06-06	2017-12-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mayo Elbow Performance Score (MEPS)\n[ Time Frame: 12 months ]\n\nclinical and functional outcome""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mayo Elbow Performance Score (MEPS)\n[ Time Frame: 12 months ]\n\nclinical and functional outcome""}]	NA	NA
NCT03281616	Lifestyle in Turkish-Background Diabetics	Lifestyle interventions in Muslim patients with metabolic syndrome-a feasibility study	10.1038/s41430-018-0371-z	https://www.nature.com/articles/s41430-018-0371-z	2	2017-09-11	Completed	2014-06-01	2015-06-30	2018-12-11	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: 12 weeks ]\n\nChanges in body weight (kg) within 12 weeks of diet""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body weight reduction\n[ Time Frame: 12 weeks ]\n\nChanges in body weight (kg) within 12 weeks of diet""}]	NA	NA
NCT03299127	Imagery Rescripting in Depression	We cannot change the past, but we can change its meaning. A randomized controlled trial on the effects of self-help imagery rescripting on depression	10.1016/j.brat.2018.02.007	https://pubmed.ncbi.nlm.nih.gov/29597112/	3	2017-09-27	Completed	2017-04-01	2017-07-30	2018-02-26	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II\n[ Time Frame: Change in BDI-II from pre- to post-intervention (i.e. 6 week interval) ]\n\nBeck Depression Inventory II (BDI II) (Beck, Steer, & Brown, 1996). The BDI-II is a self-report scale that contains 21 Items that tap into cognitive, behavioral and somatic symptoms of depression. A follow-up assessment after six month serves as secondary outcome.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II\n[ Time Frame: Change in BDI-II from pre- to post-intervention (i.e. 6 week interval) ]\n\nBeck Depression Inventory II (BDI II) (Beck, Steer, & Brown, 1996). The BDI-II is a self-report scale that contains 21 Items that tap into cognitive, behavioral and somatic symptoms of depression. A follow-up assessment after six month serves as secondary outcome.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Beck Depression Inventory II\n[ Time Frame: Change in BDI-II from pre- to post-intervention (i.e. 6 week interval) ]\n\nBeck Depression Inventory II (BDI II) (Beck, Steer, & Brown, 1996). The BDI-II is a self-report scale that contains 21 Items that tap into cognitive, behavioral and somatic symptoms of depression. A follow-up assessment after six month serves as secondary outcome.""}]	NA
NCT03312816	Effect of Oxidized Plant Sterols on Serum Concentrations of Plant Sterol Oxidation Products (POP)	Serum Concentration of Plant Sterol Oxidation Products (POP) Compared to Cholesterol Oxidation Products (COP) after Intake of Oxidized Plant Sterols: A Randomised, Placebo-Controlled, Double-Blind Dose‒Response Pilot Study	10.3390/nu11102319	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835335/	3	2017-10-12	Completed	2017-10-01	2017-12-08	2019-09-30	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP (plant sterol oxidation products) value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP (plant sterol oxidation products) value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	NA	NA
NCT03323528	Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis	Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha)	10.1111/ijcp.13272	https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.13272	2	2017-10-24	Completed	2017-02-01	2017-07-02	2018-10-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of total responders assessed at Visit 2 (72 hours after first treatment)\n[ Time Frame: 72 hours after first treatment ]\n\ncomplete resolution of throat pain and difficulty in swallowing at Visit 2""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of total responders assessed at Visit 2 (72 hours after first treatment)\n[ Time Frame: 72 hours after first treatment ]\n\ncomplete resolution of throat pain and difficulty in swallowing at Visit 2""}]	NA	NA
NCT03331159	Evaluation of Fusion After ALIF With an Osteoinductive Material or With Homologus Bone	Clinical Outcome After Anterior Lumbar Interbody Fusion With a New Osteoinductive Bone Substitute Material: A Randomized Clinical Pilot Study	10.1097/bsd.0000000000000802	https://journals.lww.com/jspinaldisorders/fulltext/2019/08000/clinical_outcome_after_anterior_lumbar_interbody.9.aspx	1	2017-10-31	Completed	2012-07-01	2013-10-31	2019-08-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Oswestry Disability Index (ODI)\n[ Time Frame: 12 months after surgery ]\n\nPostoperative disability as measured by the Oswestry Disability Index (ODI)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Oswestry Disability Index (ODI)\n[ Time Frame: 12 months after surgery ]\n\nPostoperative disability as measured by the Oswestry Disability Index (ODI)""}]	NA	NA
NCT03378804	PIEB-PCEA vs CEI-PCEA for Abdominal Oncological Surgery. A Randomized Prospective Clinical Trial	Programmed intermittent epidural bolus versus continuous epidural infusion for postoperative analgesia after major abdominal and gynecological cancer surgery: a randomized, triple-blinded clinical trial	10.1186/s12871-018-0613-6	https://pubmed.ncbi.nlm.nih.gov/30376810/	2	2017-12-14	Completed	2017-01-01	2017-11-01	2018-10-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of additional patient-controlled bolus of ropivacaine 0.2% (consumption in ml)\n[ Time Frame: Beginning of operation -6 pm on the second postoperative day ]\n\nThe patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min. The number of additional patient-controlled boli will be read off the epidural pump at 6 pm on the day of surgery, 6 pm on the 1st day and 6 pm on the 2nd day""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of additional patient-controlled bolus of ropivacaine 0.2% (consumption in ml)\n[ Time Frame: Beginning of operation -6 pm on the second postoperative day ]\n\nThe patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min. The number of additional patient-controlled boli will be read off the epidural pump at 6 pm on the day of surgery, 6 pm on the 1st day and 6 pm on the 2nd day""}]	NA	NA
NCT03425929	Oxytocin, Trauma Disclosure and Intrusions	NA	10.1159/000496056	https://static1.squarespace.com/static/5e99fa9f3fa9f76f9cb19251/t/5ea36d9755121234097ef539/1587768728156/Scheele+et+al+2019+Psychotherapy+and+Psychosomatics.pdf	1	2018-02-01	Completed	2016-06-01	2017-03-18	2018-04-03	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total number of intrusions following the first trauma movie exposure.\n[ Time Frame: Three days following the first trauma movie exposure. ]\n\nThe participants will be asked to complete intrusion diaries at home in the evening of the days 1 to 3. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Total number of intrusions following the second trauma movie exposure.\n[ Time Frame: Three days following the second trauma movie exposure. ]\n\nThe participants will be asked to complete intrusion diaries at home in the evening of the days 4 to 6. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Neural responses to emotional faces in the amygdala.\n[ Time Frame: Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min. ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Neural responses to emotional faces in the prefrontal cortex.\n[ Time Frame: Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min. ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate prefrontal cortex responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""fMRI resting state data\n[ Time Frame: Functional data will be acquired for 6 min. ]\n\nParticipants will be instructed to lie still with open eyes during the resting state measurement and not think of anything in particular.""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Trauma disclosure (time spend discussing the movie)\n[ Time Frame: Six days following the first trauma movie exposure. ]\n\nThe intrusion diaries will contain a question for how long participants discussed the trauma movie.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total number of intrusions following the first trauma movie exposure.\n[ Time Frame: Three days following the first trauma movie exposure. ]\n\nThe participants will be asked to complete intrusion diaries at home in the evening of the days 1 to 3. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Total number of intrusions following the second trauma movie exposure.\n[ Time Frame: Three days following the second trauma movie exposure. ]\n\nThe participants will be asked to complete intrusion diaries at home in the evening of the days 4 to 6. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Neural responses to emotional faces in the amygdala.\n[ Time Frame: Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min. ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Neural responses to emotional faces in the prefrontal cortex.\n[ Time Frame: Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min. ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate prefrontal cortex responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""fMRI resting state data\n[ Time Frame: Functional data will be acquired for 6 min. ]\n\nParticipants will be instructed to lie still with open eyes during the resting state measurement and not think of anything in particular.""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Trauma disclosure (time spend discussing the movie)\n[ Time Frame: Six days following the first trauma movie exposure. ]\n\nThe intrusion diaries will contain a question for how long participants discussed the trauma movie.""}]	NA	NA
NCT03519698	Footbaths With Ginger, Mustard & Warm Water Only in Female Adolescents With & Without Anorexia Nervosa	Increasing Warmth in Adolescents with Anorexia Nervosa: A Randomized Controlled Crossover Trial Examining the Efficacy of Mustard and Ginger Footbaths	10.1155/2020/2416582	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013347/	1	2018-05-08	Completed	2015-12-15	2017-06-22	2020-01-30	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 2-Item Warmth Perception Measure (feet) from t1 to t3\n[ Time Frame: right before the footbath (t1) and 10 minutes following the footbath (t3) ]\n\nSelf-reported warmth perception at both feet assessed with the \""Herdecke warmth perception questionnaire\"" right before (t1) and 10 minutes following the footbath (t3). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a total between 0 - 8.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 2-Item Warmth Perception Measure (feet) from t1 to t3\n[ Time Frame: right before the footbath (t1) and 10 minutes following the footbath (t3) ]\n\nSelf-reported warmth perception at both feet assessed with the \""Herdecke warmth perception questionnaire\"" right before (t1) and 10 minutes following the footbath (t3). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a total between 0 - 8.""}]	NA	NA
NCT03524755	Physical Exercise for Patients Who Suffer From Weight Loss Due to Head and Neck Cancer Undergoing Medical Treatment	Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial	10.1186/s13014-018-1157-0	NA	1	2018-05-12	Completed	2013-07-10	2015-05-07	2018-11-06	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Cancer-related fatigue at post-radiotherapy and follow-up\n[ Time Frame: Baseline, post-radiotherapy (~6weeks), follow-up (~8 weeks) ]\n\nThe Multidimensional Fatigue Inventory (MFI) which consists of 20 items that measure subgroups (general, physical and mental fatigue as well as reduced motivation and reduced activity) of fatigue with a 5-point Likert scale.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Cancer-related fatigue at post-radiotherapy and follow-up\n[ Time Frame: Baseline, post-radiotherapy (~6weeks), follow-up (~8 weeks) ]\n\nThe Multidimensional Fatigue Inventory (MFI) which consists of 20 items that measure subgroups (general, physical and mental fatigue as well as reduced motivation and reduced activity) of fatigue with a 5-point Likert scale.""}]	NA	NA
NCT03584451	Evaluation of the Effect of Rehabilitation Sport After Total Hip Arthroplasty (THA)	Sports Therapy Interventions Following Total Hip Replacement	10.3238/arztebl.2019.0001	https://www.aerzteblatt.de/archiv/204208/Sporttherapeutische-Massnahmen-nach-Huefttotalendoprothese	3	2018-07-11	Completed	2015-02-01	2017-07-01	2019-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 6 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 12 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 6 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""}]	NA	NA
NCT03666338	Influence of the Initial Level of Consciousness on Early, Goal-directed Mobilization	Influence of the initial level of consciousness on early, goal-directed mobilization: a post hoc analysis	10.1007/s00134-019-05528-x	NA	2	2018-09-07	Completed	2011-07-11	2015-11-04	2019-01-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional independence at hospital discharge\n[ Time Frame: At the day of hospital discharge, on average up to 1 month ]\n\nminimal modified functional independence measure score of 8 (Scale ranging from 0-8 with the subdomain locomotion and transfer 0-4 each)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional independence at hospital discharge\n[ Time Frame: At the day of hospital discharge, on average up to 1 month ]\n\nminimal modified functional independence measure score of 8 (Scale ranging from 0-8 with the subdomain locomotion and transfer 0-4 each)""}]	NA	NA
NCT03789448	Early Access to ART for All in Swaziland: Effects on Economic Outcomes	NA	10.7554/elife.58487	https://elifesciences.org/articles/58487	2	2018-12-25	Completed	2014-09-01	2017-08-31	2020-08-24	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total healthcare expenditures (for hospitalization and primary care)\n[ Time Frame: 12 months ]\n\nIncluding direct health care costs (e.g., surgery, medication, consultation) and indirect costs (e.g., transport to clinic, payment for someone to look after children, salary lost for time off...)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Total productivity hours\n[ Time Frame: 24 hours ]\n\nTotal Hours per day spent on income generation activities""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total healthcare expenditures (for hospitalization and primary care)\n[ Time Frame: 12 months ]\n\nIncluding direct health care costs (e.g., surgery, medication, consultation) and indirect costs (e.g., transport to clinic, payment for someone to look after children, salary lost for time off...)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Total productivity hours\n[ Time Frame: 24 hours ]\n\nTotal Hours per day spent on income generation activities""}]	NA	NA
NCT03829839	Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity	Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear	10.1073/pnas.1920147117	https://www.pnas.org/content/117/21/11781	3	2019-02-01	Completed	2016-03-03	2017-08-16	2020-05-08	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neural responses to emotional faces in the amygdala subregions\n[ Time Frame: Neural activations with be measured with 7 Tesla fMRI in an emotional face matching task that lasts 20 mins ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala subregion responses to emotional faces.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neural responses to emotional faces in the amygdala subregions\n[ Time Frame: Neural activations with be measured with 7 Tesla fMRI in an emotional face matching task that lasts 20 mins ]\n\nFunctional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala subregion responses to emotional faces.""}]	NA	NA
NCT03860129	Different Volatile Anaesthetics and the Depth of Long Term ICU Sedation	Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial	10.1186/s13613-019-0594-8	https://pubmed.ncbi.nlm.nih.gov/31620921/	1	2019-02-28	Completed	2014-12-10	2017-05-05	2019-10-16	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""usage of volatile anesthetics at 0.5 MAC during ICU Sedation\n[ Time Frame: up to one week ]\n\nComparison between Isofluarne, Sevoflurane and Desflurane""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""usage of volatile anesthetics at 0.5 MAC during ICU Sedation\n[ Time Frame: up to one week ]\n\nComparison between Isofluarne, Sevoflurane and Desflurane""}]	NA	NA
NCT04209309	Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal	Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal: A Proof of Concept Study	10.1016/j.jsxm.2020.05.002	https://www.jsm.jsexmed.org/article/S1743-6095(20)30609-3/abstract	1	2019-12-19	Completed	2014-10-01	2016-07-01	2020-06-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of sexual arousal\n[ Time Frame: immediately before and after the single session of rTMS ]\n\nshort 10-item version of the Affect and Arousal Scale, which captures perceived genital, autonomic and psychological sexual arousal as well as state sexual desire""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of sexual arousal\n[ Time Frame: immediately before and after the single session of rTMS ]\n\nshort 10-item version of the Affect and Arousal Scale, which captures perceived genital, autonomic and psychological sexual arousal as well as state sexual desire""}]	NA	NA
